PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wagner, JA; Varga, K; Ellis, EF; Rzigalinski, BA; Martin, BR; Kunos, G				Wagner, JA; Varga, K; Ellis, EF; Rzigalinski, BA; Martin, BR; Kunos, G			Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock	NATURE			English	Article							NITRIC-OXIDE; HYPOTENSIVE ACTION; BRAIN CONSTITUENT; ANANDAMIDE; ANTAGONIST; CELLS	Anandamide, an endogenous cannabinoid ligand(1), binds to CB1 cannabinoid receptors(2) in the brain and mimics the neurobehavioural actions of marijuana(3,4). Cannabinoids and anandamide also elicit hypotension mediated by peripheral CB1 receptors(5-8). Here we report that a selective CB1 receptor antagonist, SR141716A(9), elicits an increase in blood pressure in rats subjected to haemorrhagic shock, whereas similar treatment of normotensive rats or intracerebroventricular administration of the antagonist during shock do not affect blood pressure. Blood from haemorrhaged rats causes hypotension in normal rats, which can be prevented by SR141716A but not by inhibition of nitric oxide synthase in the recipient. Macrophages and platelets from haemorrhaged rats elicit CB1 receptor-mediated hypotension in normotensive recipients, and incorporate arachidonic acid or ethanolamine into a product that co-elutes with anandamide on reverse-phase high-performance liquid chromatography. Also, macrophages from control rats stimulated with ionomycin or bacterial phospholipase D produce anandamide, as identified by gas chromatography and mass spectrometry. These findings indicate that activation of peripheral CB1 cannabinoid receptors contributes to haemorrhagic hypotension, and anandamide produced by macrophages may be a mediator of this effect.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University								Aiura K, 1997, J INFECT DIS, V175, P123, DOI 10.1093/infdis/175.1.123; AMRUTHESH SC, 1992, J NEUROCHEM, V58, P503, DOI 10.1111/j.1471-4159.1992.tb09749.x; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COLLINS JA, 1969, ARCH SURG-CHICAGO, V99, P484; CORTAS NK, 1990, CLIN CHEM, V36, P1440; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Ellis EF, 1995, AM J PHYSIOL-HEART C, V269, pH1859, DOI 10.1152/ajpheart.1995.269.6.H1859; FELDER CC, 1992, MOL PHARMACOL, V42, P838; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GEBREMEDHIN G, 1996, FASEB J, V10, pA302; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Lake KD, 1997, HYPERTENSION, V29, P1204, DOI 10.1161/01.HYP.29.5.1204; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NAZIRI W, 1995, J SURG RES, V59, P146, DOI 10.1006/jsre.1995.1146; Peitzman AB, 1995, CURR PROB SURG, V32, P927; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682	25	244	248	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					518	521		10.1038/37371	http://dx.doi.org/10.1038/37371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394002				2022-12-01	WOS:A1997YJ86500054
J	Ermler, U; Grabarse, W; Shima, S; Goubeaud, M; Thauer, RK				Ermler, U; Grabarse, W; Shima, S; Goubeaud, M; Thauer, RK			Crystal structure of methyl coenzyme M reductase: The key enzyme of biological methane formation	SCIENCE			English	Article							METHYLCOENZYME-M METHYLREDUCTASE; F430 PENTAMETHYL ESTER; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOGENIC BACTERIA; COMPONENT-C; INVITRO METHANOGENESIS; STRAIN MARBURG; SYSTEM; NICKEL; SPECTROSCOPY	Methyl-coenzyme M reductase (MCR), the enzyme responsible for the microbial formation of methane, is a 300-kilodalton protein organized as a hexamer in an alpha(2) beta(2) gamma(2) arrangement. The crystal structure of the enzyme from Methanobacterium thermoautotrophicum, determined at 1.45 angstrom resolution for the inactive enzyme state MCRox1-silent, reveals that two molecules of the nickel porphinoid coenzyme F-430 are embedded between the subunits alpha,alpha',beta, and gamma and alpha',alpha,beta', and gamma', forming two identical active sites. Each site is accessible for the substrate methyl-coenzyme M through a narrow channel locked after binding of the second substrate coenzyme B. Together with a second structurally characterized enzyme state (MCRsilent) containing the heterodisulfide of coenzymes M and B, a reaction mechanism is proposed that uses a radical intermediate and a nickel organic compound.	UNIV MARBURG, MIKROBIOL LAB, D-35043 MARBURG, GERMANY; MAX PLANCK INST TERR MIKROBIOL, D-35043 MARBURG, GERMANY	Philipps University Marburg; Max Planck Society	Ermler, U (corresponding author), MAX PLANCK INST BIOPHYS, HEINRICH HOFFMAN STR 7, D-60528 FRANKFURT, GERMANY.							AHN YH, 1991, J AM CHEM SOC, V113, P4700, DOI 10.1021/ja00012a059; ALBRACHT SPJ, 1988, BIOCHIM BIOPHYS ACTA, V955, P86, DOI 10.1016/0167-4838(88)90182-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERKESSEL A, 1991, BIOORG CHEM, V19, P101, DOI 10.1016/0045-2068(91)90047-S; BOKRANZ M, 1988, J BACTERIOL, V170, P568, DOI 10.1128/jb.170.2.568-577.1988; BONACKER LG, 1993, EUR J BIOCHEM, V217, P587, DOI 10.1111/j.1432-1033.1993.tb18281.x; BRNGER AT, 1992, XPLOR MANUAL VERSION; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COWTAN KD, 1994, PROTEIN CRYSTALLOGR, V31, P83; ELLEFSON WL, 1981, J BIOL CHEM, V256, P4259; ELLERMANN J, 1988, EUR J BIOCHEM, V172, P669, DOI 10.1111/j.1432-1033.1988.tb13941.x; Ermler U, 1997, STRUCTURE, V5, P635, DOI 10.1016/S0969-2126(97)00219-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARBER G, 1991, HELV CHIM ACTA, V74, P697, DOI 10.1002/hlca.19910740404; Goubeaud M, 1997, EUR J BIOCHEM, V243, P110, DOI 10.1111/j.1432-1033.1997.00110.x; HARTZELL PL, 1986, P NATL ACAD SCI USA, V83, P6726, DOI 10.1073/pnas.83.18.6726; HARTZELL PL, 1987, J BIOL CHEM, V262, P5581; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JAUN B, 1990, HELV CHIM ACTA, V73, P2209, DOI 10.1002/hlca.19900730818; JAUN B, 1993, MET IONS BIOL SYST, V29, P287; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, PROTEIN CRYSTALLOGR, V26, P83; LIN SK, 1992, HELV CHIM ACTA, V75, P1478, DOI 10.1002/hlca.19920750504; LIN SK, 1991, HELV CHIM ACTA, V74, P1725, DOI 10.1002/hlca.19910740814; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOLL KM, 1986, BIOCHEM BIOPH RES CO, V139, P889, DOI 10.1016/S0006-291X(86)80261-3; Nolling J, 1996, INT J SYST BACTERIOL, V46, P1170, DOI 10.1099/00207713-46-4-1170; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROSPERT S, 1991, FEBS LETT, V291, P371, DOI 10.1016/0014-5793(91)81323-Z; ROUVIERE PE, 1989, J BACTERIOL, V171, P4556, DOI 10.1128/jb.171.9.4556-4562.1989; SCOTT RA, 1986, FRONTIERS BIOINORGAN, P20; Sheldon Garrett Ward, 1991, P CCP4 STUD WEEK, P3; Shima S, 1997, J BIOCHEM, V121, P829, DOI 10.1093/oxfordjournals.jbchem.a021660; Thauer R, 1997, ANTON LEEUW INT J G, V71, P21, DOI 10.1023/A:1000149705588; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245	46	417	444	4	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1457	1462		10.1126/science.278.5342.1457	http://dx.doi.org/10.1126/science.278.5342.1457			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367957				2022-12-01	WOS:A1997YG85800043
J	Schmidt, WA; Kraft, HE; Vorpahl, K; Volker, L; GromnicaIhle, EJ				Schmidt, WA; Kraft, HE; Vorpahl, K; Volker, L; GromnicaIhle, EJ			Color duplex ultrasonography in the diagnosis of temporal arteritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GIANT-CELL ARTERITIS; DOPPLER ULTRASOUND FLOW; POLYMYALGIA-RHEUMATICA; CRANIAL ARTERITIS; BIOPSY; SONOGRAPHY; CRITERIA	Background The diagnosis of temporal arteritis usually requires a biopsy of the temporal artery. We examined the usefulness of color duplex ultrasonography in patients suspected of having temporal arteritis. Methods In this prospective study, all patients seen in the departments of rheumatology and ophthalmology from January 1994 to October 1996 who had clinically suspected active temporal arteritis or polymyalgia rheumatica were examined by duplex ultrasonography. The final diagnoses, made according to standard criteria, were temporal arteritis in 30 patients, 21 with biopsy-confirmed disease; polymyalgia rheumatica in 37; and negative histologic findings and a diagnosis other than temporal arteritis or polymyalgia rheumatica in 15. We also studied 30 control patients matched for age and sex to the patients with arteritis. Two ultrasound studies were performed and read before the biopsies; one ultrasonographer was unaware of the clinical information. Results In 22 (73 percent) of the 30 patients with temporal arteritis, ultrasonography showed a dark halo around the lumen of the temporal arteries. The halos disappeared after a mean of 16 days (range, 7 to 56) of treatment with corticosteroids. Twenty four patients (80 percent) had stenoses or occlusions of temporal-artery segments, and 28 patients (93 per cent) had stenoses, occlusions, or a halo. No halos were identified in the 82 patients without temporal arteritis; 6 (7 percent) had stenoses or occlusions. For each of the three types of abnormalities identified by ultrasonography, the interrater agreement was greater than or equal to 95 percent. Conclusions There are characteristic signs of temporal arteritis that can be visualized by color duplex ultrasonography. The most specific sign is a dark halo, which may be due to edema of the artery wall. In patients with typical clinical signs and a halo on ultrasonography, it may be possible to make a diagnosis of temporal arteritis and begin treatment without performing a temporal-artery biopsy. (C) 1997, Massachusetts Medical Society.	KLINIKUM BUCH, DEPT OPHTHALMOL, BERLIN, GERMANY; KLINIKUM BUCH, DEPT PATHOL, BERLIN, GERMANY; KLINIKUM BUCH, DEPT ANGIOL, BERLIN, GERMANY		Schmidt, WA (corresponding author), CLIN RHEUMATOL, ZEPERNICKER STR 1, D-13125 BERLIN, GERMANY.		Schmidt, Wolfgang/W-5599-2019	Schmidt, Wolfgang/0000-0001-7831-8738				ABURN NS, 1993, EYE, V7, P639, DOI 10.1038/eye.1993.147; ASHTONKEY M, 1991, BAILLIERE CLIN RHEUM, V5, P387, DOI 10.1016/S0950-3579(05)80061-5; BARRIER J, 1982, JAMA-J AM MED ASSOC, V248, P2158, DOI 10.1001/jama.248.17.2158; BECKMAN RL, 1990, J CLIN NEURO-OPHTHAL, V10, P304; BIENFANG DC, 1984, AM J OPHTHALMOL, V97, P526, DOI 10.1016/S0002-9394(14)76141-0; BIRD HA, 1979, ANN RHEUM DIS, V38, P434, DOI 10.1136/ard.38.5.434; BUNHOLZL C, 1988, ULTRASCHALL MED, V9, P232; Dany F, 1981, J Mal Vasc, V6, P273; DANY F, 1989, J MAL VASCUL, V14, P104; DAUMANN C, 1989, KLIN MONATSBL AUGENH, V194, P37, DOI 10.1055/s-2008-1046333; DORNBERGER V, 1987, MED WELT, V38, P1302; ELLIOTT PD, 1972, RADIOLOGY, V102, P635; FRIEDMAN G, 1988, ISRAEL J MED SCI, V24, P686; Ghanchi FD, 1996, EYE, V10, P459, DOI 10.1038/eye.1996.101; GILLANDERS LA, 1969, ANN RHEUM DIS, V28, P267, DOI 10.1136/ard.28.3.267; HO AC, 1994, ARCH OPHTHALMOL-CHIC, V112, P938, DOI 10.1001/archopht.1994.01090190086026; HORWITZ HM, 1977, J RHEUMATOL, V4, P76; HUNDER GG, 1972, ARTHRITIS RHEUM, V15, P561, DOI 10.1002/art.1780150602; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; KELLEY JS, 1978, ARCH OPHTHALMOL-CHIC, V96, P845; LIE JT, 1994, J RHEUMATOL, V21, P366; LIE JT, 1994, J RHEUMATOL, V21, P186; LIEB WE, 1992, ACTA OPHTHALMOL, V70, P50; LIOZON F, 1983, PRESSE MED, V12, P2113; LIOZON F, 1986, ANN MED INTERNE, V137, P307; MARANO SR, 1985, NEUROSURGERY, V16, P786, DOI 10.1227/00006123-198506000-00008; MENKES CJ, 1981, NOUV PRESSE MED, V10, P2371; MORGAN GJ, 1978, ARTHRITIS RHEUM, V21, P362, DOI 10.1002/art.1780210312; PUECHAL, 1995, LANCET, V346, P62; PUECHAL X, 1995, LANCET, V345, P1437, DOI 10.1016/S0140-6736(95)92626-7; SALVARANI C, 1994, ARTHRITIS RHEUM, V37, P1621, DOI 10.1002/art.1780371111; SCHMIDT WA, 1995, LANCET, V345, P866, DOI 10.1016/S0140-6736(95)93005-1; SCOTT KR, 1991, OPHTHALMIC SURG LAS, V22, P519; SIEMSSEN SJ, 1987, BRIT J PLAST SURG, V40, P73, DOI 10.1016/0007-1226(87)90015-4; SLAVIN ML, 1986, ARCH OPHTHALMOL-CHIC, V104, P1127; SMALL P, 1991, ARTHRITIS RHEUM, V34, P220, DOI 10.1002/art.1780340215; STEIGERWALT RD, 1994, INT ANGIOL, V13, P286; STOCK AL, 1980, HEAD NECK SURG, V2, P466, DOI 10.1002/hed.2890020604; VINCKIER L, 1989, J MAL VASCUL, V14, P116; VOLLRATHJUNGER C, 1989, KLIN MONATSBL AUGENH, V195, P169, DOI 10.1055/s-2008-1046431; WILLIAMSON TH, 1992, BRIT J OPHTHALMOL, V76, P690, DOI 10.1136/bjo.76.11.690	41	508	515	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1336	1342		10.1056/NEJM199711063371902	http://dx.doi.org/10.1056/NEJM199711063371902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358127				2022-12-01	WOS:A1997YE44600002
J	Shieh, SY; Ikeda, M; Taya, Y; Prives, C				Shieh, SY; Ikeda, M; Taya, Y; Prives, C			DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2	CELL			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA GENE; STRAND-BREAK-REPAIR; WILD-TYPE P53; V(D)J RECOMBINATION; BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE	DNA-damaging agents signal to p53 through as yet unidentified posttranscriptional mechanisms. Here we show that phosphorylation of human p53 at serine 15 occurs after DNA damage and that this leads to reduced interaction of p53 with its negative regulator, the oncoprotein MDM2 in vivo and in vitro. Furthermore, using purified DNA-dependent protein kinase (DNA-PK), we demonstrate that phosphorylation of p53 at serines 15 and 37 impairs the ability of MDM2 to inhibit p53-dependent transactivation. We present evidence that these effects are most likely due to a conformational change induced upon phosphorylation of p53. Our studies provide a plausible mechanism by which the induction of p53 can be modulated by DNA-PK (or other protein kinases with similar specificity) in response to DNA damage.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; MBL CO LTD, INA LABS, INA, NAGANO 396, JAPAN; NATL CANC CTR, RES INST, CHUO KU, TOKYO 104, JAPAN	Columbia University; National Cancer Center - Japan			qiao, zhixin/I-3408-2012; Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	NCI NIH HHS [CA58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bottger V, 1996, ONCOGENE, V13, P2141; CANMAN CE, 1994, CANCER RES, V54, P5054; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1995, ONCOGENE, V11, P609; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Rathmell WK, 1997, CANCER RES, V57, P68; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	63	1679	1713	0	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					325	334		10.1016/S0092-8674(00)80416-X	http://dx.doi.org/10.1016/S0092-8674(00)80416-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363941	hybrid			2022-12-01	WOS:A1997YD94100006
J	Levy, BD; Petasis, NA; Serhan, CN				Levy, BD; Petasis, NA; Serhan, CN			Polyisoprenyl phosphates in intracellular signalling	NATURE			English	Article							CELL-FREE SYSTEM; PRESQUALENE PYROPHOSPHATE; RESPIRATORY BURST; HUMAN-NEUTROPHILS; ACTIVATION; SQUALENE; NADPH; BIOSYNTHESIS; LEUKOCYTES; MECHANISM	In response to environmental stimuli, leukocyte membrane remodelling generates biologically active lipids that can serve as both intra-and extracellular mediators(1). There are several classes of lipids that can mediate inflammatory reactions.(1) We report here on a new intracellular lipid signal that regulates oxygen-radical formation in neutrophils, a key response in microbial killing, inflammation and tissue injury. Screening of neutrophil-derived extracts rich in phosphorylated, non-saponifiable lipids revealed a potent inhibitor of superoxide anion (O-2(-)) production. Structural analysis of biologically active fractions gave four major phosphorylated lipids: most abundant was presqualene diphosphate (PSDP). Upon activation of neutrophil receptors, PSDP and its monophosphate form, presqualene monophosphate (PSMP), undergo rapid remodelling. At submicromolar concentrations, PSDP but not PSMP inhibit O-2(-) production by human neutrophil cell-free oxidase preparations. We prepared PSDP and PSMP by total organic synthesis and matched both the physical properties and biological activity of the neutrophil-derived compounds. Our results indicate that PSDP, a recognized intermediate of cholesterol biosynthesis(2), is present in immune effector cells and is a potent regulator of the cellular response in host defence.	BRIGHAM & WOMENS HOSP, DEPT ANESTHESIA, CTR EXPT THERAPEUT & REPERFUS INJURY, BOSTON, MA 02115 USA; UNIV SO CALIF, DEPT CHEM, LOS ANGELES, CA 90089 USA	Harvard University; Brigham & Women's Hospital; University of Southern California			Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446				ADAIR WL, 1985, METHOD ENZYMOL, V111, P201; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Bokoch G M, 1994, Curr Opin Hematol, V1, P53; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CHEN PS, 1956, ANAL CHEM, V28, P175; COREY EJ, 1976, J AM CHEM SOC, V98, P1291, DOI 10.1021/ja00421a056; EPSTEIN WW, 1970, J BIOL CHEM, V245, P4597; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMEZCAMBRONERO J, 1991, ADV EXP MED BIOL, V314, P35; Jarstfer MB, 1996, J AM CHEM SOC, V118, P13089, DOI 10.1021/ja963308s; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MOOKHTIAR KA, 1994, J BIOL CHEM, V269, P11201; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; POPJAK G, 1969, J BIOL CHEM, V244, P1897; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; ROGERS DH, 1995, J ORG CHEM, V60, P941, DOI 10.1021/jo00109a026; SCHEER A, 1995, BIOCHEMISTRY-US, V34, P4952, DOI 10.1021/bi00015a006; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHECHTER I, 1980, J LIPID RES, V21, P277; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TOU J, 1995, LIPIDS, V30, P373, DOI 10.1007/BF02536294; VANDESSEL GAF, 1993, CRC HDB CHROMATOGRAP, P321; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27	26	54	57	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					985	990		10.1038/40180	http://dx.doi.org/10.1038/40180			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353124				2022-12-01	WOS:A1997YD29900060
J	Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM				Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM			Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							OPERATIONAL ASSESSMENT; ALGORITHM		ERASMUS UNIV ROTTERDAM,INST EPIDEMIOL & BIOSTAT,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Mannesse, CK (corresponding author), UNIV HOSP ROTTERDAM DIJKZIGT,DEPT INTERNAL MED 1,DIV GERIATR MED,ROOM D442,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							*BRIT MED ASS ROYA, 1994, BRIT NAT FORM; Egberts TCG, 1996, BRIT MED J, V313, P530; HUTCHINSON TA, 1979, JAMA-J AM MED ASSOC, V242, P633, DOI 10.1001/jama.242.7.633; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; VANKRAAIJ DJW, 1994, NETH J MED, V44, P166	5	67	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1057	1058		10.1136/bmj.315.7115.1057	http://dx.doi.org/10.1136/bmj.315.7115.1057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366733	Green Published			2022-12-01	WOS:A1997YD44500023
J	Izbicki, JR; Hosch, SB; Pichlmeier, U; Rehders, A; Busch, C; Niendorf, A; Passlick, B; Broelsch, CE; Pantel, K				Izbicki, JR; Hosch, SB; Pichlmeier, U; Rehders, A; Busch, C; Niendorf, A; Passlick, B; Broelsch, CE; Pantel, K			Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; BONE-MARROW; FOLLOW-UP; CARCINOMA; MICROMETASTASES; METASTASES; LUNG; ADENOCARCINOMA; ANTIBODIES; TISSUES	Background Current methods of disease staging often fail to detect small numbers of tumor cells in lymph nodes, Metastatic relapse may arise from these few cells. Methods We studied 1308 lymph nodes from 68 patients with esophageal cancer without overt metastases who had undergone radical en bloc esophagectomy. A total of 399 lymph nodes obtained from 68 patients were found to be free of tumor by routine histopathological analysis and were studied further for isolated tumor cells by immunohistochemical analysis with the monoclonal anti-epithelial-cell antibody Ber-EP4. This antibody did not stain lymph nodes from 24 control patients without carcinoma. Results Of the 399 ''tumor free'' lymph nodes, 67 (17 percent), obtained from 42 of the 68 patients, contained Ber-EP4-positive tumor cells. Fifteen of 30 patients who were considered free of lymph-node metastases by histopathological analysis had such cells in their lymph nodes, and 5 of the 15 had small primary tumors. Ber-EP4-positive cells found in ''tumor free'' nodes were independently predictive of significantly reduced relapse-free survival (P = 0.008) and overall survival (P=0.03). They predicted relapse both in patients without nodal metastases (P=0.01) and in those with regional lymph-node involvement (P=0.007). All 12 patients whose lymph nodes were negative on both histopathological and immunohistochemical analysis and who were available for follow-up survived without recurrence. The presence of micrometastatic tumor cells in bone marrow had no additional prognostic value. Conclusions Immunohistochemical examination of lymph nodes may improve the pathological staging of esophageal cancer. (C) 1997, Massachusetts Medical Society.	UNIV HAMBURG,ABT MATH MED,HAMBURG,GERMANY; UNIV HAMBURG,INST PATHOL,D-2000 HAMBURG,GERMANY; UNIV MUNICH,INST IMMUNOL,D-8000 MUNICH,GERMANY	University of Hamburg; University of Hamburg; University of Munich	Izbicki, JR (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,ALLGEMEINCHIRURG ABT,MARTINISTR 52,D-20246 HAMBURG,GERMANY.							ABE S, 1990, J THORAC CARDIOV SUR, V100, P287; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BUSSOLATI G, 1986, BRIT J CANCER, V54, P631, DOI 10.1038/bjc.1986.219; BYRNE J, 1987, EUR J SURG ONCOL, V13, P409; CASSON AG, 1994, ANN THORAC SURG, V58, P1569, DOI 10.1016/0003-4975(94)91986-0; CHEN MYM, 1995, J CLIN GASTROENTEROL, V21, P254, DOI 10.1097/00004836-199510000-00019; CHEN ZL, 1993, JNCI-J NATL CANCER I, V85, P493, DOI 10.1093/jnci/85.6.493; COX DR, 1972, J R STAT SOC B, V34, P187; Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; EARLAM R, 1988, DIS ESOPHAGUS, P11; GOLDMINC M, 1993, BRIT J SURG, V80, P367, DOI 10.1002/bjs.1800800335; HENNESSY TPJ, 1994, WORLD J SURG, V18, P367, DOI 10.1007/BF00316816; Hermanek P, 1992, TNM CLASSIFICATION M; *INT LUDW BREAST C, 1990, LANCET, V335, P1565; Jauch K W, 1992, Eur J Surg Oncol, V18, P553; KASPER M, 1987, EUR J CANCER CLIN ON, V23, P137, DOI 10.1016/0277-5379(87)90007-1; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; LERUT T, 1992, ANN SURG, V216, P583, DOI 10.1097/00000658-199211000-00010; LERUT TE, 1994, WORLD J SURG, V18, P379, DOI 10.1007/BF00316818; MARTINI N, 1983, ANN SURG, V198, P386, DOI 10.1097/00000658-198309000-00015; MILLIKAN KW, 1995, ARCH SURG-CHICAGO, V130, P617; MOMBURG F, 1987, CANCER RES, V47, P2883; MORITA M, 1994, SURGERY, V116, P1; OSULLIVAN GC, 1995, GASTROENTEROLOGY, V109, P1535, DOI 10.1016/0016-5085(95)90641-X; Paget S., 1889, LANCET, V133, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; RAYMOND WA, 1989, PATHOLOGY, V21, P11, DOI 10.3109/00313028909059522; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SIEWERT JR, 1992, CHIRURG, V63, P693; Thorban S, 1996, JNCI-J NATL CANCER I, V88, P1222, DOI 10.1093/jnci/88.17.1222; VOGEL SB, 1995, ANN SURG, V221, P685, DOI 10.1097/00000658-199506000-00008; WATANABE H, 1992, CHIRURG, V63, P689	34	305	332	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1188	1194		10.1056/NEJM199710233371702	http://dx.doi.org/10.1056/NEJM199710233371702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337377	Bronze			2022-12-01	WOS:A1997YB71800002
J	Cresswell, JL; Barker, DJP; Osmond, C; Egger, P; Phillips, DIW; Fraser, RB				Cresswell, JL; Barker, DJP; Osmond, C; Egger, P; Phillips, DIW; Fraser, RB			Fetal growth, length of gestation, and polycystic ovaries in adult life	LANCET			English	Article							DISEASE; WOMEN; HYPERANDROGENISM; DYSREGULATION; SECRETION; ENDOCRINE; FEATURES; HORMONE	Background Polycystic ovaries are a common disorder associated with menstrual irregularities, subfertility, hirsutism, acne, and a range of endocrine abnormalities, including high concentrations of plasma luteinising hormone (LH) and excessive androgen production. The pathophysiology is not understood. We investigated whether the disorder originates during intrauterine life. Methods We examined 235 women aged 40-42 years who were born in Sheffield, UK. We related the prevalence of polycystic ovaries and the plasma concentrations of gonadotropin hormones and androgens to the women's body size at birth, and the length of gestation. Findings 49 (21%) of the women had polycystic ovaries. We defined two groups of women with the disorder, which correspond to the two groups that commonly present clinically. The first group comprised obese women who were androgenised, with higher than normal concentrations of plasma LH and testosterone. These women had above-average birthweight and were born to overweight mothers. The second group comprised women of normal weight who had high plasma LH, but normal testosterone concentrations. These women were born after term (40 weeks' gestation). Interpretation The two common forms of polycystic ovary syndrome have different origins in intrauterine life. Obese, hirsute women with polycystic ovaries have higher than normal ovarian secretion of androgens that are associated with high birthweight and maternal obesity. Thin women with polycystic ovaries have altered hypothalamic control of LH release resulting from prolonged gestation.	UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SHEFFIELD, NO GEN HOSP, DEPT OBSTET & GYNAECOL, CTR CLIN SCI, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND	University of Southampton; Northern General Hospital; University of Sheffield			fraser, robert b/B-9856-2009	Osmond, Clive/0000-0002-9054-4655				ADAMS J, 1985, LANCET, V2, P1375; BARKER DJP, 1995, LANCET, V345, P1087, DOI 10.1016/S0140-6736(95)90821-8; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P62, DOI 10.1210/endo-68-1-62; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BURGHEN GA, 1980, J CLIN ENDOCR METAB, V50, P113, DOI 10.1210/jcem-50-1-113; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; CONWAY GS, 1992, CLIN ENDOCRINOL, V37, P119, DOI 10.1111/j.1365-2265.1992.tb02295.x; Dunaif Andrea, 1993, P301; EHRMANN DA, 1995, ENDOCR REV, V16, P322, DOI 10.1210/er.16.3.322; ERICKSON GF, 1979, J CLIN ENDOCR METAB, V49, P514, DOI 10.1210/jcem-49-4-514; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; FIORE M, 1988, CLIN CHEM, V34, P1726; FRANKS S, 1985, CLIN OBSTET GYNAECOL, V12, P605; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Gruenwald P, 1974, CIBA F S, V27, P3; HAGUE WM, 1988, CLIN ENDOCRINOL, V29, P593, DOI 10.1111/j.1365-2265.1988.tb03707.x; PASQUALI R, 1993, CLIN ENDOCRINOL, V39, P1, DOI 10.1111/j.1365-2265.1993.tb01744.x; Pfeiffer CA, 1936, AM J ANAT, V58, P195, DOI 10.1002/aja.1000580112; Phillips DIW, 1996, DIABETOLOGIA, V39, P1119; POLSON DW, 1988, LANCET, V1, P870; ROSENFIELD RL, 1990, FERTIL STERIL, V53, P785; SAAL FSV, 1980, SCIENCE, V208, P597, DOI 10.1126/science.7367881; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	25	163	169	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	1997	350	9085					1131	1135		10.1016/S0140-6736(97)06062-5	http://dx.doi.org/10.1016/S0140-6736(97)06062-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343501				2022-12-01	WOS:A1997YB19900011
J	Feldman, RMR; Correll, CC; Kaplan, KB; Deshaies, RJ				Feldman, RMR; Correll, CC; Kaplan, KB; Deshaies, RJ			A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; ACTIVATING ENZYME; CRYSTAL-STRUCTURE; PROTEIN LIGASE; YEAST; DEGRADATION; PATHWAY	In S. cerevisiae, the G1/S transition requires Cdc4p, Cdc34p, Cdc53p, Skp1p, and the Cln/Cdc28p cyclin-dependent kinase (Cdk). These proteins are thought to promote the proteolytic inactivation of the S-phase Cdk inhibitor Sic1p. We show here that Cdc4p, Cdc53p, and Skp1p assemble into a ubiquitin ligase complex named SCFCdc4p. When mixed together, SCFCdc4p sub- units, E1 enzyme, the E2 enzyme Cdc34p, and ubiquitin are sufficient to reconstitute ubiquitination of Cdk-phosphorylated Sic1p. Phosphorylated Sic1p substrate is specifically targeted for ubiquitination by binding to a Cdc4p/Skp1p subcomplex. Taken together, these data illuminate the molecular basis for the G1/S transition in budding yeast and suggest a general mechanism for phosphorylation-targeted ubiquitination in eukaryotes.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	California Institute of Technology; Massachusetts Institute of Technology (MIT)			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354	NIGMS NIH HHS [R01 GM52466-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HULBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KIPREOS E, 1995, 10 INT C EL M SUMM, P83; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, METHOD ENZYMOL, V283, P366; VERMA R, 1997, IN PRESS SCIENCE; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	700	725	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	1997	91	2					221	230		10.1016/S0092-8674(00)80404-3	http://dx.doi.org/10.1016/S0092-8674(00)80404-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346239	Bronze			2022-12-01	WOS:A1997YC35000009
J	WyssCoray, T; Masliah, E; Mallory, M; McConlogue, L; JohnsonWood, K; Lin, C; Mucke, L				WyssCoray, T; Masliah, E; Mallory, M; McConlogue, L; JohnsonWood, K; Lin, C; Mucke, L			Amyloidogenic role of cytokine TGF-beta 1 in transgenic mice and in Alzheimer's disease	NATURE			English	Article							GROWTH-FACTOR-BETA; E EPSILON-4 ALLELE; APOLIPOPROTEIN-E; EXTRACELLULAR-MATRIX; PRECURSOR PROTEIN; HEAD-INJURY; ANGIOPATHY; PLAQUES; DEPOSITION; BRAINS	Deposition of amyloid-beta peptide in the central nervous system is a hallmark of Alzheimer's disease and a possible cause of neurodegeneration(1-3). The factors that initiate or promote deposition of amyloid-beta peptide are not known. The transforming growth factor TGF-beta 1 plays a central role in the response of the brain to injury(4,5), and increased TGF-beta 1 has been found in the central nervous system of patients with Alzheimer's disease(6-8). Here we report that TGF-beta 1 induces amyloid-beta deposition in cerebral blood vessels and meninges of aged transgenic mice overexpressing this cytokine from astrocytes. Co-expression of TGF-beta 1 in transgenic mice overexpressing amyloid-precursor protein, which develop Alzheimer's like patholog(9-11), accelerated the deposition of amyloid-beta peptide. More TGF-beta 1 messenger RNA was present in post-mortem brain tissue of Alzheimer's patients than in controls, the levels correlating strongly with amyloid-beta deposition in the damaged cerebral blood vessels of patients with cerebral amyloid angiopathy, These results indicate that overexpression of TGF-beta 1 may initiate or promote amyloidogenesis in Alzheimer's disease and in experimental models and so may be a risk factor for developing Alzheimer's disease.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego	WyssCoray, T (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE MOL NEUROBIOL PROGRAM,SAN FRANCISCO,CA 94141, USA.		Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831; Mucke, Lennart/0000-0001-6256-9559				CHAO CC, 1994, CLIN DIAGN LAB IMMUN, V1, P109, DOI 10.1128/CDLI.1.1.109-110.1994; FILLIT H, 1995, LAB INVEST, V72, P249; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAAN J, 1994, DEMENTIA, V5, P210, DOI 10.1159/000106725; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; ITOH Y, 1993, J NEUROL SCI, V116, P135, DOI 10.1016/0022-510X(93)90317-R; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; PERESS NS, 1995, J NEUROPATH EXP NEUR, V54, P802, DOI 10.1097/00005072-199511000-00007; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Terry Robert D., 1994, P179; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WYSSCORAY T, 1995, AM J PATHOL, V147, P53	30	337	353	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					603	606		10.1038/39321	http://dx.doi.org/10.1038/39321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335500				2022-12-01	WOS:A1997YA00800060
J	Cox, GA; Lutz, CM; Yang, CL; Biemesderfer, D; Bronson, RT; Fu, A; Aronson, PS; Noebels, JL; Frankel, WN				Cox, GA; Lutz, CM; Yang, CL; Biemesderfer, D; Bronson, RT; Fu, A; Aronson, PS; Noebels, JL; Frankel, WN			Sodium/hydrogen exchanger gene defect in slow-wave epilepsy mutant mice	CELL			English	Article							RAT NA/H EXCHANGER; NA+/H+ ANTIPORTER; MOLECULAR-CLONING; ABSENCE SEIZURES; PH REGULATION; MOUSE; EXPRESSION; ISOFORM; NHE-1; CELLS	The ''housekeeping'' sodium/hydrogen exchanger, NHE1, mediates the electroneutral 1:1 exchange of Na+ and H+ across the plasma membrane. NHE1 is ubiquitous and is studied extensively for regulation of pH(i), cell volume, and response to growth factors. We describe a spontaneous mouse mutant, slow-wave epilepsy, (swe), with a neurological syndrome including ataxia and a unique epilepsy phenotype consisting of 3/sec absence and tonic-clonic seizures. swe was fine-mapped on Chromosome 4 and identified as a null allele of Nhe1. Mutants show selective neuronal death in the cerebellum and brainstem but otherwise are healthy. This first example of a disease-causing mutation in an Nhe gene provides a new tool for studying the delicate balance of neuroexcitability and cell survival within the CNS.	JACKSON LAB, BAR HARBOR, ME 04609 USA; YALE UNIV, SCH MED, NEW HAVEN, CT 06520 USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA; BAYLOR COLL MED, INST MOL GENET, DEPT NEUROL, DIV NEUROSCI, HOUSTON, TX 77030 USA	Jackson Laboratory; Yale University; Tufts University; United States Department of Agriculture (USDA); Baylor College of Medicine				Noebels, Jeffrey/0000-0002-2887-0839	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031348, R01NS033396, R37NS031348] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31348, NS33396, NS29702] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DJ, 1981, NEUROLOGY, V31, P1175, DOI 10.1212/WNL.31.9.1175; ANDERSON VE, 1991, EPILEPSY RES, P89; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bartolomei F, 1997, EUR NEUROL, V37, P169, DOI 10.1159/000117429; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; DOOSE H, 1973, EPILEPSIA, V14, P57, DOI 10.1111/j.1528-1157.1973.tb03942.x; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANKEL WN, 1995, MAMM GENOME, V6, P830, DOI 10.1007/BF00292431; HILDEBRANDT F, 1991, BIOCHIM BIOPHYS ACTA, V1129, P105, DOI 10.1016/0167-4781(91)90221-7; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; KAUSHIK N, 1994, MAMM GENOME, V5, P688, DOI 10.1007/BF00426074; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LENNOX WG, 1951, JAMA-J AM MED ASSOC, V146, P529, DOI 10.1001/jama.1951.03670060005002; LOISEAU P, 1995, EPILEPSIA, V36, P1182, DOI 10.1111/j.1528-1157.1995.tb01060.x; Ma E, 1997, NEUROSCIENCE, V79, P591, DOI 10.1016/S0306-4522(96)00674-4; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Maricich SM, 1997, J NEUROSCI, V17, P3675; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Neufeld MY, 1996, MOVEMENT DISORD, V11, P283, DOI 10.1002/mds.870110312; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Noebels JL, 1996, NEURON, V16, P241, DOI 10.1016/S0896-6273(00)80042-2; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Ottman R, 1997, AM J HUM GENET, V60, P667; Pasternack M, 1996, NEUROPHARMACOLOGY, V35, P1279, DOI 10.1016/S0028-3908(96)00075-5; PATEL VM, 1987, J CLIN NEUROPHYSIOL, V4, P101, DOI 10.1097/00004691-198704000-00001; Pathak BG, 1996, GENOMICS, V31, P261, DOI 10.1006/geno.1996.0045; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Pizzonia JH, 1996, J NEUROSCI RES, V44, P191, DOI 10.1002/(SICI)1097-4547(19960415)44:2<191::AID-JNR12>3.0.CO;2-9; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; RUTHERFORD PA, 1997, IN PRESS EXP NEPHROL; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHWARTZ WJ, 1978, J COMP NEUROL, V177, P335, DOI 10.1002/cne.901770210; SPRING J, 1994, GENOMICS, V21, P597, DOI 10.1006/geno.1994.1319; STERIADE M, 1995, J NEUROSCI, V15, P623; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Tombaugh GC, 1997, J NEUROPHYSIOL, V77, P639, DOI 10.1152/jn.1997.77.2.639; Trapp S, 1996, J PHYSIOL-LONDON, V496, P695, DOI 10.1113/jphysiol.1996.sp021720; TSE CM, 1992, J BIOL CHEM, V267, P9340; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WYLLIE E, 1993, TREATMENT EPILEPSY P	63	226	229	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	1997	91	1					139	148		10.1016/S0092-8674(01)80016-7	http://dx.doi.org/10.1016/S0092-8674(01)80016-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335342	hybrid			2022-12-01	WOS:A1997XZ80900016
J	Madhani, HD; Styles, CA; Fink, GR				Madhani, HD; Styles, CA; Fink, GR			MAP kinases with distinct inhibitory functions impart signaling specificity during yeast differentiation	CELL			English	Article							PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; PROTEIN-KINASES; INVASIVE GROWTH; SHUTTLE VECTORS; FUS3; CASCADE; KSS1; TRANSDUCTION	Filamentous invasive growth of S. cerevisiae requires multiple elements of the mitogen-activated protein kinase (MAPK) signaling cascade that are also components of the mating pheromone response pathway. Here we show that, despite sharing several constituents, the two pathways use different MAP kinases. The Fus3 MAPK regulates mating, whereas the Kss1 MAPK regulates filamentation and invasion; Remarkably, in addition to their kinase-dependent activation functions, Kss1 and Fus3 each have a distinct kinase-independent inhibitory function. Kss1 inhibits the filamentation pathway by interacting with its target transcription factor Ste12. Fus3 has a different inhibitory activity that prevents the inappropriate activation of invasion by the pheromone response pathway. In the absence of Fus3, there is erroneous crosstalk in which mating pheromone now activates filamentation-specific gene expression using the Kss1 MAPK.			Madhani, HD (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Madhani, Hiten/0000-0001-7400-6657				Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHENEVERT J, 1994, GENETICS, V136, P1287; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; Guthrie C, 1991, GUIDE YEAST GENETICS; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGUCHI R, 1989, PCR TECHNOLOGY; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; PRINTEN JA, 1994, GENETICS, V138, P609; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	43	363	369	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					673	684		10.1016/S0092-8674(00)80454-7	http://dx.doi.org/10.1016/S0092-8674(00)80454-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393860	Bronze			2022-12-01	WOS:A1997YH96000014
J	Palmeirim, I; Henrique, D; IshHorowicz, D; Pourquie, O				Palmeirim, I; Henrique, D; IshHorowicz, D; Pourquie, O			Avian hairy gene expression identifies a molecular clock linked to vertebrate segmentation and somitogenesis	CELL			English	Article							LOOP-HELIX REPRESSOR; CHICK-EMBRYO; SOMITE FORMATION; DROSOPHILA; EVOLUTION; PROTEINS; HOMOLOG; EMBRYOGENESIS; TRANSCRIPTION; NEUROGENESIS	We have identified and characterized c-hairy1, an avian homolog of the Drosophila segmentation gene, hairy. c-hairy1 is strongly expressed in the presomitic mesoderm, where its mRNA exhibits cyclic waves of expression whose temporal periodicity corresponds to the formation time of one somite (90 min). The apparent movement of these waves is due to coordinated pulses of c-hairy1 expression, not to cell displacement along the anteroposterior axis, nor to propagation of an activating signal. Rather, the rhythmic c-hairy mRNA expression is an autonomous property of the paraxial mesoderm. These results provide molecular evidence for a developmental clock linked to segmentation and somitogenesis of the paraxial mesoderm, and support the possibility that segmentation mechanisms used by invertebrates and vertebrates have been conserved.	DEV BIOL INST MARSEILLE IBDM,LGPD,CNRS,UMR 6545,F-13288 MARSEILLE 9,FRANCE; CNRS,INST EMBRYOL CELLULAIRE & MOL,F-94736 NOGENT SUR MARNE,FRANCE; COLL FRANCE,F-94736 NOGENT SUR MARNE,FRANCE; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Cancer Research UK			Henrique, Domingos M/E-5460-2010; Palmeirim, Isabel/F-4522-2012; Pourquié, Olivier/CAJ-5443-2022	Henrique, Domingos M/0000-0001-8869-1894; Pourquié, Olivier/0000-0001-5189-1227; Palmeirim, Isabel/0000-0003-2282-7829; Ish-Horowicz, David/0000-0001-5684-7129				BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; DAVIDSON D, 1988, DEVELOPMENT, V104, P221; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DeRobertis EM, 1997, NATURE, V387, P25, DOI 10.1038/387025a0; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holland LZ, 1997, DEVELOPMENT, V124, P1723; ISHHOROWICZ D, 1985, COLD SPRING HARB SYM, V50, P135, DOI 10.1101/SQB.1985.050.01.019; ISPIZUABELMONTE JC, 1993, CELL, V74, P645; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; Kimmel CB, 1996, TRENDS GENET, V12, P329, DOI 10.1016/S0168-9525(96)80001-1; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MEIER S, 1984, CELL DIFFER DEV, V14, P235, DOI 10.1016/0045-6039(84)90012-5; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; MENKES B, 1977, BRIT SOC DEV BIOL S, V3, P405; Muller M, 1996, DEVELOPMENT, V122, P2071; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; OKA C, 1995, DEVELOPMENT, V121, P3291; PACKARD DS, 1976, DEV BIOL, V53, P36, DOI 10.1016/0012-1606(76)90207-4; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PRIMMETT DRN, 1989, DEVELOPMENT, V105, P119; SANDER K, 1988, DEVELOPMENT, V104, P112; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; STERN CD, 1988, DEVELOPMENT, V104, P231; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; TAM PPL, 1986, SOMITES DEV EMBRYOS, P17; TAUTZ D, 1995, TRENDS GENET, V11, P23, DOI 10.1016/S0168-9525(00)88982-9; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WEISBLAT DA, 1994, CURR TOP DEV BIOL, V29, P101, DOI 10.1016/S0070-2153(08)60548-7	42	699	717	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					639	648		10.1016/S0092-8674(00)80451-1	http://dx.doi.org/10.1016/S0092-8674(00)80451-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393857	Bronze			2022-12-01	WOS:A1997YH96000011
J	Paradise, JL				Paradise, JL			Short-course antimicrobial treatment for acute otitis media - Not best for infants and young children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CLINICAL-TRIAL; DOUBLE-BLIND; DECONGESTANT-ANTIHISTAMINE; PENICILLIN TREATMENT; AMOXICILLIN; EFFICACY; CEFTRIAXONE; THERAPY; EFFUSION; 3-DAY		UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BAIN J, 1985, BRIT MED J, V291, P1243, DOI 10.1136/bmj.291.6504.1243; Barnett ED, 1997, PEDIATRICS, V99, P23, DOI 10.1542/peds.99.1.23; Bernstein J M, 1995, J RESP DIS, V16, P88; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CARLIN SA, 1991, J PEDIATR-US, V118, P178, DOI 10.1016/S0022-3476(05)80479-2; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; CHAMBERLAIN JM, 1994, CLIN PEDIATR, V33, P642, DOI 10.1177/000992289403301101; CUNNINGHAM AS, 1994, CONT PEDIATR, V11, P17; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; Gooch WM, 1996, PEDIATR INFECT DIS J, V15, P157, DOI 10.1097/00006454-199602000-00013; GREEN SM, 1993, PEDIATRICS, V91, P23; HARSTEN G, 1989, ACTA OTO-LARYNGOL, V108, P253, DOI 10.3109/00016488909125525; HATHAWAY TJ, 1994, PEDIATRICS, V94, P143; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P14, DOI 10.1097/00006454-198801000-00005; Hoberman A, 1996, PEDIATR INFECT DIS J, V15, P955, DOI 10.1097/00006454-199610000-00034; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, P463, DOI 10.1097/00006454-199705000-00002; INGVARSSON L, 1982, ACTA OTO-LARYNGOL, V94, P283, DOI 10.3109/00016488209128915; JONES R, 1986, J ROY COLL GEN PRACT, V36, P356; KALEIDA PH, 1991, PEDIATRICS, V87, P466; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NELSON CR, 1993, DRUG UTILIZATION OFF; NELSON WL, 1987, 27 INT C ANT AG CHEM; PARADISE JL, 1987, J PEDIATR-US, V111, P948, DOI 10.1016/S0022-3476(87)80226-3; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; PARADISE JL, 1995, PEDIATRICS, V96, P712; PARADISE JL, 1995, PEDIATR INFECT DIS J, V14, P429, DOI 10.1097/00006454-199505001-00005; PUCZYNSKI MS, 1987, LARYNGOSCOPE, V97, P16; SCHAPPERT SM, 1992, OFFICE VISITS OTITIS; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VARSANO I, 1988, CHEMOTHERAPY, V34, P39, DOI 10.1159/000238646	35	53	54	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1640	1642		10.1001/jama.278.20.1640	http://dx.doi.org/10.1001/jama.278.20.1640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388072				2022-12-01	WOS:A1997YG85900001
J	Greenfield, EM; Goldberg, VM				Greenfield, EM; Goldberg, VM			Genetic determination of bone density	LANCET			English	Editorial Material							OSTEOPOROSIS; ALLELES; VIEW				Greenfield, EM (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT ORTHOPAED, CLEVELAND, OH 44106 USA.							BEAMER W, 1997, J BONE MINER RES, V12, P174; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; Gong YQ, 1996, AM J HUM GENET, V59, P146; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; Lewallen DG, 1995, AAOS INSTR COURS LEC, V44, P287; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; Ralston SH, 1997, SCAND J CLIN LAB INV, V57, P114; Rogers J, 1997, ANN RHEUM DIS, V56, P85, DOI 10.1136/ard.56.2.85; Vezyroglou G, 1996, J RHEUMATOL, V23, P672	9	23	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1263	1264		10.1016/S0140-6736(05)62468-3	http://dx.doi.org/10.1016/S0140-6736(05)62468-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357401				2022-12-01	WOS:A1997YD68900003
J	Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B				Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B			Hormone replacement therapy and risk of non-fatal stroke	LANCET			English	Article							POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; FOLLOW-UP; WOMEN; USERS; COPENHAGEN; MORTALITY; COHORT	Background The effect of postmenopausal hormone replacement therapy (HRT) on the risk of subtypes of stroke is as yet unclear. To investigate the effect of oestrogen and combined oestrogen-progestagen therapy on the risk of nonfatal haemorrhagic and thromboembolic stroke, we carried out a case-control study. Methods From the Danish National Patient Register we identified all Danish women aged 45-64 years who had a non-fatal, first-ever cerebrovascular attack during 1990-92. Two age-matched controls were randomly selected for each case from the Danish National Person Register. Important correlates of hormone use and stroke, on which information was obtained from postal questionnaires, were controlled for by multivariate analyses based on log-linear graphical models. The analyses included data on 1422 cases classified in four subtypes of stroke (160 subarachnoid haemorrhage, 95 intracerebral haemorrhage, 846 thromboembolic infarction, 321 transient ischaemic attack) and 3171 controls. Findings After adjustment for confounding variables and correction for the trend in sales of HRT preparations, no significant associations were detected between current use of unopposed oestrogen replacement therapy and non-fatal subarachnoid haemorrhage (odds ratio 0.52 [95% CI 0.23-1.22]), intracerebral haemorrhage (0.15 [0.02-1.09]), or thromboembolic infarction (1.16 [0.86-1.58]), respectively, compared with never use. Current use of combined oestrogen-progestagen replacement therapy had no significant influence on the risk of subarachnoid haemorrhage (1.22 [0.79-1.89]), intracerebral haemorrhage (1.17 [0.64-2.13]), or thromboembolic infarction (1.17 [0.92-1.47]). A significantly increased incidence of transient ischaemic attacks among former users of HRT and among current users of unopposed oestrogen may to some extent be explained by selection-HRT users being more aware of symptoms than non-users. Interpretation Unopposed oestrogen and combined oestrogen-progestagen replacement therapy have no influence on the risk of non-fatal thromboembolic or haemorrhagic stroke in women aged 45-64 years.	UNIV COPENHAGEN, INST SOCIOL, COPENHAGEN, DENMARK; HERLEV HOSP, DEPT OBSTET & GYNAECOL, DK-2730 HERLEV, DENMARK	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Pedersen, AT (corresponding author), UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT OBSTET & GYNAECOL 537, KETTEGARDS ALLEE 30, DK-2650 HVIDOVRE, DENMARK.							[Anonymous], [No title captured]; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DARROCH JN, 1980, ANN STAT, V8, P522, DOI 10.1214/aos/1176345006; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Falkeborn M, 1996, EPIDEMIOLOGY, V7, P67, DOI 10.1097/00001648-199601000-00012; FEINBERG WM, 1994, CIRCULATION, V89, P2950, DOI 10.1161/01.CIR.89.6.2950; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KLEIN JP, 1995, STAT MED, V14, P1265, DOI 10.1002/sim.4780141202; LINDEGAARD O, 1993, BRIT MED J, V306, P956; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; ROSENBERG SH, 1980, WESTERN J MED, V133, P292; SALOMAA V, 1995, ARTERIOSCL THROM VAS, V15, P1549, DOI 10.1161/01.ATV.15.10.1549; SPEROFF L, 1996, EUR MENOPAUSE J, V3, P151; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WERMUTH N, 1990, J ROY STAT SOC B MET, V52, P21; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; ZHANG XH, 1995, STROKE, V26, P1774, DOI 10.1161/01.STR.26.10.1774	33	122	122	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1277	1283		10.1016/S0140-6736(97)06005-4	http://dx.doi.org/10.1016/S0140-6736(97)06005-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357407				2022-12-01	WOS:A1997YD68900009
J	Nelsen, SF; Ismagilov, RF; Trieber, DA				Nelsen, SF; Ismagilov, RF; Trieber, DA			Adiabatic electron transfer: Comparison of modified theory with experiment	SCIENCE			English	Article							CHARGE RECOMBINATION; DISTANCE DEPENDENCE; SOLVENT DEPENDENCE; ACCEPTOR COMPOUNDS; RADICAL-CATION; BIS(HYDRAZINE); SEPARATION; MOLECULES; COMPLEXES; BRIDGES	The radical cations of properly designed bishydrazines allow comparison of observed and calculated electron transfer rate constants. These compounds have rate constants small enough to be measured by dynamic electron spin resonance spectroscopy and show charge transfer bands corresponding to vertical excitation from the energy well for the charge occurring upon one hydrazine unit to that for the electron-transferred species. Analysis of the data for all six compounds studied indicates that the shape of the adiabatic surface on which electron transfer occurs can be obtained from the charge transfer band accurately enough to successfully predict the electron transfer rate constant and that explicit tunneling corrections are not required for these compounds.			Nelsen, SF (corresponding author), UNIV WISCONSIN,DEPT CHEM,1101 UNIV AVE,MADISON,WI 53706, USA.							[Anonymous], 1967, PROG INORG CHEM, DOI DOI 10.1002/9780470166093.CH7; Barbara PF, 1996, J PHYS CHEM-US, V100, P13148, DOI 10.1021/jp9605663; BIXON M, 1994, J AM CHEM SOC, V116, P7349, DOI 10.1021/ja00095a044; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; CORTES J, 1994, J PHYS CHEM-US, V98, P2527, DOI 10.1021/j100061a006; CREUTZ C, 1983, PROG INORG CHEM, V30, P1, DOI 10.1002/9780470166314.ch1; CREUTZ C, 1994, J PHOTOCH PHOTOBIO A, V82, P47, DOI 10.1016/1010-6030(94)02013-2; DOORN SK, 1989, J AM CHEM SOC, V111, P1142, DOI 10.1021/ja00185a062; GOULD IR, 1994, J AM CHEM SOC, V116, P8188, DOI 10.1021/ja00097a028; GOULD IR, 1993, CHEM PHYS, V176, P439, DOI 10.1016/0301-0104(93)80253-6; HUSH NS, 1985, COORDIN CHEM REV, V64, P135, DOI 10.1016/0010-8545(85)80047-3; HUSH NS, 1985, CHEM PHYS LETT, V117, P8, DOI 10.1016/0009-2614(85)80394-8; JORTNER J, 1988, J CHEM PHYS, V88, P167, DOI 10.1063/1.454632; JORTNER J, 1975, J CHEM PHYS, V63, P4358; KROON J, 1993, J PHYS CHEM-US, V97, P5065, DOI 10.1021/j100121a036; KROON J, 1991, ANGEW CHEM INT EDIT, V30, P1358, DOI 10.1002/anie.199113581; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEYERS AB, 1996, CHEM REV, V96, P911; Nelsen SF, 1996, J AM CHEM SOC, V118, P2047, DOI 10.1021/ja952539g; Nelsen SF, 1997, J AM CHEM SOC, V119, P6863, DOI 10.1021/ja963415m; NELSEN SF, 1993, J AM CHEM SOC, V115, P12276, DOI 10.1021/ja00079a007; NELSEN SF, 1994, J AM CHEM SOC, V116, P1589, DOI 10.1021/ja00083a062; Nelsen SF, 1996, J AM CHEM SOC, V118, P6313, DOI 10.1021/ja960500l; NELSEN SF, IN PRESS J AM CHEM S; OEVERING H, 1987, J AM CHEM SOC, V109, P3258, DOI 10.1021/ja00245a014; OEVERING H, 1989, TETRAHEDRON, V45, P4751, DOI 10.1016/S0040-4020(01)85150-4; PADDONROW MN, 1988, J PHYS CHEM-US, V92, P6958, DOI 10.1021/j100335a024; Prassides K., 1991, MIXED VALENCY SYSTEM; SUTIN N, 1983, PROG INORG CHEM, V30, P441, DOI 10.1002/9780470166314.ch9; WARMAN JM, 1991, J PHYS CHEM-US, V95, P1979, DOI 10.1021/j100158a018; WASLELEWSKI MR, 1992, CHEM REV, V92, P435	31	121	121	3	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					846	849		10.1126/science.278.5339.846	http://dx.doi.org/10.1126/science.278.5339.846			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346480	Green Accepted			2022-12-01	WOS:A1997YD47900042
J	Luh, FY; Archer, SJ; Domaille, PJ; Smith, BO; Owen, D; Brotherton, DH; Raine, ARC; Xu, X; Brizuela, L; Brenner, SL; Laue, ED				Luh, FY; Archer, SJ; Domaille, PJ; Smith, BO; Owen, D; Brotherton, DH; Raine, ARC; Xu, X; Brizuela, L; Brenner, SL; Laue, ED			Structure of the cyclin-dependent kinase inhibitor p19(Ink4d)	NATURE			English	Article							FAMILIAL MELANOMA; LARGER PROTEINS; TUMOR; CDK4; P16(INK4); NMR; SPECTROSCOPY; ALLELES; ANKYRIN; P19	In cancer, the biochemical pathways that are dominated by the two tumour-suppressor proteins, p53 and Rb, are the most frequently disrupted. Cyclin D-dependent kinases phosphorylate Rb to control its activity and they are, in turn, specifically inhibited by the Ink4 family of cyclin-dependent kinase inhibitors (CDKIs) which cause arrest at the G1 phase of the cell cycle. Mutations in Rb, cyclin D1, its catalytic subunit Cdk4, and the CDKI p16(Ink4a), which alter the protein or its level of expression, are all strongly implicated in cancer. This suggests that the Rb 'pathway' is of particular importance(1). Here we report the structure of the p19(Ink4d) protein, determined by NMR spectroscopy(2-4). The structure indicates that most mutations to the p16(Ink4a) gene, which result in loss of function, are due to incorrectly folded and/or insoluble protein(5). We propose a model for the interaction of Ink4 proteins with D-type cyclin-Cdk4/6 complexes that might provide a basis for the design of therapeutics against cancer.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CTR MOL RECOGNIT, CAMBRIDGE CB2 1QW, ENGLAND; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; MITOTIX INC, CAMBRIDGE, MA 02139 USA	University of Cambridge; DuPont			; Smith, Brian/J-1899-2015	Laue, Ernest/0000-0002-7476-4148; Smith, Brian/0000-0003-3363-4168; Luh, Frederick/0000-0001-5180-8489	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Clowes Robin T., 1995, Current Opinion in Biotechnology, V6, P81, DOI 10.1016/0958-1669(95)80013-1; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Kalus W, 1997, FEBS LETT, V401, P127, DOI 10.1016/S0014-5793(96)01465-2; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Parry D, 1996, MOL CELL BIOL, V16, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith BO, 1996, J BIOMOL NMR, V8, P360, DOI 10.1007/BF00410335; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WICK ST, 1995, ONCOGENE, V11, P2013; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YANG R, 1995, CANCER RES, V55, P2503; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734	30	89	92	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					999	1003		10.1038/40202	http://dx.doi.org/10.1038/40202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353127				2022-12-01	WOS:A1997YD29900063
J	Yang, DD; Kuan, CY; Whitmarsh, AJ; Rincon, M; Zheng, TS; Davis, RJ; Rakic, P; Flavell, RA				Yang, DD; Kuan, CY; Whitmarsh, AJ; Rincon, M; Zheng, TS; Davis, RJ; Rakic, P; Flavell, RA			Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene	NATURE			English	Article							EXCITATORY AMINO-ACIDS; KAINIC ACID; NERVOUS-SYSTEM; C-JUN; BRAIN-DAMAGE; KINASE; NEUROTOXICITY; GLUTAMATE; PATHWAY; SEIZURE	Excitatory amino acids induce both acute membrane depolarization and latent cellular toxicity, which often leads to apoptosis in many neurological disorders(1,2). Recent studies indicate that glutamate toxicity may involve the c-Jun amino-terminal kinase (JNK) group of mitogen-activated protein (MAP) kinases(3-5). One member of the JNK family, Jnk3, may be required for stress-induced neuronal apoptosis, as it is Selectively expressed in the nervous system(6,7). Here we report that disruption of the gene encoding Jnk3 in mice caused the mice to be resistant to the excitotoxic glutamate-receptor agonist kainic acid: they showed a reduction in seizure activity and hippocampal neuron apoptosis was prevented. Although application of kainic add imposed the same level of noxious stress, the phosphorylation of c-Jun and the transcriptional activity of the AP-1 transcription factor complex were markedly reduced in the mutant mice. These data indicate that the observed neuroprotection is due to the extinction of a Jnk3-mediated signalling, pathway, which is an important component in the pathogenesis of glutamate neurotoxicity.	YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA; UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV VERMONT, DEPT MED, IMMUNOBIOL PROGRAM, BURLINGTON, VT 05405 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont				Whitmarsh, Alan/0000-0003-1184-6610				BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BERGER M, 1983, NEUROSCI LETT, V39, P237, DOI 10.1016/0304-3940(83)90306-3; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FERKANY JW, 1984, NATURE, V308, P561, DOI 10.1038/308561a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; KASOF GM, 1995, J NEUROSCI, V15, P4238; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	30	1081	1140	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					865	870		10.1038/39899	http://dx.doi.org/10.1038/39899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349820				2022-12-01	WOS:A1997YC14800061
J	Malagnac, F; Wendel, B; Goyon, C; Faugeron, G; Zickler, D; Rossignol, JL; NoyerWeidner, M; Vollmayr, P; Trautner, TA; Walter, J				Malagnac, F; Wendel, B; Goyon, C; Faugeron, G; Zickler, D; Rossignol, JL; NoyerWeidner, M; Vollmayr, P; Trautner, TA; Walter, J			A gene essential for de novo methylation and development in ascobolus reveals a novel type of eukaryotic DNA methyltransferase structure	CELL			English	Article							CYTOSINE METHYLTRANSFERASE; ARABIDOPSIS-THALIANA; HOST DEFENSE; IMMERSUS; CELLS; CDNA; EXPRESSION; TRANSFORMATION; PURIFICATION; INACTIVATION	Molecular mechanisms determining methylation patterns in eukaryotic genomes still remain unresolved. We have characterized, in Ascobolus, a gene for de novo methylation. This novel eukaryotic gene, masc1, encodes a protein that has all motifs of the catalytic domain of eukaryotic C5-DNA-methyltransferases but is unique in that it lacks a regulatory N-terminal domain. The disruption of masc1 has no effect on viability or methylation maintenance but prevents the de novo methylation of DNA repeats, which takes place after fertilization, through the methylation induced premeiotically (MIP) process. Crosses between parents harboring the masc1 disruption are arrested at an early stage of sexual reproduction, indicating that the activity of Masc1, the product of the gene, is crucial in this developmental process.	MAX PLANCK INST MOL GENET,ABT TRAUTNER,D-14195 BERLIN,GERMANY; UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,F-91405 ORSAY,FRANCE	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Malagnac, Fabienne/0000-0003-1139-7691				Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; COLOT V, 1995, GENETICS, V141, P1299; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; FAUGERON G, 1989, GENE, V76, P109, DOI 10.1016/0378-1119(89)90013-9; FAUGERON G, 1990, GENETICS, V124, P585; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GOYON C, 1989, MOL CELL BIOL, V9, P2818, DOI 10.1128/MCB.9.7.2818; Goyon C, 1996, NUCLEIC ACIDS RES, V24, P3348, DOI 10.1093/nar/24.17.3348; Goyon C, 1996, MOL CELL BIOL, V16, P3054; GOYON C, 1994, J MOL BIOL, V240, P42, DOI 10.1006/jmbi.1994.1416; GRIFFITHS AJF, 1976, CAN J GENET CYTOL, V18, P35, DOI 10.1139/g76-005; GUNTHERT U, 1981, J BIOL CHEM, V256, P9340; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HAGEMANN AT, 1996, EPIGENETIC MECH GENE, P335; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KELLEHER JE, 1991, J MOL BIOL, V221, P431, DOI 10.1016/0022-2836(91)80064-2; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; Lei H, 1996, DEVELOPMENT, V122, P3195; Leonhardt H., 1993, DNA methylation: molecular biology and biological significance., P109; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; NOYERWEIDNER M, 1993, DNA METHYLATION MOL, P39; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2424; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; RHOUNIM L, 1994, CURR GENET, V26, P344, DOI 10.1007/BF00310499; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH SS, 1994, PROG NUCLEIC ACID RE, V49, P65; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	40	110	116	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					281	290		10.1016/S0092-8674(00)80410-9	http://dx.doi.org/10.1016/S0092-8674(00)80410-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346245	Bronze			2022-12-01	WOS:A1997YC35000015
J	Skowyra, D; Craig, KL; Tyers, M; Elledge, SJ; Harper, JW				Skowyra, D; Craig, KL; Tyers, M; Elledge, SJ; Harper, JW			F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex	CELL			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; G1 CYCLINS; DEGRADATION; INHIBITOR; KINASE; PROTEOLYSIS; ACTIVATION; PATHWAY; ENCODES	We have reconstituted the ubiquitination pathway for the Cdk inhibitor Sic1 using recombinant proteins. Skp1, Cdc53, and the F-box protein Cdc4 form a complex, SCFCdc4, which functions as a Sic1 ubiquitin-ligase (E3) in combination with the ubiquitin conjugating enzyme (E2) Cdc34 and E1. Cdc4 assembled with Skp1 functions as the receptor that selectively binds phosphorylated Sic1. Grr1, an F-box protein involved in Cln destruction, forms complexes with Skp1 and Cdc53 and binds phosphorylated Cln1 and Cln2, but not Sic1. Because the constituents of the SCF complex are members of protein families, SCFCdc4 in likely to serve as the prototype for a large class of E3s formed by combinatorial interactions of related family members. SCF complexes couple protein kinase signaling pathways to the control of protein abundance.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAM MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Tyers, Michael/ABE-3194-2021	Harper, Jeffrey/0000-0002-6944-7236	NIA NIH HHS [AG-11085] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HENHOZ S, 1997, IN PRESS GENES DEV; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LI F, 1997, IN PRESS EMBO J; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VISINTIN R, 1997, IN PRESS SCIENCE; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	42	1014	1042	0	52	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					209	219		10.1016/S0092-8674(00)80403-1	http://dx.doi.org/10.1016/S0092-8674(00)80403-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346238	Bronze			2022-12-01	WOS:A1997YC35000008
J	Baorto, DM; Gao, ZM; Malaviya, R; Dustin, ML; vanderMerwe, A; Lublin, DM; Abraham, SN				Baorto, DM; Gao, ZM; Malaviya, R; Dustin, ML; vanderMerwe, A; Lublin, DM; Abraham, SN			Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic	NATURE			English	Article							URINARY-TRACT INFECTIONS; ESCHERICHIA-COLI; TYPE-1 FIMBRIAE; ADHESION; PILI; IDENTIFICATION; COLONIZATION; ENDOCYTOSIS; BACTEREMIA; ACTIVATION	Strains of Escherichia coli persist within the human gut as normal commensals, but are frequent pathogens and can cause recurrent infection(1-3). Here we show that, in contrast to E. coli subjected to opsonic interactions stimulated by the host's immune response, E. coli that bind to the macrophage surface exclusively through the bacterial lectin FimH can survive inside the cell following phagocytosis. This viability is largely due to the attenuation of intracellular free-radical release and of phagosome acidification during FimH-mediated internalization, both of which are triggered by antibody-mediated internalization. This different processing of non-opsonized bacteria is supported by morphological evidence of tight-fitting phagosomes compared with looser, antibody-mediated phagosomes. We propose that non-opsonized FimH-expressing E. coli co-opt internalization of lipid-rich microdomains following binding to the FimH receptor, the glycosylphosphatidylinositol-linked protein CD48, because (1) the sterol-binding agents filipin, nystatin and methyl beta-cyclodextrin specifically block FimH-mediated internalization; (2) CD48 and the protein caveolin both accumulate on macrophage membranes surrounding bacteria; and (3) antibodies against CD48 inhibit FimH-mediated internalization. Our findings bring the traditionally extracellular E. coli into the realm of opportunistic intracellular parasitism and suggest how opportunistic infections with FimH-expressing enterobacteria could occur in a setting deprived of opsonizing antibodies.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND	Washington University (WUSTL); Washington University (WUSTL); University of Oxford			Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BERGER KH, 1994, METHOD CELL BIOL, V45, P247; BLUEB JL, 1995, BIOCHIM BIOPHYS ACTA, V1244, P79; BRAUNER A, 1994, J INFECTION, V28, P49, DOI 10.1016/S0163-4453(94)94130-0; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GBARAH A, 1993, INFECT IMMUN, V61, P1687, DOI 10.1128/IAI.61.5.1687-1693.1993; GOETZ MB, 1987, J INFECT DIS, V156, P229, DOI 10.1093/infdis/156.1.229; HAGBERG L, 1981, INFECT IMMUN, V31, P564, DOI 10.1128/IAI.31.2.564-570.1981; KEITH BR, 1990, INFECT IMMUN, V58, P3448, DOI 10.1128/IAI.58.10.3448-3454.1990; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KISIELIUS PV, 1989, INFECT IMMUN, V57, P1656, DOI 10.1128/IAI.57.6.1656-1662.1989; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LOCK R, 1990, INFECT IMMUN, V58, P37, DOI 10.1128/IAI.58.1.37-42.1990; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MAY AK, 1993, INFECT IMMUN, V61, P1667, DOI 10.1128/IAI.61.5.1667-1673.1993; OFEK I, 1995, ANNU REV MICROBIOL, V49, P239, DOI 10.1146/annurev.mi.49.100195.001323; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SAUKKONEN K, 1991, J EXP MED, V173, P1143, DOI 10.1084/jem.173.5.1143; SAUTER SL, 1993, J BIOL CHEM, V268, P15510; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SENECA H, 1981, J AM GERIATR SOC, V29, P359, DOI 10.1111/j.1532-5415.1981.tb01242.x; STURGILLKOSZYCK.S, 1994, SCIENCE, V263, P637; TEWARI R, 1993, J BIOL CHEM, V268, P3009; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	30	233	238	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					636	639		10.1038/39376	http://dx.doi.org/10.1038/39376			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335508				2022-12-01	WOS:A1997YA00800068
J	Zeidler, M; Stewart, GE; Barraclough, CR; Bateman, DE; Bates, D; Burn, DJ; Colchester, AC; Durward, W; Fletcher, NA; Hawkins, SA; Mackenzie, JM; Will, RG				Zeidler, M; Stewart, GE; Barraclough, CR; Bateman, DE; Bates, D; Burn, DJ; Colchester, AC; Durward, W; Fletcher, NA; Hawkins, SA; Mackenzie, JM; Will, RG			New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests	LANCET			English	Article							SPONGIFORM ENCEPHALOPATHIES; DECADE 1968-1977; STRAIN VARIATION; FRANCE; TRANSMISSION; WOMAN; CJD; BSE	Background In April, 1996, ten cases of Creutzfeldt-Jakob disease (CJD) with an apparently new clinicopathological phenotype were published and it was suggested that these new variant cases (nvCJD) might be causally linked to bovine spongiform encephalopathy (BSE). There have now been 21 cases of nvCJD in the UK and one case in France. We report clinical features and diagnostic test results of the first 14 cases of nvCJD in the UK. Methods Case ascertainment of CJD was mainly by direct referral from neurologists and neuropathologists. Clinical and investigative details were obtained by interview with patients' relatives and by examination of case notes. Ten cases in this report were examined while alive. Prion protein (PrP) gene analysis was carried out with informed consent from the patient or from a relative. The diagnosis of nvCJD was established histologically. Findings Eight cases were women. Mean age at onset of symptoms was 29 (16-48) years and the median duration of illness was 14 (9-35) months. All patients had early psychiatric symptoms, most often depression, and 13 were seen by a psychiatrist early in the clinical course. Eight patients developed early sensory symptoms which were persistent and often painful. Neurological signs, including ataxia and involuntary movements, developed in all cases and towards the end of the illness, most had akinetic mutism. The electroencephalogram was abnormal in most patients but typical periodic complexes of CJD were not seen in any case. Cerebral imaging was usually normal or showed non-specific abnormalities; in two cases magnetic-resonance imaging scans showed high signal in the thalamus. Interpretation Clinical features in these cases are similar and relatively distinct from other forms of CJD, suggesting that this is a new clinical phenotype consistent with a single strain of infectious agent. There is, however, some overlap with atypical cases of sporadic CJD, and the diagnosis of nvCJD remains dependent on neuropathological confirmation.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Burn, David/ABD-6052-2021	Burn, David/0000-0001-7658-1209				ALPERS M, 1987, P451; BERMAN PH, 1988, PEDIATR NEUROSCI, V14, P42, DOI 10.1159/000120361; BROWN P, 1985, European Journal of Epidemiology, V1, P42, DOI 10.1007/BF00162311; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1984, ANN NEUROL, V16, P295, DOI 10.1002/ana.410160305; BROWN P, 1979, ANN NEUROL, V6, P430, DOI 10.1002/ana.410060510; BROWN P, 1979, ANN NEUROL, V6, P438, DOI 10.1002/ana.410060511; BROWN P, 1988, NOVEL INFECTIOUS AGE, P3; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; CARABALLO-H A J, 1991, Arquivos de Neuro-Psiquiatria, V49, P218; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *DEP HLTH, 1997, CMOS UPDATE, V13, P4; DESILVA RN, IN PRESS BMJ; Deslys JP, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P465; deVillemeur TB, 1996, NEUROLOGY, V47, P690, DOI 10.1212/WNL.47.3.690; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Hornabrook R W, 1975, P N G Med J, V18, P226; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUNTER N, 1994, VET REC, V135, P400, DOI 10.1136/vr.135.17.400; KIMBERLIN RH, 1990, CAN J VET RES, V54, P30; KULCZYCKI J, 1991, EUR J EPIDEMIOL, V7, P501, DOI 10.1007/BF00143129; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MONREAL J, 1981, J NEUROL SCI, V52, P341, DOI 10.1016/0022-510X(81)90015-0; PACKER RJ, 1980, NEUROLOGY, V30, P492, DOI 10.1212/WNL.30.5.492; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; RAVERDY P, 1983, REV NEUROL, V139, P381; TRIMBLE ME, 1996, NEUROLOGY CLIN PRACT, V1, P107; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; WILL RG, 1996, PRION DIS, P119; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1996, BRIT MED J, V312, P844; ZEIDLER M, 1997, J NEUROL NEUROSUR PS, V62, P206	38	212	219	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					903	907		10.1016/S0140-6736(97)07472-2	http://dx.doi.org/10.1016/S0140-6736(97)07472-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314867				2022-12-01	WOS:A1997XY67200007
J	Zeidler, M; Johnstone, EC; Bamber, RWK; Dickens, CM; Fisher, CJ; Francis, AF; Goldbeck, R; Higgo, R; JohnsonSabine, EC; Lodge, GJ; McGarry, P; Mitchell, S; Tarlo, L; Turner, M; Ryley, P; Will, RG				Zeidler, M; Johnstone, EC; Bamber, RWK; Dickens, CM; Fisher, CJ; Francis, AF; Goldbeck, R; Higgo, R; JohnsonSabine, EC; Lodge, GJ; McGarry, P; Mitchell, S; Tarlo, L; Turner, M; Ryley, P; Will, RG			New variant Crutzfeldt-Jakob disease: psychiatric features	LANCET			English	Article							DELUSIONS	Background An apparently new variant of Creutzfeldt-Jakob disease (CJD), new variant CJD [nvCJD), was identified in the UK in 1996. There have now been 21 cases of nvCJD in the UK and one in France, Psychiatric symptoms are prominent in the initial presentation in these cases. Methods Cases of nvCJD are identified mainly by direct referral horn neurologists and neuropathologists. Detailed clinical information was obtained by review of case notes and interviewing patients' relatives. We report the psychiatric features of the first 14 cases on nvCJD in the UK. Psychiatric notes were examined in ail 13 of these cases who were seen by a psychiatrist. Results Eight cases were women. Ali 14 cases had early psychiatric features and in nine, the first symptom was psychiatric. 13 cases were seen by a psychiatrist and the majority were diagnosed as suffering from depression or depression secondary to organic disease. Two cases suffered from first-rank symptoms suggestive of psychotic illness and transient delusions and auditory or visual hallucinations occurred in the majority. Aii cases were referred to a neurologist as the illness evolved and neurological signs developed. Interpretation Psychiatric symptoms are a consistent early clinical feature in nvCJD. Analysis of the psychiatric symptoms does not suggest specific features that readily allow distinction from more common psychiatric disorders, although the occurrence of associated persistent sensory symptoms may raise the possibility of this diagnosis. Neurological signs, including ataxia, involuntary movements and cognitive impairment developed in ail cases and the evolution of increasing neurological deficits is likely to remain critical to the clinical diagnosis of nvCJD.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh				Dickens, Chris/0000-0001-6326-7544				AZORIN JM, 1993, COMPR PSYCHIAT, V34, P42, DOI 10.1016/0010-440X(93)90034-2; BERRIOS GE, 1984, BRIT J PSYCHIAT, V144, P662, DOI 10.1192/bjp.144.6.662; BROWN P, 1979, ANN NEUROL, V6, P430, DOI 10.1002/ana.410060510; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BURNS A, 1990, BRIT J PSYCHIAT, V157, P72, DOI 10.1192/bjp.157.1.72; CHAPMAN J, 1993, J NEUROL NEUROSUR PS, V56, P1109, DOI 10.1136/jnnp.56.10.1109; CUMMINGS JL, 1985, BRIT J PSYCHIAT, V146, P184, DOI 10.1192/bjp.146.2.184; ESMONDE TFG, 1994, THESIS TRINITY COLL; KESHAVAN MS, 1987, BRIT J PSYCHIAT, V151, P260, DOI 10.1192/bjp.151.2.260; MCMILLAN JF, 1984, THESIS EDINBURGH U U; *NAT CJD SURV UN D, 1995, 4 DEP EP POP SCI LON; STEVENS EM, 1979, J CLIN PSYCHIAT, V40, P445; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; WILL RG, 1984, THESIS CAMBRIDGE U U; WILL RG, 1996, PRION DIS, P119; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2	17	128	135	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					908	910		10.1016/S0140-6736(97)03148-6	http://dx.doi.org/10.1016/S0140-6736(97)03148-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY672	9314868				2022-12-01	WOS:A1997XY67200008
J	Lam, KP; Kuhn, R; Rajewsky, K				Lam, KP; Kuhn, R; Rajewsky, K			In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death	CELL			English	Article							CD4(+) T-CELLS; ANTIGEN RECEPTOR; HEAVY-CHAIN; RAG-1-DEFICIENT MICE; CLONAL SELECTION; IMMUNE-RESPONSE; LYMPHOCYTES-B; NP ANTIBODIES; EXPRESSION; APOPTOSIS	Gene targeting experiments have demonstrated that the expression of immunoglobulin heavy chain in the pre-B cell receptor (pBCR) and of heavy and light chains in the B cell antigen receptor (BCR) marks checkpoints in early B cell development that the cells have to pass to survive. To investigate whether the persistence of mature B cells in the peripheral immune system also depends on BCR expression, we have generated a transgenic mouse in which the BCR can be inducibly ablated through V region gene deletion. Ablation leads to rapid death of mature B lymphocytes, which is preceded by down-regulation of MHC antigens and up-regulation of CD95 (Fas) and can be delayed by constitutive bcl-2 expression.			Lam, KP (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Kühn, Ralf/U-1278-2017; Lam, Kong-Peng/G-5374-2012	Kühn, Ralf/0000-0003-1694-9803; Lam, Kong-Peng/0000-0002-1316-4333; Rajewsky, Klaus/0000-0002-6633-6370				BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dul JL, 1996, J IMMUNOL, V157, P2969; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SCHWARTZ RS, 1994, IMMUNOL TODAY, V15, P27, DOI 10.1016/0167-5699(94)90022-1; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TAKI S, 1993, SCIENCE, V262, P1268, DOI 10.1126/science.8235657; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; Torres RM, 1997, LAB PROTOCOLS CONDIT; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	53	912	937	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1073	1083		10.1016/S0092-8674(00)80373-6	http://dx.doi.org/10.1016/S0092-8674(00)80373-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323135	Bronze			2022-12-01	WOS:A1997XX76800013
J	Muzio, M; Ni, J; Feng, P; Dixit, VM				Muzio, M; Ni, J; Feng, P; Dixit, VM			IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling	SCIENCE			English	Article							INTERLEUKIN-1 RECEPTOR; DORSOVENTRAL SIGNAL; DROSOPHILA EMBRYO; DEATH DOMAIN; KINASE; ACTIVATION; TUBE; TRANSDUCTION; EXPRESSION; PROTEINS	The interleukin-1 receptor (IL-1R) signaling pathway leads to nuclear factor kappa B (NF-kappa B) activation in mammals and is similar to the Toll pathway in Drosophila: the IL-1R-associated kinase (IRAK) is homologous to Pelle. Two additional proximal mediators were identified that are required for IL-1R-induced NF-kappa B activation: IRAK-2, a Pelle family member, and MyD88, a death domain-containing adapter molecule. Both associate with the IL-IR signaling complex. Dominant negative forms of either attenuate IL-1R-mediated NF-kappa B activation. Therefore, IRAK-2 and MyD88 may provide additional therapeutic targets for inhibiting IL-1-induced inflammation.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012; Muzio, Marta/J-9360-2018	dixit, vishva m/0000-0001-6983-0326; Muzio, Marta/0000-0002-7761-759X				Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eriksson A, 1995, CYTOKINE, V7, P649; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hardiman G, 1996, ONCOGENE, V13, P2467; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LORD KA, 1990, ONCOGENE, V5, P1095; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MEDZHITOV R, 1997, NATURE, V38, P394; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Singh R, 1997, J CLIN INVEST, V100, P419, DOI 10.1172/JCI119549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727	27	943	1019	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1612	1615		10.1126/science.278.5343.1612	http://dx.doi.org/10.1126/science.278.5343.1612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374458				2022-12-01	WOS:A1997YJ87400037
J	VanderHeiden, MG; Chandel, NS; Williamson, EK; Schumacker, PT; Thompson, CB				VanderHeiden, MG; Chandel, NS; Williamson, EK; Schumacker, PT; Thompson, CB			Bcl-x(L) regulates the membrane potential and volume homeostasis of mitochondria	CELL			English	Article							CYTOCHROME-C-OXIDASE; CELL-DEATH; APOPTOSIS; OXYGEN; HEPATOCYTES; DNA	Mitochondrial physiology is disrupted in either apoptosis or necrosis. Here, we report that a wide variety of apoptotic and necrotic stimuli induce progressive mitochondrial swelling and outer mitochondrial membrane rupture. Discontinuity of the outer mitochondrial membrane results in cytochrome c redistribution from the intermembrane space to the cytosol followed by subsequent inner mitochondrial membrane depolarization. The mitochondrial membrane protein Bcl-x(L) can inhibit these changes in cells treated with apoptotic stimuli. In addition, Bcl-x(L)-expressing cells adapt to growth factor withdrawal or staurosporine treatment by maintaining a decreased mitochondrial membrane potential. Bcl-x(L) expression also prevents mitochondrial swelling in response to agents that inhibit oxidative phosphorylation. These data suggest that Bcl-x(L) promotes cell survival by regulating the electrical and osmotic homeostasis of mitochondria.	UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	VanderHeiden, MG (corresponding author), UNIV CHICAGO,GWEN KNAPP CTR,CHICAGO,IL 60637, USA.			Schumacker, Paul T/0000-0001-9591-2034				ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; ALLMAN R, 1990, CYTOMETRY, V11, P822, DOI 10.1002/cyto.990110708; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DECKER RS, 1980, AM J PATHOL, V98, P425; DEJONG D, 1994, CANCER RES, V54, P256; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilson AJ, 1993, PROCEDURES ELECT MIC; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	34	1186	1197	1	72	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					627	637		10.1016/S0092-8674(00)80450-X	http://dx.doi.org/10.1016/S0092-8674(00)80450-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393856	Bronze			2022-12-01	WOS:A1997YH96000010
J	Naylor, CD; Sermer, M; Chen, EL; Farine, D				Naylor, CD; Sermer, M; Chen, EL; Farine, D			Selective screening for gestational diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOLERANCE TEST VALUE; GLUCOSE-TOLERANCE; PERINATAL MORBIDITY; RISK-FACTORS; PREGNANCY; CRITERIA; WOMEN; DELIVERY; IMPACT; WEIGHT	Background The usual approach to detecting gestational diabetes mellitus is to screen all pregnant women by measuring their plasma glucose after a 50-g oral glucose load at 24 to 28 weeks' gestation. Women are referred for an oral glucose-tolerance test if the plasma glucose concentration one hour later is greater than or equal to 140 mg per deciliter (7.8 mmol per liter). We hypothesized that the efficiency of screening could be enhanced by considering women's risks of gestational diabetes on the basis of their clinical characteristics. Methods We studied 3131 pregnant women who underwent both the screening and the diagnostic tests. We randomly selected data on half the women and used them to derive new screening strategies. We categorized each woman's risk of gestational diabetes mellitus on the basis of her age, body-mass index before pregnancy, and race. We developed strategies that entailed no screening for low-risk women, usual care for intermediate-risk women, and universal screening with lower thresholds - plasma glucose values of 130 mg per deciliter (7.2 mmol per liter) or 128 mg per deciliter (7.1 mmol per liter) - for high-risk women. The strategies were validated with data on the other half of the women. Results The new strategies allowed a 34.6 percent reduction in the number of screening tests performed (95 percent confidence interval, 32.3 to 37.0 percent) and detected 81.2 to 82.6 percent of the women with gestational diabetes as compared with the 78.3 percent detected through usual care. The percentage of false positive screening tests was significantly reduced, from 19.9 percent with usual care to 16.0 percent (P = 0.02) or 15.4 percent (P < 0.001) with the new strategies, depending on the threshold values for high-risk women. Conclusions Consideration of women's clinical characteristics allows efficient selective screening for gestational diabetes. (C) 1997, Massachusetts Medical Society.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; TORONTO HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5T 2S8,CANADA; MT SINAI HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT OBSTET & GYNECOL,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Naylor, CD (corresponding author), SUNNYBROOK HLTH SCI CTR,INST CLIN EVALUAT SCI,CLIN EPIDEMIOL UNIT,G106,2075 BAYVIEW AVE,N YORK,ON M4N 3M5,CANADA.							*AM DIAB ASS, 1987, AM J OBSTET GYNECOL, V156, P488; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; *CAN TASK FORC PER, 1992, CMAJ, V147, P435; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COUSTAN DR, 1986, AM J OBSTET GYNECOL, V154, P1031, DOI 10.1016/0002-9378(86)90744-1; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9; COUSTAN DR, 1985, CLIN OBSTET GYNECOL, V28, P507, DOI 10.1097/00003081-198528030-00006; DIETRICH ML, 1987, AM J OBSTET GYNECOL, V156, P1403, DOI 10.1016/0002-9378(87)90007-X; DORNHORST A, 1992, DIABETIC MED, V9, P820, DOI 10.1111/j.1464-5491.1992.tb01900.x; *EXP COMM DIAGN CL, 1997, DIABETES CARE S1, V20, pS1183; GABBE SG, 1986, NEW ENGL J MED, V315, P1025, DOI 10.1056/NEJM198610163151609; GABBE SG, 1977, AM J OBSTET GYNECOL, V127, P465, DOI 10.1016/0002-9378(77)90436-7; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; KITZMILLER JL, 1978, AM J OBSTET GYNECOL, V131, P560, DOI 10.1016/0002-9378(78)90120-5; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LINDSAY MK, 1989, OBSTET GYNECOL, V73, P103; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MARQUETTE GP, 1985, OBSTET GYNECOL, V66, P181; METZGER BE, 1991, DIABETES, V40, P197, DOI 10.2337/diab.40.2.S197; NAHUM GG, 1993, OBSTET GYNECOL, V81, P517; *NAT DIAB DAT GROU, 1979, DIABETES, V28, P1039; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1165, DOI 10.1001/jama.275.15.1165; OSULLIVAN JB, 1973, AM J OBSTET GYNECOL, V116, P895; OSULLIVAN JB, 1980, DIABETES CARE, V3, P437, DOI 10.2337/diacare.3.3.437; OWEN J, 1995, AM J OBSTET GYNECOL, V172, P615, DOI 10.1016/0002-9378(95)90581-2; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5; *PREV SERV TASK FO, 1996, GUID CLIN PREV SERV, P193; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SERMER M, 1994, AM J OBSTET GYNECOL, V171, P607, DOI 10.1016/0002-9378(94)90072-8; Tu JV, 1997, J CLIN EPIDEMIOL, V50, P743, DOI 10.1016/S0895-4356(97)89028-2; WALKINSHAW SA, 1995, PREGNANCY CHILDBIRTH; WALKINSHAW SA, 1997, PREGNANCY CHILDBIRTH; WEEKS JW, 1994, AM J OBSTET GYNECOL, V171, P1003, DOI 10.1016/0002-9378(94)90023-X; Widness J A, 1985, Diabetes, V34 Suppl 2, P61; 1985, DIABETES S2, V34, P123	37	177	185	5	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1591	1596		10.1056/NEJM199711273372204	http://dx.doi.org/10.1056/NEJM199711273372204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371855				2022-12-01	WOS:A1997YH52100004
J	Zazopoulos, E; Lalli, E; Stocco, DM; SassoneCorsi, P				Zazopoulos, E; Lalli, E; Stocco, DM; SassoneCorsi, P			DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis	NATURE			English	Article							ACUTE REGULATORY PROTEIN; ADRENAL HYPOPLASIA CONGENITA; STAR GENE; EXPRESSION; CELLS; SUPERFAMILY; MOTIF; HMG1; CREM	Mutations in the DAX-1 gene are responsible for congenital X-linked adrenal hypoplasia, a disease that is associated with hypogonadotropic hypogonadism(1,2). DAX-1 expression is tissue-specific and is finely regulated throughout development(3-5), suggesting that it has a role in both adrenal and gonadal function. DAX-1 is an unusual member of the nuclear-receptor superfamily of transcription factors which contains no canonical zinc-finger or any other known DNA-binding motif(1). Binding sites for DAX-1 are found in the promoters of the dax-1 and StAR (for steroidogenic acute regulatory protein) genes. Here we show that DAX-1 binds DNA and acts as a powerful transcriptional repressor of StAR gene expression, leading to a drastic decrease in steroid production. We provide in vitro and in vivo evidence that DAX-1 binds to DNA hairpin structures. Our results establish DAX-1 as the first member of the nuclear receptor superfamily with novel DNA-binding features and reveal that it has regulatory properties critical to the understanding of its physiological functions.	CNRS, INSERM, ULP, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, STRASBOURG, FRANCE; TEXAS TECH UNIV, HLTH SCI CTR, DEPT BIOCHEM & CELL BIOL, LUBBOCK, TX 79430 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center			Lalli, Enzo/F-7052-2013	Lalli, Enzo/0000-0002-0584-5681	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; LALLI E, IN PRESS MOL ENDOCRI; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Schimmer B P, 1979, Methods Enzymol, V58, P570; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	25	344	354	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	1997	390	6657					311	315		10.1038/36899	http://dx.doi.org/10.1038/36899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384387				2022-12-01	WOS:A1997YG66700070
J	Kigotho, AW				Kigotho, AW			HIV-1 statistics bring good news for Uganda	LANCET			English	News Item																			0	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1456	1456		10.1016/S0140-6736(05)64230-4	http://dx.doi.org/10.1016/S0140-6736(05)64230-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371180				2022-12-01	WOS:A1997YF95300037
J	Kaplan, KB; Hyman, AA; Sorger, PK				Kaplan, KB; Hyman, AA; Sorger, PK			Regulating the yeast kinetochore by ubiquitin-dependent degradation and skp1p-mediated phosphorylation	CELL			English	Article							SACCHAROMYCES-CEREVISIAE KINETOCHORE; BUDDING YEAST; CHROMOSOME SEGREGATION; IN-VITRO; CENTROMERE; PROTEIN; BINDING; CYCLE; PROTEOLYSIS; COMPLEX	In S. cerevisiae, the four-protein Cbf3 complex binds to the essential CDEIII region of centromeric DNA to initiate kinetochore assembly. We report the reconstitution of Cbf3p from recombinant proteins and an analysis of its p58(Ctf13) and p23(Skp1) subunits. p23(Skp1) has both G1- and G2-specific functions in yeast and binds to p58(Ctf13) and to the essential Cdc4p component of the ubiquitin conjugating complex Scul(Cdc4). We show that the function of p23(Skp1) in Cbf3p is to activate p58(Ctf13) by phosphorylation. p58(Ctf13) is an unstable protein that is targeted to the proteosome, probably by Scul(Cdc4)-mediated ubiquitination. Thus, p58 appears to be activated by phosphorylation in a p23(Skp1)-dependent step and degraded by the proteosome in a ubiquitin-dependent step. We propose that coupled activation and destruction link the assembly of Cbf3p to the duplication of centromeres in S phase.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY	Massachusetts Institute of Technology (MIT); European Molecular Biology Laboratory (EMBL)			Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838	NIGMS NIH HHS [GM51464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COHENFIX O, 1996, GENE DEV, V15, P3071; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cellbio.11.1.471; JIANG W, 1993, COLD SPRING HARB SYM, V58, P669, DOI 10.1101/SQB.1993.058.01.074; KAPLAN KB, 1997, PROTEIN FUNCTION PRA, P245; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; Sorger PK, 1995, P NATL ACAD SCI USA, V92, P12026, DOI 10.1073/pnas.92.26.12026; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	31	133	135	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					491	500		10.1016/S0092-8674(00)80435-3	http://dx.doi.org/10.1016/S0092-8674(00)80435-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390558	Bronze			2022-12-01	WOS:A1997YG49200010
J	Mitchell, P; Petfalski, E; Shevchenko, A; Mann, M; Tollervey, D				Mitchell, P; Petfalski, E; Shevchenko, A; Mann, M; Tollervey, D			The exosome: A conserved eukaryotic RNA processing complex containing multiple 3'->5' exoribonucleases	CELL			English	Article							DOUBLE-STRANDED-RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; POLYACRYLAMIDE GELS; ANTIVIRAL SYSTEM; RIBOSOMAL-RNA; IN-VIVO; YEAST; PROTEINS	We identified a complex in S. cerevisiae, the ''exosome,'' consisting of the five essential proteins Rrp4p, Rrp41p, Rrp42p, Rrp43p, and Rrp44p (Dis3p). Remarkably, four of these proteins are homologous to characterized bacterial 3'-->5' exoribonucleases; Rrp44p is homologous to RNase II, while Rrp41p, Rrp42p, and Rrp43p are related to RNase PH. Recombinant Rrp4p, Rrp44p, and Rrp41p are 3'-->5' exoribonucleases in vitro that have distributive, processive, and phosphorolytic activities, respectively. All components of the exosome are required for 3' processing of the 5.8S rRNA. Human Rrp4p is found in a comparably sized complex, and expression of the hRRP4 gene in yeast complements the rrp4-1 mutation. We conclude that the exosome constitutes a highly conserved eukaryotic RNA processing complex.	EUROPEAN MOL BIOL LAB,EMBL,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013; Tollervey, David/AAR-6662-2020	Mann, Matthias/0000-0003-1292-4799; Tollervey, David/0000-0003-2894-2772; Mitchell, Phil/0000-0002-3178-0439				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; INGOLIA TD, 1982, MOL CELL BIOL, V2, P1388, DOI 10.1128/MCB.2.11.1388; KASAI T, 1977, J BIOL CHEM, V252, P8950; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; LAING S, 1996, MOL CELL BIOL, V16, P5139; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; LI ZW, 1994, J BIOL CHEM, V269, P6064; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; MIAN S, 1997, NUCLEIC ACIDS RES, V25, P3187; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MIN JJ, 1993, J BIOL CHEM, V268, P7350; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; WIDNER WR, 1993, MOL CELL BIOL, V13, P4331, DOI 10.1128/MCB.13.7.4331; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zhou ZH, 1997, J BACTERIOL, V179, P4391, DOI 10.1128/jb.179.13.4391-4395.1997	48	744	757	0	83	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					457	466		10.1016/S0092-8674(00)80432-8	http://dx.doi.org/10.1016/S0092-8674(00)80432-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390555	Bronze			2022-12-01	WOS:A1997YG49200007
J	DiPrisco, GV; Pearlstein, E; Robitaille, R; Dubuc, R				DiPrisco, GV; Pearlstein, E; Robitaille, R; Dubuc, R			Role of sensory-evoked NMDA plateau potentials in the initiation of locomotion	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; RETICULOSPINAL NEURONS; BRAIN-STEM; SPINAL-CORD; MEMBRANE-PROPERTIES; FICTIVE LOCOMOTION; SEA LAMPREY; ACTIVATION; RECEPTORS; NETWORK	Reticulospinal (RS) neurons constitute the main descending motor system of lampreys. This study reports an natural conditions whereby N-methyl-D-aspartate (NMDA)-mediated plateau potentials were elicited and associated with the onset of locomotion. Reticulospinal neurons responded in a linear fashion to mild skin stimulation. With stronger stimuli, large depolarizing plateaus with spiking activity were elicited and were accompanied by swimming movements, Calcium imaging revealed sustained intracellular calcium rise upon sensory stimulation. Blocking NMDA receptors on RS neurons prevented the plateau potentials as well as the associated rise in intracellular calcium. Thus, the activation of NMDA receptors mediates a switch from sensory-reception mode to a motor command mode in RS neurons.	UNIV QUEBEC, DEPT KINANTHROPOL, MONTREAL, PQ H3C 3P8, CANADA; UNIV MONTREAL, DEPT PHYSIOL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA	University of Quebec; University of Quebec Montreal; Universite de Montreal			Pearlstein, Edouard/P-4616-2016	Robitaille, Richard/0000-0001-6628-0146; Pearlstein, Edouard/0000-0001-9405-5667				BOWERMAN RF, 1976, COMP BIOCHEM PHYS A, V54, P1, DOI 10.1016/S0300-9629(76)80061-8; BRODIN L, 1985, BRAIN RES, V360, P139, DOI 10.1016/0006-8993(85)91229-6; BRODIN L, 1988, ARCH ITAL BIOL, V126, P317; Brodin L, 1990, PREPARATIONS VERTEBR, P103; BUCHANAN JT, 1987, BRAIN RES, V408, P321, DOI 10.1016/0006-8993(87)90397-0; CAZALETS JR, 1992, J PHYSIOL-LONDON, V455, P187, DOI 10.1113/jphysiol.1992.sp019296; CURRIE SN, 1983, BRAIN RES, V279, P238, DOI 10.1016/0006-8993(83)90183-X; DAVIS WJ, 1976, IDENTIFIED NEURONS B, P293; DELIAGINA TG, 1993, EXP BRAIN RES, V95, P421; DELIAGINA TG, 1995, J EXP BIOL, V198, P2581; DIPRISCO GV, 1995, BRAIN RES, V695, P76, DOI 10.1016/0006-8993(95)00936-K; DOUGLAS JR, 1993, J NEUROSCI, V13, P990; Drew T, 1996, EXP BRAIN RES, V111, P153; DUBUC R, 1993, J COMP NEUROL, V327, P251, DOI 10.1002/cne.903270207; DUBUC R, 1993, J COMP NEUROL, V327, P260, DOI 10.1002/cne.903270208; EATON RC, 1991, BRAIN BEHAV EVOLUT, V37, P272, DOI 10.1159/000114365; Frost WN, 1996, P NATL ACAD SCI USA, V93, P422, DOI 10.1073/pnas.93.1.422; GILLETTE R, 1978, SCIENCE, V199, P798, DOI 10.1126/science.622571; Grillner S, 1988, Adv Neurol, V47, P425; GRILLNER S, 1991, ANNU REV NEUROSCI, V14, P169, DOI 10.1146/annurev.neuro.14.1.169; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; HAGEVIK A, 1994, BRAIN RES, V636, P147, DOI 10.1016/0006-8993(94)90190-2; Hirschfeld H, 1997, J VESTIBUL RES-EQUIL, V7, P265, DOI 10.1016/S0957-4271(96)00180-2; KASICKI S, 1989, BRAIN RES, V484, P203, DOI 10.1016/0006-8993(89)90363-6; KOYAMA H, 1987, J COMP NEUROL, V264, P437, DOI 10.1002/cne.902640402; KUPFERMANN I, 1978, BEHAV BRAIN SCI, V1, P3, DOI 10.1017/S0140525X00059057; LETHBRIDGE RC, 1982, BIOL LAMPREYS, V3, P377; MCCLELLAN AD, 1984, BRAIN RES, V300, P357, DOI 10.1016/0006-8993(84)90846-1; MCCLELLAN AD, 1994, BRAIN RES, V663, P61, DOI 10.1016/0006-8993(94)90462-6; MILNER KL, 1988, BRAIN RES, V452, P273, DOI 10.1016/0006-8993(88)90031-5; NELSON DA, 1995, NEURON, V15, P23, DOI 10.1016/0896-6273(95)90061-6; Nelson S B, 1992, Curr Opin Neurobiol, V2, P484, DOI 10.1016/0959-4388(92)90184-M; NIEUWENHUYS R, 1972, J COMP NEUROL, V145, P165, DOI 10.1002/cne.901450204; ODONOVAN MJ, 1993, J NEUROSCI METH, V46, P91, DOI 10.1016/0165-0270(93)90145-H; OHTA Y, 1989, J NEUROPHYSIOL, V62, P1079, DOI 10.1152/jn.1989.62.5.1079; OMalley DM, 1996, NEURON, V17, P1145, DOI 10.1016/S0896-6273(00)80246-9; ORLOVSKY GN, 1992, EXP BRAIN RES, V90, P479; PETERSON BW, 1971, BRAIN RES, V27, P373, DOI 10.1016/0006-8993(71)90264-2; RONAN M, 1989, J COMP NEUROL, V281, P54, DOI 10.1002/cne.902810106; Rossignol S, 1996, HDB PHYSL SECTION 12, P173; Rossignol SLJ, 1988, NEURAL CONTROL RHYTH, P201; ROVAINEN CM, 1967, J NEUROPHYSIOL, V30, P1000, DOI 10.1152/jn.1967.30.5.1000; ROVAINEN CM, 1982, BIOL LAMPREYS, P1; SALT TE, 1986, NATURE, V322, P263, DOI 10.1038/322263a0; SHIMAMURA M, 1983, BRAIN RES, V260, P27, DOI 10.1016/0006-8993(83)90761-8; SILLAR KT, 1994, EUR J MORPHOL, V32, P185; SIROTA M, 1995, CAN J PHYSL PHARM, V73; SWAIN GP, 1993, J COMP NEUROL, V336, P194, DOI 10.1002/cne.903360204; WALLEN P, 1987, J NEUROSCI, V7, P2745; WICKELGREN WO, 1977, J PHYSIOL-LONDON, V270, P89, DOI 10.1113/jphysiol.1977.sp011940; WIERSMA CAG, 1964, COMP BIOCHEM PHYSIOL, V12, P509, DOI 10.1016/0010-406X(64)90153-7; Zompa IC, 1996, BRAIN RES, V718, P221, DOI 10.1016/0006-8993(96)00131-X	52	107	107	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1122	1125		10.1126/science.278.5340.1122	http://dx.doi.org/10.1126/science.278.5340.1122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353193				2022-12-01	WOS:A1997YE65200052
J	OScalaidhe, SP; Wilson, FAW; GoldmanRakic, PS				OScalaidhe, SP; Wilson, FAW; GoldmanRakic, PS			Areal segregation of face-processing neurons in prefrontal cortex	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; RHESUS-MONKEY; VISUAL PATHWAYS; MACAQUE MONKEY; UNIT-ACTIVITY; FRONTAL-LOBE; PARIETAL; MEMORY; ORGANIZATION; SUBDIVISIONS	A central issue in cognitive neuroscience concerns the functional architecture of the prefrontal cortex and the degree to which it is organized by sensory domain. To examine this issue, multiple areas of the macaque monkey prefrontal cortex were mapped for selective responses to visual stimuli that are prototypical of the brain's object vision pathway-pictorial representations of faces. Prefrontal neurons not only selectively process information related to the identity of faces but, importantly, such neurons are localized to a remarkably restricted area. These findings suggest that the prefrontal cortex is functionally compartmentalized with respect to the nature of its inputs.			OScalaidhe, SP (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038546, R37MH038546, P50MH044866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH44866, MH38546] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; BARBAS H, 1985, NEUROSCIENCE, V15, P619, DOI 10.1016/0306-4522(85)90064-8; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BATES JF, 1995, SOC NEUR ABSTR, V21, P1054; BAYLIS GC, 1987, J NEUROSCI, V7, P330; BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; Bullier J, 1996, BEHAV BRAIN RES, V76, P89, DOI 10.1016/0166-4328(95)00182-4; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; COURTNEY SM, 1996, CEREB CORTEX, V6, P1047; DESIMONE R, 1979, BRAIN RES, V178, P363, DOI 10.1016/0006-8993(79)90699-1; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1994, J NEUROSCI, V14, P6171; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; GOLDMAN PS, 1970, EXP NEUROL, V27, P291, DOI 10.1016/0014-4886(70)90222-0; GROSS CG, 1962, EXP NEUROL, V5, P453, DOI 10.1016/0014-4886(62)90057-2; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; JACOBSON S, 1977, BRAIN RES, V132, P209, DOI 10.1016/0006-8993(77)90417-6; KAWAMURA K, 1984, Neuroscience Research, V1, P89, DOI 10.1016/S0168-0102(84)80007-3; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; MACPHERSON JM, 1979, BRAIN RES, V175, P183, DOI 10.1016/0006-8993(79)90530-4; McCarthy G, 1996, CEREB CORTEX, V6, P600, DOI 10.1093/cercor/6.4.600; MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2; MISHKIN M, 1978, BRAIN RES, V143, P313, DOI 10.1016/0006-8993(78)90571-1; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; OWEN AM, 1997, TRNEDS COGN NEUROSCI, V4, P123; PASSINGHAM R, 1975, BRAIN RES, V92, P89, DOI 10.1016/0006-8993(75)90529-6; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PIGAREV IN, 1979, NEUROSCI LETT, V12, P207, DOI 10.1016/0304-3940(79)96063-4; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; ROBINSON CJ, 1980, J COMP NEUROL, V192, P69, DOI 10.1002/cne.901920105; RODMAN HR, 1993, J NEUROPHYSIOL, V70, P1115, DOI 10.1152/jn.1993.70.3.1115; RODMAN HR, 1994, CEREB CORTEX, V5, P484; ROLLS ET, 1986, EXP BRAIN RES, V65, P38; SARY G, 1993, SCIENCE, V260, P995, DOI 10.1126/science.8493538; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; Sereno A. B., 1997, Society for Neuroscience Abstracts, V23, P302; Sereno A. B., 1995, Society for Neuroscience Abstracts, V21, P282; SUZUKI H, 1983, EXP BRAIN RES, V53, P47; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; WEBSTER MJ, 1994, CEREB CORTEX, V5, P470; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	45	256	258	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1135	1138		10.1126/science.278.5340.1135	http://dx.doi.org/10.1126/science.278.5340.1135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353197				2022-12-01	WOS:A1997YE65200056
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Functional coherence of the human Y chromosome	SCIENCE			English	Article							ESCAPES X-INACTIVATION; SEX-DETERMINING REGION; AMINO-ACID-SEQUENCE; FAT-FACETS GENE; TURNER SYNDROME; MOLECULAR-CLONING; PROTEIN GENE; DROSOPHILA; EXPRESSION; MOUSE	A systematic search of the nonrecombining region or the human Y chromosome (NRY) identified 12 novel genes or families, 10 with full-length complementary DNA sequences. All 12 genes, and six of eight NRY genes or families previously isolated by less systematic means, fell into two classes. Genes in the first group were expressed in many organs; these housekeeping genes have X homologs that escape X inactivation. The second group, consisting of Y-chromosomal gene families expressed specifically in testes, may account for infertility among men with Y deletions. The coherence of the NRY's gene content contrasts with the apparently haphazard content of most eukaryotic chromosomes.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lahn, BT (corresponding author), MIT,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							Affara N, 1996, CYTOGENET CELL GENET, V73, P33; AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; ARNEMANN J, 1991, GENOMICS, V11, P108, DOI 10.1016/0888-7543(91)90107-P; Boynton ZL, 1996, J BACTERIOL, V178, P3015, DOI 10.1128/jb.178.11.3015-3024.1996; Bull J.J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; Delbridge ML, 1997, NAT GENET, V15, P131, DOI 10.1038/ng0297-131; DEVER TE, 1994, J BIOL CHEM, V269, P3212; FERGUSON-SMITH M A, 1965, J Med Genet, V2, P142, DOI 10.1136/jmg.2.2.142; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FORD CE, 1959, LANCET, V1, P711; FREIJE D, 1992, SCIENCE, V258, P1784, DOI 10.1126/science.1465614; GONDO H, 1987, J IMMUNOL, V139, P3840; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; JUST W, 1992, HUM GENET, V89, P240; KANAZAWA M, 1993, ENZYME PROTEIN, V47, P9, DOI 10.1159/000468650; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUOH SW, 1995, GENOMICS, V29, P353, DOI 10.1006/geno.1995.9994; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Madireddi MT, 1996, CELL, V87, P75, DOI 10.1016/S0092-8674(00)81324-0; MANZ E, 1993, GENOMICS, V17, P726, DOI 10.1006/geno.1993.1393; Mumm S, 1997, GENOME RES, V7, P307, DOI 10.1101/gr.7.4.307; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; SAFER D, 1991, J BIOL CHEM, V266, P4029; SALIDO EC, 1992, AM J HUM GENET, V50, P303; SALO P, 1995, HUM GENET, V95, P283, DOI 10.1007/BF00225194; SALO P, 1995, GENE CHROMOSOME CANC, V14, P210, DOI 10.1002/gcc.2870140309; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; SCHMITZ A, 1992, APPL ENVIRON MICROB, V58, P4068, DOI 10.1128/AEM.58.12.4068-4071.1992; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SCHWARTZ A, IN PRESS HUM MOL GEN; SEBOUN E, 1986, COLS SPRING HARBOR S, V1, P237; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STEN C, 1957, AM J HUM GENET, V9, P147; Stokes DG, 1996, P NATL ACAD SCI USA, V93, P7137, DOI 10.1073/pnas.93.14.7137; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUCHIYA K, 1995, AM J HUM GENET, V57, P1400; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; ZINN AR, 1993, TRENDS GENET, V9, P90, DOI 10.1016/0168-9525(93)90230-F	68	665	706	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					675	680		10.1126/science.278.5338.675	http://dx.doi.org/10.1126/science.278.5338.675			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381176				2022-12-01	WOS:A1997YC32300052
J	Burt, RA				Burt, RA			The Supreme Court speaks - Not assisted suicide but a constitutional right to palliative care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Burt, RA (corresponding author), YALE UNIV,SCH LAW,NEW HAVEN,CT 06520, USA.							Cherny N I, 1994, J Palliat Care, V10, P31; *INST MED, 1997, APPR DEATH IMPR CAR, P10; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; Pisano DJ, 1996, J LAW MED ETHICS, V24, P310, DOI 10.1111/j.1748-720X.1996.tb01872.x; Portenoy RK, 1996, J LAW MED ETHICS, V24, P296, DOI 10.1111/j.1748-720X.1996.tb01871.x	5	125	125	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1234	1236		10.1056/NEJM199710233371712	http://dx.doi.org/10.1056/NEJM199710233371712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9337388				2022-12-01	WOS:A1997YB71800012
J	Lim, H; Paria, BC; Das, SK; Dinchuk, JE; Langenbach, R; Trzaskos, JM; Dey, SK				Lim, H; Paria, BC; Das, SK; Dinchuk, JE; Langenbach, R; Trzaskos, JM; Dey, SK			Multiple female reproductive failures in cyclooxygenase 2-deficient mice	CELL			English	Article							DECIDUAL CELL REACTION; MOUSE UTERUS; SELECTIVE-INHIBITION; BLASTOCYST IMPLANTATION; PREOVULATORY FOLLICLES; OVARIAN-STEROIDS; GENE DISRUPTION; H SYNTHASE-1; EXPRESSION; RAT	Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of prostaglandins (PGs) and exists in two isoforms, COX-1 and COX-2. In spite of long-standing speculation, definitive roles of PGs in various events of early pregnancy remain elusive. We demonstrate herein that the targeted disruption of COX-2, but not COX-1, in mice produces multiple failures in female reproductive processes that include ovulation, fertilization, implantation, and decidualization. Using multiple approaches, we conclude that these defects are the direct result of target organ-specific COX-2 deficiency but are not the result of deficiency of pituitary gonadotropins or ovarian steroid hormones, or reduced responsiveness of the target organs to their respective hormones.	UNIV KANSAS, MED CTR, DEPT MOL & INTEGRAT PHYSIOL, KANSAS CITY, KS 66160 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; NIEHS, LAB EXPT CARCINOGENESIS & MUTAGENESIS, RES TRIANGLE PK, NC 27709 USA	University of Kansas; University of Kansas Medical Center; DuPont; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012304, U01HD029968, R01HD012304] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 12304, HD 33994, HD 29968] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benson GV, 1996, DEVELOPMENT, V122, P2687; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; DAS SK, 1994, DEVELOPMENT, V120, P1071; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; EPPIG JJ, 1991, BIOESSAYS, V13, P569, DOI 10.1002/bies.950131105; ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; KENNEDY TG, 1985, BIOL REPROD, V33, P140, DOI 10.1095/biolreprod33.1.140; KENNEDY TG, 1983, BIOL REPROD, V29, P1069, DOI 10.1095/biolreprod29.5.1069; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIM H, 1997, IN PRESS ENDOCRINOLO; MCMASTER MT, 1993, J REPROD FERTIL, V99, P561, DOI 10.1530/jrf.0.0990561; MCMASTER MT, 1992, MOL ENDOCRINOL, V6, P101, DOI 10.1210/me.6.1.101; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; PETERSON JW, 1996, MOL CELL BIOL, V64, P2137; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PINTO DJ, 1995, MED CHEM RES, V5, P394; PSYCHOYOS A, 1973, HDB PHYSL, P187; RANKIN JC, 1977, BIOL REPROD, V17, P549, DOI 10.1095/biolreprod17.4.549; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TSAFRIRI A, 1996, REPROD ENDOCRINOLOGY, P235; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399; WORDINGER RJ, 1986, J REPROD FERTIL, V77, P471, DOI 10.1530/jrf.0.0770471; Yang ZM, 1997, BIOL REPROD, V56, P368, DOI 10.1095/biolreprod56.2.368; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593	54	1138	1185	1	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					197	208		10.1016/S0092-8674(00)80402-X	http://dx.doi.org/10.1016/S0092-8674(00)80402-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346237				2022-12-01	WOS:A1997YC35000007
J	Boshoff, C; Endo, Y; Collins, PD; Takeuchi, Y; Reeves, JD; Schweickart, VL; Siani, MA; Sasaki, T; Williams, TJ; Gray, PW; Moore, PS; Chang, Y; Weiss, RA				Boshoff, C; Endo, Y; Collins, PD; Takeuchi, Y; Reeves, JD; Schweickart, VL; Siani, MA; Sasaki, T; Williams, TJ; Gray, PW; Moore, PS; Chang, Y; Weiss, RA			Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines	SCIENCE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; MULTICENTRIC CASTLEMANS DISEASE; KAPOSIS-SARCOMA; DNA-SEQUENCES; TAT PROTEIN; MOLECULAR-CLONING; GROWTH-FACTOR; C CHEMOKINE; CELLS; INFECTION	Unique among known human herpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) encodes chemokine-like proteins (vMIP-I and VMIP-II). VMIP-II was shown to block infection of human immunodeficiency virus-type 1 (HIV-1) on a CD4-positive cell line expressing CCR3 and to a lesser extent on one expressing CCR5, whereas both vMIP-I and VMIP-II partially inhibited HIV infection of peripheral blood mononuclear cells. Like eotaxin, VMIP-II activated and chemoattracted human eosinophils by way of CCR3. vMIP-I and VMIP-II, but not cellular MIP-1 alpha or RANTES, were highly angiogenic in the chorioallantoic assay, suggesting a possible pathogenic role in Kaposi's sarcoma.	KANAZAWA UNIV,DEPT EXPT THERAPEUT,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,DEV CTR MOL TARGET DRUGS,CANC RES INST,KANAZAWA,ISHIKAWA 920,JAPAN; NATL HEART & LUNG INST,IMPERIAL COLL SCH MED,DEPT APPL PHARMACOL,LONDON SW3 6LY,ENGLAND; ICOS,BOTHELL,WA 98021; GRYPHON SCI,SAN FRANCISCO,CA 94080; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL & EPIDEMIOL,NEW YORK,NY 10032	Kanazawa University; Kanazawa University; Imperial College London; Icos Corporation; Columbia University	Boshoff, C (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND.		Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011; ENDO, Yoshio/D-8428-2015; Reeves, Jacqueline/I-5379-2012; Moore, Patrick/GVR-8294-2022	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; ENDO, Yoshio/0000-0003-0785-2006; 	NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67391] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Angiolillo AL, 1996, ANN NY ACAD SCI, V795, P158, DOI 10.1111/j.1749-6632.1996.tb52664.x; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P761; BOSHOFF C, UNPUB; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Chadburn A, 1997, CANCER-AM CANCER SOC, V80, P788, DOI 10.1002/(SICI)1097-0142(19970815)80:4&lt;788::AID-CNCR18&gt;3.0.CO;2-P; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Danesi R, 1997, CLIN CANCER RES, V3, P265; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUPIN N, 1995, NEW ENGL J MED, V333, P798; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gessain A, 1996, BLOOD, V87, P414; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KNIGHTON D, 1977, BRIT J CANCER, V35, P347, DOI 10.1038/bjc.1977.49; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOSER B, 1993, J BIOL CHEM, V268, P7125; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OIKAWA T, 1991, CANCER LETT, V59, P57, DOI 10.1016/0304-3835(91)90136-6; ORENSTEIN JM, 1997, J ACQ IMMUN DEF SYND, V11, P735; PARRAVICINI C, IN PRES AM J PATHOL; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; WAHMAN A, 1991, EPIDEMIOL REV, V13, P178, DOI 10.1093/oxfordjournals.epirev.a036068; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; YOSHIZAKI K, 1989, BLOOD, V74, P1360	59	395	423	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					290	294		10.1126/science.278.5336.290	http://dx.doi.org/10.1126/science.278.5336.290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323208				2022-12-01	WOS:A1997YA56400045
J	Howard, J				Howard, J			Molecular motors: structural adaptations to cellular functions	NATURE			English	Review							MICROTUBULE-ACTIVATED ATPASE; SINGLE KINESIN MOLECULES; SKINNED MUSCLE-FIBERS; MYOSIN POWER STROKE; ACTIN-FILAMENTS; CONTRACTING MUSCLE; IN-VITRO; SMOOTH-MUSCLE; ADP RELEASE; CRYOELECTRON MICROSCOPY	Molecular motors are protein machines whose directed movement along cytoskeletal filaments is driven by ATP hydrolysis. Eukaryotic cells contain motors that help to transport organelles to their correct cellular locations and to establish and alter cellular morphology during cell locomotion and division. The best-studied motors, myosin from skeletal muscle and conventional kinesin from brain, are remarkably similar in structure, yet have very different functions. These differences can be understood in terms of the 'duty ratio', the fraction of the time that a motor Is attached to its filament. Differences in duty ratio can explain the diversity of structures, speeds and oligomerization states of members of the large kinesin, myosin and dynein families of motors.			Howard, J (corresponding author), UNIV WASHINGTON, DEPT PHYSIOL & BIOPHYS, BOX 357290, SEATTLE, WA 98195 USA.		Howard, Jonathon/J-7492-2016; Howard, Jonathon/D-4229-2011	Howard, Jonathon/0000-0003-0086-1196; Howard, Jonathon/0000-0003-0086-1196				Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; Bahler M, 1996, CURR OPIN CELL BIOL, V8, P18, DOI 10.1016/S0955-0674(96)80043-3; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BLOCK SM, 1995, NATURE, V378, P132, DOI 10.1038/378132a0; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRENNEN C, 1977, ANNU REV FLUID MECH, V9, P339, DOI 10.1146/annurev.fl.09.010177.002011; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CHEN YD, 1993, P NATL ACAD SCI USA, V90, P5148, DOI 10.1073/pnas.90.11.5148; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; CREVEL IMT, IN PRESS J MOL BIOL; DILLON PF, 1982, CIRC RES, V50, P799, DOI 10.1161/01.RES.50.6.799; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FERENCZI MA, 1984, J PHYSIOL-LONDON, V350, P519, DOI 10.1113/jphysiol.1984.sp015216; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FORD LE, 1985, J PHYSIOL-LONDON, V361, P131, DOI 10.1113/jphysiol.1985.sp015637; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GIBBONS BH, 1994, MOL BIOL CELL, V5, P57, DOI 10.1091/mbc.5.1.57; GILLESPIE PG, 1995, CURR OPIN NEUROBIOL, V5, P449, DOI 10.1016/0959-4388(95)80004-2; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hamasaki T, 1995, BIOPHYS J, V69, P2569, DOI 10.1016/S0006-3495(95)80128-1; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Hille B., 1992, IONIC CHANNELS EXCIT; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Huxley AF, 1996, J MUSCLE RES CELL M, V17, P507, DOI 10.1007/BF00123366; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1994, BIOPHYS J, V67, P2411, DOI 10.1016/S0006-3495(94)80728-3; HUXLEY HE, 1965, SCI AM, V213, P18, DOI 10.1038/scientificamerican1265-18; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; MOLLOY JE, 1995, BIOPHYS J, V68, pS298; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RIVOLTA MN, 1995, BBA-BIOENERGETICS, V1232, P1, DOI 10.1016/0005-2728(95)00107-1; SANGER JM, 1990, CELL MOTIL CYTOSKE S, V2; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Suzuki N, 1996, BIOPHYS J, V70, P401, DOI 10.1016/S0006-3495(96)79583-8; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WADE RH, 1993, J STRUCT BIOL, V110, P1, DOI 10.1006/jsbi.1993.1001; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YOKOTA E, 1994, J CELL SCI, V107, P353; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	88	435	438	3	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	1997	389	6651					561	567		10.1038/39247	http://dx.doi.org/10.1038/39247			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335494				2022-12-01	WOS:A1997YA00800048
J	Correll, CC; Freeborn, B; Moore, PB; Steitz, TA				Correll, CC; Freeborn, B; Moore, PB; Steitz, TA			Metals, motifs, and recognition in the crystal structure of a 5S rRNA domain	CELL			English	Article							5-S RIBOSOMAL-RNA; ESCHERICHIA-COLI; BINDING-SITES; MAJOR GROOVE; HAMMERHEAD RIBOZYME; ALPHA-SARCIN; PROTEINS; LOOP; CONFORMATION; COMPLEX	Two new RNA structures portray how non-Watson-Crick base pairs and metal ions can produce a unique RNA shape suitable for recognition by proteins. The crystal structures of a 62 nt domain of E. coli 5S ribosomal RNA and a duplex dodecamer encompassing an internal loop E have been determined at 3.0 and 1.5 Angstrom, respectively. This loop E region is distorted by three ''cross-strand purine stacks'' and three novel, water-mediated noncanonical base pairs and stabilized by a four metal ion zipper. These features give its minor groove a unique hydrogen-bonding surface and make the adjacent major groove wide enough to permit recognition by the ribosomal protein L25, which is expected to bind to this surface.	YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA; HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute			Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM-22778, GM-54216] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1983, J MOL BIOL, V171, P207, DOI 10.1016/S0022-2836(83)80353-2; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Biswas R, 1997, J MOL BIOL, V267, P1149, DOI 10.1006/jmbi.1997.0936; BRUNEL C, 1991, J MOL BIOL, V221, P293; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Correll CC, 1997, J BIOMOL STRUCT DYN, V15, P165, DOI 10.1080/07391102.1997.10508183; Dallas A, 1995, BIOCHEM CELL BIOL, V73, P887, DOI 10.1139/o95-096; DOUTHWAITE S, 1982, BIOCHEMISTRY-US, V21, P2313, DOI 10.1021/bi00539a007; DOUTHWAITE S, 1979, NUCLEIC ACIDS RES, V6, P2453, DOI 10.1093/nar/6.7.2453; GAUTHERET D, 1995, RNA, V1, P807; Gluck A, 1996, J MOL BIOL, V256, P838, DOI 10.1006/jmbi.1996.0130; HARTMANN RK, 1988, NUCLEIC ACIDS RES, V16, P3511, DOI 10.1093/nar/16.8.3511; HUBER PW, 1984, P NATL ACAD SCI-BIOL, V81, P322, DOI 10.1073/pnas.81.2.322; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1992, THESIS YALE U NEW HA; LEONTIS NB, 1984, NUCLEIC ACIDS RES, V12, P2193, DOI 10.1093/nar/12.4.2193; LEONTIS NB, 1986, BIOCHEMISTRY-US, V25, P7386, DOI 10.1021/bi00371a021; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOORE PB, 1996, RIBOSOMAL RNA STRUCT, P199; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan  T., 1993, RNA WORLD, P271; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RABINOVICH D, 1988, J MOL BIOL, V200, P151, DOI 10.1016/0022-2836(88)90340-3; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P120; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHEN Z, 1994, J MOL BIOL, V241, P415, DOI 10.1006/jmbi.1994.1517; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; TOUKIFIMPA R, 1989, BIOCHEMISTRY-US, V28, P5840, DOI 10.1021/bi00440a021; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; WU M, 1995, BIOCHEMISTRY-US, V34, P3204, DOI 10.1021/bi00010a009	43	357	359	2	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					705	712		10.1016/S0092-8674(00)80457-2	http://dx.doi.org/10.1016/S0092-8674(00)80457-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393863	Bronze			2022-12-01	WOS:A1997YH96000017
J	Kawano, T; Cui, JQ; Koezuka, Y; Toura, I; Kaneko, Y; Motoki, K; Ueno, H; Nakagawa, R; Sato, H; Kondo, E; Koseki, H; Taniguchi, M				Kawano, T; Cui, JQ; Koezuka, Y; Toura, I; Kaneko, Y; Motoki, K; Ueno, H; Nakagawa, R; Sato, H; Kondo, E; Koseki, H; Taniguchi, M			CD1d-restricted and TCR-mediated activation of V(alpha)14 NKT cells by glycosylceramides	SCIENCE			English	Article							RECEPTOR-ALPHA-CHAIN; T-CELLS; ANTITUMOR ACTIVITIES; POSITIVE SELECTION; BONE-MARROW; EXPRESSION; THYMOCYTES; ANTIGEN; GALACTOSYLCERAMIDES; MOLECULES	Natural killer T (NKT) lymphocytes express an invariant T cell antigen receptor (TCR) encoded by the V(alpha)14 and J(alpha)281 gene segments. A glycosylceramide-containing alpha-anomeric sugar with a longer fatty acyl chain (C-26) and sphingosine base (C-18) was identified as a ligand for this TCR. Glycosylceramide-mediated proliferative responses of V(alpha)14 NKT cells were abrogated by treatment with chloroquine-concanamycin A or by monoclonal antibodies against CD1dN(beta)8, CD40/CD40L, or B7/CTLA-4/CD28, but not by interference with the function of a transporter-associated protein. Thus, this lymphocyte shares distinct recognition systems with either T or NK cells.	CHIBA UNIV,SCH MED,DIV MOL IMMUNOL,CTR BIOMED SCI,CHUO KU,CHIBA 260,JAPAN; PHARMACEUT RES LAB,KIRIN BREWERY,TAKASAKI,GUMMA 37012,JAPAN; JAPAN SCI & TECHNOL CORP,CORE RES EVOL SCI & TECHNOL PROJECT,TOKYO,JAPAN	Chiba University; Kirin Brewery Company Limited; Japan Science & Technology Agency (JST)			Taniguchi, Masaru/N-7932-2015; Koseki, Haruhiko/I-3825-2014	Taniguchi, Masaru/0000-0001-7821-7179; Koseki, Haruhiko/0000-0001-8424-5854				ADACHI Y, 1995, P NATL ACAD SCI USA, V92, P1200, DOI 10.1073/pnas.92.4.1200; ALI S, 1993, BIOCHEMISTRY-US, V32, P11696, DOI 10.1021/bi00094a028; BALLAS ZK, 1990, J IMMUNOL, V145, P1039; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, J EXP MED, V182, P2091, DOI 10.1084/jem.182.6.2091; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BREIMER ME, 1975, J LIPID RES, V16, P189; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; CORVER J, 1995, J VIROL, V69, P3220, DOI 10.1128/JVI.69.5.3220-3223.1995; COSTANTINO V, 1995, LIEBIGS ANN, P1471; CROSSMAN MW, 1984, BIOCHIM BIOPHYS ACTA, V795, P411, DOI 10.1016/0005-2760(84)90092-4; CROWLEY M, 1989, CELL IMMUNOL, V118, P108, DOI 10.1016/0008-8749(89)90361-4; CUI J, 1997, SCIENCE, V278, P263; DAHIYA R, 1986, LIPIDS, V21, P107, DOI 10.1007/BF02534429; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; JENSEN PE, 1988, J IMMUNOL, V141, P2545; KARLSSON KA, 1973, BIOCHIM BIOPHYS ACTA, V316, P317, DOI 10.1016/0005-2760(73)90072-6; KAWAHARA K, 1994, BIOSCI BIOTECH BIOCH, V58, P600, DOI 10.1271/bbb.58.600; KAWASAKI S, 1994, J BACTERIOL, V176, P284, DOI 10.1128/JB.176.2.284-290.1994; Kobayashi E, 1995, ONCOL RES, V7, P529; Koseki H, 1989, Int Immunol, V1, P557, DOI 10.1093/intimm/1.6.557; LAINE RA, 1987, METHOD ENZYMOL, V138, P186; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LAVIE Y, 1994, BBA-MOL CELL RES, V1220, P323, DOI 10.1016/0167-4889(94)90156-2; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; Makino Y, 1996, P NATL ACAD SCI USA, V93, P6516, DOI 10.1073/pnas.93.13.6516; MASUDA K, 1997, J IMMUNOL, V158, P276; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Mieza MA, 1996, J IMMUNOL, V156, P4035; MORETTA L, 1994, ADV IMMUNOL, V55, P341; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; MOTOKI K, 1995, BIOL PHARM BULL, V18, P1487; NATORI T, 1993, TETRAHEDRON LETT, V34, P5591, DOI 10.1016/S0040-4039(00)73889-5; NISHIMURA K, 1985, J BIOCHEM-TOKYO, V98, P1247, DOI 10.1093/oxfordjournals.jbchem.a135391; NISHIMURA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P269; OKABE K, 1968, BIOCHEM BIOPH RES CO, V31, P137, DOI 10.1016/0006-291X(68)90043-0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; SVENNERHOLM L, 1972, BIOCHIM BIOPHYS ACTA, V280, P626, DOI 10.1016/0005-2760(72)90142-7; SYKES M, 1990, J IMMUNOL, V145, P3209; Taniguchi M, 1996, P NATL ACAD SCI USA, V93, P11025, DOI 10.1073/pnas.93.20.11025; WATANABE K, 1976, J BIOL CHEM, V251, P2385; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	53	2051	2158	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1626	1629		10.1126/science.278.5343.1626	http://dx.doi.org/10.1126/science.278.5343.1626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374463				2022-12-01	WOS:A1997YJ87400042
J	Li, P; Nijhawan, D; Budihardjo, I; Srinivasula, SM; Ahmad, M; Alnemri, ES; Wang, XD				Li, P; Nijhawan, D; Budihardjo, I; Srinivasula, SM; Ahmad, M; Alnemri, ES; Wang, XD			Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade	CELL			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; CYSTEINE PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; BCL-2 PROTEIN; LAMIN-A; GENE; ENCODES; HOMOLOG	We report here the purification of the third protein factor, Apaf-3, that participates in caspase-3 activation in vitro. Apaf-3 was identified as a member of the caspase family, caspase-9. Caspase-9 and Apaf-1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome c and dATP, an event that leads to caspase-9 activation. Activated caspase-9 in turn cleaves and activates caspase-3. Depletion of caspase-9 from S-100 extracts diminished caspase-3 activation. Mutation of the active site of caspase-9 attenuated the activation of caspase-3 and cellular apoptotic response in vivo, indicating that caspase-9 is the most upstream member of the apoptotic protease cascade that is triggered by cytochrome c and dATP.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; THOMAS JEFFERSON UNIV,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Jefferson University; Jefferson University			Alnemri, Emad S/B-4526-2010	Wang, Xiaodong/0000-0001-9885-356X	NIA NIH HHS [AG13487] Funding Source: Medline; NIGMS NIH HHS [GMRO1-55942, GM08014] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CACIOLAROSEN L, 1996, J EXP MED, V183, P1957; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DEJONG D, 1994, CANCER RES, V54, P256; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Eguchi Y, 1997, CANCER RES, V57, P1835; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICHOLSON WD, 1997, TRENDS BIOCHEM SCI, V257, P299; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Sambrook J., 1989, MOL CLONING LAB MANU; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SKOOG L, 1974, J BIOL CHEM, V249, P6434; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; SRINIVASULA SM, 1996, P NATL ACAD SCI USA, V93, P14488; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	62	6031	6262	13	416	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					479	489		10.1016/S0092-8674(00)80434-1	http://dx.doi.org/10.1016/S0092-8674(00)80434-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390557	Bronze			2022-12-01	WOS:A1997YG49200009
J	Fisher, GJ; Wang, ZQ; Datta, SC; Varani, J; Kang, S; Voorhees, JJ				Fisher, GJ; Wang, ZQ; Datta, SC; Varani, J; Kang, S; Voorhees, JJ			Pathophysiology of premature skin aging induced by ultraviolet light	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	57th Annual Meeting of the Society-for-Investigative-Dermatology	MAY 01-08, 1996	WASHINGTON, D.C.	Soc Invest Dermatol, Yonsei Univ, Coll Med, Seoul, Korea			TRETINOIN RETINOIC ACID; COLLAGENASE GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TISSUE INHIBITOR; PHOTOAGED SKIN; CROSS-LINKING; I COLLAGEN; METALLOPROTEINASES; DEGRADATION; PROMOTER	Background Long-term exposure to ultraviolet irradiation from sunlight causes premature skin aging (photoaging), characterized in part by wrinkles, altered pigmentation, and loss of skin tone. Photoaged skin displays prominent alterations in the collagenous extracellular matrix of connective tissue. We investigated the role of matrix-degrading metalloproteinases, a family of proteolytic enzymes, as mediators of collagen damage in photoaging. Methods We studied 59 whites (33 men and 26 women, ranging in age from 21 to 58 years) with light-to-moderate skin pigmentation, none of whom had current or prior skin disease. Only some of the participants were included in each of the studies. We irradiated their buttock skin with fluorescent ultraviolet lights under standard conditions and obtained skin samples from irradiated and nonirradiated areas by keratome or punch biopsy. in some studies, tretinoin and its vehicle were applied to skin under occlusion 48 hours before ultraviolet irradiation. The expression of matrix metalloproteinases was determined by in situ hybridization, immunohistology, and in situ zymography. Irradiation-induced degradation of skin collagen was measured by radioimmunoassay of soluble cross-linked telopeptides. The protein lever of tissue inhibitor of matrix metalloproteinases type 1 was determined by Western blot analysis. Results A single exposure to ultraviolet irradiation increased the expression of three matrix metalloproteinases - collagenase, a 92-kd gelatinase, and stromelysin - in skin connective tissue and outer skin layers, as compared with nonirradiated skin. The degradation of endogenous type I collagen fibrils was increased by 58 percent in irradiated skin, as compared with nonirradiated skin. Collagenase and gelatinase activity remained maximally elevated (4.4 and 2.3 times, respectively) for seven days with four exposures to ultraviolet irradiation, delivered at two-day intervals, as compared with base-line levels, Pretreatment of skin with tretinoin (all-trans-retinoic acid) inhibited the induction of matrix metalloproteinase proteins and activity (by 70 to 80 percent) in both connective tissue and outer layers of irradiated skin. Ultraviolet irradiation also induced tissue inhibitor of matrix metalloproteinases-1, which regulates the enzyme. Induction of the inhibitor was not affected by tretinoin. Conclusions Multiple exposures to ultraviolet irradiation lead to sustained elevations of matrix metalloproteinases that degrade skin collagen and may contribute to photoaging. Treatment with topical tretinoin inhibits irradiation-induced matrix metalloproteinases but not their endogenous inhibitor. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), UNIV MICHIGAN, SCH MED,DEPT DERMATOL,MED SCI 1,RM 6447, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA.		DATTA, SUBHAS CHANDRA/GRY-6638-2022	Scharffetter-Kochanek, Karin/0000-0002-9655-685X				AUTIO P, 1993, ARCH DERMATOL RES, V285, P322, DOI 10.1007/BF00371831; Bernstein EF, 1996, J AM ACAD DERMATOL, V34, P209, DOI 10.1016/S0190-9622(96)80114-9; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; CALDERONE DC, 1995, J AM ACAD DERMATOL, V32, P1016, DOI 10.1016/0190-9622(95)91342-4; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; ELLIS CN, 1990, J AM ACAD DERMATOL, V23, P629, DOI 10.1016/0190-9622(90)70265-J; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FISHER GJ, 1991, J INVEST DERMATOL, V96, P814; GACK S, 1994, J BIOL CHEM, V269, P10363; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; GILCHREST BA, 1992, BRIT J DERMATOL, V127, P25, DOI 10.1111/j.1365-2133.1992.tb16984.x; GRIFFITHS CEM, 1993, NEW ENGL J MED, V329, P530, DOI 10.1056/NEJM199308193290803; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Kaminer Michael S., 1995, P1; KANG SW, 1995, J INVEST DERMATOL, V105, P549, DOI 10.1111/1523-1747.ep12323445; KAZAMA T, 1988, J INVEST DERMATOL, V91, P560, DOI 10.1111/1523-1747.ep12476939; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; Lavker Robert M., 1995, P123; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; OHKUBO T, 1973, ACTA DERM-VENEREOL, V53, P121; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; RISTELI J, 1993, CLIN CHEM, V39, P635; SATO H, 1993, ONCOGENE, V8, P395; SCHWARTZ E, 1993, PHOTOCHEM PHOTOBIOL, V58, P841, DOI 10.1111/j.1751-1097.1993.tb04981.x; SMITH JG, 1962, J INVEST DERMATOL, V39, P347, DOI 10.1038/jid.1962.122; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; UITTO J, 1993, DERMATOLOGY GEN MED, V1, P299; WARREN R, 1992, J AM ACAD DERMATOL, V26, P558; WARREN R, 1991, J AM ACAD DERMATOL, V25, P751, DOI 10.1016/S0190-9622(08)80964-4; WEINSTOCK MA, 1994, J INVEST DERMATOL, V102, pS4, DOI 10.1111/1523-1747.ep12385720; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920; WOOLSON RF, 1987, STATISTICAL METHODS, P314; YAMAUCHI M, 1991, J INVEST DERMATOL, V97, P938	43	975	1044	8	98	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1419	1428		10.1056/NEJM199711133372003	http://dx.doi.org/10.1056/NEJM199711133372003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YF253	9358139				2022-12-01	WOS:A1997YF25300003
J	Cook, JG; Bardwell, L; Thorner, J				Cook, JG; Bardwell, L; Thorner, J			Inhibitory and activating functions for MAPK Kss1 in the S-cerevisiae filamentous-growth signalling pathway	NATURE			English	Article							PHEROMONE RESPONSE PATHWAY; YEAST SACCHAROMYCES-CEREVISIAE; INVASIVE GROWTH; KINASE CASCADE; CELL; GENE; PHOSPHORYLATION; ELEMENTS; FUS3; STE7	Mitogen-activated protein kinase (MAPK) cascades are conserved signalling modules that regulate responses to diverse extracellular stimuli, developmental cues and environmental stresses (reviewed in refs 1-3). A MAPK is phosphorylated and activated by a MAPK kinase (MAPKK), which is activated by an upstream protein kinase, such as Raf, Mos or a MAPKK kinase. Ste7, a MAPKK in the yeast Saccharomyces cerevisiae, is required for two developmental pathways: mating(4) and invasive (filamentous) growth(5,6). Kss1 and Fus3, the MAPK targets of Ste7, are required for mating(7,8), but their role in invasive growth has been unclear.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Bardwell, Lee/I-8284-2019; THORNER, Jeremy/O-6132-2019	Bardwell, Lee/0000-0002-2393-8363; THORNER, Jeremy/0000-0002-2583-500X; Cook, Jeanette/0000-0003-0849-7405				BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Sherman F., 1986, METHODS YEAST GENETI; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; ZHOU Z, 1995, MOL CELL BIOL, V13, P2069	24	218	220	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	1997	390	6655					85	88		10.1038/36355	http://dx.doi.org/10.1038/36355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363895				2022-12-01	WOS:A1997YE47700057
J	Frisch, M; Glimelius, B; vandenBrule, AJC; Wohlfahrt, J; Meijer, CJLM; Walboomers, JMM; Goldman, S; Svensson, C; Adami, HO; Melbye, M				Frisch, M; Glimelius, B; vandenBrule, AJC; Wohlfahrt, J; Meijer, CJLM; Walboomers, JMM; Goldman, S; Svensson, C; Adami, HO; Melbye, M			Sexually transmitted infection as a cause of anal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN PAPILLOMAVIRUS DNA; HOMOSEXUAL MEN; INTRAEPITHELIAL NEOPLASIA; CARCINOMA; PREVALENCE; DISEASES; PARALLEL; DENMARK; SMOKING; RISK	Background The incidence of anal cancer has increased in recent decades, particularly among women. To identify underlying risk factors, we conducted a population-based case-control study in Denmark and Sweden. Methods We conducted telephone interviews with 324 women and 93 men in whom invasive or in situ anal cancer was diagnosed between 1991 and 1994, 534 controls with adenocarcinoma of the rectum, and 554 population controls. The interviews covered a wide spectrum of possible risk factors for anal cancer. Odds ratios were calculated by logistic regression. Specimens of anal-cancer tissue and samples of rectal adenocarcinomas were tested for human papillomavirus (HPV) DNA with the polymerase chain reaction. Results Multivariate analysis revealed consistent and statistically significant associations between measures of sexual promiscuity and the risk of anal cancer in both men and women. There was a significant trend toward an association between higher numbers of partners of the opposite sex in women (P<0.001) and men (P<0.05) and strong associations with a variety of venereal diseases. In women, receptive anal intercourse, particularly before the age of 30 years, and venereal infections in the partner were also associated with an increased risk (odds ratios, 3.4 and 2.4, respectively). Fifteen percent of the men with anal cancer reported having had homosexual contact, as compared with none of the controls (P<0.001). Highrisk types of HPV, notably HPV-16, were detected in 84 percent of the anal-cancer specimens examined, whereas all rectal-adenocarcinoma specimens tested were negative for HPV. Conclusions Our study provides strong evidence that a sexually transmitted infection causes anal cancer. The presence of high-risk types of HPV, notably HPV-16 (which is known to cause cancer of the cervix), in the majority of anal-cancer tissue specimens suggests that most anal cancers are potentially preventable. (C) 1997, Massachusetts Medical Society.	UNIV UPPSALA HOSP, DEPT ONCOL, S-75185 UPPSALA, SWEDEN; VRIJE UNIV AMSTERDAM, UNIV HOSP, DEPT PATHOL, SECT MOL PATHOL, AMSTERDAM, NETHERLANDS; ERSTA HOSP, DEPT SURG, STOCKHOLM, SWEDEN; HUDDINGE UNIV HOSP, ONCOL DEPT SO STOCKHOLM, STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED EPIDEMIOL, STOCKHOLM, SWEDEN; HARVARD UNIV, DEPT EPIDEMIOL, BOSTON, MA USA; HARVARD UNIV, HARVARD CTR CANC PREVENT, BOSTON, MA USA	Uppsala University; Uppsala University Hospital; Vrije Universiteit Amsterdam; Ersta Sjukhus; Karolinska Institutet; Karolinska Institutet; Harvard University; Harvard University	Frisch, M (corresponding author), STATENS SERUM INST, DEPT EPIDEMIOL RES, DANISH EPIDEMIOL SCI CTR, DK-2300 COPENHAGEN, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785				Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BERAL V, 1974, LANCET, V1, P1037; Binkley George E., 1945, AMER JOUR DIGEST DIS, V12, P46; COOPER HS, 1979, DIS COLON RECTUM, V22, P557, DOI 10.1007/BF02587005; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988; DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HIGGINS GD, 1991, CANCER-AM CANCER SOC, V68, P561, DOI 10.1002/1097-0142(19910801)68:3<561::AID-CNCR2820680320>3.0.CO;2-R; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HOLM R, 1994, MODERN PATHOL, V7, P449; HOLMES F, 1988, GASTROENTEROLOGY, V95, P107, DOI 10.1016/0016-5085(88)90297-1; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; *IARC, 1995, IARC MON EV CARC RIS, V64; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JUDSON FN, 1980, AM J EPIDEMIOL, V112, P836, DOI 10.1093/oxfordjournals.aje.a113056; LI FP, 1982, LANCET, V2, P391; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; MELBYE M, 1994, AM J EPIDEMIOL, V139, P772, DOI 10.1093/oxfordjournals.aje.a117073; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MUNOZ N, 1989, IARC SCI PUBL, V94, P9; NOFFSINGER AE, 1995, CANCER, V75, P958, DOI 10.1002/1097-0142(19950215)75:4<958::AID-CNCR2820750410>3.0.CO;2-1; PALEFSKY JM, 1991, CANCER RES, V51, P1014; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; SAS INSTITUTE INC., 1996, SAS STAT SOFTW CHANG, p[231, 531]; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1990, J CLIN PATHOL, V43, P133, DOI 10.1136/jcp.43.2.133; SCHOLEFIELD JH, 1991, GUT, V32, P674, DOI 10.1136/gut.32.6.674; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; Schottenfeld D, 1996, CANC EPIDEMIOLOGY PR, P813; World Health Organization, 1976, INT CLASS DIS	34	460	474	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1350	1358		10.1056/NEJM199711063371904	http://dx.doi.org/10.1056/NEJM199711063371904			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358129				2022-12-01	WOS:A1997YE44600004
J	Nossal, GJV				Nossal, GJV			Host immunobiology and vaccine development	LANCET			English	Article							T-CELLS; IMMUNE-RESPONSES; INVIVO; SUBSETS	As the rules of immunoregulation become clearer, the design of vaccines and adjuvants is becoming more scientific. To understand these rules, the interactions between three kinds of cells need to be grasped. Antigen-presenting cells (APCs) initiate the immunoglobulin cascade. The most important of these are dendritic cells, which must first capture antigen, a process aided by particulate matter, the presence of natural or acquired antibodies, or the capacity to activate complement. Then T cells become activated through conjoint action of processed antigenic peptides and APC surface and secreted molecules. T cells mediate inflammation, develop cytotoxic capacity, and help in antibody formation. Whether cells of type 1 or type 2 predominate influences the direction of both cellular and humoral responses. B cells are then activated, leading to antibody formation and often to better antigen presentation. Both T and B cell memory, embedded in long-lived lymphocyte populations, aid heightened immune reactivity when the antigen is re-encountered. The best vaccines stimulate strong memory.			Nossal, GJV (corresponding author), UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA.							BERCK C, 1991, CELL, V67, P1121; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; CHILLER JM, 1970, P NATL ACAD SCI USA, V65, P551, DOI 10.1073/pnas.65.3.551; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DONNELLY JJ, 1994, J IMMUNOL METHODS, V176, P145, DOI 10.1016/0022-1759(94)90308-5; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GROSS A, 1993, J IMMUNOL, V150, P2112; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; KELSOE G, 1995, IMMUNOL TODAY, V16, P324, DOI 10.1016/0167-5699(95)80146-4; MCKENZIE SJ, 1984, J IMMUNOL, V133, P1818; MILLER JFAP, 1972, INT REV CYTOL, V33, P77, DOI 10.1016/S0074-7696(08)61449-7; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; Nossal G. J. V., 1971, Antigens, lymphoid cells and the immune response.; NOSSAL GJV, 1968, J EXP MED, V128, P839, DOI 10.1084/jem.128.4.839; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SZAKAL AK, 1989, ANNU REV IMMUNOL, V7, P91, DOI 10.1146/annurev.immunol.7.1.91; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	27	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1316	1319		10.1016/S0140-6736(97)03257-1	http://dx.doi.org/10.1016/S0140-6736(97)03257-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357421				2022-12-01	WOS:A1997YD68900044
J	Pak, DTS; Pflumm, M; Chesnokov, I; Huang, DW; Kellum, R; Marr, J; Romanowski, P; Botchan, MR				Pak, DTS; Pflumm, M; Chesnokov, I; Huang, DW; Kellum, R; Marr, J; Romanowski, P; Botchan, MR			Association of the origin recognition complex with heterochromatin and HP1 in higher eukaryotes	CELL			English	Article							POSITION-EFFECT VARIEGATION; NONHISTONE CHROMOSOMAL PROTEIN; DNA-REPLICATION; DROSOPHILA-MELANOGASTER; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL STATES; CHROMATIN STRUCTURE; CELL-CYCLE; YEAST; GENE	The origin recognition complex (ORC) is required to initiate eukaryotic DNA replication and also engages in transcriptional silencing in S. cerevisiae. We observed a striking preferential but not exclusive association of Drosophila ORC2 with heterochromatin on interphase and mitotic chromosomes. HP1, a heterochromatin-localized protein required for position effect variegation (PEV), colocalized with DmORC2 at these sites. Consistent with this localization, intact DmORC and HP1 were found in physical complex. The association was shown biochemically to require the chromodomain and shadow domains of HP1. The amino terminus of DmORC1 contained a strong HP1-binding site, mirroring an interaction found independently in Xenopus by a yeast two-hybrid screen. Finally, heterozygous DmORC2 recessive lethal mutations resulted in a suppression of PEV. These results indicate that ORC may play a widespread role in packaging chromosomal domains through interactions with heterochromatin-organizing factors.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA; MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; WELLCOME TRUST & CANC RES CAMPAIGN INST, CAMBRIDGE CB2 1QR, ENGLAND	University of California System; University of California Berkeley; McGill University				Chesnokov, Igor/0000-0002-6659-2913	NCI NIH HHS [CA09041, CA30490] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA030490, R01CA030490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3163; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Botchan M, 1996, P NATL ACAD SCI USA, V93, P9997, DOI 10.1073/pnas.93.19.9997; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Elgin S.C.R., 1978, P112; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; FOE VE, 1989, DEVELOPMENT, V107, P1; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GATTI M, 1976, CHROMOSOMA, V57, P351, DOI 10.1007/BF00332160; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HENIKOFF S, 1995, CURR TOP MICROBIOL, V197, P193; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELLUM R, 1995, J CELL SCI, V108, P1407; KELLUM R, 1995, J CELL SCI, V108, P1419; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOHE AR, 1993, GENETICS, V134, P1149; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; PAK DTS, 1996, THESIS U CALIFORNIA; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PIMPINELLI S, 1976, CHROMOSOMA, V57, P377, DOI 10.1007/BF00332161; PIMPINELLI S, 1985, GENETICS, V109, P721; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; Silver L M, 1978, Methods Cell Biol, V18, P151; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Spofford J. B., 1976, GENET BIOL DROSOPHIL, V1c, P955; SZABAD J, 1982, DEV BIOL, V93, P240, DOI 10.1016/0012-1606(82)90256-1; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	66	346	348	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					311	323		10.1016/S0092-8674(00)80415-8	http://dx.doi.org/10.1016/S0092-8674(00)80415-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363940	Bronze			2022-12-01	WOS:A1997YD94100005
J	Musey, L; Hughes, J; Schacker, T; Shea, T; Corey, L; McElrath, MJ				Musey, L; Hughes, J; Schacker, T; Shea, T; Corey, L; McElrath, MJ			Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; HIV-1 INFECTION; LYMPHOCYTE ACTIVITY; LIMITING DILUTION; IMMUNE-RESPONSES; VACCINIA VIRUS; GAG; VIREMIA; GENE; INDIVIDUALS	Background Early in human immunodeficiency virus type 1 (HIV-1) infection there is a decline in viral replication that has been attributed to host immunity, but the components of this response, particularly the ability of cytotoxic T lymphocytes to control viral burden and influence the outcome of disease, are poorly understood. Methods We prospectively studied 33 patients with primary HIV-1 infection for HIV-specific activated cytotoxic T lymphocytes and memory cytotoxic T lymphocytes and compared these lymphocyte responses with changes in viral load and clinical status over the subsequent 18 to 24 months. Results Soon after infection, activated HIV-specific cytotoxic T lymphocytes, mediated primarily by CD8+ cells, were detected in 17 of 23 patients (74 percent). Memory cytotoxic T lymphocytes were found in 6 of 6 patients tested (100 percent) during the first three months of infection and in 17 of 21 patients (81 percent) tested during the first six months. The frequencies of memory cytotoxic T lymphocytes varied markedly over time, but overall they declined over the first 6 to 8 months and then stabilized over the next 12 to 18 months. The patients with higher frequencies of Env-specific memory cytotoxic T lymphocytes had a median level of plasma HIV-1 RNA about one third that of the patients with lower frequencies (median number of RNA copies per milliliter, 22,000 vs. 62,000; P=0.006). Patients with low frequencies of Env-specific memory cytotoxic T lymphocytes (or none) in early infection had a more rapid decline to less than 300 CD4+ cells per cubic millimeter (P=0.05). Conclusions In early HIV-1 infection, the induction of memory cytotoxic T lymphocytes, particularly those specific for Env, helps control viral replication and is associated with slower declines in CD4+ cell counts. Host cytolytic effector responses appear to delay the progression of HIV-1 disease. (C) 1997, Massachusetts Medical Society.	FRED HUTCHINSON CANC RES CTR,PROGRAM INFECT DIS,DIV CLIN RES,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035605, R37AI035605, P30AI027757] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35605, AI 27757, AI 05065] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Cleveland W.S., 1993, STAT METHODS S, P309; CLOUSE KA, 1989, J CLIN MICROBIOL, V27, P2316, DOI 10.1128/JCM.27.10.2316-2323.1989; Dalod M, 1996, AIDS RES HUM RETROV, V12, P497, DOI 10.1089/aid.1996.12.497; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FLEXNER C, 1988, VIROLOGY, V166, P339, DOI 10.1016/0042-6822(88)90504-1; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAMHAMEDICHERRADI S, 1995, AIDS, V9, P421, DOI 10.1097/00002030-199509050-00002; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MCFARLAND EJ, 1993, J INFECT DIS, V167, P719, DOI 10.1093/infdis/167.3.719; MCFARLAND EJ, 1994, J INFECT DIS, V170, P766, DOI 10.1093/infdis/170.4.766; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Musey L, 1997, J EXP MED, V185, P293, DOI 10.1084/jem.185.2.293; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903; Schacker T, 1997, ANN INTERN MED, V126, P174, DOI 10.7326/0003-4819-126-2-199701150-00024; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SHPAER EG, 1994, AIDS RES HUM RETROV, V10, P1679, DOI 10.1089/aid.1994.10.1679; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; SWAIN SL, 1979, J IMMUNOL, V123, P1062; TASWELL C, 1981, J IMMUNOL, V126, P1614; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537	42	464	492	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1267	1274		10.1056/NEJM199710303371803	http://dx.doi.org/10.1056/NEJM199710303371803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345075				2022-12-01	WOS:A1997YC92000003
J	Uehata, M; Ishizaki, T; Satoh, H; Ono, T; Kawahara, T; Morishita, T; Tamakawa, H; Yamagami, K; Inui, J; Maekawa, M; Narumiya, S				Uehata, M; Ishizaki, T; Satoh, H; Ono, T; Kawahara, T; Morishita, T; Tamakawa, H; Yamagami, K; Inui, J; Maekawa, M; Narumiya, S			Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension	NATURE			English	Article							SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION; BINDING; PHOSPHATASE; CONTRACTION; INHIBITION; FAMILY; GTPASE; CA-2+; BRAIN	Abnormal smooth-muscle contractility may be a major cause of disease states such as hypertension, and a smooth-muscle relaxant that modulates this process would be useful therapeutically. Smooth-muscle contraction is regulated by the cytosolic Ca2+ concentration and by the Ca2+ sensitivity of myofilaments(1): the former activates myosin light-chain kinase and the latter is achieved partly by inhibition of myosin phosphatase(1-3). The small GTPase Rho and its target, Rho-associated kinase, participate in this latter mechanism in vitro(4-6), but their participation has not been demonstrated in intact muscles. Here we show that a pyridine derivative, Y-27632, selectively inhibits smooth-muscle contraction by inhibiting Ca2+ sensitization. We identified the Y-27632 target as a Rho-associated protein kinase, p160ROCK(7). Y-27632 consistently suppresses Rho-induced, p160ROCK-mediated formation of stress fibres in cultured cells and dramatically corrects hypertension in several hypertensive rat models. Our findings indicate that p160ROCK-mediated Ca2+ sensitization is involved in the pathophysiology of hypertension and suggest that compounds that inhibit this process might be useful therapeutically.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 60601,JAPAN	Kyoto University	Uehata, M (corresponding author), YOSHITOMI PHARMACEUT IND LTD,DISCOVERY RES TOKYO,IRUMA,SAITAMA 358,JAPAN.		Yamagami, Keiji/E-9500-2012					ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BUBIN CS, 1974, METHOD ENZYMOL, V38, P308; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SATOH H, 1984, EUR J PHARMACOL, V97, P321, DOI 10.1016/0014-2999(84)90468-0; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; TAKAYASU M, 1986, J NEUROSURG, V65, P80, DOI 10.3171/jns.1986.65.1.0080; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1	29	2430	2580	0	116	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					990	994		10.1038/40187	http://dx.doi.org/10.1038/40187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353125				2022-12-01	WOS:A1997YD29900061
J	Harvey, I; Frankel, S; Marks, R; Shalom, D; Morgan, M				Harvey, I; Frankel, S; Marks, R; Shalom, D; Morgan, M			Foot morbidity and exposure to chiropody: population based study	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL CARDIFF,COLL MED,DEPT DERMATOL,CARDIFF CF4 4XN,S GLAM,WALES; TEMPLE PEACE & HLTH,CTR APPL PUBL HLTH,CARDIFF CF1 3NW,S GLAM,WALES	Cardiff University	Harvey, I (corresponding author), DEPT SOCIAL MED,CANYNGE HALL,BRISTOL BS8 2PR,AVON,ENGLAND.		Morgan, Maria/D-3379-2009	Morgan, Maria/0000-0002-5182-7222				BENNETT N, 1996, RESULTS 1994 GEN HOU; BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; CARTWRIGHT A, 1986, MORE TROUBLE FEET; *CHIR TASK FORC, 1994, FEET 1; Harvey I, 1996, BRIT J CANCER, V74, P1302, DOI 10.1038/bjc.1996.534	5	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1054	1055		10.1136/bmj.315.7115.1054	http://dx.doi.org/10.1136/bmj.315.7115.1054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366731	Green Published			2022-12-01	WOS:A1997YD44500020
J	Greene, EA; Pietrokovski, S; Henikoff, S; Bork, P; Attwood, TK; Hood, L; Bairoch, A				Greene, EA; Pietrokovski, S; Henikoff, S; Bork, P; Attwood, TK; Hood, L; Bairoch, A			Building gene families	SCIENCE			English	Article									EUROPEAN MOL BIOL LAB, HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY; UCL, LONDON WC1E 6BT, ENGLAND; UNIV WASHINGTON, SEATTLE, WA 98195 USA; UNIV GENEVA, CH-1211 GENEVA 4, SWITZERLAND	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of London; University College London; University of Washington; University of Washington Seattle; University of Geneva	Greene, EA (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Bork, Peer/F-1813-2013; Bairoch, Amos/X-7411-2019	Bork, Peer/0000-0002-2627-833X; Bairoch, Amos/0000-0003-2826-6444; Henikoff, Steven/0000-0002-7621-8685; Pietrokovski, Shmuel/0000-0001-8573-5863					0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					615	626						12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381172				2022-12-01	WOS:A1997YC32300040
J	Kelner, KL				Kelner, KL			The importance of telomerase	SCIENCE			English	Editorial Material																		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822	5	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					600	600		10.1126/science.278.5338.600	http://dx.doi.org/10.1126/science.278.5338.600			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381167				2022-12-01	WOS:A1997YC32300035
J	Patterson, C; Rosenthal, C				Patterson, C; Rosenthal, C			Living a little more dangerously	LANCET			English	Article							HEALTH; RISK; DISCOURSE		MCMASTER UNIV,OFF GERONTOL STUDIES,HAMILTON,ON,CANADA	McMaster University	Patterson, C (corresponding author), MCMASTER UNIV,DIV GERIATR MED,HAMILTON,ON L8N 3Z5,CANADA.							*ASS RES SCI ENJ, 1997, WORKSH VAL PLEAS QUE; CONNIDIS I, 1987, AGING CANADA SOCIAL, P451; KAUFMAN SR, 1994, MED ANTHROPOL Q, V8, P430, DOI 10.1525/maq.1994.8.4.02a00060; LAVE LB, 1987, SCIENCE, V236, P291, DOI 10.1126/science.3563509; LUPTON D, 1993, INT J HEALTH SERV, V23, P425, DOI 10.2190/16AY-E2GC-DFLD-51X2; MACMILLAN MS, 1994, J ADV NURS, V29, P249; RODIN J, 1986, SCIENCE, V233, P1271, DOI 10.1126/science.3749877; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Tierney MC, 1997, CAN J AGING, V16, P177, DOI 10.1017/S0714980800014288	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1164	1165		10.1016/S0140-6736(97)08231-7	http://dx.doi.org/10.1016/S0140-6736(97)08231-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB199	9343519				2022-12-01	WOS:A1997YB19900047
J	OssarehNazari, B; Bachelerie, F; Dargemont, C				OssarehNazari, B; Bachelerie, F; Dargemont, C			Evidence for a role of CRM1 in signal-mediated nuclear protein export	SCIENCE			English	Article							ORDER CHROMOSOME STRUCTURE; LOCALIZATION SIGNALS; IMPORT FACTOR; LEPTOMYCIN-B; REV PROTEIN; IDENTIFICATION; YEAST; TRANSPORT; INTERACTS; PATHWAY	Chromosome maintenance region 1 (CRM1), a protein that shares sequence similarities with the karyopherin beta family of proteins involved in nuclear import pathway, was shown to form a complex with the leucine-rich nuclear export signal (NES), This interaction was inhibited by leptomycin B, a drug that prevents the function of the CRM1 protein in yeast, To analyze the role of the CRM1-NES interaction in nuclear export, a transport assay based on semipermeabilized cells was developed. In this system, which reconstituted NES-, cytosol-, and energy-dependent nuclear export, leptomycin B specifically blocked export of NES-containing proteins, Thus, the CRM1 protein could act as a NES receptor involved in nuclear protein export.	INST CURIE,CNRS,UMR 144,F-75248 PARIS 05,FRANCE; INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			BACHELERIE, FRANCOISE/F-8823-2013	BACHELERIE, FRANCOISE/0000-0002-0399-3277				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MELCHIOR F, 1993, J CELL BIOL, V123, P215; MICHAEL WM, 1995, CELL, V83, P415; MICHAEL WM, 1997, EMBO J, V12, P3587; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NISHI K, 1994, J BIOL CHEM, V269, P6320; OSSAREHNAZARI B, UNPUB; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; ROUT M, 1997, LCELL, V89, P715; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	37	616	627	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					141	144		10.1126/science.278.5335.141	http://dx.doi.org/10.1126/science.278.5335.141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311922				2022-12-01	WOS:A1997XZ12400058
J	Albillos, A; Dernick, G; Horstmann, H; Almers, W; deToledo, GA; Lindau, M				Albillos, A; Dernick, G; Horstmann, H; Almers, W; deToledo, GA; Lindau, M			The exocytotic event in chromaffin cells revealed by patch amperometry	NATURE			English	Article							ADRENAL-MEDULLARY CELLS; FUSION PORE; TRANSMITTER RELEASE; TIME-COURSE; SECRETORY GRANULES; SINGLE VESICLES; CATECHOLAMINES; FORMS	In mast cells and granulocytes, exocytosis starts with the formation of a fusion pore(1-3). It has been suggested that neurotransmitters may be released through such a narrow pore without full fusion(4,5). However, owing to the small size of the secretory vesicles containing neurotransmitter, the properties of the fusion pore formed during Ca2+-dependent exocytosis and its role in transmitter release are still unknown, Here we investigate exocytosis of individual chromaffin granules by using cell-attached capacitance measurements(3,6) combined,vith electrochemical detection of catecholamines(7,8), achieved by inserting a carbon-fibre electrode into the patch pipette. This allows the simultaneous determination of the opening of individual fusion pores and of the kinetics of catecholamine release from the same vesicle, We found that the fusion-pore diameter stays at <3 nm for a variable period, which can last for several seconds, before it expands, Transmitter is released much faster through this pore than in mast cells, generating a 'foot' signal(8) which precedes the amperometric spike. Occasionally, the narrow pore forms only transiently and does not expand, allowing complete transmitter release without full fusion of the vesicle with the plasma membrane.	MPI MED RES,DEPT MOL & CELL RES,D-69128 HEIDELBERG,GERMANY; UNIV SEVILLA,DEPT PHYSIOL & BIOPHYS,E-41009 SEVILLE,SPAIN	University of Sevilla			Alvarez de Toledo, Guillermo/I-2888-2015; Lindau, Manfred/ABD-3449-2021; Albillos, Almudena/AAA-9098-2019	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Lindau, Manfred/0000-0002-5722-9557; ALBILLOS, ALMUDENA/0000-0003-3315-9715				ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; BACH G, 1967, QUANTITATIVE METHODS, P23; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Chen BM, 1997, J NEUROSCI, V17, P904; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; Chow Robert H., 1995, P245; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; GASNIER B, 1987, FEBS LETT, V222, P215, DOI 10.1016/0014-5793(87)80222-3; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; Moser T, 1995, PFLUG ARCH EUR J PHY, V431, P196, DOI 10.1007/BF00410191; NEHER E, 1993, NATURE, V363, P497, DOI 10.1038/363497a0; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; SCHERMAN D, 1988, NEUROSCIENCE, V27, P1029, DOI 10.1016/0306-4522(88)90207-2; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; Walker A, 1996, PFLUG ARCH EUR J PHY, V432, P885, DOI 10.1007/s004240050212; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	30	461	469	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					509	512		10.1038/39081	http://dx.doi.org/10.1038/39081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333242				2022-12-01	WOS:A1997XY90900060
J	Nightingale, SL				Nightingale, SL			New requirement for pediatric data on drug products proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, JAMA-J AM MED ASSOC, V273, P279	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-01	WOS:A1997XX30300008
J	Warner, KE; Slade, J; Sweanor, DT				Warner, KE; Slade, J; Sweanor, DT			The emerging market for long-term nicotine maintenance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTES; TOBACCO; GUM; ADDICTION; SMOKING	In increasing numbers, Americans will seek to satisfy nicotine addictions through the use of novel nicotine-delivery products devoid of several of the poisons that make cigarettes so deadly. In the vanguard are tobacco industry devices that heat tobacco derivatives rather than burn tobacco, and pharmaceutical industry nicotine-replacement products, with nicotine gum and the patch now available over the counter. Ostensibly, these 2 industries have diametrically opposed objectives, the tobacco industry striving to sustain nicotine addictions, the pharmaceutical industry to end them. However, a series of technological, economic, political, regulatory, and social developments augurs a strange-bedfellows competition in which these industries will vie for shares of a new multibillion dollar long-term nicotine-maintenance market. Regulatory options range from encouraging competition to banning all nicotine-delivery devices. A more realistic approach discourages use of the most dangerous products, while making less hazardous products readily available to adults.	UNIV MED & DENT NEW JERSEY, DEPT MED, NEW BRUNSWICK, NJ USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, ST PETERS MED CTR, NEW BRUNSWICK, NJ 08903 USA; NON SMOKERS RIGHTS ASSOC, OTTAWA, ON, CANADA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Warner, KE (corresponding author), UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT & POLICY, 109 S OBSERV, ANN ARBOR, MI 48109 USA.			Warner, Kenneth/0000-0002-8214-1776				*ASH, 1996, ASH SMOK HLTH RE MAY, P2; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; BENOWITZ NL, 1996, NIH PUBLICATION, P93; BRODER K, 1990, J NATL CANCER I, V82, P8, DOI 10.1093/jnci/82.1.8; Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; CAMPBELL WI, 1994, REGULATION TOBACCO P, P542; Cunningham R, 1995, TOB CONTROL, V4, P80, DOI DOI 10.1136/TC.4.1.80; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DAVIS RM, 1993, TOB CONTROL, V2, P11; Eliasson B, 1996, CIRCULATION, V94, P878, DOI 10.1161/01.CIR.94.5.878; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; GIOVINO GA, 1996, NIH PUBLICATION, P39; Glantz SA., 1996, CIGARETTE PAPERS; GORI GB, 1978, JAMA-J AM MED ASSOC, V240, P1255; HARRIS JE, 1994, 4803 NBER; HEISHMAN SJ, 1993, DRUG ALCOHOL DEPEN, V34, P11, DOI 10.1016/0376-8716(93)90041-N; Heishman SJ, 1994, EXP CLIN PSYCHOPHARM, V2, P345, DOI 10.1037/1064-1297.2.4.345; HENNINGFIELD JE, 1996, NATL I HLTH PUBLICAT, P113; HILTS PJ, 1994, NY TIMES        1127, P1; Hilts PJ, 1996, SMOKE SCREEN TRUTH T; HILTS PJ, 1994, NY TIMES        1127, P13; HOLBROOK J, 1983, HARRISONS PRINCIPLES, P1303; HUGHES JR, 1995, TOB CONTROL, V4, pS33; HWANG SL, 1996, WALL STREET J   0521; JAMIESON S, 1997, CHARLOTTE OBSER 0317, pE1; JARVIK ME, 1993, NICOTINE ADDICTION P, P245; JIMENEZRUIZ C, 1997, NICOTINE REPLACEMENT; KLUGER R, 1996, ASHES ASHES AM HUNDR; KOZLOWSKI LT, 1996, NAT I HLTH PUBLICATI, P161; Leischow SJ, 1996, AM J HEALTH BEHAV, V20, P364; LEISCHOW SJ, 1996, J ADDICT DIS, V15, P146; LONGO WE, 1995, CANCER RES, V55, P2232; Mahood G., 1995, TOB CONTROL, V4, P10, DOI [10.1136/tc.4.1.10, DOI 10.1136/TC.4.1.10]; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Murray RP, 1996, CHEST, V109, P438, DOI 10.1378/chest.109.2.438; Oster G, 1996, MED CARE, V34, P389, DOI 10.1097/00005650-199605000-00002; PAULY JL, 1995, TOB CONTROL, V4, P261, DOI DOI 10.1136/TC.4.3.261; Puska P, 1995, TOB CONTROL, V4, P231, DOI [10.1136/tc.4.3.231, DOI 10.1136/TC.4.3.231]; RJ Reynolds Tobacco Co, 1988, CHEM BIOL STUD NEW C; Rodu B., 1995, SMOKERS ONLY SMOKELE; RUSSELL MAH, 1991, BRIT J ADDICT, V86, P653; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; SCHWARTZ J, 1997, WASH POST       0426, pA1; SLADE J, 1989, J PSYCHOACTIVE DRUGS, V21, P281, DOI 10.1080/02791072.1989.10472169; SLADE J, 1993, NICOTINE ADDICTION P, P3; SLADE J, 1992, TOBACCO CONTROL S, V1, pS10; Smith CJ, 1996, MUTAT RES-ENVIR MUTA, V361, P1, DOI 10.1016/S0165-1161(96)90222-8; Steimle S, 1996, J NATL CANCER I, V88, P1341, DOI 10.1093/jnci/88.19.1341; *TOB HLTH PROGR, IN PRESS GUID CONTR; TOMAR SL, 1996, TOB CONTROL, V5, P77; U.S. Department of Health and Human Services, 1990, US DEP HLTH HUM SERV; *US DEP HHS, 1996, FED REGISTER, V61, P44396; *US DEP HHS, 1996, NAT I HLTH PUBL; US Department of Health and Human Services, 1988, US DEP HLTH HUM SERV, VCDC 88-8406; US Department of Health and Human Services National Center for Health Statistics, 1989, US DEP HLTH HUM SERV, V169; WEST R, 1991, BRIT J ADDICT, V86, P485; WILKE M, 1996, ADVERTISING AGE 0819, P10; WILLNER JS, 1983, FAMILY MED, P1662	59	72	73	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1087	1092		10.1001/jama.278.13.1087	http://dx.doi.org/10.1001/jama.278.13.1087			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315768				2022-12-01	WOS:A1997XX30300033
J	Steinhoff, MC; AbdElKhalek, MK; Khallaf, N; Hamza, HS; ElAyadi, A; Orabi, A; Fouad, H; Kamei, M				Steinhoff, MC; AbdElKhalek, MK; Khallaf, N; Hamza, HS; ElAyadi, A; Orabi, A; Fouad, H; Kamei, M			Effectiveness of clinical guidelines for the presumptive treatment of streptococcal pharyngitis in Egyptian children	LANCET			English	Article							RHEUMATIC HEART-DISEASE; DEVELOPING-COUNTRIES; DIAGNOSIS; FEVER; PREVENTION; MANAGEMENT	Background Primary prevention of acute rheumatic fever requires antibiotic treatment of acute streptococcal pharyngitis. In developing countries, clinicians must rely on clinical guidelines for presumptive treatment of streptococcal pharyngitis since bacterial culture and rapid diagnostic tests are not feasible. We evaluated the WHO Acute Respiratory Infection guideline in a large urban paediatric clinic in Egypt. Methods Children between 2 and 13 years of age who had a sore throat and pharyngeal erythema were enrolled in the study. Clinical, historical, and demographic information was recorded and a throat culture for group A P-haemolytic streptococci was done. Sensitivity (% of true-positive throat cultures) and specificity (% of true-negative throat cultures] were calculated for each clinical feature. The effect of various guidelines on correct presumptive treatment for throat-culture status was calculated. Findings Of 451 children with pharyngitis, 107 (24%) had group A beta-haemolytic streptococci on throat culture. A purulent exudate was seen in 22% (99/450) of these children and this sign was 31% sensitive and 81% specific for a positive culture. The WHO Acute Respiratory Infections [ARI) guidelines, which suggest treatment for pharyngeal exudate plus enlarged and tender cervical node, were 12% sensitive and 94% specific; 13/107 children with a positive throat culture would correctly receive antibiotics and 323/344 with a negative throat culture would, correctly, not receive antibiotics. Based on our data we propose a modified guideline whereby exudate or large cervical nodes would indicate antibiotic treatment, and this guideline would be 84% sensitive and 40% specific; 90/107 children with a positive throat culture would correctly receive antibiotics and 138/344 with a negative throat culture would, correctly, not receive antibiotics. Interpretation The WHO ARI clinical guideline has a high specificity but low sensitivity that limits the unnecessary use of antibiotics, but does not treat 88% of children with a positive streptococcal throat culture who are al risk of acute rheumatic fever. A modified guideline may be more useful in this population. Prospective studies of treatment guidelines from many regions are needed to assess their use since the frequency of pharyngitis varies.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; CAIRO UNIV,ABU REESH HOSP,SCH MED,CAIRO,EGYPT; MINIST HLTH CAIRO,CAIRO,EGYPT	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	Steinhoff, MC (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,624 N BROADWAY,SUITE 125,BALTIMORE,MD 21205, USA.							AGARWAL BL, 1981, LANCET, V2, P910; *AM AC PED COMM IN, 1994, RED BOOK, P430; ARGUEDAS A, 1992, J PEDIATR-US, V121, P569, DOI 10.1016/S0022-3476(05)81146-1; BREESE BB, 1954, J PEDIATR-US, V44, P670, DOI 10.1016/S0022-3476(54)80008-4; CHERAYIL BJ, 1987, TROP PEDIAT, V33, P157; DIPPEL DWJ, 1992, J FAM PRACTICE, V34, P149; EISENBERG MJ, 1993, EUR HEART J, V4, P122; el-Kholy A, 1973, J Med Microbiol, V6, P101; ELKHOLY A, 1980, J INFECT DIS, V141, P759, DOI 10.1093/infdis/141.6.759; GORDIS L, 1973, NEW ENGL J MED, V289, P331, DOI 10.1056/NEJM197308162890701; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; MAJEED HA, 1993, ANN TROP PAEDIATR, V13, P65, DOI 10.1080/02724936.1993.11747626; MARKOWITZ M, 1991, PEDIATR INFECT DIS J, V10, pS11, DOI 10.1097/00006454-199110001-00003; MARKOWITZ M, 1985, J PEDIATR-US, V106, P545, DOI 10.1016/S0022-3476(85)80069-X; MCLAREN MJ, 1994, ANN INTERN MED, V120, P243, DOI 10.7326/0003-4819-120-3-199402010-00012; *RHEUM FEV COMM AM, 1977, THROAT CULT RAT TREA; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P80; SOROUR AH, 1969, J EGYPT MED ASS S8, V52, P1; TILLERMAN M, 1961, AM J DIS CHILD, V101, P476; WANNAMAKER LW, 1972, AM J DIS CHILD, V124, P352, DOI 10.1001/archpedi.1972.02110150050009; WANNAMAKER LW, 1984, MANAGEMENT PHARYNGIT, P25; *WHO, 1995, B WORLD HEALTH ORGAN, V73, P735; *WHO, 1991, WHOARI905, P41; *WHO, 1994, JOINT WHO ISFC M PRI, P4; 1995, B WORLD HEALTH ORGAN, V73, P583	25	64	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					918	921		10.1016/S0140-6736(97)03317-5	http://dx.doi.org/10.1016/S0140-6736(97)03317-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314870				2022-12-01	WOS:A1997XY67200010
J	Busettini, C; Masson, GS; Miles, FA				Busettini, C; Masson, GS; Miles, FA			Radial optic flow induces vergence eye movements with ultra-short latencies	NATURE			English	Article							OCULAR-FOLLOWING RESPONSES; SUPERIOR TEMPORAL AREA; MACAQUE MONKEY; EXPANSION CONTRACTION; ROTATION CELLS; SELF-MOTION; DORSAL PART; MST NEURONS; DEPENDENCE; DIRECTION	An observer moving forwards through the environment experiences a radial pattern of image motion on each retina, Such patterns of optic now are a potential source of information about the observer's rate of progress(1), direction of heading(2) and time to reach objects that lie ahead(3). As the viewing distance changes there must be changes in the vergence angle between the two eyes so that both foveas remain aligned on the object of interest in the scene ahead. Here we show that radial optic flow can elicit appropriately directed (horizontal) vergence eye movements with ultra-short latencies (roughly 80 ms) in human subjects. Centrifugal flow, signalling forwards motion, increases the vergence angle, whereas centripetal now decreases the vergence angle. These vergence eye movements are still evident when the observer's view of the flow pattern is restricted to the temporal hemifield of one eye, indicating that these responses do not result from anisotropies in motion processing but from a mechanism that senses the radial pattern of now. We hypothesize that flow-induced vergence is but one of a family of rapid ocular reflexes, mediated by the medial superior temporal cortex, compensating for translational disturbance of the observer.	NEI, SENSORIMOTOR RES LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				Busettini C, 1996, NATURE, V380, P342, DOI 10.1038/380342a0; Busettini C, 1996, J NEUROPHYSIOL, V75, P1392, DOI 10.1152/jn.1996.75.4.1392; BUSETTINI C, 1994, EXP BRAIN RES, V100, P484, DOI 10.1007/BF02738407; Busettini C., 1994, Society for Neuroscience Abstracts, V20, P1403; Cohen Gal A., 1996, Society for Neuroscience Abstracts, V22, P964; Collewijn H, 1990, Rev Oculomot Res, V4, P213; CornilleauPeres V, 1996, TRENDS NEUROSCI, V19, P196, DOI 10.1016/S0166-2236(96)10025-4; DEJONG BM, 1994, BRAIN, V117, P1039; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; DUFFY CJ, 1995, J NEUROSCI, V15, P5192; ENRIGHT JT, 1987, PERCEPTION, V16, P731, DOI 10.1068/p160731; ERKELENS CJ, 1986, J PHYSIOL-LONDON, V379, P145, DOI 10.1113/jphysiol.1986.sp016245; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GELLMAN RS, 1990, VISUAL NEUROSCI, V5, P107, DOI 10.1017/S0952523800000158; KAWANO K, 1994, J NEUROPHYSIOL, V71, P2305, DOI 10.1152/jn.1994.71.6.2305; KAWANO K, 1997, PARIETAL LOBE CONTRI, P185; Lappe M, 1996, J NEUROSCI, V16, P6265; LEE DN, 1980, PHILOS T R SOC B, V290, P169, DOI 10.1098/rstb.1980.0089; LEE DN, 1976, PERCEPTION, V5, P437, DOI 10.1068/p050437; MASSON GS, 1997, NATURE, V389, P293; MILES FA, 1995, STUD VIS INFORM PROC, V6, P47; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; Prokop T, 1997, EXP BRAIN RES, V114, P63, DOI 10.1007/PL00005624; SAITO H, 1986, J NEUROSCI, V6, P145; Takemura A., 1997, Society for Neuroscience Abstracts, V23, P1557; Takeuchi T, 1997, VISION RES, V37, P2083, DOI 10.1016/S0042-6989(96)00225-8; TANAKA K, 1989, J NEUROPHYSIOL, V62, P642, DOI 10.1152/jn.1989.62.3.642; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	30	71	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					512	515		10.1038/37359	http://dx.doi.org/10.1038/37359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394000				2022-12-01	WOS:A1997YJ86500052
J	AuBuchon, JP; Birkmeyer, JD; Busch, MP				AuBuchon, JP; Birkmeyer, JD; Busch, MP			Safety of the blood supply in the United States: Opportunities and controversies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS IMMUNE GLOBULIN; COST-EFFECTIVENESS ANALYSIS; DETERGENT-TREATED PLASMA; FRESH-FROZEN PLASMA; RISK; INFECTION; TRANSFUSION; HEALTH	The risk for viral transmission by transfusion has been reduced dramatically through improved techniques for selecting and testing blood donors. Initiatives to further improve the safety of the blood supply, including more stringent donor qualifications, additional testing for infectious disease markers, viral inactivation processes, and refinement of transfusion decisions, are possible. However, because the risk for viral transmission by allogeneic transfusion is already low, additional measures will have limited yield and poor cost-effectiveness. Furthermore, unexpected side effects of some of these ''improvements'' may reduce the safety of the blood supply by introducing new risks. Cost-effectiveness analyses of blood safety initiatives have highlighted such successes as the introduction of virus-specific assays for screening donated blood and have identified other interventions that have poor cost-effectiveness estimates. They have also quantitated the threshold level at which the risks of an intervention outweigh its benefits. These analyses have had little effect on decisions about blood safety, possibly because of overwhelming fear of AIDS and difficulties in applying cost-effectiveness estimates to a politically and emotionally charged issue. Future interventions for improving blood supply safety must be evaluated thoroughly and chosen carefully so that the intended goals are met. Communication with the public should be undertaken so that the public understands that some of the desired measures may result in inefficient allocation of health care resources.	DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL & MED, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT SURG, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT COMMUNITY & FAMILY MED, LEBANON, NH 03756 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94118 USA	Dartmouth College; Dartmouth College; Dartmouth College; University of California System; University of California San Francisco	AuBuchon, JP (corresponding author), DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL, 1 MED CTR DR, LEBANON, NH 03756 USA.				NHLBI NIH HHS [N01-HB-47114] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047114] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, JAMA, V274, P1374; [Anonymous], 1987, BAND PLAYED POLITICS; Au Buchon J. P., 1996, Transfusion (Bethesda), V36, p43S; AUBUCHON JP, 1994, JAMA-J AM MED ASSOC, V272, P1210, DOI 10.1001/jama.272.15.1210; AuBuchon JP, 1997, TRANSFUSION, V37, P45, DOI 10.1046/j.1537-2995.1997.37197176950.x; BASKETT TF, 1990, CAN MED ASSOC J, V142, P337; BenHur E, 1996, AIDS, V10, P1183, DOI 10.1097/00002030-199609000-00002; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563; Busch M., 1996, Transfusion (Bethesda), V36, p59S; Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1995, MOL GENETICS DIAGNOS; COHEN BJ, 1990, J VIROL METHODS, V30, P233, DOI 10.1016/0166-0934(90)90065-N; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; Elixhauser A, 1991, Int J Technol Assess Health Care, V7, P604; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; Evans RW, 1996, TRANSFUSION, V36, P671, DOI 10.1046/j.1537-2995.1996.36896374368.x; EVANS RW, 1986, SURG CLIN N AM, V66, P603; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HOROWITZ B, 1992, BLOOD, V79, P826; HUX JE, 1994, J GEN INTERN MED, V9, P195, DOI 10.1007/BF02600123; Kleinman S, 1996, CLIN PRACTICE TRANSF; Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x; Korelitz JJ, 1996, TRANSFUSION, V36, P232, DOI 10.1046/j.1537-2995.1996.36396182141.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Lefrere JJ, 1996, TRANSFUSION, V36, P394, DOI 10.1046/j.1537-2995.1996.36596282581.x; Leveton Lauren B., 1995, HIV BLOOD SUPPLY ANA, P49; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; Lynch TJ, 1996, TRANSFUSION, V36, P770, DOI 10.1046/j.1537-2995.1996.36996420751.x; MINTZ PD, 1992, AM J CLIN PATHOL, V98, P150, DOI 10.1093/ajcp/98.2.150; MORGAN MG, 1993, SCI AM, V269, P32, DOI 10.1038/scientificamerican0793-32; NELSON KE, 1995, INFECT DIS TESTING B; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SCHNEIDERMAN LJ, 1992, AM J PUBLIC HEALTH, V82, P584, DOI 10.2105/AJPH.82.4.584; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WILLIAMSON LM, 1995, VOX SANG, V69, P159, DOI 10.1111/j.1423-0410.1995.tb02590.x	49	124	128	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					904	909		10.7326/0003-4819-127-10-199711150-00009	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382369				2022-12-01	WOS:A1997YF54500007
J	Wong, JK; Hezareh, M; Gunthard, HF; Havlir, DV; Ignacio, CC; Spina, CA; Richman, DD				Wong, JK; Hezareh, M; Gunthard, HF; Havlir, DV; Ignacio, CC; Spina, CA; Richman, DD			Recovery of replication-competent HIV despite prolonged suppression of plasma viremia	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; TYPE-1; EXPRESSION; SEQUENCE; PROTEASE	In evaluating current combination drug regimens for treatment of human immunodeficiency virus (HIV) disease, it is important to determine the existence of viral reservoirs. After depletion of CD8 cells from the peripheral blood mononuclear cells (PBMCs) of both patients and normal donors, activation of patient CD4 lymphocytes with immobilized antibodies to CD3 and CD28 enabled the isolation of virus from PBMCs of six patients despite the suppression of their plasma HIV RNA to fewer than 50 copies per milliliter for up to 2 years. Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,TREATMENT CTR,SAN DIEGO,CA 92103; VET AFFAIRS SAN DIEGO HEALTHCARE SYST,SAN DIEGO,CA 92063	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Wong, JK (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		gunthard, huldrych f/F-1724-2011	gunthard, huldrych f/0000-0002-1142-6723	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, U01AI038858, K11AI001361] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MATSUYAMA T, 1989, AIDS RES HUM RETROV, V5, P139, DOI 10.1089/aid.1989.5.139; Mulder J, 1997, J CLIN MICROBIOL, V35, P1278, DOI 10.1128/JCM.35.5.1278-1280.1997; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Sanchez G, 1997, J VIROL, V71, P2233, DOI 10.1128/JVI.71.3.2233-2240.1997; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1989, IMMUNOLOGY, V66, P628; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	25	1721	1763	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1291	1295		10.1126/science.278.5341.1291	http://dx.doi.org/10.1126/science.278.5341.1291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360926				2022-12-01	WOS:A1997YG04300045
J	Korth, C; Stierli, B; Streit, P; Moser, M; Schaller, O; Fischer, R; SchulzSchaeffer, W; Kretzschmar, H; Raeber, A; Braun, U; Ehrensperger, F; Hornemann, S; Glockshuber, R; Riek, R; Billeter, M; Wuthrich, K; Oesch, B				Korth, C; Stierli, B; Streit, P; Moser, M; Schaller, O; Fischer, R; SchulzSchaeffer, W; Kretzschmar, H; Raeber, A; Braun, U; Ehrensperger, F; Hornemann, S; Glockshuber, R; Riek, R; Billeter, M; Wuthrich, K; Oesch, B			Prion (PrPSc)-specific epitope defined by a monoclonal antibody	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; PROTEIN PRP; MICE; GENE; FORMS	Prions are infectious particles causing transmissible spongiform encephalopathies (TSEs). They consist, at least in part, of an isoform (PrPSc) of the ubiquitous cellular prion protein (PrPC). Conformational differences between PrPC and PrPSc are evident from increased beta-sheet content and protease resistance in PrPSc (refs 1-3). Here we describe a monoclonal antibody, 15B3, that can discriminate between the normal and disease-specific forms of PrP. Such an antibody has been long sought as it should be invaluable far characterizing the infectious particle as well as for diagnosis of TSEs such as bovine spongiform encephalopathy (BSE) or Creutzfeldt-Jakob disease (CJD) in humans. 15B3 specifically precipitates bovine, murine or human PrPSc, but not PrPC, suggesting that it recognizes an epitope common to prions from different species. Using immobilized synthetic peptides, iue mapped three polypeptide segments in PrP as the 15B3 epitope. In the NMR structure of recombinant mouse PrP, segments 2 and 3 of the 15B3 epitope are near neighbours in space, and segment 1 is located in a different part nf the molecule, We discuss models for the PrPSc-specific epitope that ensure close spatial proximity of all three 15B3 segments, either by intermolecular contacts in oligomeric forms of the prion protein or by intramolecular rearrangement.	UNIV ZURICH, BRAIN RES INST, CH-8029 ZURICH, SWITZERLAND; ETH ZURICH, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; UNIV GOTTINGEN, INST NEUROPATHOL, D-37075 GOTTINGEN, GERMANY; UNIV ZURICH, INST NEUROPATHOL, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH, KLIN WIEDERKAUER & PFERDEMED, CH-8057 ZURICH, SWITZERLAND; UNIV ZURICH, INST VET PATHOL, CH-8057 ZURICH, SWITZERLAND; ETH ZURICH, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Gottingen; University of Zurich; University of Zurich; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Korth, C (corresponding author), UNIV ZURICH, PRION AG, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Korth, Carsten/F-7433-2010; Billeter, Martin/A-8293-2010	Riek, Roland/0000-0002-6333-066X				Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHANDLER RL, 1961, LANCET, V1, P1378; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Glockshuber R, 1997, TRENDS BIOCHEM SCI, V22, P241, DOI 10.1016/S0968-0004(97)01070-0; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Kaneko K, 1997, J MOL BIOL, V270, P574, DOI 10.1006/jmbi.1997.1135; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1994, BIOCHEMISTRY-US, V33, P5926, DOI 10.1021/bi00185a033; PADAN EA, 1985, J BIOL CHEM, V260, P8280; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Warwicker J, 1996, BIOCHEM BIOPH RES CO, V226, P777, DOI 10.1006/bbrc.1996.1428; Weiss S, 1996, BIOCHEM BIOPH RES CO, V219, P173, DOI 10.1006/bbrc.1996.0201	27	516	566	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					74	77		10.1038/36337	http://dx.doi.org/10.1038/36337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363892				2022-12-01	WOS:A1997YE47700054
J	Fredricks, DN; Relman, DA				Fredricks, DN; Relman, DA			Cultivation of Whipple bacillus: the irony and the ecstasy	LANCET			English	Editorial Material							DISEASE; IDENTIFICATION		STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Fredricks, DN (corresponding author), STANFORD UNIV,MED CTR,DEPT MED,DIV INFECT DIS & GEOG MED,STANFORD,CA 94305, USA.			Relman, David A./0000-0001-8331-1354; Fredricks, David/0000-0003-2735-6800				BEUSCHER HU, 1995, INFECT IMMUN, V63, P1270, DOI 10.1128/IAI.63.4.1270-1277.1995; DOBBINS WO, 1981, GASTROENTEROLOGY, V80, P1468; Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18; Janeway C. A., 2001, IMMUNE SYSTEM HLTH D; MARACK P, 1994, CELL, V76, P323; Ramzan NN, 1997, ANN INTERN MED, V126, P520, DOI 10.7326/0003-4819-126-7-199704010-00004; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Schoedon G, 1997, J INFECT DIS, V176, P672, DOI 10.1086/514089; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; TRIER JS, 1965, GASTROENTEROLOGY, V48, P684; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z	12	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1262	1263		10.1016/S0140-6736(97)22044-1	http://dx.doi.org/10.1016/S0140-6736(97)22044-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357400	Green Submitted			2022-12-01	WOS:A1997YD68900002
J	MacKie, RM; Hunter, D; Hunter, JAA; Rankin, R; Evans, A; McLaren, K; Fallowfield, M; Hutcheon, A; Morris, A				MacKie, RM; Hunter, D; Hunter, JAA; Rankin, R; Evans, A; McLaren, K; Fallowfield, M; Hutcheon, A; Morris, A			Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94	BRITISH MEDICAL JOURNAL			English	Article							TRENDS	Objective: To determine the changing incidence of and mortality from cutaneous malignant melanoma in Scotland from 1979 to 1994. Design: Detailed registration of clinical and pathological features, surgical and other treatment, and follow up of all cases of cutaneous malignant melanoma diagnosed from 1979 to 1994 and registered with specialist database for Scotland. Setting: Scotland. Subjects: 6288 patients with invasive primary cutaneous malignant melanoma diagnosed between 1 January 1979 and 31 December 1994. Results: The annual age standardised incidence of cutaneous malignant melanoma rose significantly from 3.5 to 7.8 per 100 000 per year in men and from 6.8 to 12.3 per 100 000 per year in women (P < 0.001 for both). World standardised rates increased from 2.7 to 6.0 per 100 000 per year in men and 4.6 to 8.50 per 100 000 in women. The incidence of melanoma continued to increase significantly in men of all ages during the study but the rate stabilised in women after 1986. Mortality from cutaneous malignant melanoma was 1.3 per million per annum in men in 1979, rising to 2.3 per million per annum in 1994 (P < 0.01); it was 2.4 per million per annum in women in 1979, falling to 1.9 per million per annum in 1994 (P = 0.09). The underlying mortality trends showed a continuing rise for men but a downward trend for women that was not significant (P = 0.09). In men, melanoma free survival was 69% at 5 years and 61% at 10 years; in women the corresponding rates were 82% and 75%. Younger patients had higher survival rates, which were not entirely explained by thinner rumours. Over the 15 year period, survival rates improved by 12% overall, only partly owing to thinner tumours. Conclusions: In Scotland the incidence of melanoma in women has stabilised, while mortality associated with melanoma in women shows a downward trend.	RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV EDINBURGH,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; RAIGMORE HOSP,INVERNESS IV8 3UJ,SCOTLAND; NINEWELLS HOSP,DUNDEE DD2 1UB,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,GLASGOW G11 6NJ,LANARK,SCOTLAND; ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND; TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND	University of Edinburgh; University of Dundee; University of Glasgow; University of Aberdeen	MacKie, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,ROBERTSON BLDG,GLASGOW G12 8QQ,LANARK,SCOTLAND.							Balzi D, 1997, CANCER CAUSE CONTROL, V8, P85, DOI 10.1023/A:1018491323442; BRAHME EM, 1994, CANCER, V73, P2324; BURTON RC, 1994, MELANOMA RES, V4, P107, DOI 10.1097/00008390-199404000-00005; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; Giles GG, 1996, BMJ-BRIT MED J, V312, P1121; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; MACKIE RM, 1985, LANCET, V2, P859; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MELIA J, 1995, BRIT J CANCER, V72, P224, DOI 10.1038/bjc.1995.307; *OFF POP CENS SURV, 1995, MORT STAT CAUS E DH2; *OFF POP CENS SURV, 1994, CANC STAT REG EN MB1; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; ROUSH GC, 1992, CANCER-AM CANCER SOC, V69, P1714, DOI 10.1002/1097-0142(19920401)69:7&lt;1714::AID-CNCR2820690712&gt;3.0.CO;2-Z; SCOTTO J, 1991, INT J CANCER, V49, P490, DOI 10.1002/ijc.2910490403; STREETLY A, 1995, INT J EPIDEMIOL, V24, P897, DOI 10.1093/ije/24.5.897	15	128	128	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1117	1121						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374883	Green Published			2022-12-01	WOS:A1997YE61500019
J	Fuhlbrigge, RC; Kieffer, JD; Armerding, D; Kupper, TS				Fuhlbrigge, RC; Kieffer, JD; Armerding, D; Kupper, TS			Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells	NATURE			English	Article							P-SELECTIN; LEUKOCYTE ADHESION; FUCOSYL-TRANSFERASE; GLYCOPROTEIN LIGAND; PHYSIOLOGICAL FLOW; MYELOID CELLS; FUCT-VII; RECEPTOR; MOLECULE; BINDING	T cells play a pathogenic role in many inflammatory and certain malignant skin diseases, including psoriasis, atopic and allergic contact dermatitis, and cutaneous T-cell lymphoma(1-6). Memory T cells that infiltrate the skin express a unique skin-homing receptor called cutaneous lymphocyte-associated antigen (CLA), a carbohydrate epitope that facilitates the targeting of T cells to inflamed skin(1,7,8). CLA is defined by both its reactivity with a unique monoclonal antibody, HECA-452, and its activity as a ligand for E-selectin(2,9-11), but the structure of the protein component of CLA has not previously been defined. Here we report that CLA is an inducible carbohydrate modification of P-selectin glycoprotein ligand-1 (PSGL-1), a known surface glycoprotein that is expressed constitutively on all human peripheral-blood T cells, Cultured peripheral-blood T cells can be differentiated into CLA-bearing cells, which bind both E-selectin and P-selectin, or CLA-negative cells, which bind P-selectin but do not bind E-selectin, suggesting that there is independent regulation of selectin-binding phenotypes, We propose that differential post-translational modification of a single cell-surface receptor, PSGL-1, mediated by fucosyltransferase VII, serves as a mechanism for regulating tissue-specific homing of memory T cells.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV DERMATOL,HARVARD SKIN DIS RES CTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Kupper, Thomas/O-4962-2019					ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ALON R, 1994, J CELL BIOL, V127, P1485, DOI 10.1083/jcb.127.5.1485; BABI LFS, 1995, J IMMUNOL, V154, P1543; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Diacovo TG, 1996, J EXP MED, V183, P1193, DOI 10.1084/jem.183.3.1193; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; JONES DA, 1994, J CLIN INVEST, V94, P2443, DOI 10.1172/JCI117612; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kieffer JD, 1995, BIOCHEM BIOPH RES CO, V217, P466, DOI 10.1006/bbrc.1995.2799; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Lowe John B., 1994, P163; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Pitzalis C, 1996, ARTHRITIS RHEUM, V39, P137, DOI 10.1002/art.1780390118; ROOK AH, 1995, HEMATOL ONCOL CLIN N, V9, P997, DOI 10.1016/S0889-8588(18)30054-6; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Wagers AJ, 1996, BLOOD, V88, P2125, DOI 10.1182/blood.V88.6.2125.bloodjournal8862125	27	420	443	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					978	981		10.1038/40166	http://dx.doi.org/10.1038/40166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353122				2022-12-01	WOS:A1997YD29900058
J	Ikeya, M; Lee, SMK; Johnson, JE; McMahon, AP; Takada, S				Ikeya, M; Lee, SMK; Johnson, JE; McMahon, AP; Takada, S			Wnt signalling required for expansion of neural crest and CNS progenitors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; VITAL DYE ANALYSIS; MOUSE EMBRYO; CELL-MIGRATION; INT-1 PROTOONCOGENE; EXPRESSION; TRANSFORMATION; HINDBRAIN; PATHWAYS; DOMAINS	Interactions between cells help to elaborate pattern within the vertebrate central nervous system (CNS)(1). The genes Wnt-1 and Wnt-3a, which encode members of the Wnt family of cysteine-rich secreted signals, are coexpressed at the dorsal midline of the developing neural tube, coincident with dorsal patterning(2,3). Each signal is essential for embryonic development, Wnt-1 for midbrain patterning(4,5) and Wnt-3a for formation of the paraxial mesoderm(6), but the absence of a dorsal neural-tube phenotype in each mutant suggests that Wnt signalling may be redundant. Here we demonstrate that in the absence of both Wnt-1 and Wnt-3a there is a marked deficiency in neural crest derivatives, which originate from the dorsal neural tube(7), and a pronounced reduction in dorsolateral neural precursors within the neural tube itself. These phenotypes do not seem to result from a disruption in the mechanisms responsible for establishing normal dorsoventral polarity. Rather, our results are consistent with a model in which local Wnt signalling regulates the expansion of dorsal neural precursors. Given the widespread expression of different Wnt genes in discrete areas of the mammalian neural tube(3), this may represent a general model for the action of Wnt signalling in the developing CNS.	KYOTO UNIV, FAC SCI, CTR MOL & DEV BIOL, SAKYO KU, KYOTO 60601, JAPAN; HARVARD UNIV, BIOLABS, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	Kyoto University; Harvard University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Johnson, Jane/F-8881-2010; McMahon, Andrew P/ABE-7520-2020	Ikeya, Makoto/0000-0002-3930-8032; /0000-0002-8605-2746; Takada, Shinji/0000-0003-4125-6056				Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Couly G, 1996, DEVELOPMENT, V122, P3393; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Kontges G, 1996, DEVELOPMENT, V122, P3229; Le Douarin N.M., 1982, NEURAL CREST; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P319; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SERBEDZIJA GN, 1989, DEVELOPMENT, V106, P809; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	30	560	571	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					966	970		10.1038/40146	http://dx.doi.org/10.1038/40146			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353119				2022-12-01	WOS:A1997YD29900055
J	Dahmane, N; Lee, J; Robins, P; Heller, P; Altaba, ARI				Dahmane, N; Lee, J; Robins, P; Heller, P; Altaba, ARI			Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours	NATURE			English	Article							BASAL-CELL CARCINOMAS; HUMAN HOMOLOG; CANDIDATE GENE; EXPRESSION; MUTATIONS; IDENTIFICATION; ONCOGENE; PROTEIN	Sporadic basal cell carcinoma (BCC) is the most common type of malignant cancer in fair-skinned adults. Familial BCCs and a fraction of sporadic BCCs have lost the function of Patched (Ptc), a Sonic hedgehog (Shh) receptor(1-3) that acts negatively on this signalling pathway. Overexpression of Shh can induce BCCs in mice(4). Here we show that ectopic expression of the zinc-finger transcription factor Gli1 in the embryonic frog epidermis results in the development of tumours that express endogenous Gli1. We also show that Shh and the Gli genes are normally expressed in hair follicles, and that human sporadic BCCs consistently express Gli1 but not Shh or Gli3. Because Gli1, but not Gli3, acts as a target and mediator of Shh signalling(5), our results suggest that expression of GLi(1) in basal cells induces BCC formation. Moreover, loss of Ptc or overexpression of Shh cannot be the sole causes of Gli1 induction and sporadic BCC formation, as they do not occur consistently. Thus any mutations leading to the expression of Gli1 in basal cells are predicted to induce CC formation.	NYU,MED CTR,SKIRBALL INST,DEV GENET PROGRAM,NEW YORK,NY 10016; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016	New York University; New York University; New York University				Ruiz i Altaba, Ariel/0000-0003-2292-3933				Ackerman A.B., 1993, NEOPLASMS FOLLICULAR; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; ALTABA ARI, 1995, DEV BIOL, V1270, P299; ALTABA ARI, 1993, ESSENTIAL DEV BIOL P; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GRIMWOOD RE, 1986, J INVEST DERMATOL, V86, P191, DOI 10.1111/1523-1747.ep12284253; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Lee J, 1997, DEVELOPMENT, V124, P2537; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; ROBERTS WM, 1989, CANCER RES, V49, P5407; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5048; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; XIAO HG, 1994, PEDIATR NEUROSURG, V20, P178, DOI 10.1159/000120783	29	515	539	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					876	881		10.1038/39918	http://dx.doi.org/10.1038/39918			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349822				2022-12-01	WOS:A1997YC14800063
J	Lowe, SL; Peter, F; Subramaniam, VN; Wong, SH; Hong, WJ				Lowe, SL; Peter, F; Subramaniam, VN; Wong, SH; Hong, WJ			A SNARE involved in protein transport through the Golgi apparatus	NATURE			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; VESICULAR TRANSPORT; FUSION; VESICLES; COMPLEX; ER; BOS1P; YEAST	In eukaryotic cells, the Golgi apparatus receives newly synthesized proteins from the endoplasmic reticulum (ER) and delivers them after covalent modification to their destination in the cell. These proteins move from the inside (cis) face to the plasma-membrane side (trans) of the Golgi, through a stack of cisternae, towards the trans-Golgi network (TGN), but very little is known about how proteins are moved through the Golgi compartments. In a model known as the maturation model, no special transport process was considered necessary, with protein movement along the Golgi being achieved by maturation of the cisternae. Alternatively, proteins could be transported by vesicles or membrane tubules. Although little is known about membrane-tubule-mediated transport, the molecular mechanism for vesicle-mediated transport is quite well understood, occurring through docking of SNAREs on the vesicle with those on the target membrane. We have now identified a protein of relative molecular mass 27K which is associated with the Golgi apparatus. The cytoplasmic domain of this protein or antibodies raised against it quantitatively inhibit transport in vitro from the ER to the trans-Golgi/TGN, acting at a stage between the cis/medial- and the trans-Golgi/TGN. This protein, which behaves like a SNARE and has been named GS27 (for Golgi SNARE of 27K), is identical to membrin, a protein implicated earlier in ER-to-Golgi transport. Our results suggest that protein movement from medial- to the trans-Golgi/TGN depends on SNARE-mediated vesicular transport.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 119076,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010	Subramaniam, V. Nathan/0000-0002-4583-7790				BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HONG W, 1996, PROTEIN TRAFFICKING; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; Lowe SL, 1996, J CELL SCI, V109, P209; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1992, J CELL BIOL, V119, P1077; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	28	69	73	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					881	884		10.1038/39923	http://dx.doi.org/10.1038/39923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349823				2022-12-01	WOS:A1997YC14800064
J	Cerritelli, ME; Cheng, NQ; Rosenberg, AH; McPherson, CE; Booy, FP; Steven, AC				Cerritelli, ME; Cheng, NQ; Rosenberg, AH; McPherson, CE; Booy, FP; Steven, AC			Encapsidated conformation of bacteriophage T7 DNA	CELL			English	Article							DOUBLE-STRANDED DNA; CRYO-ELECTRON-MICROSCOPY; HERPES-SIMPLEX VIRUS; X-RAY-DIFFRACTION; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; SIMIAN VIRUS-40; WILD-TYPE; HEADS; ORGANIZATION	The structural organization of encapsidated T7 DNA was investigated by cryo-electron microscopy and image processing. A tail-deletion mutant was found to present two preferred views of phage heads: views along the axis through the capsid vertex where the connector protein resides and via which DNA is packaged; and side views perpendicular to this axis. The resulting images reveal striking patterns of concentric rings in axial views, and punctate arrays in side views. As corroborated by computer modeling, these data establish that the T7 chromosome is spooled around this axis in approximately six coaxial shells in a quasicrystalline packing, possibly guided by the core complex on the inner surface of the connector.	NIAMSD,STRUCT BIOL LAB,NIH,BETHESDA,MD 20892; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); United States Department of Energy (DOE); Brookhaven National Laboratory								ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; AUBREY KL, 1992, BIOCHEMISTRY-US, V31, P11835, DOI 10.1021/bi00162a023; BAKER TS, 1989, BIOPHYS J, V55, P243, DOI 10.1016/S0006-3495(89)82799-7; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1985, P NATL ACAD SCI USA, V82, P7960, DOI 10.1073/pnas.82.23.7960; BOOY FP, 1985, J MOL BIOL, V184, P667, DOI 10.1016/0022-2836(85)90312-2; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; BOOY FP, 1992, P 50 ANN M EMSA, V1, P452; BOOY FP, 1992, MEMBRANE FUSION, P21; Casjens S., 1988, BACTERIOPHAGES, V1, P16; Cerritelli ME, 1996, J MOL BIOL, V258, P286, DOI 10.1006/jmbi.1996.0250; Cerritelli ME, 1996, J MOL BIOL, V258, P299, DOI 10.1006/jmbi.1996.0251; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; CHUNG YB, 1990, J MOL BIOL, V216, P939, DOI 10.1016/S0022-2836(99)80012-6; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DIERKSEN K, 1995, BIOPHYS J, V68, P1416, DOI 10.1016/S0006-3495(95)80314-0; DONATE LE, 1990, VIROLOGY, V179, P936, DOI 10.1016/0042-6822(90)90172-N; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EARNSHAW WC, 1979, J MOL BIOL, V134, P575, DOI 10.1016/0022-2836(79)90368-1; EARNSHAW WC, 1978, CELL, V14, P559, DOI 10.1016/0092-8674(78)90242-8; EARNSHAW WC, 1977, NATURE, V268, P598, DOI 10.1038/268598a0; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; Garcia LR, 1996, J BACTERIOL, V178, P6921, DOI 10.1128/jb.178.23.6921-6929.1996; GELLERT M, 1964, J MOL BIOL, V8, P341, DOI 10.1016/S0022-2836(64)80197-2; HARRISON SC, 1983, J MOL BIOL, V171, P577, DOI 10.1016/0022-2836(83)90045-1; HUD NV, 1995, BIOPHYS J, V69, P1355, DOI 10.1016/S0006-3495(95)80002-0; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; KOSTURKO LD, 1979, CELL, V16, P515, DOI 10.1016/0092-8674(79)90026-6; LEPAULT J, 1987, EMBO J, V6, P1507, DOI 10.1002/j.1460-2075.1987.tb02393.x; LEPAULT J, 1985, J MOL BIOL, V182, P431, DOI 10.1016/0022-2836(85)90202-5; Livolant F, 1996, PROG POLYM SCI, V21, P1115, DOI 10.1016/S0079-6700(96)00016-0; MOFFATT BA, 1988, J BACTERIOL, V170, P2095, DOI 10.1128/jb.170.5.2095-2105.1988; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; NORTH AC, 1961, NATURE, V191, P1242, DOI 10.1038/1911242a0; RICHARDS KE, 1973, J MOL BIOL, V78, P255, DOI 10.1016/0022-2836(73)90114-9; ROEDER GS, 1977, VIROLOGY, V76, P263, DOI 10.1016/0042-6822(77)90302-6; SERWER P, 1986, J MOL BIOL, V190, P509, DOI 10.1016/0022-2836(86)90019-7; SERWER P, 1992, J MOL BIOL, V223, P999, DOI 10.1016/0022-2836(92)90258-L; Serwer P, 1997, J STRUCT BIOL, V120, P32, DOI 10.1006/jsbi.1997.3895; SERWER P, 1976, J MOL BIOL, V107, P271, DOI 10.1016/S0022-2836(76)80005-8; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; Steven A. C., 1986, ELECT MICROSCOPY PRO, P1; Steven AC, 1997, FASEB J, V11, P733, DOI 10.1096/fasebj.11.10.9271358; THOMAS GJ, 1990, J RAMAN SPECTROSC, V21, P569, DOI 10.1002/jrs.1250210908; TRUS BL, 1992, P NATL ACAD SCI USA, V89, P11508, DOI 10.1073/pnas.89.23.11508; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; WIDOM J, 1983, J MOL BIOL, V171, P419, DOI 10.1016/0022-2836(83)90038-4	49	298	302	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					271	280		10.1016/S0092-8674(00)80409-2	http://dx.doi.org/10.1016/S0092-8674(00)80409-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346244	Bronze			2022-12-01	WOS:A1997YC35000014
J	Zandi, E; Rothwarf, DM; Delhase, M; Hayakawa, M; Karin, M				Zandi, E; Rothwarf, DM; Delhase, M; Hayakawa, M; Karin, M			The I kappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for I kappa B phosphorylation and NF-kappa B activation	CELL			English	Article							SITE-SPECIFIC PHOSPHORYLATION; INDUCED APOPTOSIS; CELL-DEATH; PROTEINS; SIGNAL; FAMILY; UBIQUITINATION; DISSOCIATION; PROTEOLYSIS; DEGRADATION	Recently we purified a 900 kDa cytokine-responsive I kappa B kinase complex (IKK) and molecularly cloned one of its subunits, IKK alpha, a serine kinase. We now describe the molecular cloning and characterization of IKK beta, a second subunit of the IKK complex. IKK beta is 50% identical to IKK alpha and like it contains a kinase domain, a leucine zipper, and a helix-loop-helix. Although IKK alpha and IKK beta can undergo homotypic interaction, they also interact with each other and the functional IKK complex contains both subunits. The catalytic activities of both IKK alpha and IKK beta make essential contributions to I kappa B phosphorylation and NF-kappa B activation. While the interactions between IKK alpha and IKK beta may be mediated through their leucine zipper motifs, their helix-loop-helix motifs may be involved in interactions with essential regulatory subunits.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LAB GENE REGULAT & SIGNAL TRANSDUCT,LA JOLLA,CA 92093	University of California System; University of California San Diego			Delhase, Mireille/ABE-5256-2021	Delhase, Mireille/0000-0003-2312-1051	NCI NIH HHS [CA50528] Funding Source: Medline; NIEHS NIH HHS [ES06376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	28	1564	1635	1	43	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					243	252		10.1016/S0092-8674(00)80406-7	http://dx.doi.org/10.1016/S0092-8674(00)80406-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346241	Bronze			2022-12-01	WOS:A1997YC35000011
J	Nakao, A; Afrakhte, M; Moren, A; Nakayama, T; Christian, JL; Heuchel, R; Itoh, S; Kawabata, N; Heldin, NE; Heldin, CH; tenDijke, P				Nakao, A; Afrakhte, M; Moren, A; Nakayama, T; Christian, JL; Heuchel, R; Itoh, S; Kawabata, N; Heldin, NE; Heldin, CH; tenDijke, P			Identification of Smad7, a TGF beta-inducible antagonist of TGF-beta signalling	NATURE			English	Article							MESODERM INDUCTION; XENOPUS-EMBRYOS; EXPRESSION; PROTEINS	TGF-beta signals from the membrane to the nucleus through serine. threonine kinase receptors and their downstream effecters, termed SMAD proteins(1). The activated TGF-beta receptor induces phosphorylation of two such proteins, Smad2 and Smad3 (refs 2-6), which form hetero-oligomeric complex(es) with Smad4/DPC4 (refs 5-10) that translocate to the nucleus(2,4,5,7), where they then regulate transcriptional responses(11,12). However, the mechanisms by which the intracellular signals of TGF-beta are switched off are unclear. Here we report the identification of Smad7, which is related to Smad6 (ref. 13). Transfection of Smad7 blocks responses mediated by TGF-beta in mammalian cells, and injection of Smad7 RNA into Xenopus embryos blocks activin/TGF-beta signalling. Smad7 associates stably with the TGF-beta receptor complex, but is not phosphorylated upon TGF-beta stimulation. TGF beta-mediated phosphorylation of Smad2 and Smad3 is inhibited by Smad7, indicating that the antagonistic effect of Smad7 is exerted at this important regulatory step. TGF-beta rapidly induces expression of Smad7 mRNA, suggesting that Smad7 may participate in a negative feedback loop to control TGF-beta responses.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN; OREGON HLTH SCI UNIV,SCH MED,DEPT CELL & DEV BIOL,L215,PORTLAND,OR 97201; JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; JAPAN SOC PROMOT SCI,RES FUTURE PROGRAM,TOSHIMA KU,TOKYO 170,JAPAN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital; Oregon Health & Science University; Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science			Heuchel, Rainer/P-7875-2019; Nakayama, Takuya/J-5812-2015; Dijke, Peter ten/AAG-4660-2021	Heuchel, Rainer/0000-0002-2782-585X; Nakayama, Takuya/0000-0002-5531-6710; Dijke, Peter ten/0000-0002-7234-342X; Itoh, Susumu/0000-0002-7967-0730				Afrakhte M, 1996, INT J CANCER, V68, P802; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MOON RT, 1989, TECHNIQUE, V1, P76; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	29	1478	1590	3	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					631	635		10.1038/39369	http://dx.doi.org/10.1038/39369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335507				2022-12-01	WOS:A1997YA00800067
J	Hall, TMT; Porter, JA; Young, KE; Koonin, EV; Beachy, PA; Leahy, DJ				Hall, TMT; Porter, JA; Young, KE; Koonin, EV; Beachy, PA; Leahy, DJ			Crystal structure of a hedgehog autoprocessing domain: Homology between hedgehog and self-splicing proteins	CELL			English	Article							TERMINAL CLEAVAGE PRODUCT; SONIC HEDGEHOG; AUTOPROTEOLYTIC CLEAVAGE; CIRCULAR PERMUTATIONS; ANOMALOUS DIFFRACTION; PATTERNING ACTIVITY; XENOPUS-LAEVIS; INDUCTION; ALIGNMENT; SEQUENCE	The similar to 25 kDa carboxy-terminal domain of Drosophila Hedgehog protein (Hh-C) possesses an autoprocessing activity that results in an intramolecular cleavage of full-length Hedgehog protein and covalent attachment of a cholesterol moiety to the newly generated amino-terminal fragment. We have identified a 17 kDa fragment of Hh-C (Hh-C-17) active in the initiation of autoprocessing and report here its crystal structure. The Hh-C-17 structure comprises two homologous subdomains that appear to have arisen from tandem duplication of a primordial gene. Residues in the Hh-C-17 active site have been identified, and their role in Hedgehog autoprocessing probed by site-directed mutagenesis. Aspects of sequence, structure, and reaction mechanism are conserved between Hh-C-17 and the self-splicing regions of inteins, permitting reconstruction of a plausible evolutionary history of Hh-C and the inteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOL BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; NIH, NATL CTR BIOTECHNOL INFORMAT, NATL LIB MED, BETHESDA, MD 20894 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)			Hall, Traci/F-5849-2019	Hall, Traci/0000-0001-6166-3009				Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Burglin TR, 1996, CURR BIOL, V6, P1047, DOI 10.1016/S0960-9822(02)70659-3; BURNCROT DA, 1995, MOL CELL BIOL, V15, P2294; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; EKKER SC, 1995, DEVELOPMENT, V121, P2337; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HEINEMANN U, 1995, TRENDS BIOCHEM SCI, V20, P349, DOI 10.1016/S0968-0004(00)89073-8; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JONES DH, 1992, BIOTECHNIQUES, V12, P528; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P141, DOI 10.1016/S0968-0004(00)88989-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; PIETROKOVSKI S, 1997, IN PRESS PROT SCI; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P777, DOI 10.1073/pnas.72.3.777; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	51	224	233	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	1997	91	1					85	97		10.1016/S0092-8674(01)80011-8	http://dx.doi.org/10.1016/S0092-8674(01)80011-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335337	hybrid			2022-12-01	WOS:A1997XZ80900011
J	Xu, J; Dodd, RL; Makino, CL; Simon, MI; Baylor, DA; Chen, J				Xu, J; Dodd, RL; Makino, CL; Simon, MI; Baylor, DA; Chen, J			Prolonged photoresponses in transgenic mouse rods lacking arrestin	NATURE			English	Article							PHOSPHODIESTERASE ACTIVATION; RETINAL RODS; IN-VIVO; RHODOPSIN; PROTEIN; BINDING; PHOTORECEPTORS; INACTIVATION; PHOTOTRANSDUCTION; PHOSPHORYLATION	Arrestins are soluble cytoplasmic proteins that bind to G-protein-coupled receptors, thus switching off activation of the G protein and terminating the signalling pathway that triggers the cellular response(1,2). Although visual arrestin has been shown to quench the catalytic activity of photoexcited, phosphorylated rhodopsin in a reconstituted system(3), its role in the intact rod cell remains unclear because phosphorylation alone reduces the catalytic activity of rhodopsin(4-6). Here we have recorded photocurrents of rods from transgenic mice in which one or both copies of the arrestin gene were disrupted, Photoresponses were unaffected when arrestin expression was halved, indicating that arrestin binding is not rate limiting for recovery of the rod photoresponse, as it is in Drosophila(7,8). With arrestin absent, the flash response displayed a rapid partial recovery followed by a prolonged final phase, This behaviour indicates that an arrestin-independent mechanism initiates the quench of rhodopsin's catalytic activity and that arrestin completes the quench, The intensity dependence of the photoresponse in rods lacking arrestin further suggests that, although arrestin is required for normal signal termination, it does not participate directly in light adaptation.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; CALTECH,DIV BIOL,PASADENA,CA 91125	Stanford University; California Institute of Technology			Makino, Clint Lawrence/H-8428-2019	Makino, Clint Lawrence/0000-0002-6005-9069				ADMUS G, 1997, INVEST OPHTH VIS SCI, V38, P283; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1987, RETINAL PROTEINS, P497; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CONE RA, 1969, NATURE, V221, P820, DOI 10.1038/221820a0; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEE RH, EXP EYE RES, V51, P325; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Palczewski K, 1996, EXP EYE RES, V63, P599, DOI 10.1006/exer.1996.0151; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PENN JS, 1986, EXP EYE RES, V43, P915, DOI 10.1016/0014-4835(86)90070-9; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RAPORT CJ, 1994, INVEST OPHTH VIS SCI, V35, P2932; SCHREMSER JL, 1995, EXP EYE RES, V61, P17, DOI 10.1016/S0014-4835(95)80054-9; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	30	261	263	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					505	509		10.1038/39068	http://dx.doi.org/10.1038/39068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333241				2022-12-01	WOS:A1997XY90900059
J	Liu, Q; Fischer, U; Wang, F; Dreyfuss, G				Liu, Q; Fischer, U; Wang, F; Dreyfuss, G			The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins	CELL			English	Article							MOTOR-NEURON GENE; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; COILED BODY; MOLECULAR ANALYSIS; CDNA CLONING; SURVIVAL; BINDING; DELETIONS; CAP; IDENTIFICATION	Spinal muscular atrophy (SMA), one of the most common fatal autosomal recessive diseases, is characterized by degeneration of motor neurons and muscular atrophy. The SMA disease gene, termed Survival of Motor Neurons (SMN), is deleted or mutated in over 98% of SMA patients. The function of the SMN protein is unknown. We found that SMN is tightly associated with a novel protein, SIP1, and together they form a specific complex with several spliceosomal snRNP proteins. SMN interacts directly with several of the snRNP Sm core proteins, including B, D1-3, and E. Interestingly, SIP1 has significant sequence similarity with Brr1, a yeast protein critical for snRNP biogenesis. these findings suggest a role for SMN and SIP1 in spliceosomal snRNP biogenesis and function and provide a likely molecular mechanism for the cause of SMA.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013; Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020	Dreyfuss, Gideon/0000-0001-8129-8774; Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BOHMANN K, 1995, J CELL SCI S, V19, P107; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CHANG JG, 1995, AM J HUM GENET, V57, P1503; CHOI YD, 1984, J CELL BIOL, V99, P1997; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; CZEIZEI A, 1989, J MED GENET, V21, P761; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FEENEY RJ, 1989, J BIOL CHEM, V264, P5776; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HERRMANN H, 1995, EMBO J, V14, P2076; LATCHMAN D S, 1990, New Biologist, V2, P297; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Liu Q, 1996, COLD SPRING HARB SYM, V61, P689; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; Munsat TL., 1991, NEUROMUSCULAR DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604	50	521	538	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1013	1021		10.1016/S0092-8674(00)80367-0	http://dx.doi.org/10.1016/S0092-8674(00)80367-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323129	hybrid			2022-12-01	WOS:A1997XX76800007
J	Blatchford, O; Davidson, LA; Murray, WR; Blatchford, M; Pell, J				Blatchford, O; Davidson, LA; Murray, WR; Blatchford, M; Pell, J			Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER; HEMORRHAGE; MORTALITY	Objectives: To determine the incidence and case fatality of acute upper gastrointestinal haemorrhage in the west of Scotland and to identify associated factors. Design: Case ascertainment study. Setting: All hospitals treating adults with acute upper gastrointestinal haemorrhage in the west of Scotland. Subjects: 1882 patients aged 15 years and over treated in hospitals for acute upper gastrointestinal haemorrhage during a six month period. Main outcome measures:Incidence of acute upper gastrointestinal haemorrhage per 100 000 population per year, and case fatality. Results: The annual incidence was 172 per 100 000 people aged 15 and over. The annual population mortality was 14.0 per 100 000. Both were higher among elderly people, men, and patients resident in areas of greater social deprivation. Overall case fatality nias 8.2%. This was higher-among those who bled as inpatients after admission for other reasons (42%) and those admitted as tertiary referrals (16%). Factors associated with increased case fatality were age, uraemia, pre-existing malignancy, hepatic failure, hypotension, cardiac failure, and frank haematemesis or a history of syncope at presentation. Social deprivation, sex, and anaemia sere not associated with increased case fatality after adjustment for other factors. Conclusions: The incidence of acute upper gastrointestinal haemorrhage was 67% greater than the highest previously reported incidence in the United Kingdom, which may be partially attributable to the greater social deprivation in the west of Scotland and may be related to the increased prevalence of Helicobacter pylori. Fatality after acute upper gastrointestinal haemorrhage was associated with age, comorbidity, hypotension, and raised blood urea concentrations on admission, Although deprivation tvas associated with Increased incidence, it was not related to the risk of fatality.	ROYAL COLL PHYS & SURG GLASGOW, GLASGOW G2 5RJ, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM NHS, GLASGOW G31 2ER, LANARK, SCOTLAND; EASTERHOUSE HLTH CTR, GLASGOW G34 9HQ, LANARK, SCOTLAND; GREATER GLASGOW HLTH BOARD, DEPT PUBL HLTH, GLASGOW G1 1ET, LANARK, SCOTLAND									ALLAN R, 1976, Q J MED, V45, P533; BROWN RC, 1976, BRIT MED J, V1, P35, DOI 10.1136/bmj.1.6000.35; CLASON AE, 1986, BRIT J SURG, V73, P985, DOI 10.1002/bjs.1800731213; FALAIYE JM, 1978, NIGERIAN MED J, V8, P526; HUNT PS, 1979, BRIT MED J, V1, P1238, DOI 10.1136/bmj.1.6173.1238; JOHNSTON SJ, 1973, BRIT MED J, V3, P655, DOI 10.1136/bmj.3.5882.655; JONES PF, 1973, BRIT MED J, V3, P660, DOI 10.1136/bmj.3.5882.660; KOHLI H S, 1992, Health Bulletin (Edinburgh), V50, P14; LENNARDJONES JE, 1992, J ROY COLL PHYS LOND, V26, P281; MACLEOD IA, 1982, BRIT J SURG, V69, P256, DOI 10.1002/bjs.1800690509; McLoone P., 1994, CARSTAIRS SCORES SCO; MORGAN AG, 1988, SCAND J GASTROENTERO, V23, P51; MORRIS R, 1991, DEPRIVATION HLTH SCO; OHMANN C, 1992, SCAND J GASTROENTERO, V27, P571, DOI 10.3109/00365529209000121; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; *SCOTT HLTH SERV C, 1978, WHAT HAS BEEN HAPP P; *SPSS, 1993, SPSS WIND; VANZANTEN SJOV, 1995, ALIMENT PHARM THERAP, V9, P41; VELLACOTT KD, 1982, BRIT MED J, V284, P548, DOI 10.1136/bmj.284.6315.548; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	22	230	235	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	1997	315	7107					510	514		10.1136/bmj.315.7107.510	http://dx.doi.org/10.1136/bmj.315.7107.510			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329304	Green Published			2022-12-01	WOS:A1997XU50600016
J	Blader, P; Rastegar, S; Fischer, N; Strahle, U				Blader, P; Rastegar, S; Fischer, N; Strahle, U			Cleavage of the BMP-4 antagonist chordin by zebrafish tolloid	SCIENCE			English	Article							BONE MORPHOGENETIC PROTEIN-1; DROSOPHILA-MELANOGASTER; PATTERN-FORMATION; LARVAL CUTICLE; ZYGOTIC LOCI; SPEMANN ORGANIZER; XENOPUS CHORDIN; C-PROTEINASE; BETA FAMILY; GENE	Dorsoventral patterning of vertebrate and Drosophila embryos requires bone morphogenetic proteins (BMPs) and antagonists of BMP activity. The Drosophila gene tolloid encodes a metalloprotease similar to BMP-1 that interacts genetically with decapentaplegic, the Drosophila homolog of vertebrate BMP-2/4. Zebrafish embryos overexpressing a zebrafish homolog of tolloid were shown to resemble loss-of-function mutations in chordino, the zebrafish homolog of the Xenopus BMP-4 antagonist Chordin. Furthermore, Chordin was degraded by COS cells expressing Tolloid. These data suggest that Tolloid antagonizes Chordin activity by proteolytically cleaving Chordin, A conserved function for zebrafish and Drosophila Tolloid during embryogenesis is proposed.	UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Rastegar, Sepand/E-2324-2015; Straehle, Uwe/K-7054-2013	Rastegar, Sepand/0000-0003-4411-5646; Blader, Patrick/0000-0003-3299-6108				BLADER P, UNPUB; BOURGUET W, 1995, PROTEIN EXPRES PURIF, V6, P604, DOI 10.1006/prep.1995.1079; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALE L, 1992, DEVELOPMENT, V115, P573; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JOLY JS, 1993, DEVELOPMENT, V119, P1261; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Mullins MC, 1996, DEVELOPMENT, V123, P81; Neave B, 1997, MECH DEVELOP, V62, P183, DOI 10.1016/S0925-4773(97)00659-X; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; PUSCHEL AW, 1992, MECH DEVELOP, V38, P197, DOI 10.1016/0925-4773(92)90053-M; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; Westerfield M, 1995, ZEBRAFISH BOOK; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1985, DEV BIOL, V111, P359, DOI 10.1016/0012-1606(85)90490-7	42	162	174	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1937	1940		10.1126/science.278.5345.1937	http://dx.doi.org/10.1126/science.278.5345.1937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395394				2022-12-01	WOS:A1997YL00200032
J	Krishnan, V; Pereira, FA; Qiu, Y; Chen, CH; Beachy, PA; Tsai, SY; Tsai, MJ				Krishnan, V; Pereira, FA; Qiu, Y; Chen, CH; Beachy, PA; Tsai, SY; Tsai, MJ			Mediation of Sonic Hedgehog induced expression of COUP-TFII by a protein phosphatase	SCIENCE			English	Article							TERMINAL CLEAVAGE PRODUCT; MOTOR-NEURON INDUCTION; FLOOR PLATE; KINASE-A; GENE; RECEPTOR; NOTOCHORD; HOMOLOG; TUBE	A Sonic hedgehog (Shh) response element was identified in the chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) promoter that binds to a factor distinct from Gli, a gene known to mediate Shh signaling. Although this binding activity is specifically stimulated by Shh-N (amino-terminal signaling domain), it can also be unmasked with protein phosphatase treatment in the mouse cell line P19, and induction by Shh-N can be blocked by phosphatase inhibitors. Thus, Shh-N signaling may result in dephosphorylation of a target factor that is required for activation of COUP-TFII-, Islet1-, and Gli response element-dependent gene expression. This finding identifies another step in the Shh-N signaling pathway.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Baylor College of Medicine; Howard Hughes Medical Institute; Johns Hopkins University				Pereira, Fred/0000-0003-2100-0280				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; CHEN CH, COMMUNICATION; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Concordet JP, 1996, DEVELOPMENT, V122, P2835; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Krishnan V, 1997, MOL ENDOCRINOL, V11, P1458, DOI 10.1210/me.11.10.1458; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MONSOROBURQ AH, 1995, MECH DEVELOP, V53, P157, DOI 10.1016/0925-4773(95)00426-2; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229	24	123	129	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1947	1950		10.1126/science.278.5345.1947	http://dx.doi.org/10.1126/science.278.5345.1947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395397				2022-12-01	WOS:A1997YL00200035
J	Chow, CW; Rincon, M; Cavanagh, J; Dickens, M; Davis, RJ				Chow, CW; Rincon, M; Cavanagh, J; Dickens, M; Davis, RJ			Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway	SCIENCE			English	Article							KINASE; FAMILY; MORPHOGENESIS; CALCINEURIN; ACTIVATION; DROSOPHILA; INDUCTION; RECEPTOR; DOMAIN; MEMBER	The nuclear factor of activated T cells (NFAT) group of transcription factors is retained in the cytoplasm of quiescent cells, NFAT activation is mediated in part, by induced nuclear import, This process requires calcium-dependent dephosphorylation of NFAT caused by the phosphatase calcineurin, The c-Jun amino-terminal kinase (JNK) phosphorylates NFAT4 on two sites, Mutational removal of the JNK phosphorylation sites caused constitutive nuclear localization of NFAT4, in contrast, JNK activation in calcineurin-stimulated cells caused nuclear exclusion of NFAT4. These findings show that the nuclear accumulation of NFAT4 promoted by calcineurin is opposed by the JNK signal transduction pathway.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOL MED, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA; UNIV VERMONT, DEPT MED, PROGRAM IMMUNOBIOL, BURLINGTON, VT 05405 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont			Dickens, Martin/B-2001-2012		NCI NIH HHS [CA58396, CA65831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHOW CW, UNPUB; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; RAPP UR, 1994, ONCOGENE, V9, P3493; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	28	298	306	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 28	1997	278	5343					1638	1641		10.1126/science.278.5343.1638	http://dx.doi.org/10.1126/science.278.5343.1638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374467				2022-12-01	WOS:A1997YJ87400046
J	Su, XZ; Kirkman, LA; Fujioka, H; Wellems, TE				Su, XZ; Kirkman, LA; Fujioka, H; Wellems, TE			Complex polymorphisms in an similar to 330 kDa protein are linked to chloroquine-resistant P-falciparum in Southeast Asia and Africa	CELL			English	Article							PARASITE PLASMODIUM-FALCIPARUM; INFECTED HUMAN-ERYTHROCYTES; DRUG-RESISTANCE; CROSS-RESISTANCE; PFMDR1 GENE; MALARIA; INVITRO; AMPLIFICATION; PYRIMETHAMINE; SENSITIVITY	Chloroquine resistance in a P. falciparum cross maps as a Mendelian trait to a 36 kb segment of chromosome 7. This segment harbors cg2, a gene encoding a unique similar to 330 kDa protein with complex polymorphisms. A specific set of polymorphisms in 20 chloroquine-resistant parasites from Asia and Africa, in contrast with numerous differences in 21 sensitive parasites, suggests selection of a cg2 allele originating in Indochina over 40 years ago. One chloroquine-sensitive clone exhibited this allele, suggesting another resistance component. South American parasites have cg2 polymorphisms consistent with a separate origin of resistance. CG2 protein is found at the parasite periphery, a site of chloroquine transport, and in association with hemozoin of the digestive vacuole, where chloroquine inhibits heme polymerization.	NIAID, NIH, BETHESDA, MD 20892 USA; CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Case Western Reserve University				Su, Xinzhuan/0000-0003-3246-3248	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035827] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35827] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1990, ADV PARASIT, V29, P151, DOI 10.1016/S0065-308X(08)60106-2; Allen M J, 1994, PCR Methods Appl, V4, P71; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BARNES DA, 1992, EMBO J, V11, P3067, DOI 10.1002/j.1460-2075.1992.tb05378.x; BAYOUMI RAL, 1993, T ROY SOC TROP MED H, V87, P454, DOI 10.1016/0035-9203(93)90034-N; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BRAY PG, 1994, MOL BIOCHEM PARASIT, V63, P87, DOI 10.1016/0166-6851(94)90011-6; BRAY PG, 1992, BIOCHEM PHARMACOL, V44, P1317, DOI 10.1016/0006-2952(92)90532-N; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; De DY, 1996, AM J TROP MED HYG, V55, P579, DOI 10.4269/ajtmh.1996.55.579; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLAN SA, 1993, MOL BIOCHEM PARASIT, V61, P137, DOI 10.1016/0166-6851(93)90166-U; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FITCH CD, 1970, SCIENCE, V169, P289, DOI 10.1126/science.169.3942.289; FITCH CD, 1983, CIBA F SYMP, V94, P222; FITCH CD, 1969, P NATL ACAD SCI USA, V64, P1181, DOI 10.1073/pnas.64.4.1181; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; FREESE JA, 1991, B WORLD HEALTH ORGAN, V69, P707; Galfre G, 1981, Methods Enzymol, V73, P3; GEARY TG, 1983, J PARASITOL, V69, P97, DOI 10.2307/3281283; GINSBURG H, 1991, BIOCHEM PHARMACOL, V41, P1463, DOI 10.1016/0006-2952(91)90562-J; Hawley SR, 1996, ANTIMICROB AGENTS CH, V40, P2345, DOI 10.1128/AAC.40.10.2345; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; Kotecka BM, 1997, ANTIMICROB AGENTS CH, V41, P1369, DOI 10.1128/AAC.41.6.1369; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Liang H, 1997, MOL BIOCHEM PARASIT, V84, P241, DOI 10.1016/S0166-6851(96)02791-0; Loureiro LF, 1996, ANN TROP MED PARASIT, V90, P223, DOI 10.1080/00034983.1996.11813048; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; MARTINEY JA, 1995, J BIOL CHEM, V270, P22393, DOI 10.1074/jbc.270.38.22393; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; PETERS W, 1989, LANCET, V2, P334, DOI 10.1016/S0140-6736(89)90522-9; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; Ridley RG, 1996, ANTIMICROB AGENTS CH, V40, P1846, DOI 10.1128/AAC.40.8.1846; ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SIXSMITH DG, 1984, AM J TROP MED HYG, V33, P772, DOI 10.4269/ajtmh.1984.33.772; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; Su XZ, 1996, NUCLEIC ACIDS RES, V24, P1574, DOI 10.1093/nar/24.8.1574; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; TRIGLIA T, 1991, MOL CELL BIOL, V11, P5244, DOI 10.1128/MCB.11.10.5244; VERDIER F, 1985, ANTIMICROB AGENTS CH, V27, P561, DOI 10.1128/AAC.27.4.561; vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	64	297	311	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					593	603		10.1016/S0092-8674(00)80447-X	http://dx.doi.org/10.1016/S0092-8674(00)80447-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393853	Bronze			2022-12-01	WOS:A1997YH96000007
J	Furberg, CD; Psaty, BM				Furberg, CD; Psaty, BM			JNC VI: Timing is everything	LANCET			English	Editorial Material									UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Furberg, CD (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27109, USA.							Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Garber AM, 1997, CIRCULATION, V95, P1642; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; *JOINT NAT COMM DE, IN PRESS ARCH INTERN; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; PEARCE KA, 1997, IN PRESS AM J HYPERT; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TATTI P, 1997, CIRCULATION S, V96	10	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1413	1414		10.1016/S0140-6736(05)64202-X	http://dx.doi.org/10.1016/S0140-6736(05)64202-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371160				2022-12-01	WOS:A1997YF95300003
J	Scott, G; Goldberg, D; Weir, M; Cameron, S; Peutherer, J; Carrington, D; Follett, E; Leadbetter, G; Scoular, A				Scott, G; Goldberg, D; Weir, M; Cameron, S; Peutherer, J; Carrington, D; Follett, E; Leadbetter, G; Scoular, A			Prevalence of HIV-1 infection among heterosexual men and women attending genitourinary clinics in Scotland: unlinked anonymous testing	BRITISH MEDICAL JOURNAL			English	Article									RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND; ROYAL FREE HOSP,DEPT GENITOURINARY MED,LONDON NW3 2QG,ENGLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV EDINBURGH,DEPT MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT VIROL,LONDON SW17 0RE,ENGLAND; ROYAL INFIRM,DEPT GENITOURINARY MED,GLASGOW G4 0SF,LANARK,SCOTLAND; ROYAL INFIRM,DEPT GENITOURINARY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Edinburgh; St Georges University London; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh								ARTENSTEIN AW, 1995, LANCET, V346, P1197, DOI 10.1016/S0140-6736(95)92900-2; Goldberg D, 1996, SCOT MED J, V41, P131, DOI 10.1177/003693309604100501; MacDonagh SE, 1996, BRIT MED J, V313, P532; *U COLL MIDDL SCH, 1993, DIS REP CDR REV, V3, pR1; *UK HLTH DEP, 1995, HIV AIDS HLTH PROM E	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1281	1282		10.1136/bmj.315.7118.1281	http://dx.doi.org/10.1136/bmj.315.7118.1281			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390056	Green Published			2022-12-01	WOS:A1997YG64500023
J	Yarnold, J				Yarnold, J			Benefits of post-mastectomy radiotherapy	LANCET			English	Editorial Material							BREAST-CANCER; TRIALS				Yarnold, J (corresponding author), INST CANC RES,DEPT RADIOTHERAPY,SUTTON SM2 5PT,SURREY,ENGLAND.			Yarnold, John/0000-0002-9010-1854				AUQUIER A, 1992, EUR J CANCER, V28A, P433, DOI 10.1016/S0959-8049(05)80070-X; CUZICK J, 1987, CANCER TREAT REP, V71, P15; *EARL BREAST CANC, 1995, NEW ENGL J MED, V333, P1444; *EARL BREAST CANC, 1996, NEW ENGL J MED, V334, P1003; FISHER B, 1980, CANCER-AM CANCER SOC, V46, P1009, DOI 10.1002/1097-0142(19800815)46:4+<1009::AID-CNCR2820461326>3.0.CO;2-H; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402	7	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1415	1416		10.1016/S0140-6736(05)64204-3	http://dx.doi.org/10.1016/S0140-6736(05)64204-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371162				2022-12-01	WOS:A1997YF95300005
J	Prigge, ST; Kolhekar, AS; Eipper, BA; Mains, RE; Amzel, LM				Prigge, ST; Kolhekar, AS; Eipper, BA; Mains, RE; Amzel, LM			Amidation of bioactive peptides: The structure of peptidylglycine alpha-hydroxylating monooxygenase	SCIENCE			English	Article							DOPAMINE-BETA-HYDROXYLASE; ENZYME-BOUND COPPER; MACROMOLECULAR STRUCTURES; PROTEIN; SITE; STEREOCHEMISTRY; IDENTIFICATION; BIOSYNTHESIS; INTERMEDIATE; SPECTROSCOPY	Many neuropeptides and peptide hormones require amidation at the carboxyl terminus for activity. Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the amidation of these diverse physiological regulators. The amino-terminal domain of the bifunctional PAM protein is a peptidylglycine alpha-hydroxylating monooxygenase (PHM) with two coppers that cycle through cupric and cuprous oxidation states. The anomalous signal of the endogenous coppers was used to determine the structure of the catalytic core of oxidized rat PHM with and without bound peptide substrate. These structures strongly suggest that the PHM reaction proceeds via activation of substrate by a copper-bound oxygen species. The mechanistic and structural insight gained from the PHM structures can be directly extended to dopamine beta-monooxygenase.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Prigge, Sean/GVS-9197-2022	Prigge, Sean/0000-0001-9684-1733; Amzel, L. Mario/0000-0002-0129-9572	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R56DK032949, R37DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044692] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32949] Funding Source: Medline; NIGMS NIH HHS [GM44692] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BATTERSBY AR, 1976, J CHEM SOC PERK T 1, P1056, DOI 10.1039/p19760001056; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Boswell JS, 1996, BIOCHEMISTRY-US, V35, P12241, DOI 10.1021/bi960742y; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; EVANS SV, 1993, J MOL GRAPHICS, V11, P268; FITZPATRICK PF, 1986, J BIOL CHEM, V261, P4510; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; Grimmelikhuijzen CJP, 1996, INT REV CYTOL, V167, P37, DOI 10.1016/S0074-7696(08)61345-5; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; KIZER JS, 1986, ENDOCRINOLOGY, V118, P2262, DOI 10.1210/endo-118-6-2262; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERKLER DJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P93, DOI 10.1006/abbi.1995.1140; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; MILLER SM, 1985, BIOCHEMISTRY-US, V24, P2114, DOI 10.1021/bi00330a004; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; NEWTON MD, 1997, J ELECTROANAL CHEM, V5025, P1; NOGUCHI M, 1992, BIOCHEM J, V283, P883, DOI 10.1042/bj2830883; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PING DS, 1992, J AM CHEM SOC, V114, P3998, DOI 10.1021/ja00036a071; RAMER SE, 1988, J AM CHEM SOC, V110, P8526, DOI 10.1021/ja00233a032; REEDY BJ, 1994, J AM CHEM SOC, V116, P1924, DOI 10.1021/ja00084a037; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; SUZUKI K, 1993, EUR J BIOCHEM, V213, P93, DOI 10.1111/j.1432-1033.1993.tb17738.x; Yonekura H, 1996, BIOCHEM BIOPH RES CO, V218, P495, DOI 10.1006/bbrc.1996.0088; ZABRISKIE TM, 1991, J CHEM SOC CHEM COMM, P571, DOI 10.1039/c39910000571	40	291	293	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1300	1305		10.1126/science.278.5341.1300	http://dx.doi.org/10.1126/science.278.5341.1300			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360928				2022-12-01	WOS:A1997YG04300047
J	Johnston, C				Johnston, C			Cervical adenocarcinoma in situ: a persistent clinical dilemma	LANCET			English	Editorial Material							UTERINE CERVIX; IN-SITU; INSITU; CONIZATION; MANAGEMENT				Johnston, C (corresponding author), UNIV MICHIGAN,MED CTR,DEPT OBSTET & GYNAECOL,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.							AYER B, 1987, ACTA CYTOL, V31, P397; BERTRAND M, 1987, AM J OBSTET GYNECOL, V157, P21, DOI 10.1016/S0002-9378(87)80338-1; CULLIMORE JE, 1992, BRIT J OBSTET GYNAEC, V99, P314, DOI 10.1111/j.1471-0528.1992.tb13730.x; Denehy TR, 1997, OBSTET GYNECOL, V90, P1, DOI 10.1016/S0029-7844(97)00122-1; HOPKINS MP, 1988, OBSTET GYNECOL, V71, P842; IM DD, 1995, GYNECOL ONCOL, V59, P179; MUNTZ HG, 1992, OBSTET GYNECOL, V80, P935; NICKLIN JL, 1991, AUST NZ J OBSTET GYN, V31, P179, DOI 10.1111/j.1479-828X.1991.tb01814.x; POYNOR EA, 1995, GYNECOL ONCOL, V57, P158, DOI 10.1006/gyno.1995.1118; WILDRICH T, 1996, GYNECOL ONCOL, V61, P304	10	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1337	1338		10.1016/S0140-6736(05)65129-X	http://dx.doi.org/10.1016/S0140-6736(05)65129-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365443				2022-12-01	WOS:A1997YE87200003
J	Skov, L; Clemmensen, O; Baadsgaard, O				Skov, L; Clemmensen, O; Baadsgaard, O			Thin cutaneous malignant melanoma and the MIN terminology	LANCET			English	Editorial Material							CRITERIA		ODENSE UNIV HOSP,DEPT DERMATOL,DK-5000 ODENSE,DENMARK	University of Southern Denmark; Odense University Hospital	Skov, L (corresponding author), UNIV COPENHAGEN,GENTOFTE HOSP,DEPT DERMATOL,DK-2900 HELLERUP,DENMARK.		Skov, Lone/W-3575-2018	Skov, Lone/0000-0002-4784-9680				Cook MG, 1996, HISTOPATHOLOGY, V28, P497, DOI 10.1046/j.1365-2559.1996.d01-464.x; *CRC MEL PATH PAN, 1997, J CLIN PATHOL, V50, P202; DEWIT PEJ, 1993, EUR J CANCER, V29A, P831, DOI 10.1016/S0959-8049(05)80419-8; Farmer ER, 1996, HUM PATHOL, V27, P528, DOI 10.1016/S0046-8177(96)90157-4; HASTRUP N, 1994, HISTOPATHOLOGY, V24, P503; THORN M, 1994, BRIT J CANCER, V70, P743, DOI 10.1038/bjc.1994.388	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1264	1265		10.1016/S0140-6736(05)62469-5	http://dx.doi.org/10.1016/S0140-6736(05)62469-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357402				2022-12-01	WOS:A1997YD68900004
J	Marques, G; Musacchio, M; Shimell, MJ; WunnenbergStapleton, K; Cho, KWY; OConnor, MB				Marques, G; Musacchio, M; Shimell, MJ; WunnenbergStapleton, K; Cho, KWY; OConnor, MB			Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-1; TGF-BETA FAMILY; PROCOLLAGEN C-PROTEINASE; SHORT GASTRULATION GENE; DORSAL-VENTRAL PATTERN; XENOPUS CHORDIN; ASTACIN FAMILY; GROWTH-FACTOR; TOLLOID GENE; CELL FATES	During early Drosophila embryogenesis, several zygotic gene products act to establish a posttranscriptional activity gradient of the morphogen DPP. Among these molecules, Tolloid, a putative metalloprotease related to BMP-1, enhances DPP function, while SOG, an ortholog of the Xenopus organizer Chordin, inhibits DPP function. Using epistasis tests and a Xenopus secondary axis induction assay, we show that TLD negates the inhibitory effects of SOG/CHD on DPP/BMP-type ligands. In transient transfection assays, we demonstrate that TLD cleaves SOG and that cleavage is stimulated by DPP. We propose that formation of the embryonic DPP activity gradient involves the opposing effects of SOG inhibiting DPP and TLD processing SOG to release DPP from the inhibitory complex.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92697; UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities			O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD001158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054704, K04GM000599] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01158] Funding Source: Medline; NIGMS NIH HHS [GM00599, GM54704] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GELBART WM, 1989, DEVELOPMENT, V107, P65; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Hoffmann FM, 1991, CURR OPIN CELL BIOL, V3, P947, DOI 10.1016/0955-0674(91)90112-C; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIROV N, 1994, MOL CELL BIOL, V14, P713, DOI 10.1128/MCB.14.1.713; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G., 1997, ASTACINS STRUCTURE F, P191; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; Nieuwkoop P.D., 1994, SYSTEMATICAL CHRONOL, DOI 10.1201/9781003064565-29; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; PIROTTA V, 1986, DROSOPHILA PRACTICAL, P83; RAY RP, 1991, DEVELOPMENT, V113, P35; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	52	297	311	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					417	426		10.1016/S0092-8674(00)80425-0	http://dx.doi.org/10.1016/S0092-8674(00)80425-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363950	Bronze			2022-12-01	WOS:A1997YD94100015
J	Piccolo, S; Agius, E; Lu, B; Goodman, S; Dale, L; DeRobertis, EM				Piccolo, S; Agius, E; Lu, B; Goodman, S; Dale, L; DeRobertis, EM			Cleavage of chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; SHORT GASTRULATION; XENOPUS EMBRYO; GENE; BMP-4; INDUCTION; RECEPTOR	The Xolloid secreted metalloprotease, a tolloid-related protein, was found to cleave Chordin and Chordin/ BMP-4 complexes at two specific sites in biochemical experiments. Xolloid mRNA blocks secondary axes caused by chordin, but not by noggin, follistatin, or dominant-negative BMP receptor, mRNA injection. Xolloid-treated Chordin protein was unable to antagonize BMP activity. Furthermore, Xolloid digestion released biologically active BMPs from Chordin/BMP inactive complexes. Injection of dominant-negative Xolloid mRNA indicated that the in vivo function of Xolloid is to limit the extent of Spemann's organizer field. We propose that Xolloid regulates organizer function by a novel proteolytic mechanism involving a double inhibition pathway required to pattern the dorsoventral axis: XOLL inverted left perpendicular CHD inverted inverted perpendicular BMPs --> BMPR.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of London; University College London			Dale, Leslie/C-6709-2008; agius, Eric/AHC-9705-2022	Agius, Eric/0000-0003-2123-9283; De Robertis, Edward/0000-0002-7843-1869; PICCOLO, STEFANO/0000-0002-2037-0004	NICHD NIH HHS [R37 HD21502-11, R37 HD021502, R37 HD021502-13] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DALE L, 1992, DEVELOPMENT, V115, P573; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Dosch R, 1997, DEVELOPMENT, V124, P2325; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; GOODMAN S, 1997, IN PRESS DEV BIOL; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; JONES CM, 1992, DEVELOPMENT, V115, P639; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Lin JJ, 1997, DEV GROWTH DIFFER, V39, P43; MAENO M, 1993, GENE, V134, P257, DOI 10.1016/0378-1119(93)90103-A; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Moon RT, 1997, CELL, V88, P725, DOI 10.1016/S0092-8674(00)81915-7; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	45	331	347	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					407	416		10.1016/S0092-8674(00)80424-9	http://dx.doi.org/10.1016/S0092-8674(00)80424-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363949	Bronze, Green Accepted			2022-12-01	WOS:A1997YD94100014
J	Grotta, J				Grotta, J			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA - The best current option for most patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TISSUE-PLASMINOGEN-ACTIVATOR; URGENT THERAPY; MINUTES				Grotta, J (corresponding author), UNIV TEXAS,SCH MED,DEPT NEUROL,6431 FANNIN,SUITE 7044,HOUSTON,TX 77030, USA.		Grotta, James/AAH-7423-2021					Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; [Anonymous], 1996, NEUROLOGY, V47, P835; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1993, THROMBOLYTIC THERAPY, V2, P59; DONMAN GA, 1995, LANCET, V345, P578; *EUR COOP AC STROK, 1995, JAMA-J AM MED ASSOC, V274, P1017; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; *MULT AC STROK TRI, 1996, NEW ENGL J MED, V335, P145; *MULT AC STROK TRI, 1995, LANCET, V346, P1509; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581	13	42	42	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1310	1313						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345085				2022-12-01	WOS:A1997YC92000013
J	Haigney, E; Morgan, R; King, D; Spencer, B				Haigney, E; Morgan, R; King, D; Spencer, B			Breast examinations in older women: questionnaire survey of attitudes of patients and doctors	BRITISH MEDICAL JOURNAL			English	Article									WIRRAL HOSP,DEPT MED ELDERLY,WIRRAL L49 5PE,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool								ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; AMSTERDAM E, 1987, J SURG ONCOL, V180, P183; Ries LAB, 1989, NIH PUBLICATION; SHELDON T, 1996, EFFECTIVE HLTH CARE, V2, P1	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1058	1059		10.1136/bmj.315.7115.1058	http://dx.doi.org/10.1136/bmj.315.7115.1058			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366734	Green Published			2022-12-01	WOS:A1997YD44500024
J	DeRisi, JL; Iyer, VR; Brown, PO				DeRisi, JL; Iyer, VR; Brown, PO			Exploring the metabolic and genetic control of gene expression on a genomic scale	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; MESSENGER-RNAS; ENCODING GENE; PROTEIN; COMPLEX; GLUCOSE; PATHWAY; CARBON; HYBRIDIZATION	DNA microarrays containing virtually every gene of Saccharomyces cerevisiae were used to carry out a comprehensive investigation of the temporal program of gene expression accompanying the metabolic shift from fermentation to respiration. The expression profiles observed for genes with known metabolic functions pointed to features of the metabolic reprogramming that occur during the diauxic shift, and the expression patterns of many previously uncharacterized genes provided clues to their possible functions. The same DNA microarrays were also used to identify genes whose expression was affected by deletion of the transcriptional co-repressor TUP1 or overexpression of the transcriptional activator YAP1. These results demonstrate the feasibility and utility of this approach to genomewide exploration of gene expression patterns.	STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000044, R21HG000450, R01HG000450] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00450, T32 HG00044] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DeRisi J, 1996, NAT GENET, V14, P457; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FERNANDEZ M, 1994, MOL GEN GENET, V242, P727; Fondrat C, 1996, COMPUT APPL BIOSCI, V12, P363; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GUTIERREZ A, 1994, APPL ENVIRON MICROB, V60, P1783; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HERRERO P, 1995, YEAST, V11, P137, DOI 10.1002/yea.320110205; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KOWALSKI LR, 1995, MOLMICROBIOL, V115, P341; KRATZER S, 1995, GENE, V161, P75, DOI 10.1016/0378-1119(95)00289-I; LASHKARI D, IN PRESS P NATL ACAD; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARTINEZ PM, 1996, EMBO J, V15, P2227; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; MUHEIM A, 1991, EUR J BIOCHEM, V195, P369, DOI 10.1111/j.1432-1033.1991.tb15715.x; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; PLANTA RJ, 1988, TRENDS GENET, V4, P64, DOI 10.1016/0168-9525(88)90042-X; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; ROSENKRANTZ M, 1994, MOL MICROBIOL, V13, P119, DOI 10.1111/j.1365-2958.1994.tb00407.x; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; SCHOLER A, 1993, CURR GENET, V23, P375, DOI 10.1007/BF00312621; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; VISWANATHAN M, 1994, GENE, V148, P149, DOI 10.1016/0378-1119(94)90249-6; VNDENBERG MA, 1996, J BIOL CHEM, V271, P28953; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; Yin ZK, 1996, MOL MICROBIOL, V20, P751, DOI 10.1111/j.1365-2958.1996.tb02514.x	41	3446	3686	1	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					680	686		10.1126/science.278.5338.680	http://dx.doi.org/10.1126/science.278.5338.680			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381177				2022-12-01	WOS:A1997YC32300053
J	Lima, CD; Klein, MG; Hendrickson, WA				Lima, CD; Klein, MG; Hendrickson, WA			Structure-based analysis of catalysis and substrate definition in the HIT protein family	SCIENCE			English	Article							X-RAY STRUCTURE; TRANSITION-STATE ANALOG; NEUTRON-DIFFRACTION; CRYSTAL-STRUCTURES; URIDINE VANADATE; IDENTIFICATION; COMPLEX; URIDYLYLTRANSFERASE; PHOSPHOHISTIDINE; DICTYOSTELIUM	The histidine triad (HIT) protein family is among the most ubiquitous and highly conserved in nature, but a biological activity has not yet been identified for any member of the HIT family. Fragile histidine triad protein (FHIT) and protein kinase C interacting protein (PKCI) were used in a structure-based approach to elucidate characteristics of in vivo ligands and reactions. Crystallographic structures of ape, substrate analog, pentacovalent transition-state analog, and product slates of both enzymes reveal a catalytic mechanism and define substrate characteristics required for catalysis, thus unifying the HIT family as nucleotidyl hydrolases, transferases, or both. The approach described here may be useful in identifying structure-function relations between protein families identified through genomics.	HERBERT IRVING CANC CTR, NEW YORK, NY 10032 USA; INST HUMAN NUTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Lima, CD (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Lima, Christopher/0000-0002-9163-6092	NCI NIH HHS [T32CA09503] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEINSTEINJAFFE I, 1985, ORGANOMETALLICS, V4, P1189, DOI 10.1021/om00126a009; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; Holm L, 1997, STRUCTURE, V5, P165, DOI 10.1016/S0969-2126(97)00176-7; Holm L, 1997, TRENDS BIOCHEM SCI, V22, P116, DOI 10.1016/S0968-0004(97)01021-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; LIMA CD, 1996, P NATL ACAD SCI USA, V93, P5355; LINDQVIST Y, 1994, EUR J BIOCHEM, V221, P139, DOI 10.1111/j.1432-1033.1994.tb18722.x; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; ROBINSON AK, 1993, BIOCHIM BIOPHYS ACTA, V1161, P139, DOI 10.1016/0167-4838(93)90207-8; ROBINSON K, 1994, BIOCHEM J, V304, P662, DOI 10.1042/bj3040662; ROSE ZB, 1982, METHOD ENZYMOL, V87, P42; SERAPHIN B, 1992, J DNA SEQUENCING MAP, V3, P177; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; THRALL SH, 1983, BIOCHEMISTRY-US, V32, P1803; Tse-Dinh Y.-C., 1980, J BIOL CHEM, V255, P5560; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; WEI YF, 1991, METHOD ENZYMOL, V200, P388; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; WESTBROOK ML, 1996, P IUCR COMPUTING SCH; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	34	190	197	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					286	290		10.1126/science.278.5336.286	http://dx.doi.org/10.1126/science.278.5336.286			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323207				2022-12-01	WOS:A1997YA56400044
J	Moody, DB; Reinhold, BB; Guy, MR; Beckman, EM; Frederique, DE; Furlong, ST; Ye, S; Reinhold, VN; Sieling, PA; Modlin, RL; Besra, GS; Porcelli, SA				Moody, DB; Reinhold, BB; Guy, MR; Beckman, EM; Frederique, DE; Furlong, ST; Ye, S; Reinhold, VN; Sieling, PA; Modlin, RL; Besra, GS; Porcelli, SA			Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells	SCIENCE			English	Article							MYCOLIC ACIDS; CD1 FAMILY; MYCOBACTERIUM; IDENTIFICATION; RESTRICTS; GENES	The human CD1b protein presents lipid antigens to T cells, but the molecular mechanism is unknown. Identification of mycobacterial glucose monomycolate (GMM) as a CD1b-presented glycolipid allowed determination of the structural requirements for its recognition by T cells. Presentation of GMM to CD1b-restricted T cells was not affected by substantial variations in its lipid tails, but was extremely sensitive to chemical alterations in its carbohydrate or other polar substituents. These findings support the view that the recently demonstrated hydrophobic CD1 groove binds the acyl chains of lipid antigens relatively nonspecifically, thereby positioning the hydrophilic components for highly specific interactions with T cell antigen receptors.	BRIGHAM & WOMENS HOSP,DIV RHEUMATOL IMMUNOL & ALLERGY,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BOSTON UNIV,SCH MED,MASS SPECTROMETRY UNIT,BOSTON,MA 02118; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90033; UNIV CALIF LOS ANGELES,SCH MED,DEPT IMMUNOL & MICROBIOL,LOS ANGELES,CA 90033	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; Colorado State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001988] Funding Source: NIH RePORTER; NCRR NIH HHS [RR10888] Funding Source: Medline; NIAMS NIH HHS [AR01988] Funding Source: Medline; NIGMS NIH HHS [GM54045] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12737; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1969, EUR J BIOCHEM, V13, P117; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; DATTA AK, 1991, CARBOHYD RES, V218, P95, DOI 10.1016/0008-6215(91)84089-W; EADS J, 1993, J BIOL CHEM, V268, P26375; KANEDA K, 1988, J GEN MICROBIOL, V134, P2213; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MINNIKIN DE, 1984, ARCH MICROBIOL, V139, P225, DOI 10.1007/BF00402005; NATSUHARA Y, 1990, CANCER IMMUNOL IMMUN, V31, P99, DOI 10.1007/BF01742373; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	20	376	379	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					283	286		10.1126/science.278.5336.283	http://dx.doi.org/10.1126/science.278.5336.283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323206				2022-12-01	WOS:A1997YA56400043
J	Andersen, SSL; Ashford, AJ; Tournebize, R; Gavet, O; Sobel, A; Hyman, AA; Karsenti, E				Andersen, SSL; Ashford, AJ; Tournebize, R; Gavet, O; Sobel, A; Hyman, AA; Karsenti, E			Mitotic chromatin regulates phosphorylation of Stathmin/Op18	NATURE			English	Article							MICROTUBULE DYNAMICS; EGG EXTRACTS; CELL CYCLE; PROTEIN; XENOPUS; CHROMOSOMES; KINASE; ONCOPROTEIN-18; ORGANIZATION; PHOSPHATASE	Meiotic and mitotic spindles are required for the even segregation of duplicated chromosomes to the two daughter cells. The mechanism of spindle assembly is not fully understood, but two have been proposed that are not mutually exclusive(1-3). The 'search and capture' model suggests that dynamic microtubules become progressively captured and stabilized by the kinetochores on chromosomes, leading to spindle assembly(3,4). The 'local stabilization' model proposes that chromosomes change the state of the cytoplasm around them, making it more favourable to microtubule polymerization(2,5-9). It has been shown(10,11) that Stathmin/Op18 inhibits microtubule polymerization in vitro by interaction with tubulin(12), and that overexpression in tissue culture cells of non-phosphorylatable mutants of Stathmin/Op18 prevents the assembly of mitotic spindles(13). We have used Xenopus egg extracts and magnetic chromatin beads(14) to show that mitotic chromatin induces phosphorylation of Stathmin/Op18. We have also shown the Stathmin/Op18 is one of the factors regulated by mitotic chromatin that governs preferential microtubule growth around chromosomes during spindle assembly.	EUROPEAN MOL BIOL LAB,CELL BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY; INSERM,U440,F-75005 PARIS,FRANCE	European Molecular Biology Laboratory (EMBL); Institut National de la Sante et de la Recherche Medicale (Inserm)			Andersen, Søren S. L./O-1915-2017; Tournebize, Regis/K-7847-2018; Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017	Andersen, Søren S. L./0000-0002-3625-1640; Tournebize, Regis/0000-0003-3718-3130; Hyman, Anthony A/0000-0003-3664-154X				ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; Belmont L, 1996, TRENDS BIOCHEM SCI, V21, P197, DOI 10.1016/S0968-0004(96)80013-2; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; CURMI PA, IN PRESS J BIOL CHEM; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FELIX MA, 1994, CELL CYCLE PRACTICAL, P253; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MAREK LF, 1978, CHROMOSOMA, V68, P367, DOI 10.1007/BF00327171; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MASSON D, 1995, J CELL BIOL, V131, P1015, DOI 10.1083/jcb.131.4.1015; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; SAMANTA A, 1995, P NATL ACAD SCI USA, V92, P6582, DOI 10.1073/pnas.92.14.6582; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; TOURNEBIZE R, IN PRESS EMBO J; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287	30	112	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					640	643		10.1038/39382	http://dx.doi.org/10.1038/39382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335509				2022-12-01	WOS:A1997YA00800069
J	Aparicio, OM; Weinstein, DM; Bell, SP				Aparicio, OM; Weinstein, DM; Bell, SP			Components and dynamics of DNA replication complexes in S-cerevisiae: Redistribution of MCM proteins and Cdc45p during S phase	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MINICHROMOSOME MAINTENANCE; CHROMOSOMAL REPLICATION; POLYMERASE-EPSILON; CDC6 PROTEIN; ARS ELEMENTS; XENOPUS; INITIATION	In S. cerevisiae, the chromatin structure of DNA replication origins changes as cells become competent for DNA replication, suggesting that G1 phase-specific association of replication factors with origin DNA regulates entry into S phase. We demonstrate that ORC, Cdc45p, and MCM proteins are components of prereplication complexes (pre-RC). The MOM-origin association is dependent upon ORC and Cdc6p. During S phase, MCM proteins and Cdc45p dissociate from origin DNA and associate with nonorigin DNA with similar kinetics as DNA Polymerase a, which is present at DNA replication forks. Our results identify protein components of the pre-RC and a novel replication complex appearing at the G1/S transition (the RC), and suggest that after initiation MCM proteins and Cdc45p move with eukaryotic replication forks.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				Aparicio, Oscar/0000-0002-5591-0277; Bell, Stephen/0000-0002-2876-610X	NIGMS NIH HHS [GM52339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1992, DNA REPLICATION, P931; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/S0968-0004(96)10013-X; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DUTTA A, 1997, IN PRESS ANN REV CEL, V13; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MAINE GT, 1984, GENETICS, V106, P365; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MOIR D, 1982, GENETICS, V100, P547; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; NEWLON CS, 1991, GENETICS, V129, P343; NEWLON CS, 1991, GENETICS, V130, P235; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Shcherbakova PV, 1996, GENETICS, V142, P717; SIKORSKI RS, 1989, GENETICS, V122, P19; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZHU JG, 1992, MOL CELL BIOL, V12, P4733, DOI 10.1128/MCB.12.10.4733; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	50	624	634	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					59	69		10.1016/S0092-8674(01)80009-X	http://dx.doi.org/10.1016/S0092-8674(01)80009-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335335	Bronze			2022-12-01	WOS:A1997XZ80900009
J	Michaelis, C; Ciosk, R; Nasmyth, K				Michaelis, C; Ciosk, R; Nasmyth, K			Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids	CELL			English	Article							STRAND-BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; DNA-REPLICATION; FISSION YEAST; TOPOISOMERASE-II; BUDDING YEAST; GENE; CONDENSATION; COMPLEX	Cohesion between sister chromatids opposes the splitting force exerted by microtubules, and loss of this cohesion is responsible for the subsequent separation of sister chromatids during anaphase. We describe three chromosmal proteins that prevent premature separation of sister chromatids in yeast. Two, Smc1p and Smc3p, are members of the SMC family, which are putative ATPases with coiled-coil domains. A third protein, which we call Scc1p, binds to chromosomes during S phase, dissociates from them at the metaphase-to-anaphase transition, and is degraded by the anaphase promoting complex. Association of Scc1p with chromatin depends on Smc1p. Proteins homologous to Scclp exist in a variety of eukaryotic organisms including humans. A common cohesion apparatus might be used by all eukaryotic cells during both mitosis and meiosis.	RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Ciosk, Rafal/L-7327-2013	Ciosk, Rafal/0000-0003-2234-6216; Nasmyth, Kim/0000-0001-7030-4403				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BERENS C, 1992, J BIOL CHEM, V267, P1945; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Callan H.G, 1986, LAMPBRUSH CHROMOSOME; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLLOWAY SL, 1993, CELL, V73, P13093; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; McKay MJ, 1996, GENOMICS, V36, P305, DOI 10.1006/geno.1996.0466; MOLNAR M, 1995, GENETICS, V141, P61; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Rose M, 1990, LAB COURSE MANUAL ME; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIBBENS RV, 1993, J CELL BIOL, V80, P674; SPENCER F, 1990, GENETICS, V124, P237; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; YAMADA H, 1994, YEAST, V10, P883, DOI 10.1002/yea.320100704; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	41	1145	1164	2	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					35	45		10.1016/S0092-8674(01)80007-6	http://dx.doi.org/10.1016/S0092-8674(01)80007-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335333	Bronze			2022-12-01	WOS:A1997XZ80900007
J	Spraggon, G; Everse, SJ; Doolittle, RF				Spraggon, G; Everse, SJ; Doolittle, RF			Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin	NATURE			English	Article							ELECTRON-MICROSCOPY; GAMMA-CHAIN; PLASMINOGEN-ACTIVATOR; POLYMERIZATION; IDENTIFICATION; LOCALIZATION; SITES; REQUIREMENTS; ASSOCIATION; MOLECULES	In blood coagulation, units of the protein fibrinogen pack together to form a fibrin clot, but a crystal structure for fibrinogen is needed to understand how this is achieved. The structure of a cove fragment (fragment D) from human fibrinogen has now been determined to 2.9 Angstrom resolution. The 86K three-chained structure consists of a coiled-coil region and two homologous globular entities oriented at approximately 130 degrees to each other, Additionally, the covalently bound dimer of fragment D, known as 'doubte-D', was isolated from human fibrin, crystallized in the presence of a Gly-Pro-Arg-Pro-amide peptide ligand, which simulates the donor polymerization site, and its structure solved by molecular replacement with the model of fragment D.	UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bailey K, 1943, NATURE, V151, P716, DOI 10.1038/151716a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; COHEN C, 1961, J POLYM SCI, V49, P144; DANG CV, 1985, J BIOL CHEM, V260, P9713; DONAHUE JP, 1994, P NATL ACAD SCI USA, V91, P12178, DOI 10.1073/pnas.91.25.12178; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P1563, DOI 10.1002/pro.5560011204; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1710, DOI 10.1021/bi00627a029; EBERT RF, 1994, 1994 INDEX VARIANT H; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVERSE SJ, 1995, PROTEIN SCI, V4, P1013; FU YP, 1995, GENOMICS, V30, P71, DOI 10.1006/geno.1995.0010; FUREY W, IN PRESS METHODS ENZ; Gerloff DL, 1997, PROTEINS, V27, P279; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUDRYCLERGEON G, 1974, PATHOL BIOL, V22, P47; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, NEWSLETT PROTEIN CRY, V31, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIHALYI E, 1963, BIOCHIM BIOPHYS ACTA, V67, P90; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MOSESSON MW, 1995, J CLIN INVEST, V96, P1053, DOI 10.1172/JCI118091; MOSESSON MW, 1995, J STRUCT BIOL, V115, P88, DOI 10.1006/jsbi.1995.1033; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V748, P86, DOI 10.1016/0167-4838(83)90030-4; Okumura N, 1996, THROMB HAEMOSTASIS, V75, P887; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; PIZZO SV, 1973, J BIOL CHEM, V248, P4574; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHIELEN WJG, 1991, BIOCHEM J, V276, P655, DOI 10.1042/bj2760655; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1993, J BIOL CHEM, V268, P26618; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	50	371	397	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					455	462		10.1038/38947	http://dx.doi.org/10.1038/38947			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333233				2022-12-01	WOS:A1997XY90900045
J	Chowienczyk, P; Ritter, J				Chowienczyk, P; Ritter, J			Arginine: NO more than a simple aminoacid?	LANCET			English	Editorial Material							NITRIC-OXIDE; HYPERCHOLESTEROLEMIC PATIENTS				Chowienczyk, P (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.			Chowienczyk, Phil/0000-0003-4507-038X				BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; CASINO PR, 1994, J AM COLL CARDIOL, V23, P844, DOI 10.1016/0735-1097(94)90628-9; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; MACALLISTER RJ, 1994, BRIT J PHARMACOL, V112, P43, DOI 10.1111/j.1476-5381.1994.tb13026.x; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510	10	26	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					901	902		10.1016/S0140-6736(05)63263-1	http://dx.doi.org/10.1016/S0140-6736(05)63263-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314865				2022-12-01	WOS:A1997XY67200005
J	Hershey, GKK; Friedrich, MF; Esswein, LA; Thomas, ML; Chatila, TA				Hershey, GKK; Friedrich, MF; Esswein, LA; Thomas, ML; Chatila, TA			The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; HYPER-IGE SYNDROME; TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; SH2 DOMAIN; IL-4; ERYTHROPOIETIN; ALLERGENS; EXPOSURE; ASTHMA	Background Atopic diseases are very common, and atopy has a strong genetic predisposition. Methods Using single-strand conformation polymorphism analysis and DNA sequencing, we searched for mutations in the alpha subunit of the interleukin-4 receptor that would predispose persons to atopy. We examined the prevalence of the alleles among patients with allergic inflammatory disorders and among 50 prospectively recruited adults. Subjects with atopy were identified on the basis of an elevated serum IgE level (greater than or equal to 95 IU per milliliter) or a positive radioimmunosorbent test in response to standard inhalant allergens. The signaling function of mutant interleukin-4 receptor alpha was examined by flow cytometry, binding assays, and immunoblotting. Results A novel interleukin-4 receptor alpha allele was identified in which guanine was substituted for adenine at nucleotide 1902, causing a change from glutamine to arginine at position 576 (R576) in the cytoplasmic domain of the interleukin-4 receptor alpha protein. The R576 allele was common among patients with allergic inflammatory disorders (found in 3 of 3 patients with the hyper-IgE syndrome and 4 of 7 patients with severe atopic dermatitis) and among the 50 prospectively recruited adults (found in 13 of 20 subjects with atopy and 5 of 30 without atopy; P=0.001; relative risk of atopy among those with a mutant allele, 9.3). The R576 allele was associated with higher levels of expression of CD23 by interleukin-4 than the wild-type allele. This enhanced signaling was associated with a change in the binding specificity of the adjacent tyrosine residue at position 575 to signal-transducing molecules. Conclusions The R576 allele of interleukin-4 receptor alpha is strongly associated with atopy. This mutation may predispose persons to allergic diseases by altering the signaling function of the receptor. (C) 1997, Massachusetts Medical Society.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, DIV IMMUNOL RHEUMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)				Chatila, Talal/0000-0001-7439-2762; Khurana Hershey, Gurjit/0000-0001-6663-977X				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Bonnefoy JY, 1996, ANN NY ACAD SCI, V796, P59, DOI 10.1111/j.1749-6632.1996.tb32567.x; BUCKLEY RH, 1996, IMMUNOLOGIC DISORDER, P409; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1988, LANCET, V1, P86; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; Geha R S, 1989, Immunodefic Rev, V1, P155; Gelderloos JA, 1996, ONCOGENE, V13, P2367; Glantz SA., 1997, PRIMER BIOSTATISTICS; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG SK, 1993, ANN ALLERGY, V70, P347; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; ISHIZAKA A, 1990, IMMUNOLOGY, V70, P414; KIRCHNER SG, 1985, RADIOLOGY, V156, P362, DOI 10.1148/radiology.156.2.4011897; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; YOUNG RP, 1992, CLIN EXP ALLERGY, V22, P205, DOI 10.1111/j.1365-2222.1992.tb03074.x; ZEIGER RS, 1993, ALLERGY PRINCIPLES P, V2, P1137	48	586	630	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1720	1725		10.1056/NEJM199712113372403	http://dx.doi.org/10.1056/NEJM199712113372403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392697				2022-12-01	WOS:A1997YK65300003
J	Cardo, DM; Culver, DH; Ciesielski, CA; Srivastava, PU; Marcus, R; Abiteboul, D; Heptonstall, J; Ippolito, G; Lot, F; McKibben, P; Bell, DM				Cardo, DM; Culver, DH; Ciesielski, CA; Srivastava, PU; Marcus, R; Abiteboul, D; Heptonstall, J; Ippolito, G; Lot, F; McKibben, P; Bell, DM			A case-control study of HIV seroconversion in health care workers after percutaneous exposure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE TREATMENT; HEPATITIS-B; RISK; TRANSMISSION; INFECTION; TYPE-1; BLOOD; INFANT	Background The average risk of human immunodeficiency virus (HIV) infection after percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence this risk are not well understood. Methods We conducted a case-control study Of health care workers with occupational, percutaneous exposure to HIV-infected blood. The case patients were those who became seropositive after exposure to HIV, as reported by national surveillance systems in France, Italy, the United Kingdom, and the United States. The controls were health care workers in a prospective surveillance project who were exposed to HIV but did not seroconvert. Results Logistic-regression analysis based on 33 case patients and 665 controls showed that significant risk factors for seroconversion were deep injury (odds ratio=15; 95 percent confidence interval, 6.0 to 41), injury with a device that was visibly contaminated with the source patient's blood (odds ratio=6.2; 95 percent confidence interval, 2.2 to 21), a procedure involving a needle placed in the source patient's artery or vein (odds ratio=4.3; 95 percent confidence interval, 1.7 to 12), and exposure to a source patient who died of the acquired immunodeficiency syndrome within two months afterward (odds ratio=5.6; 95 percent confidence interval, 2.0 to 16). The case patients were significantly less likely than the controls to have taken zidovudine after the exposure (odds ratio=0.19; 95 percent confidence interval, 0.06 to 0.52). Conclusions The risk of HIV infection after percutaneous exposure increases with a larger volume of blood and, probably, a higher titer of HIV in the source patient's blood. Postexposure prophylaxis with zidovudine appears to be protective. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL,NATL CTR HIV STD & TB PREVENT,DIV HIV AIDS,ATLANTA,GA 30333; INST NATL RECH & SECUR,PARIS,FRANCE; GRP ETUD RISQUE EXPOSIT SANG,PARIS,FRANCE; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; CTR RIFERIMENTO AIDS COORDINAMENTO STUDIO ITALIAN,ROME,ITALY; RESEAU NATL SANTE PUBL,ST MAURICE,FRANCE	Centers for Disease Control & Prevention - USA; Public Health England	Cardo, DM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,1600 CLIFTON RD,MAIL STOP E-68,ATLANTA,GA 30333, USA.		Ippolito, Giuseppe/J-7207-2017	Ippolito, Giuseppe/0000-0002-1076-2979; Marcus, Ruthanne/0000-0002-9094-0674				BELL DM, 1992, INFECT AGENT DIS, V1, P263; BELL DM, 1997, AM J MED 5B, V102; BLACK R, 1997, AM J MED, V102; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAMBERLAND ME, IN PRESS HOSP INFECT; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; GERBERDING JL, 1997, AM J MED 5B, V102; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JOCHIMSEN EM, 1997, AM J MED 5B, V102; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LAFON SW, 1993, 30 INT C ANT AG CHEM; LOES SK, 1995, NEW ENGL J MED, V333, P1367; LOES SK, 1995, NEW ENGL J MED, V333, P408; LOT F, 1995, B EPIDEMIOL HEBD, V44, P193; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; *PHS, 1990, MMWR-MORBID MORTAL W, V39, P1; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Weisburd Guillermo, 1996, P460; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468; 1991, MMWR-MORBID MORTAL W, V40, P1	27	780	817	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1485	1490		10.1056/NEJM199711203372101	http://dx.doi.org/10.1056/NEJM199711203372101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366579				2022-12-01	WOS:A1997YG24900001
J	Meystre, CJN; Burley, NMJ; Ahmedzai, S				Meystre, CJN; Burley, NMJ; Ahmedzai, S			What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY-RESUSCITATION; CANCER; VIEWS		UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SECT PALLIAT MED,DEPT SURG & ANAESTHET SCI,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	Meystre, CJN (corresponding author), LEICESTERSHIRE HOSPICE,LEICESTER LE3 9QE,LEICS,ENGLAND.			Ahmedzai, Sam/0000-0002-2028-8510				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; HILL ME, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677; MORGAN R, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677a; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; World Health Organization, 1979, HDB REP RES CANC TRE	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1202	1203		10.1136/bmj.315.7117.1202	http://dx.doi.org/10.1136/bmj.315.7117.1202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393223	Green Published			2022-12-01	WOS:A1997YF25200020
J	Yamauchi, T; Ueki, K; Tobe, K; Tamemoto, H; Sekine, N; Wada, M; Honjo, M; Takahashi, M; Takahashi, T; Hirai, H; Tushima, T; Akanuma, Y; Fujita, T; Komuro, I; Yazaki, Y; Kadowaki, T				Yamauchi, T; Ueki, K; Tobe, K; Tamemoto, H; Sekine, N; Wada, M; Honjo, M; Takahashi, M; Takahashi, T; Hirai, H; Tushima, T; Akanuma, Y; Fujita, T; Komuro, I; Yazaki, Y; Kadowaki, T			Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone	NATURE			English	Article							C-FOS PROMOTER; INTERFERON-GAMMA; BINDING-SITES; INTACT-CELLS; ACTIVATION; SUBSTRATE-1; MICE; SHC; TRANSCRIPTION; ASSOCIATION	When growth hormone binds to its receptor, which belongs to the cytokine receptor superfamily(1), it activates the Janus kinase Jak2(2) which has tyrosine-kinase activity and initiates an activation of several key intracellular proteins (for example, mitogen-activated protein (MAP) kinases(3-6)) that eventually execute the biological actions induced by growth hormone, including the expression of particular genes. In contrast to receptors that themselves have tyrosine kinase activity, the signalling pathways leading to MAP kinase activation(7,8) that are triggered by growth hormone are poorly understood, but appear to be mediated by the proteins GrB2 and Shc(9). We now show that growth hormone stimulates tyrosine phosphorylation of the receptor for epidermal growth factor (EGFR) and its association with Grb2 and at the same time stimulates MAP kinase activity in liver, an important target tissue of growth hormone, Expression of EGFR and its mutants revealed that growth-hormone-induced activation of MAP kinase and expression of the transcription factor c-fos requires phosphorylation of tyrosines on EGFR, but not its own intrinsic tyrosine-kinase activity, Moreover, tyrosine at residue 1,068 of the EGFR is proposed to be one of the principal phosphorylation sires and Grb2-binding sites stimulated by growth hormone via Jak2. Our results indicate that the role of EGFR in signalling by growth hormone is to be phosphorylated by Jak2, thereby providing docking sites for Grb2 and activating MAP kinases and gene expression, independently of the intrinsic tyrosine kinase activity of EGFR. This may represent a novel cross-talk pathway between the cytokine receptor superfamily and growth factor receptor.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 4,TOKYO 112,JAPAN; MITSUI TOATSU CHEM CO LTD,LIFE SCI LABS,MOBARA 297,JAPAN; UNIV TOKYO,DEPT VET PHYSIOL,TOKYO 113,JAPAN; TOKYO WOMENS MED COLL,DEPT INTERNAL MED 2,TOKYO 162,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Women's Medical University; Asahi Life Foundation				Takahashi, Tokiharu/0000-0002-5785-8660				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; FRANK SJ, 1995, J BIOL CHEM, V270, P14765; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MeunierDurimort C, 1996, EUR J BIOCHEM, V237, P660, DOI 10.1111/j.1432-1033.1996.0660p.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sekine N, 1996, ENDOCRINOLOGY, V137, P1841, DOI 10.1210/en.137.5.1841; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	30	244	252	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					91	96		10.1038/36369	http://dx.doi.org/10.1038/36369			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363897				2022-12-01	WOS:A1997YE47700059
J	Nightingale, SL				Nightingale, SL			Education program for reducing risks with unpasteurized juices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-01	WOS:A1997YC91700007
J	DeGrendele, HC; Estess, P; Siegelman, MH				DeGrendele, HC; Estess, P; Siegelman, MH			Requirement for CD44 in activated T cell extravasation into an inflammatory site	SCIENCE			English	Article							ADHESION MOLECULE; ENDOTHELIAL-CELLS; HYALURONATE; LYMPHOCYTES; RECOGNITION; MIGRATION; ARTHRITIS; ANTIGEN; INVIVO; SUPERANTIGENS	Leukocytes extravasate from the blood into inflammatory sites through complementary ligand interactions between leukocytes and endothelial cells, Activation of T cells increases their binding to hyaluronate (HA) and enables CD44-mediated primary adhesion (rolling). This rolling could be induced in vivo in murine V(beta)8(+) T cells in response to specific superantigen stimulation; it was initially found in lymph nodes, then in peripheral blood, and finally within the peritoneum, the original inflamed site. The migration of V(beta)8(+) cells into the peritoneal cavity was dependent on CD44 and HA, as shown by inhibition studies. Thus, CD44-HA interactions can target lymphocytes to specific extralymphoid effector sites.	UNIV TEXAS, SW MED CTR, DEPT PATHOL, MOL PATHOL LAB, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [R01 CA57471] Funding Source: Medline; NHLBI NIH HHS [HL56746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057471] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CAHILL RNP, 1976, J EXP MED, V143, P870, DOI 10.1084/jem.143.4.870; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; DEGRENDELE HC, UNPUB; GUY GD, 1978, J EXP MED, V148, P1661; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HERRMANN T, 1992, EUR J IMMUNOL, V22, P1935, DOI 10.1002/eji.1830220739; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KENNETT RH, 1980, MONOCLONAL ANTIBODIE; KOSTER FT, 1971, J EXP MED, V133, P864, DOI 10.1084/jem.133.4.864; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MAROKO PR, 1977, NEW ENGL J MED, V296, P898, DOI 10.1056/NEJM197704212961603; MCCORMACK JE, 1993, J IMMUNOL, V150, P3785; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MOHAMADZADEH M, UNPUB; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SPRENT J, 1971, CELL IMMUNOL, V2, P171, DOI 10.1016/0008-8749(71)90036-0; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SZLAVY L, 1985, ANGIOLOGY, V36, P452, DOI 10.1177/000331978503600707; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zeidler A, 1995, AUTOIMMUNITY, V21, P245, DOI 10.3109/08916939509001943	32	459	481	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					672	675		10.1126/science.278.5338.672	http://dx.doi.org/10.1126/science.278.5338.672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381175				2022-12-01	WOS:A1997YC32300051
J	LaMendola, NP; Bever, TG				LaMendola, NP; Bever, TG			Peripheral and cerebral asymmetries in the rat	SCIENCE			English	Article							TOPOGRAPHICAL DISORIENTATION; POSTERIOR PARIETAL; UNILATERAL REMOVAL; SPATIAL DEFICITS; CORTEX LESIONS; VIBRISSAE; SYSTEM; MEMORY; DISCRIMINATION; LATERALIZATION	Rats learn a novel foraging pattern better with their right-side whiskers than with their left-side whiskers, They also learn better with the left cerebral hemisphere than with the right hemisphere. Rotating an already learned maze relative to the external environment most strongly reduces right-whisker performance; starting an already learned maze at a different location most strongly reduces left-whisker performance. These results suggest that the right-periphery-left-hemisphere system accesses a map-like representation of the foraging problem, whereas the left-periphery-right-hemisphere system accesses a rote path. Thus, as in humans, functional asymmetries in rats can be elicited by both peripheral and cortical manipulation, and each hemisphere makes qualitatively distinct contributions to a complex natural behavior.	UNIV ARIZONA, PROGRAM COGNIT SCI, TUCSON, AZ 85721 USA; UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85721 USA	University of Arizona; University of Arizona								ADELSTEIN A, 1991, BEHAV NEUROSCI, V105, P459, DOI 10.1037/0735-7044.105.3.459; AHL AS, 1986, VET RES COMMUN, V10, P245, DOI 10.1007/BF02213989; AMMASSARITEULE M, 1985, BEHAV BRAIN RES, V17, P9, DOI 10.1016/0166-4328(85)90003-8; BANICH M, 1997, NEUROPSYCHOLOGY NEUR, pCH6; BEVER TG, 1970, MECH LANGUAGE DEV, P186; Bianki V. L., 1988, RIGHT LEFT HEMISPHER; Bradshaw JL., 1993, EVOLUTION LATERAL AS; Brown Halle D., 1995, P77; Burcham K. J., 1996, Society for Neuroscience Abstracts, V22, P682; CASTELLANO MA, 1989, BEHAV NEUROSCI, V103, P46, DOI 10.1037/0735-7044.103.1.46; Cohen, 1993, MEMORY AMNESIA HIPPO, DOI 10.1136/jnnp.58.1.128-a; COLLINS RL, 1968, J HERED, V59, P9, DOI 10.1093/oxfordjournals.jhered.a107656; CORWIN JV, 1994, BEHAV BRAIN RES, V61, P79, DOI 10.1016/0166-4328(94)90010-8; COWELL PE, IN PRESS LATERALITY; CROWNE DP, 1992, BEHAV NEUROSCI, V106, P808, DOI 10.1037/0735-7044.106.5.808; De Renzi E., 1982, DISORDERS SPACE EXPL; DIMATTIA BV, 1988, BEHAV NEUROSCI, V102, P397, DOI 10.1037/0735-7044.102.3.397; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; FRANCO L, 1977, NEUROPSYCHOLOGIA, V15, P107, DOI 10.1016/0028-3932(77)90120-8; Gallistel CR, 1996, J EXP BIOL, V199, P211; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154, DOI 10.1152/jn.1956.19.2.154; GUICROBLES E, 1989, BEHAV BRAIN RES, V31, P285, DOI 10.1016/0166-4328(89)90011-9; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; HEFFNER HE, 1986, J NEUROPHYSIOL, V56, P683, DOI 10.1152/jn.1986.56.3.683; HUSTON JP, 1986, EXP NEUROL, V93, P380, DOI 10.1016/0014-4886(86)90198-6; HUTSON KA, 1986, J NEUROPHYSIOL, V56, P1196, DOI 10.1152/jn.1986.56.4.1196; JACOBS RA, 1991, COGNITIVE SCI, V15, P219, DOI 10.1207/s15516709cog1502_2; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KESNER RP, 1989, BEHAV NEUROSCI, V103, P956, DOI 10.1037/0735-7044.103.5.956; KIMURA D, 1973, SCI AM, V228, P70, DOI 10.1038/scientificamerican0373-70; KING VR, 1992, BEHAV BRAIN RES, V50, P53; Kinsbourne M., 1975, ATTENTION PERFORM, VV, P81; KOLB B, 1984, BEHAV NEUROSCI, V98, P44, DOI 10.1037/0735-7044.98.1.44; Kolb B., 1990, CEREBRAL CORTEX RAT, P437; KOROLEVA VI, 1993, NEUROSCI LETT, V149, P153, DOI 10.1016/0304-3940(93)90759-E; KOSSLYN SM, 1987, PSYCHOL REV, V94, P148, DOI 10.1037/0033-295X.94.2.148; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEVY J, 1969, NATURE, V224, P614, DOI 10.1038/224614a0; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; MEHTA Z, 1991, CORTEX, V27, P153, DOI 10.1016/S0010-9452(13)80121-9; MILANI H, 1989, BEHAV NEUROSCI, V103, P1067, DOI 10.1037/0735-7044.103.5.1067; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; NOTTEBOHM F, 1976, J COMP PHYSIOL, V108, P171, DOI 10.1007/BF02169047; O'Keefe J, 1991, Hippocampus, V1, P230, DOI 10.1002/hipo.450010303; O'Keefe J., 1978, HIPPOCAMPUS SPATIAL; OLTON DS, 1977, SCI AM, V236, P82, DOI 10.1038/scientificamerican0677-82; RATCLIFF G, 1973, J NEUROL NEUROSUR PS, V36, P448, DOI 10.1136/jnnp.36.3.448; SCHIFFMA.HR, 1970, ANIM BEHAV, V18, P290, DOI 10.1016/S0003-3472(70)80040-9; SHERMAN GF, 1985, CEREBRAL LATERALIZAT, P89; THOR DH, 1973, PSYCHOL REP, V33, P815, DOI 10.2466/pr0.1973.33.3.815; VINCENT SB, 1912, BEHAV MONOGR, V9, P1; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; ZIMMERBERG B, 1974, SCIENCE, V185, P623, DOI 10.1126/science.185.4151.623	54	60	60	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	1997	278	5337					483	486		10.1126/science.278.5337.483	http://dx.doi.org/10.1126/science.278.5337.483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YB355	9334310				2022-12-01	WOS:A1997YB35500050
J	Wong, FL; Boice, JD; Abramson, DH; Tarone, RE; Kleinerman, RA; Stovall, M; Goldman, MB; Seddon, JM; Tarbell, N; Fraumeni, JF; Li, FP				Wong, FL; Boice, JD; Abramson, DH; Tarone, RE; Kleinerman, RA; Stovall, M; Goldman, MB; Seddon, JM; Tarbell, N; Fraumeni, JF; Li, FP			Cancer incidence after retinoblastoma - Radiation dose and sarcoma risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOFT-TISSUE SARCOMAS; BILATERAL RETINOBLASTOMA; HEREDITARY RETINOBLASTOMA; TRILATERAL RETINOBLASTOMA; SURVIVORS; TUMORS; RADIOTHERAPY; NEOPLASMS; CARCINOMAS; MORTALITY	Context.-There is a substantial risk of a second cancer for persons with hereditary retinoblastoma, which is enhanced by radiotherapy. Objective.-To examine long-term risk of new primary cancers in survivors of childhood retinoblastoma and quantify the role of radiotherapy in sarcoma development. Design.-Cohort incidence study of patients with retinoblastoma followed for a median of 20 years, and nested case-control study of a radiation dose-response relationship for bone and soft tissue sarcomas. Setting/Participants.-A total of 1604 patients with retinoblastoma who survived at least 1 year after diagnosis, identified from hospital records in Massachusetts and New York during 1914 to 1984. Results.-Incidence of subsequent cancers was statistically significantly elevated only in the 961 patients with hereditary retinoblastoma, in whom 190 cancers were diagnosed, vs 6.3 expected in the general population (relative risk [RR], 30 [95% confidence interval, 26-47]), Cumulative incidence (+/-SE) of a second cancer at 50 years after diagnosis was 51.0% (+/-6.2%) for hereditary retinoblastoma, and 5.0% (+/-3.0%) for nonhereditary retinoblastoma. All 114 sarcomas of diverse histologic types occurred in patients with hereditary retinoblastoma. For soft tissue sarcomas, the RRs showed a stepwise increase at all dose categories, and were statistically significant at 10 to 29.9 Gy and 30 to 59.9 Gy. A radiation risk for all sarcomas combined was evident at doses above 5 Gy, rising to 10.7-fold at doses of 60 Gy or greater (P<.05). Conclusions.-Genetic predisposition has a substantial impact on risk of subsequent cancers in retinoblastoma patients, which is further increased by radiation treatment. A radiation dose-response relationship is demonstrated for all sarcomas and, for the first time in humans, for soft tissue sarcomas. Retinoblastoma patients should be examined for new cancers and followed into later life to determine whether their extraordinary cancer risk extends to common cancers of adulthood.	NCI, DIV CANC EPIDEMIOL & GENET, NIH, ROCKVILLE, MD 20892 USA; UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX USA; NEW YORK HOSP, CORNELL MED CTR, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital				Kleinerman, Ruth/0000-0001-7415-2478	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085604] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-85604, N02-CP-33013] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; [Anonymous], 1986, Natl Cancer Inst Monogr, V70, P1; BADER JL, 1982, CANCER GENET CYTOGEN, V5, P203, DOI 10.1016/0165-4608(82)90026-7; BOICE JD, 1985, NATL CANCER I MONOGR, V68, P1; DAVIS FG, 1989, CANCER RES, V49, P6130; DERKINDEREN DJ, 1987, OPHTHALMIC PAED GEN, V8, P23, DOI 10.3109/13816818709028511; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FOLBERG R, 1983, ARCH OPHTHALMOL-CHIC, V101, P1562; FRANCOIS J, 1980, OPHTHALMOLOGICA, V181, P93, DOI 10.1159/000309033; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN EA, 1992, CANCER-AM CANCER SOC, V70, P423, DOI 10.1002/1097-0142(19920715)70:2<423::AID-CNCR2820700209>3.0.CO;2-B; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; Kony SJ, 1997, LANCET, V350, P91, DOI 10.1016/S0140-6736(97)01116-1; LASKIN WB, 1988, CANCER-AM CANCER SOC, V62, P2330, DOI 10.1002/1097-0142(19881201)62:11<2330::AID-CNCR2820621113>3.0.CO;2-2; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; Moll AC, 1996, INT J CANCER, V67, P515, DOI 10.1002/(SICI)1097-0215(19960807)67:4<515::AID-IJC9>3.0.CO;2-V; MONSON RR, 1969, COMPUT BIOMED RES, V105, P529; PESIN SR, 1989, AM J OPHTHALMOL, V107, P121, DOI 10.1016/0002-9394(89)90209-2; PRESTON DL, 1991, EPICURE USERS GUIDE; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; ROBINSON E, 1988, JNCI-J NATL CANCER I, V80, P233, DOI 10.1093/jnci/80.4.233; RUKA W, 1991, EUR J SURG ONCOL, V17, P585; SCHIFTER S, 1983, CANCER, V51, P1746, DOI 10.1002/1097-0142(19830501)51:9<1746::AID-CNCR2820510930>3.0.CO;2-G; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; *UN SCI COMM EFF A, 1994, 1994 UN SCI COMM EFF, VE; *WHO, 1976, ICD O INT CLASSIFICA; WINTHER J, 1988, CANCER, V62, P1458, DOI 10.1002/1097-0142(19881001)62:7<1458::AID-CNCR2820620735>3.0.CO;2-2; XU HJ, 1991, CANCER RES, V51, P2735; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P70	38	462	473	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1262	1267		10.1001/jama.278.15.1262	http://dx.doi.org/10.1001/jama.278.15.1262			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333268				2022-12-01	WOS:A1997XZ70900032
J	Hansen, SK; Takada, S; Jacobson, RH; Lis, JT; Tjian, R				Hansen, SK; Takada, S; Jacobson, RH; Lis, JT; Tjian, R			Transcription properties of a cell type-specific TATA-binding protein, TRF	CELL			English	Article							RNA-POLYMERASE-II; ALCOHOL-DEHYDROGENASE GENE; DIRECT BASAL TRANSCRIPTION; RICH ACTIVATION MOTIF; CRYSTAL-STRUCTURE; DNA-BINDING; FUNCTIONAL-ANALYSIS; DROSOPHILA; COMPLEX; PROMOTER	Eukaryotic cells are thought to contain a single TATA-binding protein (TBP) that directs transcription by cellular RNA polymerases. Here we report a cell type-specific TBP-related factor (TRF) that can form a stable TRF/IIA/IIB TATA DNA complex and substitute for TBP in directing RNA polymerase II transcription in vitro. Transfection studies reveal that TRF can differentially mediate activation by some enhancer proteins but not others. Like TBP, TRF forms a stable complex containing multiple novel subunits, nTAFs. Antibody staining of embryos and polytene chromosomes reveals cell type-specific expression and gene-selective properties consistent with the shaker/male sterile phenotype of trf mutants. These findings suggest TRF is a homolog of TBP that functions to direct tissue-and gene-specific transcription.	CORNELL UNIV,BIOCHEM SECT,ITHACA,NY 14853	Cornell University	Hansen, SK (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.				NATIONAL CANCER INSTITUTE [R37CA025417, R01CA025417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025232, R01GM025232] Funding Source: NIH RePORTER; NCI NIH HHS [CA25417] Funding Source: Medline; NIGMS NIH HHS [GM25232] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BRAY SJ, 1988, EMBO J, V7, P177, DOI 10.1002/j.1460-2075.1988.tb02798.x; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PAPAZIAN DM, 1988, ANNU REV PHYSIOL, V50, P379; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PASCAL E, 1992, THESIS U CALIFORNIA; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Shopland LS, 1996, CHROMOSOMA, V105, P158, DOI 10.1007/BF02509497; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wang X, 1997, P NATL ACAD SCI USA, V94, P433, DOI 10.1073/pnas.94.2.433; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	50	149	152	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					71	83		10.1016/S0092-8674(01)80010-6	http://dx.doi.org/10.1016/S0092-8674(01)80010-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335336	hybrid			2022-12-01	WOS:A1997XZ80900010
J	Nesse, RM; Berridge, KC				Nesse, RM; Berridge, KC			Psychoactive drug use in evolutionary perspective	SCIENCE			English	Article							SENSITIZATION; ADDICTION; RECEPTORS	Pure psychoactive drugs and direct routes of administration are evolutionarily novel features of our environment. They are inherently pathogenic because they bypass adaptive information processing systems and act directly on ancient brain mechanisms that control emotion and behavior. Drugs that induce positive emotions give a false signal of a fitness benefit. This signal hijacks incentive mechanisms of ''liking'' and ''wanting,'' and can result in continued use of drugs that no longer bring pleasure. Drugs that block negative emotions can impair useful defenses, although there are several reasons why their use is often safe nonetheless. A deeper understanding of the evolutionary origins and functions of the emotions and their neural mechanisms is needed as a basis Tor decisions about the use of psychoactive drugs.	UNIV MICHIGAN, INST SOCIAL RES, ANN ARBOR, MI 48106 USA; UNIV MICHIGAN, DEPT PSYCHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nesse, RM (corresponding author), UNIV MICHIGAN, DEPT PSYCHIAT, 5057 ISR, POB 1248, ANN ARBOR, MI 48106 USA.		Berridge, Kent C/C-1525-2009	Berridge, Kent C/0000-0002-6031-2626; Nesse, Randolph/0000-0003-1768-0949				Barlow DH, 1991, PSYCHOL INQ, V2, P97; BARRINGTON EJW, 1982, BRIT MED BULL, V38, P227, DOI 10.1093/oxfordjournals.bmb.a071765; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BERNTSON GG, 1993, ANN NY ACAD SCI, V702, P75, DOI 10.1111/j.1749-6632.1993.tb17243.x; Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B; BERRIDGE KC, IN PRESS UNDERSTANDI; Bloom Floyd E., 1995, P1063; Buss DM, 1996, PSYCHOL SCI, V7, P373, DOI 10.1111/j.1467-9280.1996.tb00392.x; Butler A., 1996, COMP VERTEBRATE NEUR; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; Frank R.H., 1988, PASSIONS REASON STRA; FRYXELL KJ, 1995, J MOL EVOL, V41, P85, DOI 10.1007/BF00174044; GAZZANIGA MS, 1987, INTEGRATED MIND; GELPERIN A, 1986, TRENDS NEUROSCI, V9, P323, DOI 10.1016/0166-2236(86)90098-6; Gilbert P., 1992, DEPRESSION EVOLUTION; GRAY JA, 1987, FEAR STRESS; HOEBEL BG, 1988, STEVENS HDB EXPT PSY, V1, P547; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KEFTNER D, 1996, COGNITION EMOTION, V10, P155; KETELAAR T, IN PRESS PERSONALITY; KETELAAR T, UNPUB; Kluger MJ., 1979, FEVER ITS BIOL EVOLU; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; LeDoux J.E., 1996, EMOTIONAL BRAIN; Li X, 1996, J MOL EVOL, V43, P179, DOI 10.1007/BF02338825; MARKS IM, 1994, ETHOL SOCIOBIOL, V15, P247, DOI 10.1016/0162-3095(94)90002-7; MCGUIRE MT, 1997, DARWINIAN PSYCHIAT; MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723; Nesse R M, 1990, Hum Nat, V1, P261, DOI 10.1007/BF02733986; NESSE RM, 1994, ETHOL SOCIOBIOL, V15, P339, DOI 10.1016/0162-3095(94)90007-8; Nesse RM, 1995, WHY WE GET SICK NEW; NESSE RM, 1991, PSYCHOLOQUY, V2; PEROUTKA SJ, 1994, NEUROCHEM INT, V25, P533, DOI 10.1016/0197-0186(94)90151-1; Pomerleau CS, 1997, ADDICTION, V92, P397; Pribbenow B, 1996, NEUROBIOL LEARN MEM, V66, P109, DOI 10.1006/nlme.1996.0052; PRICE J, 1994, BRIT J PSYCHIAT, V164, P309, DOI 10.1192/bjp.164.3.309; RIJDA NH, 1994, NATURE EMOTION, P59; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Shizgal P, 1997, CURR OPIN NEUROBIOL, V7, P198, DOI 10.1016/S0959-4388(97)80008-6; SMITH M, 1986, ADV HUM GENET, V15, P249; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; TOOBY J, 1990, ETHOL SOCIOBIOL, V11, P375, DOI 10.1016/0162-3095(90)90017-Z; Walker RJ, 1996, PARASITOLOGY, V113, pS3, DOI 10.1017/S0031182000077878; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; Wilson E.O., 1975, P1; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535; ZAJONC RB, 1985, SCIENCE, V228, P15, DOI 10.1126/science.3883492; [No title captured]	50	226	228	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					63	66		10.1126/science.278.5335.63	http://dx.doi.org/10.1126/science.278.5335.63			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311928				2022-12-01	WOS:A1997XZ12400033
J	Jones, CM; Taylor, GO; Whittle, JG; Evans, D; Trotter, DP				Jones, CM; Taylor, GO; Whittle, JG; Evans, D; Trotter, DP			Water fluoridation, tooth decay in 5 year olds, and social deprivation measured by the Jarman score: analysis of data from British dental surveys	BRITISH MEDICAL JOURNAL			English	Article							CARIES EXPERIENCE; AREAS; CHILDREN; IDENTIFICATION; DENTITION	Objective: To examine the effect of water fluoridation, both artificial and natural, on dental decay, after socioeconomic deprivation was controlled for. Design: Ecological study based on results from the NHS dental surveys in 5 year olds in 1991-2 and 1993-4 and Jarman underprivileged area scores from the 1991 census. Setting: Electoral wards in three areas: Hartlepool (naturally fluoridated), Newcastle and North Tyneside (fluoridated), and Salford and Trafford (non-fluoridated). Subjects: 5 year old children (n = 10 004). Intervention: Water fluoridation (artificial and occurring naturally). Main outcome measure: Ward tooth decay score (score on the ''decayed, missing, and filled tooth index'' for each electoral ward). Results: Multiple linear regression showed a significant interaction between Jarman score for ward, mean number of teeth affected by decay, and both types of water fluoridation. This confirms that the more deprived an area, the greater benefit derived from fluoridation whether natural or artificial (R-2 = 0.84, P < 0.001), At a Jarman score of zero (national mean score) there was a predicted 44% reduction in decay in fluoridated areas, increasing to a 54% reduction in wards with a Jarman score of 40 (very deprived). The area with natural fluoridation (at a level of 1.2 parts per million-higher than levels in artificially fluoridated areas) had a 66% reduction in decay, with a 74% reduction in wards with a Jarman score of 40. Conclusion: Tooth decay is confirmed as a disease associated with social deprivation, and the more socially deprived areas benefit more from fluoridation. Widespread water fluoridation is urgently needed to reduce the ''dental health divide'' by improving the dental health of the poorer people in Britain.	WESHAM PK HOSP,N W DENT PUBL HLTH,PRESTON PR4 3AL,LANCS,ENGLAND; NEWCASTLE & N TYNESIDE HLTH AUTHOR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND									BEAL JF, 1990, PREVENTION DENT DIS; BLAND M, 1993, INTRO MED STAT, P148; *BRIT FLUOR SOC, 1996, ONE MILL WAT FLUOR D; CARMICHAEL CL, 1989, BRIT DENT J, V167, P57, DOI 10.1038/sj.bdj.4806919; Ellwood R P, 1995, Community Dent Health, V12, P18; Ellwood RP, 1996, COMMUNITY DENT ORAL, V24, P1, DOI 10.1111/j.1600-0528.1996.tb00802.x; EVANS RW, 1984, COMMUNITY DENT ORAL, V12, P5, DOI 10.1111/j.1600-0528.1984.tb01401.x; HAUSEN H, 1982, COMMUNITY DENT ORAL, V10, P33, DOI 10.1111/j.1600-0528.1982.tb00357.x; HAUSEN H, 1981, COMMUNITY DENT ORAL, V9, P289, DOI 10.1111/j.1600-0528.1981.tb00348.x; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; Jarman B., 1984, BRIT MED J, V289, P587; NAYLOR MN, 1990, PREVENTION DENT DIS; NEWBRUN E, 1989, J PUBLIC HEALTH DENT, V49, P279, DOI 10.1111/j.1752-7325.1989.tb02086.x; Pitts N B, 1995, Community Dent Health, V12, P52; PITTS NB, 1997, COMMUNITY DENT HL S1, V14, pS6; PITTS NB, 1994, COMMUNITY DENT HLTH, V11, P45; Provart S J, 1995, Community Dent Health, V12, P200; Provart S J, 1995, Community Dent Health, V12, P138; Slade GD, 1996, COMMUNITY DENT ORAL, V24, P89, DOI 10.1111/j.1600-0528.1996.tb00822.x; TAYLOR GO, 1995, BRIT DENT J, V178, P47, DOI 10.1038/sj.bdj.4808644; WINTER GB, 1990, ARCH ORAL BIOL, V35, pS1, DOI 10.1016/0003-9969(90)90124-S	21	56	62	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					514	517		10.1136/bmj.315.7107.514	http://dx.doi.org/10.1136/bmj.315.7107.514			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329305	Green Published			2022-12-01	WOS:A1997XU50600017
J	Fahlke, C; Yu, HT; Beck, CL; Rhodes, TH; George, AL				Fahlke, C; Yu, HT; Beck, CL; Rhodes, TH; George, AL			Pore-forming segments in voltage-gated chloride channels	NATURE			English	Article							MOLECULAR-BASIS; DOMINANT; MYOTONIA; CELLS	The ability to differentiate between ions is a property of ion channels that is crucial for their biological functions', However, the fundamental structural features that define anion selectivity and distinguish anion-permeable from cation-permeable channels are poorly understood, Voltage-gated chloride (Cl-) channels belonging to the ClC family are ubiquitous and have been predicted to play important roles in many diverse physiological(2) and pathophysiological(3-5) processes. We have identified regions of a human skeletal muscle ClC isoform that contribute to formation of its anion-selective conduction pathway. A core structural element (pi region) of the CIC channel pore spans an accessibility barrier between the internal and external milieu, and contains an evolutionarily conserved sequence motif: GKxGPxxH. Neighbouring sequences in the third and fifth transmembrane segments also contribute to isoform-specific differences in anion selectivity, The conserved motif in the Cl- channel Pl region may constitute a 'signature' sequence for an anion-selective ion pore by analogy with the homologous GYG sequence that is essential for selectivity in voltage-gated potassium ion (K+) channel pores(6-8).	VANDERBILT UNIV,SCH MED,DEPT MED NEPHROL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL NEUROSCI,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University			Fahlke, Christoph/G-3635-2013	Fahlke, Christoph/0000-0001-8602-9952				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; DANI JA, 1983, J GEN PHYSIOL, V81, P255, DOI 10.1085/jgp.81.2.255; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1996, BIOPHYS J, V71, P695, DOI 10.1016/S0006-3495(96)79269-X; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; FAHLKE C, J GEN PHYSIOL, V110, P551; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hille B., 1992, IONIC CHANNELS EXCIT; JENTSCH TJ, 1994, CURR TOP MEMBR, V42, P35, DOI 10.1016/S0070-2161(08)60817-5; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0	21	159	161	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					529	532		10.1038/37391	http://dx.doi.org/10.1038/37391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394005				2022-12-01	WOS:A1997YJ86500057
J	Pidoplichko, VI; DeBiasi, M; Williams, JT; Dani, JA				Pidoplichko, VI; DeBiasi, M; Williams, JT; Dani, JA			Nicotine activates and desensitizes midbrain dopamine neurons	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; SYNAPTIC TRANSMISSION; RAT; ADDICTION; SYSTEM	Tobacco use in developed countries is estimated to be the single largest cause of premature death(1), Nicotine is the primary component of tobacco that drives use, and like other addictive drugs, nicotine reinforces self-administration and place preference in animal studies(2-5). Midbrain dopamine neurons normally help to shape behaviour by reinforcing biologically rewarding events, but addictive drugs such as cocaine can inappropriately exert a reinforcing influence by acting upon the mesolimbic dopamine system(3-6). Here we show that the same concentration of nicotine achieved by smokers activates and desensitizes multiple nicotinic receptors thereby regulating the activity of mesolimbic dopamine neurons, Initial application of nicotine can increase the activity of the dopamine neurons, which could mediate the rewarding aspects of tobacco use, Prolonged exposure to even these low concentrations of nicotine, however, can cause desensitization of the nicotinic receptors, which helps to explain acute tolerance to nicotine's effects, The effects suggest a cellular basis for reports that the first cigarette of the day is the most pleasurable, whereas the effect of subsequent cigarettes may depend on the interplay between activation and desensitization of multiple nicotinic receptors(5).	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Baylor College of Medicine; Baylor College of Medicine; Oregon Health & Science University			De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872				ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; BENOWITZ NL, 1989, PROG BRAIN RES, V79, P279; Bonci A, 1996, NEURON, V16, P631, DOI 10.1016/S0896-6273(00)80082-3; Briggs CA, 1996, NEUROPHARMACOLOGY, V35, P407, DOI 10.1016/0028-3908(96)00006-8; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CLARKE PBS, 1993, PROG BRAIN RES, V98, P77; CLARKE PBS, 1991, ADV PHAR SC, P285; CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4; CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P171, DOI 10.1007/BF02244174; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KANG Y, 1993, NEUROSCI RES, V18, P209, DOI 10.1016/0168-0102(93)90056-V; LESTER RAJ, 1994, NEUROPHARMACOLOGY, V33, P27, DOI 10.1016/0028-3908(94)90093-0; MARKS MJ, 1992, J NEUROSCI, V12, P2765; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MERCURI NB, 1995, EUR J NEUROSCI, V7, P462, DOI 10.1111/j.1460-9568.1995.tb00342.x; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Pich EM, 1997, SCIENCE, V275, P83; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; STOLERMAN IP, 1991, TRENDS PHARMACOL SCI, V12, P467, DOI 10.1016/0165-6147(91)90638-9; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z	30	565	572	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					401	404		10.1038/37120	http://dx.doi.org/10.1038/37120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389479				2022-12-01	WOS:A1997YH54900063
J	Culpepper, L; Froom, J				Culpepper, L; Froom, J			Routine antimicrobial treatment of acute otitis media - Is it necessary?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; PLACEBO-CONTROLLED TRIAL; ANTIBIOTIC-TREATMENT; BACTERIAL-MENINGITIS; DRUG-RESISTANCE; DAY-CARE; CHILDREN; PENICILLIN; DIAGNOSIS; THERAPY		SUNY STONY BROOK, SCH MED, DEPT FAMILY MED, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Culpepper, L (corresponding author), BOSTON UNIV, SCH MED, DEPT FAMILY MED, 1 BOSTON MED CTR PL, BOSTON, MA 02118 USA.			Culpepper, Larry/0000-0002-7655-0477	AHRQ HHS [R01 HS0703503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; BAIN J, 1985, BRIT MED J, V291, P1243, DOI 10.1136/bmj.291.6504.1243; BARNETT ED, 1995, PEDIATR CLIN N AM, V42, P509; BLUESTONE CD, 1988, OTITIS MEDIA INFANTS, P45; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; CLAESSEN JQPJ, 1992, CLIN OTOLARYNGOL, V17, P251, DOI 10.1111/j.1365-2273.1992.tb01838.x; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DENEELING AJ, 1993, RESISTENTIE TEGEN AN; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; EAVEY RD, 1985, J PEDIATR-US, V106, P402, DOI 10.1016/S0022-3476(85)80664-8; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; FADEN H, 1994, PEDIATR INFECT DIS J, V13, P609, DOI 10.1097/00006454-199407000-00005; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; Froom J, 1993, Arch Fam Med, V2, P841, DOI 10.1001/archfami.2.8.841; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HARRISON CJ, 1985, PEDIATR INFECT DIS J, V4, P641, DOI 10.1097/00006454-198511000-00009; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P14, DOI 10.1097/00006454-198801000-00005; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KALEIDA PH, 1991, PEDIATRICS, V87, P466; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; KLEIN JO, 1994, CLIN INFECT DIS, V19, P823, DOI 10.1093/clinids/19.5.823; KOSHLAND DE, 1992, SCIENCE, V257, P1021, DOI 10.1126/science.257.5073.1021; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; SUGITA R, 1983, INT J PEDIATR OTORHI, V6, P135; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; TRUJILLO H, 1989, PEDIATR INFECT DIS J, V8, P361, DOI 10.1097/00006454-198906000-00007; VAN DISHOECK H A, 1959, Acta Otolaryngol, V50, P250; van Klingeren B, 1992, Ned Tijdschr Geneeskd, V136, P860; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	42	47	47	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1643	1645		10.1001/jama.278.20.1643	http://dx.doi.org/10.1001/jama.278.20.1643			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388073				2022-12-01	WOS:A1997YG85900002
J	Xue, D; Horvitz, HR				Xue, D; Horvitz, HR			Caenorhabditis elegans CED-9 protein is a bifunctional cell-death inhibitor	NATURE			English	Article							C-ELEGANS; CYSTEINE PROTEASE; BCL-2; GENE; P35; APOPTOSIS; SURVIVAL; ENCODES; EXPRESSION; PREVENTION	The Caenorhabditis elegans gene ced-9 prevents cells from undergoing programmed cell death and encodes a protein similar to the mammalian cell-death inhibitor Bcl-2 (refs 1-7). We show here that the CED-9 protein is a substrate for the C. elegans cell-death protease CED-3 (refs 8, 9), which is a member of a family of cysteine proteases first defined by CED-3 and human interleukin-1 beta converting enzyme (ICE)(10-12). CED-9 can be cleaved by CED-3 at two sites near its amino terminus, and the presence of at least one of these sites is important for complete protection by CED-9 against cell death. Cleavage of CED-9 by CED-3 generates a carboxy-terminal product that resembles Bcl-2 in sequence and in function. Bcl-2 and the baculovirus protein p35, which inhibits cell death in different species through a mechanism that depends on the presence of its cleavage site for the CED-3/ICE family of proteases(9,13-17), inhibit cell death additively in C. elegans, Our results indicate that CED-9 prevents programmed cell death in C. elegans through two distinct mechanisms: first, CED-9 may, by analogy with p35 (refs 9, 17), directly inhibit the CED-3 protease by an interaction involving the CED-3 cleavage sites in CED-9; second, CED-9 may directly or indirectly inhibit CED-3 by means of a protective mechanism similar to that used by mammalian Bcl-2.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				XUE, DING/0000-0002-8429-8136				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; NUNEZ G, 1990, J IMMUNOL, V144, P3602; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sambrook J., 1989, MOL CLONING LAB MANU; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	98	111	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					305	308		10.1038/36889	http://dx.doi.org/10.1038/36889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384385				2022-12-01	WOS:A1997YG66700068
J	Schriger, DL; Baraff, LJ; Rogers, WH; Cretin, S				Schriger, DL; Baraff, LJ; Rogers, WH; Cretin, S			Implementation of clinical guidelines using a computer charting system - Effect on the initial care of health care workers exposed to body fluids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY; PERFORMANCE; EMERGENCY; POLICIES; DELIVERY; AUDIT	Context.-While clinical guidelines are considered an important mechanism to improve the quality of medical care, problems with implementation may limit their effectiveness, Few empirical data exist about the effect of computer-based systems for application of clinical guidelines on quality of care. Objective.-To determine whether real-time presentation of clinical guidelines using an electronic medical record can increase compliance with guidelines. Design.-Prospective off-on-off, interrupted time series with intent-to-treat analysis. Setting.-University hospital emergency department. Subjects.-Patients were 280 health care workers (50 in the baseline control phase, 156 in the intervention phase, and 74 in the postintervention control phase) who presented for initial treatment of occupational body fluid exposures, including 89% (248/280) who sustained punctures and 81% (208/257) who were exposed to blood. Physicians included resident physicians and attending physicians working in the emergency department during the study. Interventions.-Implementation of a computer charting system that provides real-time information regarding history and recommendations for laboratory testing, treatment, and disposition based on rules derived from clinical guidelines. Main Outcome Measures.-Quality of care as determined by essential items documented in the medical record and in aftercare instructions, compliance with testing and treatment guidelines, and total charges and percentage of charges attributable to guideline-endorsed activities. Results.-Mean percent documentation of 7 essential items regarding patient history in the medical record increased from 57% during the baseline period to 98% in the intervention phase (42% increase; 95% confidence interval [CI], 34%-49%) and 11 items in aftercare instruction increased from 31% at baseline to 93% during the intervention phase (62% increase; 95% CI, 51%-74%), but both decreased to baseline when the computer system was removed. Percent compliance with 4 laboratory testing guidelines increased from 63% at baseline to 83% during the intervention phase (20% increase; 95% CI, 9%-31%) but decreased to 52% when the computer system was removed, Compliance with 5 treatment guidelines increased from 83% at baseline to 96% during the intervention phase (13% increase; 95% CI, 9%-17%) and decreased to 84% following the intervention. Percentage of charges incurred for indicated laboratory tests and treatment increased from 44% at baseline to 81% during the intervention phase (37% increase; 95% CI, 22%-52%) and decreased to 36% following the intervention. Average total per-patient charges were $460, $384, and $373 in each phase, respectively. Conclusions.-Use of a computer-based system for clinical guidelines for management of patients with occupational exposure to body fluids improved documentation, compliance with guidelines, and percentage of charges spent on indicated activities, while decreasing overall charges. The parameters returned to baseline when the computer system was removed.	TUFTS UNIV NEW ENGLAND MED CTR, HLTH INST, BOSTON, MA 02111 USA; SHAN CRETIN & ASSOCIATES, SANTA MONICA, CA USA	Tufts Medical Center	Schriger, DL (corresponding author), UNIV CALIF LOS ANGELES, MED CTR, CTR EMERGENCY MED, 924 WESTWOOD BLVD, SUITE 300, LOS ANGELES, CA 90024 USA.			Schriger, David/0000-0003-0242-1127	AHRQ HHS [R18HS06284] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AG HLTH CAR POL R, 1997, GUID MED OUTC; Balas EA, 1996, J AM MED INFORM ASSN, V3, P56, DOI 10.1136/jamia.1996.96342649; BARAFF LJ, 1990, ANN EMERG MED, V19, P45; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P877; EDDY DM, 1994, METHODOLOGY PERSPECT, P5; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; GLASZIOU PP, 1994, MED DECIS MAKING, V14, P207; GO GW, 1991, ANN EMERG MED, V20, P1341, DOI 10.1016/S0196-0644(05)81078-9; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HOLBROOK J, 1990, ANN EMERG MED, V19, P139, DOI 10.1016/S0196-0644(05)81798-6; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1993, ANN NY ACAD SCI, V703, P226, DOI 10.1111/j.1749-6632.1993.tb26351.x; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; RICEJ A, 1995, MATH STAT DATA ANAL, P153; Schriger D. L., 1989, Proceedings: The Thirteenth Annual Symposium on Computer Applications in Medical Care (Cat. No.89TH0286-5), P611; Schriger DL, 1996, ANN EMERG MED, V27, P655; SHIFFMAN RN, 1994, MED DECIS MAKING, V14, P245, DOI 10.1177/0272989X9401400306; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; *STAT, 1997, STAT REF MAN REL 5, pU235; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TOEPP MC, 1996, DIRECTORY PRACTICE P; *US C, 1994, H608 OTA US C, V198; *US C, 1994, OTAH608 US C, P177; WEARS RL, 1994, ACAD EMERG MED, V1, pA35; Woolf SH, 1994, METHODOLOGY PERSPECT, P105; 1996, MMWR-MORBID MORTAL W, V45, P468	31	106	105	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1585	1590		10.1001/jama.278.19.1585	http://dx.doi.org/10.1001/jama.278.19.1585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370504				2022-12-01	WOS:A1997YF40700039
J	Imai, T; Hieshima, K; Haskell, C; Baba, M; Nagira, M; Nishimura, M; Kakizaki, M; Takagi, S; Nomiyama, H; Schall, TJ; Yoshie, O				Imai, T; Hieshima, K; Haskell, C; Baba, M; Nagira, M; Nishimura, M; Kakizaki, M; Takagi, S; Nomiyama, H; Schall, TJ; Yoshie, O			Identification and molecular characterization of fractalkine receptor CX(3)CR1, which mediates both leukocyte migration and adhesion	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; CHEMOATTRACTANT RECEPTORS; CHEMOKINE RECEPTORS; EXPRESSION; INFLAMMATION; BIOLOGY; GENE	Leukocyte trafficking at the endothelium requires both cellular adhesion molecules and chemotactic factors. Fractalkine, a novel transmembrane molecule with a CX3C-motif chemokine domain atop a mucin stalk, induces both adhesion and migration of leukocytes. Here we identify a seven-transmembrane high-affinity receptor for fractalkine and show that it mediates both the adhesive and migratory functions of fractalkine. The receptor, now termed CX(3)CR1, requires pertussis toxin-sensitive G protein signaling to induce migration but not to support adhesion, which also occurs without other adhesion molecules but requires the architecture of a chemokine domain atop the mucin stalk. Natural killer cells predominantly express CX(3)CR1 and respond to fractalkine in both migration and adhesion. Thus, fractalkine and CX(3)CR1 represent new types of leukocyte trafficking regulators, performing both adhesive and chemotactic functions.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	Kumamoto University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Imai, T (corresponding author), SHIONOGI INST MED SCI,SETTSU 566,JAPAN.		Hieshima, Kunio/AAF-7040-2019; Nomiyama, Hisayuki/F-2840-2013	Hieshima, Kunio/0000-0002-7786-4646; Nomiyama, Hisayuki/0000-0002-2716-4043; Yoshie, Osamu/0000-0003-4353-5809				Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; OIN S, 1996, EUR J IMMUNOL, V26, P640; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	21	1095	1161	1	63	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					521	530		10.1016/S0092-8674(00)80438-9	http://dx.doi.org/10.1016/S0092-8674(00)80438-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390561	Bronze			2022-12-01	WOS:A1997YG49200013
J	Rameh, LE; Tolias, KF; Duckworth, BC; Cantley, LC				Rameh, LE; Tolias, KF; Duckworth, BC; Cantley, LC			A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate	NATURE			English	Article							PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE; POLYPHOSPHOINOSITIDES; 3,4-BISPHOSPHATE; PHOSPHORYLATION; 3-MONOPHOSPHATE; PURIFICATION; SEQUENCE; 4-KINASE; KINASES; CLONING	Phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P-2), a key molecule in the phosphoinositide signalling-pathway, was thought to be synthesized exclusively by phosphorylation of PtdIns-4-P at the D-5 position of the inositol ring. The enzymes that produce PtdIns-4,5-P-2 in vitro fall into two related subfamilies (type I and type II PtdInsP-5-OH kinases, or PIP(5)Ks) based on their enzymatic properties and sequence similarities(1). Here we have reinvestigated the substrate specificities of these enzymes. As expected, the type I enzyme phosphorylates PtdIns-4-P at the D- 5 position of the inositol ring. Surprisingly, the type II enzyme, which is abundant in some tissues, phosphorylates PtdIns-5-P at the D-4 position, and thus should be considered as a 4-OH kinase, or PIP(4)K. The earlier error in characterizing the activity of the type II enzyme is due to the presence of contaminating PtdIns-5-P in commercial preparations of PtdIns-4-P. Although PtdIns-5-P was previously thought not to exist in vivo, we find evidence for the presence of this lipid in mammalian fibroblasts, establishing a new pathway for PtdIns-4,5-P-2 synthesis.	BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	Rameh, LE (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Tolias, Kimberley/0000-0002-2092-920X				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; LING LE, 1989, J BIOL CHEM, V264, P5080; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MEYERS R, 1997, J BIOL CHEM, V272, P4385; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	18	342	356	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	1997	390	6656					192	196		10.1038/36621	http://dx.doi.org/10.1038/36621			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367159				2022-12-01	WOS:A1997YF49400059
J	Ibba, M; Morgan, S; Curnow, AW; Pridmore, DR; Vothknecht, UC; Gardner, W; Lin, W; Woese, CR; Soll, D				Ibba, M; Morgan, S; Curnow, AW; Pridmore, DR; Vothknecht, UC; Gardner, W; Lin, W; Woese, CR; Soll, D			A euryarchaeal Lysyl-tRNA synthetase: Resemblance to class I synthetases	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; SEQUENCE; RECOGNITION; GENE; ARCHAEA; GENOME	The sequencing of euryarchaeal genomes has suggested that the essential protein lysyl-transfer RNA (tRNA) synthetase (LysRS) is absent from such organisms. However, a single 62-kilodalton protein with canonical LysRS activity was purified from Methanococcus maripaludis, and the gene that encodes this protein was cloned, The predicted amino acid sequence of M. maripaludis LysRS is similar to open reading frames of unassigned function in both Methanobacterium thermoautotrophicum and Methanococcus jannaschii but is unrelated to canonical LysRS proteins reported in eubacteria, eukaryotes, and the crenarchaeote Sulfolobus solfataricus. The presence of amino acid motifs characteristic of the Rossmann dinucleotide-binding domain identifies M. maripaludis LysRS as a class I aminoacyl-tRNA synthetase, in contrast to the known examples of this enzyme, which are class II synthetases, These data question the concept that the classification of aminoacyl-tRNA synthetases does not vary throughout living systems.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOL CELLULAR & DEV BIOL,NEW HAVEN,CT 06511; HAMILTON COLL,DEPT BIOL,CLINTON,NY 13323; NESTLE RES CTR,CH-1000 LAUSANNE,SWITZERLAND; UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602	Yale University; Yale University; Hamilton College; Nestle SA; University System of Georgia; University of Georgia			Vothknecht, Ute C/F-4678-2014	Vothknecht, Ute C/0000-0002-8930-0127				Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bjork Glenn R., 1995, P165; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN JS, 1994, J BACTERIOL, V176, P2699, DOI 10.1128/JB.176.9.2699-2705.1994; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FREIST W, 1995, BIOL CHEM H-S, V376, P451; Grayling RA, 1996, FEMS MICROBIOL REV, V18, P203; Hong KW, 1996, EMBO J, V15, P1983, DOI 10.1002/j.1460-2075.1996.tb00549.x; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NAGEL GM, 1995, J MOL EVOL, V40, P487; Neher R., 1963, J CHROMATOGR, V12, P329; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Ouzounis CA, 1996, J MOL EVOL, V42, P234, DOI 10.1007/BF02198849; Sensen CW, 1996, MOL MICROBIOL, V22, P175, DOI 10.1111/j.1365-2958.1996.tb02666.x; SMITH D, IN PRESS J BACTERIOL; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWANSON R, COMMUNICATION; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WATANABE K, 1994, NUCLEIC ACIDS RES, V22, P79, DOI 10.1093/nar/22.1.79; Watanabe Kimitsuna, 1995, P225	27	178	184	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1119	1122		10.1126/science.278.5340.1119	http://dx.doi.org/10.1126/science.278.5340.1119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353192				2022-12-01	WOS:A1997YE65200051
J	Stopfer, M; Bhagavan, S; Smith, BH; Laurent, G				Stopfer, M; Bhagavan, S; Smith, BH; Laurent, G			Impaired odour discrimination on desynchronization of odour-encoding neural assemblies	NATURE			English	Article							APIS-MELLIFERA; OLFACTORY NETWORK; OSCILLATIONS; HONEYBEE; CORTEX; ODORS; BULB	Stimulus-evoked oscillatory synchronization of neural assemblies has been described in the olfactory(1-5) and visual(6-8) systems of several vertebrates and invertebrates. In locusts, information about odour identity is contained in the timing of action potentials in an oscillatory population response(9-11), suggesting that oscillations may reflect a common reference far messages encoded in time, Although the stimulus-evoked oscillatory phenomenon is reliable, its roles in sensation, perception, memory formation and pattern recognition remain to be demonstrated-a task requiring a behavioural paradigm, Using honeybees, we now demonstrate that odour encoding involves, as it does in locusts, the oscillatory synchronization of assemblies of projection neurons and that this synchronization is also selectively abolished by picrotoxin, an antagonist of the GABA(A) (gamma-aminobutyric acid) receptor. By using a behavioural leaning paradigm, we show that picrotoxin-induced desynchronization impairs the discrimination of molecularly similar odorants, but not that of dissimilar odorants, It appears, therefore, that oscillatory synchronization of neuronal assemblies is functionally relevant, and essential for fine sensory discrimination This suggests that oscillatory synchronization and the kind of temporal encoding it affords provide an additional dimension by which the brain could segment spatially overlapping stimulus representations.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; OHIO STATE UNIV, DEPT ENTOMOL, COLUMBUS, OH 43210 USA	California Institute of Technology; University System of Ohio; Ohio State University			Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Stopfer, Mark/0000-0001-9200-1884				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; Bhagavan S, 1997, PHYSIOL BEHAV, V61, P107, DOI 10.1016/S0031-9384(96)00357-5; BITTERMAN ME, 1983, J COMP PSYCHOL, V97, P107, DOI 10.1037/0735-7036.97.2.107; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; Kuwabara M., 1957, Journal of the Faculty of Science Hokkaido University Zoology, V13, P458; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Laurent G, 1996, TRENDS NEUROSCI, V19, P489, DOI 10.1016/S0166-2236(96)10054-0; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MACMILLAN CS, 1987, J COMP PHYSIOL A, V160, P359, DOI 10.1007/BF00613025; MAUELSHAGEN J, 1993, J NEUROPHYSIOL, V69, P609, DOI 10.1152/jn.1993.69.2.609; Menzel R., 1983, P206; MENZEL R, 1988, NATO ASI SERIES H, V19, P335; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NEUENSCHWANDER S, 1993, EUR J NEUROSCI, V5, P870, DOI 10.1111/j.1460-9568.1993.tb00939.x; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Smith BH, 1997, BEHAV NEUROSCI, V111, P57; SMITH BH, 1989, J INSECT PHYSIOL, V35, P369, DOI 10.1016/0022-1910(89)90110-8; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371	26	690	701	1	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					70	74		10.1038/36335	http://dx.doi.org/10.1038/36335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363891				2022-12-01	WOS:A1997YE47700053
J	Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN				Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN			The impact of aerosols on solar ultraviolet radiation and photochemical smog	SCIENCE			English	Article							NITROGEN-DIOXIDE PHOTOLYSIS; SKY BRIGHTNESS MEASUREMENTS; EASTERN-UNITED-STATES; AIR-POLLUTION; ACTINIC FLUX; ATMOSPHERE; OZONE; TROPOSPHERE; SCATTERING; CLOUDS	Photochemical smog, or ground-level ozone, has been the most recalcitrant of air pollution problems, but reductions in emissions of sulfur and hydrocarbons may yield unanticipated benefits in air quality. While sulfate and some organic aerosol particles scatter solar radiation back into space and can cool Earth's surface, they also change the actinic flux of ultraviolet (UV) radiation. Observations and numerical models show that UV-scattering particles in the boundary layer accelerate photochemical reactions and smog production, but UV-absorbing aerosols such as mineral dust and soot inhibit smog production. Results could have major implications for the control of air pollution.	NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20742	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Dickerson, RR (corresponding author), UNIV MARYLAND,DEPT METEOROL,COLLEGE PK,MD 20742, USA.		Georgiy, Stenchikov/J-8569-2013; Stenchikov, Georgiy/AAA-4371-2022; Kondragunta, Shobha/F-5601-2010; Dickerson, Russell/ABB-1512-2020; Dickerson, Russell R/F-2857-2010	Kondragunta, Shobha/0000-0001-8593-8046; Dickerson, Russell/0000-0003-0206-3083; Dickerson, Russell R/0000-0003-0206-3083; Stenchikov, Georgiy Lvovich/0000-0001-9033-4925				Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; BLACKBURN TE, 1992, J GEOPHYS RES-ATMOS, V97, P10109, DOI 10.1029/92JD00504; Blindauer C, 1996, J ATMOS CHEM, V24, P1, DOI 10.1007/BF00053820; BRUEHL C, 1989, GEOPHYS RES LETT, V16, P703; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; CIVEROLO KL, 1996, THESIS U MARYLAND CO; DENTENER FJ, 1993, J GEOPHYS RES-ATMOS, V98, P7149, DOI 10.1029/92JD02979; DICKERSON RR, 1982, J GEOPHYS RES-OCEANS, V87, P4933, DOI 10.1029/JC087iC07p04933; FinlaysonPitts BJ, 1997, SCIENCE, V276, P1045, DOI 10.1126/science.276.5315.1045; Flowers EC, 1969, J APPL METEOROL, V8, P955, DOI [10.1175/1520-0450(1969)0082.0.CO;2, DOI 10.1175/1520-0450(1969)0082.0.CO;2]; FRASER RS, 1985, IEEE J GEOSCI REM GE, V23, P525; Hauglustaine DA, 1996, GEOPHYS RES LETT, V23, P2609, DOI 10.1029/96GL02474; Herman JR, 1997, J GEOPHYS RES-ATMOS, V102, P16911, DOI 10.1029/96JD03680; HOLBEN BN, 1997, 6 INT S PHYS MEAS SI, P75; HUSAR RB, 1981, ATMOS ENVIRON, V15, P1919, DOI 10.1016/0004-6981(81)90226-2; HUSAR RB, 1993, ENVIRON SCI TECHNOL, V27, P12, DOI 10.1021/es00038a001; IPCC,, 1996, CLIMATE CHANGE 1995; KAUFMAN YJ, 1986, J ATMOS SCI, V43, P1135, DOI 10.1175/1520-0469(1986)043<1135:FEFMOT>2.0.CO;2; KAUFMAN YJ, 1983, J CLIM APPL METEOROL, V22, P1694, DOI 10.1175/1520-0450(1983)022<1694:LEBADS>2.0.CO;2; KAUFMAN YJ, 1994, J GEOPHYS RES-ATMOS, V99, P10341, DOI 10.1029/94JD00229; KELLEY P, 1995, GEOPHYS RES LETT, V22, P2621, DOI 10.1029/95GL02563; KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/science.260.5106.311; KONDRAGUNTA S, 1997, THESIS U MARYLAND CO; Lary DJ, 1997, J GEOPHYS RES-ATMOS, V102, P3671, DOI 10.1029/96JD02969; LELIEVELD J, 1990, NATURE, V343, P277; Liang JY, 1997, J GEOPHYS RES-ATMOS, V102, P5993, DOI 10.1029/96JD02957; LIU S, 1901, GEOPHYS RES LETT, V18, P2265; Lu Y, 1996, CHEMOSPHERE, V32, P739, DOI 10.1016/0045-6535(96)00028-8; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; Meng Z, 1997, SCIENCE, V277, P116, DOI 10.1126/science.277.5322.116; Naja M, 1996, GEOPHYS RES LETT, V23, P81, DOI 10.1029/95GL03589; Nakajima T, 1996, APPL OPTICS, V35, P2672, DOI 10.1364/AO.35.002672; *NASA, 1994, CHEM KIN PHOT DAT US; National Academy of Sciences, 1991, RETH OZ PROBL URB RE; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; PETERSON JT, 1976, ATMOS ENVIRON, V10, P459, DOI 10.1016/0004-6981(76)90026-3; PETERSON JT, 1981, J APPL METEOROL, V20, P229, DOI 10.1175/1520-0450(1981)020<0229:ATOCNC>2.0.CO;2; PETERSON JT, 1977, ATMOS ENVIRON, V11, P689, DOI 10.1016/0004-6981(77)90177-9; PIELKE RA, 1992, METEOROL ATMOS PHYS, V49, P69, DOI 10.1007/BF01025401; Ravishankara AR, 1997, SCIENCE, V276, P1058, DOI 10.1126/science.276.5315.1058; Remer LA, 1997, J GEOPHYS RES-ATMOS, V102, P16849, DOI 10.1029/96JD01932; Rhoads KP, 1997, J GEOPHYS RES-ATMOS, V102, P18981, DOI 10.1029/97JD01078; RUGGABER A, 1994, J ATMOS CHEM, V18, P171, DOI 10.1007/BF00696813; RYAN W, IN PRESS J AIR WASTE; SEINFELD JH, 1989, SCIENCE, V243, P745, DOI 10.1126/science.243.4892.745; Shetter RE, 1996, J GEOPHYS RES-ATMOS, V101, P14631, DOI 10.1029/96JD00211; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; Systems Applications International (SAI), 1995, US GUID VAR GRID URB; *US EPA, 1996, EPA454R96005; US-EPA, 1991, EPA450491013; VARSHNEY CK, 1992, ATMOS ENVIRON B-URB, V26, P291, DOI 10.1016/0957-1272(92)90004-C; Walcek CJ, 1997, ATMOS ENVIRON, V31, P1221, DOI 10.1016/S1352-2310(96)00257-9; WISCOMBE WJ, 1980, APPL OPTICS, V19, P1505, DOI 10.1364/AO.19.001505; ZAFONTE L, 1977, ENVIRON SCI TECHNOL, V11, P483, DOI 10.1021/es60128a006	54	416	459	9	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					827	830		10.1126/science.278.5339.827	http://dx.doi.org/10.1126/science.278.5339.827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346474				2022-12-01	WOS:A1997YD47900036
J	Gamble, TR; Yoo, SH; Vajdos, FF; vonSchwedler, UK; Worthylake, DK; Wang, H; McCutcheon, JP; Sundquist, WI; Hill, CP				Gamble, TR; Yoo, SH; Vajdos, FF; vonSchwedler, UK; Worthylake, DK; Wang, H; McCutcheon, JP; Sundquist, WI; Hill, CP			Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MAJOR HOMOLOGY REGION; RETROVIRAL GAG PROTEINS; CYCLOPHILIN-A; VIRION MORPHOGENESIS; PARTICLE FORMATION; ASSOCIATION; STEPS	The carboxyl-terminal domain, residues 146 to 231, of the human immunodeficiency virus-1 (HIV-1) capsid protein [CA(146-231)] is required for capsid dimerization and viral assembly. This domain contains a stretch of 20 residues, called the major homology region (MHR), which is conserved across retroviruses and is essential for viral assembly, maturation, and infectivity. The crystal structures of CA(146-231) and CA(151-231) reveal that the globular domain is composed of four helices and an extended aminoterminal strand. CA(146-231) dimerizes through parallel packing of helix 2 across a dyad. The MHR is distinct from the dimer interface and instead forms an intricate hydrogen-bonding network that interconnects strand 1 and helices 1 and 2. Alignment of the CA(146-231) dimer with the crystal structure of the capsid amino-terminal domain provides a model for the intact protein and extends models for assembly of the central conical core of HIV-1.	UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah				McCutcheon, John/0000-0002-5489-6039	NIAID NIH HHS [R01 AI40333, R01 AI43036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043036, R01AI040333] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNER AT, 1996, X PLOR VERSION 3 843; Clish CB, 1996, FEBS LETT, V378, P43, DOI 10.1016/0014-5793(95)01419-5; CRAVEN RC, 1995, J VIROL, V69, P4213, DOI 10.1128/JVI.69.7.4213-4227.1995; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; GELDERBLOM HR, 1992, MEMBRANE INTERACTION, P33; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; GOFF S, 1981, J VIROL, V38, P238; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KRAUSSLICH HG, 1996, CURRENT TOPICS IMMUN, V214; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Orlinsky KJ, 1996, J VIROL, V70, P3440, DOI 10.1128/JVI.70.6.3440-3448.1996; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; ROSE S, 1992, PROTEINS, V13, P112, DOI 10.1002/prot.340130204; ROY O, 1996, VIROLOGY, V220, P530; STRAMBIODECASTILLIA C, 1992, J VIROL, V66, P7021, DOI 10.1128/JVI.66.12.7021-7032.1992; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Swingler S, 1997, J VIROL, V71, P4372, DOI 10.1128/JVI.71.6.4372-4377.1997; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; VONSCHWEDLER U, UNPUB; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zhang WH, 1996, J GEN VIROL, V77, P743, DOI 10.1099/0022-1317-77-4-743	36	507	518	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					849	853		10.1126/science.278.5339.849	http://dx.doi.org/10.1126/science.278.5339.849			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346481				2022-12-01	WOS:A1997YD47900043
J	Miyakawa, T; Yagi, T; Kitazawa, H; Yasuda, M; Kawai, N; Tsuboi, K; Niki, H				Miyakawa, T; Yagi, T; Kitazawa, H; Yasuda, M; Kawai, N; Tsuboi, K; Niki, H			Fyn-kinase as a determinant of ethanol sensitivity: Relation to NMDA-receptor function	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; POSTSYNAPTIC DENSITY FRACTION; LONG-TERM POTENTIATION; MUTANT MICE LACKING; TYROSINE PHOSPHORYLATION; GABA(A) RECEPTORS; A RECEPTORS; SUBUNIT 2B; RAT; ALCOHOL	Animals vary in their sensitivity to ethanol, a trait at least partly determined by genetic factors. In order to identify possible responsible genes, mice lacking Fyn, a non-receptor type tyrosine kinase, were investigated. These mice were hypersensitive to the hypnotic effect of ethanol. The administration of ethanol enhanced tyrosine phosphorylation of the N-methyl-D-aspartate receptor (NMDAR) in the hippocampus of control mice but not in Fyn-deficient mice. An acute tolerance to ethanol inhibition of NMDAR-mediated excitatory postsynaptic potentials in hippocampal slices developed in control mice but not in Fyn-deficient mice. These results indicate that Fyn affects behavioral, biochemical, and physiological responses to ethanol.	RIKEN,BRAIN SCI INST,NEUROBIOL EMOT LAB,WAKO,SAITAMA 35101,JAPAN; NATL INST PHYSIOL SCI,LAB NEUROBIOL & BEHAV GENET,OKAZAKI,AICHI 444,JAPAN; JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV TOKYO,FAC LETTERS,DEPT PSYCHOL,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Jichi Medical University; University of Tokyo			Miyakawa, Tsuyoshi/A-7741-2008	Miyakawa, Tsuyoshi/0000-0003-0137-8200				Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; GROVER CA, 1994, BRAIN RES, V642, P70, DOI 10.1016/0006-8993(94)90906-7; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HARRIS RA, 1991, ANN NY ACAD SCI, V625, P508, DOI 10.1111/j.1749-6632.1991.tb33881.x; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1990, J NEUROSCI, V10, P1372; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1996, NEUROREPORT, V7, P2723, DOI 10.1097/00001756-199611040-00063; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; TSUBOKAWA H, 1994, NEUROSCIENCE, V59, P291, DOI 10.1016/0306-4522(94)90597-5; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; WAFFORD KA, 1990, SCIENCE, V249, P291, DOI 10.1126/science.1695761; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	27	252	252	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					698	701		10.1126/science.278.5338.698	http://dx.doi.org/10.1126/science.278.5338.698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381182				2022-12-01	WOS:A1997YC32300058
J	Pal, R; GarzinoDemo, A; Markham, PD; Burns, J; Brown, M; Gallo, RC; DeVico, AL				Pal, R; GarzinoDemo, A; Markham, PD; Burns, J; Brown, M; Gallo, RC; DeVico, AL			Inhibition of HIV-1 infection by the beta-chemokine MDC	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TERMINAL SEQUENCE; DENDRITIC CELLS; CLINICAL STATE; FLOW-CYTOMETRY; T-CELLS; REPLICATION; INDIVIDUALS; INTERLEUKIN-8; RECEPTOR	CD8(+) T lymphocytes from individuals infected with human immunodeficiency virus-type 1 (HIV-1) secrete a soluble activity that suppresses infection by HIV-1. A protein associated with this activity was purified from the culture supernatant of an immortalized CD8(+) T cell clone and identified as the beta-chemokine macrophage-derived chemokine (MDC). MDC suppressed infection of CD8(+) cell-depleted peripheral blood mononuclear cells by primary non-syncytium-inducing and syncytium-inducing isolates of HIV-1 and the T cell line-adapted isolate HIV-1(IIIB). MDC was expressed in activated, but not resting, peripheral blood mononuclear cells and binds a receptor on activated primary T cells. These observations indicate that beta-chemokines are responsible for a major proportion of HIV-1-specific suppressor activity produced by primary T cells.	UNIV MARYLAND, INST HUMAN VIROL, BALTIMORE, MD 21201 USA; ADV BIOSCI LABS, KENSINGTON, NSW 20895, AUSTRALIA; UNIV MARYLAND, SCH MED, INST HUMAN DEV, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT IMMUNOL & MICROBIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore				Garzino-Demo, Alfredo/0000-0002-4095-6950	NIAID NIH HHS [N01-AI-55279] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI055279] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BADOLATO R, 1995, J IMMUNOL, V155, P4004; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barker TD, 1996, J IMMUNOL, V156, P4476; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; Blackbourn DJ, 1996, P NATL ACAD SCI USA, V93, P13125, DOI 10.1073/pnas.93.23.13125; BLUEL CC, 1996, NATURE, V382, P829; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BURNS J, IN PRESS BIOTECHNIQU; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEVICO AL, UNPUB; Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARZINODEMO A, 1995, HUM GENE THER, V6, P177, DOI 10.1089/hum.1995.6.2-177; GARZINODEMO A, UNPUB; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Greimers R, 1996, CYTOMETRY, V23, P205, DOI 10.1002/(SICI)1097-0320(19960301)23:3<205::AID-CYTO4>3.0.CO;2-H; HE J, 1997, NATURE, V385, P6445; HEBERT CA, 1990, J IMMUNOL, V145, P3033; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; Kinter AL, 1996, P NATL ACAD SCI USA, V93, P14076, DOI 10.1073/pnas.93.24.14076; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARKHAM PD, 1984, INT J CANCER, V33, P13, DOI 10.1002/ijc.2910330104; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paliard X, 1996, AIDS, V10, P1317, DOI 10.1097/00002030-199610000-00002; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; Proost Paul, 1996, Methods (Orlando), V10, P82, DOI 10.1006/meth.1996.0082; Rubbert A, 1997, AIDS RES HUM RETROV, V13, P63, DOI 10.1089/aid.1997.13.63; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; VANDAMME J, 1990, EUR J IMMUNOL, V20, P2113, DOI 10.1002/eji.1830200933; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; WALKER CM, 1989, CELL IMMUNOL, V119, P470, DOI 10.1016/0008-8749(89)90259-1; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0	53	183	194	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					695	698		10.1126/science.278.5338.695	http://dx.doi.org/10.1126/science.278.5338.695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381181				2022-12-01	WOS:A1997YC32300057
J	Muller, CW; Herrmann, BG				Muller, CW; Herrmann, BG			Crystallographic structure of the T domain DNA complex of the Brachyury transcription factor	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING PROTEIN; GENE; DROSOPHILA; ALIGNMENT	The mouse Brachyury (T) gene is the prototype of a growing family of so-called T-box genes which encode transcriptional regulators and have been identified in a variety of invertebrates and vertebrates, including humans(1-6). Mutations in Brachyury and other T-box genes result in drastic embryonic phenotypes, indicating that T-box gene products are essential in tissue specification, morphogenesis and organogenesis(7-11). The T-box encodes a DNA-binding domain of about 180 amino-acid residues, the T domain(12). Here we report the X-ray structure of ther domain from Xenopus laevis in complex with a 24-nucleotide palindromic DNA duplex. We show that the protein is bound as a dimer, interacting with the major and the minor grooves of the DNA. A new type of specific DNA contact is seen, in which a carboxy-terminal helix is deeply embedded into an enlarged minor groove without bending the DNA. Hydrophobic interactions and an unusual main-chain carbonyl contact to a guanine account for sequence-specific recognition in the minor groove by this helix. Thus the structure of this T domain complex with DNA reveals a new way in which a protein can recognize DNA.	MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY	Max Planck Society	Muller, CW (corresponding author), EUROPEAN MOL BIOL LAB, GRENOBLE OUTSTN, ILL BP 156, F-38042 GRENOBLE 9, FRANCE.		Müller, Christoph W/I-7420-2012; Pillay, Nischalan/F-9536-2012	Müller, Christoph W/0000-0003-2176-8337; 				Agulnik SI, 1996, GENETICS, V144, P249; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Herrmann Bernhard G., 1995, Seminars in Developmental Biology, V6, P385, DOI 10.1016/S1044-5781(06)80002-2; Holland PWH, 1995, DEVELOPMENT, V121, P4283; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1994, GENE DEV, V8, P2137, DOI 10.1101/gad.8.18.2137; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Knezevic V, 1997, DEVELOPMENT, V124, P411; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Li QY, 1997, NAT GENET, V15, P21; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Schulte-Merker S., 1995, Seminars in Developmental Biology, V6, P411, DOI 10.1016/S1044-5781(06)80005-8; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	30	257	260	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					884	888		10.1038/39929	http://dx.doi.org/10.1038/39929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349824				2022-12-01	WOS:A1997YC14800065
J	Rankin, AC				Rankin, AC			Non-sedating antihistamines and cardiac arrhythmia	LANCET			English	Editorial Material							DE-POINTES; TERFENADINE; INTERVAL				Rankin, AC (corresponding author), ROYAL INFIRM,DEPT CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND.							HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; LINDQUIST EIR, 1997, LANCET, V39, P1322; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Pratt CM, 1996, AM HEART J, V131, P472, DOI 10.1016/S0002-8703(96)90525-6; PRATT CM, 1994, AM J CARDIOL, V73, P346, DOI 10.1016/0002-9149(94)90006-X; RAMPE D, 1993, MOL PHARMACOL, V44, P1240; SALATA JJ, 1995, CIRC RES, V76, P110, DOI 10.1161/01.RES.76.1.110; TAN HL, 1995, ANN INTERN MED, V122, P701, DOI 10.7326/0003-4819-122-9-199505010-00009; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313	11	23	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1115	1116		10.1016/S0140-6736(05)63783-X	http://dx.doi.org/10.1016/S0140-6736(05)63783-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343494				2022-12-01	WOS:A1997YB19900003
J	Barnes, PF; Yang, ZH; PrestonMartin, S; Pogoda, JM; Jones, BE; Otaya, M; Eisenach, KD; Knowles, L; Harvey, S; Cave, MD				Barnes, PF; Yang, ZH; PrestonMartin, S; Pogoda, JM; Jones, BE; Otaya, M; Eisenach, KD; Knowles, L; Harvey, S; Cave, MD			Tuberculosis transmission in central Los Angeles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; HOMELESS MEN; SHELTER; EPIDEMIOLOGY; OUTBREAK; PTBN12	Context.-Recent studies suggest that many tuberculosis cases in urban areas result from recent transmission. Delineation of the epidemiologic links between patients is important to optimize strategies to reduce tuberculosis transmission. Objective.-To identify epidemiologic links among recently infected urban patients with tuberculosis. Design.-Prospective evaluation of patients with tuberculosis. Setting.-Central Los Angeles, Calif. Patients.-A total of 162 patients who had culture-proven tuberculosis, Interventions.-Patients were prospectively interviewed to identify their contacts and whereabouts. The IS6110-based and pTBN12-based restriction fragment length polymorphism analyses were performed on Mycobacterium tuberculosis isolates. Patients whose isolates had identical or closely related restriction fragment length polymorphism patterns were considered a cluster. Unconditional logistic regression was used to identify independent predictors of clustering. Main Outcome Measures.-Relationship of clinical and epidemiologic variables to clustering, Results.-A total of 96 (59%) of 162 patients were in 8 clusters, Only 2 of the 96 clustered patients named others in the cluster as contacts, The degree of homelessness was an independent predictor of clustering, Compared with nonclustered patients, patients in 6 clusters were significantly more likely to have spent time at 3 shelters and other locations when at least 1 patient in the cluster was contagious, and these locations were independent predictors of clustering. Among nonhomeless persons, clustered patients were significantly more likely than nonclustered patients to have used daytime services at 3 shelters, Conclusions.-(1) Traditional contact investigation does not reliably identify patients infected with the same M tuberculosis strain, and (2) locations at which the homeless congregate are important sites of tuberculosis transmission for homeless and nonhomeless persons. Measures that reduce tuberculosis transmission should be based on locations rather than on personal contacts.	UNIV SO CALIF, SCH MED, DEPT MED, DIV INFECT DIS, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90089 USA; LOS ANGELES CTY PUBL HLTH LAB, LOS ANGELES, CA USA; CTY LOS ANGELES DEPT HLTH SERV TB CONTROL PROGRAM, LOS ANGELES, CA USA; STATOLOGY, TRUCKEE, CA USA; UNIV ARKANSAS MED SCI, DEPT PATHOL, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI, DEPT ANAT, LITTLE ROCK, AR 72205 USA; JOHN L MCCLELLAN MEM VET ADM MED CTR, MED RES SERV, LITTLE ROCK, AR USA	University of Southern California; University of Southern California; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035265, R01AI035222] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35222, AI35265] Funding Source: Medline; PHS HHS [CCU901877] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1992, MMWR Recomm Rep, V41, P13; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; Breslow NE, 1980, STAT METHODS CANC RE; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P869; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; ROST K, 1993, MED CARE, V31, P189, DOI 10.1097/00005650-199303000-00001; SAS Institute INC, 1988, SAS STAT US GUID REL; SEGALMAURER S, 1994, CLIN INFECT DIS, V19, P299, DOI 10.1093/clinids/19.2.299; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987, DOI 10.1128/JCM.31.8.1987-1995.1993; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; YANG ZH, 1995, J CLIN MICROBIOL, V33, P1064, DOI 10.1128/JCM.33.5.1064-1069.1995	24	171	177	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1159	1163		10.1001/jama.278.14.1159	http://dx.doi.org/10.1001/jama.278.14.1159			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326475				2022-12-01	WOS:A1997XY42200033
J	Forsen, T; Eriksson, JG; Tuomilehto, J; Teramo, K; Osmond, C; Barker, DJP				Forsen, T; Eriksson, JG; Tuomilehto, J; Teramo, K; Osmond, C; Barker, DJP			Mother's weight in pregnancy and coronary heart disease in a cohort of Finnish men: Follow up study	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; FETAL; BIRTH; INSULIN; NUTRITION; THINNESS; GROWTH	Objective: To determine whether restricted growth in utero is associated with an increased risk of coronary heart disease among men in Finland, where rates of the disease are among the highest in the world. Design: Follow up study. Setting: Helsinki, Finland. Subjects: 3302 men born in Helsinki University Central Hospital during 1924-33 who went to school in the city of Helsinki and were resident in Finland in 1971. Main outcome measures: Standardised mortality ratios for coronary heart disease. Results: Men who were thin at birth, with low placental weight, had high death rates from coronary heart disease. Men whose mothers had a high body mass index in pregnancy also had high death rates. In a multivariate analysis the hazard ratio for coronary heart disease was 1.37 (95% confidence interval 1.20 to 1.57) (P < 0.0001) for every standard deviation decrease in ponderal index at birth and 1.24 (1.10 to 1.39) (P = 0.0004) for every standard deviation increase in mother's body mass index. The effect of mother's body mass index was restricted to mothers of below average stature. Conclusion: These findings suggest a new explanation for the epidemics of coronary heart disease that accompany Westernisation. Chronically malnourished women are short and light and their babies tend to be thin. The immediate effect of improved nutrition is that women become fat, which seems to increase the risk of coronary heart disease in the next generation. With continued improvements in nutrition, women become taller and heavier; their babies are adequately nourished; and maternal fatness no longer increases the risk of coronary heart disease, which therefore declines.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,DIABET & GENET EPIDEMIOL UNIT,FIN-00300 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,FIN-00290 HELSINKI,FINLAND	University of Southampton; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital				Osmond, Clive/0000-0002-9054-4655				Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; GODFREY KM, IN PRESS BR J OBSTET; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Keys A, 1966, Acta Med Scand Suppl, V460, P1; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; SALOMAA V, 1992, AM J EPIDEMIOL, V136, P1303, DOI 10.1093/oxfordjournals.aje.a116442; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; YLIAHO T, 1991, TEHTAALAINEN HELSING	17	285	294	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					837	840		10.1136/bmj.315.7112.837	http://dx.doi.org/10.1136/bmj.315.7112.837			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353502	Green Published			2022-12-01	WOS:A1997YA00700019
J	Fornerod, M; Ohno, M; Yoshida, M; Mattaj, IW				Fornerod, M; Ohno, M; Yoshida, M; Mattaj, IW			CRM1 is an export receptor for leucine-rich nuclear export signals	CELL			English	Article							BINDING PROTEIN COMPLEX; ORDER CHROMOSOME STRUCTURE; REV ACTIVATION DOMAIN; U-SNRNA EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; HNRNP A1; REGULATORY PROTEINS; LEPTOMYCIN-B; TRANSFER-RNA; HIV REV	CRM1 is distantly related to receptors that mediate nuclear protein import and was previously shown to interact with the nuclear pore complex. Overexpression of CRM1 in Xenopus oocytes stimulates Rev and U snRNA export from the nucleus. Conversely, leptomycin B, a cytotoxin that is shown to bind to CRM1 protein, specifically inhibits the nuclear export of Rev and U snRNAs. In vitro, CRM1 forms a leptomycin B-sensitive complex involving cooperative binding of both RanGTP and the nuclear export signal (NES) from either the Rev or PKI proteins. We conclude that CRM1 is an export receptor for leucine-rich nuclear export signals and discuss a model for the role of RanGTP in CRM1 function and in nuclear export in general.	EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV TOKYO, DEPT BIOTECHNOL, TOKYO 113, JAPAN	European Molecular Biology Laboratory (EMBL); University of Tokyo			Yoshida, Minoru/C-8049-2014; Fornerod, Maarten/A-7503-2010	Yoshida, Minoru/0000-0002-4376-5674; Fornerod, Maarten/0000-0002-6166-3030; Mattaj, Iain/0000-0002-5537-8284				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CESTARI IN, 1993, BIOTECHNIQUES, V14, P404; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1996, ONCOGENE, V13, P1801; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fridell RA, 1997, J CELL SCI, V110, P1325; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	63	1675	1705	0	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1051	1060		10.1016/S0092-8674(00)80371-2	http://dx.doi.org/10.1016/S0092-8674(00)80371-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323133	Bronze			2022-12-01	WOS:A1997XX76800011
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Primary target	SCIENCE			English	Article																		Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; Gardner RL, 1997, INT J DEV BIOL, V41, P235	3	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1848	1848		10.1126/science.277.5333.1848	http://dx.doi.org/10.1126/science.277.5333.1848			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324771				2022-12-01	WOS:A1997XX29800053
J	Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P				Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P			Inappropriate drug-donation practices in Bosnia and Herzegovina, 1992 to 1996	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EARTHQUAKE		EUROPEAN ASSOC HLTH & DEV,B-1000 BRUSSELS,BELGIUM; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO)			Autier, Philippe/A-4402-2014	Autier, Philippe/0000-0003-1538-5321				ALI HM, 1988, LANCET, V333, P538; AUTIER P, 1990, LANCET, V335, P1388; BERCKMANS P, 1996, DRUG DONATION PRACTI; COHEN S, 1990, LANCET, V336, P745, DOI 10.1016/0140-6736(90)92233-8; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; Hogerzeil HV, 1997, BRIT MED J, V314, P737, DOI 10.1136/bmj.314.7082.737; Michael M, 1996, JAMA-J AM MED ASSOC, V276, P364, DOI 10.1001/jama.276.5.364; OFFERHAUS L, 1992, LANCET, V339, P607; *RES MED DEV, 1996, ECH MED ENTR PAYS EU; SCHOUTEN E, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684; *UN INF MED ETH DE, 1994, MED UT EUR REC DESTR; United Nations Environment Programme, 1989, BAS CONV CONTR TRANS; VANDERHEIDE B, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684a; *WAR HLTH CROSS BR, 1996, EUR COR ANN REP 1995; *WEMOS PHARM PROJ, 1991, EXP DEADL EXP STOR E; *WHO, 1994, WHO MISS FORM YUG; *WHO, 1996, WHODAP962; *WHO, 1992, WHO TECH REP SER, V825, P1; *WHO, 1994, MED SUPPL DON GUID W; ZEBALLOS JL, 1986, DISASTERS, V10, P141, DOI 10.1111/j.1467-7717.1986.tb00579.x	20	24	26	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1842	1845		10.1056/NEJM199712183372512	http://dx.doi.org/10.1056/NEJM199712183372512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400045				2022-12-01	WOS:A1997YL85500012
J	Kim, JM; Mayfield, SP				Kim, JM; Mayfield, SP			Protein disulfide isomerase as a regulator of chloroplast translational activation	SCIENCE			English	Article							PSBA MESSENGER-RNA; CHLAMYDOMONAS-REINHARDTII; GENE-EXPRESSION; PHOTOSYSTEM-II; THIOREDOXIN REDUCTASE; NUCLEAR; BINDING; BIOGENESIS; BARLEY; MUTANT	Light-regulated translation of chloroplast messenger RNAs (mRNAs) requires transacting factors that interact with the 5' untranslated region (UTR) of these mRNAs, Chloroplast polyadenylate-binding protein (cPABP) specifically binds to the 5'-UTR of the psbA mRNA and is essential for translation of this mRNA, A protein disulfide isomerase that is localized to the chloroplast and copurifies with cPABP was shown to modulate the binding of cPABP to the 5'-UTR of the psbA mRNA by reversibly changing the redox status of cPABP through redox potential or adenosine 5'-diphosphate-dependent phosphorylation. This mechanism allows for a simple reversible switch regulating gene expression in the chloroplast.	Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Kim, JM (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.			Kim, Jungmook/0000-0003-1735-5564	NIGMS NIH HHS [GM54659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Robinson C., 1994, V139, P273; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Yohn CB, 1996, MOL CELL BIOL, V16, P3560; YOHN CB, UNPUB	25	190	203	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1954	1957		10.1126/science.278.5345.1954	http://dx.doi.org/10.1126/science.278.5345.1954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395399				2022-12-01	WOS:A1997YL00200037
J	Chiu, AY; Perez, PE; Parker, RN				Chiu, AY; Perez, PE; Parker, RN			Impact of banning alcohol on outpatient visits in Barrow, Alaska	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AVAILABILITY; DRINKING; IOWA	Context.-Community availability of alcohol affects alcohol consumption patterns and alcohol-related health and social problems. In Barrow, Alaska, an isolated community at the northernmost reaches of the United States, during a 33-month period, possession and importation of alcohol were legal, completely banned, made legal again, and then banned again. Objective.-To determine the impact of these public policy changes on alcohol-related outpatient visits at the area hospital. Design.-Retrospective review of outpatient records; time-series analysis of alcohol-related visits with respect to community alcohol policy. Main Outcome Measures.-Total monthly outpatient visits for alcohol-related problems. Results.-There was a substantial decrease in the number of alcohol-related outpatient visits when the ban on possession and importation was imposed compared with baseline. When the ban was lifted, outpatient visits increased; when the ban was reimposed, the number of outpatient visits again decreased. Interrupted time-series analyses confirm that the alcohol ban, its lifting, and its reimposition had a statistically significant and negative effect on the number of alcohol-related outpatient visits (P<.05). Conclusion.-In a geographically isolated community, the prohibition of alcohol can be an effective public health intervention, reducing the health problems associated with alcohol use.	N SLOPE BOROUGH PHYS SERV,BARROW,AK; SAMUEL SIMMONDS MEM HOSP PHYS SERV,BARROW,AK; PREVENT RES CTR,BERKELEY,CA	Pacific Institute for Research & Evaluation (PIRE)					NIAAA NIH HHS [AA09146] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009146] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALBRECHT E, 1984, CIRCUMPOLAR HLTH 84, P327; [Anonymous], 1976, TIME SERIES ANAL; BONDY S, 1995, JAMA-J AM MED ASSOC, V274, P1832, DOI 10.1001/jama.274.23.1832; BROWER CD, 1942, 50 YEARS ZERO, P137; CAMPBELL DT, 1966, EXPT QUASI-EXPT DESI; Gruenewald PJ, 1996, ADDICTION, V91, P967, DOI 10.1046/j.1360-0443.1996.9179674.x; HILD CM, 1981, CIRCUMPOLAR HLTH, V81, P502; HOLDER HD, 1990, BRIT J ADDICT, V85, P1615; HOLDER HD, 1988, CONT DRUG PROBL, V15, P47; LOFTIN C, 1982, AM SOCIOL REV, V47, P393, DOI 10.2307/2094995; MCCLEARY R, 1988, APPLIED TIME SERIES; OMALLEY PM, 1991, J STUD ALCOHOL, V52, P478, DOI 10.15288/jsa.1991.52.478; PARKER RN, 1997, ANN M KETT BRUUN SOC; Parker Robert N., 1995, ALCOHOL HOMICIDE DEA; SKOG OJ, 1986, BRIT J ADDICT, V81, P365; VINGILIS ER, 1979, J CRIM JUST, V12, P161; WAGENAAR AC, 1991, J STUD ALCOHOL, V52, P162, DOI 10.15288/jsa.1991.52.162; WAGENAAR AC, 1983, ALCOHOL YOUNG DRIVER; WOOD JB, 1996, BARROW RECLAMATION	19	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1775	1777		10.1001/jama.278.21.1775	http://dx.doi.org/10.1001/jama.278.21.1775			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH987	9388156				2022-12-01	WOS:A1997YH98700034
J	Elena, SF; Lenski, RE				Elena, SF; Lenski, RE			Test of synergistic interactions among deleterious mutations in bacteria	NATURE			English	Article							ESCHERICHIA-COLI; EVOLUTION; FITNESS; SEX; ADAPTATION; ADVANTAGE	Identifying the forces responsible for the origin and maintenance of sexuality remains one of the greatest unsolved problems in biology(1-6). The mutational deterministic hypothesis postulates that sex is an adaptation that allows deleterious mutations to be purged from the genome; it requires synergistic interactions, which means that two mutations would be more harmful together than expected from their separate effects(4,5), We generated 225 genotypes of Escherichia coli carrying one, two or three successive mutations and measured their fitness relative to an unmutated competitor. The relationship between mutation number and average fitness is nearly log-linear, We also constructed 27 recombinant genotypes having pairs of mutations whose separate and combined effects on fitness were determined. Several pairs exhibit significant interactions for fitness, but they are antagonistic as often as they are synergistic These results do not support the mutational deterministic hypothesis for the evolution of sex.			Elena, SF (corresponding author), MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA.		Elena, Santiago F./A-4191-2011	Elena, Santiago F./0000-0001-8249-5593; Lenski, Richard/0000-0002-1064-8375				Bell G., 1982, MASTERPIECE NATURE; CHAO L, 1988, J THEOR BIOL, V133, P99, DOI 10.1016/S0022-5193(88)80027-4; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; DEVISSER JAG, IN PRESS EVOLUTION; deVisser JAGM, 1996, P ROY SOC B-BIOL SCI, V263, P193, DOI 10.1098/rspb.1996.0031; ELENA SF, IN PRESS GENETICA; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; Hurst Laurence D., 1996, Trends in Ecology and Evolution, V11, P46, DOI 10.1016/0169-5347(96)81041-X; Kibota TT, 1996, NATURE, V381, P694, DOI 10.1038/381694a0; KIMURA M, 1966, GENETICS, V54, P1337; KITIGAWA O, 1969, GENETICS, V57, P809; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Maynard-Smith J., 1978, MODELS ECOLOGY; MUKAI T, 1969, GENETICS, V61, P749; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; Redfield RJ, 1997, GENETICS, V146, P27; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Sokal R., 1981, BIOMETRY; SPASSKY B, 1965, GENETICS, V52, P653; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WILLIS JH, 1993, EVOLUTION, V47, P864, DOI [10.2307/2410190, 10.1111/j.1558-5646.1993.tb01240.x]; Zeyl C, 1997, NATURE, V388, P465, DOI 10.1038/41312; ZYSKIND J, 1989, RECOMBINANT DNA LAB	30	319	323	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					395	398		10.1038/37108	http://dx.doi.org/10.1038/37108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389477				2022-12-01	WOS:A1997YH54900061
J	SchlagRey, M; Amador, N; Sanchez, H; Schlag, J				SchlagRey, M; Amador, N; Sanchez, H; Schlag, J			Antisaccade performance predicted by neuronal activity in the supplementary eye field	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; RHESUS-MONKEYS; MOVEMENTS; SACCADES; CONNECTIONS; INITIATION; FIXATION; LESIONS; SYSTEM; GOAL	The voluntary control of gaze implies the ability to make saccadic eye movements specified by abstract instructions, as well as the ability to repress unwanted orientating to sudden stimuli, Both of these abilities are challenged in the antisaccade task, because it requires subjects to look at an unmarked location opposite to a dashed stimulus, without glancing at it(1,2). Performance on this task depends on the frontal/prefrontal cortex and related structures(3-8), but the neuronal operations underlying antisaccades are not understood. It is not known, for example, how excited visual neurons that normally trigger a saccade to a target (a prosaccade) can activate oculomotor neurons directing gaze in the opposite direction, Visual neurons might, perhaps, alter their receptive fields depending on whether they receive a pro-or antisaccade instruction, If the receptive field is not altered, the antisaccade goal must be computed and imposed from the top down to the appropriate oculomotor neurons. Here we show, using recordings from the supplementary eye field (a frontal cortex oculomotor centre) in monkeys, that visual and movement neurons retain the same spatial selectivity across randomly mixed pro-and antisaccade trials, However, these neurons consistently fire more before antisaccades than prosaccades with the same trajectories, suggesting a mechanism through which voluntary antisaccade commands can override reflexive glances.	UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SchlagRey, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROBIOL,LOS ANGELES,CA 90095, USA.							BECKER W, 1979, VISION RES, V19, P967, DOI 10.1016/0042-6989(79)90222-0; Chen LTL, 1996, J NEUROSCI, V16, P3067; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FISCHER B, 1992, EXP BRAIN RES, V89, P415; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; Goldberg ME, 1989, NEUROBIOLOGY SACCADI, P283; GUITTON D, 1985, EXP BRAIN RES, V58, P455; HALLETT PE, 1978, VISION RES, V18, P1279, DOI 10.1016/0042-6989(78)90218-3; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; HUERTA MF, 1990, J COMP NEUROL, V293, P299, DOI 10.1002/cne.902930211; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; REMINGTON RW, 1992, PERCEPT PSYCHOPHYS, V51, P279, DOI 10.3758/BF03212254; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; Russo GS, 1996, J NEUROPHYSIOL, V76, P825, DOI 10.1152/jn.1996.76.2.825; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHILLER PH, 1987, J NEUROPHYSIOL, V57, P1033, DOI 10.1152/jn.1987.57.4.1033; SCHLAG J, 1987, J NEUROPHYSIOL, V57, P179, DOI 10.1152/jn.1987.57.1.179; SCHLAG J, 1992, EXP BRAIN RES, V90, P302; Schlag J., 1993, Society for Neuroscience Abstracts, V19, P785; SCHLAG J, IN PRESS J NEUROPHYS; SCHLAGREY M, 1992, J NEUROPHYSIOL, V67, P1003, DOI 10.1152/jn.1992.67.4.1003; SEGRAVES MA, 1993, J NEUROPHYSIOL, V69, P1880, DOI 10.1152/jn.1993.69.6.1880; SHOOK BL, 1990, J COMP NEUROL, V301, P618, DOI 10.1002/cne.903010410; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454, DOI 10.1152/jn.1996.75.1.454; Thompson KG, 1996, J NEUROPHYSIOL, V76, P4040, DOI 10.1152/jn.1996.76.6.4040; TIAN JR, 1991, NEUROLOGY, V41, P875, DOI 10.1212/WNL.41.6.875; Weber H, 1995, PERCEPTION, V24, P1265, DOI 10.1068/p241265	30	279	282	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					398	401		10.1038/37114	http://dx.doi.org/10.1038/37114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389478				2022-12-01	WOS:A1997YH54900062
J	Settles, AM; Yonetani, A; Baron, A; Bush, DR; Cline, K; Martienssen, R				Settles, AM; Yonetani, A; Baron, A; Bush, DR; Cline, K; Martienssen, R			Sec-independent protein translocation by the maize Hcf106 protein	SCIENCE			English	Article							ESCHERICHIA-COLI; THYLAKOID MEMBRANE; SIGNAL PEPTIDE; TRANSPORT; EXPORT; PATHWAY; MUTATIONS; HOMOLOG; NUCLEAR; BINDING	The bacterial Sec and signal recognition particle (ffh-dependent) protein translocation mechanisms are conserved between prokaryotes and higher plant chloroplasts. A third translocation mechanism in chloroplasts [the proton concentration difference (Delta pH) pathway] was previously thought to be unique. The hcf106 mutation of maize disrupts the localization of proteins transported through this Delta pH pathway in isolated chloroplasts. The Hcf106 gene encodes a receptor-like thylakoid membrane protein, which shows homology to open reading frames from all completely sequenced bacterial genomes, which suggests that the Delta pH pathway has been conserved since the endosymbiotic origin of chloroplasts. Thus, the third protein translocation pathway, of which HCF106 is a component, is found in both bacteria and plants.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; EMORY UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,ATLANTA,GA 30322; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; USDA ARS,PHOTOSYNTHESIS RES UNIT,URBANA,IL 61801; UNIV ILLINOIS,DEPT PLANT BIOL,URBANA,IL 61801	Cold Spring Harbor Laboratory; Emory University; State University System of Florida; University of Florida; United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign			Bush, Daniel R/AAG-8444-2019; Cline, Kenneth/J-6238-2013	Bush, Daniel/0000-0002-9160-5077; Settles, A. Mark/0000-0002-5846-0996				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARKAN A, 1986, EMBO J, V5, P1421, DOI 10.1002/j.1460-2075.1986.tb04378.x; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DAS L, 1995, PLANT CELL, V7, P287, DOI 10.1105/tpc.7.3.287; ERNST F, 1994, J BIOL CHEM, V269, P12840; ETTINGER WF, 1992, PLANT PHYSIOL, V99, P791, DOI 10.1104/pp.99.2.791; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; KNOTT TG, 1994, J BIOL CHEM, V269, P4505; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; LEE JH, 1985, J BACTERIOL, V162, P344, DOI 10.1128/JB.162.1.344-352.1985; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MANT A, 1995, J BIOL CHEM, V270, P23275, DOI 10.1074/jbc.270.40.23275; MARTIENSSEN RA, 1989, EMBO J, V8, P1633, DOI 10.1002/j.1460-2075.1989.tb03553.x; MARTIENSSEN RA, 1987, PLANT MEMBRANES STRU, P181; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; VOELKER R, 1997, GENETICS, V154, P467; YATES M, COMMUNICATION; YUAN J, 1994, J BIOL CHEM, V268, P18463; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; [No title captured]	41	225	238	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1467	1470		10.1126/science.278.5342.1467	http://dx.doi.org/10.1126/science.278.5342.1467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367960				2022-12-01	WOS:A1997YG85800046
J	Mayho, P				Mayho, P			Multidrug resistant tuberculosis and HIV: a personal experience	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1317	1317		10.1136/bmj.315.7118.1317	http://dx.doi.org/10.1136/bmj.315.7118.1317			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390087	Green Published			2022-12-01	WOS:A1997YG64500076
J	Metlay, JP; Kapoor, WN; Fine, MJ				Metlay, JP; Kapoor, WN; Fine, MJ			Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFIDENCE-INTERVALS; CLINICAL-PREDICTION; CHEST; ANTIBIOTICS; RELIABILITY; OUTPATIENTS; ADULTS	Community-acquired pneumonia is an important cause of acute respiratory symptoms (eg, cough) in the ambulatory care setting, Distinguishing pneumonia from other causes of respiratory illnesses, such as acute bronchitis and upper respiratory tract infections, has important therapeutic and prognostic implications, The reference standard for diagnosing pneumonia is chest radiography, but it is likely that many physicians rely on the patient's history and their physical examination to diagnose or exclude this disease. A review of published studies of patients suspected of having pneumonia reveals that there are no individual clinical findings, or combinations of findings, that can rule in the diagnosis of pneumonia for a patient suspected of having this illness, However, some studies have shown that the absence of any vital sign abnormalities or any abnormalities on chest auscultation substantially reduces the likelihood of pneumonia to a point where further diagnostic evaluation may be unnecessary, This article reviews the literature on the appropriate use of the history and physical examination in diagnosing community-acquired pneumonia.	MASSACHUSETTS GEN HOSP, DEPT MED, GEN INTERNAL MED UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV PITTSBURGH, DEPT MED, CTR RES HLTH CARE, DIV GEN INTERNAL MED, PITTSBURGH, PA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					BHP HRSA HHS [5 T32 PE11001-08] Funding Source: Medline	BHP HRSA HHS		Albaum MN, 1996, CHEST, V110, P343, DOI 10.1378/chest.110.2.343; Bullowa JGM, 1935, ARCH INTERN MED, V55, P558, DOI 10.1001/archinte.1935.00160220028003; CENTOR RM, 1992, MED DECIS MAKING, V12, P229, DOI 10.1177/0272989X9201200309; COCHRANE AL, 1951, LANCET, V260, P1007; DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8; EMERMAN CL, 1991, ANN EMERG MED, V20, P1215, DOI 10.1016/S0196-0644(05)81474-X; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FLETCHER CM, 1964, METHOD INFORM MED, V3, P98, DOI 10.1055/s-0038-1636275; Forgacs P, 1969, Br J Dis Chest, V63, P1, DOI 10.1016/S0007-0971(69)80039-2; Gennis P, 1989, J Emerg Med, V7, P263, DOI 10.1016/0736-4679(89)90358-2; GILBERT VE, 1989, AM REV RESPIR DIS, V140, P1012, DOI 10.1164/ajrccm/140.4.1012; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GRAHAM NMH, 1990, EPIDEMIOL REV, V12, P149, DOI 10.1093/oxfordjournals.epirev.a036050; Hasley PB, 1996, ARCH INTERN MED, V156, P2206, DOI 10.1001/archinte.156.19.2206; HECKERLING PS, 1986, ARCH INTERN MED, V146, P1321, DOI 10.1001/archinte.146.7.1321; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MELBYE H, 1992, Scandinavian Journal of Primary Health Care, V10, P226, DOI 10.3109/02813439209014066; Metlay J. P., 1997, JGIM, V12, P77; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; ORR PH, 1993, J FAM PRACTICE, V36, P507; OSMER JC, 1966, SOUTHERN MED J, V59, P75, DOI 10.1097/00007611-196601000-00014; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCHILLING RSF, 1955, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.4905.65; SINGAL BM, 1989, ANN EMERG MED, V18, P13, DOI 10.1016/S0196-0644(89)80304-X; SMYLLIE HC, 1965, LANCET, V2, P412; SPITERI MA, 1988, LANCET, V1, P873; THACKER RE, 1982, CHEST, V81, P672, DOI 10.1378/chest.81.6.672	33	316	327	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1440	1445		10.1001/jama.278.17.1440	http://dx.doi.org/10.1001/jama.278.17.1440			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9356004				2022-12-01	WOS:A1997YC91700032
J	Nightingale, SL				Nightingale, SL			Proposed rule on women in clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-01	WOS:A1997YC91700006
J	Ryan, TM; Ciavatta, DJ; Townes, TM				Ryan, TM; Ciavatta, DJ; Townes, TM			Knockout-transgenic mouse model of sickle cell disease	SCIENCE			English	Article							BETA-GLOBIN LOCUS; YEAST ARTIFICIAL CHROMOSOME; HEMOGLOBIN-S; DEVELOPMENTAL REGULATION; DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; MICE; POLYMERIZATION; THALASSEMIA; GELATION	When transgenic mice that expressed human sickle hemoglobin were mated with mice having knockout mutations of the mouse alpha-and beta-globin genes, animals were produced that synthesized only human hemoglobin in adult red blood cells. Similar to many human patients with sickle cell disease, the mice developed a severe hemolytic anemia and extensive organ pathology. Numerous sickled erythrocytes were observed in peripheral blood. Although chronically anemic, most animals survived for 2 to 9 months and were fertile. Drug and genetic therapies can now be tested in this mouse model of sickle cell disease.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Ryan, Thomas/0000-0002-8982-0253	NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NCI NIH HHS [CA13148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BRITTENHAM GM, 1985, BLOOD, V65, P183; Bunn HFL, 1986, HEMOGLOBIN MOL GENET; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CREPEAU RH, 1978, NATURE, V274, P616, DOI 10.1038/274616a0; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; EATON WA, 1987, BLOOD, V70, P1245; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; Fabry ME, 1996, J CLIN INVEST, V98, P2450, DOI 10.1172/JCI119062; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; NOGUCHI CT, 1981, BLOOD, V58, P1057; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Popp RA, 1997, BLOOD, V89, P4204, DOI 10.1182/blood.V89.11.4204; RHODA MD, 1988, BIOCHIM BIOPHYS ACTA, V952, P208, DOI 10.1016/0167-4838(88)90117-3; Roberts NA, 1997, BLOOD, V89, P713, DOI 10.1182/blood.V89.2.713; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; RYAN TM, UNPUB; SERJEANT GR, 1970, BRIT J HAEMATOL, V19, P635, DOI 10.1111/j.1365-2141.1970.tb01647.x; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; Weatherall DJ., 1981, THALASSEMIA SYNDROME; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WOOD WG, 1985, NATURE, V313, P320, DOI 10.1038/313320a0; YANG BL, 1995, P NATL ACAD SCI USA, V92, P11608, DOI 10.1073/pnas.92.25.11608	34	202	211	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					873	876		10.1126/science.278.5339.873	http://dx.doi.org/10.1126/science.278.5339.873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346487				2022-12-01	WOS:A1997YD47900049
J	Kuusisto, J; Koivisto, K; Mykkanen, L; Helkala, EL; Vanhanen, M; Hanninen, T; Kervinen, K; Kesaniemi, YA; Riekkinen, PJ; Laakso, M				Kuusisto, J; Koivisto, K; Mykkanen, L; Helkala, EL; Vanhanen, M; Hanninen, T; Kervinen, K; Kesaniemi, YA; Riekkinen, PJ; Laakso, M			Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study	BRITISH MEDICAL JOURNAL			English	Article							DEMENTIA; RISK; HYPERINSULINEMIA; POLYMORPHISM; HYPERTENSION; DIAGNOSIS; LEVEL; BRAIN; AGE; SEX	Objective: To determine the association between features of the insulin resistance syndrome and Alzheimer's disease. Design: Cross sectional population based study. Subjects: 980 people aged 69 to 78 (349 men, 631 women). Setting: Population of Kuopio, eastern Finland. Main outcome measures: Presence of features of the insulin resistance syndrome and diagnosis of Alzheimer's disease by detailed neurological and neuropsychological evaluation. Results: 46 (4.7%) subjects were classified as having probable or possible Alzheimer's disease. In univariate analyses, apolipoprotein E4 phenotype (odds ratio; 95% confidence interval 3.24: 1.77 to 5.92), age (1.16; 1.05 to 1.29), low level of education (0.82; 0.72 to 0.93), low total cholesterol concentration (0.77; 0.59 to 1.00), high systolic blood pressure (1.01; 1.00 to 1.03), high fasting and 2 hour plasma glucose concentrations (1.11; 1.01 to 1.23 and 1.08; 1.03 to 1.13, respectively), high fasting and 2 hour insulin concentrations (1.05; 1.02 to 1.08 and 1.003; 1.00 to 1.01, respectively), and abnormal glucose tolerance (1.86; 1.23 to 2.80) were significantly associated with Alzheimer's disease. In multivariate analysis including apolipoprotein E4 phenotype, age, education, systolic blood pressure, total cholesterol concentration, fasting glucose concentration, and insulin concentration, apolipoprotein E4 phenotype, age, education, total cholesterol, and insulin were significantly associated with Alzheimer's disease. In 532 non-diabetic subjects without the e4 allele hyperinsulinaemia was associated with an increased risk for Alzheimer's disease (prevalence of disease 7.5% v 1.4% in normoinsulinaemic subjects, P = 0.0004). In contrast, in the 228 with the e4 allele hyperinsulinaemia had no effect on the risk of disease (7.0% v 7.1%, respectively). Conclusion: Features of the insulin resistance syndrome are associated with Alzheimer's disease independently of apolipoprotein E4 phenotype.	KUOPIO UNIV HOSP,DEPT MED,FIN-70211 KUOPIO,FINLAND; KUOPIO UNIV HOSP,DEPT NEUROL,FIN-70211 KUOPIO,FINLAND; OULU UNIV HOSP,DEPT INTERNAL MED,OULU,FINLAND; UNIV OULU,BIOCTR,OULU,FINLAND	Kuopio University Hospital; Kuopio University Hospital; University of Oulu; University of Oulu			Laakso, Mikko/AHB-7022-2022	Laakso, Mikko/0000-0003-1250-3425; Landin-Wilhelmsen, Kerstin/0000-0003-1998-5105				American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BASKIN DG, 1987, ANNU REV PHYSIOL, V49, P335, DOI 10.1146/annurev.ph.49.030187.002003; BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EHNHOLM C, 1986, J LIPID RES, V27, P227; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KILANDER L, 1993, ACTA NEUROL SCAND, V87, P294, DOI 10.1111/j.1600-0404.1993.tb05511.x; Koivisto K, 1992, J Geriatr Psychiatry Neurol, V5, P162; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1991, ARTERIOSCLER THROMB, V11, P1068, DOI 10.1161/01.ATV.11.4.1068; LANDIN K, 1993, J INTERN MED, V233, P357, DOI 10.1111/j.1365-2796.1993.tb00684.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PALOMAKI P, 1994, J CLIN EPIDEMIOL, V47, P659, DOI 10.1016/0895-4356(94)90213-5; PRINCE M, 1994, NEUROLOGY, V44, P97; Prineas R.J., 1982, MINNESOTA CODE MANUA; RAZAY G, 1994, AGE AGEING, V23, P396, DOI 10.1093/ageing/23.5.396; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WARRINGTON EK, 1966, BRAIN, V89, P53, DOI 10.1093/brain/89.1.53; WEINFELD FD, 1981, STROKE S1, V12, P32; *WHO, 1982, MONICA MAN CVD MNC; *WHO, 1985, WHO TECH RECP SER, V727; *WHO, 1990, MONICA MAN CVD MNC	33	346	362	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1045	1049		10.1136/bmj.315.7115.1045	http://dx.doi.org/10.1136/bmj.315.7115.1045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366728	Green Published			2022-12-01	WOS:A1997YD44500017
J	Caterina, MJ; Schumacher, MA; Tominaga, M; Rosen, TA; Levine, JD; Julius, D				Caterina, MJ; Schumacher, MA; Tominaga, M; Rosen, TA; Levine, JD; Julius, D			The capsaicin receptor: a heat-activated ion channel in the pain pathway	NATURE			English	Article							ROOT GANGLION-CELLS; SENSORY NEURONS; CHEMICAL-STRUCTURE; CATION CHANNEL; DROSOPHILA TRP; RUTHENIUM RED; CALCIUM-ENTRY; RAT; RESINIFERATOXIN; ACID	Capsaicin, the main pungent ingredient in 'hot' chilli peppers, elicits a sensation of burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system. We have used an expression cloning strategy based on calcium influx to Isolate a functional cDNA encoding a capsaicin receptor from sensory neurons. This receptor is a non-selective cation channel that is structurally related to members of the TRP family of ion channels. The cloned capsaicin receptor Is also activated by increases in temperature In the noxious range, suggesting that it functions as a transducer of painful thermal stimuli in vivo.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								AMANN R, 1990, N-S ARCH PHARMACOL, V341, P108; BERKLEY R, 1992, PEPPERS COOKBOOK; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Campbell E., 1993, CAPSAICIN STUDY PAIN, P255; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; CREM RJ, 1991, SCIENCE, V254, P1388; DEVRIES DJ, 1989, LIFE SCI, V44, P711, DOI 10.1016/0024-3205(89)90382-2; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; FEIGIN AM, 1995, NEUROREPORT, V6, P2134, DOI 10.1097/00001756-199511000-00009; Fields H. L., 1987, PAIN; FORBES CA, 1988, NEUROSCI LETT S, V32, pS3; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HOLZER P, 1991, PHARMACOL REV, V43, P143; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JAMES IF, 1993, CAPSAICIN STUDY PAIN, P83; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; Kirschstein T, 1997, NEUROSCI LETT, V231, P33, DOI 10.1016/S0304-3940(97)00533-8; Kress M, 1996, NEUROSCI LETT, V211, P5, DOI 10.1016/0304-3940(96)12691-4; LIU L, 1994, P NATL ACAD SCI USA, V91, P738, DOI 10.1073/pnas.91.2.738; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Oh U, 1996, J NEUROSCI, V16, P1659; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PETERSEN M, 1993, PAIN, V54, P37, DOI 10.1016/0304-3959(93)90097-9; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; SATINOFF E, 1964, AM J PHYSIOL, V206, P1389, DOI 10.1152/ajplegacy.1964.206.6.1389; Scoville W.L., 1912, J PHARM SCI-US, V1, P453, DOI [10.1002/jps.3080010520, DOI 10.1002/JPS.3080010520]; SEGUELA P, 1993, J NEUROSCI, V13, P596; SNYDER SH, 1977, SCI AM, V236, P44, DOI 10.1038/scientificamerican0377-44; SZALLASI A, 1994, GEN PHARMACOL-VASC S, V25, P223, DOI 10.1016/0306-3623(94)90049-3; SZALLASI A, 1989, NEUROSCIENCE, V30, P515, DOI 10.1016/0306-4522(89)90269-8; Szallasi A, 1996, PAIN, V68, P195, DOI 10.1016/S0304-3959(96)03202-2; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; SZOLCSANYI J, 1976, ARZNEIMITTEL-FORSCH, V26, P33; Szolcsanyi J., 1993, CAPSAICIN STUDY PAIN, P1; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WINTER J, 1990, BRAIN RES, V520, P131, DOI 10.1016/0006-8993(90)91698-G; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOODBURY JE, 1980, J ASSOC OFF ANA CHEM, V63, P556; YEATS JC, 1992, J PHYSIOL-LONDON, V446, pP390	49	6449	6836	85	981	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					816	824		10.1038/39807	http://dx.doi.org/10.1038/39807			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349813				2022-12-01	WOS:A1997YC14800048
J	Rieckhof, GE; Casares, F; Ryoo, HD; AbuShaar, M; Mann, RS				Rieckhof, GE; Casares, F; Ryoo, HD; AbuShaar, M; Mann, RS			Nuclear translocation of extradenticle requires homothorax, which encodes an extradenticle-related homeodomain protein	CELL			English	Article							DROSOPHILA-MELANOGASTER; HOMEOBOX GENE; HOMEOTIC TRANSFORMATION; ULTRABITHORAX PROTEINS; ECTOPIC EXPRESSION; SEGMENTAL IDENTITY; BITHORAX COMPLEX; MYELOID-LEUKEMIA; DNA-BINDING; UBX GENE	We show that homothorax (hth) is required for the Hox genes to pattern the body of the fruit fly, Drosophila melanogaster, hth is necessary for the nuclear localization of an essential HOX cofactor, Extradenticle (EXD), and encodes a homeodomain protein that shares extensive identity with the product of Meis1, a murine proto-oncogene. MEIS1 is able to rescue hth mutant phenotypes and can induce the cytoplasmic-to-nuclear translocation of EXD in cell culture and Drosophila embryos. Thus, Meis1 is a murine homolog of hth. MEIS1/HTH also specifically binds to EXD with high affinity in vitro. These data suggest a novel and evolutionarily conserved mechanism for regulating HOX activity in which a direct protein-protein interaction between EXD and HTH results in EXD's nuclear translocation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032	Columbia University			Casares, Fernando/M-5451-2019	Casares, Fernando/0000-0002-2181-3858	NIGMS NIH HHS [R01 GM058575, R01 GM054510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510, R01GM058575] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspland SE, 1997, DEVELOPMENT, V124, P741; BURGLIN T, 1994, GUIDEBOOK HOMEOBOX G, P26; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHAN SK, 1996, EMBO J, V15, P2477; CHEN SK, 1997, DEVELOPMENT, V124, P2007; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FEINSTEIN PG, 1995, GENETICS, V140, P573; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; HAMILTON BA, 1991, P NATL ACAD SCI USA, V88, P2731, DOI 10.1073/pnas.88.7.2731; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KARPEN GH, 1992, GENETICS, V132, P737; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; Nakamura T, 1996, ONCOGENE, V13, P2235; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Paro R., 1996, EPIGENETIC MECH GENE, P507; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATTATUCCI AM, 1991, GENETICS, V129, P443; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; PIRROTTA V, 1995, GENETICS, V141, P1439; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; RODER L, 1992, DEVELOPMENT, V115, P1017; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SUN YH, 1995, GENETICS, V141, P1075; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHITE RAH, 1985, EMBO J, V4, P2035, DOI 10.1002/j.1460-2075.1985.tb03889.x; WIESCHAUS E, 1986, LOOKING EMBRYOS DROS, P199; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	59	377	381	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					171	183		10.1016/S0092-8674(00)80400-6	http://dx.doi.org/10.1016/S0092-8674(00)80400-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346235	hybrid			2022-12-01	WOS:A1997YC35000005
J	Troemel, ER; Kimmel, BE; Bargmann, CI				Troemel, ER; Kimmel, BE; Bargmann, CI			Reprogramming chemotaxis responses: Sensory neurons define olfactory preferences in C-elegans	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NUCLEOTIDE-GATED CHANNEL; GLR-1 GLUTAMATE-RECEPTOR; CHEMOSENSORY NEURONS; ENCODES; SYSTEM; CELLS; GENES	Different olfactory cues elicit distinct behaviors such as attraction, avoidance, feeding, or mating. In the nematode C. elegans, these cues are sensed by a small number of olfactory neurons, each of which expresses several different odorant receptors. The type of behavioral response elicited by an odorant could be specified by the olfactory receptor or by the olfactory neuron in which the receptor is activated. The attractive odorant diacetyl is detected by the receptor protein ODR-10, which is normally expressed in the AWA olfactory neurons. The repulsive odorant 2-nonanone is detected by the AWB olfactory neurons. Transgenic animals that express ODR-10 in AWB rather than AWA avoid diacetyl, while maintaining qualitatively normal responses to other attractive and repulsive odorants. Animals that express ODR-10 simultaneously in AWA and AWB have a defective response to diacetyl, possibly because of conflicting olfactory inputs. Thus, an animal's preference for an odor is defined by the sensory neurons that express a given odorant receptor molecule.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM NEUROSCI,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,GENET PROGRAM,DEPT ANAT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Troemel, ER (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM DEV BIOL,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.			Bargmann, Cornelia/0000-0002-8484-0618	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BRENNER S, 1974, GENETICS, V77, P71; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, LEARN MEMORY, V4, P179, DOI 10.1101/lm.4.2.179; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; COLBERT HA, 1997, IN PRESS J NEUROSCI; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MICHEL WC, 1991, J NEUROPHYSIOL, V65, P446, DOI 10.1152/jn.1991.65.3.446; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; ZECHMAN JM, 1986, J CHROMATOGR, V377, P49, DOI 10.1016/S0378-4347(00)80760-4	29	289	306	0	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					161	169		10.1016/S0092-8674(00)80399-2	http://dx.doi.org/10.1016/S0092-8674(00)80399-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346234	Bronze			2022-12-01	WOS:A1997YC35000004
J	Riethmacher, D; SonnenbergRiethmacher, E; Brinkmann, V; Yamaai, T; Lewin, GR; Birchmeier, C				Riethmacher, D; SonnenbergRiethmacher, E; Brinkmann, V; Yamaai, T; Lewin, GR; Birchmeier, C			Severe neuropathies in mice with targeted mutations in the ErbB3 receptor	NATURE			English	Article							NERVOUS-SYSTEM; GROWTH-FACTOR; SCHWANN-CELL; NEUREGULIN; DIFFERENTIATION; HEREGULIN; GENE; NEUROTROPHIN-3; REQUIREMENT; MYELINATION	Neuregulins and their specific receptors, members of the ErbB family of tyrosine kinases, have been implicated in the control of growth and development of Schwann cells(1-3), specialized cells that wrap around nerve axons to provide electrical insulation. Here we use gene targeting to generate mice that lack ErbB3, a high-affinity neuregulin receptor(4-6). Homozygous erbB3 mutant embryos lack Schwann-cell precursors and Schwann cells that accompany peripheral axons of sensory and motor neurons. The initial development of motor neurons and sensory neurons of dorsal root ganglia occurs as it should, but at later stages most motor neurons (79%) and sensory neurons in dorsal root ganglia (82%) undergo cell death in erbB3 mutant embryos. Degeneration of the peripheral nervous system in erbB3 mutant pups is thus much more severe than the cell death in mice that lack neurotrophins or neurotrophin receptors(7,8). We also show that ErbB3 functions in a cell-autonomous way during the development of Schwann cells, but not in the survival of sensory or motor neurons. Our results indicate that sensory and motor neurons require factors for their survival that are provided by developing Schwann cells.	MAX DELBRUCK CTR MOL MED,DEPT MED GENET,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT CELL BIOL,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT NEUROSCI,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Brinkmann, Volker/A-6015-2009; Lewin, Gary R/B-8028-2011; Riethmacher, Dieter/A-6242-2010; Riethmacher, Dieter/AAP-2227-2021; Riethmacher, Dieter/AAB-8690-2022	Riethmacher, Dieter/0000-0002-4206-5529; Lewin, Gary/0000-0002-2890-6352				Barinaga M, 1996, SCIENCE, V273, P1657, DOI 10.1126/science.273.5282.1657; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Davies A. M., 1995, NEURAL CELL CULTURE, P153; DONG Z, 1995, NEURON, V15, P686; ElShamy WM, 1996, NEURON, V16, P963, DOI 10.1016/S0896-6273(00)80119-1; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; KUCERA J, 1995, NEUROSCIENCE, V69, P321, DOI 10.1016/0306-4522(95)00221-4; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE G, 1993, GLIA, V7, P163; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MEYER D, IN PRESS DEVELOPMENT; Ockel M, 1996, DEVELOPMENT, V122, P301; ORR UA, 1993, P NATL ACAD SCI USA, V90, P1867; PAPAIOANNOU V, 1993, GENE TARGETING PRACT, P1807; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1996, J BIOL CHEM, V271, P19022; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1	30	557	568	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					725	730		10.1038/39593	http://dx.doi.org/10.1038/39593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338783				2022-12-01	WOS:A1997YA95900054
J	Mechanic, LJ; Dikman, S; CunninghamRundles, C				Mechanic, LJ; Dikman, S; CunninghamRundles, C			Granulomatous disease in common variable immunodeficiency	ANNALS OF INTERNAL MEDICINE			English	Article							HYPOGAMMAGLOBULINEMIA; FAILURE	Background: Granulomatous lesions are occasionally found in the lymphoid or solid organs of patients with common variable immunodeficiency. Objective: To examine the clinical and immunologic conditions in patients with common variable immunodeficiency who have granulomas. Design: Case series. Setting: Large tertiary care medical center. Patients: 17 hypogammaglobulinaemic patients with common variable immunodeficiency whose organ or tissue biopsy samples contained noncaseating granulomas. Measurements: Results of lymphocyte function tests. Results: Eight of 17 patients had granulomas at some point before hypogammaglobulinemia was diagnosed. Sixteen of the 17 had deficient T-cell proliferation to mitogens. Although 14 patients received standard treatment with intravenous immunoglobulin, they have had substantial illness, including frequent autoimmune disease. Conclusions: Dysregulated T-cell function or macrophage activation may have been involved in formation of granulomas and increased illness in hypogammaglobulinaemic patients with common variable immunodeficiency. Delay in recognition of antibody deficiency may have contributed to the severity of illness in these patients.	MT SINAI MED CTR, MT SINAI SCH MED, DIV CLIN IMMUNOL, NEW YORK, NY 10029 USA; MT SINAI MED CTR, MT SINAI SCH MED, DIV CLIN PATHOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA 533H] Funding Source: Medline; NCRR NIH HHS [5 M01-RR-0071] Funding Source: Medline; FDA HHS [FD-R-001162-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); FDA HHS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADELMAN DC, 1990, J ALLERGY CLIN IMMUN, V86, P512, DOI 10.1016/S0091-6749(05)80207-6; ASHERSON GL, 1980, DIAGNOSIS TREATMENT, P41; CRYSTAL RG, 1994, HARRISONS PRINCIPLES, P1683; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES S, 1981, J CLIN IMMUNOL, V1, P65, DOI 10.1007/BF00915478; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; GILBERT S, 1993, AM REV RESPIR DIS, V148, P483, DOI 10.1164/ajrccm/148.2.483; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; JAMES DG, 1993, SARCOIDOSIS, V10, P1; JAMES DG, 1985, SARCOIDOSIS OTHER GR, P128; LAZARUS DS, 1994, BBA-MOL BASIS DIS, V1226, P12, DOI 10.1016/0925-4439(94)90052-3; Leen C L, 1985, Sarcoidosis, V2, P91; PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SPICKETT GP, 1989, IMMUNOL TODAY, V10, P192, DOI 10.1016/0167-5699(89)90323-X; STAGG AJ, 1994, CLIN EXP IMMUNOL, V96, P48; World Health Organization, 1992, IMMUNODEFIC REV, P195	18	201	206	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				613	617		10.7326/0003-4819-127-8_Part_1-199710150-00005	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341059				2022-12-01	WOS:A1997YB41900005
J	Blasco, MA; Lee, HW; Hande, MP; Samper, E; Lansdorp, PM; DePinho, RA; Greider, CW				Blasco, MA; Lee, HW; Hande, MP; Samper, E; Lansdorp, PM; DePinho, RA; Greider, CW			Telomere shortening and tumor formation by mouse cells lacking telomerase RNA	CELL			English	Article							MINOR SATELLITE DNA; EMBRYO FIBROBLASTS; IMMORTAL CELLS; REPEAT ARRAYS; STEM-CELLS; SENESCENCE; LENGTH; CANCER; IDENTIFICATION; CHROMOSOMES	To examine the role of telomerase in normal and neoplastic growth, the telomerase RNA component (mTR) was deleted from the mouse germline. mTR(-/-) mice lacked detectable telomerase activity yet were viable for the six generations analyzed. Telomerase-deficient cells could be immortalized in culture, transformed by viral oncogenes, and generated tumors in nude mice following transformation. Telomeres were shown to shorten at a rate of 4.8 +/- 2.4 kb per mTR(-/-) generation. Cells from the fourth mTR(-/-) generation onward possessed chromosome ends lacking detectable telomere repeats, aneuploidy, and chromosomal abnormalities, including end-to-end fusions. These results indicate that telomerase is essential for telomere length maintenance but is not required for establishment of cell lines, oncogenic transformation, or tumor formation in mice.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; UNIV AUTONOMA MADRID,DEPT IMMUNOL & ONCOL,CTR NACL BIOTECNOL,CSIC,E-28049 MADRID,SPAIN; BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA	Cold Spring Harbor Laboratory; Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); British Columbia Cancer Agency; University of British Columbia			Blasco, Maria A./M-1694-2014; Hande, M. Prakash/B-1645-2008	Blasco, Maria A./0000-0002-4211-233X; Hande, M. Prakash/0000-0002-4511-6256; Greider, Carol/0000-0002-5494-8126; Lansdorp, Peter/0000-0001-7435-1071; DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009383] Funding Source: NIH RePORTER; NCI NIH HHS [5P30-CA45508] Funding Source: Medline; NIA NIH HHS [R01AG09383] Funding Source: Medline; NICHD NIH HHS [R01HD348880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; AUSUBEL RM, 1993, CURRENT PROTOCOLS MO; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BEDNAREK A, 1995, CANCER RES, V55, P4566; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, ONCOGENE, V11, P893; Conzen SD, 1995, ONCOGENE, V11, P2295; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DROST JB, 1995, ENVIRON MOL MUTAGEN, V25, P48, DOI 10.1002/em.2850250609; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARAGNA S, 1995, CHROMOSOMA, V103, P685, DOI 10.1007/BF00344229; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Harley C.B., 1990, METHOD MOL BIOL, P25; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1991, GENOMICS, V11, P235, DOI 10.1016/0888-7543(91)90128-2; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KRAEMER PM, 1996, J NATL CANCER I, V76, P703; Kyo S, 1997, CANCER RES, V57, P610; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NANDA I, 1995, CHROMOSOME RES, V3, P399, DOI 10.1007/BF00713889; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SINGER MS, 1994, SCIENCE, V266, P387; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	53	1695	1775	3	151	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					25	34		10.1016/S0092-8674(01)80006-4	http://dx.doi.org/10.1016/S0092-8674(01)80006-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335332	hybrid			2022-12-01	WOS:A1997XZ80900006
J	Cheng, EHY; Kirsch, DG; Clem, RJ; Ravi, R; Kastan, MB; Bedi, A; Ueno, K; Hardwick, JM				Cheng, EHY; Kirsch, DG; Clem, RJ; Ravi, R; Kastan, MB; Bedi, A; Ueno, K; Hardwick, JM			Conversion of Bcl-2 to a Bax-like death effector by caspases	SCIENCE			English	Article							CELL-DEATH; CONSERVED DOMAINS; APOPTOSIS; BCL-X(L); PROTEASE; DISTINCT; HETERODIMERIZATION; MODULATION; PATHWAYS; FODRIN	Caspases are a family of cysteine proteases implicated in the biochemical and morphological changes that occur during apoptosis (programmed cell death). The loop domain of Bcl-2 is cleaved at Asp(34) by caspase-3 (CPP32) in vitro, in cells overexpressing caspase-3, and after induction of apoptosis by Fas ligation and interleukin-3 withdrawal. The carboxyl-terminal Bcl-2 cleavage product triggered cell death and accelerated Sindbis virus-induced apoptosis, which was dependent on the BH3 homology and transmembrane domains of Bcl-2, Inhibitor studies indicated that cleavage of Bcl-2 may further activate downstream caspases and contribute to amplification of the caspase cascade. Cleavage-resistant mutants of Bcl-2 had increased protection from interleukin-3 withdrawal and Sindbis virus-induced apoptosis. Thus, cleavage of Bcl-2 by caspases may ensure the inevitability of cell death.	JOHNS HOPKINS SCH PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; KAGOSHIMA UNIV,FAC MED,KAGOSHIMA 890,JAPAN	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Kagoshima University				Clem, Rollie/0000-0002-2368-720X				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Haldar S, 1996, CANCER RES, V56, P1253; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; HARDWICK JP, UNPUB; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; HUTNER JJ, 1996, MOL CELL BIOL, V16, P877; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEWIS LN, UNPUB; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Middleton G, 1996, DEVELOPMENT, V122, P695; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126	46	935	1041	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1966	1968		10.1126/science.278.5345.1966	http://dx.doi.org/10.1126/science.278.5345.1966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395403				2022-12-01	WOS:A1997YL00200041
J	Lobel, HO; Kozarsky, PE				Lobel, HO; Kozarsky, PE			Update on prevention of malaria for travelers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT PLASMODIUM-VIVAX; MEFLOQUINE PROPHYLAXIS; FALCIPARUM-MALARIA; UNITED-STATES; ANTIMALARIAL-DRUGS; CHLOROQUINE; CHEMOPROPHYLAXIS; PREGNANCY; DOXYCYCLINE; REGIMENS	Individuals from industrialized nations frequently travel to countries with malaria, so health care providers need to be familiar with current recommendations for prevention of malaria, Changes in drug susceptibility of malaria parasites and evolving knowledge of how well drugs are tolerated necessitate periodic review of guidelines for prophylaxis of malaria, especially of chloroquine-resistant Plasmodium falciparum malaria, Mefloquine is the drug of choice for chemoprophylaxis for most travelers, with doxycycline and chloroquine being less effective alternatives. Mefloquine is well tolerated at prophylactic dosages, but anecdotal reports have raised concerns about its adverse effects, Resistance to this drug has emerged in parts of Southeast Asia and may spread to other regions of the world, The major disadvantages of doxycycline are the need for daily dosing, its contraindication for young children and pregnant women. and its adverse effects, Chloroquine is effective for prophylaxis only in Central America, the Caribbean, and parts of the Middle East. Few new drugs will be available in the near future because of reduced funding for antimalarial drug research and development; therefore, the usefulness of currently available drugs needs to be prolonged by rational use. Increased efforts should be made to ensure that alternative drugs will be available for prevention of malaria.	EMORY UNIV, SCH MED, DEPT MED, ATLANTA, GA 30322 USA	Emory University	Lobel, HO (corresponding author), CTR DIS CONTROL & PREVENT, MALARIA SECT, EPIDEMIOL BRANCH, DIV PARASIT DIS, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA.							ARTHUR JD, 1990, LANCET, V335, P972, DOI 10.1016/0140-6736(90)91035-9; ARTHUR JD, 1990, AM J TROP MED HYG, V43, P608, DOI 10.4269/ajtmh.1990.43.608; BALOCCO R, 1992, LANCET, V340, P309, DOI 10.1016/0140-6736(92)92403-3; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; BEHRENS RH, 1993, BRIT MED BULL, V49, P363, DOI 10.1093/oxfordjournals.bmb.a072615; BERNARD KW, 1982, JAMA-J AM MED ASSOC, V248, P3136, DOI 10.1001/jama.248.23.3136; BOUDREAU E, 1993, TROP MED PARASITOL, V44, P257; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P8, DOI 10.4269/ajtmh.1992.46.8; BRUCECHWATT LJ, 1950, BMJ-BRIT MED J, V2, P7, DOI 10.1136/bmj.2.4669.7; Buma APCCH, 1996, J INFECT DIS, V173, P1506, DOI 10.1093/infdis/173.6.1506; *CDCP, 1997, HLTH INF INT TRAV 19; Choo V, 1996, LANCET, V347, P891, DOI 10.1016/S0140-6736(96)91362-8; Collins WE, 1996, AM J TROP MED HYG, V55, P243, DOI 10.4269/ajtmh.1996.55.243; COOK GC, 1995, BRIT MED J, V311, P190, DOI 10.1136/bmj.311.6998.190b; CREAGH TH, 1992, NATO ADV SCI I A-LIF, V224, P53; Croft AMJ, 1996, LANCET, V347, P326, DOI 10.1016/S0140-6736(96)90500-0; Croft AMJ, 1997, T ROY SOC TROP MED H, V91, P199, DOI 10.1016/S0035-9203(97)90223-6; Davis TME, 1996, BRIT J CLIN PHARMACO, V42, P415, DOI 10.1111/j.1365-2125.1996.tb00003.x; DELANEY TJ, 1974, ACTA DERM-VENEREOL, V54, P487; FISH DR, 1988, BRIT MED J, V297, P526, DOI 10.1136/bmj.297.6647.526; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; HAUSER WA, 1983, EPILEPSY, P267; HELD TK, 1994, Q J MED, V87, P17; HOFFMAN SL, 1992, MED CLIN N AM, V76, P1327, DOI 10.1016/S0025-7125(16)30290-5; Huzly, 1996, J Travel Med, V3, P148, DOI 10.1111/j.1708-8305.1996.tb00729.x; Jaspers CAJJ, 1996, AM J TROP MED HYG, V55, P230, DOI 10.4269/ajtmh.1996.55.230; Keystone, 1994, J Travel Med, V1, P72, DOI 10.1111/j.1708-8305.1994.tb00566.x; LAMPE AS, 1994, EUR J CLIN MICROBIOL, V13, P332; Lobel H. O., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P225; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; LOBEL HO, IN PRESS AM J TROP M; LOBEL HO, 1993, 42 ANN M AM SOC TROP; LOVESTONE S, 1991, BRIT J PSYCHIAT, V159, P164, DOI 10.1192/bjp.159.1.164b; Luxemburger C, 1996, ANN TROP PAEDIATR, V16, P281, DOI 10.1080/02724936.1996.11747839; MACPHERSON D, 1997, 5 INT C TRAV MED MAR, P220; NOSTEN F, 1994, J INFECT DIS, V169, P595, DOI 10.1093/infdis/169.3.595; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; PANG LW, 1987, LANCET, V1, P1161; PENNIE RA, 1993, T ROY SOC TROP MED H, V87, P459, DOI 10.1016/0035-9203(93)90036-P; PERAGALLO MS, 1997, 5 INT C TRAV MED MAR; PhillipsHoward PA, 1996, DRUG SAFETY, V14, P131, DOI 10.2165/00002018-199614030-00001; Regier Darrel, 1995, P135; Schlagenhauf P, 1997, AM J TROP MED HYG, V56, P235, DOI 10.4269/ajtmh.1997.56.235; SCHUURKAMP GJ, 1992, T ROY SOC TROP MED H, V86, P121, DOI 10.1016/0035-9203(92)90531-G; SCHWARTZ IK, 1991, NEW ENGL J MED, V324, P927; Shanks, 1994, J Travel Med, V1, P40, DOI 10.1111/j.1708-8305.1994.tb00554.x; SHANKS GD, 1994, MIL MED, V159, P275, DOI 10.1093/milmed/159.4.275; SINGHARAJ P, 1987, R THAI ARMY MED J, V40, P165; Smoak BL, 1997, J INFECT DIS, V176, P831, DOI 10.1086/517315; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; Steketee RW, 1996, AM J TROP MED HYG, V55, P50, DOI 10.4269/ajtmh.1996.55.50; Takeshima S., 1994, Japanese Journal of Tropical Medicine and Hygiene, V22, P185; THAN M, 1995, T R SOC TROP MED HYG, V89, P307; TSAI TF, 1992, SEMIN PEDIAT INFECT, V3, P62; VANHAUWERE B, IN PRESS AM J TROP M; Vuurman EFPM, 1996, EUR J CLIN PHARMACOL, V50, P475, DOI 10.1007/s002280050144; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; WATANASOOK C, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P61; *WHO, 1997, INT TRAVEL HLTH VACC; Winstanley P, 1996, BRIT J CLIN PHARMACO, V42, P411, DOI 10.1111/j.1365-2125.1996.tb00002.x; WYLER DJ, 1993, NEW ENGL J MED, V329, P31, DOI 10.1056/NEJM199307013290107; 1988, LANCET, V2, P610	63	62	63	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1767	1771		10.1001/jama.278.21.1767	http://dx.doi.org/10.1001/jama.278.21.1767			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388154				2022-12-01	WOS:A1997YH98700032
J	Klenk, HP; Clayton, RA; Tomb, JF; White, O; Nelson, KE; Ketchum, KA; Dodson, RJ; Gwinn, M; Hickey, EK; Peterson, JD; Richardson, DL; Kerlavage, AR; Graham, DE; Kyrpides, NC; Fleischmann, RD; Quackenbush, J; Lee, NH; Sutton, GG; Gill, S; Kirkness, EF; Dougherty, BA; McKenney, K; Adams, MD; Loftus, B; Peterson, S; Reich, CI; McNeil, LK; Badger, JH; Glodek, A; Zhou, LX; Overbeek, R; Gocayne, JD; Weidman, JF; McDonald, L; Utterback, T; Cotton, MD; Spriggs, T; Artiach, P; Kaine, BP; Sykes, SM; Sadow, PW; DAndrea, KP; Bowman, C; Fujii, C; Garland, SA; Mason, TM; Olsen, GJ; Fraser, CM; Smith, HO; Woese, CR; Venter, JC				Klenk, HP; Clayton, RA; Tomb, JF; White, O; Nelson, KE; Ketchum, KA; Dodson, RJ; Gwinn, M; Hickey, EK; Peterson, JD; Richardson, DL; Kerlavage, AR; Graham, DE; Kyrpides, NC; Fleischmann, RD; Quackenbush, J; Lee, NH; Sutton, GG; Gill, S; Kirkness, EF; Dougherty, BA; McKenney, K; Adams, MD; Loftus, B; Peterson, S; Reich, CI; McNeil, LK; Badger, JH; Glodek, A; Zhou, LX; Overbeek, R; Gocayne, JD; Weidman, JF; McDonald, L; Utterback, T; Cotton, MD; Spriggs, T; Artiach, P; Kaine, BP; Sykes, SM; Sadow, PW; DAndrea, KP; Bowman, C; Fujii, C; Garland, SA; Mason, TM; Olsen, GJ; Fraser, CM; Smith, HO; Woese, CR; Venter, JC			The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus	NATURE			English	Article							MONOXIDE DEHYDROGENASE PATHWAY; ARCHAEBACTERIA; OXIDOREDUCTASE; CO2; OXIDATION; BACTERIA; PROTEIN; ENZYME	Archaeoglobus fulgidus is the first sulphur-metabolizing organism to have its genome sequence determined. Its genome of 2,178,400 base pairs contains 2,436 open reading frames (ORFs). The Information processing systems and the biosynthetic pathways for essential components (nucleotides, amino acids and cofactors) have extensive correlation with their counterparts in the archaeon Methanococcus jannaschii. The genomes of these two Archaea indicate dramatic differences in the way these organisms sense their environment, perform regulatory and transport functions, and gain energy. In contrast to M. jannaschii, A. fulgidus has fewer restriction-modification systems, and none of its genes appears to contain inteins. A quarter (651 ORFs) of the A. fulgidus genome encodes functionally uncharacterized yet conserved proteins, two-thirds of which are shared with M. jannaschii (428 ORFs). Another quarter of the genome encodes new proteins indicating substantial archaeal gene diversity.	INST GENOM RES TIGR,ROCKVILLE,MD 20850; UNIV ILLINOIS,DEPT MICROBIOL,CHAMPAIGN,IL 61801; ARGONNE NATL LAB,DIV MATH & COMP SCI,ARGONNE,IL 60439	J. Craig Venter Institute; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Argonne National Laboratory			Kyrpides, Nikos C./A-6305-2014; Graham, David E/F-8578-2010	Kyrpides, Nikos C./0000-0002-6131-0462; Graham, David E/0000-0001-8968-7344; Fraser, Claire/0000-0003-1462-2428; Kerlavage, Anthony/0000-0002-3954-9653; loftus, brendan/0000-0001-8871-8356; Sykes, Sean/0000-0001-8344-5176; Quackenbush, John/0000-0002-2702-5879				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Clark D. P., 1996, ESCHERICHIA COLI SAL, P343; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cooling FB, 1996, APPL ENVIRON MICROB, V62, P2999, DOI 10.1128/AEM.62.8.2999-3004.1996; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DAI YR, UNPUB ARCH MICROBIOL; Edgell DR, 1997, J BACTERIOL, V179, P2632, DOI 10.1128/jb.179.8.2632-2640.1997; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GORRIS LGM, 1991, BIOFACTORS, V3, P29; HUBER R, 1995, NATURE, V376, P57, DOI 10.1038/376057a0; IBBA M, UNPUB P NATL ACAD SC; KAGAWA HK, 1995, J MOL BIOL, V253, P712, DOI 10.1006/jmbi.1995.0585; Kletzin A, 1996, J BACTERIOL, V178, P248, DOI 10.1128/jb.178.1.248-257.1996; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; KUNOW J, 1994, EUR J BIOCHEM, V223, P503, DOI 10.1111/j.1432-1033.1994.tb19019.x; LaPaglia C, 1997, APPL ENVIRON MICROB, V63, P3158, DOI 10.1128/AEM.63.8.3158-3163.1997; MARSH TL, 1994, P NATL ACAD SCI USA, V91, P4180, DOI 10.1073/pnas.91.10.4180; MOLLERZINKHAN D, 1990, ARCH MICROBIOL, V153, P215, DOI 10.1007/BF00249070; NISHIHARA M, 1995, J BIOCHEM-TOKYO, V117, P933, DOI 10.1093/oxfordjournals.jbchem.a124822; NOLL KM, 1988, J BACTERIOL, V170, P4315, DOI 10.1128/jb.170.9.4315-4321.1988; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SCHAUDER R, 1986, ARCH MICROBIOL, V145, P162, DOI 10.1007/BF00446775; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; SPEICH N, 1994, MICROBIOL-UK, V140, P1273, DOI 10.1099/00221287-140-6-1273; STETTER KO, 1995, ASM NEWS, V61, P285; STETTER KO, 1988, SYST APPL MICROBIOL, V10, P172, DOI 10.1016/S0723-2020(88)80032-8; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; STETTER KO, 1987, SCIENCE, V236, P822, DOI 10.1126/science.236.4803.822; STETTER KO, 1992, PROKARYOTES, P707; Sutton G.G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tersteegen A, 1997, EUR J BIOCHEM, V244, P862, DOI 10.1111/j.1432-1033.1997.00862.x; THAUER RK, 1995, BIOTECH HAN, V8, P33; THORNEBENE TG, 1979, SCIENCE, V203, P51; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VORHOLT J, 1995, ARCH MICROBIOL, V163, P112, DOI 10.1007/s002030050179; WALDMANN T, 1995, HOPPESEYLERS BIOL CH, V376, P119; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	43	1184	2282	1	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					364	&		10.1038/37052	http://dx.doi.org/10.1038/37052			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389475	Bronze			2022-12-01	WOS:A1997YH54900052
J	Hordijk, PL; tenKlooster, JP; vanderKammen, RA; Michiels, F; Oomen, LCJM; Collard, JG				Hordijk, PL; tenKlooster, JP; vanderKammen, RA; Michiels, F; Oomen, LCJM; Collard, JG			Inhibition of invasion of epithelial cells by Tiam1-Rac signaling	SCIENCE			English	Article							E-CADHERIN; RAS TRANSFORMATION; ADHESION; GENE; IDENTIFICATION; PROTEIN; CATENIN; CDC42; RAC1; RHO	Tiam1 encodes an exchange factor for the Rho-like guanosine triphosphatase Rac. Both Tiam1 and activated RacV12 promote invasiveness of T lymphoma cells. In epithelial Madin-Darby canine kidney (MDCK) cells, Tiam1 localized to adherens junctions. Ectopic expression of Tiam1 or RacV12 inhibited hepatocyte growth factor-induced scattering by increasing E-cadherin-mediated cell-cell adhesion accompanied by actin polymerization at cell-cell contacts. In Ras-transformed MDCK cells, expression of Tiam1 or RacV12 restored E-cadherin-mediated adhesion, resulting in phenotypic reversion and loss of invasiveness. These data suggest an invasion-suppressor role for Tiam1 and Rac in epithelial cells.	NETHERLANDS CANC INST,DIV CELL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Hordijk, Peter/0000-0002-3348-078X; ten Klooster, Jean Paul/0000-0002-4979-7482				BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FURLONG RA, 1992, BIOESSAYS, V14, P613, DOI 10.1002/bies.950140908; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MICHIELS F, UNPUB; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIELDY AJ, 1995, MOL CELL BIOL, V15, P110; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Webb CP, 1996, J CELL SCI, V109, P2371	27	384	399	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1464	1466		10.1126/science.278.5342.1464	http://dx.doi.org/10.1126/science.278.5342.1464			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367959				2022-12-01	WOS:A1997YG85800045
J	Draper, GJ; Little, MP; Sorahan, T; Kinlen, LJ; Bunch, KJ; Conquest, AJ; Kendall, GM; Kneale, GW; Lancashire, RJ; Muirhead, CR; OConnor, CM; Vincent, TJ				Draper, GJ; Little, MP; Sorahan, T; Kinlen, LJ; Bunch, KJ; Conquest, AJ; Kendall, GM; Kneale, GW; Lancashire, RJ; Muirhead, CR; OConnor, CM; Vincent, TJ			Cancer in the offspring of radiation workers: a record linkage study	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; CHILDHOOD LEUKEMIA; PATERNAL EXPOSURE; WEST-BERKSHIRE; YOUNG-PEOPLE; NUCLEAR SITE; MICE; CHILDREN; IRRADIATION; SURVIVORS	Objectives: To test the ''Gardner hypothesis'' that childhood leukaemia and non-Hodgkin lymphoma can be caused by fathers' exposure to ionising radiation before the conception of the child, and, more generally, to investigate whether such radiation exposure of either parent is a cause of childhood cancer. Design: Case-control study. Setting: Great Britain. Subjects: 35 949 children diagnosed as having cancer, together with matched controls. Main outcome measures: Parental employment as radiation worker as defined by inclusion in the National Registry for Radiation Workers and being monitored for external radiation before conception of child; cumulative dose of external ionising radiation for various periods of employment before conception; dose during pregnancy. Results: After cases studied by Gardner and colleagues were excluded, fathers of children with leukaemia or non-Hodgkin lymphoma were significantly more likely than fathers of controls to have been radiation workers (relative risk 1.77, 95% confidence interval 1.05 to 3.03) but there was no dose-response relation for any of the exposure periods studied; indeed, the association was greatest for those with doses below the level of detection. No increased risk was found for fathers with a lifetime preconception dose of 100 mSv or more, or with a dose in the 6 months before conception of 10 mSv or more. There was no increased risk for the group of other childhood cancers. Mothers' radiation work was associated with a significant increase of childhood cancer (relative risk 5.00, 1.42 to 26.94; based on 15 cases and 3 controls). Only four of the case mothers and no controls were radiation workers during pregnancy. Conclusions: These results do not support the hypothesis that paternal preconception irradiation is a cause of childhood leukaemia and non-Hodgkin lymphoma; the observed associations may be chance findings or result from exposure to infective or other agents. If there is any increased risk for the children of fathers who are radiation workers, it is small in absolute terms: in Britain the average risk by age 15 years is 6.5 per 10 000; our best estimate, using all available data, is that the increase is 5.4 per 10 000. For mothers, the numbers are too small for reliable estimates of the risk, if any, to be made.	NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND; UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV OXFORD,CRC,CANC EPIDEMIOL RES GRP,DEPT PUBL HLTH,OXFORD OX2 6HE,ENGLAND; UNIV BIRMINGHAM,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Oxford; University of Birmingham	Draper, GJ (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,S PARKS RD,OXFORD OX2 6HJ,ENGLAND.		Kendall, Gerald/AAW-5538-2021	Muirhead, Colin/0000-0001-5394-1267; Little, Mark/0000-0003-0980-7567				Alexander FE, 1997, BRIT J CANCER, V75, P457, DOI 10.1038/bjc.1997.77; ANDERSSON M, 1994, J NATL CANCER I, V86, P1866, DOI 10.1093/jnci/86.24.1866; BRESLOW N, 1982, IARC SCI PUBLICATION, V32; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; *COMM MED ASP RAD, 1996, 4 COMARE DEP HLTH; COSGROVE GE, 1993, MUTAT RES, V319, P71, DOI 10.1016/0165-1218(93)90032-9; *CYT SOFTW, 1993, LOGX TURB VERS 1 1; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; DRAPER GJ, 1997, R298 NAT RAD PROT BO; DRAPER GJ, 1989, IARC SCI PUBL, V96, P275; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GILMAN E A, 1988, Journal of Radiological Protection, V8, P3, DOI 10.1088/0952-4746/8/1/301; HAWKINS MM, 1995, BRIT J CANCER, V71, P1335, DOI 10.1038/bjc.1995.259; Health and Safety Executive, 1993, HSE INV LEUK OTH CAN; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; KENDALL GM, 1992, R251 NAT RAD PROT BO; KINLEN L, 1988, LANCET, V2, P1323; Kinlen L. J., 1997, Journal of Radiological Protection, V17, P63, DOI 10.1088/0952-4746/17/2/003; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; KINLEN LJ, 1995, BMJ-BRIT MED J, V310, P763, DOI 10.1136/bmj.310.6982.763; KINLEN LJ, 1995, CANCER CAUSE CONTROL, V6, P445, DOI 10.1007/BF00052185; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KOHN HI, 1965, RADIAT RES, V25, P423, DOI 10.2307/3571983; Little M. P., 1996, Journal of Radiological Protection, V16, P25, DOI 10.1088/0952-4746/16/1/004; Little M. P., 1994, Journal of Radiological Protection, V14, P187, DOI 10.1088/0952-4746/14/3/001; Little M. P., 1994, Journal of Radiological Protection, V14, P203, DOI 10.1088/0952-4746/14/3/002; Little M. P., 1993, Journal of Radiological Protection, V13, P161, DOI 10.1088/0952-4746/13/3/001; Little M. P., 1992, Journal of Radiological Protection, V12, P203, DOI 10.1088/0952-4746/12/4/001; LITTLE MP, 1993, J RADIOL PROTECT, V13, P295; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P1257; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P1462; MICHAELIS J, 1994, ARBEITSMED SOZIALMED, V29, P324; MICHAELIS J, 1995, ARBEITSMED SOZIALMED, V30, P78; NOMURA T, 1991, J RADIAT RES, V32, P64, DOI 10.1269/jrr.32.SUPPLEMENT2_64; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; Petridou E, 1996, BRIT J CANCER, V73, P1278, DOI 10.1038/bjc.1996.245; Pobel D, 1997, BRIT MED J, V314, P101, DOI 10.1136/bmj.314.7074.101; PRESTON DL, 1996, EPICURE RELEASE 2 0; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; Stiller CA, 1996, BMJ-BRIT MED J, V313, P1297, DOI 10.1136/bmj.313.7068.1297; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; TAKAHASHI T, 1992, CANCER RES, V52, P1948; United Nations Scientific Committee on the Effects of Atomic Radiation Sources, 1982, ION RAD SOURC BIOL E; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041	51	85	88	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1181	1188		10.1136/bmj.315.7117.1181	http://dx.doi.org/10.1136/bmj.315.7117.1181			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393219	Green Published			2022-12-01	WOS:A1997YF25200015
J	Wood, KW; Sakowicz, R; Goldstein, LSB; Cleveland, DW				Wood, KW; Sakowicz, R; Goldstein, LSB; Cleveland, DW			CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment	CELL			English	Article							KINESIN-LIKE PROTEIN; PREDICTING COILED COILS; MITOTIC SPINDLE; DIRECTIONAL INSTABILITY; MICROTUBULE DEPOLYMERIZATION; CRYSTAL-STRUCTURE; MITOSIS; MOTILITY; POSITION; DOMAIN	Mitosis requires dynamic attachment of chromosomes to spindle microtubules. This interaction is mediated largely by kinetochores. During prometaphase, forces exerted at kinetochores, in combination with polar ejection forces, drive congression of chromosomes to the metaphase plate. A major question has been whether kinetochore-associated microtubule motors play an important role in congression. Using immunodepletion from and antibody addition to Xenopus egg extracts, we show that the kinetochore-associated kinesin-like motor protein CENP-E is essential for positioning chromosomes at the metaphase plate. We further demonstrate that CENP-E powers movement toward microtubule plus ends in vitro. These findings support a model in which CENP-E functions in congression to tether kinetochores to dynamic microtubule plus ends.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	Wood, KW (corresponding author), UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,CELL BIOL LAB,LA JOLLA,CA 92093, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Brown KD, 1996, J CELL SCI, V109, P961; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CASSIMERIS L, 1994, J CELL SCI, V107, P285; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Duesbery NS, 1997, P NATL ACAD SCI USA, V94, P9165, DOI 10.1073/pnas.94.17.9165; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; HOWARD J, 1993, MOTILITY ASSAYS MOTO, P105; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1992, METHOD ENZYMOL, P478; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Khodjakov A, 1996, J CELL BIOL, V135, P315, DOI 10.1083/jcb.135.2.315; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cb.04.110188.002523; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1985, CHROMOSOMA, V92, P313, DOI 10.1007/BF00329815; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAWIN KE, 1991, J CELL BIOL, V112, P929; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Waters JC, 1996, J CELL SCI, V109, P2823; Wilson PG, 1997, J CELL SCI, V110, P451; YAO X, 1997, IN PRESS J CELL BIOL; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	50	331	335	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					357	366		10.1016/S0092-8674(00)80419-5	http://dx.doi.org/10.1016/S0092-8674(00)80419-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363944	Bronze			2022-12-01	WOS:A1997YD94100009
J	Watkins, J				Watkins, J			Effectiveness of influenza vaccination policy at targeting patients at high risk of complications during winter 1994-5: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article											Watkins, J (corresponding author), GWENT HLTH AUTHOR,PONTYPOOL NP4 OYP,GWENT,WALES.							CURWEN M, 1990, BRIT MED J, V300, P896; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1069	1070		10.1136/bmj.315.7115.1069	http://dx.doi.org/10.1136/bmj.315.7115.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366738	Green Published			2022-12-01	WOS:A1997YD44500028
J	vanWeel, C; Michels, J				vanWeel, C; Michels, J			Dying, not old age, to blame for costs of health care	LANCET			English	Article											vanWeel, C (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				GREENBERG I, 1997, HLTH SERV RES, V31, P723; Perls TT, 1996, ARCH INTERN MED, V156, P754, DOI 10.1001/archinte.156.7.754; RUWAARD D, 1997, VOLKSGEZONDHEID TOEK; van Noordt M, 1992, Gesundheitswesen, V54, P173; *VAND HLTH STAT NE, 1996, STAT NETH; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17	6	27	27	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1159	1160		10.1016/S0140-6736(97)08312-8	http://dx.doi.org/10.1016/S0140-6736(97)08312-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343516	Green Submitted			2022-12-01	WOS:A1997YB19900044
J	Gu, JGG; MacDermott, AB				Gu, JGG; MacDermott, AB			Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses	NATURE			English	Article							SYNAPTIC TRANSMISSION; GATED CURRENTS; CHANNELS; CALCIUM; DORSAL; RAT; NICOTINE	Painful stimuli to the skin initiate action potentials in the peripheral terminals of dorsal root ganglion (DRG) neurons. These action potentials propagate to DRG central terminals in the dorsal horn of the spinal cord, evoking release of excitatory transmitters such as glutamate onto postsynaptic dorsal horn neurons. P2X receptors, a family of ligand-gated ion channels(1,2) activated by the endogenous ligand ATP, are highly expressed by DRG neurons(3-5). Immunoreactivity to P2X receptors has been identified in the dorsal horn superficial laminae associated with nociceptive DRG central terminals(5), suggesting the presence of presynaptic P2X receptors. Here we have used a DRG-dorsal horn co-culture system to show that P2X receptors are localized at presynaptic sites on DRG neurons; that activation of these receptors results in increased frequency of spontaneous glutamate release; and that activation of P2X receptors at or near presynaptic DRG nerve terminals elicits action potentials that cause evoked glutamate release. Thus activation of P2X receptors at DRG central terminals can modify sensory signal throughput, and might even initiate sensory signals at central synapses without direct peripheral input. This putative central modulation and generation of sensory signals maybe associated with physiological and pathological pain sensation, making presynaptic P2X receptors a possible target for pain therapy.	COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	Gu, JGG (corresponding author), COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.							Bardoni R, 1997, J NEUROSCI, V17, P5297; BEAN BP, 1990, J NEUROSCI, V10, P11; BEHHAM CD, 1987, NATURE, V328, P275; Burnstock G, 1996, CIBA F SYMP, V198, P1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cook SP, 1997, NATURE, V387, P505, DOI 10.1038/387505a0; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LI J, 1995, J NEUROSCI, V15, P3357; Liu HT, 1997, NATURE, V386, P721, DOI 10.1038/386721a0; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCLAREN GJ, 1994, BRIT J PHARMACOL, V111, P913, DOI 10.1111/j.1476-5381.1994.tb14825.x; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; North RA, 1996, CIBA F SYMP, V198, P91; REICHLING DB, 1991, J PHYSIOL-LONDON, V441, P199, DOI 10.1113/jphysiol.1991.sp018746; ROGERS M, 1995, BIOPHYS J, V68, P501, DOI 10.1016/S0006-3495(95)80211-0; ROY ML, 1992, J NEUROSCI, V12, P2104; SEGAL MM, 1990, J NEUROPHYSIOL, V64, P1390, DOI 10.1152/jn.1990.64.5.1390; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; WHITE TD, 1985, BRAIN RES, V334, P372, DOI 10.1016/0006-8993(85)90235-5	22	412	434	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					749	753		10.1038/39639	http://dx.doi.org/10.1038/39639			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338789				2022-12-01	WOS:A1997YA95900060
J	Howell, BW; Hawkes, R; Soriano, P; Cooper, JA				Howell, BW; Hawkes, R; Soriano, P; Cooper, JA			Neuronal position in the developing brain is regulated by mouse disabled-1	NATURE			English	Article							ABL TYROSINE KINASE; TARGETED DISRUPTION; CORTICAL-NEURONS; CEREBRAL-CORTEX; REELER MICE; CELL; MUTATION; PROTEIN; PROTOONCOGENE; MIGRATION	During mammalian brain development, immature neurons migrate radially from the neuroectoderm to defined locations, giving rise to characteristic cell layers(1,2). Here we show that targeted disruption of the mouse disabled1 (mdab1) gene(3) disturbs neuronal layering in the cerebral cortex, hippocampus and cerebellum. The gene encodes a cytoplasmic protein, mDab1 p80, which is expressed and tyrosine-phosphorylated in the developing nervous system(3). It is likely to be an adaptor protein, docking to others through its phosphotyrosine residues and protein-interacting domain(4). The mdab1 mutant phenotype is very similar to that of the reeler mouse(5-7). The product of the reeler gene, Reelin, is a secreted protein that has been proposed to act as an extracellular signpost for migrating neurons(8-10). Because mDab1 is expressed in wild-type cortical neurons, and Reelin expression is normal in mdab1 mutants, mDab1 may be part of a Reelin-regulated or parallel pathway that controls the final positioning of neurons.	UNIV CALGARY, DEPT ANAT, CALGARY, AB T2N 4N1, CANADA; UNIV CALGARY, NEUROSCI RES GRP, CALGARY, AB T2N 4N1, CANADA	University of Calgary; University of Calgary	Howell, BW (corresponding author), FRED HUTCHINSON CANC RES CTR, 1100 FAIRVIEW AVE N, SEATTLE, WA 98109 USA.		Soriano, Philippe M/E-5797-2015; Hawkes, Richard/F-7971-2011	Soriano, Philippe M/0000-0002-0427-926X; Howell, Brian/0000-0002-0204-0773				Caviness V S Jr, 1982, Brain Res, V256, P293; CAVINESS VS, 1973, J COMP NEUROL, V147, P235, DOI 10.1002/cne.901470206; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFFINET AM, 1979, ANAT EMBRYOL, V157, P205, DOI 10.1007/BF00305160; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1984, DEV BRAIN RES, V16, P263, DOI 10.1016/0165-3806(84)90031-2; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOFFARTH RM, 1995, J NEUROSCI, V15, P4838; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; LANNOO MJ, 1991, J COMP NEUROL, V310, P215, DOI 10.1002/cne.903100207; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; McConnell S K, 1992, Curr Opin Neurobiol, V2, P23, DOI 10.1016/0959-4388(92)90156-F; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; Miyata T, 1996, J COMP NEUROL, V372, P215; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; ONESHIMA H, IN PRESS NEUROSCI RE; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SMEYNE RJ, 1995, MOL CELL NEUROSCI, V6, P230, DOI 10.1006/mcne.1995.1019; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANFIELD BB, 1979, J COMP NEUROL, V185, P393, DOI 10.1002/cne.901850302; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	30	594	607	1	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					733	737		10.1038/39607	http://dx.doi.org/10.1038/39607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338785				2022-12-01	WOS:A1997YA95900056
J	Rittinger, K; Walker, PA; Eccleston, JF; Smerdon, SJ; Gamblin, SJ				Rittinger, K; Walker, PA; Eccleston, JF; Smerdon, SJ; Gamblin, SJ			Structure at 1.65 angstrom of RhoA and its GTPase-activating protein in complex with a transition-state analogue	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING PROTEINS; HYDROLYSIS; MECHANISM; RAC	Small G proteins of the Rho family, which includes Rho, pac and Cdc42Hs, regulate phosphorylation pathways that control a range of biological functions including cytoskeleton formation and cell proliferation(1-7). They operate as molecular switches, cycling between the biologically active GTP-bound form and the inactive GDP-bound state, Their rate of hydrolysis of GTP to GDP by virtue of their intrinsic GTPase activity is slow, but can be accelerated by up to 10(5)-fold through interaction with rhoGAP, a GTPase-activating protein that stimulates Rho-family proteins(8,9). As such, rhoGAP plays a crucial role in regulating Rho-mediated signalling pathways. Here we report the crystal structure of RhoA and rhoGAP complexed with the transition-state analogue GDP.AlF4- at 1.65 Angstrom resolution. There is a rotation of 20 degrees between the Rho and rhoGAP proteins in this complex when compared with the ground-state complex Cdc42Hs.GMPPNP/rhoGAP, in which Cdc42Hs is bound to the non-hydrolysable GTP analogue GMPPNP(10). Consequently, in the transition state complex but not in the ground state, the rhoGAP domain contributes a residue, Arg85(GAP), directly into the active site of the G protein, We propose that this residue acts to stabilize the transition state of the GTPase reaction. RhoGAP also appears to function by stabilizing several regions of RhoA that are important in signalling the hydrolysis of GTP.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Rittinger, Katrin/D-2586-2014	Rittinger, Katrin/0000-0002-7698-4435; Smerdon, Stephen/0000-0001-5688-8465				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WITTINGHOFER A, 1993, HDB EXPT PHARM, V108, P195; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579	30	346	355	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					758	762		10.1038/39651	http://dx.doi.org/10.1038/39651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338791				2022-12-01	WOS:A1997YA95900062
J	Sheldon, M; Rice, DS; DArcangelo, G; Yoneshima, H; Nakajima, K; Mikoshiba, K; Howell, BW; Cooper, JA; Goldowitz, D; Curran, T				Sheldon, M; Rice, DS; DArcangelo, G; Yoneshima, H; Nakajima, K; Mikoshiba, K; Howell, BW; Cooper, JA; Goldowitz, D; Curran, T			Scrambler and yotari disrupt the disabled gene and produce a reeler-like phenotype in mice	NATURE			English	Article							ABL TYROSINE KINASE; LEPTIN RECEPTOR; DROSOPHILA; MOUSE; PROTEIN; ENCODES; NEURONS; DOMAIN; ORGANIZATION; EXPRESSION	Formation of the mammalian brain requires choreographed migration of neurons to generate highly ordered laminar structures such as those in the cortices of the forebrain and the cerebellum, These processes are severely disrupted by mutations in reelin(1) which cause widespread misplacement of neurons and associated ataxia in reeler mice(2,3). Reelin is a large extracellular protein secreted by pioneer neurons that coordinates cell positioning during neurodevelopment(1,4-8). Two new autosomal recessive mouse mutations, scrambler(9) and yotari(10) have been described that exhibit a phenotype identical to reeler(9-11). Here we report that scrambler and yotari arise from mutations in mdab1 (ref, 12), a mouse gene related to the Drosophila gene disabled (dab)(13). Both scrambler and yotari mice express mutated forms of mdab1 messenger RNA and little or no mDab1 protein. mDab1 is a phosphoprotein that appears to function as an intracellular adaptor in protein kinase pathways, Expression analysis indicates that mdab1 is expressed in neuronal populations exposed to Reelin. The similar phenotypes of reeler, scrambler, yotari and mdab1 null mice(14) indicate that Reelin and mDab1 function as signalling molecules that regulate cell positioning in the developing brain.	ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA; UNIV TOKYO, INST MED SCI, DEPT MOL NEUROBIOL, MINATO KU, TOKYO 108, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOL NEUROBIOL LAB, TSUKUBA, IBARAKI 305, JAPAN; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV TENNESSEE, COLL MED, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tokyo; RIKEN; Fred Hutchinson Cancer Center; University of Tennessee System; University of Tennessee Health Science Center			Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Nakajima, Kazunori/L-3396-2013; Curran, Tom/D-7515-2011; Mikoshiba, Katsuhiko/N-7943-2015	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Nakajima, Kazunori/0000-0003-1864-9425; D'Arcangelo, Gabriella/0000-0003-1575-1010; Howell, Brian/0000-0002-0204-0773; Goldowitz, Daniel/0000-0003-4756-4017				Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1995, NATURE, V374, P675, DOI 10.1038/374675a0; GOLDOWITZ D, IN PRESS J NEUROSCI; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Miyata T, 1997, J NEUROSCI, V17, P3599; Miyata T, 1996, J COMP NEUROL, V372, P215; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YONESHINA H, IN PRESS NEUROSCI RE; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	31	526	539	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					730	733		10.1038/39601	http://dx.doi.org/10.1038/39601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338784				2022-12-01	WOS:A1997YA95900055
J	Coulthard, MG; Lambert, HJ; Keir, MJ				Coulthard, MG; Lambert, HJ; Keir, MJ			Occurrence of renal scars in children after their first referral for urinary tract infection	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM, DEPT MED PHYS, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND	Newcastle University - UK	Coulthard, MG (corresponding author), ROYAL VICTORIA INFIRM, DEPT CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.			Lambert, Heather/0000-0003-4389-4078				[Anonymous], 1991, J R Coll Physicians Lond, V25, P36; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; RICKWOOD AMK, 1992, BRIT MED J, V304, P663, DOI 10.1136/bmj.304.6828.663; VERNON S, 1994, LANCET, V4, P344; Vernon SJ, 1997, BMJ-BRIT MED J, V315, P905	5	58	60	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					918	919						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361542				2022-12-01	WOS:A1997YB07300026
J	Hines, PJ				Hines, PJ			Nota bene: Neurobiology - Unconscious odors	SCIENCE			English	Editorial Material							RECEPTORS; FAMILY											BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0	5	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					79	79		10.1126/science.278.5335.79	http://dx.doi.org/10.1126/science.278.5335.79			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9340759				2022-12-01	WOS:A1997XZ12400039
J	Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD				Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD			Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: A thrombolytic predictive instrument	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-CARE-UNIT; TISSUE PLASMINOGEN-ACTIVATOR; ACUTE CARDIAC ISCHEMIA; QRS SCORING SYSTEM; RANDOMIZED TRIAL; CLINICAL-TRIAL; THERAPY; MULTICENTER; MORTALITY; STREPTOKINASE	Background: Thrombolytic therapy can be life-saving in patients with acute myocardial infarction. However, if given too late or insufficiently selectively, it may provide little benefit but still cause serious complications and incur substantial costs. Objective: To develop a thrombolytic predictive instrument for real-time use in emergency medical service settings that could 1) identify patients likely to benefit from thrombolysis and 2) facilitate the earliest possible use of this therapy. Design: Creation and validation of logistic regression-based predictive instruments based on secondary analysis of clinical data. Patients: 4911 patients who had acute myocardial infarction and ST-segment elevation on electrocardiogram; 3483 received thrombolytic therapy. Measurements: Data were obtained from 13 major clinical trials and registries and directly from medical records, including electrocardiograms obtained at presentation. Input variables include presenting clinical and electrocardiographic features; predictive models generate probabilities for acute (30-day) mortality if and if not treated with thrombolysis, 1-year mortality rates if and if not treated with thrombolysis, cardiac arrest if and if not treated with thrombolysis, thrombolysis-related intracranial hemorrhage, and thrombolysis-related major bleeding episode requiring transfusion. Together, these models constitute the thrombolytic predictive instrument. Results: The predictive models generated the following mean predictions for patients in the Thrombolytic Predictive Instrument Database: 30-day mortality rate, 7.1%; 1-year mortality rate, 10.9%; rate of cardiac arrest, 3.7%; rate of thrombolysis-related intracranial hemorrhage, 0.6%; and rate of other thrombolysis-related major bleeding episodes, 5.0%. They discriminated well between persons having and those not having the predicted outcome; areas under the receiver-operating characteristic (ROC) curve were between 0.77 and 0.84 for the five outcomes. Calibration between each instrument's predicted and observed rates was excellent. Validation of the predictive instruments for 30-day and 1-year mortality, done on a separate test dataset, yielded areas under the ROC curve of 0.76 for each. Conclusions: After the basic features of a clinical presentation are entered into a computerized electrocardiograph, the predictions of the thrombolytic predictive instrument can be printed on the electrocardiogram report. This decision aid may facilitate earlier and more appropriate use of thrombolytic therapy in patients with acute myocardial infarction.	BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; DUKE UNIV, MED CTR, DURHAM, NC 27705 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, LOS ANGELES, CA 90024 USA	Boston University; Duke University; University of Washington; University of Washington Seattle; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Selker, HP (corresponding author), TUFTS UNIV, CTR CARDIOVASC HLTH SERV RES, DIV CLIN CARE RES, SCH MED, NEW ENGLAND MED CTR, BOSTON, MA 02111 USA.		Maynard, Charles/N-3906-2015; Schmid, Christopher H./J-2398-2014	Maynard, Charles/0000-0002-1644-7814; Schmid, Christopher H./0000-0002-0855-5313	AHRQ HHS [R01 HS06208] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; ANDERSON WD, 1988, AM J CARDIOL, V61, P729, DOI 10.1016/0002-9149(88)91056-9; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CAIRNS CB, 1992, J ELECTROCARDIOL, V24, P46; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CENTOR RM, 1991, MED DECIS MAKING, V11, P102, DOI 10.1177/0272989X9101100205; CHAMBERS JM, 1992, STAT MODELS S, P249; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Gunnar R M, 1990, Circulation, V82, P664; HASTIE TJ, 1990, GEN ADDITIVE MODELS, P95; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; LAROSA JH, 1992, P NAT HEART LUNG BLO; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MAYNARD C, 1995, MED DECIS MAKING, V15, P38, DOI 10.1177/0272989X9501500107; Midgette AS, 1996, AM J CARDIOL, V78, P389, DOI 10.1016/S0002-9149(96)00325-6; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; *SAS I INC, 1989, SAS STAT US GUID VER, P1077; SCHMID CH, 1997, IN PRESS J CLIN EPID; SELKER HP, 1988, J ELECTROCARDIOL, V21, pS11, DOI 10.1016/0022-0736(88)90047-7; SELKER HP, 1994, MED CARE, V32, P1040, DOI 10.1097/00005650-199410000-00005; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; SELKER HP, 1995, J INVEST MED, V43, P468; SELKER HP, 1989, AM J MED, V87, P491; SELKER HP, 1994, CIRCULATION, V90, P1657, DOI 10.1161/01.CIR.90.4.1657; SELKER HP, 1992, THROMBOLYTIC PREDICT, P9; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; Wall T C, 1989, N C Med J, V50, P363; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211	45	69	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					538	556		10.7326/0003-4819-127-7-199710010-00006	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00006			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313022				2022-12-01	WOS:A1997XY73300006
J	Levine, S; Kaiser, L; Leferovich, J; Tikunov, B				Levine, S; Kaiser, L; Leferovich, J; Tikunov, B			Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; HUMAN SKELETAL-MUSCLE; MYOFIBRILLAR PROTEIN-TURNOVER; FIBER TYPES; ELECTROPHORETIC SEPARATION; SINGLE FIBERS; SLOW MYOSIN; NORMAL MEN; FATIGUE; EXERCISE	Background In patients with severe chronic obstructive pulmonary disease, the diaphragm undergoes physiologic adaptations characterized by an increase in energy expenditure and relative resistance to fatigue. We hypothesized that these physiologic characteristics would be associated with structural adaptations consisting of an increased proportion of less-fatigable slow-twitch muscle fibers and slow isoforms of myofibrillar proteins. Methods We obtained biopsy specimens of the diaphragm from 6 patients with severe chronic obstructive pulmonary disease (mean [+/-SE] forced expiratory volume in one second, 33+/-4 percent of the predicted value; residual volume, 259+/-25 percent of the predicted value) and 10 control subjects. The proportions of the various isoforms of myosin heavy chains, myosin light chains, troponin, and tropomyosin were determined by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis. We also used immunocytochemical techniques to determine the proportions of the various types of muscle fibers. Results The diaphragm-biopsy specimens from the patients had higher percentages of slow myosin heavy chain I (64+/-3 vs. 45+/-2 percent, P<0.001), and lower percentages of fast myosin heavy chains IIa (29+/-3 vs. 39+/-2 percent, P=0.01) and IIb (8+/-1 vs. 17+/-1 percent, P<0.001) than the diaphragms of the controls. Similar differences were noted when immunohistochemical techniques were used to compare the percentages of these fiber types in the two groups. In addition, the patients had higher percentages of the slow isoforms of myosin light chains, troponins, and tropomyosin, whereas the controls had higher percentages of the fast isoforms of these proteins. Conclusions Severe chronic obstructive pulmonary disease increases the slow-twitch characteristics of the muscle fibers in the diaphragm, an adaptation that increases resistance to fatigue. (C) 1997, Massachusetts Medical Society.	ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,CRIT CARE DIV,PHILADELPHIA,PA 19104; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104; UNIV PENN,DIV THORAC SURG,PHILADELPHIA,PA 19104	Drexel University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania	Levine, S (corresponding author), ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,DIV PULM,UNIV & WOODLAND AVES,PHILADELPHIA,PA 19104, USA.		Kaiser, Larry/L-7940-2019					AUBIER M, 1981, J APPL PHYSIOL, V50, P538, DOI 10.1152/jappl.1981.50.3.538; BATES PC, 1983, BIOCHEM J, V214, P593, DOI 10.1042/bj2140593; BAUMANN H, 1987, PFLUG ARCH EUR J PHY, V409, P349, DOI 10.1007/BF00583788; BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1983, J APPL PHYSIOL, V55, P8, DOI 10.1152/jappl.1983.55.1.8; BILLETER R, 1981, EUR J BIOCHEM, V116, P389, DOI 10.1111/j.1432-1033.1981.tb05347.x; DHOOT GK, 1979, NATURE, V278, P714, DOI 10.1038/278714a0; EDWARDS RHT, 1977, J PHYSIOL-LONDON, V272, P769, DOI 10.1113/jphysiol.1977.sp012072; GRANDMONTLEBLANC A, 1977, CAN J BIOCHEM CELL B, V55, P949, DOI 10.1139/o77-142; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HAVERBERG LN, 1975, BIOCHEM J, V152, P503, DOI 10.1042/bj1520503; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; HUGHES SM, 1993, DEV BIOL, V158, P183, DOI 10.1006/dbio.1993.1178; JAKOBSSON P, 1990, EUR RESPIR J, V3, P192; JOHNSON BD, 1993, J PHYSIOL-LONDON, V460, P385, DOI 10.1113/jphysiol.1993.sp019477; KANNER RE, 1984, CLIN PULMONARY FUNCT; KELSEN SG, 1996, PULMONARY REHABILITA, V91, P117; KLITGAARD H, 1990, PFLUG ARCH EUR J PHY, V416, P470, DOI 10.1007/BF00370757; KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P55, DOI 10.1111/j.1748-1716.1990.tb08975.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFRAMBOISE WA, 1990, BIOCHIM BIOPHYS ACTA, V1035, P109, DOI 10.1016/0304-4165(90)90181-U; LARSSON L, 1985, MUSCLE NERVE, V8, P714, DOI 10.1002/mus.880080815; LARSSON L, 1991, AM J PHYSIOL, V261, pC93, DOI 10.1152/ajpcell.1991.261.1.C93; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; LEFEROVICH JM, 1995, J NEUROSCI, V15, P596; LEVINE S, 1988, J APPL PHYSIOL, V64, P672, DOI 10.1152/jappl.1988.64.2.672; Levine S, 1996, AM J PHYSIOL-CELL PH, V271, pC1480, DOI 10.1152/ajpcell.1996.271.5.C1480; MADOR MJ, 1993, AM REV RESPIR DIS, V148, P1571, DOI 10.1164/ajrccm/148.6_Pt_1.1571; MANCINI DM, 1992, CIRCULATION, V86, P909, DOI 10.1161/01.CIR.86.3.909; MOXHAM J, 1981, THORAX, V36, P164, DOI 10.1136/thx.36.3.164; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLKEY MI, 1995, AM J RESP CRIT CARE, V152, P959, DOI 10.1164/ajrccm.152.3.7663810; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; SANCHEZ J, 1985, B EUR PHYSIOPATH RES, V21, P351; SANCHEZ J, 1982, B EUR PHYSIOPATH RES, V18, P901; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SMERDU V, 1994, AM J PHYSIOL-CELL PH, V267, pC1723, DOI 10.1152/ajpcell.1994.267.6.C1723; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Tikunov BA, 1996, J MOL CELL CARDIOL, V28, P2537, DOI 10.1006/jmcc.1996.0245; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; Winer BJ., 1971, STAT PRINCIPLES EXPT	44	251	262	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1799	1806		10.1056/NEJM199712183372503	http://dx.doi.org/10.1056/NEJM199712183372503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400036				2022-12-01	WOS:A1997YL85500003
J	Lazaridis, T; Karplus, M				Lazaridis, T; Karplus, M			''New view'' of protein folding reconciled with the old through multiple unfolding simulations	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; NUCLEATION-CONDENSATION MECHANISM; CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATE; ENERGY; PRINCIPLES	Twenty-four molecular dynamics trajectories of chymotrypsin inhibitor 2 provide a direct demonstration of the diversity of unfolding pathways. Comparison with experiments suggests that the transition state region for folding and unfolding occurs early with only 25 percent of the native contacts and that the root-mean-square deviations between contributing structures can be as large as 15 angstroms. Nevertheless, a statistically preferred unfolding pathway emerges from the simulations; disruption of tertiary interactions between the helix and a two-stranded portion of the beta sheet is the primary unfolding event. The results suggest a synthesis of the ''new'' and the classical view of protein folding with a preferred pathway on a funnel-like average energy surface.	HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; UNIV STRASBOURG 1,INST LE BEL,ISIS,LAB CHIM BIOPHYS,F-67000 STRASBOURG,FRANCE	Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALONSO DOV, 1995, J MOL BIOL, V247, P501, DOI 10.1006/jmbi.1994.0156; BALDWIN RL, 1994, NATURE, V369, P183, DOI 10.1038/369183a0; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; DILL KA, 1995, PROTEIN SCI, V4, P561; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Guo ZY, 1997, P NATL ACAD SCI USA, V94, P10161, DOI 10.1073/pnas.94.19.10161; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; Karplus Martin, 1992, P127; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Li AJ, 1996, J MOL BIOL, V257, P412, DOI 10.1006/jmbi.1996.0172; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Neira JL, 1996, FOLD DES, V1, P189, DOI 10.1016/S1359-0278(96)00031-4; Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061; Nolting B, 1997, P NATL ACAD SCI USA, V94, P826, DOI 10.1073/pnas.94.3.826; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Onuchic JN, 1996, FOLD DES, V1, P441, DOI 10.1016/S1359-0278(96)00060-0; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SCHOEMAKER BA, 1997, P NATL ACAD SCI USA, V94, P777; SHAKHNOVICH EI, 1989, BIOPHYS CHEM, V34, P187, DOI 10.1016/0301-4622(89)80058-4; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933	28	486	490	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1928	1931		10.1126/science.278.5345.1928	http://dx.doi.org/10.1126/science.278.5345.1928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395391				2022-12-01	WOS:A1997YL00200029
J	Biederer, T; Volkwein, C; Sommer, T				Biederer, T; Volkwein, C; Sommer, T			Role of Cue1p in ubiquitination and degradation at the ER surface	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; PROTEASOME PATHWAY; PROTEIN; COMPLEX; TRANSLOCATION; SEC61P; ENZYME	Endoplasmic reticulum (ER) degradation of aberrant proteins is mediated by the ubiquitin-proteasome pathway. Here, a membrane-bound component of the ubiquitin system, Cue1p, was identified. It was shown to recruit the soluble ubiquitin-conjugating enzyme Ubc7p to the ER membrane. In the absence of Cue1p, unassembled and thus cytosolically mislocalized Ubc7p was unable to participate in ER degradation or in the turnover of soluble non-ER proteins. Moreover, ubiquitination by Cue1p-assembled Ubc7p and Ubc6p was a prerequisite for retrograde transport of lumenal substrates out of the ER, which suggests that ubiquitination is mechanistically integrated into the ER degradation process.	MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Biederer, Thomas/AAZ-6133-2021	Biederer, Thomas/0000-0003-0912-1514				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Papworth C, 1996, STRATEGIES, V9, P4, DOI DOI 10.1080/08924562.1996.11000299; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975	22	312	314	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1806	1809		10.1126/science.278.5344.1806	http://dx.doi.org/10.1126/science.278.5344.1806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388185				2022-12-01	WOS:A1997YJ90100051
J	DeAngelis, PL; Jing, W; Graves, MV; Burbank, DE; VanEtten, JL				DeAngelis, PL; Jing, W; Graves, MV; Burbank, DE; VanEtten, JL			Hyaluronan synthase of chlorella virus PBCV-1	SCIENCE			English	Article							STREPTOCOCCUS-PYOGENES; SEQUENCE; PROTEIN; ALGA	Sequence analysis of the 330-kilobase genome of the virus PBCV-1 that infects a chlorella-like green algae revealed an open reading frame, A98R, with similarity to several hyaluronan synthases. Hyaluronan is an essential polysaccharide found in higher animals as well as in a few pathogenic bacteria. Expression of the A98R gene product in Escherichia coli indicated that the recombinant protein is an authentic hyaluronan synthase. A98R is expressed early in PBCV-1 infection and hyaluronan is produced in infected algae. These results demonstrate that a virus can encode an enzyme capable of synthesizing a carbohydrate polymer and that hyaluronan exists outside of animals and their pathogens.	UNIV NEBRASKA,DEPT PLANT PATHOL,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln	DeAngelis, PL (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,940 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497, R01GM032441] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32441, R01-GM56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F, 1995, SHORT PROTOCOLS MOL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBANK DE, 1983, SCIENCE, V219, P994; CARTER GR, 1953, AM J VET RES, V14, P475; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DEANGELIS PL, UNPUB; GRAVES M, UNPUB; HARMON BG, 1991, AM J VET RES, V52, P1507; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KNUDSON CB, 1993, FASEB J, V7, P1234; LANDSTEIN D, UNPUB; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MOFFATT BA, 1986, J MOL BIOL, V189, P113; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; PUMMILL PE, UNPUB; QUINN RW, 1957, BIOCHEM J, V95, P290; Reisser W., 1992, ALGAE SYMBIOSES; ROHOZINSKI J, 1989, VIROLOGY, V168, P363, DOI 10.1016/0042-6822(89)90277-8; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SKRDLA MP, 1984, VIROLOGY, V135, P308, DOI 10.1016/0042-6822(84)90188-0; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; VANETTEN JL, 1991, MICROBIOL REV, V55, P586, DOI 10.1128/MMBR.55.4.586-620.1991; VANETTEN JL, 1995, MOL CELLS, V5, P99; VANETTEN JL, 1985, VIROLOGY, V140, P135, DOI 10.1016/0042-6822(85)90452-0; WANG IN, 1993, P NATL ACAD SCI USA, V90, P3840, DOI 10.1073/pnas.90.9.3840; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; YAMADA T, 1991, APPL ENVIRON MICROB, V57, P3433, DOI 10.1128/AEM.57.12.3433-3437.1991; ZHANG YP, 1994, VIROLOGY, V202, P1079, DOI 10.1006/viro.1994.1444	34	96	112	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1800	1803		10.1126/science.278.5344.1800	http://dx.doi.org/10.1126/science.278.5344.1800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388183	Green Published			2022-12-01	WOS:A1997YJ90100049
J	Palkova, Z; Janderova, B; Gabriel, J; Zikanova, B; Pospisek, M; Forstova, J				Palkova, Z; Janderova, B; Gabriel, J; Zikanova, B; Pospisek, M; Forstova, J			Ammonia mediates communication between yeast colonies	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; LOCALIZATION; EXPRESSION; GROWTH	Under certain growth conditions unicellular organisms behave as highly organized multicellular structures. For example, the fruiting bodies of myxobacteria(1) and of the slime mould Dictyostelium discoideum(2) form structures composed of non-dividing motile cells. Although non-motile, yeasts can create organized structures, colonies in which cells communicate and act in a coordinated fashion. Colony morphologies are characteristic for different species and strains. Here we describe that, in addition to short-range intracolony cell-cell communication, yeasts exhibit long-distance signals between neighbouring colonies. The volatile alkaline compound ammonia, transmitted by yeast colonies in pulses, has been identified as a substance mediating the intercolony signal. The first alkaline pulse produced by neighbouring colonies is non-directed and is followed by acidification of the medium. The second pulse seems to be enhanced and is oriented towards the neighbour colony. Ammonia signalling results in growth inhibition of the facing parts of both colonies. This phenomenon is observed in different yeast genera. The presence of amino acids in the medium is required for ammonia production, Colonies derived from the yeast Saccharomyces cerevisiae shr3 mutant, defective in localization of amino-acid permeases(3), do not produce detectable amounts of ammonia and do not exhibit asymmetric growth inhibition.	ACAD SCI CZECH REPUBL,INST MICROBIOL,CR-14220 PRAGUE 4,CZECH REPUBLIC	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Palkova, Z (corresponding author), CHARLES UNIV,DEPT GENET & MICROBIOL,VINICNA 5,PRAGUE 12844 2,CZECH REPUBLIC.		Zikánová, Blanka/P-9993-2017; Gabriel, Jiri/H-2473-2014; Palkova, Zdena/M-8692-2014; Pospisek, Martin/A-9100-2008; Forstova, Jitka/L-7328-2017	Zikánová, Blanka/0000-0002-2599-4713; Palkova, Zdena/0000-0002-0864-8042; Gabriel, Jiri/0000-0001-9341-3434; Forstova, Jitka/0000-0003-0219-506X; Pospisek, Martin/0000-0002-9490-8911				CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; KOCKOVAKRATOCHV.A, 1990, YEASTS YEAST LIKE OR; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MARAZ A, 1979, PROTOPLASTS APPLICAT, P35; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; SCHAAP P, 1995, DEV BIOL, V168, P179, DOI 10.1006/dbio.1995.1070; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHIMKETS LJ, 1990, MICROBIOL REV, V54, P473, DOI 10.1128/MMBR.54.4.473-501.1990; SUOMALAINEN H, 1967, J I BREWING, V73, P477; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	15	170	177	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					532	536		10.1038/37398	http://dx.doi.org/10.1038/37398			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394006				2022-12-01	WOS:A1997YJ86500058
J	Hamblin, R; Harrison, A; Boyle, S				Hamblin, R; Harrison, A; Boyle, S			The supertanker's not for turning	LANCET			English	Editorial Material											Hamblin, R (corresponding author), KINGS FUND, LONDON W1M 0AN, ENGLAND.							APPLEBY J, 1994, HLTH SERVICE J, V104, P36; Dixon J, 1997, BRIT MED J, V314, P86, DOI 10.1136/bmj.314.7074.86; NEWTON JN, 1995, BRIT MED J, V311, P783, DOI 10.1136/bmj.311.7008.783; *NHS EX, 1997, EX LETT, V97, P42	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1493	1494		10.1016/S0140-6736(05)63937-2	http://dx.doi.org/10.1016/S0140-6736(05)63937-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388394				2022-12-01	WOS:A1997YH11500005
J	Endres, MJ; Jaffer, S; Haggarty, B; Turner, JD; Doranz, BJ; OBrien, PJ; Kolson, DL; Hoxie, JA				Endres, MJ; Jaffer, S; Haggarty, B; Turner, JD; Doranz, BJ; OBrien, PJ; Kolson, DL; Hoxie, JA			Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOPLASMIC DOMAIN; REPLICATION; EXPRESSION	Retroviral vectors containing CD4 and an appropriate chemokine receptor were evaluated for the ability to transduce cells infected with human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV). These CD4-chemokine receptor pseudotypes were able to target HIV- and SIV-infected cell lines and monocyte-derived macrophages in a manner that corresponded to the specificity of the viral envelope glycoprotein for its CD4-chemokine receptor complex. This approach could offer a way to deliver antiviral genes directly to HIV-infected cells in vivo and could provide an additional treatment strategy in conjunction with existing antiviral therapies.	UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Endres, MJ (corresponding author), UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104, USA.		O'Brien, Peter J/B-5182-2013; Good (formerly Turner), Julie/I-8305-2018	O'Brien, Peter J/0000-0003-4127-2718; 	NHLBI NIH HHS [HL 07439] Funding Source: Medline; NIAID NIH HHS [AI33854, AI40880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033854, R01AI040880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLIET JW, IN PRESS J VIROL; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COLLMAN R, 1989, J EXP MED, V170, P1149, DOI 10.1084/jem.170.4.1149; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; ENDRES M, UNPUB; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; LABRANCHE CC, 1995, J VIROL, V69, P5217, DOI 10.1128/JVI.69.9.5217-5227.1995; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nolan GP, 1997, CELL, V90, P821, DOI 10.1016/S0092-8674(00)80345-1; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5	22	59	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1462	1464		10.1126/science.278.5342.1462	http://dx.doi.org/10.1126/science.278.5342.1462			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367958				2022-12-01	WOS:A1997YG85800044
J	Kunst, F; Ogasawara, N; Moszer, I; Albertini, AM; Alloni, G; Azevedo, V; Bertero, MG; Bessieres, P; Bolotin, A; Borchert, S; Borriss, R; Boursier, L; Brans, A; Braun, M; Brignell, SC; Bron, S; Brouillet, S; Bruschi, CV; Caldwell, B; Capuano, V; Carter, NM; Choi, SK; Codani, JJ; Connerton, IF; Cummings, NJ; Daniel, RA; Denizot, F; Devine, KM; Dusterhoft, A; Ehrlich, SD; Emmerson, PT; Entian, KD; Errington, J; Fabret, C; Ferrari, E; Foulger, D; Fritz, C; Fujita, M; Fujita, Y; Fuma, S; Galizzi, A; Galleron, N; Ghim, SY; Glaser, P; Goffeau, A; Golightly, EJ; Grandi, G; Guiseppi, G; Guy, BJ; Haga, K; Haiech, J; Harwood, CR; Henaut, A; Hilbert, H; Holsappel, S; Hosono, S; Hullo, MF; Itaya, M; Jones, L; Joris, B; Karamata, D; Kasahara, Y; KlaerrBlanchard, M; Klein, C; Kobayashi, Y; Koetter, P; Koningstein, G; Krogh, S; Kumano, M; Kurita, K; Lapidus, A; Lardinois, S; Lauber, J; Lazarevic, V; Lee, SM; Levine, A; Liu, H; Masuda, S; Mauel, C; Medigue, C; Medina, N; Mellado, RP; Mizuno, M; Moestl, D; Nakai, S; Noback, M; Noone, D; OReilly, M; Ogawa, K; Ogiwara, A; Oudega, B; Park, SH; Parro, V; Pohl, TM; Portetelle, D; Porwollik, S; Prescott, AM; Presecan, E; Pujic, P; Purnelle, B; Rapoport, G; Rey, M; Reynolds, S; Rieger, M; Rivolta, C; Rocha, E; Roche, B; Rose, M; Sadaie, Y; Sato, T; Scanlan, E; Schleich, S; Schroeter, R; Scoffone, F; Sekiguchi, J; Sekowska, A; Seror, SJ; Serror, P; Shin, BS; Soldo, B; Sorokin, A; Tacconi, E; Takagi, T; Takahashi, H; Takemaru, K; Takeuchi, M; Tamakoshi, A; Tanaka, T; Terpstra, P; Tognoni, A; Tosato, V; Uchiyama, S; Vandenbol, M; Vannier, F; Vassarotti, A; Viari, A; Wambutt, R; Wedler, E; Wedler, H; Weitzenegger, T; Winters, P; Wipat, A; Yamamoto, H; Yamane, K; Yasumoto, K; Yata, K; Yoshida, K; Yoshikawa, HF; Zumstein, E; Yoshikawa, H; Danchin, A				Kunst, F; Ogasawara, N; Moszer, I; Albertini, AM; Alloni, G; Azevedo, V; Bertero, MG; Bessieres, P; Bolotin, A; Borchert, S; Borriss, R; Boursier, L; Brans, A; Braun, M; Brignell, SC; Bron, S; Brouillet, S; Bruschi, CV; Caldwell, B; Capuano, V; Carter, NM; Choi, SK; Codani, JJ; Connerton, IF; Cummings, NJ; Daniel, RA; Denizot, F; Devine, KM; Dusterhoft, A; Ehrlich, SD; Emmerson, PT; Entian, KD; Errington, J; Fabret, C; Ferrari, E; Foulger, D; Fritz, C; Fujita, M; Fujita, Y; Fuma, S; Galizzi, A; Galleron, N; Ghim, SY; Glaser, P; Goffeau, A; Golightly, EJ; Grandi, G; Guiseppi, G; Guy, BJ; Haga, K; Haiech, J; Harwood, CR; Henaut, A; Hilbert, H; Holsappel, S; Hosono, S; Hullo, MF; Itaya, M; Jones, L; Joris, B; Karamata, D; Kasahara, Y; KlaerrBlanchard, M; Klein, C; Kobayashi, Y; Koetter, P; Koningstein, G; Krogh, S; Kumano, M; Kurita, K; Lapidus, A; Lardinois, S; Lauber, J; Lazarevic, V; Lee, SM; Levine, A; Liu, H; Masuda, S; Mauel, C; Medigue, C; Medina, N; Mellado, RP; Mizuno, M; Moestl, D; Nakai, S; Noback, M; Noone, D; OReilly, M; Ogawa, K; Ogiwara, A; Oudega, B; Park, SH; Parro, V; Pohl, TM; Portetelle, D; Porwollik, S; Prescott, AM; Presecan, E; Pujic, P; Purnelle, B; Rapoport, G; Rey, M; Reynolds, S; Rieger, M; Rivolta, C; Rocha, E; Roche, B; Rose, M; Sadaie, Y; Sato, T; Scanlan, E; Schleich, S; Schroeter, R; Scoffone, F; Sekiguchi, J; Sekowska, A; Seror, SJ; Serror, P; Shin, BS; Soldo, B; Sorokin, A; Tacconi, E; Takagi, T; Takahashi, H; Takemaru, K; Takeuchi, M; Tamakoshi, A; Tanaka, T; Terpstra, P; Tognoni, A; Tosato, V; Uchiyama, S; Vandenbol, M; Vannier, F; Vassarotti, A; Viari, A; Wambutt, R; Wedler, E; Wedler, H; Weitzenegger, T; Winters, P; Wipat, A; Yamamoto, H; Yamane, K; Yasumoto, K; Yata, K; Yoshida, K; Yoshikawa, HF; Zumstein, E; Yoshikawa, H; Danchin, A			The complete genome sequence of the Gram-positive bacterium Bacillus subtilis	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; DNA-SEQUENCES; REPLICATION; TERMINATORS; COMPETENCE; PROJECT; STRANDS; REGION; ACIDS	Bacillus subtilis Is the best-characterized member of the Gram-positive bacteria. Its genome of 4,214,810 base pairs comprises 4,100 protein-coding genes. Of these protein-coding genes, 53% are represented once, while a quarter of the genome corresponds to several gene families that have been greatly expanded by gene duplication, the largest family containing 77 putative ATP-binding transport proteins. In addition, a large proportion of the genetic capacity is devoted to the utilization of a variety of carbon sources, including many plant-derived molecules. The identification of five signal peptidase genes, as well as several genes for components of the secretion apparatus, is important given the capacity of Bacillus strains to secrete large amounts of industrially important enzymes. Many of the genes are involved in the synthesis of secondary metabolites, Including antibiotics, that are more typically associated with Streptomyces species. The genome contains at least ten prophages or remnants of prophages, indicating that bacteriophage Infection has played an important evolutionary role in horizontal gene transfer, in particular In the propagation of bacterial pathogenesis.	NARA INST SCI & TECHNOL, GRAD SCH BIOL SCI, NARA 63001, JAPAN; INST PASTEUR, UNITE REGULAT EXPRESS GENET, F-75724 PARIS 15, FRANCE; UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL, I-27100 PAVIA, ITALY; INRA, F-78352 JOUY EN JOSAS, FRANCE; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; HUMBOLDT UNIV BERLIN, INST GENET & MIKROBIOL, D-10115 BERLIN, GERMANY; UNIV LIEGE, CTR INGN PROT, INST CHIM B6, B-4000 LIEGE, BELGIUM; QIAGEN GMBH, D-40724 HILDEN, GERMANY; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MICROBIOL IMMUNOL & VIROL SCI, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; UNIV GRONINGEN, DEPT GENET, NL-9751 NN HAREN, NETHERLANDS; UNIV PARIS 06, ATELIER BIOINFORMAT, F-75005 PARIS, FRANCE; INT CTR GENET ENGN & BIOTECHNOL, AREA SCI PK, I-34012 TRIESTE, ITALY; GENENCOR INT, PALO ALTO, CA 94304 USA; KRIBB, APPL MICROBIOL RES DIV, BACTERIAL MOL GENET RES UNIT, TAEJON 305600, SOUTH KOREA; INST NATL RECH INFORMAT & AUTOMAT, F-78153 LE CHESNAY, FRANCE; INST FOOD RES, READING LAB, DEPT FOOD MACROMOL SCI, READING RG6 6BZ, BERKS, ENGLAND; UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; CNRS, CHIM BACTERIENNE LAB, F-13402 MARSEILLE 09, FRANCE; TRINITY COLL DUBLIN, DEPT GENET, DUBLIN, IRELAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT BIOCHEM & GENET, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; NATL INST GENET, CTR RADIOISOTOPE, MISHIMA, SHIZUOKA 411, JAPAN; FUKUYAMA UNIV, FAC ENGN, DEPT BIOTECHNOL, HIROSHIMA 72902, JAPAN; UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, FAC SCI AGRON, B-1348 LOUVAIN, BELGIUM; NOVO NORDISK BIOTECH, DAVIS, CA 95616 USA; ENIRICERCHE SPA, I-20097 SAN DONATO MILANESE, MILAN, ITALY; UNIV TOKYO, INST MOL & CELLULAR BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV VERSAILLES, LAB GENOME & INFORMAT, F-78035 VERSAILLES, FRANCE; TOKYO UNIV AGR & TECHNOL, FAC AGR, FUCHU, TOKYO 183, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; INST PASTEUR, SERV INFORMAT SCI, F-75724 PARIS 15, FRANCE; UNIV LAUSANNE, INST GENET & BIOL MICROBIENNES, CH-1005 LAUSANNE, SWITZERLAND; FREE UNIV AMSTERDAM, FAC BIOL, DEPT MOL MICROBIOL, MBW BCA, NL-1081 HV AMSTERDAM, NETHERLANDS; CHONGJU UNIV, COLL SCI & ENGN, CHONJU, SOUTH KOREA; UNIV PARIS 11, INST GENET & MICROBIOL, CNRS, URA 2225, F-91405 ORSAY, FRANCE; CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN; NATL INST BASIC BIOL, OKAZAKI, AICHI 444, JAPAN; GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; FAC AGRON, DEPT MICROBIOL, B-5030 GEMBLOUX, BELGIUM; BMF, BIOTECH RES, D-69434 HIRSCHHORN, GERMANY; SHINSHU UNIV, FAC TEXT SCI & TECHNOL, DEPT APPL BIOL, UEDA, NAGANO 386, JAPAN; UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MINATO KU, TOKYO 108, JAPAN; TOKAI UNIV, SCH MARINE SCI & TECHNOL, DEPT MARINE SCI, SHIZUOKA 424, JAPAN; COMMISS EUROPEAN COMMUNITIES, DG XII E 1, SDME 878, B-1049 BRUSSELS, BELGIUM; AGOWA GMBH, D-12489 BERLIN, GERMANY	Nara Institute of Science & Technology; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Pavia; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Goethe University Frankfurt; Humboldt University of Berlin; University of Liege; QIAGEN GmbH; Newcastle University - UK; University of Groningen; UDICE-French Research Universities; Sorbonne Universite; International Center for Genetic Engineering & Biotechnology (ICGEB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of Oxford; Centre National de la Recherche Scientifique (CNRS); Trinity College Dublin; Newcastle University - UK; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Fukuyama University; University of Tsukuba; Universite Catholique Louvain; Novo Nordisk; Eni SpA; University of Tokyo; UDICE-French Research Universities; Universite Paris Saclay; Tokyo University of Agriculture & Technology; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Lausanne; Vrije Universiteit Amsterdam; Cheongju University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Shinshu University; University of Tokyo; Tokai University	Kunst, F (corresponding author), INST PASTEUR, UNITE BIOCHIM MICROBIENNE, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Sorokin, Alexei/AAV-4666-2020; Glaser, Philippe/O-2641-2015; Choi, Soo-Keun/AAF-2432-2019; Azevedo, Vasco/B-1556-2019; Kasahara, Yasuhiro/C-8620-2012; Azevedo, Vasco A.C/F-4315-2011; Serror, Pascale/ABA-1314-2021; Borriss, Rainer/C-5026-2012; Pujic, Petar/ACY-1850-2022; Entian, Karl-Dieter/D-3080-2011; Levine, Alex/A-6867-2008; Daniel, Richard A./I-2850-2019; Lapidus, Alla L/I-4348-2013; Ogasawara, Naotake/B-7971-2011; Pupin, Maude/I-7437-2015; Rocha, Eduardo/B-7009-2009; haiech, jacques J/F-2890-2010; Ehrlich, S./Y-2423-2019; Parro, Victor/K-3788-2014; Mellado, Rafael P/D-2680-2009; Errington, Jeff/G-1832-2011; Yoshida, Ken-ichi/R-8863-2016; Rocha, Eduardo/A-4727-2008; TAKEUCHI, Michio/H-6592-2013; Bolotine, Alexandre/AAW-1156-2020; Sekiguchi, Junichi/F-9963-2010; Harwood, Colin/AGF-0120-2022	Sorokin, Alexei/0000-0002-8653-9896; Glaser, Philippe/0000-0003-4156-2782; Azevedo, Vasco/0000-0002-4775-2280; Azevedo, Vasco A.C/0000-0002-4775-2280; Serror, Pascale/0000-0002-8446-9011; Borriss, Rainer/0000-0003-3726-1004; Pujic, Petar/0000-0003-1957-8534; Daniel, Richard A./0000-0002-6483-5897; Lapidus, Alla L/0000-0003-0427-8731; Pupin, Maude/0000-0003-3197-0715; Rocha, Eduardo/0000-0001-7704-822X; Ehrlich, S./0000-0002-7563-4046; Errington, Jeff/0000-0002-6977-9388; Yoshida, Ken-ichi/0000-0002-3383-4664; Bolotine, Alexandre/0000-0002-5878-8270; Capuano, Veronique/0000-0001-8738-0947; Parro, Victor/0000-0003-3738-0724; Lazarevic, Vladimir/0000-0002-6839-2536; Brans, Alain/0000-0003-4001-2762; Wipat, Anil/0000-0001-7310-4191; Danchin, Antoine/0000-0002-6350-5001; Connerton, Ian/0000-0001-8652-8938; Fujita, Masaya/0000-0003-0060-5328; haiech, jacques/0000-0003-2908-8053; Bertero, Michela/0000-0002-2012-6706; Rivolta, Carlo/0000-0002-0733-9950; Harwood, Colin/0000-0002-3624-0001; Choi, Soo-Keun/0000-0001-7757-4748; Grandi, Guido/0000-0001-9724-2185; Jones, Louis/0000-0002-3080-9770				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; AZEVEDO V, 1993, P NATL ACAD SCI USA, V90, P6047, DOI 10.1073/pnas.90.13.6047; Billoud B, 1996, NUCLEIC ACIDS RES, V24, P1395, DOI 10.1093/nar/24.8.1395; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; BURKHOLDER PR, 1947, AM J BOT, V34, P345, DOI 10.2307/2437147; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; Danchin A, 1997, DNA Res, V4, P9, DOI 10.1093/dnares/4.1.9; DANIEL RA, 1994, J MOL BIOL, V235, P209, DOI 10.1016/S0022-2836(05)80027-0; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; FICHANT GA, 1995, NUCLEIC ACIDS RES, V23, P2900; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; Glemet E, 1997, COMPUT APPL BIOSCI, V13, P137; Goffeau A, 1997, NATURE, V387, P5, DOI DOI 10.1038/387005B0.PUBMED:9169864; HARWOOD CR, 1992, TRENDS BIOTECHNOL, V10, P247, DOI 10.1016/0167-7799(92)90233-L; HENAUT A, 1996, ESCHERICHIA COLI SAL, P2047; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; ITAYA M, 1993, J BACTERIOL, V175, P741, DOI 10.1128/JB.175.3.741-749.1993; Kaneko T, 1996, DNA Res, V3, P109; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; Kasahara Y, 1997, DNA Res, V4, P155, DOI 10.1093/dnares/4.2.155; Krogh S, 1996, MICROBIOL-UK, V142, P2031, DOI 10.1099/13500872-142-8-2031; Kunst F., 1995, MICROBIOLOGY, V389, P84; LANDES C, 1992, NUCLEIC ACIDS RES, V20, P3631, DOI 10.1093/nar/20.14.3631; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Luttinger A, 1996, MOL MICROBIOL, V19, P343, DOI 10.1046/j.1365-2958.1996.380907.x; MEDIGUE C, 1995, GENE, V165, pGC37, DOI 10.1016/0378-1119(95)00636-K; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; Moszer I, 1996, MICROBIOL-UK, V142, P2987, DOI 10.1099/13500872-142-11-2987; MOSZER I, 1995, MICROBIOL-SGM, V141, P261, DOI 10.1099/13500872-141-2-261; NUSSINOV R, 1981, J MOL EVOL, V17, P237, DOI 10.1007/BF01732761; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; Ogasawara N, 1996, MICROBIOL-UK, V142, P2993, DOI 10.1099/13500872-142-11-2993; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; Presecan E, 1997, MICROBIOL-SGM, V143, P3313, DOI 10.1099/00221287-143-10-3313; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; Sorokin A, 1996, GENOME RES, V6, P448, DOI 10.1101/gr.6.5.448; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; SUUTARI M, 1992, BIOCHIM BIOPHYS ACTA, V1126, P119, DOI 10.1016/0005-2760(92)90281-Y; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	49	3017	7445	21	561	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	1997	390	6657					249	256		10.1038/36786	http://dx.doi.org/10.1038/36786			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384377	Green Accepted, hybrid, Green Submitted			2022-12-01	WOS:A1997YG66700052
J	Kim, WR; Poterucha, JJ; Hermans, JE; Therneau, TM; Dickson, ER; Evans, RW; Gross, JB				Kim, WR; Poterucha, JJ; Hermans, JE; Therneau, TM; Dickson, ER; Evans, RW; Gross, JB			Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; hepatitis C; interferon-alpha; age factors; quality-adjusted life-years	NON-B-HEPATITIS; TERM FOLLOW-UP; CHRONIC NON-A; CONTROLLED TRIAL; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; POSTTRANSFUSION HEPATITIS; VIRUS GENOTYPES; LIVER-DISEASE; UNITED-STATES	Background: Interferon-alpha is effective in only a small number of patients with chronic hepatitis C, although prolonged treatment may increase the response rate. There is concern that the expense of interferon-alpha therapy may not be justified by the low response rates and uncertain long-term benefit. Objective: To compare clinical and economic outcomes after 6 months and 12 months of interferon-alpha therapy for chronic hepatitis C. Design: A Markov model depicting the natural progression of chronic hepatitis C. On the basis of this model, a simulated trial compared no therapy with 6 and 12 months of interferon-alpha therapy at standard doses (3 million U three times weekly). Patients: Four age-specific cohorts (30, 40, 50, and 60 years of age) with chronic hepatitis C. Measurements: Number of deaths from liver disease, total costs, and cumulative quality-adjusted life-years (QALYs). Results: Six and 12 months of interferon-alpha treatment gained 0.25 QALYs at an incremental cost of $1000 and 0.37 QALYs at an incremental cost of $1900, respectively. Thus, although 6 months of interferon-alpha therapy was less efficacious than 12 months of therapy, it was more cost-effective ($4000 per QALY gained compared with $5000 per QALY gained). Nonetheless, in patients younger than 60 years of age, both 6 and 12 months of therapy compared favorably with other established medical interventions, such as screening mammography and cholesterol reduction programs. Important variables affecting the cost-effectiveness of interferon-alpha treatment included the cost and efficacy of interferon-alpha, the cost of treatment for decompensated cirrhosis, and quality of life in patients with chronic hepatitis C. Conclusion: From the standpoint of cost-effectiveness, interferon-alpha therapy for 6 or 12 months may be justified in patients with chronic hepatitis C. The possible exception is patients older than 60 years of age.	MAYO CLIN & MAYO FDN, DIV GASTROENTEROL & HEPATOL W19, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, SECT HLTH SERV EVALUAT, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic				Kim, W. Ray/0000-0002-3030-860X	NIDDK NIH HHS [DK34238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Ampurdanes S, 1996, J HEPATOL, V25, P827, DOI 10.1016/S0168-8278(96)80285-6; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; Belle S H, 1995, Clin Transpl, P19; BENNETT WG, 1995, HEPATOLOGY, V22, P735; BROWN DM, 1994, DIGESTIVE DIS US EPI; Cane EJ, 1996, NEW ENGL J MED, V334, P815, DOI 10.1056/NEJM199603283341302; *CDCP HEP BRANCH, 1997, 1997 HEP C FACT SHEE; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1002/hep.1840220303; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVIS GL, 1994, CLIN THER, V16, P334; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Evans R W, 1995, Liver Transpl Surg, V1, P61, DOI 10.1002/lt.500010114; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Friedlander L, 1996, DIGEST DIS SCI, V41, P1678, DOI 10.1007/BF02087924; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Hoofnagle JH, 1996, NEW ENGL J MED, V334, P1470, DOI 10.1056/NEJM199605303342210; Kim W R, 1995, Clin Transpl, P315; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KIYOSAWA K, 1994, INTERVIROLOGY, V37, P101, DOI 10.1159/000150363; KORETZ RL, 1990, HEPATOLOGY, V12, P880; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1016/0270-9139(91)90288-7; *NAT CTR HLTH STAT, 1994, VIT STAT US A, V2; Petitti DB, 1994, METAANALYSIS DECISIO, P119; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1002/hep.1840130220; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Torrance GW, 1987, METHODS EC EVALUATIO; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; VAQUER P, 1994, LIVER, V14, P265; WEJSTAL R, 1991, LIVER, V11, P143; Wong LL, 1997, ARCH INTERN MED, V157, P1429, DOI 10.1001/archinte.157.13.1429; YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13; YOUSUF M, 1992, SCAND J GASTROENTERO, V27, P812, DOI 10.3109/00365529209011189; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; 1995, DRUG TOPICS RED BOOK	49	151	151	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					866	+		10.7326/0003-4819-127-10-199711150-00002	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382364				2022-12-01	WOS:A1997YF54500002
J	Swanton, C; Mann, DJ; Fleckenstein, B; Neipel, F; Peters, G; Jones, N				Swanton, C; Mann, DJ; Fleckenstein, B; Neipel, F; Peters, G; Jones, N			Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins	NATURE			English	Article							DEPENDENT KINASES; KAPOSIS-SARCOMA; DNA-SEQUENCES; IDENTIFICATION; TRANSITION; CANCER; P27	The passage of mammalian cells through the restriction point into the S phase of the cell cycle is regulated by the activities of Cdk4 and Cdk6 complexed with the D-type cyclins and by cyclin E/Cdk2 (refs 1-3). The activities of these holoenzymes are constrained by CDK inhibitory proteins(4,5). The importance of the restriction point is illustrated by its deregulation in many tumour cells(6,7) and upon infection with DNA tumour viruses(8). Here we describe the properties of cyclins encoded by two herpesviruses, herpesvirus saimiri (HVS) which can transform blood lymphocytes(9) and induce malignancies of lymphoid origin in New World primates(9,10) and human herpesvirus 8 (HHV8) implicated as a causative agent of Kaposi's sarcoma and body cavity lymphomas(11,12). Both viral cyclins form active kinase complexes with Cdk6 that are resistant to inhibition by the CDK inhibitors p16(Ink4a), p21(Cip1) and p27(Kip1). Furthermore, ectopic expression of a viral cyclin prevents G1 arrest imposed by each inhibitor and stimulates cell-cycle progression in quiescent fibroblasts. These results suggest a new mechanism for deregulation of the cell cycle and indicate that the viral cyclins may contribute to the oncogenic nature of these viruses.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNIV ERLANGEN NURNBERG,INST KLIN & MOL VIROL,D-8520 ERLANGEN,GERMANY	Cancer Research UK; University of Erlangen Nuremberg				Swanton, Charles/0000-0002-4299-3018				BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P252; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; KATO J, 1993, GENE DEV, V7, P331; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	25	273	282	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					184	187		10.1038/36606	http://dx.doi.org/10.1038/36606			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367157				2022-12-01	WOS:A1997YF49400057
J	Butler, RN				Butler, RN			Population aging and health	BRITISH MEDICAL JOURNAL			English	Article											Butler, RN (corresponding author), MT SINAI MED CTR,INT LONGEV CTR US,NEW YORK,NY 10029, USA.							BRINSTOCK RH, IN PRESS LIFE OLDER; HOBBS FB, 1996, CURRENT POPULATION R, P23; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593	3	81	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1082	1084		10.1136/bmj.315.7115.1082	http://dx.doi.org/10.1136/bmj.315.7115.1082			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366742	Green Published			2022-12-01	WOS:A1997YD44500033
J	RiesgoEscovar, JR; Hafen, E				RiesgoEscovar, JR; Hafen, E			Common and distinct roles of DFos and DJun during Drosophila development	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; C-FOS; GENE-EXPRESSION; NULL MUTATION; AP-1 COMPLEX; CELL FATE; HOMOLOG; TRANSCRIPTION; MORPHOGENESIS; PATHWAYS	The Drosophila homolog of c-Jun regulates epithelial cell shape changes during the process of dorsal closure in mid-embryogenesis. Here, mutations in the DFos gene are described. In dorsal closure, DFos cooperates with DJun by regulating the expression of dpp; Dpp acts as a relay signal that triggers cell shape changes and DFos expression in neighboring cells. In addition to the joint requirement of DFos and DJun during dorsal closure, DFos functions independently of DJun during early stages of embryogenesis. These findings demonstrate common and distinct roles of DFos and DJun during embryogenesis and suggest a conserved link between AP-1 (activating protein-1) and TGF-beta (transforming growth factor-beta) signaling during epithelial cell shape changes.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich								BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLENZ M, 1996, SEMIN CELL DEV BIOL, V7, P113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; FEHON RG, 1994, DEVELOPMENT, V120, P545; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Heitzler P, 1996, GENETICS, V143, P1271; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JURGENS G, 1984, ROUX ARCH DEVEL BIOL, V193, P183; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; LINDSEY DL, 1992, GENETICS BIOL DROSOP; LIU ZG, 1997, CURR OPIN CELL BIOL, V9, P240; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; RAY RP, 1991, DEVELOPMENT, V113, P35; Riese J, 1997, DEVELOPMENT, V124, P3353; RIESGOESCOVAR J, UNPUB; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; Rusch J, 1997, DEVELOPMENT, V124, P303; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; TATEI K, 1995, MECH DEVELOP, V51, P157, DOI 10.1016/0925-4773(95)00349-5; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	35	122	125	2	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					669	672		10.1126/science.278.5338.669	http://dx.doi.org/10.1126/science.278.5338.669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381174				2022-12-01	WOS:A1997YC32300050
J	David, RJ; Collins, JW				David, RJ; Collins, JW			Differing birth weight among infants of US-born blacks, African-born blacks, and US-born whites	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; PRETERM DELIVERY; RACIAL-DIFFERENCES; WOMEN; PREGNANCY; MORTALITY; HEALTH; RACE; OUTCOMES; AGE	Background In the United States, the birth weights of infants of black women are lower than those of infants of white women. The extent to which the lower birth weights among blacks are related to social or genetic factors is unclear. Methods We used vital records for 1980 through 1995 from Illinois to determine the distribution of birth weights among infants born to three groups of women - U.S.-born blacks, African-born blacks, and U.S.-born whites. Results The mean birth weight of 44,046 infants of U.S.-born white women was 3446 g, that of 3135 infants of African-born black women was 3333 g, and that of 43,322 infants of U.S.-born black women was 3089 g. The incidence of low birth weight (weight less than 2500 g) was 13.2 percent among infants of U.S.-born black women and 7.1 percent among infants of African-born black women, as compared with 4.3 percent among infants of U.S, born white women (relative risks, 3.1 and 1.6, respectively). Among the women at lowest risk (those 20 to 39 years old, with 12 years of education for themselves and their spouses, early prenatal care, gravida 2 or 3, and no previous fetal loss), the rate of low birth weight in infants of African-born black women (3.6 percent) was closer to the rate in infants of U.S, born white women (2.4 percent), and the rate in infants of U.S.-born black women remained high (7.5 percent). Conclusions The birth-weight patterns of infants of African-born black women and U.S.-born white women are more closely related to one another than to the birth weights of infants of U.S.-born black women. (C) 1997, Massachusetts Medical Society.	UNIV ILLINOIS,SCH MED,DEPT PEDIAT,CHICAGO,IL; CHILDRENS MEM HOSP,DIV NEONATOL,CHICAGO,IL 60614; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	David, RJ (corresponding author), COOK CTY CHILDRENS HOSP,DIV NEONATOL,700 S WOOD ST,CHICAGO,IL 60612, USA.							ADAMS J, 1973, SCIENCE, V180, P1137, DOI 10.1126/science.180.4091.1137; AMINI SB, 1994, OBSTET GYNECOL, V83, P342; *BUR CENS, 1993, CP215 BUR CENS; CABRAL H, 1990, AM J PUBLIC HEALTH, V80, P70, DOI 10.2105/AJPH.80.1.70; CHAKRABORTY R, 1991, Ethnicity and Disease, V1, P245; COLLINS JW, 1990, AM J PUBLIC HEALTH, V80, P679, DOI 10.2105/AJPH.80.6.679; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; DAVID R J, 1991, Ethnicity and Disease, V1, P236; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FOX SH, 1994, AM J EPIDEMIOL, V139, P1008, DOI 10.1093/oxfordjournals.aje.a116940; Friedman Daniel J., 1993, Ethnicity and Disease, V3, P255; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; GLASS B, 1953, AM J HUM GENET, V5, P11; GOLDENBERG RL, 1991, OBSTET GYNECOL, V78, P782; HULSEY TC, 1991, AM J OBSTET GYNECOL, V164, P1299, DOI 10.1016/0002-9378(91)90703-T; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; KLEINMAN JC, 1991, AM J DIS CHILD, V145, P194, DOI 10.1001/archpedi.1991.02160020086023; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; KRIEGER N, 1993, AM J PREV MED, V9, P82, DOI 10.1016/S0749-3797(18)30666-4; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; LITTLE RE, 1987, AM J HUM GENET, V40, P512; MAGNUS P, 1984, CLIN GENET, V26, P289; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; NAYLOR AF, 1967, ANN HUM GENET, V31, P71, DOI 10.1111/j.1469-1809.1967.tb02021.x; Oliver Roland, 1988, SHORT HIST AFRICA; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; REED TE, 1969, SCIENCE, V165, P762, DOI 10.1126/science.165.3895.762; ROWLEY DL, 1993, AM J PREV MED, V9, P1; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SHEEHAN TJ, 1995, NEW ENGL J MED, V333, P386; VALANIS BM, 1979, SOC BIOL, V26, P189; WASSE H, 1994, AM J PUBLIC HEALTH, V84, P1505, DOI 10.2105/AJPH.84.9.1505; WILCOX A, 1990, J PEDIATR-US, V116, P7, DOI 10.1016/S0022-3476(05)81638-5; WILCOX AJ, 1983, INT J EPIDEMIOL, V12, P314, DOI 10.1093/ije/12.3.314; Wildschut H I, 1991, Paediatr Perinat Epidemiol, V5, P363, DOI 10.1111/j.1365-3016.1991.tb00722.x; Witzig R, 1996, ANN INTERN MED, V125, P675, DOI 10.7326/0003-4819-125-8-199610150-00008	37	335	339	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1209	1214		10.1056/NEJM199710233371706	http://dx.doi.org/10.1056/NEJM199710233371706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337381				2022-12-01	WOS:A1997YB71800006
J	Duhamel, JR; Bremmer, F; BenHamed, S; Graf, W				Duhamel, JR; Bremmer, F; BenHamed, S; Graf, W			Spatial invariance of visual receptive fields in parietal cortex neurons	NATURE			English	Article							RESPONSE PROPERTIES; MACAQUE MONKEY; AREA MT; SPACE; CONNECTIONS; MOVEMENT; MEMORY; GAZE	Spatial information is conveyed to the primary visual cortex in retinal coordinates, Movement trajectory programming, however, requires a transformation from this sensory frame of reference into a frame appropriate for the selected part of the body, such as the eye, head or arms(1-4). To achieve this transformation, visual information must be combined with information from other sources: for instance, the location of an object of interest can be defined with respect to the observer's head if the position of the eyes in the orbit is known and is added to the object's retinal coordinates, Here we show that in a subdivision of the monkey parietal lobe, the ventral intraparietal area (VIP), the activity of visual neurons is modulated by eye-position signals, as in many other areas of the cortical visual system(5-10). We find that individual receptive fields of a population of VIP neurons are organized along-a continuum, from eye to head coordinates, In the latter case, neurons encode the azimuth and/or elevation of a visual stimulus, independently of the direction in which the eyes are looking, thus representing spatial locations explicitly in at least a head-centred frame of reference.	RUHR UNIV BOCHUM,DEPT ZOOL & NEUROBIOL,D-44780 BOCHUM,GERMANY	Ruhr University Bochum	Duhamel, JR (corresponding author), COLL FRANCE,CNRS,LAB PHYSIOL PERCEPT & ACT,11 PL MARCELIN BERTELOT,F-75005 PARIS,FRANCE.		Duhamel, Jean-René/M-4723-2017; Bremmer, Frank/F-3268-2012; Ben Hamed, Suliann/O-6070-2014	Duhamel, Jean-René/0000-0003-0210-1027; Bremmer, Frank/0000-0003-1597-7407; Ben Hamed, Suliann/0000-0003-1510-7284				ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; Bernshtein N. A, 1967, COORDINATION REGULAT; BOUSSAOUD D, 1993, EXP BRAIN RES, V91, P202; Bremmer F, 1997, J NEUROPHYSIOL, V77, P944, DOI 10.1152/jn.1997.77.2.944; BREMMER F, 1997, CONTRIBUTION PARIETA, P619; Colby CL, 1996, COGNITIVE BRAIN RES, V5, P105, DOI 10.1016/S0926-6410(96)00046-8; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P487; Duhamel J.-R, 1991, BRAIN SPACE; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; DUHAMEL JR, IN PRESS J NEUROPHYS; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; GALLETTI C, 1989, J NEUROSCI, V9, P1112; Galletti C, 1995, EUR J NEUROSCI, V7, P2486, DOI 10.1111/j.1460-9568.1995.tb01047.x; GALLETTI C, 1993, EXP BRAIN RES, V96, P221; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; HYVARINEN J, 1981, BRAIN RES, V206, P287, DOI 10.1016/0006-8993(81)90533-3; LEWIS JW, 1996, SOC NEUR ABSTR, V22; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; MATELLI M, 1994, SOC NEUR ABSTR, V20; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; TANNE J, 1996, SOC NEUR ABSTR, V22; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P190, DOI 10.1002/cne.902480204; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	29	427	430	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					845	848		10.1038/39865	http://dx.doi.org/10.1038/39865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349815				2022-12-01	WOS:A1997YC14800056
J	Papavasiliou, F; Casellas, R; Suh, HY; Qin, XF; Besmer, E; Pelanda, R; Nemazee, D; Rajewsky, K; Nussenzweig, MC				Papavasiliou, F; Casellas, R; Suh, HY; Qin, XF; Besmer, E; Pelanda, R; Nemazee, D; Rajewsky, K; Nussenzweig, MC			V(D)J recombination in mature B cells: A mechanism for altering antibody responses	SCIENCE			English	Article							HEAVY-CHAIN GENE; GERMINAL-CENTERS; ALLELIC EXCLUSION; TRANSGENIC MICE; IMMUNE-RESPONSE; MATURATION; RAG-1; REARRANGEMENT; LYMPHOCYTES; GENERATION	The clonal selection theory states that B lymphocytes producing high-affinity immunoglobulins are selected from a pool of cells undergoing antibody gene mutation. Somatic hypermutation is a well-documented mechanism for achieving diversification of immune responses in mature B cells. Antibody genes were also found to be modified in such cells in germinal centers by recombination of the variable (V), diversity (D), and joining (J) segments. The ability to alter immunoglobulin expression by V(D)J recombination in the selective environment of the germinal center may be an additional mechanism for inactivation or diversification of immune responses.	ROCKEFELLER UNIV,MOL IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; INST IMMUNOL,D-79108 FREIBURG,GERMANY; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLOGNE,GENET INST,WAYERTAL,GERMANY	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Jewish Health; University of Cologne			Nussenzweig, Michel/AAE-7292-2019	Rajewsky, Klaus/0000-0002-6633-6370; QIN, FRANK XIAOFENG/0000-0002-5395-0304	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033608, R01AI033890, R29AI033890] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33890, R01 AI033608] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BURNET FM, 1959, CLONAL SELECTION THE; CASELLAS R, UNPUB; CEBRA JJ, 1966, J EXP MED, V123, P547, DOI 10.1084/jem.123.3.547; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hikida M, 1997, J IMMUNOL, V158, P2509; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Kelsoe G, 1996, Semin Immunol, V8, P179, DOI 10.1006/smim.1996.0022; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1994, IMMUNOL REV, V137, P173, DOI 10.1111/j.1600-065X.1994.tb00664.x; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEARSE M, 1988, P NATL ACAD SCI USA, V85, P6082, DOI 10.1073/pnas.85.16.6082; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; TALMAGE DW, 1959, SCIENCE, V129, P1643, DOI 10.1126/science.129.3364.1643; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P825; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	44	208	213	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					298	301		10.1126/science.278.5336.298	http://dx.doi.org/10.1126/science.278.5336.298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323210				2022-12-01	WOS:A1997YA56400047
J	Sames, D; Chen, XT; Danishefsky, SJ				Sames, D; Chen, XT; Danishefsky, SJ			Convergent total synthesis of a tumour-associated mucin motif	NATURE			English	Article							GLYCOSYL PHOSPHITES; OLIGOSACCHARIDES; CELLS; CARBOHYDRATE; RECOGNITION; LEUKOSIALIN; PHOSPHATES; VACCINES; ANTIGENS; GLYCANS	Synthetic glycoconjugates that mimic cell-surface tumour antigens (glycolipids or glycoproteins with unusual carbohydrate structural motifs) have been shown to trigger humoral responses in murine and human immune systems(1-3). This raises the exciting possibility of inducing active immunity with fully synthetic carbohydrate vaccines, particularly if vaccine compounds can be synthesized that resemble the surface environment of transformed cells even more closely. Glycopeptides seem particularly suitable for this purpose. In contrast to most glycolipids and the carbohydrates themselves, glycopeptides bind to major histocompatibility complex molecules, and, in favourable cases, can stimulate T cells and lead to the expression of receptors that recognize the carbohydrate part of a glycopeptide with high specificity(4-8). The preparation of glycopeptides and glycoproteins remains, however, a difficult challenge(9-12): earlier synthesis methods have been inefficient, and established cloning approaches that allow engineering of global glycopatterns produce only heterogeneous glycoproteins(13). Here we report an efficient strategy of the synthesis of tumour-associated mucin glycopeptides with clustered trisaccharide glycodomains corresponding to the (2,6)-sialyl T antigen. Our approach involves construction of the complete glycodomain in the first stage, followed by convergent coupling to amino acid residues and subsequent incorporation of the glycosyl amino acid units into a peptide chain. This general strategy allows the assembly of molecules in which selected glycoforms can be incorporated at any desired position of the peptide chain. The resultant fully synthetic O-linked glycopeptide clusters are the closest homogeneous mimics of cell-surface mucins at present available, and so are promising compounds for the development of anticancer vaccines.	MEM SLOAN KETTERING CANC CTR,BIOORGAN CHEM LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Memorial Sloan Kettering Cancer Center; Columbia University								Bill RM, 1996, CHEM BIOL, V3, P145, DOI 10.1016/S1074-5521(96)90255-0; BILODEAU MT, 1996, ANGEW CHEM INT EDIT, V35, P1381; Carlstedt I, 1997, BIOCHEM SOC T, V25, P214, DOI 10.1042/bst0250214; DECK B, 1995, J IMMUNOL, V155, P1074; Elofsson M, 1997, TETRAHEDRON, V53, P369, DOI 10.1016/S0040-4020(96)00992-1; FINN OJ, 1995, IMMUNOL REV, V145, P61, DOI 10.1111/j.1600-065X.1995.tb00077.x; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; IIJIMA H, 1989, CARBOHYD RES, V186, P95, DOI 10.1016/0008-6215(89)84008-X; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; JENSON T, 1997, J IMMUNOL, P3769; JIANG JJ, 1994, SYNTHETIC COMMUN, V24, P187, DOI 10.1080/00397919408013818; KONDO H, 1994, J ORG CHEM, V59, P864, DOI 10.1021/jo00083a032; KUNZ H, 1997, GLYCOPEPTIDES RELATE, P23; Liebe B, 1997, ANGEW CHEM INT EDIT, V36, P618, DOI 10.1002/anie.199706181; MARTIN TJ, 1993, GLYCOCONJUGATE J, V10, P16, DOI 10.1007/BF00731182; MOURITSEN S, 1994, EUR J IMMUNOL, V24, P1066, DOI 10.1002/eji.1830240509; NAKAHARA Y, 1994, ACS SYM SER, V560, P249; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; Paulsen H, 1997, J CHEM SOC PERK T 1, P281, DOI 10.1039/a604123j; PAULSEN H, 1988, LIEBIGS ANN CHEM, P75; Qui D., 1997, TETRAHEDRON LETT, V38, P45; Ragupathi G, 1997, ANGEW CHEM INT EDIT, V36, P125, DOI 10.1002/anie.199701251; SAITOH O, 1991, CANCER RES, V51, P2854; SCHMIDT RR, 1994, ADV CARBOHYD CHEM BI, V50, P84; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SIM MM, 1993, J AM CHEM SOC, V115, P2260, DOI 10.1021/ja00059a023; SZABO L, 1995, CARBOHYD RES, V274, P11, DOI 10.1016/0008-6215(95)00016-M; TOYOKUNI T, 1995, CHEM SOC REV, V24, P231, DOI 10.1039/cs9952400231; TSUDA T, 1996, J CHEM SOC CHEM COMM, P2779; Witte K, 1997, J AM CHEM SOC, V119, P2114, DOI 10.1021/ja961846z	31	102	105	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					587	591		10.1038/39292	http://dx.doi.org/10.1038/39292			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335496				2022-12-01	WOS:A1997YA00800055
J	Vallet, V; Chraibi, A; Gaeggeler, HP; Horisberger, JD; Rossier, BC				Vallet, V; Chraibi, A; Gaeggeler, HP; Horisberger, JD; Rossier, BC			An epithelial serine protease activates the amiloride-sensitive sodium channel	NATURE			English	Article							TOAD URINARY-BLADDER; SUBUNITS; CELLS; MUTATIONS	Sodium balance, and ultimately blood pressure and extracellular fluid volume, is maintained by precise regulation of the activity of the epithelial sodium channel (ENaC)(1-3). In a Xenopus kidney epithelial cell Line (A6), exposure of the apical membrane to the protease inhibitor aprotinin reduces transepithelial sodium transport. Sodium-channel activity can be restored by subsequent exposure to the nonspecific protease trypsin. Using A6 cells and a functional complementation assay to detect increases in ENaC activity, we have cloned a 329-residue protein belonging to the serine protease family. We show that coexpression of this protein with ENaC in Xenopus oocytes increases the activity of the sodium channel by two- to threefold. This channel-activating protease (CAP1) is expressed in kidney, gut, lung, skin and ovary. Sequence analysis predicts that CAP1 is a secreted and/or glycosylphosphatidylinositol-anchored protein: ENaC activity would thus be regulated by the activity of a protease expressed at the surface of the same cell. This previously undiscovered mechanism for autocrine regulation may apply to other ion channels, in particular to members of the ENaC family that are present in neurons and epithelial cells.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	University of Lausanne			Horisberger, Jean-Daniel/A-2538-2009					CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHRAIBI A, UNPUB J GEN PHYSL; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANDLER JS, 1979, P NATL ACAD SCI USA, V76, P4151, DOI 10.1073/pnas.76.8.4151; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; LEWIS SA, 1991, J MEMBRANE BIOL, V122, P77, DOI 10.1007/BF01872741; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; ORCE GG, 1980, AM J PHYSIOL, V239, pF459, DOI 10.1152/ajprenal.1980.239.5.F459; PUOTI A, 1995, AM J PHYSIOL, V38, pC188; ROSSIER BC, 1997, J AM SOC NEPHROL, V9, P980; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483	18	424	432	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					607	610		10.1038/39329	http://dx.doi.org/10.1038/39329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335501				2022-12-01	WOS:A1997YA00800061
J	Bruce, ME; Will, RG; Ironside, JW; McConnell, I; Drummond, D; Suttie, A; McCardle, L; Chree, A; Hope, J; Birkett, C; Cousens, S; Fraser, H; Bostock, CJ				Bruce, ME; Will, RG; Ironside, JW; McConnell, I; Drummond, D; Suttie, A; McCardle, L; Chree, A; Hope, J; Birkett, C; Cousens, S; Fraser, H; Bostock, CJ			Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; SCRAPIE INCUBATION; DIFFERENT STRAINS; RODENTS; LINES; SHEEP	There are many strains of the agents that cause transmissible spongiform encephalopathies (TSEs) or 'prion' diseases, These strains are distinguishable by their disease characteristics in experimentally infected animals, in particular the incubation periods and neuropathology they produce in panels of inbred mouse strains(1-4). We have shown that the strain of agent from cattle affected by bovine spongiform encephalopathy (BSE) produces a characteristic pattern of disease in mice that is retained after experimental passage through a variety of intermediate species(5-7). This BSE 'signature' has also been identified in transmissions to mice of TSEs of domestic cats and two exotic species of ruminant(6,8), providing the first direct evidence for the accidental spread of a TSE between species, Twenty cases of a clinically and pathologically atypical form of Creutzfeldt-Jakob disease (CJD), referred to as 'new variant' CJD (vCJD)(9), have been recognized in unusually young people in the United Kingdom, and a further case has been reported in France(10). This has raised serious concerns that BSE may have spread to humans, putatively by dietary exposure, Here we report the interim results of transmissions of sporadic CJD and VJD to mice, Our data provide strong evidence that the same agent strain is involved in both BSE and vCJD.	WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; INST ANIM HLTH,NEWBURY RG20 7NN,BERKS,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND	University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of London; London School of Hygiene & Tropical Medicine	Bruce, ME (corresponding author), INST ANIM HLTH,BBSRC MRC NEUROPATHOGENESIS UNIT,W MAINS RD,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND.		Hope, James/C-4966-2011	Ironside, James/0000-0001-5869-2108				Bell JE, 1997, NEUROPATH APPL NEURO, V23, P26, DOI 10.1111/j.1365-2990.1997.tb01182.x; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; CARP RI, 1991, J GEN VIROL, V72, P293, DOI 10.1099/0022-1317-72-2-293; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1971, MOL GEN GENET, V112, P73, DOI 10.1007/BF00266934; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; FARQUHAR CF, 1994, TRANSMISSIBLE SPONGI, P301; Foster JD, 1996, VET REC, V138, P546, DOI 10.1136/vr.138.22.546; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; FRASER H, 1994, VET REC, V134, P449, DOI 10.1136/vr.134.17.449; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; Fraser H, 1996, BRAIN PATHOL, V6, P89, DOI 10.1111/j.1750-3639.1996.tb00788.x; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; Hill AF, 1997, LANCET, V350, P188, DOI 10.1016/S0140-6736(05)62356-2; Kirkwood B., 1988, BR K ESSENTIALS MED; Mardia K.V., 1979, MULTIVARIATE ANAL; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; Tateishi J, 1996, SEMIN VIROL, V7, P175, DOI 10.1006/smvy.1996.0022; TATEISHI J, 1979, ANN NEUROL, V5, P581, DOI 10.1002/ana.410050616; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	28	1586	1630	1	104	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					498	501		10.1038/39057	http://dx.doi.org/10.1038/39057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333239				2022-12-01	WOS:A1997XY90900057
J	Novacek, MJ; Rougier, GW; Wible, JR; McKenna, MC; Dashzeveg, D; Horovitz, I				Novacek, MJ; Rougier, GW; Wible, JR; McKenna, MC; Dashzeveg, D; Horovitz, I			Epipubic bones in eutherian mammals from the late Cretaceous of Mongolia	NATURE			English	Article							FLAMING CLIFFS; DINOSAUR	An important transformation in the evolution of mammals was the loss of the epipubic bones. These are elements projecting anteriorly from the pelvic girdle into the abdominal region in a variety of Mesozoic mammals, related tritylodonts, marsupials and monotremes but not in living eutherian (placental) mammals(1-3). Here we describe a new eutherian from the Late Cretaceous period of Mongolia, and report the first record of epipubic bones in two distinct eutherian lineages. The presence of epipubic bones and other primitive features suggests that these groups occupy a basal position in the Eutheria. It has been argued that the epipubic bones support the pouch in living mammals(1,3,4), but epipubic bones have since been related to locomotion and suspension of the litter mass of several attached, lactating offspring(5). The loss of the epipubic bones in eutherians can be related to the evolution of prolonged gestation, which would not require prolonged external attachment of altricial young. Thus the occurrence of epipubic bones in two Cretaceous eutherians suggests that the dramatic modifications connected with typical placental reproduction(3,6,7) may have been later events in the evolution of the Eutheria.	UNIV LOUISVILLE, SCH MED, DEPT ANAT SCI & NEUROBIOL, LOUISVILLE, KY 40292 USA; MONGOLIAN ACAD SCI, INST GEOL, ULAANBAATAR, MONGOLIA	University of Louisville; Mongolian Academy of Sciences	Novacek, MJ (corresponding author), AMER MUSEUM NAT HIST, DEPT VERTEBRATE PALEONTOL, NEW YORK, NY 10024 USA.							DASHZEVEG D, 1995, NATURE, V374, P446, DOI 10.1038/374446a0; FOURIE S, 1962, NAVORSINGE NASIONALE, V2, P7; GREGORY WILLIAM K., 1926, AMER MUS NOVITATES, V225, P1; JELLISON WL, 1945, J MAMMAL, V26, P146, DOI 10.2307/1375090; KIELAN-JAWOROWSKA Z, 1975, Palaeontologia Polonica, V33, P5; Kielan-Jaworowska Z, 1981, PALAEONTOLOGIA POLON, V42, P25; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSK.Z, 1977, PALAEONTOL POL, V37, P55; KIELANJAWOROWSKA Z, 1975, NATURE, V255, P698, DOI 10.1038/255698a0; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; LECHE W, 1891, BIOL FOREN FORHANDL, V3, P120; LILLEGRAVEN JA, 1987, BIOL J LINN SOC, V32, P281, DOI 10.1111/j.1095-8312.1987.tb00434.x; Lilligraven J. A., 1969, Paleontological Contributions University of Kansas, VNo. 50, P1; MACPHEE RDE, 1993, MAMMAL PHYLOGENY : PLACENTALS, P13; MARSHALL LG, 1979, ZOOL J LINN SOC-LOND, V66, P369, DOI 10.1111/j.1096-3642.1979.tb01914.x; McKenna MC, 1975, PHYLOGENY PRIMATES, P2146, DOI [10.1007/978-1-4684-2166-8_2, DOI 10.1007/978-1-4684-2166-8_2]; NORELL MA, 1995, NATURE, V378, P774, DOI 10.1038/378774a0; NORELL MA, 1994, SCIENCE, V266, P779, DOI 10.1126/science.266.5186.779; NOVACEK MJ, 1986, B AM MUS NAT HIST, V183, P1; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NOVACEK MJ, 1994, SCI AM, V271, P60, DOI 10.1038/scientificamerican1294-60; Reig O.A., 1987, P1; RENFREE MB, 1993, MAMMAL PHYLOGENY, P4; ROUGIER G. W., 1993, THESIS U BUENOS AIRE; Springer Mark S., 1997, P129; Tyndale-Biscoe CH., 1987, REPROD PHYSL MARSUPI; VAUGHN PETER PAUL, 1956, JOUR ELISHA MITCHELL SCI SOC, V72, P243; WHITE TD, 1989, J THEOR BIOL, V139, P343, DOI 10.1016/S0022-5193(89)80213-9	29	92	97	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					483	486		10.1038/39020	http://dx.doi.org/10.1038/39020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333234				2022-12-01	WOS:A1997XY90900052
J	Solomon, CG; Willett, WC; Carey, VJ; RichEdwards, J; Hunter, DJ; Colditz, GA; Stampfer, MJ; Speizer, FE; Spiegelman, D; Manson, JE				Solomon, CG; Willett, WC; Carey, VJ; RichEdwards, J; Hunter, DJ; Colditz, GA; Stampfer, MJ; Speizer, FE; Spiegelman, D; Manson, JE			A prospective study of pregravid determinants of gestational diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; PHYSICAL-ACTIVITY; INSULIN-SECRETION; CIGARETTE-SMOKING; RISK-FACTORS; WEIGHT-GAIN; WOMEN; PREVALENCE; POPULATION; CRITERIA	Context.-Gestational diabetes mellitus (GDM) affects 3% to 5% of pregnancies. Knowledge of risk factors for GDM is needed to identify possible preventive strategies. Objective.-To assess whether recognized determinants of non-insulin-dependent diabetes mellitus also may be markers for increased risk of GDM. Design.-Prospective cohort study. Setting.-The Nurses' Health Study II, which involves female US nurses aged 25 to 42 years at entry. Participants.-The analyses included 14 613 women without previous GDM or other known diabetes who reported a singleton pregnancy between 1990 and 1994. Of these women, 722 (4.9%) reported a new diagnosis of GDM. Main Outcome Measure: Self-report of GDM, validated by medical record review in a subset. Results.-In multivariate analyses including age, pregravid body mass index (BMI), and other GDM risk factors, the risk for GDM increased significantly with increasing maternal age (P for trend, <.01) and family history of diabetes mellitus (relative risk, 1.68; 95% confidence interval [CI], 1.39-2.04). Relative risks for GDM were 2.13 (95% CI, 1.65-2.74) for pregravid BMI of 25 to 29.9 kg/m(2) and 2.90 (95% CI, 2.15-3.91) for BMI of 30 kg/m(2) or more (vs BMI of <20 kg/m(2)). Risk for GDM increased with greater weight gain in early adulthood, and it also increased among nonwhite women. Pregravid current smokers had a relative risk for GDM of 1.43 (95% CI, 1.14-1.80), and pregravid vigorous exercise was associated with a nonsignificant reduction in GDM risk. Conclusions.-Advanced maternal age, family history of diabetes mellitus, nonwhite ethnicity, higher BMI, weight gain in early adulthood, and cigarette smoking predict increased GDM risk. These observations may facilitate the identification of women at particular risk for GDM and suggest potential strategies for reducing this risk even before a woman becomes pregnant, such as avoiding substantial weight gain and smoking.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV GEN MED,SECT CLIN EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, ENDOCRINE HYPERTENS DIV, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT MATERNAL & CHILD HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Solomon, CG (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA050385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50385] Funding Source: Medline; NIDDK NIH HHS [DK-36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAULIEU MD, 1992, CAN MED ASSOC J, V147, P435; BELL DSH, 1990, DIABETES CARE, V13, P1196, DOI 10.2337/diacare.13.11.1196; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; BUNG P, 1991, DIABETES, V40, P182, DOI 10.2337/diab.40.2.S182; CHARLES MA, 1993, DIABETES CARE, V16, P593, DOI 10.2337/diacare.16.4.593; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COX NJ, 1994, DIABETES, V43, P166, DOI 10.2337/diab.43.1.166; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; DOOLEY SL, 1991, INT J GYNECOL OBSTET, V35, P13, DOI 10.1016/0020-7292(91)90057-C; DORNHORST A, 1992, DIABETIC MED, V9, P820, DOI 10.1111/j.1464-5491.1992.tb01900.x; GOLDMAN JA, 1967, ISRAEL J MED SCI, V3, P561; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; HARRIS MI, 1991, DIABETES CARE, V14, P639, DOI 10.2337/diacare.14.7.639; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Kanders B., 1991, CONNS CURRENT THERAP, P524; KJOS SL, 1990, AM J OBSTET GYNECOL, V163, P93, DOI 10.1016/S0002-9378(11)90676-0; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUHL C, 1991, DIABETES, V40, P18, DOI 10.2337/diab.40.2.S18; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MARTIN AO, 1985, AM J OBSTET GYNECOL, V151, P471, DOI 10.1016/0002-9378(85)90272-8; METZGER BE, 1993, DIABETES CARE, V16, P1598, DOI 10.2337/diacare.16.12.1598; OSULLIVAN JB, 1973, AM J OBSTET GYNECOL, V116, P895; OSULLIVAN JB, 1982, JAMA-J AM MED ASSOC, V248, P949, DOI 10.1001/jama.248.8.949; OSULLIVAN JB, 1984, CARBOHYD METABOL, P174; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; SIMMONS D, 1995, J INTERN MED, V237, P315, DOI 10.1111/j.1365-2796.1995.tb01181.x; Solomon CG, 1996, DIABETES CARE, V19, P12, DOI 10.2337/diacare.19.1.12; THOMAS F, 1994, DIABETES, V43, P63, DOI 10.2337/diabetes.43.1.63; TROY LM, 1995, INT J OBESITY, V19, P570; VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	36	534	543	1	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1078	1083		10.1001/jama.278.13.1078	http://dx.doi.org/10.1001/jama.278.13.1078			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315766				2022-12-01	WOS:A1997XX30300031
J	Baylin, SB				Baylin, SB			Tying it all together: Epigenetics, genetics, cell cycle, and cancer	SCIENCE			English	Editorial Material							DNA-METHYLTRANSFERASE ACTIVITY; EMBRYONIC STEM-CELLS; DE-NOVO METHYLATION; CPG ISLAND; NUCLEAR ANTIGEN; 5-METHYLCYTOSINE CONTENT; DEPENDENT KINASES; REPLICATION; MOUSE; PCNA		DEPT MED,BALTIMORE,MD 21231		Baylin, SB (corresponding author), JOHNS HOPKINS COMPREHENS CANC CTR,BALTIMORE,MD 21231, USA.							Ahuja N, 1997, CANCER RES, V57, P3370; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BAYLIN SB, IN PRESS ADV CANC RE; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FEINBERG AP, 1988, CANCER RES, V48, P1159; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KO IJ, 1996, GENE DEV, V10, P1054; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAIRD PW, 1994, HUM MOL GENET, V3; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092	61	160	169	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1948	1949		10.1126/science.277.5334.1948	http://dx.doi.org/10.1126/science.277.5334.1948			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9333948				2022-12-01	WOS:A1997XX84900028
J	Gardner, SG; Bingley, PJ; Sawtell, PA; Weeks, S; Gale, EAM; Bell, RAF; Dunger, DB; Mukhtar, A; OMalley, BP; Silk, BR; Smith, EH; Scott, RDM; Latham, PJ; Lakhani, PK; Paton, RC; Ackland, FM; Fox, CJ; Griffin, NK; Matthews, DR; Neil, HAW; Mann, NP; Simpson, HCR; Brown, RS; Knight, AH; Cowen, JM; Pearce, JC; Cheetham, CH; Gallen, IW; Sandler, L; Westcott, T				Gardner, SG; Bingley, PJ; Sawtell, PA; Weeks, S; Gale, EAM; Bell, RAF; Dunger, DB; Mukhtar, A; OMalley, BP; Silk, BR; Smith, EH; Scott, RDM; Latham, PJ; Lakhani, PK; Paton, RC; Ackland, FM; Fox, CJ; Griffin, NK; Matthews, DR; Neil, HAW; Mann, NP; Simpson, HCR; Brown, RS; Knight, AH; Cowen, JM; Pearce, JC; Cheetham, CH; Gallen, IW; Sandler, L; Westcott, T			Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD IDDM; MELLITUS; RISK; EUROPE; ONSET	Objectives: To monitor incidence of insulin dependent diabetes in children in Oxford health region since 1985, and to look for any evidence of disproportionate increase in children aged under 5, Design: Primary ascertainment of cases of childhood diabetes was by prospective registration of all patients with insulin dependent diabetes diagnosed before age 15 years between 1985 and 1996 and resident in Oxford region at time of diagnosis, This was supplemented by examination of centralised hospital discharge records and death certificates, Secondary case ascertainment was by postal surveys of general practitioners in 1987 and 1996, Setting: Area formerly administered by Oxford Regional Health Authority. Subjects: 1037 children presenting with insulin dependent diabetes under age of 15 years, Main outcome measures: Incidence of insulin dependent diabetes in children aged 0-4, 5-9, and 10-14 years during 1985-95, Results: Overall incidence of diabetes in children aged 0-15 was 18.6 cases/100 000/year and showed an annual increase of 4% from 1985 to 1996. This was mainly due to a rapid increase in children aged 0-4 years, in whom there was an annual increase of 11% (95% confidence interval 6% to 15%, P < 0.0001), while the annual increase in those aged 5-9 was 4% (0 to 7%, P = 0.05) and in those aged 10-14 was 1% (-2% to 4%, P = 0.55), Conclusions: Incidence of insulin dependent diabetes in children aged under 5 years has risen markedly in the Oxford region over the past decade, The cause of the increase is unknown, but environmental influences encountered before birth or in early postnatal life are likely to be responsible.	UNIV BRISTOL,SOUTHMEAD HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND; HORTON GEN HOSP,BANBURY,OXON,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; KETTERING DIST HOSP,KETTERING,NORTHANTS,ENGLAND; KING EDWARD VII HOSP,WINDSOR,ENGLAND; MILTON KEYNES DIST GEN HOSP,MILTON KEYNES,BUCKS,ENGLAND; NORTHAMPTON GEN HOSP,NORTHAMPTON,ENGLAND; RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND; ROYAL BERKSHIRE HOSP,READING RG1 5AN,BERKS,ENGLAND; STOKE MANDEVILLE HOSP,AYLESBURY HP21 8AL,BUCKS,ENGLAND; WEXHAM PK HOSP,SLOUGH SL2 4HL,BERKS,ENGLAND; WYCOMBE GEN HOSP,HIGH WYCOMBE,BUCKS,ENGLAND	Southmead Hospital; University of Bristol; University of Oxford; Radcliffe Infirmary; Royal Berkshire Hospital								BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BINGLEY PJ, IN PRESS DIABETES; BLOM L, 1991, DIABETOLOGIA, V34, P176, DOI 10.1007/BF00418272; BLOOM A, 1975, BRIT MED J, V2, P580; BURDEN AC, 1989, DIABETIC MED, V6, P334; DAHLQUIST GG, 1995, DIABETES, V44, P408, DOI 10.2337/diabetes.44.4.408; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; *DIAB EP RES INT G, 1990, DIABETES, V39, P858; Ellis TM, 1996, LANCET, V347, P1464, DOI 10.1016/S0140-6736(96)91690-6; GINSBERGFELLNER F, 1985, REV INFECT DIS, V7, P5170; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; GREEN A, 1985, DIABETOLOGIA, V28, P339; HENDERSON P, 1949, BRIT MED J, V1, P478, DOI 10.1136/bmj.1.4602.478; LEVYMARCHAL C, 1995, DIABETOLOGIA, V38, P823, DOI 10.1007/s001250050359; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PINKNEY JH, 1994, DIABETOLOGIA, V37, P70; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; STAINES A, 1993, DIABETOLOGIA, V36, P1282, DOI 10.1007/BF00400806; TUOMILEHTO J, 1991, DIABETOLOGIA, V34, P282, DOI 10.1007/BF00405089; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; VANDERAUWERA B, 1995, J CLIN ENDOCR METAB, V80, P2567, DOI 10.1210/jc.80.9.2567; WADSWORTH E, 1995, BRIT MED J, V310, P700, DOI 10.1136/bmj.310.6981.700	23	182	187	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					713	717		10.1136/bmj.315.7110.713	http://dx.doi.org/10.1136/bmj.315.7110.713			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314756	Green Published			2022-12-01	WOS:A1997XX67400022
J	Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H				Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H			Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis	ANNALS OF INTERNAL MEDICINE			English	Article							NASAL VENTILATION; NATURAL-HISTORY; PREDICTION; DISEASE	Background: Noninvasive positive-pressure ventilation may benefit patients with amyotrophic lateral sclerosis and respiratory insufficiency. Objective: To determine 1) whether patients tolerant of noninvasive positive-pressure ventilation have better survival than intolerant patients and 2) whether bulbar symptoms account for intolerance of noninvasive positive-pressure ventilation. Design: Observational cohort study. Setting: Tertiary care referral center. Patients: 39 patients with amyotrophic lateral sclerosis who were treated with noninvasive positive-pressure ventilation. Intervention: Noninvasive positive-pressure ventilation was started for patients with new orthopnea, new hypercapnia, or both. Patients were divided into two groups: those tolerant of and those intolerant of noninvasive positive-pressure ventilation. Results: The risk for death from onset of respiratory insufficiency was higher for intolerant patients than for tolerant patients. (relative risk, 3.1 [95% CI, 1.8 to 9.6]). Moderate or severe bulbar symptoms were more prevalent among intolerant patients than among tolerant patients (67% compared with 33%; P = 0.04). Conclusions: Among patients with amyotrophic lateral sclerosis, those who are tolerant of noninvasive positive-pressure ventilation have better survival than do those who are intolerant. Bulbar symptoms partially account for intolerance of noninvasive positive-pressure ventilation.	WAYNE STATE UNIV, SCH MED, DETROIT, MI 48201 USA; CLEVELAND CLIN FDN, DEPT PULM & CRIT CARE MED, CLEVELAND, OH 44195 USA; CLEVELAND CLIN FDN, DEPT NEUROL, CLEVELAND, OH 44195 USA	Wayne State University; Cleveland Clinic Foundation; Cleveland Clinic Foundation			Aboussouan, Loutfi/O-2317-2019	Aboussouan, Loutfi/0000-0003-2716-0904				BACH JR, 1993, CHEST, V104, P1553, DOI 10.1378/chest.104.5.1553; BACH JR, 1994, LANCET, V344, P752, DOI 10.1016/S0140-6736(94)92242-X; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BROOKS BR, 1991, ADV NEUROL, V56, P521; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CROWLEY J, 1984, ANNU REV PUBL HEALTH, V5, P385; FALLAT RJ, 1979, ARCH NEUROL-CHICAGO, V36, P74, DOI 10.1001/archneur.1979.00500380044004; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; HILL NS, 1994, CHEST, V105, P337, DOI 10.1378/chest.105.2.337; HILLEL AD, 1989, NEUROEPIDEMIOLOGY, V8, P142, DOI 10.1159/000110176; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; JABLECKI CK, 1989, MUSCLE NERVE, V12, P833, DOI 10.1002/mus.880121008; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; Oppenheimer Edward Anthony, 1993, Palliative Medicine, V7, P49; RAPHAEL JC, 1994, LANCET, V343, P1600	16	254	260	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					450	453		10.7326/0003-4819-127-6-199709150-00006	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313002				2022-12-01	WOS:A1997XV77900006
J	Sunahara, RK; Tesmer, JJG; Gilman, AG; Sprang, SR				Sunahara, RK; Tesmer, JJG; Gilman, AG; Sprang, SR			Crystal structure of the adenylyl cyclase activator G(S alpha)	SCIENCE			English	Article							G-PROTEIN; GTP HYDROLYSIS; ALPHA-SUBUNITS; CHOLERA-TOXIN; BETA-GAMMA; TRANSDUCIN; MECHANISM; RECEPTORS; STIMULATION; EXPRESSION	The crystal structure of G(S alpha), the heterotrimeric G protein alpha subunit that stimulates adenylyl cyclase, was determined at 2.5 Angstrom in a complex with guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). G(S alpha) is the prototypic member of a family of GTP-binding proteins that regulate the activities of effectors in a hormone-dependent manner. Comparison of the structure of G(S alpha).GTP gamma S with that of G(i alpha).GTP gamma S suggests that their effector specificity is primarily dictated by the shape of the binding surface formed by the switch II helix and the alpha 3-beta 5 loop, despite the high sequence homology of these elements. In contrast, sequence divergence explains the inability of regulators of G protein signaling to stimulate the GTPase activity of G(S alpha). The beta gamma binding surface of G(S alpha) is largely conserved in sequence ana structure to that of G(i alpha), whereas differences in the surface formed by the carboxyl-terminal helix and the alpha 4-beta 6 loop may mediate receptor specificity.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENJAMIN DR, 1995, J MOL BIOL, V254, P681, DOI 10.1006/jmbi.1995.0647; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERMAN DM, IN PRESS J BIOL CHEM; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; ITOH H, 1991, J BIOL CHEM, V266, P16226; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VANDOP C, 1984, J BIOL CHEM, V259, P696; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	42	247	255	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1943	1947		10.1126/science.278.5345.1943	http://dx.doi.org/10.1126/science.278.5345.1943			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395396				2022-12-01	WOS:A1997YL00200034
J	Hviid, SF; Madsen, MB; Gunnlaugsson, HP; Goetz, W; Knudsen, JM; Hargraves, RB; Smith, P; Britt, D; Dinesen, AR; Mogensen, CT; Olsen, M; Pedersen, CT; Vistisen, L				Hviid, SF; Madsen, MB; Gunnlaugsson, HP; Goetz, W; Knudsen, JM; Hargraves, RB; Smith, P; Britt, D; Dinesen, AR; Mogensen, CT; Olsen, M; Pedersen, CT; Vistisen, L			Magnetic properties experiments on the Mars Pathfinder lander: Preliminary results	SCIENCE			English	Article							SNC METEORITES; SOIL; CLUES; DUST	Many of the particles currently suspended in the martian atmosphere are magnetic, with an average saturation magnetization of about 4 A.m(2)/kg (amperes times square meters per kilogram). The particles appear to consist of claylike aggregates stained or cemented with ferric oxide (Fe2O3); at least some of the stain and cement is probably maghemite (gamma-Fe2O3). The presence of the gamma phase would imply that Fe2+ ions leached from the bedrock, passing through a state as free Fe2+ ions dissolved in liquid water. These particles could be a freeze-dried precipitate from ground water poured out on the surface. An alternative is that the magnetic particles are titanomagnetite occurring in palagonite and inherited directly from a basaltic precursor.	PRINCETON UNIV,DEPT GEOSCI,PRINCETON,NJ 08544; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721	Princeton University; University of Arizona	Hviid, SF (corresponding author), UNIV COPENHAGEN,NIELS BOHR INST ASTRON PHYS & GEOPHYS,OERSTED LAB,COPENHAGEN,DENMARK.		Madsen, Morten Bo/D-2082-2011; Gunnlaugsson, Haraldur/L-6535-2016	Madsen, Morten Bo/0000-0001-8909-5111; Gunnlaugsson, Haraldur/0000-0002-8958-0245				ALT JC, 1988, MAR GEOL, V81, P227, DOI 10.1016/0025-3227(88)90029-1; BANIN A, 1993, J GEOPHYS RES-PLANET, V98, P20831, DOI 10.1029/93JE02500; BELL JF, 1990, J GEOPHYS RES-SOLID, V95, P14447, DOI 10.1029/JB095iB09p14447; BURNS RG, 1980, NATURE, V285, P647, DOI 10.1038/285647a0; BURNS RG, 1993, GEOCHIM COSMOCHIM AC, V57, P4555, DOI 10.1016/0016-7037(93)90182-V; Clark B. C.  III, 1977, Journal of Geophysical Research, V82, P4577, DOI 10.1029/JS082i028p04577; COEY JMD, 1990, J GEOPHYS RES-SOLID, V95, P14423, DOI 10.1029/JB095iB09p14423; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; GUNNLAUGSSON HP, IN PRESS PLANET SPAC; HANEL R, 1972, ICARUS, V17, P423, DOI 10.1016/0019-1035(72)90009-7; Hapke B., 1993, THEORY REFLECTANCE E; Hargraves R. B., 1977, Journal of Geophysical Research, V82, P4547, DOI 10.1029/JS082i028p04547; HUNT GR, 1973, ICARUS, V18, P459, DOI 10.1016/0019-1035(73)90155-3; KOCH CB, 1995, PHYS CHEM MINER, V22, P333; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MORRIS RV, 1989, J GEOPHYS RES-SOLID, V94, P2760, DOI 10.1029/JB094iB03p02760; MORRIS RV, 1990, J GEOPHYS RES-SOLID, V95, P14427, DOI 10.1029/JB095iB09p14427; Oyama V. I., 1977, Journal of Geophysical Research, V82, P4669, DOI 10.1029/JS082i028p04669; Pollack J. B., 1977, Journal of Geophysical Research, V82, P4479, DOI 10.1029/JS082i028p04479; POLLACK JB, 1995, J GEOPHYS RES-PLANET, V100, P5235, DOI 10.1029/94JE02640; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; SINGER RB, 1984, B AM ASTRON SOC, V16, P679; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; SMITH PH, 1997, J GEOPHYS RES, V102, P3953; Wendlandt W. M., 1966, REFLECTANCE SPECTROS; [No title captured]	26	87	89	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1768	1770		10.1126/science.278.5344.1768	http://dx.doi.org/10.1126/science.278.5344.1768			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388172				2022-12-01	WOS:A1997YJ90100038
J	Mayo, MW; Wang, CY; Cogswell, PC; RogersGraham, KS; Lowe, SW; Der, CJ; Baldwin, AS				Mayo, MW; Wang, CY; Cogswell, PC; RogersGraham, KS; Lowe, SW; Der, CJ; Baldwin, AS			Requirement of NF-kappa B activation to suppress p53-independent apoptosis induced by oncogenic Ras	SCIENCE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; C-JUN; CELL-DEATH; ALPHA PROTEOLYSIS; CANCER-THERAPY; R-RAS; H-RAS; PHOSPHORYLATION; TRANSFORMATION; PROTEIN	The ras proto-oncogene is frequently mutated in human tumors and functions to chronically stimulate signal transduction cascades resulting in the synthesis or activation of specific transcription factors, including Ets, c-Myc, c-Jun, and nuclear factor kappa B (NF-kappa B). These Ras-responsive transcription factors are required for transformation, but the mechanisms by which these proteins facilitate oncogenesis have not been fully established. Oncogenic Ras was shown to initiate a p53-independent apoptotic response that was suppressed through the activation of NF-kappa B. These results provide an explanation for the requirement of NF-kappa B for Ras-mediated oncogenesis and provide evidence that Ras-transformed cells are susceptible to apoptosis even if they do not express the p53 tumor-suppressor gene product.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH DENT, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH DENT, DEPT ENDODONT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill				Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, P01CA013106, R01CA072771] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106, CA72771, CA52072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHEN CY, 1995, ONCOGENE, V11, P1487; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLMESMCNARY M, UNPUB; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LIN HJ, 1997, MOL CELL BIOL, V15, P4536; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MAYO MW, UNPUB; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUIN RG, 1995, NATURE, V374, P457; QUO ML, 1997, MOL CARCINOG, V18, P221; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Yang BS, 1996, MOL CELL BIOL, V16, P538	59	500	521	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 5	1997	278	5344					1812	1815		10.1126/science.278.5344.1812	http://dx.doi.org/10.1126/science.278.5344.1812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388187	Green Submitted			2022-12-01	WOS:A1997YJ90100053
J	Smith, PH; Bell, JF; Bridges, NT; Britt, DT; Gaddis, L; Greeley, R; Keller, HU; Herkenhoff, KE; Jaumann, R; Johnson, JR; Kirk, RL; Lemmon, M; Maki, JN; Malin, MC; Murchie, SL; Oberst, J; Parker, TJ; Reid, RJ; Sablotny, R; Soderblom, LA; Stoker, C; Sullivan, R; Thomas, N; Tomasko, MG; Ward, W; Wegryn, E				Smith, PH; Bell, JF; Bridges, NT; Britt, DT; Gaddis, L; Greeley, R; Keller, HU; Herkenhoff, KE; Jaumann, R; Johnson, JR; Kirk, RL; Lemmon, M; Maki, JN; Malin, MC; Murchie, SL; Oberst, J; Parker, TJ; Reid, RJ; Sablotny, R; Soderblom, LA; Stoker, C; Sullivan, R; Thomas, N; Tomasko, MG; Ward, W; Wegryn, E			Results from the Mars Pathfinder camera	SCIENCE			English	Article							SPECTRAL REFLECTANCE; VIKING LANDERS; IRON-OXIDES; DUST; SPECTROSCOPY; MINERALOGY; HEMATITE; PYROXENE; SURFACE	Images of the martian surface returned by the Imager for Mars Pathfinder (IMP) show a complex surface of ridges and troughs covered by rocks that have been transported and modified by fluvial, aeolian, and impact processes. Analysis of the spectral signatures in the scene (at 440- to 1000-nanometer wavelength) reveal three types of rock and four classes of soil. Upward-looking IMP images of the predawn sky show thin, bluish clouds that probably represent water ice forming on local atmospheric haze (opacity similar to 0.5). Haze particles are about 1 micrometer in radius and the water vapor column abundance is about 10 precipitable micrometers.	CORNELL UNIV,ITHACA,NY 14853; CALTECH,JET PROP LAB,PASADENA,CA 91109; US GEOL SURVEY,FLAGSTAFF,AZ 86001; ARIZONA STATE UNIV,TEMPE,AZ 85287; MAX PLANCK INST AERON,KATHENBURG LINDAU,GERMANY; DLR,BERLIN,GERMANY; MALIN SPACE SCI SYST,SAN DIEGO,CA; JOHNS HOPKINS UNIV,APPL PHYS LAB,BALTIMORE,MD 21218; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey; Arizona State University; Arizona State University-Tempe; Max Planck Society; Helmholtz Association; German Aerospace Centre (DLR); Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Smith, PH (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.		Lemmon, Mark/X-2333-2019; Jaumann, Ralf/N-1001-2018; Murchie, Scott L/E-8030-2015; Sullivan, Robert/AAR-8193-2020; Johnson, Jeffrey R/F-3972-2015; Bridges, Nathan T/D-6341-2016; Lemmon, Mark T/E-9983-2010; Stoker, Carol/ABE-1381-2021; Thomas, Nicolas/G-4693-2015	Lemmon, Mark/0000-0002-4504-5136; Jaumann, Ralf/0000-0002-9759-6597; Murchie, Scott L/0000-0002-1616-8751; Johnson, Jeffrey R/0000-0002-5586-4901; Lemmon, Mark T/0000-0002-4504-5136; Stoker, Carol/0000-0001-7265-292X; Thomas, Nicolas/0000-0002-0146-0071				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; ARVIDSON RE, 1989, REV GEOPHYS, V27, P39, DOI 10.1029/RG027i001p00039; BAGNOLD RA, 1954, PHYSICS BLOWN SAND D; BELL JF, 1990, J GEOPHYS RES-SOLID, V95, P14447, DOI 10.1029/JB095iB09p14447; BELL JF, 1996, MINERAL SPECTROSCOPY, P359; BISHOP JL, 1993, GEOCHIM COSMOCHIM AC, V57, P4583, DOI 10.1016/0016-7037(93)90184-X; CLANCY T, 1997, COMMUNICATION; CLOUTIS EA, 1991, J GEOPHYS RES-PLANET, V96, P22809, DOI 10.1029/91JE02512; COSTA JE, 1983, GEOL SOC AM BULL, V94, P986, DOI 10.1130/0016-7606(1983)94<986:PROFPF>2.0.CO;2; FRENCH LM, 1988, ICARUS, V75, P127, DOI 10.1016/0019-1035(88)90131-5; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; GREELEY R, 1984, WIND GEOLOGICAL PROC; Greeley R., 1992, MARS, P730; Grundy WM, 1992, ASTEROIDS COMETS MET, P215; GUINNESS EA, 1987, J GEOPHYS RES-SOLID, V92, pE575, DOI 10.1029/JB092iB04p0E575; Hviid SF, 1997, SCIENCE, V278, P1768, DOI 10.1126/science.278.5344.1768; Jakosky B. M., 1992, MARS, P969; JAMES P, 1997, COMMUNICATION; KAHN R, 1981, J GEOPHYS RES-SPACE, V86, P5833, DOI 10.1029/JA086iA07p05833; KLASSEN KP, 1979, J GEOPHYS RES, V84, P8478; KOMAR PD, 1987, SEDIMENTOLOGY, V34, P1165, DOI 10.1111/j.1365-3091.1987.tb00599.x; KOMAR PD, 1989, FLOODS HYDROLOGICAL, P107; KOMAR PD, 1991, SEDIMENTOLOGY, V38; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; Malin M. C., 1988, 4041 NASA, P502; MALIN MC, 1981, 84211 NASA, P272; MCCORD TB, 1977, ICARUS, V31, P25, DOI 10.1016/0019-1035(77)90069-0; MORRIS RV, 1995, J GEOPHYS RES-PLANET, V100, P5319, DOI 10.1029/94JE01500; MORRIS RV, 1985, J GEOPHYS RES-SOLID, V90, P3126, DOI 10.1029/JB090iB04p03126; MURCHIE S, 1993, ICARUS, V105, P454, DOI 10.1006/icar.1993.1141; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; Mutch T. A., 1977, Journal of Geophysical Research, V82, P4452, DOI 10.1029/JS082i028p04452; MUTCH TA, 1976, SCIENCE, V194, P87, DOI 10.1126/science.194.4260.87; MUTCH TA, 1976, SCIENCE, V193, P791, DOI 10.1126/science.193.4255.791; OCONNOR JE, 1992, GEOL SOC AM BULL, V104, P267, DOI 10.1130/0016-7606(1992)104<0267:MAIOPD>2.3.CO;2; POLLACK JB, 1981, J ATMOS SCI, V38, P3, DOI 10.1175/1520-0469(1981)038<0003:AMGCEW>2.0.CO;2; POLLACK JB, 1995, J GEOPHYS RES-PLANET, V100, P5235, DOI 10.1029/94JE02640; POLLACK JB, 1980, J ATMOS SCI, V37, P868, DOI 10.1175/1520-0469(1980)037<0868:SBNPOS>2.0.CO;2; REID R, 1997, THESIS U ARIZONA; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; RODDY DJ, 1977, IMPACT EXPLOSION CRA, P489; SCHOFIELD T, 1997, SCIENCE, V278, P1752; SHARP RP, 1984, GEOL SOC AM BULL, V95, P1398, DOI 10.1130/0016-7606(1984)95<1398:SGFVLO>2.0.CO;2; SHERMAN DM, 1982, J GEOPHYS RES, V87, P169, DOI 10.1029/JB087iB12p10169; SINGER RB, 1982, J GEOPHYS RES, V87, P159, DOI 10.1029/JB087iB12p10159; Smith PH, 1997, J GEOPHYS RES-PLANET, V102, P4003, DOI 10.1029/96JE03568; Zellner B., 1994, LUNAR PLANET SCI C, V25, P1541; ZUREK RW, 1982, ICARUS, V50, P288, DOI 10.1016/0019-1035(82)90127-0	48	216	217	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1758	1765		10.1126/science.278.5344.1758	http://dx.doi.org/10.1126/science.278.5344.1758			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388170				2022-12-01	WOS:A1997YJ90100036
J	Taipale, P; Hiilesmaa, V; Salonen, R; Ylostalo, P				Taipale, P; Hiilesmaa, V; Salonen, R; Ylostalo, P			Increased nuchal translucency as a marker for fetal chromosomal defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIRST-TRIMESTER; TRANSVAGINAL SONOGRAPHY; CYSTIC HYGROMA; 1ST TRIMESTER; ALPHA-FETOPROTEIN; GESTATIONAL-AGE; DOWNS-SYNDROME; ULTRASOUND; THICKNESS; FETUSES	Background Screening for trisomy 21 (Down's syndrome) by measuring maternal serum alpha-fetoprotein, chorionic gonadotropin, and estriol concentrations and then performing chorionic-villus sampling or amniocentesis identifies approximately 60 percent of fetuses with this disorder. We used ultrasonography to detect increased nuchal translucency and cystic hygroma, which are characteristic features of fetuses with chromosomal defects. Methods We performed transvaginal ultrasonography in 10,010 unselected adolescents and women less than 40 years of age with live singleton fetuses at 10 to 15.9 weeks of gestation. Increased fetal nuchal translucency was defined as an area of translucency at least 3 mm in width, and cystic hygromas were defined as septated, fluid-filled sacs in the nuchal region. Subjects whose fetuses had these findings were offered fetal karyotyping. Information on pregnancies, deliveries, and neonates was subsequently obtained from hospital records and national birth and malformation registries. Results Nuchal translucency or cystic hygroma was seen in 76 fetuses (0.8 percent), of which 18 (24 percent) had an abnormal karyotype. The sensitivity for trisomies 21, 18, and 13 combined was 62 percent (13 of 21 fetuses), and the sensitivity for trisomy 21 alone was 54 percent (7 of 13 fetuses). Conclusions The use of transvaginal ultrasonography to detect increased nuchal translucency and cystic hygroma is a sensitive test for fetal aneuploidy. It can be done earlier in pregnancy than serum screening, and it decreases the subsequent need for chorionic-villus sampling or amniocentesis. (C) 1997, Massachusetts Medical Society.	JORVI HOSP,DEPT OBSTET & GYNECOL,SF-02740 ESPOO,FINLAND		Taipale, P (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							BENACERRAF BR, 1992, RADIOLOGY, V184, P239, DOI 10.1148/radiology.184.1.1535162; BEWLEY S, 1995, BRIT J OBSTET GYNAEC, V102, P386, DOI 10.1111/j.1471-0528.1995.tb11290.x; BRAITHWAITE JM, 1995, BRIT J RADIOL, V68, P720, DOI 10.1259/0007-1285-68-811-720; BRONSHTEIN M, 1992, PRENATAL DIAG, V12, P587, DOI 10.1002/pd.1970120704; COMAS C, 1995, ULTRASOUND OBST GYN, V5, P26, DOI 10.1046/j.1469-0705.1995.05010026.x; CULLEN MT, 1990, PRENATAL DIAG, V10, P643, DOI 10.1002/pd.1970101004; DAYA S, 1993, AM J OBSTET GYNECOL, V168, P903, DOI 10.1016/S0002-9378(12)90842-X; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HAFNER E, 1995, ULTRASOUND OBST GYN, V6, P330, DOI 10.1046/j.1469-0705.1995.06050330.x; JACKSON S, 1995, ULTRASOUND OBST GYN, V5, P55, DOI 10.1046/j.1469-0705.1995.05010055.x; MACGREGOR SN, 1987, OBSTET GYNECOL, V70, P344; MOONEY RA, 1994, OBSTET GYNECOL, V84, P298; NADEL A, 1993, OBSTET GYNECOL, V82, P43; NICOLAIDES KH, 1994, BRIT J OBSTET GYNAEC, V101, P782, DOI 10.1111/j.1471-0528.1994.tb11946.x; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; PANDYA PP, 1995, ULTRASOUND OBST GYN, V5, P334, DOI 10.1046/j.1469-0705.1995.05050334.x; PANDYA PP, 1994, OBSTET GYNECOL, V84, P420; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; SABBAGHA RE, 1994, DIAGNOSTIC ULTRASOUN, P155; Salonen R, 1997, ACTA OBSTET GYN SCAN, V76, P817, DOI 10.3109/00016349709024358; SALVESEN KA, 1995, ULTRASOUND OBST GYN, V6, P293, DOI 10.1046/j.1469-0705.1995.06040293.x; SANTOLAYA J, 1992, OBSTET GYNECOL, V79, P256; SHULMAN LP, 1992, OBSTET GYNECOL, V80, P80; SNIJDERS RJM, 1994, PRENATAL DIAG, V14, P543, DOI 10.1002/pd.1970140706; TIMORTRITSCH IE, 1993, OBSTET GYNECOL, V81, P742; VANZALENSPROCK RM, 1992, AM J OBSTET GYNECOL, V167, P94, DOI 10.1016/S0002-9378(11)91634-2; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WILSON RD, 1992, PRENATAL DIAG, V12, P755, DOI 10.1002/pd.1970120908	29	144	156	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1654	1658		10.1056/NEJM199712043372303	http://dx.doi.org/10.1056/NEJM199712043372303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385124	Bronze			2022-12-01	WOS:A1997YJ87100003
J	Boehm, T; Folkman, J; Browder, T; OReilly, MS				Boehm, T; Folkman, J; Browder, T; OReilly, MS			Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance	NATURE			English	Article							ANGIOGENESIS	Acquired drug resistance is a major problem in the treatment of cancer. Of the more than 500,000 annual deaths from cancer in the United States', many follow the development of resistance to chemotherapy. The emergence of resistance depends in part on the genetic instability, heterogeneity and high mutational rate of tumour cells'. In contrast, endothelial cells are genetically stable, homogenous and have a low mutational rate. Therefore, anti-angiogenic therapy directed against a tumour's endothelial cells should, in principle, induce little or no drug resistance, Endostatin(3), a potent angiogenesis inhibitor, was administered to mice bearing Lewis lung carcinoma, T241 fibrosarcoma or B16F10 melanoma. Treatment was stopped when tumours had regressed. Tumours were then allowed to re-grow and endostatin therapy was resumed. After 6, 4 or 2 treatment cycles, respectively, no tumours recurred after discontinuation of therapy, These experiments show that drug resistance does not develop in three tumour types treated with a potent angiogenesis inhibitor, An unexpected finding is that repeated cycles of antiangiogenic therapy are followed by prolonged tumour dormancy without further therapy.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC CTR,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Boehm, T (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,HUNNEWELL 103,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							Brem Harold, 1994, Surgical Forum, V45, P674; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOLDIN A, 1981, EUR J CANCER, V17, P129, DOI 10.1016/0014-2964(81)90027-X; Hill D. L., 1975, REV CYCLOPHOSPHAMIDE; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; LI PL, 1993, CANC MED, V1, P322; MORROW CS, 1993, CANC MED, V1, P618; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562	13	1449	1675	2	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					404	407		10.1038/37126	http://dx.doi.org/10.1038/37126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389480				2022-12-01	WOS:A1997YH54900064
J	Anderson, DM; Maraskovsky, E; Billingsley, WL; Dougall, WC; Tometsko, ME; Roux, ER; Teepe, MC; DuBose, RF; Cosman, D; Galibert, L				Anderson, DM; Maraskovsky, E; Billingsley, WL; Dougall, WC; Tometsko, ME; Roux, ER; Teepe, MC; DuBose, RF; Cosman, D; Galibert, L			A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; BIOLOGICAL CHARACTERIZATION; INTERLEUKIN-4 RECEPTOR; SUPERFAMILY; ACTIVATION; MURINE; PROTEINS; CLONING; CD40; LYMPHOCYTES	Dendritic cells are rare haematopoietic cells that reside in a number of organs and tissues. By capturing, processing and presenting antigens to T cells, dendritic cells are essential for immune surveillance and the regulation of specific immunity(1-4) Several members of the tumour necrosis factor receptor (TNFR) superfamily are integral to the regulation of the immune response. These structurally related proteins modulate cellular functions ranging from proliferation and differentiation to inflammation and cell survival or death(5,6). The functional activity of dendritic cells is greatly increased by signalling through the TNFR family member CD40 (refs 7, 8). Here we report the characterization of RANK (for receptor activator of NF-kappa B), a new member of the TNFR family derived from dendritic cells, and the isolation of a RANK ligand (RANKL) by direct expression screening. RANKL augments the ability of dendritic cells to stimulate naive T-cell proliferation in a mixed lymphocyte reaction, and increases the survival of RANK(+) T cells generated with interleukin-4 and transforming growth factor (TGF)-beta. Thus RANK and RANKL seem to be important regulators of interactions between T cells and dendritic cells.	IMMUNEX RES & DEV CORP, DEPT IMMUNOBIOL, SEATTLE, WA 98101 USA; IMMUNEX RES & DEV CORP, DEPT BIOINFORMAT, SEATTLE, WA 98101 USA		Anderson, DM (corresponding author), IMMUNEX RES & DEV CORP, DEPT MOL BIOL, 51 UNIV ST, SEATTLE, WA 98101 USA.			Dougall, William/0000-0001-9487-251X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Baker SJ, 1996, ONCOGENE, V12, P1; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CAUX C, 1996, BLOOD CEL B, V7, P263; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; DEJONG R, 1994, INT IMMUNOL, V6, P631, DOI 10.1093/intimm/6.4.631; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MADSEN M, 1980, J IMMUNOL METHODS, V33, P323, DOI 10.1016/0022-1759(80)90003-4; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; ROTHE M, 1995, SCIENCE, V269, P124; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5	30	1795	1939	3	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					175	179		10.1038/36593	http://dx.doi.org/10.1038/36593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367155				2022-12-01	WOS:A1997YF49400055
J	BenArie, N; Bellen, HJ; Armstrong, DL; McCall, AE; Gordadze, PR; Guo, QX; Matzuk, MM; Zoghbi, HY				BenArie, N; Bellen, HJ; Armstrong, DL; McCall, AE; Gordadze, PR; Guo, QX; Matzuk, MM; Zoghbi, HY			Math1 is essential for genesis of cerebellar granule neurons	NATURE			English	Article							PRONEURAL GENE; NERVOUS-SYSTEM; MOUSE-BRAIN; MUTANT MICE; CELLS; EXPRESSION; PROTOONCOGENE; DELETION; PROTEIN; WNT-1	The cerebellum is essential for fine motor control of movement and posture, and its dysfunction disrupts balance and impairs control of speech, limb and eye movements. The developing cerebellum consists mainly of three types of neuronal cells: granule cells in the external germinal layer, Purkinje cells, and neurons of the deep nuclei(1). The molecular mechanisms that underlie the specific determination and the differentiation of each of these neuronal subtypes are unknown. Math1 (refs 2, 3), the mouse homologue of the Drosophila gene atonal(4), encodes a basic helix-loop-helix transcription factor that is specifically expressed in the precursors of the external germinal layer and their derivatives. Here we report that mice lacking Math1 fail to form granule cells and are born with a cerebellum that is devoid of an external germinal layer. To our knowledge, Math1 is the first gene to be shown to be required in vivo for the genesis of granule cells, and hence the predominant neuronal population in the cerebellum.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Ben-Arie, Nissim/K-4997-2012	Zoghbi, Huda/0000-0002-0700-3349; Bellen, Hugo/0000-0001-5992-5989				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; ALBRECHT U, 1997, VISUALIZATION GENE E, P23; ALTMAN J, 1996, DEV CEREBELLAR SYSTE; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HALLONET MER, 1993, EUR J NEUROSCI, V5, P1145, DOI 10.1111/j.1460-9568.1993.tb00969.x; Hatten ME, 1997, CURR OPIN NEUROBIOL, V7, P40, DOI 10.1016/S0959-4388(97)80118-3; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Heintz Nathaniel, 1993, V6, P19; His W., 1891, ABHANDLUNGEN KONI MP, V29, P1; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; *MOUS GEN INF JACK, 1996, MOUS GEN DAT 3 1; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMAS KR, 1990, NATURE, V346, P845; TOHYAMA T, 1992, LAB INVEST, V66, P303; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WURST W, 1994, DEVELOPMENT, V120, P2065; Yang XW, 1996, DEVELOPMENT, V122, P555; 1997, FRONTIERS BIOSCIENCE	29	504	519	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					169	172		10.1038/36579	http://dx.doi.org/10.1038/36579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367153				2022-12-01	WOS:A1997YF49400053
J	Inbal, B; Cohen, O; PolakCharcon, S; Kopolovic, J; Vadai, E; Eisenbach, L; Kimchi, A				Inbal, B; Cohen, O; PolakCharcon, S; Kopolovic, J; Vadai, E; Eisenbach, L; Kimchi, A			DAP kinase links the control of apoptosis to metastasis	NATURE			English	Article							LUNG-CARCINOMA; EXTRACELLULAR-MATRIX; CELLS; TUMORIGENESIS; SUPPRESSION; SELECTION; DEATH; GENE	DAP kinase is a new type of calcium/calmodulin-dependent enzyme that phosphorylates serine/threonine residues on proteins. Its structure contains ankyrin repeats and the 'death' domain, and it is associated with the cell cytoskeleton(1-3). The gene encoding DAP kinase was initially isolated as a positive mediator of apoptosis induced by interferon-gamma, by using a strategy of functional cloning(4). We have now tested whether this gene has tumour-suppressive activity We found that lung carcinoma clones, characterized by their highly aggressive metastatic behaviour and originating from two independent murine lung tumours, did not express DAP kinase, in contrast to their low-metastatic counterparts. Restoration of DAP kinase to physiological levels in high-metastatic Lewis carcinoma cells suppressed their ability to form lung metastases after intravenous injection into syngeneic mice, and delayed local tumour growth in a foreign 'microenvironment'. Conversely, in vivo selection of rare lung lesions following injection into syngeneic mice of low-metastatic Lewis carcinoma cells or of DAP kinase transfectants, was associated with loss of DAP kinase expression. In situ TUNEL staining of tumour sections revealed that DAP kinase expression from the transgene raised the incidence of apoptosis in vivo. DAP-kinase transfectants also showed increased sensitivity in vitro to apoptotic stimuli, of the sort encountered by metastasizing cells at different stages of malignancy. We propose that loss of DAP kinase expression provides a unique mechanism that links suppression of apoptosis to metastasis.	WEIZMANN INST SCI, DEPT MOL GENET, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; CHAIM SHEBA MED CTR, DEPT HISTOPATHOL, IL-52621 TEL HASHOMER, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center				Eisenbach, Lea R/0000-0002-4816-1968				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LAYTON MG, 1984, BRIT J CANCER, V49, P415, DOI 10.1038/bjc.1984.67; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nikiforov MA, 1996, ONCOGENE, V13, P1709; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WEISS L, 1992, CANCER METAST REV, V11, P227, DOI 10.1007/BF01307179; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; Yamauchi A, 1996, BLOOD, V87, P5127, DOI 10.1182/blood.V87.12.5127.bloodjournal87125127	30	341	362	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	1997	390	6656					180	184		10.1038/36599	http://dx.doi.org/10.1038/36599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367156				2022-12-01	WOS:A1997YF49400056
J	Turner, G; Robinson, H; Wake, S; Laing, S; Partington, M				Turner, G; Robinson, H; Wake, S; Laing, S; Partington, M			Case finding for the fragile X syndrome and its consequences	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; CARRIERS; ALLELES		SYDNEY CHILDRENS HOSP,FRAGILE X PROGRAM,SYDNEY,NSW,AUSTRALIA	University of Sydney	Turner, G (corresponding author), HUNTER GENET,FRAGILE X PROGRAM,POB 84,NEWCASTLE,NSW 2298,AUSTRALIA.							Kooy RF, 1996, AM J MED GENET, V64, P241, DOI 10.1002/(SICI)1096-8628(19960809)64:2<241::AID-AJMG1>3.0.CO;2-X; Partington MW, 1996, AM J MED GENET, V64, P370, DOI 10.1002/(SICI)1096-8628(19960809)64:2<370::AID-AJMG27>3.0.CO;2-B; Robinson H, 1996, AM J MED GENET, V64, P198, DOI 10.1002/(SICI)1096-8628(19960712)64:1<198::AID-AJMG36>3.0.CO;2-G; ROUSSEAU F, 1995, AM J HUM GENET, V57, P1006; SMITH RA, 1990, BRIT MED J, V300, P1112, DOI 10.1136/bmj.300.6732.1112; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; TURNER G, 1992, LANCET, V339, P1210, DOI 10.1016/0140-6736(92)91142-U; Turner G, 1996, AM J MED GENET, V64, P196, DOI 10.1002/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G; WEBB T, 1987, J MED GENET, V23, P396; Zhong N, 1996, AM J MED GENET, V64, P261, DOI 10.1002/(SICI)1096-8628(19960809)64:2<261::AID-AJMG5>3.0.CO;2-X	10	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1223	1226		10.1136/bmj.315.7117.1223	http://dx.doi.org/10.1136/bmj.315.7117.1223			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393231	Green Published			2022-12-01	WOS:A1997YF25200032
J	Paszty, C; Brion, CM; Manci, E; Witkowska, HE; Stevens, ME; Mohandas, N; Rubin, EM				Paszty, C; Brion, CM; Manci, E; Witkowska, HE; Stevens, ME; Mohandas, N; Rubin, EM			Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease	SCIENCE			English	Article							BETA-S-GLOBINS; MOUSE MODEL; HIGH EXPRESSION; ALPHA-GLOBINS; GENE; THALASSEMIA; HYPOXIA; SAD	To create mice expressing exclusively human sickle hemoglobin (HbS), transgenic mice expressing human alpha-, gamma-, and beta(s)-globin were generated and bred with knockout mice that had deletions of the murine alpha- and beta-globin genes. These sickle cell mice have the major features (irreversibly sickled red cells, anemia, multiorgan pathology) found in humans with sickle cell disease and, as such, represent a useful in vivo system to accelerate the development of improved therapies for this common genetic disease.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DEPT SUBCELLULAR STRUCT, BERKELEY, CA 94720 USA; UNIV S ALABAMA, DOCTORS HOSP, CENTRALIZED PATHOL UNIT SICKLE CELL DIS, MOBILE, AL 36604 USA; CHILDRENS HOSP OAKLAND, RES INST, OAKLAND, CA 94609 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of South Alabama; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Paszty, C (corresponding author), UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, CTR HUMAN GENOME, 1 CYCLOTRON RD, MS 74-157, BERKELEY, CA 94720 USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB007086] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579, P60HL020985] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31579, HL20985, N01-HB-07086] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAUHAN PM, 1983, PATHOL ANNU, V18, P253; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; DALAND GA, 1948, J LAB CLIN MED, V33, P1082; Embury SH, 1994, SICKLE CELL DIS BASI; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; Paszty C, 1997, Curr Opin Hematol, V4, P88; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; RUBIN EM, 1991, J CLIN INVEST, V87, P639, DOI 10.1172/JCI115041; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723	21	351	356	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					876	878		10.1126/science.278.5339.876	http://dx.doi.org/10.1126/science.278.5339.876			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346488	Green Submitted			2022-12-01	WOS:A1997YD47900050
J	Hughes, JB; Daily, GC; Ehrlich, PR				Hughes, JB; Daily, GC; Ehrlich, PR			Population diversity: Its extent and extinction	SCIENCE			English	Article							GENE FLOW; BIODIVERSITY	Genetically distinct populations are an important component of biodiversity. This work estimates the number of populations per area of a sample of species from literature on population differentiation and the average range area of a species from a sample of distribution maps. This yields an estimate of about 220 populations per species, or 1.1 to 6.6 billion populations globally. Assuming that population extinction is a linear function of habitat loss, approximately 1800 populations per hour (16 million annually) are being destroyed in tropical forests alone.			Hughes, JB (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.		Martiny, Jennifer/AAB-9323-2019	Martiny, Jennifer/0000-0002-2415-1247				ALLEN TB, 1983, FIELD GUIDE BIRDS N; [Anonymous], 1997, NATURES SERVICES; BARROWCLOUGH GF, 1983, PERSPECTIVES ORNITHO; BROWN IL, 1980, OECOLOGIA, V47, P239, DOI 10.1007/BF00346827; Burt W., 1976, FIELD GUIDE MAMMALS, V3rd; Corbet G.B., 1992, P1; EHRLICH PR, 1992, AMBIO, V21, P219; EHRLICH PR, 1993, AMBIO, V22, P64; ERWIN T L, 1982, Coleopterists Bulletin, V36, P74; *FAO UN, 1990, FOR RES ASS TROP COU; FRANCE R, 1992, AM NAT, V139, P342, DOI 10.1086/285330; Gaston K.J., 1994, RARITY, P1, DOI [10.1007/978-94-011-0701-3_1, DOI 10.1007/978-94-011-0701-3_1, 10.1007/978-94-011-0701-3]; Hammond PM, 1995, GLOBAL BIODIVERSITY, P113; Hawksworth D. L, 1991, BIODIVERSITY MICROOR; KINGDON J, 1971, E AFRICAN MAMMALS A, V2; KINGDON J, 1971, E AFRICAN MAMMALS A, V3; LAVERY S, 1995, HEREDITY, V74, P531, DOI 10.1038/hdy.1995.75; Lawton JH, 1995, EXTINCTION RATES; Lee DS, 1980, ATLAS N AM FRESHWATE, DOI DOI 10.5962/BHL.TITLE.141711; Legge JT, 1996, CONSERV BIOL, V10, P85, DOI 10.1046/j.1523-1739.1996.10010085.x; MAC ARTHUR ROBERT H., 1967; MYERS N, 1984, PRIMARY SOURCE; PAGEL MD, 1991, AM NAT, V137, P791, DOI 10.1086/285194; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; PIMM SL, 1995, P NATL ACAD SCI USA, V92, P9343, DOI 10.1073/pnas.92.20.9343; RAPPORT EH, 1982, AEROGRAPHY GEOGRAPHI; RASMUSSEN IR, 1992, OECOLOGIA, V89, P277, DOI 10.1007/BF00317228; RAVEN PH, 1985, FUTURIST, V19, P8; RAVEN PH, 1983, B ESA            SPR, P4; Ridgely RS, 1989, BIRDS S AM, V1; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCOTT JA, 1986, BUTTERFLIES N AM; Sinnott E. W., 1950, PRINCIPLES GENETICS; Tsukada E, 1982, BUTTERFLIES S E ASIA, VI; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V4; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V3; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V2; Webb, 1984, BUTTERFLIES DORSET; WILSON E O, 1992; [No title captured]	40	330	353	3	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					689	692		10.1126/science.278.5338.689	http://dx.doi.org/10.1126/science.278.5338.689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381179				2022-12-01	WOS:A1997YC32300055
J	Bandmann, O; Vaughan, J; Holmans, P; Marsden, CD; Wood, NW				Bandmann, O; Vaughan, J; Holmans, P; Marsden, CD; Wood, NW			Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease	LANCET			English	Article							POLYMERASE CHAIN-REACTION; 5'-FLANKING REGION; OXIDATIVE STRESS; GENE; POLYMORPHISM; SMOKING; SUSCEPTIBILITY; CARCINOGENS; EXPRESSION; METABOLISM	Background Epidemiological studies have identified positive family history and exposure to environmental toxins as risk factors for Parkinson's disease (PD). An inherited defect of xenobiotic metabolism could result in increased susceptibility to such toxins. We investigated the frequency of functionally relevant polymorphisms in six detoxification enzymes among patients with PD to elucidate the relation between these polymorphisms and the disease. Methods We obtained brain-tissue samples from 100 patients with apparently sporadic PD and blood samples from 100 living patients with familiar PD. For the control group, we extracted DNA from the tissue of 100 pathologically normal brains. The six enzymes analysed in these three groups were: CYP2D6, CYP2E1, NAD(P)H-menadione reductase, glutathione transferases M1 and T1, and N-acetyltransferase 2. We also investigated N-acetyltransferase 2 in 100 blood samples from patients with genetically proven Huntington's disease. We used PCR-based methods and restriction-enzyme analysis to detect polymorphisms. Findings The slow acetylator genotype for N-acetyltransferase 2 was more common in the familial PD group (69%) than in all controls (37%). Even after correction for multiple comparisons, this result remained highly significant (p=0.002) for familial PD compared with normal controls (odds ratio 3.79 [95% CI 2.08-6.90]) and compared with Huntington's disease (2.45 [1.37-4.38], p=0.004). The slow acetylator frequency for N-acetyltransferase 2 for sporadic PD was between that for Huntington's disease and familiar PD. The frequencies of all the other polymorphisms were similar in the two study groups and the normal control group. Interpretation We found an association between the slow acetylator genotype for N-acetyltransferase 2 and familial PD. Further studies are needed to investigate the biological relevance of these findings, but slow acetylation could lead to impaired ability of patients with familial PD to handle neurotoxic substances.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND; UNIV WALES COLL MED,NEUROPSYCHIAT GENET UNIT,CARDIFF CF4 4XN,S GLAM,WALES	University of London; University College London; Cardiff University			Holmans, Peter/F-4518-2015; Wood, Nicholas W/C-2505-2009	Holmans, Peter/0000-0003-0870-9412; Wood, Nicholas W/0000-0002-9500-3348; Bandmann, Oliver/0000-0003-3149-0252				ARMSTRONG M, 1993, HUM GENET, V91, P616; ARMSTRONG M, 1992, LANCET, V339, P1017, DOI 10.1016/0140-6736(92)90537-D; Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; Chen CL, 1996, PHARMACOGENETICS, V6, P187, DOI 10.1097/00008571-199604000-00005; DEXTER D, 1986, LANCET, V2, P639; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; Diederich N, 1996, ANN NEUROL, V40, P463, DOI 10.1002/ana.410400319; Gibb W., 1989, DISORDERS MOVEMENT C, P33; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P559, DOI 10.1093/oxfordjournals.jbchem.a123619; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; IGBOKWE E, 1993, E AFR MED J, V70, P807; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; LADERO JM, 1989, EUR J CLIN PHARMACOL, V37, P391, DOI 10.1007/BF00558506; LIN HJ, 1993, AM J HUM GENET, V52, P827; MARAGANORE DM, 1991, MOVEMENT DISORD, V6, P205, DOI 10.1002/mds.870060303; MONTOLIU C, 1995, J NEUROCHEM, V65, P2561; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; PAYAMI H, 1989, AM J HUM GENET, V45, P541; PETERS L, 1994, XENOBIOTICA, V24, P1013, DOI 10.3109/00498259409043298; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Rijk M. C., 1997, J NEUROL NEUROSUR PS, V62, P10, DOI DOI 10.1136/JNNP.62.1.10; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003; SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; Sies H, 1988, GLUTATHIONE CONJUGAT; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SNYDER SH, 1986, NEUROLOGY, V36, P250, DOI 10.1212/WNL.36.2.250; TRAVER RD, 1992, CANCER RES, V52, P797; TSUNEOKA Y, 1993, J BIOCHEM, V114, P263, DOI 10.1093/oxfordjournals.jbchem.a124164; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WATANABE J, 1994, J BIOCHEM-TOKYO, V116, P321, DOI 10.1093/oxfordjournals.jbchem.a124526; Wood N, 1997, J NEUROL NEUROSUR PS, V62, P305, DOI 10.1136/jnnp.62.4.305	36	108	111	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1136	1139		10.1016/S0140-6736(97)03495-8	http://dx.doi.org/10.1016/S0140-6736(97)03495-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343502				2022-12-01	WOS:A1997YB19900012
J	Barr, FA; Puype, M; Vandekerckhove, J; Warren, G				Barr, FA; Puype, M; Vandekerckhove, J; Warren, G			GRASP65, a protein involved in the stacking of Golgi cisternae	CELL			English	Article							3-DIMENSIONAL ELECTRON-MICROSCOPY; CELL-FREE SYSTEM; VESICULAR TRANSPORT; NITRIC-OXIDE; APPARATUS; MEMBRANES; FRAGMENTS; NSF	NEM prevents mitotic reassembly of Golgi cisternae into stacked structures. The major target of NEM is a 65 kDa protein conserved from yeast to mammals. Antibodies to this protein and a recombinant form of it block cisternal stacking in a cell-free system, justifying its designation as a Golgi ReAssembly Stacking Protein (GRASP65). One of the two minor targets of NEM is GM130, previously implicated in the docking of transport vesicles and mitotic fragmentation of the Golgi stack. GRASP65 is complexed with GM130 and is tightly bound to Golgi membranes, even under mitotic conditions when both are heavily phosphorylated. These results link vesicle docking, stacking of Golgi cisternae, and the disruption of both of these interactions during mitosis.	FLANDERS INST BIOTECHNOL,DEPT BIOCHEM,B-9000 GHENT,BELGIUM	Flanders Institute for Biotechnology (VIB)	Barr, FA (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Barr, Francis/0000-0001-7518-253X				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMOS WB, 1968, J CELL BIOL, V38, P466, DOI 10.1083/jcb.38.2.466; Becker B, 1996, MICROBIOL REV, V60, P697, DOI 10.1128/MMBR.60.4.697-721.1996; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CLUETT EB, 1992, J CELL SCI, V103, P773; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRANKE WW, 1972, Z ZELLFORSCH MIK ANA, V132, P365, DOI 10.1007/BF02450714; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; GOLGI C, 1898, ARCH ITAL BIOL, V30, P60; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MOLLENHAUER HH, 1966, ANN REV PLANT PHYSIO, V17, P27, DOI 10.1146/annurev.pp.17.060166.000331; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SAPPERSTEIN SK, 1996, J CELL BIOL, V132, P765; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WHALEY WG, 1976, GOLGI APPARATUS, V2	30	337	344	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					253	262		10.1016/S0092-8674(00)80407-9	http://dx.doi.org/10.1016/S0092-8674(00)80407-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346242	Bronze			2022-12-01	WOS:A1997YC35000012
J	Barcellos, LF; Thomson, G; Carrington, M; Schafer, J; Begovich, AB; Lin, P; Xu, XH; Min, BQ; Marti, D; Klitz, W				Barcellos, LF; Thomson, G; Carrington, M; Schafer, J; Begovich, AB; Lin, P; Xu, XH; Min, BQ; Marti, D; Klitz, W			Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis - Evidence of a new susceptibility locus in Caucasian and Chinese patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASIC-PROTEIN GENE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; APOLIPOPROTEIN-E; LINKAGE DISEQUILIBRIUM; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; SHANGHAI CHINESE; HLA; POLYMORPHISM; COMPLEX	Context.-Susceptibility to multiple sclerosis (MS) involves a genetically complex autoimmune component. However, except for genes in the HLA system, specific susceptibility loci are unknown or unconfirmed. Objective.-To investigate several loci spanning 3 candidate regions for a role in multiple sclerosis (MS) susceptibility in 2 ethnic groups using both single-locus and haplotype analyses. The 3 regions include HLA on chromosome 6p21.3, APOE on chromosome 19q13.2, and MBP (myelin basic protein) on chromosome 18q23. Design.-Case-control association testing. Subjects.-A total of 120 Caucasian patients with MS and 107 unrelated control individuals from California, and 32 patients and 32 unrelated control individuals from Beijing, China. All patients with MS were diagnosed as having clinically definite disease according to published criteria. Main Outcome Measures.-chi(2) Testing of loci and individual alleles and haplotypes. Haplotype frequencies were estimated with standard maximum likelihood methods. Results.-The HLA effect is due to the class II DR2 haplotype, DRB1*1501-DQA1*0102-DRB1*0602; contributions to MS susceptibility from additional DRB1-DQB1 alleles or other HLA region loci were not observed. Variation within the MBP locus on chromosome 18q23 showed no effect in MS. The distribution of haplotypes from 5 loci within the chromosome 19q13.2 region, including D19S178, D19S574, APOE, APOC2, and D19S219, differed between patient and control samples. D19S574 showed a significant effect (P=.015) in Caucasian patients with MS due to the increased frequency of a single allele (P=.002). The APOE variation, prominent in other neurological diseases, showed no influence on MS susceptibility, despite its location within the chromosome 19q13.2 region. interaction effects between DR2 and chromosome 19q13.2 or MBP in MS susceptibility were not apparent. Conclusions.-The significant chromosome 19q13.2 single-locus and multilocus haplotype associations with MS in Caucasian and Chinese patient samples indicate an effect from a nearby disease susceptibility locus. These initial observations are an encouraging step toward the description of non-HLA genetic susceptibility to MS.	UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA; ROCHE MOL SYST INC, DEPT HUMAN GENET, ALAMEDA, CA USA; CHILDRENS HOSP, OAKLAND RES INST, OAKLAND, CA 94609 USA; NCI, INTRAMURAL RES SUPPORT PROGRAM, SAIC FREDERICK, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21701 USA; UNIV CALIF DAVIS, DEPT NEUROL, DAVIS, CA USA; BEIJING UNION MED COLL HOSP, DEPT NEUROL, BEIJING 100730, PEOPLES R CHINA	University of California System; University of California Berkeley; Roche Holding; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Davis; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035326] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; ALLEN M, 1994, HUM IMMUNOL, V39, P41, DOI 10.1016/0198-8859(94)90099-X; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Baur M.P., 1980, HISTOCOMPATIBILITY T, P955; BenNun A, 1996, J NEUROL, V243, pS14, DOI 10.1007/BF00873697; BIAN HJ, 1992, NEUROEPIDEMIOLOGY, V11, P52, DOI 10.1159/000110911; CARRINGTON M, 1994, HUM MOL GENET, V3, P218, DOI 10.1093/hmg/3.1.218; CARRINGTON M, 1994, HUM IMMUNOL, V41, P234, DOI 10.1016/0198-8859(94)90041-8; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CLERGETDARPOUX F, 1992, ANN HUM GENET, V56, P145, DOI 10.1111/j.1469-1809.1992.tb01140.x; Cohen J., 2013, STAT POWER ANAL BEHA, DOI 10.4324/9780203771587; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; GOODKIN DE, 1991, ARCH NEUROL-CHICAGO, V48, P805, DOI 10.1001/archneur.1991.00530200041016; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HAINES JL, 1993, AM J HUM GENET, V53, P266; HASHIMOTO LL, 1993, J NEUROIMMUNOL, V44, P77, DOI 10.1016/0165-5728(93)90270-9; HILLERT J, 1994, ANN NEUROL, V36, pS15, DOI 10.1002/ana.410360706; HILTON AA, 1995, J NEUROCHEM, V65, P309; Ibsen SN, 1996, ACTA NEUROL SCAND, V93, P236; Imanish T, 1992, HLA 1991, V1, P1065; KAMBOH MI, 1995, HUM BIOL, V67, P195; KELLARWOOD HF, 1995, J NEUROIMMUNOL, V58, P183, DOI 10.1016/0165-5728(95)00015-T; KELLY MA, 1995, J CLIN PATHOL-CL MOL, V48, pM111; KELLY MA, 1995, HUM IMMUNOL, V42, P203, DOI 10.1016/0198-8859(94)00094-7; KLITZ W, 1995, AM J HUM GENET, V57, P1436; Kuokkanen S, 1996, NAT GENET, V13, P477, DOI 10.1038/ng0896-477; KURTZKE JF, 1983, MULTIPLE SCLEROSIS P, P47; LONG JC, 1995, AM J HUM GENET, V56, P799; MARTIN M, 1995, HUM MOL GENET, V4, P423, DOI 10.1093/hmg/4.3.423; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NILLESEN WM, 1992, NUCLEIC ACIDS RES, V18, P428; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAMACHANDRAN S, 1995, TISSUE ANTIGENS, V46, P140, DOI 10.1111/j.1399-0039.1995.tb02492.x; RISCH N, 1990, AM J HUM GENET, V46, P242; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; RISCH N, 1987, AM J HUM GENET, V40, P1; RISCH N, 1992, AM J HUM GENET, V51, P673; ROTH MP, 1994, J NEUROIMMUNOL, V51, P93, DOI 10.1016/0165-5728(94)90133-3; ROTH MP, 1995, J NEUROIMMUNOL, V61, P117, DOI 10.1016/0165-5728(95)00078-G; ROTH MP, 1995, HUM IMMUNOL, V43, P276, DOI 10.1016/0198-8859(95)91033-T; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SERJEANTSON SW, 1992, EUR J IMMUNOGENET, V19, P11, DOI 10.1111/j.1744-313X.1992.tb00043.x; SPURKLAND A, 1994, HUM IMMUNOL, V39, P299, DOI 10.1016/0198-8859(94)90273-9; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A; VANDEVYVER C, 1994, J NEUROIMMUNOL, V52, P97, DOI 10.1016/0165-5728(94)90167-8; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISS KM, 1993, GENETIC VARIATION HU, P180; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WOOD NW, 1994, J NEUROL NEUROSUR PS, V57, P1191, DOI 10.1136/jnnp.57.10.1191	57	67	69	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1256	1261		10.1001/jama.278.15.1256	http://dx.doi.org/10.1001/jama.278.15.1256			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333267				2022-12-01	WOS:A1997XZ70900031
J	Bolognia, JL; Edelson, RL				Bolognia, JL; Edelson, RL			Spread of antibiotic-resistant bacteria from acne patients to personal contacts - a problem beyond the skin?	LANCET			English	Editorial Material							STAPHYLOCOCCI; ERYTHROMYCIN; THERAPY				Bolognia, JL (corresponding author), YALE UNIV,SCH MED,DEPT DERMATOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Edelson, Richard/AAD-4826-2019					CRAWFORD WW, 1979, J INVEST DERMATOL, V72, P187, DOI 10.1111/1523-1747.ep12676385; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; HARKAWAY KS, 1992, BRIT J DERMATOL, V126, P586; LEYDEN JJ, 1983, J AM ACAD DERMATOL, V8, P41, DOI 10.1016/S0190-9622(83)70005-8; LYEDEN JJ, 1997, J GERIATR DERMATO SA, V5, pA1; Miller YW, 1996, J ANTIMICROB CHEMOTH, V38, P829; MURRAY PR, 1994, MED MICROBIOLOGY, V176, P292	7	10	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					972	973		10.1016/S0140-6736(05)64063-9	http://dx.doi.org/10.1016/S0140-6736(05)64063-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329508				2022-12-01	WOS:A1997XZ71000004
J	MacCoun, R; Reuter, P				MacCoun, R; Reuter, P			Interpreting Dutch cannabis policy: Reasoning by analogy in the legalization debate	SCIENCE			English	Article							DRUG PROHIBITION	The Dutch depenalization and subsequent de facto legalization of cannabis since 1976 is used here to highlight the strengths and limitations of reasoning by analogy as a guide for projecting the effects of relaxing drug prohibitions. While the Dutch case and other analogies have flaws, they appear to converge in suggesting that reductions in criminal penalties have limited effects on drug use-at least for marijuana-but that commercial access is associated with growth in the drug-using population.	UNIV MARYLAND,SCH PUBL AFFAIRS,COLLEGE PK,MD 20742; UNIV MARYLAND,DEPT CRIMINOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	MacCoun, R (corresponding author), UNIV CALIF BERKELEY,RICHARD & RHODA GOLDMAN SCH PUBL POLICY,BERKELEY,CA 94720, USA.		MacCoun, Robert/N-1765-2019; MacCoun, Robert/D-1702-2011	MacCoun, Robert/0000-0003-0929-4423; 				Brown Jodi M., 1996, CORRECTIONAL POPULAT; COHEN P, 1997, CANNABIS USE AMSTERD; Cohen P., 1996, CANNABIS USE STEPPIN; COHEN P, COMMUNICATION; Cook T.D., 1979, QUASIEXPERIMENTATION; DEZWART WM, 1997, KERNGEGEVENS ROKEN D; DRIESSEN FM, 1989, ALCOHOL DRUGS ANDERE, V15, P2; *DRUG ENF ADM, ILL DRUG WHOL RET PR; DUKE SB, 1993, LONGEST RUNNING WAR; *EUR MON CTR DRUG, 1996, 1995 EUR MON CTR DRU; EVERINGHAM S, UNPUB 1993 NATL HOUS; *GEN ACC OFF, 1997, TGGD977 GAO; Goldstein A., 1994, ADDICTION BIOL DRUG; Hartnoll R., 1994, MULTICITY STUDY DRUG; Jansen A.C.M., 1991, CANNABIS AMSTERDAM G; Johnston LD, 1981, MARIJUANA DECRIMINAL; Johnston LD, 1995, NATL SURVEY RESULTS; KANDEL DB, 1991, MILBANK Q, V69, P365, DOI 10.2307/3350102; Kaplan J., 1970, MARIJUANA NEW PROHIB; KLEBER HD, 1994, NEW ENGL J MED, V330, P361, DOI 10.1056/NEJM199402033300514; Kleiman M, 1992, EXCESS DRUG POLICY R; KORF DJ, 1988, TIJDSCHR ALCOHOL DRU, V14, P81; LANGEMEIJER MPS, IN PRESS ILLICIT DRU; Leuw E, 1994, PROHIBITION LEGALIZA, P23; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MACCOUN R, IN PRESS DRUG WAR LE; MACCOUN RJ, 1993, PSYCHOL BULL, V113, P497, DOI 10.1037/0033-2909.113.3.497; MACCOUN RJ, 1993, J DRUG ISSUES, V23, P615, DOI 10.1177/002204269302300404; MACCOUN RJ, 1993, PSYCHOACTIVE DRUGS H, P103; MACCOUN RJ, 1995, POLICIES STRATEGIES; MEYENFELDT LH, 1996, EUROPEAN DRUG POLICI, P97; *MIN FOR AFF MIN H, 1995, DRUGS POL NETH CONT; *MIN JUST, DUTCH DRUGS POL; MIRON JA, 1995, J ECON PERSPECT, V9, P175, DOI 10.1257/jep.9.4.175; MIRON JA, 1991, AM ECON REV, V81, P242; NADELMANN E, 1989, SCIENCE, V245, P739; *NORW MIN HLTH SOC, 1997, NEW TRENDS DRUG AB N; *OFF NAT DRUG CONT, 1997, NAT DRUG CONTR STRAT; *OFF NAT DRUG CONT, 1993, STAT LOC SPEND DRUG; RHODES W, 1995, WHAT AM USERS SPEND; SANDWIJK JP, 1995, LICIT ILLICIT DRUG U, V2; SANDWIJK JP, 1991, LICIT ILLICIT DRUG U; SINGLE E W, 1989, Journal of Public Health Policy, V10, P456, DOI 10.2307/3342518; *SUBST AB MENT HLT, 1994, MED EX DAT STAT 1 B, V14; *SUBST AB MENT HLT, NAT HOUS SURV DRUG A; UCHTENHAGEN A, 1997, PROGRAMME MED PRESCR; *UN, 1981, 2 UN SURV CRIME TREN; WILSON JQ, 1991, COMMENTARY, V89, P21; Wisotsky Steven., 1992, SOC SUSPECTS WAR DRU; 1997, MMWR-MORBID MORTAL W, V45, P392	50	91	94	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					47	52		10.1126/science.278.5335.47	http://dx.doi.org/10.1126/science.278.5335.47			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311925				2022-12-01	WOS:A1997XZ12400030
J	Quill, TE; Dresser, R; Brock, DW				Quill, TE; Dresser, R; Brock, DW			The rule of double effect - A critique of its role in end-of-life decision making	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; EUTHANASIA; PAIN; VIEWS; DEATH		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	University of Rochester; Case Western Reserve University; Brown University								*ABIM, 1996, ED RES DOC; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; [Anonymous], 1992, ANN INTERN MED, V117, P947; [Anonymous], 1985, MOD PEN COD COMM, P229; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BROCK DW, 1997, MED ETHICS, P363; BRODY H, 1993, J CLIN ETHIC, V4, P112; Cantor NL, 1996, KENNEDY INST ETHIC J, V6, P107; Cherny N I, 1994, J Palliat Care, V10, P31; *COUNC ETH JUD AFF, 1992, JAMA-J AM MED ASSOC, V276, P2229; Donagan Alan, 1977, ETHICS; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; FOLEY KM, 1995, PAIN FORUM, V4, P163; Fried C., 1978, RIGHT WRONG; GARCIA JLA, 1995, ENCY BIOETHICS, V2, P636; Graber MA, 1996, J GEN INTERN MED, V11, P71, DOI 10.1007/BF02599581; GRANFIELD D, 1971, ABORTION DECISION, P126; *HAST CTR, 1987, GUID TERM LIF SUST T; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; JOHNPAUL II, 1995, CATH C MARCH 30, P189; KASS LR, 1993, HASTINGS CENT REP, V23, P34, DOI 10.2307/3562279; Kenny A., 1973, ANATOMY SOUL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KUHSE H, 1987, SANCTITYY LIFE DOCRI; Mangan J.T., 1949, THEOL STUD, V10, P41, DOI [DOI 10.1177/004056394901000102, 10.1177/004056394901000102]; MARQUIS DB, 1991, J MED PHILOS, V16, P515, DOI 10.1093/jmp/16.5.515; MEISEL A, 1995, RIGHT DIE; Nagel T., 1989, VIEW NOWHERE; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Pellegrino E D, 1992, J Clin Ethics, V3, P95; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; QUILL TE, IN PRESS JAMA; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; The SUPPORT Principal Investigators, 1995, J AMER MED ASSOC, V274, P1591; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; Ventafridda V, 1990, J Palliat Care, V6, P7; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	41	229	235	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1768	1771		10.1056/NEJM199712113372413	http://dx.doi.org/10.1056/NEJM199712113372413			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK653	9392707				2022-12-01	WOS:A1997YK65300013
J	Rees, G; Frith, CD; Lavie, N				Rees, G; Frith, CD; Lavie, N			Modulating irrelevant motion perception by varying attentional load in an unrelated task	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; MONKEY VISUAL-CORTEX; AREA MT; SUPERIOR COLLICULUS; MACAQUE; MECHANISMS; SEGREGATION; PATHWAYS; FMRI	Lavie's theory of attention proposes that the processing load in a relevant task determines the extent to which irrelevant distracters are processed. This theory was tested by asking participants in a study to perform linguistic tasks of low or high load while ignoring irrelevant visual motion in the periphery of the display. Although task and distracter were unrelated, both functional imaging of motion-related activity in cortical area V5 and psychophysical measures of the motion aftereffect showed reduced motion processing during high load in the linguistic task. These findings fulfill the prediction that perception of irrelevant distracters depends on the relevant processing load.	UNIV LONDON UNIV COLL,DEPT PSYCHOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	Rees, G (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,12 QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Rees, Geraint/C-1493-2008; Frith, Chris D/A-2171-2009	Rees, Geraint/0000-0002-9623-7007; Frith, Chris D/0000-0002-8665-0690	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broadbent D.E., 1958, PERCEPTION COMMUNICA; Buchel C, 1997, CEREB CORTEX, V7, P768, DOI 10.1093/cercor/7.8.768; CHAUDHURI A, 1991, NATURE, V344, P641; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DESIMONE R, 1989, Society for Neuroscience Abstracts, V15, P162; DESIMONE R, 1990, COLD SH Q B, V55, P963; FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; Gibson J.J., 1950, PERCEPTION VISUAL WO, DOI DOI 10.2307/1419017; GIBSON JJ, 1977, SCAND J PSYCHOL, V18, P161, DOI 10.1111/j.1467-9450.1977.tb00272.x; GIRARD P, 1989, J NEUROPHYSIOL, V62, P1287, DOI 10.1152/jn.1989.62.6.1287; GROSS CG, 1991, NEUROPSYCHOLOGIA, V29, P497, DOI 10.1016/0028-3932(91)90007-U; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; LAVIE N, 1994, PERCEPT PSYCHOPHYS, V56, P182; MOTTER BC, 1981, J NEUROSCI, V1, P3, DOI 10.1523/JNEUROSCI.01-01-00003.1981; Neill W. Trammell, 1995, P207, DOI 10.1016/B978-012208930-5/50008-8; OCraven KM, 1997, NEURON, V18, P591, DOI 10.1016/S0896-6273(00)80300-1; RODMAN HR, 1990, J NEUROSCI, V10, P1154; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shipp S, 1995, J ANAT, V187, P547; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; SHULMAN GL, 1991, J EXP PSYCHOL HUMAN, V17, P726, DOI 10.1037/0096-1523.17.3.726; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; Treisman A., 1984, VARIETIES ATTENTION, P29; TRELSMAN AM, 1969, PSYCHOL REV, V76, P282; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; UNGERLEIDER LG, 1984, J COMP NEUROL, V223, P368, DOI 10.1002/cne.902230304; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; ZEKI S, 1991, J NEUROSCI, V11, P641	34	458	469	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1616	1619		10.1126/science.278.5343.1616	http://dx.doi.org/10.1126/science.278.5343.1616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YJ874	9374459				2022-12-01	WOS:A1997YJ87400038
J	Stanner, SA; Bulmer, K; Andres, C; Lantseva, OE; Borodina, V; Poteen, VV; Yudkin, JS				Stanner, SA; Bulmer, K; Andres, C; Lantseva, OE; Borodina, V; Poteen, VV; Yudkin, JS			Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BLOOD-PRESSURE; FETAL GROWTH; BIRTH-WEIGHT; NONDIABETIC SUBJECTS; IN-UTERO; INSULIN; LIFE; MEN; HYPERTENSION	Objective: To investigate the relation between decreased maternal food intake and risk factors for coronary heart disease in adult life. Design: Cross sectional study. Subjects: 169 subjects exposed to malnutrition in utero (intrauterine group) during the siege of Leningrad (now St Petersburg) in 1941-4; 192 subjects born in Leningrad just before rationing began, before the siege (infant group); and 188 subjects born concurrently with the first two groups but outside the area of the siege (unexposed group). Setting: Ott Institute of Obstetrics and Gynaecology, St Petersburg. Main outcome measures: Development of risk factors for coronary heart disease and diabetes mellitus-obesity, blood pressure, glucose tolerance, insulin concentrations, lipids, albumin excretion rate, and clotting factors. Results: There was no difference between the subjects exposed to starvation in utero and those starved during infant life in: (a) glucose tolerance (mean fasting glucose: intrauterine group 5.2 (95% confidence interval 5.1 to 5.3), Infant group 5.3 (5.1 to 5.5), P = 0.94; mean 2 hour glucose: intrauterine group 6.1 (5.8 to 6.4), infant group 6.0 (5.7 to 6.3), P = 0.99); (b) insulin concentration; (c) blood pressure; (d) lipid concentration; or (e) coagulation factors. Concentrations of von Willebrand factor were raised in the intrauterine group (156.5 (79.1 to 309.5)) compared with the infant group (127.6 (63.9 to 254.8); P < 0.001), and female subjects in the intrauterine group had a stronger interaction between obesity and both systolic (P = 0.01) and diastolic (P = 0.04) blood pressure than in the infant group. Short adult stature was associated with raised concentrations of glucose and insulin 2 hours after a glucose load-independently of siege exposure. Subjects in the unexposed group had non-systematic differences in subscapular to triceps skinfold ratio, diastolic blood pressure, and clotting factors compared with the exposed groups. Conclusions: Intrauterine malnutrition tvas not associated with glucose intolerance, dyslipidaemia, hypertension, or cardiovascular disease in adulthood. Subjects exposed to malnutrition showed evidence of endothelial dysfunction and a stronger influence of obesity on blood pressure.	RUSSIAN ACAD MED SCI, OTT INST OBSTET & GYNAECOL, ST PETERSBURG, RUSSIA	Russian Academy of Medical Sciences; Ott Institute of Obstetrics, Gynecology & Reproductology	Stanner, SA (corresponding author), UCL, SCH MED, DEPT MED, LONDON N19 3UA, ENGLAND.		Yudkin, John S/C-1988-2008					ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1995, PLACENTA, V16, P317, DOI 10.1016/0143-4004(95)90118-3; BARKER DJP, 1982, FETAL INFANT ORIGINS; BENNETT KA, 1986, HUM BIOL, V58, P751; BROWN DC, 1991, DIABETOLOGIA, V34, P531, DOI 10.1007/BF00403292; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; MARMOT MG, 1984, LANCET, V1, P1003; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT HEART J, V73, P116; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MOHAMEDALI V, 1995, DIABETOLOGIA, V38, P1110; Office of Population Censuses and Surveys, 1980, CLASS OCC; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PAVLOV DV, 1965, LENINGRAD 1941 BLOCK; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; Robbins DC, 1996, DIABETES, V45, P242, DOI 10.2337/diabetes.45.2.242; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; ROSE GA, 1988, WHO MONOGRAPH SERIES, V56; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Stein Z., 1975, FAMINE HUM DEV DUTCH; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WALKER M, 1989, INT J EPIDEMIOL, V18, P602, DOI 10.1093/ije/18.3.602; WEINKOVE C, 1974, S AFR MED J, V48, P1888; *WHO STUD GROUP, 1985, WHO TECH REP SER, V727, P9	41	328	337	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	1997	315	7119					1342	1348		10.1136/bmj.315.7119.1342	http://dx.doi.org/10.1136/bmj.315.7119.1342			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402775	Green Published			2022-12-01	WOS:A1997YJ21800022
J	Finzi, D; Hermankova, M; Pierson, T; Carruth, LM; Buck, C; Chaisson, RE; Quinn, TC; Chadwick, K; Margolick, J; Brookmeyer, R; Gallant, J; Markowitz, M; Ho, DD; Richman, DD; Siliciano, RF				Finzi, D; Hermankova, M; Pierson, T; Carruth, LM; Buck, C; Chaisson, RE; Quinn, TC; Chadwick, K; Margolick, J; Brookmeyer, R; Gallant, J; Markowitz, M; Ho, DD; Richman, DD; Siliciano, RF			Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DYNAMICS IN-VIVO; PERIPHERAL-BLOOD; LIFE-SPAN; T-CELL; INFECTION; LYMPHOCYTES; RESISTANCE; PLASMA; INHIBITOR	The hypothesis that quiescent CD4(+) T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4(+) T lymphocytes. The frequency of resting CD4(+) T cells harboring talent HIV-l was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4(+) T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Diego; University of California System; University of California San Diego			Buck, Christopher/G-8358-2017; Quinn, Thomas/A-2494-2010	Buck, Christopher/0000-0003-3165-8094; 	NIAID NIH HHS [AI28108, AI23871, AI27670] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, R01AI028108, R37AI028108, R01AI023871] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CHUN TW, IN PRESS P NATL ACAD; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; EBERLE J, 1995, AIDS RES HUM RETROV, V11, P671, DOI 10.1089/aid.1995.11.671; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FINZI DD, UNPUB; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P707; Mellors J. W., 1995, International Antiviral News, V3, P8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATEL SS, 1988, J IMMUNOL, V141, P3726; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PLATAK M, 1993, SCIENCE, V259, P1749; Sanchez G, 1997, J VIROL, V71, P2233, DOI 10.1128/JVI.71.3.2233-2240.1997; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Stellbrink HJ, 1997, AIDS, V11, P1103, DOI 10.1097/00002030-199709000-00004; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WONG JK, IN PRESS P NATL ACAD	33	2358	2422	4	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1295	1300		10.1126/science.278.5341.1295	http://dx.doi.org/10.1126/science.278.5341.1295			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360927				2022-12-01	WOS:A1997YG04300046
J	Lacronique, V; Boureux, A; DellaValle, V; Poirel, H; Quang, CT; Mauchauffe, M; Berthou, C; Lessard, M; Berger, R; Ghysdael, J; Bernard, OA				Lacronique, V; Boureux, A; DellaValle, V; Poirel, H; Quang, CT; Mauchauffe, M; Berthou, C; Lessard, M; Berger, R; Ghysdael, J; Bernard, OA			A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RECEPTOR SUPERFAMILY; HEMATOPOIETIC-CELLS; TYROSINE KINASE; GENE; TEL; T(12-21); DEFECTS	The Janus family of tyrosine kinases (JAK) plays an essential role in development and in coupling cytokine receptors to downstream intracellular signaling events. A t(9;12)(p24;p13) chromosomal translocation in a T cell childhood acute lymphoblastic leukemia patient was characterized and shown to fuse the 3' portion of JAK2 to the 5' region of TEL, a gene encoding a member of the ETS transcription factor family, The TEL-JAK2 fusion protein includes the catalytic domain of JAK2 and the TEL-specific oligomerization domain, TEL-induced oligomerization of TEL-JAK2 resulted in the constitutive activation of its tyrosine kinase activity and conferred cytokine-independent proliferation to the interleukin-3-dependent Ba/F3 hematopoietic cell line.	INST GENET MOL, INSERM, U301, F-75010 PARIS, FRANCE; INST GENET MOL, CNRS, SD 401 301, F-75010 PARIS, FRANCE; CTR UNIV ORSAY, INST CURIE, SECT RECH, CNRS, UNITE MIXTE RECH 146, F-91405 ORSAY, FRANCE; CTR HOSP REG BREST, HOP MORVAN, LAB CYTOGENET, UNITE HEMATOL, F-29609 BREST, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; CHU Brest; Universite de Bretagne Occidentale			QUANG, christine TRAN/G-7508-2016; Bernard, Olivier A./E-5721-2016; GHYSDAEL, Jacques/F-3377-2013; Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bernard OA, 1996, LEUKEMIA LYMPHOMA, V23, P459, DOI 10.3109/10428199609054854; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIURA O, 1994, BLOOD, V84, P1501; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429	25	645	677	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1309	1312		10.1126/science.278.5341.1309	http://dx.doi.org/10.1126/science.278.5341.1309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360930				2022-12-01	WOS:A1997YG04300049
J	Wallace, MR; Chamberlin, CJ; Zerboni, L; Sawyer, MH; Oldfield, EC; Olson, PE; Arvin, AM				Wallace, MR; Chamberlin, CJ; Zerboni, L; Sawyer, MH; Oldfield, EC; Olson, PE; Arvin, AM			Reliability of a history of previous varicella infection in adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				ZOSTER VIRUS-INFECTIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDREN; SUSCEPTIBILITY; CHICKENPOX; ANTIBODY; VACCINE; REINFECTION; RESPONSES	Context.-Apparent second episodes of varicella are reported in immunocompetent hosts, but laboratory confirmation of prior immune status has rarely been possible. Objective.-To evaluate adult patients with varicella who claimed to have had previous varicella to determine whether they had true second episodes or primary cases with inaccurate clinical histories. Design.-Adult subjects with varicella who enrolled in an antiviral treatment trial were interviewed about a history of varicella. The clinical course of varicella was documented prospectively in all subjects. Serum samples that predated the acute illness were obtained from the US Navy's central serum storage facility for subjects who reported a previous episode of varicella. These stored samples were tested in parallel by enzyme-linked immunosorbent assay, latex agglutination, and Western blot for IgG antibodies to varicella-zoster virus (VZV), Participants.-Twenty military personnel with varicella and a history of the disease. Setting.-A military hospital in San Diego, Calif. Main Outcome Measure.-Presence or absence of antibodies to VZV. Results.-Twenty (10.8%) of 184 adults with serologically confirmed acute varicella reported a prior history of varicella. The clinical course of these 20 patients did not differ from those with no history of varicella. Serum samples that had been collected a mean of 12.4 months (median, 12 months; range, 3 days to 34 months) before the incident episode were available for 19 subjects. All 19 serum samples lacked IgG antibodies to VZV, Conclusion.-A history of previous varicella infection in adults with varicella may not be reliable. True second episodes of varicella are probably rare in immunocompetent adults.	NAVAL MED CTR, DIV INFECT DIS, DEPT INTERNAL MED, SAN DIEGO, CA 94305 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT INFECT DIS, STANFORD, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, SAN DIEGO, CA USA	United States Department of Defense; United States Navy; Naval Medical Center San Diego; Stanford University; Stanford University; University of California System; University of California San Diego								ACHESON DWK, 1988, J INFECTION, V16, P193, DOI 10.1016/S0163-4453(88)94122-9; ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361; BAXTER JD, 1994, CLIN INFECT DIS, V18, P785, DOI 10.1093/clinids/18.5.785; FELDMAN S, 1987, PEDIATRICS, V80, P465; Gallagher J, 1996, OCCUP MED-OXFORD, V46, P289, DOI 10.1093/occmed/46.4.289; GERSHON AA, 1990, J INFECT DIS, V161, P661, DOI 10.1093/infdis/161.4.661; GERSHON AA, 1981, AM J MED SCI, V282, P12, DOI 10.1097/00000441-198107000-00002; GERSHON AA, 1984, J INFECT DIS, V149, P137, DOI 10.1093/infdis/149.2.137; GERSHON AA, 1995, PEDIATR INFECT DIS J, V14, P742, DOI 10.1097/00006454-199509000-00003; GORDON JE, 1962, AM J MED SCI, V244, P132; GUERVICH I, 1990, INFECT CONT HOSP EP, V11, P510; JUNKER AK, 1994, J MED VIROL, V43, P119, DOI 10.1002/jmv.1890430204; Junker K, 1989, Curr Probl Dermatol, V18, P152; JURA E, 1989, PEDIATR INFECT DIS J, V8, P586, DOI 10.1097/00006454-198909000-00003; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; LOCKSLEY RM, 1985, J INFECT DIS, V152, P1172, DOI 10.1093/infdis/152.6.1172; MARTIN KA, 1994, J INFECT DIS, V170, P991, DOI 10.1093/infdis/170.4.991; MCKINNEY WP, 1989, AM J INFECT CONTROL, V17, P26, DOI 10.1016/S0196-6553(89)80009-4; MORENS DM, 1980, ANN INTERN MED, V93, P414, DOI 10.7326/0003-4819-93-3-414; MYERS MG, 1982, PEDIATRICS, V70, P199; PALUMBO PE, 1984, J GEN VIROL, V65, P2141, DOI 10.1099/0022-1317-65-12-2141; ROSS AH, 1962, NEW ENGL J MED, V267, P369, DOI 10.1056/NEJM196208232670801; ROTBART HA, 1993, J INFECT DIS, V167, P195, DOI 10.1093/infdis/167.1.195; STEELE RW, 1982, PEDIATRICS, V70, P604; STEINBERG SP, 1991, J CLIN MICROBIOL, V29, P1527, DOI 10.1128/JCM.29.7.1527-1529.1991; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; vonSeidlein L, 1996, J PEDIATR-US, V128, P52, DOI 10.1016/S0022-3476(96)70427-4; Wallace MR, 1996, J INFECT DIS, V174, P249, DOI 10.1093/infdis/174.2.249; WALLACE MR, 1994, SOUTHERN MED J, V87, P74, DOI 10.1097/00007611-199401000-00016; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669	31	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1520	1522		10.1001/jama.278.18.1520	http://dx.doi.org/10.1001/jama.278.18.1520			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363973				2022-12-01	WOS:A1997YE44500037
J	Tjandra, N; Bax, A				Tjandra, N; Bax, A			Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium	SCIENCE			English	Article							QUANTITATIVE J-CORRELATION; PHOSPHOLIPID MICELLES; HUMAN UBIQUITIN; PROTEINS; RELAXATION; SPECTROSCOPY; RESOLUTION	In isotropic solution, internuclear dipolar couplings average to zero as a result of rotational diffusion. By dissolving macromolecules in a dilute aqueous nematic discotic liquid-crystalline medium containing widely spaced magnetically oriented particles, a tunable degree of solute alignment with the magnetic field can be created while retaining the high resolution and sensitivity of the regular isotropic nuclear magnetic resonance (NMR) spectrum. Dipolar couplings between H-1-H-1, H-1-C-13, H-1-N-15, and C-13-C-13 pairs in such an oriented macromolecule no longer average to zero, and are readily measured. Distances and angles derived from dipolar couplings in human ubiquitin are in excellent agreement with its crystal structure. The approach promises to improve the accuracy of structures determined by NMR, and extend the size limit.	NIDDKD, CHEM PHYS LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Tjandra, N (corresponding author), NHLBI, BIOPHYS CHEM LAB, NIH, BLDG 10, BETHESDA, MD 20892 USA.							Bax A, 1997, J BIOMOL NMR, V10, P289, DOI 10.1023/A:1018308717741; BODEN N, 1987, J PHYS CHEM-US, V91, P4092, DOI 10.1021/j100299a031; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; Emsley J. W., 1975, NMR SPECTROSCOPY USI; GRIESINGER C, 1986, J CHEM PHYS, V85, P6837, DOI 10.1063/1.451421; Harrison WJ, 1996, FARADAY DISCUSS, V104, P139, DOI 10.1039/fd9960400139; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kung HC, 1995, J MAGN RESON SER B, V109, P323, DOI 10.1006/jmrb.1995.9987; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MacArthur MW, 1996, J MOL BIOL, V264, P1180, DOI 10.1006/jmbi.1996.0705; METZ G, 1995, J AM CHEM SOC, V117, P564, DOI 10.1021/ja00106a078; Ottiger M, 1997, J AM CHEM SOC, V119, P9825, DOI 10.1021/ja971639e; RAM P, 1988, BIOCHIM BIOPHYS ACTA, V940, P289, DOI 10.1016/0005-2736(88)90203-9; SANDERS CR, 1994, PROG NUCL MAG RES SP, V26, P421, DOI 10.1016/0079-6565(94)80012-X; SANDERS CR, 1992, BIOCHEMISTRY-US, V31, P8898, DOI 10.1021/bi00152a029; SAUPE A, 1963, PHYS REV LETT, V11, P462, DOI 10.1103/PhysRevLett.11.462; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; Tjandra N, 1997, J MAGN RESON, V124, P512, DOI 10.1006/jmre.1996.1088; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; Tolman JR, 1996, J MAGN RESON SER B, V112, P245, DOI 10.1006/jmrb.1996.0138; Tolman JR, 1997, NAT STRUCT BIOL, V4, P292, DOI 10.1038/nsb0497-292; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Vold RR, 1996, J MAGN RESON SER B, V113, P267, DOI 10.1006/jmrb.1996.0187; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	31	1428	1445	4	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1111	1114		10.1126/science.278.5340.1111	http://dx.doi.org/10.1126/science.278.5340.1111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353189				2022-12-01	WOS:A1997YE65200048
J	Sun, XW; Kuhn, L; Ellerbrock, TV; Chiasson, MA; Bush, TJ; Wright, TC				Sun, XW; Kuhn, L; Ellerbrock, TV; Chiasson, MA; Bush, TJ; Wright, TC			Human papillomavirus infection in women infected with the human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CERVICAL INTRAEPITHELIAL NEOPLASIA; CHAIN-REACTION AMPLIFICATION; RISK; DYSPLASIA	Background Among women infected with the human immunodeficiency virus (HIV), there is a high prevalence of human papillomavirus (HPV) infections. However, little is known about the natural history of HPV infections in HIV-seropositive women, and persistent HPV infections may explain the increased risk of cervical squamous intraepithelial lesions and invasive cervical cancer in HIV-seropositive women. Methods A total of 220 HIV-seropositive and 231 HIV-seronegative women in the New York City area were evaluated at two or more semiannual gynecologic examinations that included a Pap test, a test for HPV DNA, and colposcopy. Results HPV DNA was detected at the initial ex amination in 56 percent of the HIV-seropositive and 31 percent of the HIV-seronegative women. After four examinations, the cumulative prevalence of HPV infection was 83 percent in the seropositive women and 62 percent in the seronegative women (P<0.001). Persistent HPV infections were found in 24 percent of the seropositive women but in only 4 percent of the seronegative women (P<0.001). Twenty percent of the seropositive women and 3 percent of the seronegative women had persistent infections with HPV-16-associated viral types (16, 31, 33, 35, or 58) or HPV-18-associated types (18 or 45) (P<0.001), which are most strongly associated with cervical cancer. The detection of HPV DNA in women with previously negative tests was not associated with sexual activity during the interval since the preceding examination. Conclusions HIV-seropositive women have a high rate of persistent HPV infections with the types of HPV that are strongly associated with the development of high-grade squamous intraepithelial lesions and invasive cervical cancer. These persistent infections may explain the increased incidence of squamous intraepithelial lesions in HIV-seropositive women. (C) 1997, Massachusetts Medical Society.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10027; COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY 10027; CTR DIS CONTROL & PREVENT,NATL CTR HIV STD & TB PREVENT,DIV HIV AIDS PREVENT,ATLANTA,GA; NEW YORK CITY DEPT HLTH,BUR DIS INTERVENT RES,NEW YORK,NY 10013	Columbia University; Columbia University; Columbia University; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene			Manzotti, Grazia/C-5985-2008		PHS HHS [U64/CCU206822] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1982, EPIDEMIOLOGIC RES; BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077; Bernard HU, 1996, J INFECT DIS, V173, P516; Chiasson MA, 1997, OBSTET GYNECOL, V89, P690, DOI 10.1016/S0029-7844(97)00069-0; Collett, 2014, MODELLING SURVIVAL D; EVANDER M, 1995, J INFECT DIS, V171, P1026, DOI 10.1093/infdis/171.4.1026; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Hillemanns P, 1996, AIDS, V10, P1641, DOI 10.1097/00002030-199612000-00008; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; *IIARC, 1995, IARC MON EV CARC RIS, V64; KOULOS JP, 1993, GYNECOL ONCOL, V48, P364, DOI 10.1006/gyno.1993.1064; KREISS JK, 1992, SEX TRANSM DIS, V19, P54, DOI 10.1097/00007435-199201000-00011; LAGA M, 1992, INT J CANCER, V50, P45, DOI 10.1002/ijc.2910500110; LUNGU O, 1992, MOL CELL PROBE, V6, P145, DOI 10.1016/0890-8508(92)90059-7; MANOS MM, 1989, CANCER CEL, V7, P209; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; WILLIAMS AB, 1994, OBSTET GYNECOL, V83, P205; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591	20	403	421	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1343	1349		10.1056/NEJM199711063371903	http://dx.doi.org/10.1056/NEJM199711063371903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358128				2022-12-01	WOS:A1997YE44600003
J	Burkey, Y; Black, M; Reeve, H				Burkey, Y; Black, M; Reeve, H			Patients' views on their discharge from follow up in outpatient clinics: qualitative study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To discover the views of patients about their discharge from outpatient clinics, to detect any change in these perceptions over time, and explore how the discharge process might be improved for the patient. Design: A qualitative study comprising in-depth or semistructured interviews with patients 2 weeks and 3 months after discharge from an outpatient clinic. Subjects: 45 patients who had attended outpatient clinics on three or more occasions. Setting: Five general medical outpatient clinics from a Manchester provider trust. Main outcome measures: Aspects of the discharge consultation valued by patients included confidence that the doctor knew and understood their case; clarity of the discharge process; an explanation of the reasons for discharge; information about treatment, future care, and the mechanism for re-referral; and being seen by doctors who sought their views and allowed time for questions and reflection. Conclusions: Patients' views about their discharge changed over time and varied in relation to several factors, which included patients' perceptions of the discharge process, patients' expectations, the way in which the outpatient clinics were organised, and patients' relationships with, and confidence in, their general practitioners.	UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV SALFORD,PUBL HLTH RES & RESOURCE CTR,SALFORD M5 4QA,LANCS,ENGLAND; UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND	University of Manchester; University of Salford; University of Manchester								Burkey Y, 1997, FAM PRACT, V14, P29, DOI 10.1093/fampra/14.1.29; *DEP HLTH, 1995, OUTP WARD ATT ENGL F; FAULKNER A, 1993, EVALUATION DELIVERY; Fitzpatrick R., 1984, EXPERIENCE ILLNESS, P154; Horder J P, 1985, Health Trends, V17, P64; Lester J P, 1980, J R Coll Gen Pract, V30, P230; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Shaw C D, 1981, Health Trends, V13, P107; Stacey M, 1994, RES PEOPLES HLTH, P85; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008	10	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1138	1141						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374889				2022-12-01	WOS:A1997YE61500028
J	Sun, FL; Dean, WL; Kelsey, G; Allen, ND; Reik, W				Sun, FL; Dean, WL; Kelsey, G; Allen, ND; Reik, W			Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome	NATURE			English	Article							GROWTH-FACTOR-II; PERINATAL LETHALITY; TRANSGENIC MICE; GENE; OVERGROWTH; METHYLATION; EXPRESSION; H19; CHROMOSOME-7; MUTATIONS	The gene IGF2, which encodes a fetal insulin-like growth factor, is imprinted, so only one of two parental copies of the gene is expressed, The altered expression of IGF2 has been implicated in Beckwith-Wiedemann syndrome, a human fetal overgrowth syndrome, which is characterized by overgrowth of several organs and an increased risk of developing childhood tumours, We have introduced Igf2 transgenes into the mouse genome by using embryonic stern cells, which leads to transactivation of the endogenous Igf2 gene, The consequent overexpression of Igf2 results in most of the symptoms of Beckwith-Wiedemann syndrome, including prenatal overgrowth, polyhydramnios, fetal and neonatal lethality, disproportionate organ overgrowth including tongue enlargement, and skeletal abnormalities. These phenotypes establish Igf2 overexpression as a key determinant of Beckwith-Wiedemann syndrome.	BABRAHAM INST,DEPT GENET & DEV,LAB DEV GENET & IMPRINTING,CAMBRIDGE CB2 4AT,ENGLAND; BABRAHAM INST,DEPT GENET & DEV,DEV NEUROBIOL LAB,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			allen, nick d/A-4336-2010; Reik, Wolf/I-6794-2012	Dean, Wendy/0000-0001-9441-5044; Reik, Wolf/0000-0003-0216-9881; Kelsey, Gavin/0000-0002-9762-5634; Allen, Nicholas/0000-0003-4009-186X				BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ELLIOTT M, 1994, J MED GENET, V31, P560, DOI 10.1136/jmg.31.7.560; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; Hatada I, 1997, J BIOL CHEM, V272, P9120, DOI 10.1074/jbc.272.14.9120; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HEDBORG F, 1994, AM J PATHOL, V145, P802; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEE JE, 1993, MOL REPROD DEV, V35, P382, DOI 10.1002/mrd.1080350411; LEE JT, 1997, NATURE, V386, P272; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; McLaughlin KJ, 1996, DEVELOPMENT, V122, P265; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; Sambrook J., 1989, MOL CLONING LAB MANU; Sasaki H, 1996, DNA Res, V3, P331, DOI 10.1093/dnares/3.5.331; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; SLATTER RE, 1994, J MED GENET, V31, P749, DOI 10.1136/jmg.31.10.749; WALTER J, 1996, EPIGENETIC MECHANISM, P1195; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WARD A, 1992, INSULIN LIKE GROWTH, P45; Ward Andrew, 1997, Genes and Function, V1, P25; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	44	250	260	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					809	815		10.1038/39797	http://dx.doi.org/10.1038/39797			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349812				2022-12-01	WOS:A1997YC14800047
J	Jack, RS; Fan, XL; Bernheiden, M; Rune, G; Ehlers, M; Weber, A; Kirsch, G; Mentel, R; Furll, B; Freudenberg, M; Schmitz, G; Stelter, F; Schutt, C				Jack, RS; Fan, XL; Bernheiden, M; Rune, G; Ehlers, M; Weber, A; Kirsch, G; Mentel, R; Furll, B; Freudenberg, M; Schmitz, G; Stelter, F; Schutt, C			Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection	NATURE			English	Article							FREE-FLOW ISOTACHOPHORESIS; CD14; ENDOTOXIN; MICE; LPS; LIPOPROTEINS; MONOCYTES; RECEPTOR; SHOCK	An invading pathogen must be held in check by the innate immune system until a specific immune response can be mounted. In the case of Gram-negative bacteria, the principal stimulator of the innate immune system is Lipopolysaccharide (LPS), a component of the bacterial outer membrane(1). In vitro, LPS is bound by lipopolysaccharide-binding protein (LBP)(2) and transferred to CD14-the LPS receptor on the macrophage surface(3,4)-or to high-density lipoprotein (HDL) particles(5,6). Transfer to CD14 triggers an inflammatory response which is crucial for keeping an infection under control. Here we investigate how LBP functions in vivo by using LBP-deficient mice. Surprisingly, we find that LBP is not required in vivo for the clearance of LPS from the circulation, but is essential for the rapid induction of an inflammatory response by small amounts of LPS or Gram-negative bacteria and for survival of an intraperitoneal Salmonella infection.	UNIV GREIFSWALD,INST ANAT,D-17489 GREIFSWALD,GERMANY; UNIV GREIFSWALD,NUKL MED KLIN & POLIKLIN,D-17489 GREIFSWALD,GERMANY; UNIV GREIFSWALD,INST MED MIKROBIOL,D-17489 GREIFSWALD,GERMANY; MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY; UNIV KLINIKUM REGENSBURG,KLIN CHEM & LAB MED,D-93042 REGENSBURG,GERMANY	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; University of Regensburg	Jack, RS (corresponding author), UNIV GREIFSWALD,INST IMMUNOL & TRANSFUS MED,SAUERBRUCHSTR,D-17489 GREIFSWALD,GERMANY.			Freudenberg, Marina Alexandra/0000-0001-5894-1805				FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GALLAY P, 1994, P NATL ACAD SCI USA, V91, P7922, DOI 10.1073/pnas.91.17.7922; Grunwald U, 1996, J IMMUNOL, V157, P4119; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; JACK RS, 1995, EUR J IMMUNOL, V25, P1436, DOI 10.1002/eji.1830250545; NOWICKA G, 1990, J LIPID RES, V31, P1947; NOWICKA G, 1990, J LIPID RES, V31, P1173; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHMITZ G, 1997, HDB LIPOPROTEIN TEST, P477; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schutt C, 1995, RES IMMUNOL, V146, P339, DOI 10.1016/0923-2494(96)81038-8; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J IMMUNOL, V158, P3925; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025	18	283	297	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					742	745		10.1038/39622	http://dx.doi.org/10.1038/39622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338787				2022-12-01	WOS:A1997YA95900058
J	Dolan, RJ; Fink, GR; Rolls, E; Booth, M; Holmes, A; Frackowiak, RSJ; Friston, KJ				Dolan, RJ; Fink, GR; Rolls, E; Booth, M; Holmes, A; Frackowiak, RSJ; Friston, KJ			How the brain learns to see objects and faces in an impoverished context	NATURE			English	Article							INFERIOR TEMPORAL CORTEX; SELECTIVE ATTENTION; EXTRASTRIATE CORTEX; RECOGNITION MEMORY; NEURONS	A degraded image of an object or face, which appears meaningless when seen for the first time, is easily recognizable after viewing an undegraded version of the same image(1), The neural mechanisms by which this form of rapid perceptual learning facilitates perception are not well understood. Psychological theory suggests the involvement of systems for processing stimulus attributes, spatial attention and feature binding(2), as well as those involved in visual imagery(3). Here we investigate where and how this rapid perceptual learning is expressed in the human brain by using functional neuroimaging to measure brain activity during exposure to degraded images before and after exposure to the corresponding undegraded versions (Fig. 1), Perceptual learning of faces or objects enhanced the activity of inferior temporal regions known to be involved in face and object recognition respectively(4-6). In addition, both face and object learning led to increased activity in medial and lateral parietal regions that have been implicated in attention(7) and visual imagery(8). We observed a strong coupling between the temporal face area and the medial parietal cortex when, and only when, faces were perceived, This suggests that perceptual learning involves direct interactions between areas involved in face recognition and those involved in spatial attention, feature binding and memory recall.	ROYAL FREE HOSP,SCH MED,ACAD DEPT PSYCHIAT,LONDON NW3,ENGLAND; UNIV OXFORD,DEPT EXPT PSYCHOL,OXFORD OX1 3UD,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Oxford	Dolan, RJ (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON W1N 3BG,ENGLAND.		Frackowiak, Richard/H-4383-2011; Fink, Gereon R./AFW-9377-2022; Friston, Karl/D-9230-2011; Fink, Gereon R./E-1616-2012; Frackowiak, Richard S/I-1809-2013	Frackowiak, Richard/0000-0002-3151-822X; Fink, Gereon R./0000-0002-8230-1856; Friston, Karl/0000-0001-7984-8909; Fink, Gereon R./0000-0002-8230-1856; Rolls, Edmund/0000-0003-3025-1292; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Clark VP, 1996, NEUROIMAGE, V4, P1, DOI 10.1006/nimg.1996.0025; DESIMONE R, 1979, BRAIN RES, V178, P363, DOI 10.1016/0006-8993(79)90699-1; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; FLETCHER P, 1995, NEUROIMAGE, V2, P196; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853, DOI 10.1126/science.7638604; Friston KJ, 1997, HUM BRAIN MAPP, V5, P133, DOI 10.1002/(SICI)1097-0193(1997)5:2<133::AID-HBM7>3.0.CO;2-4; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GROSS CG, 1979, NEUROPSYCHOLOGIA, V17, P215, DOI 10.1016/0028-3932(79)90012-5; GROSS CG, 1972, HDB SENSORY PHYSL, V7, P451; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; ISHAI A, 1995, SCIENCE, V268, P1772, DOI 10.1126/science.7792605; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kosslyn S.M., 1996, IMAGE BRAIN RESOLUTI; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAMACHANDRAN VS, 1994, ARTFUL EYE, P249; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SAKIA K, 1994, NEUROREPORT, V5, P829; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TANAKA K, 1986, J NEUROSCI, V6, P134; Tovee MJ, 1996, NEUROREPORT, V7, P2757, DOI 10.1097/00001756-199611040-00070; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549	30	295	296	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					596	599		10.1038/39309	http://dx.doi.org/10.1038/39309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335498	Green Submitted			2022-12-01	WOS:A1997YA00800058
J	Kroman, N; Wohlfahrt, J; Andersen, KW; Mouridsen, HT; Westergaard, T; Melbye, M				Kroman, N; Wohlfahrt, J; Andersen, KW; Mouridsen, HT; Westergaard, T; Melbye, M			Time since childbirth and prognosis in primary breast cancer: population based study	BRITISH MEDICAL JOURNAL			English	Article							FULL TERM PREGNANCY; WOMEN; RISK; INCREASE; BIRTH; AGE	Objective: To investigate whether time since birth of last child was of prognostic importance in Women with primary breast cancer. Design: Retrospective cohort study based on a population based database of breast cancer diagnoses with detailed information on tumour characteristics, treatment regimens, reproductive factors, and vital status. Setting: Denmark. Subjects: 5652 women with primary breast cancer aged 45 years or less at the time of diagnosis. Main outcome measures: 5 and 10 year survival; relative risk of dying. Results: Women diagnosed in the first 2 years after last childbirth had a crude 5 year survival of 58.7% and 10 year survival of 46.1% compared with 78.4% and 66.0% for Women whose last childbirth was more than 2 years before their diagnosis. After adjustment for age, reproductive factors, and stage of disease (tumour size, axillary nodal status, and histological grading), a diagnosis sooner than 2 years since last childbirth was significantly associated with a poor survival (relative risk 1.58, 95% confidence interval 1.24 to 2.02) compared with women who gave birth more than 5 years previously. Further analyses showed that the effect was not modified by age at diagnosis, tumour size, and nodal status. Conclusion: A diagnosis of breast cancer less than 2 years after having given birth is associated with a particularly pool-survival irrespective of the stage of disease at debut. Therefore, a recent pregnancy should be regarded as a negative prognostic factor and should be considered in. counselling these patients and in the decisions regarding adjuvant treatment.	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN,DENMARK; CENT HOSP HILLEROD,DEPT SURG A,DK-3400 HILLEROD,DENMARK; RIGSHOSP,DANISH BREAST CANC COOPERAT GRP,DK-2100 COPENHAGEN,DENMARK	Aarhus University; Statens Serum Institut; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen				melbye, mads/0000-0001-8264-6785				ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; BOETANI JCM, 1988, PREV MED, V17, P634; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; Clark R M, 1989, Clin Oncol (R Coll Radiol), V1, P11, DOI 10.1016/S0936-6555(89)80004-4; COX DR, 1972, J R STAT SOC B, V34, P187; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; GRUBBS CJ, 1983, J NATL CANCER I, V71, P625; GUINEE VF, 1994, LANCET, V343, P1587; HART CA, 1988, BAILLIERE CLIN IMMUN, V2, P735; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; MAX MH, 1984, AM SURGEON, V50, P23; Michels KB, 1996, LANCET, V347, P431, DOI 10.1016/S0140-6736(96)90010-0; PETREK JA, 1994, MONOGR NCI, P113; *SAS I, 1992, P229 SAS I STAT; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; STIRRAT GM, 1994, BRIT MED J, V308, P1385, DOI 10.1136/bmj.308.6941.1385; STORM HH, 1991, CANC REGISTRATION PR, P220; TRETLI S, 1988, BRIT J CANCER, V58, P382, DOI 10.1038/bjc.1988.224; VONSCHOULTZ E, 1995, J CLIN ONCOL, V13, P430, DOI 10.1200/JCO.1995.13.2.430; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578	21	72	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					851	855		10.1136/bmj.315.7112.851	http://dx.doi.org/10.1136/bmj.315.7112.851			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353505	Green Published			2022-12-01	WOS:A1997YA00700023
J	Neuenschwander, H; Modell, B				Neuenschwander, H; Modell, B			Audit of process of antenatal screening for sickle cell disorders at a north London hospital	BRITISH MEDICAL JOURNAL			English	Article									UCL, SCH MED, WHITTINGTON HOSP, DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5HT, ENGLAND	University of London; University College London; UCL Medical School					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Modell B, 1997, BRIT MED J, V315, P779, DOI 10.1136/bmj.315.7111.779; MODELL M, 1990, BRIT MED J, V300, P1702, DOI 10.1136/bmj.300.6741.1702; PETROU M, 1992, J MED GENET, V29, P820, DOI 10.1136/jmg.29.11.820; *STAND MED ADV COM, 1994, REPORT WORKING PARTY	4	17	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					784	785						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345171				2022-12-01	WOS:A1997XY91100021
J	Golombek, MP; Cook, RA; Economou, T; Folkner, WM; Haldemann, AFC; Kallemeyn, PH; Knudsen, JM; Manning, RM; Moore, HJ; Parker, TJ; Rieder, R; Schofield, JT; Smith, PH; Vaughan, RM				Golombek, MP; Cook, RA; Economou, T; Folkner, WM; Haldemann, AFC; Kallemeyn, PH; Knudsen, JM; Manning, RM; Moore, HJ; Parker, TJ; Rieder, R; Schofield, JT; Smith, PH; Vaughan, RM			Overview of the Mars Pathfinder Mission and assessment of landing site predictions	SCIENCE			English	Article							THERMAL INERTIA; PHYSICAL-PROPERTIES; ALBEDO	Chemical analyses returned by Mars Pathfinder indicate that some rocks may be high in silica, implying differentiated parent materials. Rounded pebbles and cobbles and a possible conglomerate suggest fluvial processes that imply liquid water in equilibrium with the atmosphere and thus a warmer and wetter past. The moment of inertia indicates a central metallic core of 1300 to 2000 kilometers in radius. Composite airborne dust particles appear magnetized by freeze-dried maghemite stain or cement that may have been leached from crustal materials by an active hydrologic cycle. Remote-sensing data at a scale of generally greater than similar to 1 kilometer and an Earth analog correctly predicted a rocky plain safe for landing and roving with a variety of rocks deposited by catastrophic floods that are relatively dust-free.	UNIV CHICAGO, ENRICO FERMI INST, CHICAGO, IL 60637 USA; UNIV COPENHAGEN, NIELS BOHR INST, DK-1168 COPENHAGEN, DENMARK; US GEOL SURVEY, ASTROGEOL TEAM, MENLO PK, CA 94025 USA; MAX PLANCK INST CHEM, D-55128 MAINZ, GERMANY; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA	University of Chicago; University of Copenhagen; Niels Bohr Institute; United States Department of the Interior; United States Geological Survey; Max Planck Society; University of Arizona	Golombek, MP (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, PASADENA, CA 91109 USA.		Haldemann, Albert F C/I-9224-2012	Haldemann, Albert F C/0000-0003-3741-8841				Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1972, 144 GEOL SOC AM, P73; Christensen P., 1992, MARS SPACE SCI SERIE, P686; CHRISTENSEN PR, 1986, ICARUS, V68, P217, DOI 10.1016/0019-1035(86)90020-5; CHRISTENSEN PR, 1982, J GEOPHYS RES, V87, P9985, DOI 10.1029/JB087iB12p09985; CHRISTENSEN PR, 1986, J GEOPHYS RES-SOLID, V91, P3533, DOI 10.1029/JB091iB03p03533; Edgett KS, 1997, J GEOPHYS RES-PLANET, V102, P4107, DOI 10.1029/96JE02825; Farmer C. B., 1977, Journal of Geophysical Research, V82, P4225, DOI 10.1029/JS082i028p04225; FOLKNER WM, 1997, SCIENCE, V278, P1748; Golombek M, 1997, J GEOPHYS RES-PLANET, V102, P4117, DOI 10.1029/96JE03319; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3953, DOI 10.1029/96JE02805; GOLOMBEK MP, 1995, MARS PATHFINDER LA 1, V2, P63; GOLOMBEK MP, 1994, MARS PATHFINDER LA 2, P47; GUINNESS EA, 1987, J GEOPHYS RES E S, V575; HABERLE RM, 1991, ICARUS, V90, P187, DOI 10.1016/0019-1035(91)90100-8; Haldeman AFC, 1997, J GEOPHYS RES-PLANET, V102, P4097, DOI 10.1029/96JE03321; Harmon JK, 1997, J GEOPHYS RES-PLANET, V102, P4081, DOI 10.1029/96JE01953; HAYASHI JN, 1995, J GEOPHYS RES-PLANET, V100, P5277, DOI 10.1029/94JE02449; HOWINGTONKRAUS E, 1995, MARS PATHF LAND SI 2, V2, P38; HVIID SF, 1997, SCIENCE, V278, P1767; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; KONOPLIV AS, 1995, JPL PUBL, P73; LONGHI J, 1992, MARS, P184; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; Mitchell JK., 1972, P 3 LUNAR SCI C, P3235; OLHOEFT GR, 1975, EARTH PLANET SC LETT, V24, P394, DOI 10.1016/0012-821X(75)90146-6; PALLUCONI FD, 1981, ICARUS, V45, P415, DOI 10.1016/0019-1035(81)90044-0; PLESKOT LK, 1981, ICARUS, V45, P179, DOI 10.1016/0019-1035(81)90013-0; Pollack J. B., 1977, Journal of Geophysical Research, V82, P4479, DOI 10.1029/JS082i028p04479; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; Rice JW, 1997, J GEOPHYS RES-PLANET, V102, P4185, DOI 10.1029/96JE02824; RIEDER R, 1997, SCIENCE, V278, P1770; *ROV TEAM, 1997, SCIENCE, V278, P1764; Schofield JT, 1997, SCIENCE, V278, P1752, DOI 10.1126/science.278.5344.1752; SMITH PH, 1997, SCIENCE, V278, P1757; SPENCER DA, 1995, 95379 AM ASTR SOC AM; THOMPSON TW, 1989, P LUN PLAN SCI C, V19, P409; Yoder CF, 1997, J GEOPHYS RES-PLANET, V102, P4065, DOI 10.1029/96JE03642; Zurek R.W., 1992, MARS, P835; [No title captured]	42	187	194	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1743	1748		10.1126/science.278.5344.1743	http://dx.doi.org/10.1126/science.278.5344.1743			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388167				2022-12-01	WOS:A1997YJ90100033
J	Schofield, JT; Barnes, JR; Crisp, D; Haberle, RM; Larsen, S; Magalhaes, JA; Murphy, JR; Seiff, A; Wilson, G				Schofield, JT; Barnes, JR; Crisp, D; Haberle, RM; Larsen, S; Magalhaes, JA; Murphy, JR; Seiff, A; Wilson, G			The Mars Pathfinder atmospheric structure investigation meteorology (ASI/MET) experiment	SCIENCE			English	Article							MARTIAN ATMOSPHERE; BOUNDARY-LAYER; THERMAL TIDES; DUST STORMS; DEVILS; MODEL	The Mars Pathfinder atmospheric structure investigation/meteorology (ASI/MET) experiment measured the vertical density, pressure, and temperature structure of the martian atmosphere from the surface to 160 km, and monitored surface meteorology and climate for 83 sols (1 sol = 1 martian day = 24.7 hours). The atmospheric structure and the weather record are similar to those observed by the Viking 1 lander (VL-1) at the same latitude, altitude, and season 21 years ago, but there are differences related to diurnal effects and the surface properties of the landing site. These include a cold nighttime upper atmosphere; atmospheric temperatures that are 10 to 12 degrees kelvin warmer near the surface; light slope-controlled winds; and dust devils, identified by their pressure, wind, and temperature signatures. The results are consistent with the warm, moderately dusty atmosphere seen by VL-1.	OREGON STATE UNIV,COLL OCEAN & ATMOSPHER SCI,CORVALLIS,OR 97331; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; RISO NATL LAB,DK-4000 ROSKILDE,DENMARK; SAN JOSE STATE UNIV FDN,SAN JOSE,CA; ARIZONA STATE UNIV,TEMPE,AZ	Oregon State University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Technical University of Denmark; California State University System; San Jose State University; Arizona State University; Arizona State University-Tempe	Schofield, JT (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Crisp, David/F-6642-2017	Crisp, David/0000-0002-4573-9998				CLANCY R, UNPUB; Clancy RT, 1996, ICARUS, V122, P36, DOI 10.1006/icar.1996.0108; Folkner W. M., COMMUNICATION; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; GIERASCH P, 1968, PLANET SPACE SCI, V16, P615, DOI 10.1016/0032-0633(68)90102-5; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; HABERLE RM, 1993, J ATMOS SCI, V50, P1544, DOI 10.1175/1520-0469(1993)050<1544:ABLMFM>2.0.CO;2; Haberle RM, 1997, J GEOPHYS RES-PLANET, V102, P13301, DOI 10.1029/97JE01334; Hess S. L., 1977, Journal of Geophysical Research, V82, P4559, DOI 10.1029/JS082i028p04559; JAKOSKY BM, IN PRESS ICARUS; James P.B., 1992, MARS, P934; LOPEZPUERTAS M, 1995, ICARUS, V114, P113, DOI 10.1006/icar.1995.1047; MAGALHAES JA, 1995, ICARUS, V113, P277, DOI 10.1006/icar.1995.1024; MURPHY JR, 1990, J GEOPHYS RES-SOLID, V95, P14555, DOI 10.1029/JB095iB09p14555; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; Rivell T, 1997, J SPACECRAFT ROCKETS, V34, P265, DOI 10.2514/2.3211; RYAN JA, 1983, J GEOPHYS RES-OCEANS, V88, P1005, DOI 10.1029/JC088iC15p11005; Seiff A, 1997, J GEOPHYS RES-PLANET, V102, P4045, DOI 10.1029/96JE03320; Seiff A., 1977, Journal of Geophysical Research, V82, P4364, DOI 10.1029/JS082i028p04364; SHARMAN RD, 1980, J ATMOS SCI, V37, P1994, DOI 10.1175/1520-0469(1980)037<1994:MAPPFV>2.0.CO;2; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; THOMAS P, 1985, SCIENCE, V230, P175, DOI 10.1126/science.230.4722.175; TILLMAN JE, 1994, J ATMOS SCI, V51, P1709, DOI 10.1175/1520-0469(1994)051<1709:TBLOMF>2.0.CO;2; TILLMAN JE, 1988, J GEOPHYS RES-ATMOS, V93, P9433, DOI 10.1029/JD093iD08p09433; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; Wilson RJ, 1996, J ATMOS SCI, V53, P1290, DOI 10.1175/1520-0469(1996)053<1290:CMSOTT>2.0.CO;2; WOLFF MJ, IN PRESS B AM ASTRON; Zurek R.W., 1992, MARS, P835; ZUREK RW, 1981, SCIENCE, V213, P437, DOI 10.1126/science.213.4506.437	29	339	342	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1752	1758		10.1126/science.278.5344.1752	http://dx.doi.org/10.1126/science.278.5344.1752			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388169				2022-12-01	WOS:A1997YJ90100035
J	Frey, M				Frey, M			Risks and prevention of Dupuytren's contracture	LANCET			English	Editorial Material											Frey, M (corresponding author), UNIV VIENNA,SCH MED,DEPT SURG,PLAST & RECONSTRUCT SURG SECT,WAEHRINGER GUERTEL 18,A-1090 VIENNA,AUSTRIA.							Burge P, 1997, J BONE JOINT SURG BR, V79B, P206, DOI 10.1302/0301-620X.79B2.6990; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Sinha A, 1997, J BONE JOINT SURG BR, V79B, P211, DOI 10.1302/0301-620X.79B2.6670	3	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1568	1568		10.1016/S0140-6736(05)64010-X	http://dx.doi.org/10.1016/S0140-6736(05)64010-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393334				2022-12-01	WOS:A1997YH98600006
J	Duan, D; Winter, C; Cowley, S; Hume, JR; Horowitz, B				Duan, D; Winter, C; Cowley, S; Hume, JR; Horowitz, B			Molecular identification of a volume-regulated chloride channel	NATURE			English	Article							RESISTANCE P-GLYCOPROTEIN; CL CURRENTS; PROTEIN; CELLS; EXPRESSION; MYOCYTES; ELECTROPHYSIOLOGY; CLONING	A volume-regulated chloride current (I-Cl.vol) is ubiquitously present in mammalian cells, and is required for the regulation of electrical activity cell volume, intracellular pH, immunological responses, cell proliferation and differentiation. However, the molecule responsible for I-Cl.vol has yet to be determined(1-3). Although three putative chloride channel proteins expressed from cloned genes (P-glycoprotein(4), pI(Cln), (ref. 5) and ClC-2 (ref. 6)) have been proposed to be the molecular equivalent of I-Cl.vol, neither P-glycoprotein nor pI(Cln), is thought to be a chloride channel or part thereof(7,8), and the properties of expressed ClC-2 channels differ from native I-Cl.vol (refs. 3, 6). Here we report that functional expression in NIH/3T3 cells of a cardiac clone of another member of the CIC family, ClC-3, results in a large basally active chloride conductance, which is strongly modulated by cell volume and exhibits many properties identical to those of I-Cl.vol in native cells(1-3,9-13). A mutation of asparagine to lysine at position 579 at the end of the transmembrane domains of ClC-3 abolishes the outward rectification and changes the anion selectivity from I- > Cl- to Cl- > I- but leaves swelling activation intact. Because ClC-3 is a channel protein belonging to a large gene family of chloride channels(3,14), these results indicate that ClC-3 encodes I-Cl.vol in many native mammalian cells.	UNIV NEVADA,SCH MED,DEPT CELL BIOL & PHYSIOL,RENO,NV 89557	Nevada System of Higher Education (NSHE); University of Nevada Reno								BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUAN D, 1995, CIRC RES, V77, P379, DOI 10.1161/01.RES.77.2.379; Duan D, 1997, CIRC RES, V80, P103, DOI 10.1161/01.RES.80.1.103; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P266; FORENZ C, 1996, P NATL ACAD SCI USA, V93, P13362; GRIMDER S, 1992, NATURE, V360, P759; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; HAMILL OP, 1981, PFLUGERS ARCH, V422, P143; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; Jentsch TJ, 1996, CURR OPIN NEUROBIOL, V6, P303, DOI 10.1016/S0959-4388(96)80112-7; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Meyer K, 1996, J GEN PHYSIOL, V108, P177, DOI 10.1085/jgp.108.3.177; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Shuba LM, 1996, J PHYSIOL-LONDON, V491, P69, DOI 10.1113/jphysiol.1996.sp021197; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDENBERG JI, 1994, J GEN PHYSIOL, V104, P997, DOI 10.1085/jgp.104.6.997; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629	30	401	444	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					417	421		10.1038/37151	http://dx.doi.org/10.1038/37151			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389484				2022-12-01	WOS:A1997YH54900068
J	Ellrodt, G; Cook, DJ; Lee, J; Cho, M; Hunt, D; Weingarten, S				Ellrodt, G; Cook, DJ; Lee, J; Cho, M; Hunt, D; Weingarten, S			Evidence-based disease management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; DEPENDENT DIABETES-MELLITUS; MEDICAL LITERATURE; USERS GUIDES; INTERVENTIONAL TRIAL; COST-EFFECTIVENESS; CRITICAL PATHWAYS; PRIMARY-CARE; RECOMMENDATIONS; DECISION	Disease management is an approach to patient care that emphasizes coordinated, comprehensive care along the continuum of disease and across health care delivery systems, Evidence-based medicine is an approach to practice and teaching that integrates pathophysiological rationale, caregiver experience, and patient preferences with valid and current clinical research evidence, Using diabetes mellitus as an example, we describe the importance of evidence-based medicine to the development of disease management programs, We present a method for developing and implementing evidence-based clinical guidelines, clinical pathways, and algorithms and describe the creation of systems to measure and report processes and outcomes that could drive quality improvement in diabetes care, Multidisciplinary teams are ideally suited to develop, lead, and implement evidence-based disease management programs, since they play an essential role in the preventive, diagnostic, and therapeutic decisions for patients with diabetes throughout the course of their disease.	UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, HLTH SERV RES FELLOWSHIP PROGRAM, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DEPT MED, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DEPT PHARM, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,HLTH SERV RES, DEPT MED, LOS ANGELES, CA 90048 USA; MCMASTER UNIV, FAC HLTH SCI, DEPT MED, DIV GEN INTERNAL MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; McMaster University; McMaster University								ALBERTI KGMM, 1994, DIABETIC MED, V11, P899, DOI 10.1111/j.1464-5491.1994.tb00376.x; Aucott JN, 1996, J GEN INTERN MED, V11, P139, DOI 10.1007/BF02600265; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BLANK LL, 1992, ANN INTERN MED, V117, P778; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; COOK DJ, 1995, CAN MED ASSOC J, V153, P755; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DEIGNAN M, 1995, PATIENT FOCUSED CARE; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; ELLRODT AG, 1995, PATIENT FOCUSED CARE; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; Fang E, 1996, ARCH FAM MED, V5, P528, DOI 10.1001/archfami.5.9.528; FELD MJ, 1990, CLIN PRACTICE GUIDEL; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hiss RG, 1996, ANN INTERN MED, V124, P180, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00021; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; LavizzoMourey R, 1996, ANN INTERN MED, V124, P919, DOI 10.7326/0003-4819-124-10-199605150-00010; Lee TH, 1996, J GEN INTERN MED, V11, P174, DOI 10.1007/BF02600271; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LUMSDON K, 1995, HOSP HEALTH NETWORK, V69, P34; MEYER LC, 1993, CASE MANAGER, V4, P54; Mulrow CD, 1996, J GEN INTERN MED, V11, P185, DOI 10.1007/BF02600275; NANNIPIERI M, 1995, DIABETES CARE, V18, P1, DOI 10.2337/diacare.18.1.1; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; NOBLE J, 1994, J GEN INTERN MED, V9, pS31, DOI 10.1007/BF02598116; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1417; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1971; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1249; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1793; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1575; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; PETERS AL, 1991, ANN INTERN MED, V115, P45, DOI 10.7326/0003-4819-115-1-45; Quickel KE, 1996, ANN INTERN MED, V124, P160, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00016; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SCHOENBAUM SC, 1995, AGENCY HLTH CARE POL; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; SINGER DE, 1992, ANN INTERN MED, V116, P683; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; TAN MH, 1992, CAN MED ASSOC J, V147, P697; The Boston Consulting Group, 1995, PROM DIS MAN; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TINKER LF, 1994, J AM DIET ASSOC, V94, P507, DOI 10.1016/0002-8223(94)90212-7; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WEINGARTEN SR, IN PRESS AM REV RESP; WILCZYNSKI NL, 1994, P ANN S COMP APPL ME, V17, P601; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; Yandell B, 1995, Qual Manag Health Care, V3, P55	74	273	276	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1687	1692		10.1001/jama.278.20.1687	http://dx.doi.org/10.1001/jama.278.20.1687			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388089				2022-12-01	WOS:A1997YG85900031
J	Klenerman, P; Hengartner, H; Zinkernagel, RM				Klenerman, P; Hengartner, H; Zinkernagel, RM			A non-retroviral RNA virus persists in DNA form	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL MEMORY; IMMUNOLOGICAL MEMORY; INFECTION; SEQUENCE; ANTIGEN; ESCAPE; ASSAY	Infection of adult mice with lymphocytic choriomeningitis virus (LCMV), a non-cytopathic segmented RNA virus, leads initially to generalized infection, followed by clearance and subsequent lifelong immunity. Indirect evidence has suggested that viral antigens may persist in lymphoid tissues during the phase of immunological memory, but viral genomic RNA has not been detected in previous studies(1,2). During a search for persistent virus in the spleen, we identified LCMV-specific sequences present as DNA by polymerase chain reaction (PCR) in mice over 200 days after infection. In vivo and in vitro studies revealed that reverse transcription of viral RNA into complementary DNA occurred after acute infection of cells of its natural hosts, mouse and hamster, but not of other species and could be inhibited in vitro by azidothymidine (AZT), indicating that this was mediated by endogenous reverse transcriptase activity. These findings reveal a surprising and new pathway of interaction between exogenous RNA viruses and endogenous retroviral, and perhaps other host components, that results in the persistence of virally determined DNA. We speculate that the latter may function in vivo as a form of DNA vaccine.	UNIV ZURICH HOSP,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital				klenerman, paul/0000-0003-4307-9161				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Coffin J, 1993, REVERSE TRANSCRIPTAS, P445; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; KAGI D, 1994, NATURE, V369, P91; Kundig TM, 1996, P NATL ACAD SCI USA, V93, P9716, DOI 10.1073/pnas.93.18.9716; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LEHMANNG.F, 1967, NATURE, V213, P770, DOI 10.1038/213770a0; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P28; Loewer Roswitha, 1996, Proceedings of the National Academy of Sciences of the United States of America, V93, P5177; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; OLDSTONE MB, 1971, SCIENCE, V174, P843, DOI 10.1126/science.174.4011.843; OLDSTONE MBA, 1982, NATURE, V300, P360, DOI 10.1038/300360a0; Oxenius A, 1995, EUR J IMMUNOL, V25, P3402, DOI 10.1002/eji.1830251230; PEASE LR, 1980, NATURE, V286, P398, DOI 10.1038/286398a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; Planz O, 1996, NATURE, V382, P726, DOI 10.1038/382726a0; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; RAWLS WE, 1976, J GEN VIROL, V33, P421, DOI 10.1099/0022-1317-33-3-421; ROMANOWSKI V, 1985, VIRUS RES, V3, P101, DOI 10.1016/0168-1702(85)90001-2; Salvato MS, 1993, ARENAVIRIDAE, P133; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; SKYULEV Y, 1996, IMMUNITY, V4, P565; SLIFKA MK, 1995, J VIROL, V69, P1895, DOI 10.1128/JVI.69.3.1895-1902.1995; SMITH MS, 1987, J VIROL, V61, P3769, DOI 10.1128/JVI.61.12.3769-3773.1987; WIENER AM, 1986, ANNU REV BIOCHEM, V55, P631; YOKOYAMA M, 1995, J VIROL, V69, P2684, DOI 10.1128/JVI.69.4.2684-2688.1995; ZHDANOV VM, 1975, NATURE, V256, P471, DOI 10.1038/256471a0; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	30	142	145	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					298	301		10.1038/36876	http://dx.doi.org/10.1038/36876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384383				2022-12-01	WOS:A1997YG66700066
J	RayCoquard, I; Philip, T; Lehmann, M; Fervers, B; Farsi, F; Chauvin, F				RayCoquard, I; Philip, T; Lehmann, M; Fervers, B; Farsi, F; Chauvin, F			Impact of a clinical guidelines program for breast and colon cancer in a French cancer center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CARCINOMA; RADIATION-THERAPY; RANDOMIZED TRIAL; ADJUVANT THERAPY; FOLLOW-UP; FLUOROURACIL; CHEMOTHERAPY; WOMEN; METASTASES; MEDICINE	Context.-Between 1993 and 1994, the 80 physicians in the French comprehensive cancer center, Leon Berard, developed and implemented a Clinical Practice Guidelines (CPGs) project based on an analysis of the literature and a consensus of intrainstitutional experts. Objective.-The aims of this project are to assist community-based oncologists in their decision making and to minimize inappropriate variation in practices. A study was designed to assess the impact of CPGs on management of breast and colon cancer. Design.-A ''before-after'' study, using institutional computerized records of patients with breast or colon cancer. Setting.-Records for 100 women with localized breast cancer were randomly selected from those available in 1993 and 1995, and those for all patients newly referred with colon cancer in 1993 and 1995 (77 and 81 patients, respectively). Medical decisions on these records were analyzed to assess their compliance with the CPGs. (A systematic search of the literature was performed to determine the scientific evidence for noncompliant decisions.) Results.-Of 375 available medical decisions, 350 were assessable. The compliance rate with CPGs for breast cancer was significantly higher in 1995 compared with 1993, 54% (54/99; 95% confidence interval [CI]; 44%-64%) vs 19% (18/95; 95% CI, 11%-27%) (P<.001), The compliance rate for colon cancer was also significantly higher in 1995 than in 1993, 70% (62/88; 95% CI, 60%-80%) vs 50% (34/68; 95% CI, 38%-62%) (P=.009), In 1993, 42% (40/95; 95% CI, 32%-52%) of medical decisions for breast cancer and in 1995, 68% (67/99; 95% CI, 59%-77%) conformed with the CPGs or were judged to be based on ''scientific evidence.'' In 1993, 71% (48/68; 95% CI, 60%-81%) of medical decisions for colon cancer, and in 1995 81% (71/88; 95% CI, 73%-89%) conformed with the CPGs or were judged to be based on scientific evidence. Conclusions.-Compliance rates were significantly higher in 1995 for both cancers. The development and implementation of CPGs for cancer management seem to result in significant changes in medical practice, although a causal relationship between changes and CPGs is not demonstrated in this study.	FEDERAT NATL CTR LUTTE CONTRE CANC, PARIS, FRANCE		RayCoquard, I (corresponding author), CTR LEON BERARD, 28 RUE LAENNEC, F-69008 LYON, FRANCE.		Fervers, Béatrice/AAD-1847-2022	Fervers, Béatrice/0000-0003-3498-6499				ALLEE PE, 1989, INT J RADIAT ONCOL, V17, P1171, DOI 10.1016/0360-3016(89)90522-1; ASLER VB, 1954, ANN SURG, V139, P846; BEKRADA M, 1994, B CANC, V6, P562; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; BUDD GT, 1987, J CLIN ONCOL, V5, P272, DOI 10.1200/JCO.1987.5.2.272; CALLE R, 1980, B CANCER, V67, P313; COBURN MC, 1994, J AM COLL SURGEONS, V179, P65; Coombes RC, 1996, J CLIN ONCOL, V14, P35, DOI 10.1200/JCO.1996.14.1.35; *EARL BREAST CANC, 1992, LANCET, V339, P1; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1446, DOI 10.1001/jama.265.11.1446; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; *FED NAT CTR LUTT, 1995, STAND OPT REC PRIS C, P110; Field MJ, 1990, CLIN PRACTICE GUIDEL, P38; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAYWARD RSA, 1993, CAN MED ASSOC J, V148, P507; HUGUES K, 1991, P AN M AM SOC CLIN, V10, P145; HURTELOUP P, 1988, J CLIN ONCOL, V6, P679; JAGER W, 1991, J TUMOR MARKER ONCOL, V6, P56; JAKESZ R, 1994, CHIRURG, V65, P497; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LIVRAGHI T, 1991, RADIOLOGY, V179, P709, DOI 10.1148/radiology.179.3.2027979; MARGOLESE RG, 1989, ARCH SURG-CHICAGO, V124, P548; MARGOLIS CZ, 1983, JAMA-J AM MED ASSOC, V249, P627, DOI 10.1001/jama.249.5.627; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; ROUGIER P, 1992, P AM SOC CLIN ONCOL, V111, P63; RUTQVIST LE, 1993, RADIOTHER ONCOL, V26, P104, DOI 10.1016/0167-8140(93)90090-U; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2_Supplement.2S; SCHAAKEKONING C, 1985, INT J RADIAT ONCOL, V11, P1759, DOI 10.1016/0360-3016(85)90028-8; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SCHOLL SM, 1994, EUR J CANCER, V30A, P645, DOI 10.1016/0959-8049(94)90537-1; SHERMAN DM, 1978, CANCER, V41, P2013, DOI 10.1002/1097-0142(197805)41:5<2013::AID-CNCR2820410549>3.0.CO;2-T; SUNSHINE JA, 1985, AM J SURG, V150, P44, DOI 10.1016/0002-9610(85)90008-X; *UN INT CONTR CANC, 1988, UICC TNM CLASS TUM M, P99; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; WAZER DE, 1994, CANCER, V74, P878, DOI 10.1002/1097-0142(19940801)74:3<878::AID-CNCR2820740314>3.0.CO;2-4; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646; ZANIBONI A, 1993, P AN M AM SOC CLIN, V12, P191; [No title captured]	45	91	91	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1591	1595		10.1001/jama.278.19.1591	http://dx.doi.org/10.1001/jama.278.19.1591			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370505				2022-12-01	WOS:A1997YF40700040
J	Marcellin, P; Boyer, N; Gervais, A; Martinot, M; Pouteau, M; Castelnau, C; Kilani, A; Areias, J; Auperin, A; Benhamou, JP; Degott, C; Erlinger, S				Marcellin, P; Boyer, N; Gervais, A; Martinot, M; Pouteau, M; Castelnau, C; Kilani, A; Areias, J; Auperin, A; Benhamou, JP; Degott, C; Erlinger, S			Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy	ANNALS OF INTERNAL MEDICINE			English	Article						RNA, viral; hepatitis C-like viruses; hepatitis C; interferon-alpha; aminotransferases	NON-B-HEPATITIS; CHRONIC NON-A; CHRONIC ACTIVE HEPATITIS; CONTROLLED TRIAL; FOLLOW-UP; VIRUS-RNA; ALFA-2B; CIRRHOSIS; PLACEBO; SYSTEM	Background: Less than 20% of patients with chronic hepatitis C have a sustained response to interferon-alpha therapy. The long-term benefit of interferon-alpha with regard to hepatic viral clearance and histologic improvement remains unknown. Objective: To determine the long-term biochemical, virologic, and histologic outcomes in patients with chronic hepatitis C who have a sustained response to interferon-alpha therapy. Design: Prospective cohort study. Setting: University hospital. Patients: 80 patients who had chronic hepatitis C, had a sustained biochemical and virologic response to interferon-alpha therapy, and were followed for at least 12 months. Measurements: Serum hepatitis C virus (HCV) RNA detected by polymerase chain reaction (PCR); HCV genotyping determined by line probe assay; liver histologic studies; liver HCV RNA detected by PCR on frozen liver tissue samples (in 27 patients); and repeated measurements of serum alanine aminotransferase (ALT) levels. Liver biopsy was done before treatment in all 80 patients, and at least one biopsy was done in 69 patients 1 to 6 years after treatment. Results: The 80 patients had follow-up 1 to 7.6 years (mean +/- SD, 4.0 +/- 2.0 years) after interferon-alpha treatment. The follow-up period was 1, 2, 3, 4, 5, 6, and more than 6 years in 11, 13, 14, 18, 10, 12, and 2 patients, respectively, after the end of therapy. During the entire follow-up period, 93% (95% CI, 84% to 97%) of patients had persistently normal serum ALT levels. Serum HCV RNA remained undetectable in 96% (CI, 89% to 99%) of patients, A comparison of liver histologic findings before and 1 to 6.2 years after interferon-alpha treatment showed a clear improvement in 94% (CI, 83% to 99%) of patients, In 62% of patients, the last biopsy done showed normal or nearly normal histologic findings. Liver HCV RNA was detectable before treatment in all 13 patients tested and was undetectable 1 to 5 years after treatment in all 27 patients tested. Conclusions: In patients with chronic hepatitis C who have persistently normal serum ALT levels and no detectable serum HCV RNA 6 months after interferon-alpha therapy, a long-term sustained biochemical and virologic response is generally seen. This response is associated with an absence of detectable intrahepatic HCV RNA and marked histologic improvement.	HOP BEAUJON, UNITE RECH PHYSIOPATHOL HEPAT, INSERM U24, F-92118 CLICHY, FRANCE; HOP BEAUJON, SERV ANAT & CYTOL PATHOL, F-92118 CLICHY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Marcellin, P (corresponding author), HOP BEAUJON, SERV HEPATOL, 100 BLVD GEN LECLERC, F-92118 CLICHY, FRANCE.		Yang, Chen/G-1379-2010					Bacon B. R., 1995, Hepatology, V22, p152A; Benhamou J. P., 1995, Hepatology, V22, p151A; BHATTACHERJEE V, 1995, J GEN VIROL, V76, P1737, DOI 10.1099/0022-1317-76-7-1737; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIMARTINO V, 1995, HEPATOLOGY, V22, P1216; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1016/0270-9139(91)90288-7; MARCELLIN P, 1994, LIVER, V14, P302; MARCELLIN P, 1994, HEPATOLOGY, V20, pA154; MARTINOTPEIGNOUX M, 1992, J INFECT DIS, V165, P595, DOI 10.1093/infdis/165.3.595; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1016/0270-9139(93)90215-9; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1002/hep.1840190538; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993	28	480	490	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					875	+		10.7326/0003-4819-127-10-199711150-00003	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382365				2022-12-01	WOS:A1997YF54500003
J	Xu, XP; Rijcken, B; Schouten, JP; Weiss, ST				Xu, XP; Rijcken, B; Schouten, JP; Weiss, ST			Airways responsiveness and development and remission of chronic respiratory symptoms in adults	LANCET			English	Article							RANDOM-POPULATION SAMPLE; BRONCHIAL RESPONSIVENESS; PULMONARY-FUNCTION; ASTHMA; INFLAMMATION; EPIDEMIOLOGY; EOSINOPHILS; HISTAMINE; COMMUNITY; SMOKING	Background Many patients with chronic obstructive lung disease show increased airways responsiveness to histamine. We investigated the hypothesis that increased airways responsiveness predicts the development and remission of chronic respiratory symptoms. Methods We used data from 24-year follow-up (1965-90) of 2684 participants in a cohort study in Vlagtwedde and Vlaardingen, Netherlands. Increased airways responsiveness was defined as a PC10 value (concentration of histamine for which challenge led to a 10% fall in forced expiratory volume in 1 s) of less than 8 mg/mL. Information on respiratory symptoms was collected by means of a standard questionnaire every 3 years. Logistic regression was used to control for age, area of residence, cigarette smoking status, and sex. Findings Participants with increased airways responsiveness (1281 observations) were more likely than those without increased airways responsiveness (5801 observations) to develop the following symptoms during any 3-year follow-up interval: chronic cough (odds ratio 1.9 [95% CI 1.2-2.9]), chronic phlegm (2.0 [1.3-3.0]), dyspnoea (2.3 [1.5-3.5]), asthmatic attacks (3.7 [2.2-6.1]), and persistent wheeze (2.7 [1.7-4.4]). The estimate of the odds ratio for the development of any of the six symptoms was 1.7 (1.2-2.3). Participants with increased airways responsiveness were less likely than those without this characteristic to show remission of these respiratory symptoms. The estimate of the odds ratio for the remission of any of the six symptoms was 0.42 (0.28-0.61). Interpretation These prospective analyses show that increased airways responsiveness is positively associated with the development of chronic. respiratory symptoms and negatively associated with the remission of these symptoms in adults.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; UNIV GRONINGEN, UNIV HOSP GRONINGEN, DEPT EPIDEMIOL, GRONINGEN, NETHERLANDS	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Groningen					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL049460] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49460] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FREW AJ, 1992, AM REV RESPIR DIS, V146, P878, DOI 10.1164/ajrccm/146.4.878; HELSING KJ, 1979, AM REV RESPIR DIS, V120, P1221; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; LEFKOPOULOU M, 1989, J AM STAT ASSOC, V84, P810, DOI 10.2307/2289671; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; ORIE NGM, 1961, BRONCHITIS INT S, P44; PHAM QT, 1984, BRIT J IND MED, V41, P267; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; RIJCKEN B, 1989, AM REV RESPIR DIS, V140, P615, DOI 10.1164/ajrccm/140.3.615; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; VANDERLE.R, 1972, INT J EPIDEMIOL, V1, P47, DOI 10.1093/ije/1.1.47; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VANDERLENDE R, 1981, CLIN RES PROC, V17, P775; VANDERLENDE R, 1969, EPIDEMIOLOGY CHRONIC; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; XU X, 1994, EUR RESPIR J, V7, P1056; XU X, 1991, American Review of Respiratory Disease, V143, pA90; XU XP, 1995, CHEST, V108, P656, DOI 10.1378/chest.108.3.656; XU XP, 1995, AM J EPIDEMIOL, V141, P554, DOI 10.1093/oxfordjournals.aje.a117471	27	94	99	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1431	1434		10.1016/S0140-6736(97)10041-1	http://dx.doi.org/10.1016/S0140-6736(97)10041-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371166				2022-12-01	WOS:A1997YF95300009
J	Bennett, AM; Tonks, NK				Bennett, AM; Tonks, NK			Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; CYCLIN D1; MYOGENIC DIFFERENTIATION; MYOD FAMILY; FACTOR-BETA; EXPRESSION; INHIBITION; MYOBLASTS; CELLS; RAS	The signal transduction pathway or pathways linking extracellular signals to myogenesis are poorly defined. Upon mitogen withdrawal from C2C12 myoblasts, the mitogen-activated protein kinase (MAPK) p42Erk2 is inactivated concomitant with up-regulation of muscle-specific genes, Overexpression of MAPK phosphatase-1 (MKP-1) inhibited p42Erk2 activity and was sufficient to relieve the inhibitory effects of mitogens on muscle-specific gene expression. Later during myogenesis, endogenous expression of MKP-1 decreased. MKP-1 overexpression during differentiation prevented myotube formation despite appropriate expression of myosin heavy chain, This indicates that muscle-specific gene expression is necessary but not sufficient to commit differentiated myocytes to myotubes and suggests a function for the MAPKs during the early and late stages of skeletal muscle differentiation.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory				Bennett, Anton/0000-0001-5187-7599				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BENNETT AJ, UNPUB; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KONG YF, 1995, MOL CELL BIOL, V15, P5205; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	29	298	307	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1288	1291		10.1126/science.278.5341.1288	http://dx.doi.org/10.1126/science.278.5341.1288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360925				2022-12-01	WOS:A1997YG04300044
J	Dove, SK; Cooke, FT; Douglas, MR; Sayers, LG; Parker, PJ; Michell, RH				Dove, SK; Cooke, FT; Douglas, MR; Sayers, LG; Parker, PJ; Michell, RH			Osmotic stress activates phosphatidylinositol-3,5-bisphosphate synthesis	NATURE			English	Article							INOSITOL PHOSPHATE ISOMERS; LIQUID-CHROMATOGRAPHY; CELLS; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; POLYPHOSPHOINOSITIDE; TRISPHOSPHATE; PURIFICATION; METABOLISM; PATHWAY; YEAST	Inositol phospholipids play multiple roles in cell signalling systems. Two widespread eukaryotic phosphoinositide-based signal transduction mechanisms, phosphoinositidase C-catalysed phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2) hydrolysis and 3-OH kinase-catalysed PtdIns(4,5)P-2 phosphorylation, make the second messengers inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) sn-1,2-diacylglycerol and PtdIns(3,4,5)P-3 (refs 1-7). In addition, PtdIns(4,5)P-2 and PtdIns3P have been implicated in exocytosis and membrane trafficking(8). We now show that when the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe are hyperosmotically stressed, they rapidly synthesize phosphatidylinositol-3,5-bisphosphate (PtdIns(3,5)P-2) by a process that involves activation of a PtdIns3P 5-OH kinase. This PtdIns(3,5)P-2 accumulation only occurs in yeasts that have an active vps34-encoded PtdIns 3-OH kinase, showing that this latter kinase makes the PtdIns3P needed for PtdIns(3,5)P-2 synthesis and indicating that PtdIns(3,5)P-2 may have a role in sorting vesicular proteins. PtdIns(3,5)P-2 is also present in mammalian and plant cells: in monkey Cos-7 cells, its labelling is inversely related to the external osmotic pressure. The stimulation of a PtdIns3P 5-OH kinase-catalysed synthesis of PtdIns(3,5)P-2, a molecule that might be a new type of phosphoinositide 'second messenger', thus appears to be central to a widespread and previously uncharacterized regulatory pathway.	UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	University of Birmingham; University of Birmingham; Cancer Research UK	Dove, SK (corresponding author), UNIV BIRMINGHAM,CTR CLIN RES IMMUNOL & SIGNALLING,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Michell, Robert H/AAT-4974-2020; Parker, Peter j/D-5192-2013	Michell, Robert H/0000-0001-9422-9858; parker, peter/0000-0002-6218-2933				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Jenkinson S, 1995, Methods Mol Biol, V41, P151; LETCHER AJ, 1990, METHODS INOSITIDE RE, P31; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; WREGGETT KA, 1989, BIOCHEM J, V262, P997, DOI 10.1042/bj2620997; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	27	380	390	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					187	192		10.1038/36613	http://dx.doi.org/10.1038/36613			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367158				2022-12-01	WOS:A1997YF49400058
J	Macfarlane, J; Holmes, W; Macfarlane, R; Britten, N				Macfarlane, J; Holmes, W; Macfarlane, R; Britten, N			Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE BRONCHITIS; PRIMARY-CARE; CONSULTATION; COMMUNITY	Objective: To assess patients' views and expectations when they consult their general practitioner with acute lower respiratory symptoms and the influence these have on management. Design: General practitioners studied consecutive, previously well adults and recorded clinical data, the certainty regarding their prescribing decision, and the influence of non-clinical factors on that decision. Patients completed a questionnaire at home after the consultation. Setting: 76 doctors from suburban, inner city, and rural practices. Subjects: 1014 eligible patients entered; 787 (78%) returned the questionnaire. Main outcome measures: The views of the patient, the views of and antibiotic prescription by the doctor. Results: Most patients thought that their symptoms were caused by an infection (662) and that antibiotics would help (656) and had both wanted (564) and expected (561) such a prescription. 146 requested an antibiotic, 587 received one. Of the 643 patients who thought they had an infection, 582 wanted an antibiotic and thought it would help. Severity of symptoms did not relate to wanting antibiotics. For those prescribed antibiotics, their doctor thought they were definitely indicated in only 116 cases and not indicated in 126. Patient pressure most commonly influenced the decision to prescribe even when the doctor thought antibiotics were not indicated. Doctors considered antibiotics definitely indicated in only 1% of the group in whom patient pressure influenced the prescribing decision. Patients who did not receive an antibiotic that they wanted were much more likely to express dissatisfaction. Dissatisfied patients reconsulted for the same symptoms twice as often as satisfied patients. Conclusion: Patients presenting with acute lower respiratory symptoms often believe that infection is the problem and antibiotics the answer. Patients' expectations have a significant influence on prescribing, even when their doctor judges that antibiotics are not indicated.	SHERRINGTON PK MED PRACTICE, NOTTINGHAM NG5 2EJ, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND	University of London; King's College London	Macfarlane, J (corresponding author), CITY HOSP NOTTINGHAM, RESP INFECT UNIT, HUCKNALL RD, NOTTINGHAM NG5 1PB, ENGLAND.							Armstrong D, 1996, BRIT MED J, V312, P949; *AUD COMM, 1994, PRESCR IMPR MOR RAT; BAIN DJG, 1983, BRIT MED J, V287, P1269, DOI 10.1136/bmj.287.6401.1269; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; BRITTEN N, 1996, THESIS U LONDON; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; Davey PG, 1996, BRIT MED J, V312, P613, DOI 10.1136/bmj.312.7031.613; HOLMES WF, IN PRESS BR J GEN PR; Howie J G, 1973, J R Coll Gen Pract, V23, P895; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; HOWIE JGR, 1978, BRIT MED J, V2, P1342, DOI 10.1136/bmj.2.6148.1342; HOWIE JGR, 1974, BRIT MED J, V2, P540, DOI 10.1136/bmj.2.5918.540; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane J, 1997, RESP MED, V91, P427, DOI 10.1016/S0954-6111(97)90258-4; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; MOLSTAD S, 1994, FAM PRACT, V11, P282, DOI 10.1093/fampra/11.3.282; MONTO A S, 1971, American Journal of Epidemiology, V94, P269; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; ORR PH, 1993, J FAM PRACTICE, V36, P507; RAPAPORT J, 1979, J R COLL GEN PRACT, V29, P468; VENKATESAN P, 1995, THORAX, V50, P481, DOI 10.1136/thx.50.5.481; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; WEBB S, 1994, BRIT J GEN PRACT, V44, P165	26	336	346	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	1997	315	7117					1211	1214		10.1136/bmj.315.7117.1211	http://dx.doi.org/10.1136/bmj.315.7117.1211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393228	Green Published			2022-12-01	WOS:A1997YF25200027
J	Parker, D				Parker, D			Health effects of child labour	LANCET			English	Editorial Material											Parker, D (corresponding author), MINNESOTA DEPT HLTH,POB 9441,MINNEAPOLIS,MN 55440, USA.							ASTHANA S, 1995, SOC SCI MED, V40, P177, DOI 10.1016/0277-9536(94)E0066-2; Harvey PJ, 1994, TRADING AWAY FUTURE; ISLAM MA, 1994, EUR J CLIN NUTR, V48, P416; PARKER DL, 1997, STOLEN DREAMS PORTRA; RAJU T N K, 1989, Indian Journal of Pediatrics, V56, P193, DOI 10.1007/BF02726606; SAIYED HN, 1995, INDIAN J MED RES, V102, P138	6	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1395	1396		10.1016/S0140-6736(05)65169-0	http://dx.doi.org/10.1016/S0140-6736(05)65169-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365469				2022-12-01	WOS:A1997YE87200051
J	Scott, K; Sun, YM; Beckingham, K; Zuker, CS				Scott, K; Sun, YM; Beckingham, K; Zuker, CS			Calmodulin regulation of Drosophila light-activated channels and receptor function mediates termination of the light response in vivo	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; PHOTORECEPTOR CELL; INDUCED PHOSPHORYLATION; PROTEIN-KINASE; PHOSRESTIN-I; TRP; GENE; PHOTOTRANSDUCTION; ARRESTIN; CA2+	Calmodulin (CAM) participates in a variety of intracellular transduction processes by modulating signaling molecules in response to calcium changes. We report the characterization of Drosophila Cam mutants and the role of CAM in photoreceptor cell function. Contrary to current models of excitation and TRP channel function, we demonstrate that the transient phenotype of trp mutants can be explained by CAM regulation of the TRPL channel rather than by the loss of a store-operated conductance leading to depletion of the internal stores. We also analyzed light responses in a variety of mutant and transgenic backgrounds and demonstrate the importance of calmodulin in mediating calcium-dependent negative regulation of phototransduction. Our results show that CAM coordinates termination of the light response by modulating receptor and ion channel activity.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; RICE UNIV,DEPT BIOCHEM,HOUSTON,TX 77005; RICE UNIV,DEPT CELL BIOL,HOUSTON,TX 77005	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rice University; Rice University								Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; Arnon A, 1997, SCIENCE, V275, P1119, DOI 10.1126/science.275.5303.1119; Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1988, MOL ASPECTS CELLULAR; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DOYLE KE, 1990, J MOL BIOL, V213, P599, DOI 10.1016/S0022-2836(05)80245-1; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1993, P ROY SOC B-BIOL SCI, V252, P223, DOI 10.1098/rspb.1993.0069; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Heiman RG, 1996, P NATL ACAD SCI USA, V93, P2420, DOI 10.1073/pnas.93.6.2420; Hofstee CA, 1996, VISUAL NEUROSCI, V13, P897, DOI 10.1017/S0952523800009147; Kahn ES, 1997, J NEUROCHEM, V68, P169; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; Maniatis T., 1982, MOL CLONING; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; Minke B, 1996, CURR OPIN NEUROBIOL, V6, P459, DOI 10.1016/S0959-4388(96)80050-X; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PETERSEN CH, 1995, BIOCHEM J, V311, P31; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; XU T, 1993, DEVELOPMENT, V117, P1223; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335; YEANDLE S, 1957, STUDIES SLOW POTENTI; YOSHIOKA T, 1983, BIOCHEM BIOPH RES CO, V111, P567, DOI 10.1016/0006-291X(83)90344-3; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	59	167	169	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					375	383		10.1016/S0092-8674(00)80421-3	http://dx.doi.org/10.1016/S0092-8674(00)80421-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363946	Bronze			2022-12-01	WOS:A1997YD94100011
J	Woronicz, JD; Gao, X; Cao, Z; Rothe, M; Goeddel, DV				Woronicz, JD; Gao, X; Cao, Z; Rothe, M; Goeddel, DV			I kappa B kinase-beta: NF-kappa B activation and complex formation with I kappa B kinase-alpha and NIK	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR; FAMILY	Activation of the transcription factor nuclear factor kappa B (NF-kappa B) by inflammatory cytokines requires the successive action or NF-kappa B-inducing kinase (NIK) and I kappa B kinase-alpha (IKK-alpha). A widely expressed protein kinase was identified that is 52 percent identical to IKK-alpha. I kappa B kinase-beta (IKK-beta) activated NF-kappa B when overexpressed and phosphorylated serine residues 32 and 36 of I kappa B-alpha and serines 19 and 23 of I kappa B-beta. The activity of IKK-beta was stimulated by tumor necrosis factor and interleukin-1 treatment. IKK-alpha and IKK-beta formed heterodimers that interacted with NIK. Overexpression of a catalytically inactive form of IKK-beta blocked cytokine-induced NF-kappa B activation. Thus, an active I kappa B kinase complex may require three distinct protein kinases.	TULARIK, S SAN FRANCISCO, CA 94080 USA									Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CONNELLY MA, 1995, CELL MOL BIOL RES, V41, P5437; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gao X., UNPUB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUANG J, IN PRESS P NATL ACAD; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOCK BA, 1995, GENOMICS, V27, P348, DOI 10.1006/geno.1995.1054; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WORONICZ JD, UNPUB	22	1054	1119	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					866	869		10.1126/science.278.5339.866	http://dx.doi.org/10.1126/science.278.5339.866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346485				2022-12-01	WOS:A1997YD47900047
J	McIntire, SL; Reimer, RJ; Schuske, K; Edwards, RH; Jorgensen, EM				McIntire, SL; Reimer, RJ; Schuske, K; Edwards, RH; Jorgensen, EM			Identification and characterization of the vesicular GABA transporter	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; BRAIN SYNAPTIC VESICLES; CAENORHABDITIS-ELEGANS; C-ELEGANS; ACETYLCHOLINE TRANSPORTER; MONOAMINE TRANSPORTER; ACTIVE-TRANSPORT; GLUTAMATE UPTAKE; RAT-BRAIN; EXPRESSION	Synaptic transmission involves the regulated exocytosis of vesicles filled with neurotransmitter. Classical transmitters are synthesized in the cytoplasm, and so must be transported into synaptic vesicles. Although the vesicular transporters for monoamines and acetylcholine have been identified, the proteins responsible for packaging the primary inhibitory and excitatory transmitters, gamma-aminobutyric acid (GABA) and glutamate remain unknown(1,2) Studies in the nematode Caenorhabditis elegans have implicated the gene unc-47 in the release of GABA(3). Here we show that the sequence of unc-47 predicts a protein with ten transmembrane domains, that the gene is expressed by GABA neurons, and that the protein colocalizes,vith synaptic vesicles. Further, a rat homologue of unc-47 is expressed by central GABA neurons and confers vesicular GABA transport in transfected cells with kinetics and substrate specificity similar to those previously reported for synaptic vesicles from the brain. Comparison of this vesicular GABA transporter (VGAT) with a vesicular transporter for monoamines shows that there are differences in the bioenergetic dependence of transport, and these presumably account for the differences in structure. Thus VGAT is the first of a new family of neurotransmitter transporters.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL,GRAD PROGRAM CELL BIOL & BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah								ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BRENNER S, 1974, GENETICS, V77, P71; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CARLSON MD, 1989, J NEUROCHEM, V53, P1889, DOI 10.1111/j.1471-4159.1989.tb09258.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHRISTENSEN H, 1991, EUR J PHARM-MOLEC PH, V207, P73, DOI 10.1016/S0922-4106(05)80040-9; CLARK SG, 1994, GENETICS, V137, P987; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FERGUSON EL, 1985, GENETICS, V110, P17; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; FYKSE EM, 1988, J NEUROCHEM, V50, P1237, DOI 10.1111/j.1471-4159.1988.tb10599.x; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; NAITO S, 1983, J BIOL CHEM, V258, P696; NONET MI, IN PRESS J NEUROSCI; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; SASSOON D, 1993, GUIDE TECHNIQUES MOU, P384; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	30	648	670	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					870	876		10.1038/39908	http://dx.doi.org/10.1038/39908			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349821				2022-12-01	WOS:A1997YC14800062
J	Sisk, JE; Moskowitz, AJ; Whang, W; Lin, JD; Fedson, DS; McBean, AM; Plouffe, JF; Cetron, MS; Butler, JC				Sisk, JE; Moskowitz, AJ; Whang, W; Lin, JD; Fedson, DS; McBean, AM; Plouffe, JF; Cetron, MS; Butler, JC			Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCUS-PNEUMONIAE; TENTATIVE GUIDELINES; ECONOMIC EVALUATIONS; RISK; EFFICACY; COUNTY; IMMUNIZATION; POPULATION; INFLUENZA; DISEASE	Context.-Clinical, epidemiologic, and policy considerations support updating the cost-effectiveness of pneumococcal vaccination for elderly people and targeting the evaluation only to prevention of pneumococcal bacteremia. Objective.-To assess the implications for medical costs and health effects of vaccination against pneumococcal bacteremia in elderly people. Design.-Cost-effectiveness analysis of pneumococcal vaccination compared with no vaccination, from a societal perspective. Setting and Participants.-The elderly population aged 65 years and older in the United States in 3 geographic areas: metropolitan Atlanta, Ga; Franklin County, Ohio; and Monroe County, New York. Main Outcome Measures.-Incremental medical costs and health effects, expressed in quality-adjusted life-years per person vaccinated. Results.-Vaccination was cost saving, ie, it both reduced medical expenses and improved health, for all age groups and geographic areas analyzed in the base case, For people aged 65 years and older, vaccination saved $8.27 and gained 1.21 quality-adjusted days of life per person vaccinated, Vaccination of the 23 million elderly people unvaccinated in 1993 would have gained about 78 000 years of healthy life and saved $194 million, In univariate sensitivity analysis, the results remained cost saving except for doubling vaccination costs, including future medical costs of survivors, and lowering vaccination effectiveness, With assumptions most unfavorable to vaccination, cost per quality-adjusted life-year ranged from $35 822 for ages 65 to 74 years to $598 487 for ages 85 years and older. In probabilistic sensitivity analysis, probability intervals were more narrow, with less than 5% probability that the ratio for ages 85 years and older would exceed $100 000. Conclusions.-Pneumococcal vaccination saves costs in the prevention of bacteremia alone and is greatly underused among the elderly population, on both health and economic grounds. These results support recent recommendations of the Advisory Committee on Immunization Practices and public and private efforts under way to improve vaccination rates.	SUNY STONY BROOK, STONY BROOK, NY 11794 USA; PASTEUR MERIEUX MSD, LYON, FRANCE; UNIV MINNESOTA, MINNEAPOLIS, MN USA; OHIO STATE UNIV, COLUMBUS, OH 43210 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Sanofi-Aventis; Sanofi France; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; Centers for Disease Control & Prevention - USA	Sisk, JE (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, DIV HLTH POLICY & MANAGEMENT, 600 W 168TH ST, 6TH FLOOR, NEW YORK, NY 10032 USA.		Whang, William/AAE-3853-2019	Moskowitz, Alan/0000-0002-4412-9450				*ACP TASK FORC AD, 1994, GUID AD IMM, P107; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CAMPBELL JF, 1989, HAWAII MED J, V48, P517; *CDC, 1984, MMWR-MORBID MORTAL W, V33, P273; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P506; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CHIANG CL, 1991, ANNU REV PUBL HEALTH, V12, P281, DOI 10.1146/annurev.pu.12.050191.001433; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; ERICKSON P, 1995, STAT NOTES, V7, P1; FARR BM, 1995, ARCH INTERN MED, V155, P2336, DOI 10.1001/archinte.155.21.2336; Fedson D S, 1992, Clin Geriatr Med, V8, P183; FEDSON D S, 1990, Journal of the American Medical Association, V264, P1117, DOI 10.1001/jama.264.9.1117; Fedson D S, 1993, Semin Respir Infect, V8, P285; FEDSON DS, 1994, ARCH INTERN MED, V154, P2531, DOI 10.1001/archinte.154.22.2531; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P113; Fedson DS, 1994, VACCINES, P517; FORRESTER HL, 1987, AM J MED, V83, P425, DOI 10.1016/0002-9343(87)90751-0; GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437; Gold MR., 1996, COST EFFECTIVENESS H; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; HILLIER FS, 1974, OPER RES, P620; HIRSCHMANN JV, 1994, ARCH INTERN MED, V154, P373, DOI 10.1001/archinte.154.4.373; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300; LASCHOBER MA, 1996, HLTH HLTH CARE MED P, P44; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MCBEAN AM, 1991, ARCH INTERN MED, V151, P2009, DOI 10.1001/archinte.151.10.2009; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; PLOUFFE JF, 1994, J CLIN MICROBIOL, V32, P1606, DOI 10.1128/JCM.32.6.1606-1607.1994; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; RIDDIOUGH M A, 1983, Journal of the American Medical Association, V249, P3189, DOI 10.1001/jama.249.23.3189; Schoenbaum S C, 1993, HMO Pract, V7, P5; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMBERKOFF MS, 1994, SEMIN RESPIR INFECT, V8, P294; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SISK JE, 1986, ANN INTERN MED, V104, P78; *US C OFF TECHN AS, 1990, COSTS EFF COL CANC S; *US C OFF TECHN AS, 1990, COSTS EFF CERV CANC; *US COUNC EC ADV, 1997, EC REP PRES, P365; *US PHS, 1991, HLTH PEOPL 2000 NAT; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004; WILLEMS JS, 1981, J INFECT DIS, V144, P486, DOI 10.1093/infdis/144.5.486; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616	52	267	276	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1333	1339		10.1001/jama.278.16.1333	http://dx.doi.org/10.1001/jama.278.16.1333			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343464				2022-12-01	WOS:A1997YA90500034
J	Chen, WR; Midtgaard, J; Shepherd, GM				Chen, WR; Midtgaard, J; Shepherd, GM			Forward and backward propagation of dendritic impulses and their synaptic control in mitral cells	SCIENCE			English	Article							RAT OLFACTORY-BULB; PYRAMIDAL NEURONS; ACTION-POTENTIALS; INITIATION; RECORDINGS; SLICES; CA2+	The site of impulse initiation is crucial for the integrative actions of mammalian central neurons, but this question is currently controversial. Some recent studies support classical evidence that the impulse always arises in the soma-axon hillock region, with back-propagation through excitable dendrites, whereas others indicate that the dendrites are sufficiently excitable to initiate impulses that propagate forward along the dendrite to the soma-axon hillock. This issue has been addressed in the olfactory mitral cell, in which excitatory synaptic input is restricted to the distal tuft of a single primary dendrite. In rat olfactory bulb slices, dual whole cell recordings were made at or near the soma and from distal sites on the primary dendrite. The results show that the impulse can be initiated in either the soma-axon hillock or in the distal primary dendrite, and that the initiation site is controlled physiologically by the excitatory synaptic inputs to the distal tuft and inhibitory synaptic inputs near the soma.	UNIV COPENHAGEN,DEPT MED PHYSIOL,DK-2200 COPENHAGEN N,DENMARK	University of Copenhagen	Chen, WR (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.							BENARDO LS, 1982, J NEUROSCI, V2, P1614; Cajal S.R., 1911, HISTOLOGIE SYSTEME N; CALLAWAY JC, 1995, J NEUROSCI, V15, P2777; CHANG HT, 1952, COLD SPRING HARB SYM, V17, P189, DOI 10.1101/SQB.1952.017.01.019; Chen W., UNPUB; Chen WR, 1997, BRAIN RES, V745, P189, DOI 10.1016/S0006-8993(96)01150-X; CRAGG BG, 1955, J PHYSIOL-LONDON, V129, P608, DOI 10.1113/jphysiol.1955.sp005382; DEFELIPE J, 1992, PROG NEUROBIOL, V39, P563, DOI 10.1016/0301-0082(92)90015-7; Ennis M, 1996, NEUROREPORT, V7, P989, DOI 10.1097/00001756-199604100-00007; HAMILTON KA, 1989, BRAIN RES, V338, P181; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; HUGUENARD JR, 1989, P NATL ACAD SCI USA, V86, P2473, DOI 10.1073/pnas.86.7.2473; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P695, DOI 10.1113/jphysiol.1974.sp010772; LEVETEAU J, 1965, SCIENCE, V175, P170; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MORI K, 1982, J NEUROSCI, V2, P497; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORI K, 1975, BRAIN RES, V100, P685, DOI 10.1016/0006-8993(75)90170-5; Nickell WT, 1996, BRAIN RES BULL, V39, P57, DOI 10.1016/0361-9230(95)02042-X; RALL W, 1968, J NEUROPHYSIOL, V31, P884, DOI 10.1152/jn.1968.31.6.884; RALL W, 1966, EXP NEUROL, V14, P44, DOI 10.1016/0014-4886(66)90023-9; REGEHR WG, 1994, CURR BIOL, V4, P436, DOI 10.1016/S0960-9822(00)00096-8; SCOTT JW, 1987, NEUROBIOLOGY TASTE S, P151; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; SHEPHERD GM, 1977, HDB PHYSL          1, V1, P945; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; Stuart G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WELLIS DP, 1987, CHEM SENSES, V12, P707	38	195	204	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					463	467		10.1126/science.278.5337.463	http://dx.doi.org/10.1126/science.278.5337.463			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334305				2022-12-01	WOS:A1997YB35500045
J	Hajduk, PJ; Meadows, RP; Fesik, SW				Hajduk, PJ; Meadows, RP; Fesik, SW			Drug design - Discovering high-affinity ligands for proteins	SCIENCE			English	Editorial Material											Hajduk, PJ (corresponding author), ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064, USA.							BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387; ECKER DJ, 1995, BIO-TECHNOL, V13, P351, DOI 10.1038/nbt0495-351; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hajduk PJ, 1997, J MED CHEM, V40, P3144, DOI 10.1021/jm9703404; HAJDUK PJ, IN PRESS J AM CHEM S; HAJDUK PJ, 1997, IN PRESS J AM CHEM S, V119, P5818; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; OLEJNICZAK ET, 1997, IN PRESS J AM CHEM S, V119, P5828; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; VERLINDE CLMJ, 1992, J COMPUT AID MOL DES, V6, P131, DOI 10.1007/BF00129424	12	171	181	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					497	&		10.1126/science.278.5337.497	http://dx.doi.org/10.1126/science.278.5337.497			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381145				2022-12-01	WOS:A1997YB35500054
J	Ellegren, H; Lindgren, G; Primmer, CR; Moller, AP				Ellegren, H; Lindgren, G; Primmer, CR; Moller, AP			Fitness loss and germline mutations in barn swallows breeding in Chernobyl	NATURE			English	Article							HIRUNDO-RUSTICA; MISMATCH REPAIR; DNA; RADIATION; EVOLUTION; ACCIDENT	The severe nuclear accident at Chernobyl in 1986 resulted in the worst reported accidental exposure of radioactive material to free-living organisms(1). Short-term effects on human populations inhabiting polluted areas include increased incidence of thyroid cancer(2), infant leukaemia(3), and congenital malformations in newborns(4). Two recent studies(5,6) have reported, although with some controversy(7,8), that germline mutation rates were increased in humans and voles living close to Chernobyl, but little is known about the viability of the organisms affected(9). Here we report an increased frequency of partial albinism, a morphological aberration associated with a loss of fitness, among barn swallows, Hirundo rustica, breeding close to Chernobyl. Heritability estimates indicate that mutations causing albinism were at least partly of germline origin. Furthermore, evidence for an increased germline mutation rate was obtained from segregation analysis at two hypervariable microsatellite loci, indicating that mutation events in barn swallows from Chernobyl were two-to tenfold higher than in birds from control areas in Ukraine and Italy.	UNIV PARIS 06,CNRS,URA 258,ECOL LAB,F-75252 PARIS 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Ellegren, H (corresponding author), SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,BOX 597,S-75124 UPPSALA,SWEDEN.		Primmer, Craig R/B-8179-2008; Moller, Anders/O-6665-2016	Primmer, Craig R/0000-0002-3687-8435; Moller, Anders/0000-0003-3739-4675				ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; Baker RJ, 1996, NATURE, V380, P707, DOI 10.1038/380707a0; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; Dubrova YE, 1996, NATURE, V383, P226, DOI 10.1038/383226b0; Dyck J., 1985, DICT BIRDS, P472; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; HANOTTE O, 1994, MOL ECOL, V3, P529, DOI 10.1111/j.1365-294X.1994.tb00133.x; Hillis DM, 1996, NATURE, V380, P665, DOI 10.1038/380665a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MOLLER AP, 1993, P ROY SOC B-BIOL SCI, V252, P51, DOI 10.1098/rspb.1993.0045; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petridou E, 1996, NATURE, V382, P352, DOI 10.1038/382352a0; Primmer CR, 1996, NAT GENET, V13, P391, DOI 10.1038/ng0896-391; Primmer CR, 1996, HEREDITAS, V124, P281, DOI 10.1111/j.1601-5223.1996.00281.x; PRIMMER CR, 1995, MOL ECOL, V4, P493, DOI 10.1111/j.1365-294X.1995.tb00243.x; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Saino N, 1997, EVOLUTION, V51, P562, DOI 10.1111/j.1558-5646.1997.tb02443.x; Satoh C, 1996, NATURE, V383, P226, DOI 10.1038/383226a0; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; [No title captured]	23	195	213	0	103	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					593	596		10.1038/39303	http://dx.doi.org/10.1038/39303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335497				2022-12-01	WOS:A1997YA00800057
J	Rodriguez, I; Basler, K				Rodriguez, I; Basler, K			Control of compartmental affinity boundaries by hedgehog	NATURE			English	Article							DROSOPHILA IMAGINAL DISKS; PROTEIN KINASE-A; SIGNAL-TRANSDUCTION; ENGRAILED GENE; PATTERN; EXPRESSION; ENCODES	In Drosophila, each segmental primordium is subdivided into two cell populations, the anterior (A) and posterior (P) compartments by the selective activity of the transcription factor Engrailed (En) in P cells(1-4). Under En control, P cells secrete, but cannot respond to, the signalling protein Hedgehog (Hh)(5-7). In contrast, and by default, A cells are programmed to respond to Hh by expressing other signalling molecules, such as Decapentaplegic (Dpp) and Wingless (Wg), which organize growth and patterning in both compartments(5,7-9). Cells of the A and P compartments do not intermix, apparently as a consequence of their having distinct cell affinities that cause them to maximize contact with cells of the same compartment, while minimizing contact with cells from the other compartment(10). This failure to mix has previously been ascribed to an autonomous and direct role for En in specifying a P, as opposed to an A, cell affinity(3,11-13). However, an alternative hypothesis is that Hh secreted by P cells induces A cells to acquire a distinct cell affinity, ensuring that a stable 'affinity boundary' forms wherever P and A cells meet, Here we show that the affinity boundary that segregates A and P cells into adjacent but immiscible cell populations is to a large extent a consequence of local Hh signalling, rather than a reflection of an intrinsic affinity difference between A and P cells.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich			Rodriguez, Isabel/J-2636-2017	Rodriguez, Isabel/0000-0002-7322-4756; Basler, Konrad/0000-0003-3534-1529				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Burke R, 1996, DEVELOPMENT, V122, P2261; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; Lawrence P.A., 1986, P229; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	31	112	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	1997	389	6651					614	618		10.1038/39343	http://dx.doi.org/10.1038/39343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335503				2022-12-01	WOS:A1997YA00800063
J	TunstallPedoe, H; Woodward, M; Tavendale, R; Brook, RA; McCluskey, MK				TunstallPedoe, H; Woodward, M; Tavendale, R; Brook, RA; McCluskey, MK			Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MYOCARDIAL-INFARCTION; LIFE-STYLE; ALCOHOL-CONSUMPTION; PLASMA-FIBRINOGEN; PASSIVE SMOKING; SERUM COTININE; BLOOD-PRESSURE; CASE-FATALITY; MORTALITY	Objective: To compare prediction by 27 different factors in men and women of coronary heart disease events, coronary deaths, and deaths from all causes. Design: Cohort study. Setting: Scottish population study. Subjects: In 1984-7 random sampling of residents aged 40-59 produced 11 629 men and women who generated survey clinic questionnaires, examination findings, and blood and urine specimens. Main outcome measures: Subsequent death, coronary artery surgery, and myocardial infarction. Risks were calculated for each category of factor or fifth of continuous variables. 27 factors were ranked by descending age adjusted hazard ratio of the top to bottom class in each factor, by sex and end point. Results: Follow up averaged; 7.6 years, during which the 5754 men had 404 coronary events, 159 coronary deaths, and 383 deaths and the 5875 women 177, 47, and 208 respectively The rankings for factors for the three end points were mainly similar in men and women, although hazard ratios were often higher in women. Classical risk factors ranked better for predicting coronary risk than newer ones. Yet strong prediction of coronary risk was no guarantee of significant prediction of all cause mortality. Findings included an anomalous coronary protective role for type A behaviour in women; raised plasma fibrinogen as a strong predictor of all end points; and an unexpectedly powerful protective relation of dietary potassium to all cause mortality. Conclusions: These initial unifactorial rankings and comparisons must be interpreted with caution until potential interaction, confounding, and problems of measurement and causation are further explored.			TunstallPedoe, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.		Woodward, Mark/L-6817-2017; Woodward, Mark/D-8492-2015	Woodward, Mark/0000-0001-9800-5296				BORTNER RW, 1969, J CHRON DIS, V22, P87, DOI 10.1016/0021-9681(69)90061-7; Collett, 2014, MODELLING SURVIVAL D; CROMBIE I, 1990, HLTH ED J, V49, P71; CROMBIE IK, 1990, BRIT HEART J, V64, P199; CROMBIE IK, 1989, STATISTICIAN, V38, P25; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HUGHES MD, 1993, BIOMETRICS, V49, P1056, DOI 10.2307/2532247; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KNOX SS, 1993, J PSYCHOSOM RES, P709; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LEE AJ, 1993, BRIT HEART J, V69, P338; LEE AJ, 1993, BRIT J HAEMATOL, V83, P616, DOI 10.1111/j.1365-2141.1993.tb04699.x; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; Morrison C, 1997, BMJ-BRIT MED J, V314, P541, DOI 10.1136/bmj.314.7080.541; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; Prineas R.J., 1982, MINNESOTA CODE MANUA; RICHEDWARDS JW, 1995, AM J EPIDEMIOL, V142, P909, DOI 10.1093/oxfordjournals.aje.a117738; ROSE G, 1980, LANCET, V1, P523; Rose G.A., 1982, CARDIOVASCULAR SURVE; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SMITH CB, 1992, EUR J CLIN NUTR, V46, P75; SMITH CB, 1992, EUR J CLIN NUTR, V46, P85; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH W C S, 1987, Health Bulletin (Edinburgh), V45, P211; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1990, BRIT HEART J, V64, P295; SWEETNAM PM, 1994, CIRCULATION, V90, P769, DOI 10.1161/01.CIR.90.2.769; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105; TUNSTALLPEDOE H, 1995, J EPIDEMIOL COMMUN H, V49, P139, DOI 10.1136/jech.49.2.139; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, 1991, J CLIN EPIDEMIOL, V44, P1411, DOI 10.1016/0895-4356(91)90102-F; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; *WHO, 1996, WORLD HLTH STAT ANN; *WHO MONICA PROJ, 1989, WORLD HLTH STAT ANN, P27; WHO MONICA Project, 1990, MONICA MAN; WOODWARD M, 1990, STATISTICIAN, V39, P319, DOI 10.2307/2349049; WOODWARD M, 1993, ADDICTION, V88, P821, DOI 10.1111/j.1360-0443.1993.tb02096.x; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103	49	259	263	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					722	729		10.1136/bmj.315.7110.722	http://dx.doi.org/10.1136/bmj.315.7110.722			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314758	Green Published			2022-12-01	WOS:A1997XX67400024
J	Strickberger, SA; Man, KC; Daoud, EG; Goyal, R; Brinkman, K; Knight, BP; Weiss, R; Bahu, M; Morady, F				Strickberger, SA; Man, KC; Daoud, EG; Goyal, R; Brinkman, K; Knight, BP; Weiss, R; Bahu, M; Morady, F			Adenosine-induced atrial arrhythmia: A prospective analysis	ANNALS OF INTERNAL MEDICINE			English	Article						atrial fibrillation; adenosine; tachycardia, supraventricular; electrophysiology; Wolff-Parkinson-White syndrome	PARKINSON-WHITE SYNDROME; INTRAVENOUS ADENOSINE; COMPLEX TACHYCARDIA; ACCESSORY PATHWAY; HEART-RATE; FIBRILLATION; FLUTTER; DIAGNOSIS; CONDUCTION; POTASSIUM	Background: Adenosine is considered safe and effective for paroxysmal supraventricular tachycardia (PSVT), but anecdotal experience suggests that adenosine can precipitate atrial arrhythmias. Objectives: To determine the frequency and mechanisms of adenosine-induced atrial arrhythmias. Setting: Clinical electrophysiology laboratory at a university medical center. Design: Prospective observational study. Patients: 200 consecutive patients with PSVT undergoing an electrophysiology procedure. Intervention: During PSVT, 12 mg of adenosine was administered centrally through the femoral vein. Measurements: Frequency of adenosine-induced atrial fibrillation. Results: Paroxysmal supraventricular tachycardia terminated after adenosine administration in 198 patients (99% [95% CI, 96% to 100%]). Adenosine led to atrial fibrillation (n = 22) or atrial fibrillation and atrial flutter (n = 2) in 24 patients (12% [CI, 7.5% to 16.5%]). An atrial premature complex occurred in all 24 patients who developed atrial fibrillation, atrial flutter, or both and in 102 of the 176 patients (58%) who did not (P < 0.001). The mean (+/-SD) time from the preceding atrial complex to the atrial premature complex was shorter when an atria[ arrhythmia occurred, and the mean ratio of this interval to the preceding atrial cycle length was also lower when atrial fibrillation developed (0.37 +/- 0.16 compared with 0.49 +/- 0.16; P = 0.002). Conclusions: The incidence of atrial fibrillation induced by 12 mg of adenosine administered through the femoral vein was 12%. Fibrillation seems to be associated with a ''long-short'' atrial sequence. If the mechanism of PSVT is unknown and the Wolff-Parkinson-White syndrome is possible, administration of adenosine should be limited to medical facilities that have emergency resuscitation equipment.			Strickberger, SA (corresponding author), UNIV MICHIGAN, MED CTR, 1500 E MED CTR DR, BOX 0022, ANN ARBOR, MI 48109 USA.							BELARDINELLI L, 1983, AM J PHYSIOL, V244, pH734, DOI 10.1152/ajpheart.1983.244.5.H734; BIAGGIONI I, 1986, LIFE SCI, V39, P2229, DOI 10.1016/0024-3205(86)90401-7; BRODSKY MA, 1995, AM HEART J, V130, P564, DOI 10.1016/0002-8703(95)90367-4; CONTI JB, 1995, AM J CARDIOL, V75, P952, DOI 10.1016/S0002-9149(99)80698-5; Cosio FG, 1996, J CARDIOVASC ELECTR, V7, P60, DOI 10.1111/j.1540-8167.1996.tb00461.x; DIMARCO JP, 1990, ANN INTERN MED, V113, P104, DOI 10.7326/0003-4819-113-2-104; DOMANOVITS H, 1994, EUR HEART J, V15, P589, DOI 10.1093/oxfordjournals.eurheartj.a060553; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; EXNER DV, 1995, ANN INTERN MED, V122, P351, DOI 10.7326/0003-4819-122-5-199503010-00005; FEDIDA D, 1989, AM J PHYSIOL, V256, pH1500, DOI 10.1152/ajpheart.1989.256.5.H1500; *FUJ US INC MEDC R, 1996, PACK INS AD; GARRATT CJ, 1994, AM J CARDIOL, V74, P401, DOI 10.1016/0002-9149(94)90415-4; GARRATT CJ, 1990, AM J CARDIOL, V65, P868, DOI 10.1016/0002-9149(90)91428-9; GARRATT CJ, 1991, CIRCULATION, V84, P1962, DOI 10.1161/01.CIR.84.5.1962; GRIFFITH MJ, 1988, LANCET, V1, P672; Herbert ME, 1997, ANN EMERG MED, V29, P172, DOI 10.1016/S0196-0644(97)70324-X; JOHNSON EA, 1956, NATURE, V178, P1174, DOI 10.1038/1781174a0; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO, P181; Kim IB, 1996, CIRCULATION, V94, P2961, DOI 10.1161/01.CIR.94.11.2961; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; Lerman BB, 1996, J CARDIOVASC ELECTR, V7, P559, DOI 10.1111/j.1540-8167.1996.tb00563.x; LI HGG, 1994, J AM COLL CARDIOL, V24, P728, DOI 10.1016/0735-1097(94)90021-3; LOPEZ JA, 1994, TEX HEART I J, V21, P130; MORADY F, 1988, J AM COLL CARDIOL, V11, P1235, DOI 10.1016/0735-1097(88)90287-2; NUNAIN SO, 1992, CARDIOVASC RES, V26, P939, DOI 10.1093/cvr/26.10.939; ONUNAIN S, 1993, AM J CARDIOL, V71, P248, DOI 10.1016/0002-9149(93)90748-2; RANKIN AC, 1993, BRIT HEART J, V69, P263; RENSMA PL, 1988, CIRC RES, V62, P395, DOI 10.1161/01.RES.62.2.395; Silverman AJ, 1996, AM J EMERG MED, V14, P300, DOI 10.1016/S0735-6757(96)90182-5; SLADE AKB, 1993, BRIT HEART J, V70, P91; SMEETS JLRM, 1986, CIRC RES, V58, P96, DOI 10.1161/01.RES.58.1.96; Smith JR, 1997, PACE, V20, P743, DOI 10.1111/j.1540-8159.1997.tb03897.x; TEBBENJOHANNS J, 1995, PACE, V18, P743, DOI 10.1111/j.1540-8159.1995.tb04673.x; WALKER KW, 1995, PACE, V18, P441, DOI 10.1111/j.1540-8159.1995.tb02543.x; WELLS JL, 1978, PACE, V1, P426, DOI 10.1111/j.1540-8159.1978.tb03504.x; WEST GA, 1985, PFLUG ARCH EUR J PHY, V403, P75, DOI 10.1007/BF00583285; WHALLEY DW, 1995, PACE, V18, P1556, DOI 10.1111/j.1540-8159.1995.tb06742.x; WIENER N, 1946, Arch Inst Cardiol Mex, V16, P205	39	71	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					417	422		10.7326/0003-4819-127-6-199709150-00001	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312997				2022-12-01	WOS:A1997XV77900001
J	Zuckerman, E; Zuckerman, T; Levine, AM; Douer, D; Gutekunst, K; Mizokami, M; Qian, DG; Velankar, M; Nathwani, BN; Fong, TL				Zuckerman, E; Zuckerman, T; Levine, AM; Douer, D; Gutekunst, K; Mizokami, M; Qian, DG; Velankar, M; Nathwani, BN; Fong, TL			Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma	ANNALS OF INTERNAL MEDICINE			English	Article							ESSENTIAL MIXED CRYOGLOBULINEMIA; NON-A; LYMPHOPROLIFERATIVE DISORDERS; PERIPHERAL-BLOOD; UNITED-STATES; RISK-FACTORS; HCV; ASSAY; DONORS; RNA	Background: Several studies from Europe have reported a high prevalence (9% to 32%) of chronic hepatitis C virus (HCV) infection in patients with B-cell non-Hodgkin lymphoma. It has been suggested that HCV plays a role in the pathogenesis of B-cell non-Hodgkin lymphoma. Objective: To determine the prevalence of HCV infection in patients with B-cell lymphoma in the United States. Design: Controlled, cross-sectional analysis. Setting: University medical center. Patients: 120 patients with B-cell lymphoma (78% were Hispanic, 9% were black, 7% were Asian, and 6% were white), 154 patients with other malignant hematologic conditions (control group 1), and 114 patients with nonmalignant conditions (control group 2). Measurements: Samples were tested for antibodies to HCV by enzyme-linked immunosorbent assay. Hepatitis C virus RNA was detected by reverse-transcription polymerase chain reaction. Genotyping for HCV was done with genotype-specific primers from the HCV core region. Results: infection with HCV was detected in 26 patients (22% [95% CI, 15% to 30%]) with B-cell lymphoma compared with 7 of 154 patients (4.5%) in control group 1 and 6 of 114 patients (5%) in control group 2 (P < 0.001). Risk factors for HCV infection were present in 15 patients (60%) with B-cell lymphoma and occurred a median of 15 years before diagnosis of lymphoma. Monocytoid B-cell lymphoma was the most common type of lymphoma found in HCV-positive patients (23% compared with 7% in HCV-negative patients) (P = 0.034). Conclusions: The prevalence of HCV infection was higher in patients with B-cell non-Hodgkin lymphoma than in controls. The possible role of HCV in the pathogenesis of B-cell lymphoma warrants further investigation.	UNIV SO CALIF, SCH MED, DIV HEMATOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA; ROCHE MOL SYST, SOMERVILLE, NJ 08876 USA; NAGOYA CITY UNIV, SCH MED, NAGOYA, AICHI 467, JAPAN	University of Southern California; University of Southern California; Roche Holding; Nagoya City University								AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COGLIATTI SB, 1990, J CLIN PATHOL, V43, P619, DOI 10.1136/jcp.43.8.619; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; ELLIS M, 1995, EUR J CLIN INVEST, V25, P833, DOI 10.1111/j.1365-2362.1995.tb01692.x; FERRI C, 1993, EUR J CLIN INVEST, V23, P399, DOI 10.1111/j.1365-2362.1993.tb00782.x; FERRI C, 1994, BRIT J HAEMATOL, V88, P392, DOI 10.1111/j.1365-2141.1994.tb05036.x; FERRI C, 1993, BLOOD, V82, P3701; FRANZIN F, 1995, BRIT J HAEMATOL, V90, P548, DOI 10.1111/j.1365-2141.1995.tb05582.x; Hanley J, 1996, LANCET, V347, P1339, DOI 10.1016/S0140-6736(96)90991-5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lau JYN, 1996, ANN INTERN MED, V124, P868, DOI 10.7326/0003-4819-124-10-199605150-00002; McColl MD, 1996, BRIT J HAEMATOL, V92, P771; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MONTALTO G, 1995, HEPATOLOGY, V22, P1409; MONTEVERDE A, 1988, ACTA HAEMATOL-BASEL, V79, P20, DOI 10.1159/000205684; MONTEVRDE A, 1994, P M HCV CRYOGLOBULIN, P34; MUSSINI C, 1995, BLOOD, V85, P1144, DOI 10.1182/blood.V85.4.1144.bloodjournal8541144; NATHWANI BN, 1992, HUM PATHOL, V23, P1061, DOI 10.1016/0046-8177(92)90270-D; NATHWANI BN, 1992, NEOPLASTIC HEMATOPAT, P555; NGAN BY, 1991, HUM PATHOL, V22, P409, DOI 10.1016/0046-8177(91)90125-9; NOLTE FS, 1995, J CLIN MICROBIOL, V33, P1775, DOI 10.1128/JCM.33.7.1775-1778.1995; Ohno T, 1997, J CLIN MICROBIOL, V35, P201, DOI 10.1128/JCM.35.1.201-207.1997; PAWLOTSKY JM, 1995, ANN INTERN MED, V122, P169, DOI 10.7326/0003-4819-122-3-199502010-00002; Pioltelli P, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91328-8; PORTER DD, 1986, PROG MED VIROL, V33, P42; ROSENBERG SA, 1982, CANCER, V49, P2112; SANTINI GF, 1993, BLOOD, V82, P2932; SAXENA S, 1995, LAB MED, V26, P682, DOI 10.1093/labmed/26.10.682; SHEIBANI K, 1988, CANCER, V62, P1531, DOI 10.1002/1097-0142(19881015)62:8<1531::AID-CNCR2820620814>3.0.CO;2-A; SHEIBANI K, 1986, AM J PATHOL, V124, P310; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Silvestri F, 1996, BLOOD, V87, P4296, DOI 10.1182/blood.V87.10.4296.bloodjournal87104296; VANDERPOEL C, 1991, TRANSFUSION, V31, P777; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X	39	347	351	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					423	428		10.7326/0003-4819-127-6-199709150-00002	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312998				2022-12-01	WOS:A1997XV77900002
J	Studitsky, VM; Kassavetis, GA; Geiduschek, EP; Felsenfeld, G				Studitsky, VM; Kassavetis, GA; Geiduschek, EP; Felsenfeld, G			Mechanism of transcription through the nucleosome by eukaryotic RNA polymerase	SCIENCE			English	Article							CHAIN ELONGATION; INITIATION; TEMPLATES; DNA; CHROMATIN; COMPLEXES; INVITRO	Nucleosomes, the nucleohistone subunits of chromatin, are present on transcribed eukaryotic genes but do not prevent transcription. It is shown here that the large yeast RNA polymerase III transcribes through a single nucleosome. This takes place through a direct internal nucleosome transfer in which histones never leave the DNA template, During this process, the polymerase pauses with a pronounced periodicity of 10 to 11 base pairs, which is consistent with restricted rotation in the DNA loop formed during transfer. Transcription through nucleosomes by the eukaryotic enzyme and by much smaller prokaryotic RNA polymerases thus shares many features, reflecting an important property of nucleosomes.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Diego; University of California System; University of California San Diego			Studitsky, Vasily/A-9382-2014					BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; CLARK DJ, 1995, NUCLEOSOME, P207; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; LUSE D, 1995, CHROMATIN STRUCTURE, P104; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; NDLER E, 1997, CELL, V89, P33; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TENHEGGELERBORDIER B, 1995, EMBO J, V14, P2561, DOI 10.1002/j.1460-2075.1995.tb07254.x; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T	25	161	162	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1960	1963		10.1126/science.278.5345.1960	http://dx.doi.org/10.1126/science.278.5345.1960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395401				2022-12-01	WOS:A1997YL00200039
J	Erkinjuntti, T; Ostbye, T; Steenhuis, R; Hachinski, V				Erkinjuntti, T; Ostbye, T; Steenhuis, R; Hachinski, V			The effect of different diagnostic criteria on the prevalence of dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DSM-III-R; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; APOLIPOPROTEIN-E; NINDS-AIREN; ICD-10; POPULATION; HEALTH; DISORDERS; ATROPHY	Background There are several widely used sets of criteria for the diagnosis of dementia, but little is known about their degree of agreement and their effects on estimates of the prevalence of dementia. Methods We examined 1879 men and women 65 years of age or older who were enrolled in the Canadian Study of Health and Aging and calculated the proportion given a diagnosis of dementia according to six commonly used classification systems: the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM), third edition (DSM-III), the third edition, revised, of the DSM (DSM-III-R), the fourth edition of the DSM (DSM-IV), the World Health Organization's International Classification of Diseases (ICD), 9th revision (ICD-9) and 10th revision (ICD-10), and the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX). The degree of concordance among classification schemes and the importance of various factors in determining diagnostic agreement or disagreement were examined. Results The proportion of subjects with dementia varied from 3.1 percent when we used the criteria of the ICD-10 to 29.1 percent when the DSM-III criteria were used. The six classification systems identified different groups of subjects as having dementia; only 20 subjects were given a diagnosis of dementia according to all six systems. The classifications based on the various systems differed little according to the patients' age, sex, educational level, or status with respect to institutionalization. The factors that most often caused disagreement in diagnosis between DSM-III and ICD-10 were long-term memory, executive function, social activities, and duration of symptoms. Conclusions The commonly used criteria for diagnosis can differ by a factor of 10 in the number of subjects classified as having dementia. Such disagreement has serious implications for research and treatment, as well as for the right of many older persons to drive, make a will, and handle financial affairs. (C) 1997, Massachusetts Medical Society.	UNIV WESTERN ONTARIO,DEPT EPIDEMIOL & BIOSTAT,LONDON,ON N6A 5C1,CANADA; UNIV HELSINKI,DEPT NEUROL,MEMORY RES UNIT,HELSINKI,FINLAND; UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON N6A 5C1,CANADA; LONDON HLTH SCI CTR,PSYCHOL SERV,LONDON,ENGLAND	Western University (University of Western Ontario); University of Helsinki; Western University (University of Western Ontario)								American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; BRONISCH T, 1994, PSYCHOPATHOLOGY, V27, P312, DOI 10.1159/000284889; Cummings JL, 1992, DEMENTIA CLIN APPROA; ERKINJUNTTI T, 1993, ARCH NEUROL-CHICAGO, V50, P305, DOI 10.1001/archneur.1993.00540030069017; ERKINJUNTTI T, 1993, CEREBROVASC DIS, V3, P3, DOI 10.1159/000108661; FICHTER MM, 1995, BRIT J PSYCHIAT, V166, P621, DOI 10.1192/bjp.166.5.621; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; HACHINSKI V, 1992, LANCET, V340, P645; HENDERSON AS, 1994, PSYCHOL MED, V24, P473, DOI 10.1017/S0033291700027446; HILLER W, 1994, PSYCHOPATHOLOGY, V27, P19, DOI 10.1159/000284844; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OSTBYE T, 1994, CAN MED ASSOC J, V151, P1457; OSTBYE T, 1995, CAN MED ASSOC J, V152, P158; Pohjasvaara T, 1997, STROKE, V28, P785, DOI 10.1161/01.STR.28.4.785; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHUCKIT MA, 1994, ADDICTION, V89, P1629, DOI 10.1111/j.1360-0443.1994.tb03764.x; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Soininen HS, 1996, TRENDS NEUROSCI, V19, P224, DOI 10.1016/0166-2236(96)10027-8; STEENHUIS RE, 1995, J CLIN EXP NEUROPSYC, V17, P773, DOI 10.1080/01688639508405166; TATEMICHI T K, 1992, Neurology, V42, P413; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TOMASSON K, 1993, ACTA PSYCHIAT SCAND, V88, P311, DOI 10.1111/j.1600-0447.1993.tb03465.x; TUOKKO H, 1995, J CLIN EXP NEUROPSYC, V17, P352, DOI 10.1080/01688639508405129; Wetterling T, 1996, STROKE, V27, P30, DOI 10.1161/01.STR.27.1.30; *WHO, 1992, INT CLASS DIS, P311; World Health Organization, 1977, INT CLASS DIS; 1994, CAN MED ASSOC J, V150, P899	33	337	345	2	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1667	1674		10.1056/NEJM199712043372306	http://dx.doi.org/10.1056/NEJM199712043372306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YJ871	9385127				2022-12-01	WOS:A1997YJ87100006
J	OhkiHamazaki, H; Watase, K; Yamamoto, K; Ogura, H; Yamano, M; Yamada, K; Maeno, H; Imaki, J; Kikuyama, S; Wada, E; Wada, K				OhkiHamazaki, H; Watase, K; Yamamoto, K; Ogura, H; Yamano, M; Yamada, K; Maeno, H; Imaki, J; Kikuyama, S; Wada, E; Wada, K			Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity	NATURE			English	Article							LUNG-CARCINOMA CELLS; LEPTIN LEVELS; MOLECULAR-CLONING; PEPTIDE RECEPTOR; PLASMA	Mammalian bombesin-like peptides are widely distributed in the central nervous system as well as in the gastrointestinal tract, where they modulate smooth-muscle contraction, exocrine and endocrine processes, metabolism and behaviour(1). They bind to G-protein-coupled receptors on the cell surface to elicit their effects, Bombesin-like peptide receptors cloned so far include, gastrin-releasing peptide receptor (GRP-R)(2,3), neuromedin B receptor (NMB-R)(4,5), and bombesin receptor subtype-3 (BRS-3)(6,7). However, despite the molecular characterization of BRS-3, determination of its function has been difficult as a result of its low affinity for bombesin and its lack of an identified natural ligand, We have generated BRS-3-deficient mice in an attempt to determine the in vivo function of the receptor, Mice lacking functional BRS-3 developed a mild obesity, associated with hypertension and impairment of glucose metabolism, They also exhibited reduced metabolic rate, increased feeding efficiency and subsequent hyperphagia, Our data suggest that BRS-3 is required for the regulation of endocrine processes and metabolism responsible for energy balance and adiposity, BRS-3-deficient mice provide a useful new model for the investigation of human obesity and associated diseases.	TOKYO INST PSYCHIAT,DEPT NEUROCHEM,SETAGAYA KU,TOKYO 156,JAPAN; WASEDA UNIV,SCH EDUC,DEPT BIOL,SHINJUKU KU,TOKYO 16950,JAPAN; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN; OSAKA PREFECTURAL COLL HLTH SCI,HABIKINO,OSAKA 583,JAPAN; NIPPON MED COLL,DEPT ANAT,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Institute of Psychiatry; Waseda University; Eisai Co Ltd; Nippon Medical School	OhkiHamazaki, H (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT DEGENERAT NEUROL DIS,KODAIRA,TOKYO 187,JAPAN.		Ohki-Hamazaki, Hiroko/R-5489-2019	Ohki-Hamazaki, Hiroko/0000-0003-4658-5385; Yamamoto, Kazutoshi/0000-0002-7935-7015				BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; FATHI Z, 1993, J BIOL CHEM, V268, P5979; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OhkiHamazaki H, 1997, BRAIN RES, V762, P165, DOI 10.1016/S0006-8993(97)00380-6; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; Wu JM, 1996, MOL PHARMACOL, V50, P1355; YAMAMOTO K, 1982, ENDOCRINOL JAPON, V29, P159; YANOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435	19	239	250	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					165	169		10.1038/36568	http://dx.doi.org/10.1038/36568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367152				2022-12-01	WOS:A1997YF49400052
J	Nightingale, SL				Nightingale, SL			New requirements for labeling of dietary supplements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-01	WOS:A1997YC91700005
J	delPeso, L; GonzalezGarcia, M; Page, C; Herrera, R; Nunez, G				delPeso, L; GonzalezGarcia, M; Page, C; Herrera, R; Nunez, G			Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt	SCIENCE			English	Article							CELL-DEATH; ONCOGENE; APOPTOSIS; SURVIVAL; BCL-2	BAD is a distant member of the Bcl-2 family that promotes cell death. Phosphorylation of BAD prevents this. BAD phosphorylation induced by interleukin-3 (IL-3) was inhibited by specific inhibitors of phosphoinositide 3-kinase (PI 3-kinase), Akt, a survival-promoting serine-threonine protein kinase, was activated by IL-3 in a PI 3-kinase-dependent manner. Active, but not inactive, forms of AM were found to phosphorylate BAD in vivo and in vitro at the same residues that are phosphorylated in response to IL-3, Thus, the proapoptotic function of BAD is regulated by the PI 3-kinase-Akt pathway.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Pfizer			del Peso, Luis/K-9391-2014; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; 	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DELPESO L, UNPUB; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRANKE TF, 1997, CELL, V88, P355; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	24	1034	1066	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					687	689						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381178				2022-12-01	WOS:A1997YC32300054
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Worlds collide	SCIENCE			English	Editorial Material																		Feng MZ, 1997, NAT BIOTECHNOL, V15, P866, DOI 10.1038/nbt0997-866	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					501	501						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381146				2022-12-01	WOS:A1997YB35500055
J	Sidow, A; Bulotsky, MS; Kerrebrock, AW; Bronson, RT; Daly, MJ; Reeve, MP; Hawkins, TL; Birren, BW; Jaenisch, R; Lander, ES				Sidow, A; Bulotsky, MS; Kerrebrock, AW; Bronson, RT; Daly, MJ; Reeve, MP; Hawkins, TL; Birren, BW; Jaenisch, R; Lander, ES			Serrate2 is disrupted in the mouse limb-development mutant syndactylism	NATURE			English	Article							NOTCH LOCUS; DROSOPHILA	The mouse syndactylism (sin) mutation impairs some of the earliest aspects of limb development and leads to subsequent abnormalities in digit formation(1-3). In sin homozygotes, the apical ectodermal ridge (AER) is hyperplastic by embryonic day 10.5, leading to abnormal dorsoventral thickening of the limb bud, subsequent merging of the skeletal condensations that give rise to cartilage and bone in the digits, and eventual fusion of digits. The AER hyperplasia and its effect on early digital patterning distinguish sm from many other syndactylies that result from later failure of cell death in the interdigital areas(4,5). Here we use positional cloning to show that the gene mutated in sm mice encodes the putative Notch ligand Serrate2. The results provide direct evidence that a Notch signalling pathway is involved in the earliest stages of Limb-bud patterning and support the idea that an ancient genetic mechanism underlies both AER formation in vertebrates and wing-margin formation in files(6,7). In addition to cloning the sm gene, we have mapped three modifiers of sm, for which we suggest possible candidate genes.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University			Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752				Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gruneberg H., 1956, Journal of Genetics, V54, P113, DOI 10.1007/BF02981706; GRUNEBERG H, 1960, GENET RES, V1, P196; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JOHNSON DR, 1969, J EMBRYOL EXP MORPH, V21, P285; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LYON MF, 1996, GENETIC VARIANTS STR; MILAIRE J., 1967, ARCH BIOL, V78, P223; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; *MOUS GEN DAT, 1997, MOUS GEN INF; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; Sambrook J, 1989, MOL CLONING; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; Wilkinson DG, 1992, SITU HYBRIDIZATION P; XU T, 1992, DEVELOPMENT, V115, P913	23	96	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					722	725		10.1038/39587	http://dx.doi.org/10.1038/39587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338782				2022-12-01	WOS:A1997YA95900053
J	Zuger, A; Sharp, VL				Zuger, A; Sharp, VL			'HIV specialists': The time has come	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY-CARE PHYSICIANS; AIDS; EXPERIENCE; INFECTION		ST LUKES ROOSEVELT HOSP,HIV AIDS CTR,NEW YORK,NY 10019; BETH ISRAEL HOSP,HIV COMPREHENS CARE CLIN,NEW YORK,NY; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10467	Mount Sinai St. Luke's; Mount Sinai West; Yeshiva University; Albert Einstein College of Medicine								*AM COLL PHYS INF, 1994, ANN INTERN MED, V120, P310; *AM SOC INT MED, 1995, REINV MAN CAR; BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KAHN JG, 1995, J ACQ IMMUN DEF SYND, V8, pS53; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LAURENCE J, 1995, AIDS READER, V5, P110; LEWIS CE, 1986, J GEN INTERN MED, V1, P287, DOI 10.1007/BF02596205; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PAAUW DS, 1995, JAMA-J AM MED ASSOC, V274, P1380, DOI 10.1001/jama.274.17.1380; SANDE MA, 1994, J INFECT DIS, V169, P1197, DOI 10.1093/infdis/169.6.1197; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; Soloway B, 1997, AIDS Clin Care, V9, P37; VERGHESE A, 1993, CLIN INFECT DIS, V16, P459, DOI 10.1093/clind/16.4.459; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILSON IB, 1995, J ACQ IMMUN DEF SYND, V8, pS31	18	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1131	1132		10.1001/jama.278.14.1131	http://dx.doi.org/10.1001/jama.278.14.1131			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326457				2022-12-01	WOS:A1997XY42200002
J	Poole, CJM				Poole, CJM			Hazards of powdered surgical gloves	LANCET			English	Editorial Material							LATEX				Poole, CJM (corresponding author), DUDLEY PRIOR HLTH NHS TRUST,DEPT OCCUPAT HLTH,DUDLEY DY2 7BX,ENGLAND.							BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; *DEP HLTH, 1996, LAT SENS HLTH CAR SE; HAGLUND U, 1997, EUR J SURG S579, V163; Heese A, 1996, HAUTARZT, V47, P817, DOI 10.1007/s001050050514; LAMPE AS, 1988, LANCET, V2, P1140; Newsom SWB, 1997, OCCUP MED-OXFORD, V47, P155, DOI 10.1093/occmed/47.3.155; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					973	974		10.1016/S0140-6736(05)64064-0	http://dx.doi.org/10.1016/S0140-6736(05)64064-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329509				2022-12-01	WOS:A1997XZ71000005
J	Koob, GF; LeMoal, M				Koob, GF; LeMoal, M			Drug abuse: Hedonic homeostatic dysregulation	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; STRESS-INDUCED SENSITIZATION; NUCLEUS-ACCUMBENS; ETHANOL WITHDRAWAL; ALCOHOL DEPENDENCE; EXTRACELLULAR DOPAMINE; MOLECULAR MECHANISMS; COCAINE WITHDRAWAL; RECEPTOR AGONISTS; OPIATE-WITHDRAWAL	Understanding the neurobiological mechanisms of addiction requires an integration of basic neuroscience with social psychology, experimental psychology, and psychiatry. Addition is presented as a cycle of spiralling dysregulation of brain reward systems that progressively increases, resulting in compulsive drug use and a loss of control over drug-taking. Sensitization and counteradaptation are hypothesized to contribute to this hedonic homeostatic dysregulation, and the neurobiological mechanisms involved, such as the mesolimbic dopamine system, opioid peptidergic systems, and brain and hormonal stress systems, are beginning to be characterized. This framework provides a realistic approach to identifying the neurobiological factors that produce vulnerability to addiction and to relapse in individuals with a history of addiction.	UNIV BORDEAUX 2, INSERM, U259, F-33077 BORDEAUX, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Koob, GF (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL CVN7, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		LE MOAL, Michel/B-5125-2008		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA006420, R37AA008459, R01AA008459, P60AA006420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004043] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06420, AA08459] Funding Source: Medline; NIDA NIH HHS [DA04043] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; [Anonymous], 1972, RELIG HIST AM PEOPLE; Baumeister R.F., 1994, LOSING CONTROL WHY P; Bergman J., 1990, Behav Pharmacol, V1, P355; Bindra D., 1976, THEORY INTELLIGENT B; Cabib S, 1996, PSYCHOPHARMACOLOGY, V128, P331, DOI 10.1007/s002130050142; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CAINE SB, 1995, BRAIN RES, V692, P47; Carrera M. R. A., 1995, Society for Neuroscience Abstracts, V21, P725; CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407; CHEN JP, 1991, NEUROSCI LETT, V129, P136, DOI 10.1016/0304-3940(91)90739-G; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; COOLS AR, IN PRESS PHARM BIOCH; CRABBE JC, 1992, TRENDS PHARMACOL SCI, V13, P212, DOI 10.1016/0165-6147(92)90066-F; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; Deroche V, 1997, J PHARMACOL EXP THER, V281, P1401; DEROCHE V, 1992, BRAIN RES, V598, P343, DOI 10.1016/0006-8993(92)90205-N; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; Ellenhorn MJ., 1997, MED TOXICOLOGY DIAGN, P610; ENGEL JA, 1992, NOVEL PHARM INTERVEN, P68; EPPINGJORDAN M, 1995, NEUR ABSTR, V21, P719; ETTENBERG A, 1982, PHYSIOL BEHAV, V28, P873, DOI 10.1016/0031-9384(82)90207-4; Gold LH, 1996, BEHAV PHARMACOL, V7, P589; HEIMER L, 1991, ADV EXP MED BIOL, V295, P1; HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74; HENRY DJ, 1992, ANN NY ACAD SCI, V654, P88, DOI 10.1111/j.1749-6632.1992.tb25958.x; Heyser C. J., 1995, Society for Neuroscience Abstracts, V21, P1698; HEYSER CJ, IN PRESS NEUROPSYCHO; Himmelsbach CK, 1943, FED PROC, V2, P201; HYYTIA P, 1995, EUR J PHARMACOL, V283, P151, DOI 10.1016/0014-2999(95)00314-B; Institute of Medicine, 1996, PATHW ADD; JAFFE J H, 1990, P522; Johnston JB, 1923, J COMP NEUROL, V35, P337, DOI 10.1002/cne.900350502; JUNG CG, 1969, PSYCHOL ENERGY MEANI, V8; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; Koob George F., 1995, P759; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KOOB GF, 1993, SEMIN NEUROSCI, V5, P351; KOOB GF, 1987, BRAIN REWARD SYSTEMS, P35; KOOP GF, IN PRESS J PSYCHOPHA; Kreek M.J., 1987, PSYCHOPHARMACOLOGY 3, P1597; LAULIN JP, IN PRESS EUR J PHARM; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G; MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17; MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.1993.00410180039004; MURPHY JM, 1987, PHARMACOL BIOCHEM BE, V26, P389, DOI 10.1016/0091-3057(87)90134-1; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Piazza PV, 1996, P NATL ACAD SCI USA, V93, P8716, DOI 10.1073/pnas.93.16.8716; PIAZZA PV, IN PRESS BRAIN RES R; PICH EM, 1995, J NEUROSCI, V15, P5439; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S; Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Russell M. A. H., 1976, DRUGS DRUG DEPENDENC, P182; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Schulteis G, 1997, PSYCHOPHARMACOLOGY, V129, P56, DOI 10.1007/s002130050162; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; Schulteis G, 1996, NEUROCHEM RES, V21, P1437, DOI 10.1007/BF02532385; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3; Shaham Y, 1996, J NEUROSCI, V16, P1957; Shippenberg TS, 1996, J PHARMACOL EXP THER, V276, P545; SHIPPENBERG TS, 1992, ANN NY ACAD SCI, V654, P347, DOI 10.1111/j.1749-6632.1992.tb25980.x; Smith Devyn, COMMUNICATION; Solomon R.L, 1977, PSYCHOPATHOLOGY EXPT, P124; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Spanagel R, 1996, EUR J PHARMACOL, V305, P39, DOI 10.1016/0014-2999(96)00174-4; Sterling P., 1988, HDB LIFE STRESS COGN, P629, DOI DOI 10.1016/0005-7967(90)90076-U; Stewart J., 1987, METHODS ASSESSING RE, P211; Tabakoff B., 1992, SUBSTANCE ABUSE COMP, P152; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; VOLPICELLI JR, 1986, LIFE SCI, V38, P841, DOI 10.1016/0024-3205(86)90601-6; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B; Weiss F, 1996, J NEUROSCI, V16, P3474; WHITE FJ, 1991, BIOL BASES DRUG TOLE, P153; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8; World Health Organization, 1990, INT STAT CLASS DIS R; Zhou Y, 1996, EUR J PHARMACOL, V315, P31, DOI 10.1016/S0014-2999(96)00672-3; Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351	99	1793	1833	5	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					52	58		10.1126/science.278.5335.52	http://dx.doi.org/10.1126/science.278.5335.52			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311926				2022-12-01	WOS:A1997XZ12400031
J	Gordon, GS; Sitnikov, D; Webb, CD; Teleman, A; Straight, A; Losick, R; Murray, AW; Wright, A				Gordon, GS; Sitnikov, D; Webb, CD; Teleman, A; Straight, A; Losick, R; Murray, AW; Wright, A			Chromosome and low copy plasmid segregation in E-coli: Visual evidence for distinct mechanisms	CELL			English	Article							POLAR-CAP FORMATION; ESCHERICHIA-COLI; TN7 TRANSPOSITION; CELL-DIVISION; P1 PLASMID; PROTEIN; BINDING; REPLICATION; EXPRESSION; CLONING	We have investigated DNA segregation in E. coli by inserting multiple lac operator sequences into the chromosome near the origin of replication (oriC), in the hisC gene, a terminus marker, and into plasmids P1 and F. Expression of a GFP-LacI fusion protein allowed visualization of lac operator localization. oriC was shown to be specifically localized at or near the cell poles, and when duplicated, one copy moved to the site of new pole formation near the site of cell division. In contrast, P1 and F localized to the cell center and on duplication appeared to move rapidly to the quarter positions in the cell. Our analysis suggests that different active processes are involved in movement and localization of the chromosome and of the two plasmids during segregation.	TUFTS UNIV,DEPT MOL BIOL & MICROBIOL,BOSTON,MA 02111; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Tufts University; Harvard University; University of California System; University of California San Francisco			Teleman, Aurelio A/E-6864-2013; Teleman, Aurelio/V-8470-2019	Teleman, Aurelio A/0000-0002-4237-9368; Teleman, Aurelio/0000-0002-4237-9368; Straight, Aaron/0000-0001-5885-7881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038035, R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38035, GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, J MOL BIOL, V226, P661, DOI 10.1016/0022-2836(92)90623-R; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; AUSTIN S, 1986, J BACTERIOL, V168, P1010, DOI 10.1128/jb.168.2.1010-1013.1986; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DeBoy RT, 1996, J BACTERIOL, V178, P6184, DOI 10.1128/jb.178.21.6184-6191.1996; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HELMSTETTER CE, 1990, RES MICROBIOL, V141, P30, DOI 10.1016/0923-2508(90)90095-8; HELMSTETTER CE, 1987, J MOL BIOL, V197, P195, DOI 10.1016/0022-2836(87)90118-5; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HIRAGA S, 1993, CURR OPIN GENE DEV, V5, P789; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; LOBNEROLESEN A, 1992, J BACTERIOL, V174, P7883; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; NANNINGA N, 1990, RES MICROBIOL, V141, P103, DOI 10.1016/0923-2508(90)90102-V; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; OGDEN GB, 1986, BACTERIAL CHROMATIN, P45; Pogliano J, 1997, P NATL ACAD SCI USA, V94, P559, DOI 10.1073/pnas.94.2.559; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; ROTHFIELD LI, 1994, CELL, V77, P963, DOI 10.1016/0092-8674(94)90435-9; SCHAECHTER M, 1993, JOHN INN S, P61; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Wheeler RT, 1997, CELL, V88, P577, DOI 10.1016/S0092-8674(00)81898-X; WIENTJES FB, 1991, RES MICROBIOL, V142, P333, DOI 10.1016/0923-2508(91)90049-G; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; WILSON K, 1992, SHORT PROTOCOLS MOL; WOLDRINGH CL, 1990, RES MICROBIOL, V141, P39, DOI 10.1016/0923-2508(90)90096-9; WOLDRINGH CL, 1987, J GEN MICROBIOL, V133, P575; Wolkow CA, 1996, GENE DEV, V10, P2145, DOI 10.1101/gad.10.17.2145; Wu LJ, 1997, EMBO J, V16, P2161, DOI 10.1093/emboj/16.8.2161; YANG YX, 1993, INFECT IMMUN, V61, P3907, DOI 10.1128/IAI.61.9.3907-3913.1993	45	311	313	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1113	1121		10.1016/S0092-8674(00)80377-3	http://dx.doi.org/10.1016/S0092-8674(00)80377-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323139	Bronze			2022-12-01	WOS:A1997XX76800017
J	Kume, S; Muto, A; Inoue, T; Suga, K; Okano, H; Mikoshiba, K				Kume, S; Muto, A; Inoue, T; Suga, K; Okano, H; Mikoshiba, K			Role of inositol 1,4,5-trisphosphate receptor in ventral signaling in Xenopus embryos	SCIENCE			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; BONE MORPHOGENETIC PROTEIN-4; EARLY AMPHIBIAN EMBRYOS; MESODERM INDUCTION; NEURAL INDUCTION; HOMEOBOX GENE; SPEMANN ORGANIZER; LAEVIS EMBRYOS; EARLY RESPONSE; LITHIUM	The inositol 1,4,5-trisphosphate (IP3) receptor is a calcium ion channel involved in the release of free Ca2+ from intracellular stores. For analysis of the role of IP3-induced Ca2+ release (IICR) on patterning of the embryonic body, monoclonal antibodies that inhibit IICR were produced. Injection of these blocking antibodies into the ventral part of early Xenopus embryos induced modest dorsal differentiation. A close correlation between IICR blocking potencies and ectopic dorsal axis induction frequency suggests that an active IP3-Ca2+ signal may participate in the modulation of ventral differentiation.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT NEUROANAT,SUITA,OSAKA 565,JAPAN; CORE RES EVOLUT SCI & TECHNOL,JST,SUITA,OSAKA 565,JAPAN; RIKEN,BRAIN SCI INST,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; Osaka University; Japan Science & Technology Agency (JST); RIKEN	Kume, S (corresponding author), ERATO,JST,MIKOSHIBA CALCIOSIGNAL NET PROJECT,MEGURO KU,2-9-3 SHIMO MEGURO,TOKYO 153,JAPAN.		Kume, Shoen/M-4356-2016; Okano, Hideyuki/I-7584-2019; Mikoshiba, Katsuhiko/N-7943-2015; Inoue, Takafumi/AAM-9533-2020	Kume, Shoen/0000-0002-4292-205X; Inoue, Takafumi/0000-0002-2728-0060				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; Ault KT, 1996, DEVELOPMENT, V122, P2033; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHEN YP, 1994, DEV BIOL, V161, P70, DOI 10.1006/dbio.1994.1008; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1988, DEVELOPMENT, V102, P85; DALE L, 1992, DEVELOPMENT, V115, P573; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KUEM S, 1997, MECH DEVELOP, V66, P157; Kume S, 1997, DEV BIOL, V182, P228, DOI 10.1006/dbio.1996.8479; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUME S, UNPUB; LETTICE LA, 1993, DEVELOPMENT, V117, P263; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; Muto A, 1996, J CELL BIOL, V135, P181, DOI 10.1083/jcb.135.1.181; NIEUWKOOP PD, 1967, NORMAL DEV TABLE XEN; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355	44	98	99	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1940	1943		10.1126/science.278.5345.1940	http://dx.doi.org/10.1126/science.278.5345.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395395				2022-12-01	WOS:A1997YL00200033
J	Martin, KA; Wyatt, R; Farzan, M; Choe, H; Marcon, L; Desjardins, E; Robinson, J; Sodroski, J; Gerard, C; Gerard, NP				Martin, KA; Wyatt, R; Farzan, M; Choe, H; Marcon, L; Desjardins, E; Robinson, J; Sodroski, J; Gerard, C; Gerard, NP			CD4-independent binding of SIV gp120 to rhesus CCR5	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; OLIGOMERIC STRUCTURE; HTLV-III; AIDS PATIENTS; T-CELLS; RECEPTOR; HIV-1; CD4; IDENTIFICATION	CCR5 and CD4 are coreceptors for immunodeficiency virus entry into target cells, The gp120 envelope glycoprotein from human immunodeficiency virus strain HIV-1(YU2) bound human CCR5 (CCR5(hu)) or rhesus macaque CCR5 (CCR5(rh)) only in the presence of CD4. The gp120 from simian immunodeficiency virus strain SIVmac239 bound CCR5(rh) without CD4, but CCR5(hu) remained CD4-dependent. The CD4-independent binding of SIVmac239 gp120 depended on a single amino acid, Asp(13), in the CCR5(rh) amino-terminus. Thus, CCR5-binding moieties on the immunodeficiency virus envelope glycoprotein can be generated by interaction with CD4 or by direct interaction with the CCR5 amino-terminus. These results may have implications for the evolution of receptor use among lentiviruses as well as utility in the development of effective intervention.	DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,PERLMUTTER LAB,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV PADUA,SCH MED,INST MICROBIOL,I-35121 PADUA,ITALY; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; TULANE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70112; BETH ISRAEL DEACONESS HOSP,DEPT MED,CHILDRENS HOSP,PERLMUTTER LAB,BOSTON,MA 02115; BETH ISRAEL DEACONESS HOSP,DEPT PEDIAT,CHILDRENS HOSP,PERLMUTTER LAB,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of Padua; Harvard University; Harvard T.H. Chan School of Public Health; Tulane University; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital				Farzan, Michael/0000-0002-2990-5319; Martin, Kathleen/0000-0002-1748-0034	NHLBI NIH HHS [HL36162, HL51366] Funding Source: Medline; NIAID NIH HHS [AI41581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051366, R01HL036162, R37HL036162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; ENDRESMJ, 1996, CELL, V87, P745; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; FARZAN M, IN PRESS J VIROL; GERARD NP, UNPUB; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; KANG CY, 1993, J IMMUNOL, V151, P449; KENT KA, 1995, J MED PRIMATOL, V24, P145, DOI 10.1111/j.1600-0684.1995.tb00160.x; Kent KA, 1993, P 8 C CENT GARD I PA, P167; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Marcon L, 1997, J VIROL, V71, P2522, DOI 10.1128/JVI.71.3.2522-2527.1997; MARTIN KH, UNPUB; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Robinson J, UNPUB; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Willett BJ, 1997, NATURE, V385, P587, DOI 10.1038/385587a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT RE, UNPUB	35	105	106	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1470	1473		10.1126/science.278.5342.1470	http://dx.doi.org/10.1126/science.278.5342.1470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367961				2022-12-01	WOS:A1997YG85800047
J	Brambilla, R; Gnesutta, N; Minichiello, L; White, G; Roylance, AJ; Herron, CE; Ramsey, M; Wolfer, DP; Cestari, V; RossiArnaud, C; Grant, SGN; Chapman, PF; Lipp, HP; Sturani, E; Klein, R				Brambilla, R; Gnesutta, N; Minichiello, L; White, G; Roylance, AJ; Herron, CE; Ramsey, M; Wolfer, DP; Cestari, V; RossiArnaud, C; Grant, SGN; Chapman, PF; Lipp, HP; Sturani, E; Klein, R			A role for the Ras signalling pathway in synaptic transmission and long-term memory	NATURE			English	Article							MUSCARINIC RECEPTORS; EXCHANGE FACTOR; PROTEIN; POTENTIATION; ACTIVATION; AMYGDALA; MICE; IDENTIFICATION; PLASTICITY; INDUCTION	Members of the Ras subfamily of small guanine-nucleotide-binding proteins are essential for controlling normal and malignant cell proliferation as well as cell differentiation(1). The neuronal-specific guanine-nucleotide-exchange factor, Ras-GRF/CDC25Mm (refs 2-4), induces Ras signalling in response to Ca2+ influx(5) and activation of G-protein-coupled receptors in vitro(6), suggesting that it plays a role in neurotransmission and plasticity in vivo(7). Here we report that mice lacking Ras-GRF are impaired in the process of memory consolidation, as revealed by emotional conditioning tasks that require the function of the amygdala; learning and short-term memory are intact. Electrophysiological measurements in the basolateral amygdala reveal that long-term plasticity is abnormal in mutant mice. In contrast, Ras-GRF mutants do not reveal major deficits in spatial learning tasks such as the Morris water maze, a test that requires hippocampal function. Consistent with apparently normal hippocampal functions, Ras-GRF mutants show normal NMDA (N-methyl-D-aspartate) receptor-dependent long-term potentiation in this structure. These results implicate Ras-GRF signalling via the Ras/MAP kinase pathway in synaptic events leading to formation of long-term memories.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,I-20133 MILAN,ITALY; UNIV WALES COLL CARDIFF,SCH MOL & MED BIOSCI,PHYSIOL UNIT,CARDIFF CF1 3US,S GLAM,WALES; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,CTR NEUROSCI,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND; UNIV ZURICH,INST ANAT,CH-8057 ZURICH,SWITZERLAND; CNR,IST PSICOBIOL & PSICOFARMACOL,I-00198 ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,I-00185 ROME,ITALY	European Molecular Biology Laboratory (EMBL); University of Milan; Cardiff University; University of Edinburgh; University of Edinburgh; University of Zurich; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Minichiello, Liliana/AAA-7190-2022; Brambilla, Riccardo/A-6082-2010; Gnesutta, Nerina/I-5432-2015; Wolfer, David P/B-3293-2016; ROSSI-ARNAUD, Clelia/J-7870-2019; Klein, Ruediger/C-6147-2008	Gnesutta, Nerina/0000-0002-2465-8881; Wolfer, David P/0000-0002-5957-1401; ROSSI-ARNAUD, Clelia/0000-0001-5006-6583; Klein, Ruediger/0000-0002-3109-0163; Grant, Seth/0000-0001-8732-8735; Cestari, Vincenzo/0000-0002-9623-157X; Brambilla, Riccardo/0000-0003-3569-5706	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAHILL L, 1990, BEHAV NEUROSCI, V104, P532, DOI 10.1037/0735-7044.104.4.532; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAPMAN PF, 1992, SYNAPSE, V11, P310, DOI 10.1002/syn.890110406; CHAPMAN PF, 1990, SYNAPSE, V6, P271, DOI 10.1002/syn.890060306; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Maren S, 1996, NEURON, V16, P237, DOI 10.1016/S0896-6273(00)80041-0; Marshall C., 1995, GUIDEBOOK SMALL GTPA, P65; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; OLTON DS, 1978, BRAIN RES, V139, P215; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SCHUTZ RA, 1979, PHYSIOL BEHAV, V23, P97, DOI 10.1016/0031-9384(79)90128-8; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; WATANABE Y, 1995, NEUROSCI RES, V21, P317, DOI 10.1016/0168-0102(94)00867-F; ZIPPEL R, 1997, MOL BRAIN RES, V48, P140; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	389	399	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					281	286		10.1038/36849	http://dx.doi.org/10.1038/36849			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384379				2022-12-01	WOS:A1997YG66700062
J	Hu, FB; Stampfer, MJ; Manson, JE; Rimm, E; Colditz, GA; Rosner, BA; Hennekens, CH; Willett, WC				Hu, FB; Stampfer, MJ; Manson, JE; Rimm, E; Colditz, GA; Rosner, BA; Hennekens, CH; Willett, WC			Dietary fat intake and the risk of coronary heart disease in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADIPOSE-TISSUE; FOLLOW-UP; PLASMA-LIPOPROTEINS; SERUM-CHOLESTEROL; ACID COMPOSITION; UNITED-STATES; MORTALITY; LIPIDS; DEATH; MEN	Background The relation between dietary intake of specific types of fat, particularly trans unsaturated fat, and the risk of coronary disease remains unclear. We therefore studied this relation in women enrolled in the Nurses' Health Study. Methods We prospectively studied 80,082 women who were 34 to 59 years of age and had no known coronary disease, stroke, cancer, hypercholesterolemia, or diabetes in 1980. Information on diet was obtained at base line and updated during follow-up by means of validated questionnaires. During 14 years of follow-up, we documented 939 cases of nonfatal myocardial infarction or death from coronary heart disease. Multivariate analyses included age, smoking status, total energy intake, dietary cholesterol intake, percentages of energy obtained from protein and specific types of fat, and other risk factors. Results Each increase of 5 percent of energy intake from saturated fat, as compared with equivalent energy intake from carbohydrates, was associated with a 17 percent increase in the risk of coronary disease (relative risk, 1.17; 95 percent confidence interval, 0.97 to 1.41; P=0.10). As compared with equivalent energy from carbohydrates, the relative risk for a 2 percent increment in energy intake from trans unsaturated fat was 1.93 (95 percent confidence interval, 1.43 to 2.61; P<0.001); that for a 5 percent increment in energy from monounsaturated fat was 0.81 (95 percent confidence interval, 0.65 to 1.00; P=0.05); and that for a 5 percent increment in energy from polyunsaturated fat was 0.62 (95 percent confidence interval, 0.46 to 0.85; P=0.003). Total fat intake was not significantly related to the risk of coronary disease (for a 5 percent increase in energy from fat, the relative risk was 1.02; 95 percent confidence interval, 0.97 to 1.07; P=0.55). We estimated that the replacement of 5 percent of energy from saturated fat with energy from unsaturated fats would reduce risk by 42 percent (95 percent confidence interval, 23 to 56; P<0.001) and that the replacement of 2 percent of energy from trans fat with energy from unhydrogenated, unsaturated fats would re; duce risk by 53 percent (95 percent confidence interval, 34 to 67; P<0.001). Conclusions Our findings suggest that replacing saturated and trans unsaturated fats with unhydrogenated monounsaturated and polyunsaturated fats is more effective in preventing coronary heart disease in women than reducing overall fat intake. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009; Cole, Tim J/B-7883-2008; Hu, Frank/C-1919-2013; Robles-Sardin, Alma E/M-7714-2015	Colditz, Graham/0000-0002-7307-0291; Cole, Tim J/0000-0001-5711-8200; Robles-Sardin, Alma E/0000-0003-2044-7793	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL34594, HL24074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; *DEP AGR, 1992, AGR HDB SERIES; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; Esrey KL, 1996, J CLIN EPIDEMIOL, V49, P211, DOI 10.1016/0895-4356(95)00066-6; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; GARG A, 1992, DIABETES CARE, V15, P1572, DOI 10.2337/diacare.15.11.1572; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; GRUNDY S M, 1982, Circulation, V65, p839A; GRUNDY SM, 1988, ARTERIOSCLEROSIS, V8, P95, DOI 10.1161/01.ATV.8.1.95; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Katan MB, 1997, NEW ENGL J MED, V337, P563; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI 10.1146/annurev.nutr.15.1.473; KEYS A, 1966, AM J CLIN NUTR, V19, P175; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCKEIGUE P, 1995, LANCET, V345, P269, DOI 10.1016/S0140-6736(95)90269-4; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; Norris J, 1997, AM J PUBLIC HEALTH, V87, P740, DOI 10.2105/AJPH.87.5.740; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P3894, DOI 10.1073/pnas.87.10.3894; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; Rose G.A., 1982, CARDIOVASCULAR SURVE; Sacks F, 1994, J Cardiovasc Risk, V1, P3, DOI 10.1097/00043798-199406000-00002; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; TRICHOPOULOS D, 1995, LANCET, V345, P1108; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722	40	1167	1231	1	125	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1491	1499		10.1056/NEJM199711203372102	http://dx.doi.org/10.1056/NEJM199711203372102			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366580				2022-12-01	WOS:A1997YG24900002
J	Prodeus, AP; Zhou, XN; Maurer, M; Galli, SJ; Carroll, MC				Prodeus, AP; Zhou, XN; Maurer, M; Galli, SJ; Carroll, MC			Impaired mast cell-dependent natural immunity in complement C3-deficient mice	NATURE			English	Article							NECROSIS-FACTOR-ALPHA; ARTHUS REACTION; TNF-ALPHA; INFECTION; RELEASE; MOUSE; C5A; HISTAMINE; RECEPTOR	The complement system is widely regarded as essential for normal inflammation, not least because of its ability to activate mast cells(1-5). However, recent studies have called into question the importance of complement in several examples of mast cell-dependent inflammatory responses(6-9). To investigate the role of complement in mast cell-dependent natural immunity, we examined the responses of complement-deficient mice(10,11) to caecal ligation and puncture(12), model of acute septic peritonitis(12,13) that is dependent on mast cells and tumour necrosis factor-alpha (TNF-alpha). We found that C4- or C3-deficient mice(10,11) '' were much more sensitive to caecal ligation and puncture than wild-type (WT) controls (100% versus 20% in 24-h mortality, respectively). C3-deficient mice also exhibited reductions in peritoneal mast cell degranulation, production of TNF-alpha, neutrophil infiltration and clearance of bacteria. Treating the C3-deficient mice with purified C3 protein enhanced activation of peritoneal mast cells, TNF-alpha production, neutrophil recruitment, opsonophagocytosis of bacteria and resistance to caecal ligation and puncture, confirming that the defects were complement-dependent. These results provide formal evidence that complement activation is essential for the full expression of innate immunity in this mast cell-dependent model of bacterial infection.	BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center	Prodeus, AP (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115, USA.		Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; DASILVA WD, 1967, J EXP MED, V125, P921, DOI 10.1084/jem.125.5.921; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Fischer MB, 1996, J IMMUNOL, V157, P549; Fischer MB, 1997, J IMMUNOL, V159, P976; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.immunol.12.1.775; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; LEPOW IH, 1970, AM J PATHOL, V61, P13; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NILSSON UR, 1967, J EXP MED, V125, P1, DOI 10.1084/jem.125.1.1; RAMOS BF, 1994, J IMMUNOL, V152, P1380; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; Reid RR, 1997, J IMMUNOL, V159, P970; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VRANIAN G, 1981, J IMMUNOL, V126, P2302; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385	30	224	228	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					172	175		10.1038/36586	http://dx.doi.org/10.1038/36586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367154				2022-12-01	WOS:A1997YF49400054
J	Nightingale, SL				Nightingale, SL			Workshop on minimizing medical product errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-01	WOS:A1997YC91700008
J	Matilla, A; Koshy, BT; Cummings, C; Isobe, T; Orr, HT; Zoghbi, HY				Matilla, A; Koshy, BT; Cummings, C; Isobe, T; Orr, HT; Zoghbi, HY			The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1	NATURE			English	Article							EXPRESSION ANALYSIS; TYPE-1; GENE; REPEAT; CONSTRUCTION; CLONING; MATRIX; YEAST; SCA1	Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder characterized by ataxia, progressive motor deterioration, and loss of cerebellar Purkinje cells(1). SCA1 belongs to a growing group of neurodegenerative disorders caused by expansion of CAG repeats, which encode glutamine(2). Although the proteins containing these repeats are widely expressed, the neurodegeneration in SCA1 and other polyglutamine diseases selectively involves a few neuronal subtypes. The mechanism(s) underlying this neuronal specificity is unknown. Here we show that the cerebellar leucine-rich acidic nuclear protein (LANP)(3) interacts with ataxin-1, the SCA1 gene product. LANP is expressed predominantly in Purkinje cells, the primary site of pathology in SCAT. The interaction between LANP and ataxin-1 is significantly stronger when the number of glutamines is increased. Immunofluorescence studies demonstrate that both LANP and ataxin-1 colocalize in nuclear matrix-associated subnuclear structures. The features of the interaction between ataxin-1 and LANP, their spatial and temporal patterns of expression, and the colocalization studies indicate that cerebellar LANP is involved in the pathogenesis of SCA1.	BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CELL & MOL BIOL PROGRAM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,TOKYO 158,JAPAN; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Tokyo Metropolitan University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			MATILLA-DUEÑAS, ANTONI/C-7980-2011; Isobe, Toshiaki/Q-9279-2017	MATILLA-DUEÑAS, ANTONI/0000-0002-3514-4181; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X				Banfi S, 1996, HUM MOL GENET, V5, P33, DOI 10.1093/hmg/5.1.33; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; MATILLA A, UNPUB P NATL ACAD SC; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SMITH KE, 1995, FEBS LETT, V357, P86, DOI 10.1016/0014-5793(94)01328-X; WONG YHH, 1987, J NEUROCHEM, V48, P1434, DOI 10.1111/j.1471-4159.1987.tb05682.x; ZOGHBI H, 1985, SEMIN CELL BIOL, V6, P29	22	215	223	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					974	978		10.1038/40159	http://dx.doi.org/10.1038/40159			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353121				2022-12-01	WOS:A1997YD29900057
J	Bonita, R				Bonita, R			Added years, onus or bonus?	LANCET			English	Article											Bonita, R (corresponding author), UNIV AUCKLAND,N SHORE HOSP,FAC MED & HLTH SCI,PRIVATE BAG 93-503,AUCKLAND 1,NEW ZEALAND.							ALVAREZ J, 1995, WORLD HEALTH FORUM, V16, P361; Beaglehole R, 1997, PUBLIC HLTH CROSSROA; Bonita Ruth, 1996, World Health Statistics Quarterly, V49, P134; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MCCALLUM J, 1997, AGEING SOCIAL POLICY; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; ROBINE JM, 1997, REV CLIN GERONTOLOGY, V7, P73; SEN K, 1994, AGEING DEBATES DEMOG; van den Bos GAM, 1995, EUR J PUBLIC HEALTH, V5, P29, DOI DOI 10.1093/EURPUB/5.1.29; [WHO] World Health Organization, 1997, HLTH ENV SUST DEV 5; *WORLD BANK, 1996, HUM DEV REP 1995	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1167	1168		10.1016/S0140-6736(97)08459-6	http://dx.doi.org/10.1016/S0140-6736(97)08459-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343521				2022-12-01	WOS:A1997YB19900049
J	Bonni, A; Sun, Y; NadalVicens, M; Bhatt, A; Frank, DA; Rozovsky, I; Stahl, N; Yancopoulos, GD; Greenberg, ME				Bonni, A; Sun, Y; NadalVicens, M; Bhatt, A; Frank, DA; Rozovsky, I; Stahl, N; Yancopoulos, GD; Greenberg, ME			Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; FIBRILLARY ACIDIC PROTEIN; CEREBRAL-CORTEX; CNTF RECEPTOR; TRANSCRIPTION; CELLS; GENE; GFAP; DIFFERENTIATION; NEUROGENESIS	A mechanism by which members of the ciliary neurotrophic factor (CNTF)-leukemia inhibitory factor cytokine family regulate gliogenesis in the developing mammalian central nervous system was characterized, Activation of the CNTF receptor promoted differentiation of cerebral cortical precursor cells into astrocytes and inhibited differentiation of cortical precursors along a neuronal lineage, Although CNTF stimulated both the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and Ras-mitogen-activated protein kinase signaling pathways in cortical precursor cells, the JAK-STAT signaling pathway selectively enhanced differentiation of these precursors along a glial lineage, These findings suggest that cytokine activation of the JAK-STAT signaling pathway may be a mechanism by which cell fate is controlled during mammalian development.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,NEUROGERONTOL DIV,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT SCI BIOL,LOS ANGELES,CA 90089; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Southern California; University of Southern California; Regeneron					NCI NIH HHS [R01 CA43855] Funding Source: Medline; NICHD NIH HHS [NIHP30-HD 18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BESNARD F, 1991, J BIOL CHEM, V266, P18877; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BONNI A, UNPUB; CONDORELLI DF, 1994, J NEUROSCI RES, V39, P694, DOI 10.1002/jnr.490390610; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kahn MA, 1997, J NEUROCHEM, V68, P1413; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Richards LJ, 1996, EUR J NEUROSCI, V8, P291, DOI 10.1111/j.1460-9568.1996.tb01213.x; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Sun Y, 1996, MOL CELL NEUROSCI, V7, P152, DOI 10.1006/mcne.1996.0012; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WARE CB, 1995, DEVELOPMENT, V121, P1283; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Williams BP, 1997, NEURON, V18, P553, DOI 10.1016/S0896-6273(00)80297-4; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; ZIA Z, 1995, J NEUROSCI, V16, P5425	35	808	834	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					477	483		10.1126/science.278.5337.477	http://dx.doi.org/10.1126/science.278.5337.477			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334309				2022-12-01	WOS:A1997YB35500049
J	Brzozowski, AM; Pike, ACW; Dauter, Z; Hubbard, RE; Bonn, T; Engstrom, O; Ohman, L; Greene, GL; Gustafsson, JA; Carlquist, M				Brzozowski, AM; Pike, ACW; Dauter, Z; Hubbard, RE; Bonn, T; Engstrom, O; Ohman, L; Greene, GL; Gustafsson, JA; Carlquist, M			Molecular basis of agonism and antagonism in the oestrogen receptor	NATURE			English	Article							LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; IDENTIFICATION; MECHANISMS; ACTIVATION; COMPLEX; SITES	Oestrogens are involved in the growth, development and homeostasis of a number of tissues(1). The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER)(2). Hormone binding to the ligand-binding domain (LED) of the ER initiates a series of molecular events culminating in the activation or repression of target genes, Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery(3,4). Here we report the crystal structures of the LED of ER in complex with the endogenous oestrogen, 17 beta-oestradiol, and the selective antagonist raloxifene(5), at resolutions of 3.1 and 2.6 Angstrom, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties, Agonist and antagonist bind at the same site within the core of the LED but demonstrate different binding modes, In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LED, providing structural evidence of the mechanism of antagonism.	UNIV YORK, DEPT CHEM, PROT STRUCT GRP, YORK YO1 5DD, N YORKSHIRE, ENGLAND; KARO BIO AB, NOVUM, S-14157 HUDDINGE, SWEDEN; UNIV CHICAGO, BEN MAY INST CANC RES, CHICAGO, IL 60637 USA; KAROLINSKA INST, S-14186 HUDDINGE, SWEDEN	University of York - UK; Karolinska Institutet; University of Chicago; Karolinska Institutet								Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CIOCCA DR, 1995, ENDOCR REV, V16, P35, DOI 10.1210/er.16.1.35; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Draper MW, 1996, J BONE MINER RES, V11, P835; Ekena K, 1997, J BIOL CHEM, V272, P5069, DOI 10.1074/jbc.272.8.5069; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Grese TA, 1997, J MED CHEM, V40, P146, DOI 10.1021/jm9606352; Hegy GB, 1996, STEROIDS, V61, P367, DOI 10.1016/0039-128X(96)00042-6; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Laskowski R.A., 1993, J APPL CRYSTALLOGR A, V42, P140; LHorset F, 1996, MOL CELL BIOL, V16, P6029; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAKDEL F, 1993, MOL ENDOCRINOL, V7, P1408, DOI 10.1210/me.7.11.1408; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	29	2738	2834	5	226	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					753	758		10.1038/39645	http://dx.doi.org/10.1038/39645			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338790				2022-12-01	WOS:A1997YA95900061
J	Vernon, SJ; Coulthard, MG; Lambert, HJ; Keir, MJ; Matthews, JNS				Vernon, SJ; Coulthard, MG; Lambert, HJ; Keir, MJ; Matthews, JNS			New renal scarring in children who at age 3 and 4 years had had normal scans with dimercaptosuccinic acid: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION; REFLUX; SCARS; UROGRAPHY	Objective: To determine up to what age children remain at risk of developing a new renal scar from a urinary tract infection. Design: Follow up study. Families of children who had normal ultrasound scans and scanning with dimercaptosuccinic acid (DMSA) after referral with a urinary tract infection when aged 3 (209) or 4 (220) were invited to bring the children for repeat scans 2-11 years later. A history of infections since the original scan was obtained for children not having a repeat scan. Setting: Teaching hospital. Subjects: Children from three health districts in whom a normal scan had been obtained at age 3-4 years in 1985-1992 because of a urinary tract infection. Main outcome measure: Frequency of new renal scars in each age group. Results:In each group, about 97% of children either had repeat scanning (over 80%) or were confidently believed by their general practitioner or parent not to have had another urinary infection. The rate of further infections since the original scan was similar in the 3 and 4 year old groups (48/176 (27%) and 55/179 (31%)). Few children in either group known to have had further urinary infections did not have repeat scanning (3/209 (1.4%) and 4/220 (1.8%)). In the 3 year old group, 2.4% (5/209) had one or more new kidney scars at repeat scanning,(one sided 95% confidence interval up to 5.0%), whereas none of the 4 year olds did (one sided 95% confidence interval up to 1.4%). The children who developed scars were all aged under 3.4 years when scanned originally. Conclusions: Children with a urinary tract infection but unscarred kidneys after the third birthday have about a 1 in 40 risk of developing a scar subsequently but after the fourth birthday the risk is either very low or zero. Thus the need for urinary surveillance is much reduced in a large number of children.	ROYAL VICTORIA INFIRM, DEPT CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; ROYAL VICTORIA INFIRM, DEPT MED PHYS, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT STAT, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Lambert, Heather/0000-0003-4389-4078				AGGARWAL VK, 1991, ARCH DIS CHILD, V66, P1284, DOI 10.1136/adc.66.11.1284; [Anonymous], 1991, J R Coll Physicians Lond, V25, P36; *BIRM REFL STUD GR, 1987, BRIT MED J, V293, P237; BLYTH CR, 1986, J AM STAT ASSOC, V81, P843, DOI 10.2307/2289018; Brooks D, 1977, J R Coll Gen Pract, V27, P678; Coulthard MG, 1997, BMJ-BRIT MED J, V315, P918; GOLDRAICH NP, 1989, PEDIATR NEPHROL, V3, P1, DOI 10.1007/BF00859614; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; HODSON CJ, 1965, BRIT MED J, V2, P191, DOI 10.1136/bmj.2.5455.191; JAKOBSSON B, 1994, ARCH DIS CHILD, V70, P111, DOI 10.1136/adc.70.2.111; MERRICK MV, 1980, BRIT J RADIOL, V53, P544, DOI 10.1259/0007-1285-53-630-544; OLBING H, 1992, J UROLOGY, V148, P1653, DOI 10.1016/S0022-5347(17)36995-1; RANSLEY PG, 1978, BR J RADIOL S, V14; ROLLESTON GL, 1974, ARCH DIS CHILD, V49, P531, DOI 10.1136/adc.49.7.531; SHAH KJ, 1978, ARCH DIS CHILD, V53, P210, DOI 10.1136/adc.53.3.210; SHIMADA K, 1989, International Urology and Nephrology, V21, P153, DOI 10.1007/BF02550803; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; VERBER IG, 1989, ARCH DIS CHILD, V64, P1533, DOI 10.1136/adc.64.11.1533; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9; WHITEAR P, 1990, BRIT J RADIOL, V63, P438, DOI 10.1259/0007-1285-63-750-438; WINTER AL, 1983, J UROLOGY, V129, P1190, DOI 10.1016/S0022-5347(17)52634-8	21	79	82	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					905	908						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361538				2022-12-01	WOS:A1997YB07300020
J	Stade, K; Ford, CS; Guthrie, C; Weis, K				Stade, K; Ford, CS; Guthrie, C; Weis, K			Exportin 1 (Crm1p) is an essential nuclear export factor	CELL			English	Article							ORDER CHROMOSOME STRUCTURE; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; FISSION YEAST; PORE COMPLEX; HNRNP A1; NUCLEOCYTOPLASMIC TRANSPORT; SCHIZOSACCHAROMYCES-POMBE; POLY(A)(+) RNA	Nuclear protein export is mediated by nuclear export signals (NESs), but the mechanisms governing this transport process are not well understood. Using a novel protein export assay in S. cerevisiae, we identify CRM1 as an essential mediator of nuclear protein export in yeast. Crm1p shows homology to importin beta-like transport factors and is able to specifically interact with both the NES motif and the Ran GTPase. A mutation in the shuttling protein Crm1p affects not only protein export, but also mRNA export, indicating that these pathways are tightly coupled in S. cerevisiae. The presented data are consistent with the conclusion that Crm1p is a carrier for the NES-mediated protein export pathway. We propose CRM1 be renamed exportin 1 (XPO1).	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Weis, Karsten/F-5719-2011	Weis, Karsten/0000-0001-7224-925X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021119, R01GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Cole CN, 1997, SEMIN CELL DEV BIOL, V8, P71, DOI 10.1006/scdb.1996.0124; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; MELCHIOR F, 1994, J CELL BIOL, V124, P217; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; TURI TG, 1994, J BIOL CHEM, V269, P24229; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	61	932	942	0	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1041	1050		10.1016/S0092-8674(00)80370-0	http://dx.doi.org/10.1016/S0092-8674(00)80370-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323132	Bronze			2022-12-01	WOS:A1997XX76800010
J	Yaffe, MB; Schutkowski, M; Shen, MH; Zhou, XZ; Stukenberg, PT; Rahfeld, JU; Xu, J; Kuang, J; Kirschner, MW; Fischer, G; Cantley, LC; Lu, KP				Yaffe, MB; Schutkowski, M; Shen, MH; Zhou, XZ; Stukenberg, PT; Rahfeld, JU; Xu, J; Kuang, J; Kirschner, MW; Fischer, G; Cantley, LC; Lu, KP			Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism	SCIENCE			English	Article							PROLYL CIS/TRANS ISOMERASES; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CELL-CYCLE; M-PHASE; MITOSIS; FAMILY; ASSOCIATION; ANTIBODY; BINDING	Pin1 is an essential and conserved mitotic peptidyl-prolyl isomerase (PPlase) that is distinct from members of two other families of conventional PPlases, cyclophilins and FKBPs (FK-506 binding proteins). In response to their phosphorylation during mitosis, Pin1 binds and regulates members of a highly conserved set of protein; that overlaps with antigens recognized by the mitosis-specific monoclonal antibody MPM-2. Pin1 is here shown to be a phosphorylation-dependent PPlase that specifically recognizes the phosphoserine-proline or phosphothreonine-proline bonds present in mitotic phosphoproteins. Both Pin1 and MPM-2 selected similar phosphorylated serine-proline-containing peptides, providing the basis for the specific interaction between Pin1 and MPM-2 antigens. Pin1 preferentially isomerized proline residues preceded by phosphorylated serine or threonine with up to 1300-fold selectivity compared with unphosphorylated peptides. Pin1 may thus regulate mitotic progression by catalyzing sequence-specific and phosphorylation-dependent proline isomerization.	BETH ISRAEL DEACONESS MED CTR, DEPT MED, DIV HEMATOL ONCOL, CANC BIOL PROGRAM, BOSTON, MA 02215 USA; BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL DEACONESS MED CTR, DEPT SURG, BOSTON, MA 02215 USA; MAX PLANCK RES UNIT ENZYMOL PROT FOLDING, D-06120 HALLE, GERMANY; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CLIN INVEST, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Max Planck Society; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Stukenberg, Todd/0000-0002-6788-2111; Schutkowski, MIke/0000-0003-0919-7076	NIGMS NIH HHS [R01 GM056203, GM56230, GM56203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BERNHARDT A, 1997, INT J PEPT PROT RES, V50, P143; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHUTKOWSKI M, 1995, BIOCHEMISTRY-US, V34, P13016, DOI 10.1021/bi00040a012; SHEN M, UNPUB; TAAGEPERA S, 1994, MOL BIOL CELL, V5, P1243, DOI 10.1091/mbc.5.11.1243; VOLINIA S, UNPUB; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	671	699	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	1997	278	5345					1957	1960		10.1126/science.278.5345.1957	http://dx.doi.org/10.1126/science.278.5345.1957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395400				2022-12-01	WOS:A1997YL00200038
J	Spitzer, WO				Spitzer, WO			Balanced view of risks of oral contraceptives	LANCET			English	Editorial Material											Spitzer, WO (corresponding author), STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94301, USA.							Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Spitzer WO, 1997, HUM REPROD, V12, P2347, DOI 10.1093/humrep/12.11.2347; *WHO COLL STUD CAR, 1997, LANCET, V349, P1202	3	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1566	1567		10.1016/S0140-6736(05)64008-1	http://dx.doi.org/10.1016/S0140-6736(05)64008-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393332				2022-12-01	WOS:A1997YH98600004
J	Jamora, C; Takizawa, PA; Zaarour, RF; Denesvre, C; Faulkner, J; Malhotra, V				Jamora, C; Takizawa, PA; Zaarour, RF; Denesvre, C; Faulkner, J; Malhotra, V			Regulation of Golgi structure through heterotrimeric G proteins	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; TRIMERIC G-PROTEINS; ALPHA-SUBUNITS; MEMBRANES REQUIRES; GUANINE-NUCLEOTIDE; VESICLE FORMATION; COATED VESICLES; BREFELDIN-A; TRANSPORT	We have previously shown that ilimaquinone (IQ), a marine sponge metabolite, causes complete vesiculation of the Golgi stacks. By reconstituting the I-mediated vesiculation of the Golgi apparatus in permeabilized cells, we now demonstrate that this process does not require ARF and coatomers, which are necessary for the formation of Golgi-derived COPI vesicles. We find that IQ-mediated Golgi vesiculation is inhibited by G-alpha(s)-GDP and G-alpha(13)-GDP. Interestingly, adding beta-gamma subunits in the absence of IQ is sufficient to vesiculate Golgi stacks. Our findings reveal that I-mediated Golgi vesiculation occurs through activation of heterotrimeric G proteins and that it is the free beta-gamma, and not the activated alpha subunit, that triggers Golgi vesiculation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography			Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943; Zaarour, Rania/0000-0001-9132-5940	NIGMS NIH HHS [GM46224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIDALGO J, 1995, J CELL SCI, V108, P1805; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAIER O, 1995, BIOCHEM BIOPH RES CO, V208, P135, DOI 10.1006/bbrc.1995.1315; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MALLABIABARRENA A, 1995, CELL, V83, P667, DOI 10.1016/0092-8674(95)90177-9; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557	40	99	99	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					617	626		10.1016/S0092-8674(00)80449-3	http://dx.doi.org/10.1016/S0092-8674(00)80449-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393855	Bronze			2022-12-01	WOS:A1997YH96000009
J	MacDonald, TM; Morant, SV; Robinson, GC; Shield, MJ; McGilchrist, MM; Murray, FE; McDevitt, DG				MacDonald, TM; Morant, SV; Robinson, GC; Shield, MJ; McGilchrist, MM; Murray, FE; McDevitt, DG			Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLEEDING PEPTIC-ULCER; ELDERLY PERSONS; ASPIRIN; COMPLICATIONS; ANALGESICS; RISK	Objectives: To determine the profile of risk of upper gastrointestinal toxicity during continuous treatment with, and after cessation of, non-steroidal anti-inflammatory drugs. Design: Cohort study with a prospectively constructed, population based, record linkage database containing details of exposure to all community dispensed non-steroidal anti-inflammatory drugs and also all admissions to hospital for upper gastrointestinal diagnoses. Setting: The population of Tayside, Scotland. Subjects: 52 293 subjects aged 50 and over who received one or more non-steroidal anti-inflammatory between 1 January 1989 and 31 December 1991 and 73 792 subjects who did not receive one during the same period (controls). Main outcome measures: Admission to hospital for upper gastrointestinal bleeding and perforation, and admission for other upper gastrointestinal diagnoses. Results: About 2% of the non-steroidal anti-inflammatory cohort were admitted with an upper gastrointestinal event during the study period compared with 1.4% of controls. The risk of admission for upper gastrointestinal haemorrhage and perforation was constant during continuous non-steroidal anti-inflammatory exposure and carried over after the end of exposure. The results were similar for admissions for all upper gastrointestinal events. Conclusion: This study provides evidence that non-steroidal anti-inflammatory toxicity persists with continuous exposure. There seems to be carryover toxicity after the end of prescribing. These findings have implications for the management of patients requiring non-steroidal anti-inflammatory drugs.	SEARLE, HIGH WYCOMBE HP12 4HL, BUCKS, ENGLAND	Pfizer	MacDonald, TM (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MED MONITORING UNIT, DEPT CLIN PHARMACOL, DUNDEE DD1 9SY, SCOTLAND.			MacDonald, Thomas/0000-0001-5189-6669; Morant, Steven/0000-0001-5674-3784				BEARD K, 1987, ARCH INTERN MED, V147, P1621, DOI 10.1001/archinte.147.9.1621; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BEARDON PHG, 1989, Q J MED, V71, P497; *BRIT MED ASS ROYA, 1994, BRIT NAT FORM, P34; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; Dornan S, 1995, Health Bull (Edinb), V53, P274; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GRAHAM DY, 1988, GASTROENTEROLOGY, V95, P327, DOI 10.1016/0016-5085(88)90487-8; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; HENRY DA, 1987, BRIT MED J, V295, P1227, DOI 10.1136/bmj.295.6608.1227; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MCCULLAGH P, 1989, MONOGRAPHS STAT APPL, V37, P193; *OFF POP SENS SURV, 1990, TAB LIST CLASS SURG; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SHORROCK CJ, 1990, GASTROENTEROLOGY, V99, P334, DOI 10.1016/0016-5085(90)91013-V; SOMERVILLE K, 1986, LANCET, V1, P462; World Health Organization, 1977, INT CLASS DIS; YOLA M, 1994, J CLIN EPIDEMIOL, V47, P731, DOI 10.1016/0895-4356(94)90170-8	23	236	246	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	1997	315	7119					1333	1337		10.1136/bmj.315.7119.1333	http://dx.doi.org/10.1136/bmj.315.7119.1333			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402773	Green Published			2022-12-01	WOS:A1997YJ21800020
J	Poole, CJM; Hill, DJ; Christie, JL; Birch, J				Poole, CJM; Hill, DJ; Christie, JL; Birch, J			Deficient colour vision and interpretation of histopathology slides: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PATHOLOGISTS; BLINDNESS	Objective: To determine whether histopathologists with deficient colour vision make more errors in slide interpretation than those with normal colour vision. Design: Examination of projected transparencies of histopathological slides under standardised conditions by subjects whose colour discriminating ability was accurately assessed. Setting: Departments of histopathology in 45 hospitals in the United Kingdom. Subjects: 270 male histopathologists and medical laboratory scientific officers. Main outcome measures: Number of slides correctly identified by subjects whose colour vision was measured on the Ishihara, City University, and Farnsworth-Munsell 100 hue tests. Results: Mean (SD) scores (out of 10) for doctors with colour deficient vision were 9.4 (0.7) for 9.9 (0.4) for controls (P < 0.01) and 7.5 (1.6) v 9.4 (0.7) for scientific officers (P < 0.001). When subjects with colour deficient vision were categorised into severe, moderate, or mild, there was a significant trend towards those with severe deficiency making more mistakes (P < 0.001). Conclusions: Histopathologists and medical laboratory scientific officers should have their colour vision tested; if they are found to have a severe prolan or deutan deficiency, they should be advised to adopt a safe system of working.	DUDLEY GRP HOSP NHS TRUST,DEPT HISTOPATHOL,DUDLEY DY2 7BX,ENGLAND; CITY UNIV LONDON,DEPT OPTOMETRY & VISUAL SCI,LONDON EC1V 0HB,ENGLAND	City University London	Poole, CJM (corresponding author), DUDLEY PRIOR HLTH NHS TRUST,CENT CLIN,DEPT OCCUPAT HLTH,DUDLEY DY2 7BX,ENGLAND.							Birch J., 1993, DIAGNOSIS DEFECTIVE; BOGMAN MJJT, 1992, LANCET, V339, P185, DOI 10.1016/0140-6736(92)90255-2; CURRIER RD, 1994, ARCH NEUROL-CHICAGO, V51, P1090, DOI 10.1001/archneur.1994.00540230028008; LEACH C, 1979, INTRO STATISTICS NON; RIGBY HS, 1991, J CLIN PATHOL, V44, P745, DOI 10.1136/jcp.44.9.745; SPALDING JAB, 1993, BRIT J GEN PRACT, V43, P32; VORSTER BJ, 1979, LANCET, V2, P1295; 1991, LANCET, V338, P1302	8	34	34	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1279	1281		10.1136/bmj.315.7118.1279	http://dx.doi.org/10.1136/bmj.315.7118.1279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390055	Green Published			2022-12-01	WOS:A1997YG64500022
J	Forget, F; Pierrehumbert, RT				Forget, F; Pierrehumbert, RT			Warming early Mars with carbon dioxide clouds that scatter infrared radiation	SCIENCE			English	Article							ATMOSPHERE; CLIMATE; TEMPERATURES; VENUS; WET	Geomorphic evidence that Mars was warm enough to support flowing water about 3.8 billion years ago presents a continuing enigma that cannot be explained by conventional greenhouse warming mechanisms. Model calculations show that the surface of early Mars could have been warmed through a scattering variant of the greenhouse effect, resulting from the ability of the carbon dioxide ice clouds to reflect the outgoing thermal radiation back to the surface, This process could also explain how Earth avoided an early irreversible glaciation and could extend the size of the habitable zone on extrasolar planets around stars.	UNIV CHICAGO,DEPT GEOPHYS SCI,CHICAGO,IL 60637	University of Chicago	Forget, F (corresponding author), UNIV PARIS 06,CNRS,METEOROL DYNAM LAB,BOITE POSTALE 99,4 PL JUSSIEU,F-75252 PARIS 05,FRANCE.			Pierrehumbert, Raymond/0000-0002-5887-1197				CADEIRA K, 1992, NATURE, V359, P226; EMANUEL KA, 1994, Q J ROY METEOR SOC, V120, P1111, DOI 10.1002/qj.49712051902; Fanale F.P., 1992, MARS, P1135; Forget F, 1996, J GEOPHYS RES-PLANET, V101, P16865, DOI 10.1029/96JE01077; FORGET F, 1995, J GEOPHYS RES, V100, P2119; Hansen GB, 1997, J GEOPHYS RES-PLANET, V102, P21569, DOI 10.1029/97JE01875; JENSEN EJ, 1994, GEOPHYS RES LETT, V21, P2023, DOI 10.1029/94GL01358; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KASTING JF, 1984, ICARUS, V57, P335, DOI 10.1016/0019-1035(84)90122-2; Kasting JF, 1997, SCIENCE, V276, P1213, DOI 10.1126/science.276.5316.1213; KASTING JF, 1993, ICARUS, V101, P108, DOI 10.1006/icar.1993.1010; MANABE S, 1967, J ATMOS SCI, V24, P241, DOI 10.1175/1520-0469(1967)024<0241:TEOTAW>2.0.CO;2; McKay CP, 1997, ORIGINS LIFE EVOL B, V27, P263, DOI 10.1023/A:1006500116990; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1993, ICARUS, V103, P1, DOI 10.1006/icar.1993.1055; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SAMUELSON RE, 1967, ASTROPHYS J, V147, P782, DOI 10.1086/149053; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; STANSBERRY JA, 1995, 27 ANN M DIV PLAN SC; STEPHENS GL, 1990, J ATMOS SCI, V47, P1742, DOI 10.1175/1520-0469(1990)047<1742:TROTMA>2.0.CO;2; TOON OB, 1989, J GEOPHYS RES-ATMOS, V94, P16287, DOI 10.1029/JD094iD13p16287; WHITMIRE DP, 1995, J GEOPHYS RES-PLANET, V100, P5457, DOI 10.1029/94JE03080; XU KM, 1989, MON WEATHER REV, V117, P1471, DOI 10.1175/1520-0493(1989)117<1471:ITTACU>2.0.CO;2	24	335	337	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1273	1276		10.1126/science.278.5341.1273	http://dx.doi.org/10.1126/science.278.5341.1273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360920				2022-12-01	WOS:A1997YG04300039
J	Middleton, J; Neil, S; Wintle, J; ClarkLewis, I; Moore, H; Lam, C; Auer, M; Hub, E; Rot, A				Middleton, J; Neil, S; Wintle, J; ClarkLewis, I; Moore, H; Lam, C; Auer, M; Hub, E; Rot, A			Transcytosis and surface presentation of IL-8 ky venular endothelial cells	CELL			English	Article							ATTRACTANT ACTIVATION PROTEIN-1; ERYTHROCYTE CHEMOKINE RECEPTOR; RED-BLOOD-CELLS; HUMAN-NEUTROPHILS; LEUKOCYTE ADHESION; HEPARAN-SULFATE; L-SELECTIN; HUMAN-SKIN; BINDING; INTERLEUKIN-8	Chemokines have been convincingly implicated in actuating inflammatory leukocyte emigration. To affect the circulating leukocytes, tissue-derived chemokines have to traverse the endothelial cells (ECs). This was thought to be accomplished by chemokine diffusion through the intercellular gaps. On the contrary, we show by electron microscopy that the prototype chemokine IL-8 is internalized by venular ECs abluminally and transcytosed to the luminal surface. Here, it is presented to the adherent leukocytes on the EC membrane, predominantly in association with the EC projections. The intact C terminus of IL-8, the molecule's ''immobilization'' domain, is required for the EC binding, transcytosis, and consequently, the in vivo proemigratory activity of IL-8, indicating that the described subcellular interactions of IL-8 with the ECs are functionally relevant.	NOVARTIS FORSCHUNGSINST, A-1235 VIENNA, AUSTRIA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z3, CANADA	Novartis; University of British Columbia				Neil, Stuart/0000-0003-3306-5831; Rot, Antal/0000-0002-9730-6166; Auer, Manfred/0000-0001-8920-3522				Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; CARVETH HJ, 1989, BIOCHEM BIOPH RES CO, V162, P387, DOI 10.1016/0006-291X(89)92009-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COLDITZ IG, 1990, J LEUKOCYTE BIOL, V48, P129, DOI 10.1002/jlb.48.2.129; COLDITZ IG, 1985, SURV SYN PATHOL RES, V4, P44; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DEWALD B, 1987, BIOCHEM PHARMACOL, V36, P2505, DOI 10.1016/0006-2952(87)90523-5; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; FINA L, 1990, BLOOD, V75, P2417; FURIE MB, 1995, AM J PATHOL, V146, P1287; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; KOHN S, 1992, LAB INVEST, V67, P596; Koopmann W, 1997, J BIOL CHEM, V272, P10103; LEONARD EJ, 1991, J INVEST DERMATOL, V96, P690, DOI 10.1111/1523-1747.ep12470612; LEY K, 1993, J IMMUNOL, V151, P6347; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OMOTO E, 1990, EXP CELL RES, V187, P85, DOI 10.1016/0014-4827(90)90120-Y; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PEDRESCU D, 1994, P NATL ACAD SCI USA, V91, P3014; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; ROT A, 1992, CYTOKINE, V4, P347, DOI 10.1016/1043-4666(92)90077-5; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; ROT A, 1992, BIOCH INFLAMMATION, P271; ROT A, 1993, IMMUNOLOGIST, V1, P145; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1994, CYTOKINE HDB, P419; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHUBERT C, 1989, ARCH DERMATOL RES, V281, P475, DOI 10.1007/BF00510083; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steegmaier M, 1997, J CELL SCI, V110, P687; Strieter RM, 1996, J IMMUNOL, V156, P3583; SWENSSON O, 1991, J INVEST DERMATOL, V96, P682, DOI 10.1111/1523-1747.ep12470606; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WILLIAMS EW, 1978, J MICROSC-OXFORD, V112, P319, DOI 10.1111/j.1365-2818.1978.tb00082.x; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	71	587	597	3	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					385	395		10.1016/S0092-8674(00)80422-5	http://dx.doi.org/10.1016/S0092-8674(00)80422-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363947	Bronze			2022-12-01	WOS:A1997YD94100012
J	Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W				Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - Not a panacea for ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NEUROL INST,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	Caplan, LR (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT NEUROL,314,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Mohr, J/AAO-9694-2020					Adams HP, 1996, STROKE, V27, P1711; [Anonymous], 1996, NEUROLOGY, V47, P835; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581; PESSIN MS, 1995, CEREBROVASCULAR DISEASES, P409; SLOAN MA, 1987, ARCH NEUROL-CHICAGO, V44, P748, DOI 10.1001/archneur.1987.00520190052017; YAMAGUCHI T, 1995, THROMBOLYTIC THERAPY, P111	7	147	151	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1309	1310						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345084				2022-12-01	WOS:A1997YC92000012
J	Ogg, S; Paradis, S; Gottlieb, S; Patterson, GI; Lee, L; Tissenbaum, HA; Ruvkun, G				Ogg, S; Paradis, S; Gottlieb, S; Patterson, GI; Lee, L; Tissenbaum, HA; Ruvkun, G			The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C-elegans	NATURE			English	Article							DAUER LARVA DEVELOPMENT; CAENORHABDITIS-ELEGANS; ALVEOLAR RHABDOMYOSARCOMA; INTERACTING GENES; EXPRESSION; GROWTH; TRANSLOCATION; SUPPRESSES; PROTEINS; HOMOLOG	In mammals, insulin signalling regulates glucose transport together with the expression and activity of various metabolic enzymes. In the nematode Caenorhabditis elegans, a related pathway regulates metabolism, development and longevity(1,2). Wild-type animals enter the developmentally arrested dauer stage in response to high levels of a secreted pheromone(3), accumulating large amounts of fat in their intestines and hypodermis. Mutants in DAF-2 (a homologue of the mammalian insulin receptor) and AGE-1 (a homologue of the catalytic subunit of mammalian phosphatidylinositol 3-OH kinase) arrest development at the dauer stage(3), Moreover, animals bearing weak or temperature-sensitive mutations in daf-2 and age-1 can develop reproductively, but nevertheless show increased energy storage and longevity(1,2,4,5). Here we show that null mutations in daf-16 suppress the effects of mutations in daf-2 or age-1; lack of daf-16 bypasses the need for this insulin receptor-like signalling pathway. The principal role of DAF-2/AGE-1 signalling is thus to antagonize DAF-16. daf-16 is widely expressed and encodes three members of the Fork head family of transcription factors, The DAF-2 pathway acts synergistically with the pathway activated by a nematode TGF-beta-type signal, DAF-7, suggesting that DAF-16 cooperates with nematode SMAD proteins in regulating the transcription of key metabolic and developmental control genes. The probable human orthologues of DAF-16, FKHR and AFX, may also act downstream of insulin signalling and cooperate with TGF-beta effecters in mediating metabolic regulation. These genes may be dysregulated in diabetes.	MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DORMAN JB, 1995, GENETICS, V141, P1399; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FEDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOTTLIEB S, 1994, GENETICS, V137, P107; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; KALEBIC T, 1994, CANCER RES, V54, P5531; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; NOJIMA T, 1990, VIRCHOWS ARCH A, V417, P357, DOI 10.1007/BF01605789; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PATTERSON GI, IN PRESS GENES DEV; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle D.L., 1997, GENETIC ENV REGULATI, VII, P739; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VOWELS JJ, 1992, GENETICS, V130, P105	30	1504	1552	4	176	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					994	999		10.1038/40194	http://dx.doi.org/10.1038/40194			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353126				2022-12-01	WOS:A1997YD29900062
J	Larsson, O; Barker, CJ; Sjoholm, A; Carlqvist, H; Michell, RH; Bertorello, A; Nilsson, T; Honkanen, RE; Mayr, GW; Zwiller, J; Berggren, PO				Larsson, O; Barker, CJ; Sjoholm, A; Carlqvist, H; Michell, RH; Bertorello, A; Nilsson, T; Honkanen, RE; Mayr, GW; Zwiller, J; Berggren, PO			Inhibition of phosphatases and increased Ca2+ channel activity by inositol hexakisphosphate	SCIENCE			English	Article							SERINE/THREONINE PROTEIN PHOSPHATASES; PANCREATIC BETA-CELLS; CALCIUM CHANNELS; OKADAIC ACID; 1,2,3-TRISPHOSPHATE; 1,2-BISPHOSPHATE; POLYPHOSPHATES; PURIFICATION; SPECIFICITY; ACTIVATION	Inositol hexakisphosphate (InsP(6)), the dominant inositol phosphate in insulin-secreting pancreatic beta cells, inhibited the serine-threonine protein phosphatases type 1, type 2A, and type 3 in a concentration-dependent manner. The activity of voltage-gated L-type calcium channels is increased in cells treated with inhibitors of serine-threonine protein phosphatases. Thus, the increased calcium channel activity obtained in the presence of InsP(6) might result from the inhibition of phosphatase activity. Glucose elicited a transient increase in InsP(6) concentration, which indicates that this inositol polyphosphate may modulate calcium influx over the plasma membrane and serve as a signal in the pancreatic beta cell stimulus-secretion coupling.	KAROLINSKA INST,DEPT MOL MED,ROLF LUFT CTR DIABET RES,S-17176 STOCKHOLM,SWEDEN; ASTRA PAIN CONTROL AB,NOVUM UNIT,S-14157 HUDDINGE,SWEDEN; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV S ALABAMA,COLL MED,DEPT BIOCHEM,MOBILE,AL 36688; UNIV HAMBURG,HOSP EPPENDORF,INST PHYSIOL CHEM,D-20246 HAMBURG,GERMANY; INSERM,U338,F-67084 STRASBOURG,FRANCE	Karolinska Institutet; University of Birmingham; University of South Alabama; University of Hamburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Michell, Robert H/AAT-4974-2020	Michell, Robert H/0000-0001-9422-9858; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BARKER CV, UNPUB; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CARPENTER D, 1989, BIOCHEM SOC T, V17, P3, DOI 10.1042/bst0170003; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Efanov AM, 1997, P NATL ACAD SCI USA, V94, P4435, DOI 10.1073/pnas.94.9.4435; FUKADA M, 1994, J BIOL CHEM, V269, P29206; GRAF E, 1984, J BIOL CHEM, V259, P3620; HABY C, 1994, BIOCHEM J, V298, P341, DOI 10.1042/bj2980341; HAWKINS PT, 1993, BIOCHEM J, V294, P929, DOI 10.1042/bj2940929; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; Hughes P J, 1993, Curr Opin Neurobiol, V3, P383, DOI 10.1016/0959-4388(93)90132-I; Krizanova O, 1996, GEN PHYSIOL BIOPHYS, V15, P79; LARSSON O, UNPUB; LI G, 1991, J BIOL CHEM, V267, P4349; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; POYNER DR, 1993, J BIOL CHEM, V268, P1032; SJOHOLM A, 1993, BIOSCIENCE REP, V13, P349, DOI 10.1007/BF01150479; Spiers ID, 1996, CARBOHYD RES, V282, P81, DOI 10.1016/0008-6215(95)00361-4; STUART JA, 1994, BIOCHEM J, V303, P517, DOI 10.1042/bj3030517; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3161; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WALAAS SI, 1991, PHARMACOL REV, V43, P229; ZWILLER J, UNPUB	34	115	119	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					471	474		10.1126/science.278.5337.471	http://dx.doi.org/10.1126/science.278.5337.471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334307				2022-12-01	WOS:A1997YB35500047
J	Severin, K; Lee, DH; Kennan, AJ; Ghadiri, MR				Severin, K; Lee, DH; Kennan, AJ; Ghadiri, MR			A synthetic peptide ligase	NATURE			English	Article							HELICAL COILED-COILS; GCN4 LEUCINE-ZIPPER; ELECTROSTATIC INTERACTIONS; CATALYSIS; POLYPEPTIDES; ANTIBODIES; LIGATION; DESIGN	The preparation of synthetic molecules showing the remarkable efficiencies characteristic of natural biopolymer catalysts remains a formidable challenge for chemical biology, Although significant advances have been made in the understanding of protein structure and function, the ne novo construction of such systems remains elusive(1-5). Re-engineered natural enzymes and catalytic antibodies, possessing tailored binding pockets with appropriately positioned functional groups, have been successful in catalysing a number of chemical transformations, sometimes with impressive efficiencies(6-11). But efforts to produce wholly synthetic catalytic peptides have typically resulted in compounds with questionable structural stability, let alone reactivity(1). Here we describe a 33-residue synthetic peptide, based on the coiled-coil structural motif(12-14), which efficiently catalyses the condensation of two shorter peptide fragments with high sequence-and diastereoselectivity. Depending on the substrates used, we observe rate enhancements of tenfold to 4,100-fold over the background, with catalytic efficiencies in excess of 10(4). These results augur well for the rational design of functional peptides.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute				Severin, Kay/0000-0003-2224-7234				ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; BRUICE TC, 1964, J AM CHEM SOC, V86, P738, DOI 10.1021/ja01058a044; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Corey MJ, 1996, P NATL ACAD SCI USA, V93, P11428, DOI 10.1073/pnas.93.21.11428; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DOUGLAS K T, 1992, Current Opinion in Biotechnology, V3, P370, DOI 10.1016/0958-1669(92)90165-F; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HIRSCHMANN R, 1994, SCIENCE, V265, P234, DOI 10.1126/science.8023141; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JACOBSEN JR, 1994, P NATL ACAD SCI USA, V91, P5888, DOI 10.1073/pnas.91.13.5888; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P537; JOHNSSON K, 1993, NATURE, V365, P530, DOI 10.1038/365530a0; KAISER ET, 1988, ANGEW CHEM INT EDIT, V27, P913, DOI 10.1002/anie.198809131; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; Kirby AJ, 1996, ACTA CHEM SCAND, V50, P203, DOI 10.3891/acta.chem.scand.50-0203; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; MacBeath G, 1996, CHEM BIOL, V3, P433, DOI 10.1016/S1074-5521(96)90091-5; MARTIN RB, 1962, J AM CHEM SOC, V84, P106, DOI 10.1021/ja00860a025; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Muir TW, 1996, CHEM BIOL, V3, P817, DOI 10.1016/S1074-5521(96)90067-8; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SEVERIN RS, 1997, CHEM-EUR J, V3, P1017; Smithrud DB, 1997, J AM CHEM SOC, V119, P278, DOI 10.1021/ja963167u; Tam JP, 1995, P NATL ACAD SCI USA, V92, P12485, DOI 10.1073/pnas.92.26.12485; WONG CH, 1994, ENZYMES SYNTHETIC OR; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250	31	123	125	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					706	709		10.1038/39556	http://dx.doi.org/10.1038/39556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338780				2022-12-01	WOS:A1997YA95900048
J	Gronberg, H; Isaacs, SD; Smith, JR; Carpten, JD; Bova, GS; Freije, D; Xu, JF; Meyers, DA; Collins, FS; Trent, JM; Walsh, PC; Isaacs, WB				Gronberg, H; Isaacs, SD; Smith, JR; Carpten, JD; Bova, GS; Freije, D; Xu, JF; Meyers, DA; Collins, FS; Trent, JM; Walsh, PC; Isaacs, WB			Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; PATHOLOGICAL FEATURES; RISK; RELATIVES	Context.-Approximately 9% of prostate cancer cases have been estimated to result from inheritance of mutated prostate cancer susceptibility genes. Few data exist as to whether there are clinical differences between prostate cancers that are inherited and those that occur in the general population. Objective.-To investigate phenotypic characteristics of families potentially linked to the hereditary prostate cancer 1 (HPC1) locus on chromosome 1q24-25. Design.-Retrospective case study in which clinical data were extracted from medical and pathological records. Families.-A total of 74 North American families with hereditary prostate cancer. Prostate cancer cases from the National Cancer Data Base were used as a reference population for comparison. Main Outcome Measures.-The families were divided into 2 groups: either potentially linked (33 families with 133 men with prostate cancer), and thus likely to be carrying an altered HPC1 gene, or potentially unlinked (41 families with 172 men with prostate cancer), on the basis of haplotype analysis in the region of HPC1, The age at diagnosis of prostate cancer, serum prostate-specific antigen levels, digital rectal examination status, stage, grade, primary treatment of prostate cancers, and occurrence of other cancers were compared between the groups. Results.-The mean age at diagnosis of prostate cancer for men in potentially linked families was significantly lower than for men in potentially unlinked families (63.7 vs 65.9 years, respectively, P=.01; mean age at diagnosis in the reference population was 71.6 years). Higher-grade cancers (grade 3) were more common in potentially linked families, and advanced-stage disease was found in 41% of the case patients in potentially linked families compared with 31% in both the potentially unlinked families and the reference groups (P=.03 for the tatter comparison). In the other clinical parameters, we found no significant differences between the groups, A modest excess of breast cancer and colon cancer was found in potentially linked families in comparison with potentially unlinked families, but this difference was not statistically significant. Conclusions.-Families that provide evidence for segregation of an altered HPC1 gene are characterized by multiple cases of prostate cancer that, in most respects, are indistinguishable from nonhereditary cases, However, 3 characteristics were observed: younger age at diagnosis, higher-grade tumors, and more advanced-stage disease, Our study shows that a significant fraction of hereditary prostate cancers are diagnosed in advanced stages, emphasizing the clinical importance of early detection in men potentially carrying prostate cancer susceptibility genes, These findings support the current recommendations to screen men with a positive family history of prostate cancer beginning at age 40 years.	JOHNS HOPKINS UNIV HOSP,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD; UMEA UNIV,DEPT ONCOL,UMEA,SWEDEN	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Umea University			Smith, Jeff/C-3484-2012	Smith, Jeffrey/0000-0001-8424-910X; Bova, George/0000-0003-1639-3104	NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1993, BREAST CANCER RES TR, V28, P107, DOI 10.1007/BF00666423; ANDERSON DE, 1992, J NATL CANCER I, V84, P1114, DOI 10.1093/jnci/84.14.1114; BASTACKY SI, 1995, J UROLOGY, V153, P987, DOI 10.1016/S0022-5347(01)67619-5; BOVA GS, 1995, P AM UROL ASS, V153, pA505; Breslow N., 1987, STATISTICAL METHODS; CANNON L, 1983, INHERITANCE SUSCEPTI, P47; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gronberg H, 1996, CANCER, V77, P138, DOI 10.1002/(SICI)1097-0142(19960101)77:1<138::AID-CNCR23>3.0.CO;2-5; ISAACS SD, 1995, J NATL CANCER I, V87, P991, DOI 10.1093/jnci/87.13.991; Keetch DW, 1996, J UROLOGY, V155, P1841, DOI 10.1016/S0022-5347(01)66024-5; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; METTLIN CJ, 1995, CANCER, V76, P1104, DOI 10.1002/1097-0142(19950915)76:6<1104::AID-CNCR2820760627>3.0.CO;2-D; OTT J, 1985, ANAL HUMAN GENETIC L, P200; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855	21	127	127	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1251	1255		10.1001/jama.278.15.1251	http://dx.doi.org/10.1001/jama.278.15.1251			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333266				2022-12-01	WOS:A1997XZ70900030
J	McGrath, MA				McGrath, MA			Planetary science - Io and the plasma torus	SCIENCE			English	Editorial Material											McGrath, MA (corresponding author), SPACE TELESCOPE SCI INST,3700 SAN MARTIN DR,BALTIMORE,MD 21218, USA.							Brown ME, 1997, SCIENCE, V278, P268, DOI 10.1126/science.278.5336.268; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; Galileo G., 1610, SIDEREUS NUNCIUS; HALL DT, IN PRESS ASTROPHYS J; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; NASH DB, 1986, SATELLITES; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PEALE SJ, 1979, SCIENCE, V204; SCHNEIDER NM, 1989, NASA	9	3	3	3	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					237	238		10.1126/science.278.5336.237	http://dx.doi.org/10.1126/science.278.5336.237			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9340770				2022-12-01	WOS:A1997YA56400028
J	Jewitt, DC; Matthews, HE; Owen, T; Meier, R				Jewitt, DC; Matthews, HE; Owen, T; Meier, R			Measurements of C-12/C-13, N-14/N-15, and S-32/S-34 ratios in comet Hale-Bopp (C/1995 O1)	SCIENCE			English	Article							RADIO OBSERVATIONS; ISOTOPE ABUNDANCE; HALLEY; P/HALLEY; HCN	The C-12/C-13, N-14/N-15, and S-32/S-34 isotope ratios in comet Hale-Bopp (C/1995 O1) were determined through observations taken with the James Clerk Maxwell Telescope, Measurements of rare isotopes in HCN and CS revealed isotope ratios of (HCN)-C-12/(HCN)-C-13 = 111 +/- 12, (HCN)-N-14/(HCN)-N-15 = 323 +/- 46, and (CS)-S-32/(CS)-S-34 = 27 +/- 3. Within the measurement uncertainties, the isotopic ratios are consistent with solar system values. The cometary volatiles thus have an origin in the solar system and show no evidence for an interstellar component.	NATL RES COUNCIL CANADA, HERZBERG INST ASTROPHYS, DOMINION ASTROPHYS OBSERV, VICTORIA, BC V8X 4M6, CANADA; JOINT ASTRON CTR, HILO, HI 96720 USA	National Research Council Canada	Jewitt, DC (corresponding author), UNIV HAWAII, INST ASTRON, 2680 WOODLAWN DR, HONOLULU, HI 96822 USA.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1984, ASTRON ASTROPHYS, V141, P411; CAO YX, 1993, ASTRON J, V105, P1027, DOI 10.1086/116490; Chin YN, 1996, ASTRON ASTROPHYS, V305, P960; DAHMEN G, 1995, ASTRON ASTROPHYS, V295, P194; DANKS AC, 1974, ASTROPHYS J, V194, P745, DOI 10.1086/153297; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; FRERKING MA, 1980, ASTROPHYS J, V240, P65, DOI 10.1086/158207; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; KLEINE M, 1995, ASTROPHYS J, V439, P1021, DOI 10.1086/175239; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; LIS DC, 1997, 6566 IAU; MATTHEWS H, 1997, 6567 IAU; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P469; STAWIKOWSKI A, 1964, ASTROPHYS J, V140, P1280, DOI 10.1086/148023; VANYSEK V, 1991, ASTROPHYS SPACE SC L, V167, P879; VANYSEK V, 1977, COMETS ASTEROIDS MET, P499; WILSON TL, 1994, ANNU REV ASTRON ASTR, V32, P191; WYCKOFF S, 1989, ASTROPHYS J, V339, P488, DOI 10.1086/167312	20	108	108	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					90	93		10.1126/science.278.5335.90	http://dx.doi.org/10.1126/science.278.5335.90			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311932				2022-12-01	WOS:A1997XZ12400043
J	Leshner, AI				Leshner, AI			Addiction is a brain disease, and it matters	SCIENCE			English	Article							INJECTION-DRUG USERS; MOLECULAR MECHANISMS; COCAINE; ABUSE; ADAPTATIONS; BEHAVIOR; PATHWAYS; EXPOSURE; SYSTEM	Scientific advances over the past 20 years have shown that drug addiction is a chronic, relapsing disease that results from the prolonged effects of drugs on the brain. As with many other brain diseases, addiction has embedded behavioral and social-context aspects that are important parts of the disorder itself. Therefore, the most effective treatment approaches will include biological, behavioral, and social-context components. Recognizing addiction as a chronic, relapsing brain disorder characterized by compulsive drug seeking and use can impact society's overall health and social policy strategies and help diminish the health and social costs associated with drug abuse and addiction.			Leshner, AI (corresponding author), NIDA, NIH, 5600 FISHERS LANE, ROOM 10-05, ROCKVILLE, MD 20857 USA.							American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; [Anonymous], 1994, SEMIN NEUROSCI; Baxter Jr, 1996, Semin Clin Neuropsychiatry, V1, P32; Booth RE, 1996, DRUG ALCOHOL DEPEN, V42, P11, DOI 10.1016/0376-8716(96)01257-4; Childress A R, 1988, NIDA Res Monogr, V84, P25; COLON HM, 1995, AIDS EDUC PREV, V7, P195; Daley D.C., 1997, SUBSTANCE ABUSE COMP, P458; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; ICIARDI JA, 1997, J DRUG ISSUES, V27, P261; Institute of Medicine, 1996, PATHW ADD; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; LESHNER AI, 1997, HOSP PRACTICE SPECIA; MCLELLAN AT, 1997, TREATING DRUG ABUSER, P7; Melega WP, 1997, BEHAV BRAIN RES, V84, P259, DOI 10.1016/S0166-4328(97)83333-5; Nestler EJ, 1996, MOL PSYCHIATR, V1, P190; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; OBRIEN CP, 1975, PHARMACOL REV, V27, P533; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.ne.18.030195.002335; Stephens R. C., 1993, HDB RISK AIDS INJECT, P519; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719; WEXLER HK, 1993, DRUG TREATMENT CRIMI, P261; Wiebel WW, 1996, J ACQ IMMUN DEF SYND, V12, P282, DOI 10.1097/00042560-199607000-00008	30	935	1012	1	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					45	47		10.1126/science.278.5335.45	http://dx.doi.org/10.1126/science.278.5335.45			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311924				2022-12-01	WOS:A1997XZ12400029
J	Ollmann, MM; Wilson, BD; Yang, YK; Kerns, JA; Chen, YR; Gantz, I; Barsh, GS				Ollmann, MM; Wilson, BD; Yang, YK; Kerns, JA; Chen, YR; Gantz, I; Barsh, GS			Antagonism of central melanocortin receptors in vitro and in vivo by Agouti-related protein	SCIENCE			English	Article							MELANOCYTE-STIMULATING-HORMONE; MOLECULAR-CLONING; HUMAN HOMOLOG; YELLOW MICE; CELL-LINE; GENE; EXPRESSION; MUTATION; IDENTIFICATION; LOCALIZATION	Expression of Agouti protein is normally limited to the skin where it affects pigmentation, but ubiquitous expression causes obesity. An expressed sequence tag was identified that encodes Agouti-related protein, whose RNA is normally expressed in the hypothalamus and whose levels were increased eightfold in ob/ob mice. Recombinant Agoutirelated protein was a potent, selective antagonist of Mc3r and Mc4r, melanocortin receptor subtypes implicated in weight regulation, Ubiquitous expression of human AGRP complementary DNA in transgenic mice caused obesity without altering pigmentation, Thus, Agouti-related protein is a neuropeptide implicated in the normal control of body weight downstream of leptin signaling.	STANFORD UNIV,SCH MED,BECKMAN CTR B271A,DEPT PEDIAT,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; UNIV MICHIGAN,SCH MED,DEPT SURG,ANN ARBOR,MI 48109	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NEI NIH HHS [EY07106] Funding Source: Medline; NIDDK NIH HHS [P30DK-34933] Funding Source: Medline; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KENAKIN TP, 1982, CAN J PHYSIOL PHARM, V60, P249, DOI 10.1139/y82-036; Kiefer LL, 1997, BIOCHEMISTRY-US, V36, P2084, DOI 10.1021/bi962647v; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; OLLMANN MM, UNPUB; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; QUILLAN JM, 1995, P NATL ACAD SCI USA, V92, P2894, DOI 10.1073/pnas.92.7.2894; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Siegrist W, 1997, J RECEPT SIGNAL TR R, V17, P75, DOI 10.3109/10799899709036595; Silvers W. K., 1979, COAT COLORS MICE, P6; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	1479	1537	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					135	138		10.1126/science.278.5335.135	http://dx.doi.org/10.1126/science.278.5335.135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311920				2022-12-01	WOS:A1997XZ12400056
J	Sharp, D				Sharp, D			Half-way at Kyoto - but to where?	LANCET			English	Editorial Material																		Bouma MJ, 1997, LANCET, V350, P1435, DOI 10.1016/S0140-6736(97)04509-1; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1646	1646		10.1016/S0140-6736(05)64271-7	http://dx.doi.org/10.1016/S0140-6736(05)64271-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400506				2022-12-01	WOS:A1997YK21100006
J	Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW				Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW			Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus	LANCET			English	Article							COMPLICATIONS; BEHAVIORS	Background Intensive insulin treatment effectively delays the onset and slows the progression of microvascular complications in insulin-dependent diabetes mellitus (IDDM). Variable adherence to insulin treatment is thought to contribute to poor glycaemic control, diabetic ketoacidosis, and brittle diabetes in adolescents and young adults with IDDM. We assessed the association between the prescribed insulin dose and the amount dispensed from all community pharmacies with the Diabetes Audit and Research in Tayside Scotland (DARTS) database. Methods We studied 89 patients, mean age 16 (SD 7) years, diabetes duration 8 (4) years, and glycosylated haemoglobin (HbA(1c)) 8.4 (1.9)%, who attended a teaching hospital paediatric or young-adult diabetes clinic in 1993 and 1994. The medically recommended insulin dose and cumulative volume of insulin prescriptions supplied were used to calculate the days of maximum possible insulin coverage per annum, expressed as the adherence index. Associations between glycaemic control (HbA(1c)), episodes of diabetic ketoacidosis, and all hospital admissions for acute complications and the adherence index were modelled. Findings Insulin was prescribed at 48 (19) IU/day and mean insulin collected from pharmacies was 58 (25) IU/day. 25 (28%) of the 89 patients obtained less insulin than their prescribed dose (mean deficit 115 [68; range 9-246] insulin days/annum). There was a significant inverse association between HbA(1c) and the adherence index (R-2=0.39; p<0.001). In the top quartile (HbA(1c)>10%), 14 (64%) of individuals had an adherence index suggestive of a missed dose of insulin (mean deficit 55 insulin days/annum). There were 36 admissions for complications related to diabetes. The adherence index was inversely related to hospital admissions for diabetic ketoacidosis (p<0.001) and all hospital admissions related to acute diabetes complications (p=0.008). The deterioration in glycaemic control observed in patients aged 10-20 years was associated with a significant reduction (p=0.01) in the adherence index. Interpretation We found direct evidence of poor compliance with insulin therapy in young patients with IDDM. We suggest that poor adherence to insulin treatment is the major factor that contributes to long-term poor glycaemic control and diabetic ketoacidosis in this age group.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CTR DIABET, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MED MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee; University of Dundee	Morris, AD (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, DUNDEE DD1 9SY, SCOTLAND.		Boyle, Douglas/B-9193-2017; McMahon, Alex D/C-4304-2008; Morris, Andrew D/C-2837-2009	Boyle, Douglas/0000-0002-4779-7083; MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acerini CL, 1997, LANCET, V350, P1199, DOI 10.1016/S0140-6736(97)06467-2; BEARDON PHG, 1988, PHARM MED, V3, P185; CERKONEY KAB, 1980, DIABETES CARE, V3, P594, DOI 10.2337/diacare.3.5.594; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; DeFronzo RA, 1994, DIABETES REV, V2, P209; DUNGER DB, 1995, PRACTICAL DIABETES I, V12, P63, DOI [10.1002/pdi.1960120205, DOI 10.1002/PDI.1960120205]; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; Gill GV, 1996, QJM-MON J ASSOC PHYS, V89, P839, DOI 10.1093/qjmed/89.11.839; GILL GV, 1991, BRIT MED J, V303, P285, DOI 10.1136/bmj.303.6797.285; GLASGOW RE, 1987, J CHRON DIS, V40, P399, DOI 10.1016/0021-9681(87)90173-1; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; McNabb WL, 1997, DIABETES CARE, V20, P215, DOI 10.2337/diacare.20.2.215; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178; Pound N, 1996, DIABETIC MED, V13, P510, DOI 10.1002/(SICI)1096-9136(199606)13:6<510::AID-DIA122>3.0.CO;2-W; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; RODIN GM, 1986, INT J PSYCHIAT MED, V16, P49, DOI 10.2190/HULH-CTPR-4V17-383C; Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; SCOBIE IN, 1981, LANCET, V2, P521; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1994, LANCET, V344, P765, DOI 10.1016/S0140-6736(94)92333-7; THOMPSON CJ, 1995, DIABETIC MED, V12, P429, DOI 10.1111/j.1464-5491.1995.tb00508.x; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	26	364	366	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1505	1510		10.1016/S0140-6736(97)06234-X	http://dx.doi.org/10.1016/S0140-6736(97)06234-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388398				2022-12-01	WOS:A1997YH11500009
J	Zhang, BL; Cech, TR				Zhang, BL; Cech, TR			Peptide bond formation by in vitro selected ribozymes	NATURE			English	Article							RNA; EVOLUTION; TETRAHYMENA; CATALYSIS; INVITRO; LIGANDS; DNA	An attractive solution to the problem of the origin of protein synthesis in an evolving 'RNA world' involves catalysis by nucleic acid without assistance from proteins(1,2). Indeed, even the modem ribosome has been considered to be fundamentally an RNA, machine(3), and the large ribosomal subunit can carry out peptidyl transfer in the absence of most of its protein subunits(4). Successive cycles of in vitro selection and amplification(5-7) have been used to find RNAs that perform many biochemical reactions(8-16), including transfer of an RNA-linked amino acid io their own 5'-amino-modified terminus(15). Here we demonstrate the in vitro selection of ribozymes (196 nucleotides) that perform the same pepridyl transferase reaction as the ribosome: that is, they can join amino acids by a peptide bond. Like ribosome substrates, one amino, acid (N-blocked methionine) is esterified to the 3'(2')-O of adenosine, whereas the acceptor amino acid (phenylalanine) has a free amino group. Our best characterized ribozyme recognizes the amino-acid ester substrate by binding its adenosine moiety, and is therefore capable of utilizing Leu-and Phe- as well as Met-derived substrates. Such lack of specificity with respect to the amino acid is a feature necessary for a generalized protein-synthesizing enzyme.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								AZHAYEV AV, 1977, NUCLEIC ACIDS RES, V4, P2223, DOI 10.1093/nar/4.7.2223; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; CECH TR, 1993, RNA WORLD, P239; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DAI XC, 1995, SCIENCE, V267, P237, DOI 10.1126/science.7809628; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; KRAYEVSKY AA, 1975, NUCLEIC ACIDS RES, V2, P2223, DOI 10.1093/nar/2.12.2223; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; MADEN BEH, 1968, EUR J BIOCHEM, V6, P309, DOI 10.1111/j.1432-1033.1968.tb00450.x; MERCER TFB, 1972, EUR J BIOCHEM, V28, P38; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; Noller H.F., 1993, RNA WORLD, P137; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wecker M, 1996, RNA, V2, P982; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0; Woese C, 1967, GENETIC CODE, P179	27	226	244	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					96	100		10.1038/36375	http://dx.doi.org/10.1038/36375			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363898				2022-12-01	WOS:A1997YE47700060
J	Altar, CA; Cai, N; Bliven, T; Juhasz, M; Conner, JM; Acheson, AL; Lindsay, RM; Wiegand, SJ				Altar, CA; Cai, N; Bliven, T; Juhasz, M; Conner, JM; Acheson, AL; Lindsay, RM; Wiegand, SJ			Anterograde transport of brain-derived neurotrophic factor and its role in the brain	NATURE			English	Article							PARVALBUMIN-IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; MESSENGER-RNA; BDNF; RAT; NT-3; DIFFERENTIATION; EXPRESSION; FOREBRAIN; NT-4/5	The role of neurotrophins as target-derived proteins that promote neuron survival following their retrograde transport from the terminals to the cell bodies of neurons has been firmly established in the developing peripheral nervous system. However, neurotrophins appear to have more diverse functions, particularly in the adult central nervous system. Brain-derived neurotrophic factor (BDNF), for example, produces a variety of neuromodulatory effects in the brain that are more consistent with local actions than with long-distance retrograde signalling. Here we show that BDNF is widely distributed in nerve terminals, even in brain areas such as the striatum that lack BDNF messenger RNA, and that inhibition of axonal transport or deafferentation depletes BDNF. The number of striatal neurons that contain the calcium-binding protein parvalbumin was decreased in BDNF+/- and BDNF-/- mice in direct proportion to the loss of BDNF protein, which is consistent with anterogradely supplied BDNF having a functional role in development or maintenance. Thus the anterograde transport of BDNF from neuron cell bodies to their terminals may be important for the trafficking of BDNF in the brain.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	Altar, CA (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; ALTAR CA, 1996, NEUROPROTECTIVE APPR, P160; Conner JM, 1997, J NEUROSCI, V17, P2295; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; Fawcett JP, 1997, J BIOL CHEM, V272, P8837; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KITA H, 1990, BRAIN RES, V536, P1, DOI 10.1016/0006-8993(90)90002-S; LAPPER SR, 1992, BRAIN RES, V580, P215, DOI 10.1016/0006-8993(92)90947-8; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; *NAT RES COUNC NAT, 1996, GUID CAR US LAB AN; Radka SF, 1996, BRAIN RES, V709, P122, DOI 10.1016/0006-8993(95)01321-0; SEROOGY KB, 1993, EXP NEUROL, V124, P119, DOI 10.1006/exnr.1993.1182; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WU K, 1997, MOL BRAIN RES, V43, P286; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0	28	706	723	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					856	860		10.1038/39885	http://dx.doi.org/10.1038/39885			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349818				2022-12-01	WOS:A1997YC14800059
J	Ouyang, Q; Kaplan, PD; Liu, SM; Libchaber, A				Ouyang, Q; Kaplan, PD; Liu, SM; Libchaber, A			DNA solution of the maximal clique problem	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; GENE	The maximal clique problem has been solved by means of molecular biology techniques. A pool of DNA molecules corresponding to the total ensemble of six-vertex cliques was built, followed by a series of selection processes. The algorithm is highly parallel and has satisfactory fidelity. This work represents further evidence for the ability of DNA computing to solve NP-complete search problems.	ROCKEFELLER UNIV,CTR STUDIES PHYS & BIOL,NEW YORK,NY 10021	Rockefeller University	Ouyang, Q (corresponding author), NEC RES INST,4 INDEPENDENCE WAY,PRINCETON,NJ 08540, USA.		Kaplan, Peter/A-2972-2009	Kaplan, Peter/0000-0002-2292-6862				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; CASTI J, 1997, NEW SCI, V2082, P30; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DESALLE R, 1993, EXPERIENTIA, V49, P906, DOI 10.1007/BF01952607; Eckert K A, 1991, PCR Methods Appl, V1, P17; Garey M.R., 1979, COMPUTERS INTRACTABI; Guarnieri F, 1996, SCIENCE, V273, P220, DOI 10.1126/science.273.5272.220; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAYARAMAN K, 1991, P NATL ACAD SCI USA, V88, P4084, DOI 10.1073/pnas.88.10.4084; Kaplan PD, 1997, J THEOR BIOL, V188, P333, DOI 10.1006/jtbi.1997.0475; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; Paun G., 1996, Journal of Automata, Languages and Combinatorics, V1, P27; SAMBROOK J, 1987, MOL CLONING; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4	15	375	477	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					446	449		10.1126/science.278.5337.446	http://dx.doi.org/10.1126/science.278.5337.446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334300				2022-12-01	WOS:A1997YB35500040
J	Visintin, R; Prinz, S; Amon, A				Visintin, R; Prinz, S; Amon, A			CDC20 and CDH1: A family of substrate-specific activators of APC-dependent proteolysis	SCIENCE			English	Article							B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; G1 CYCLINS; MITOSIS; DROSOPHILA; YEAST; DESTRUCTION; FIZZY; DEGRADATION	Proteolysis mediated by the anaphase-promoting complex (APC) triggers chromosome segregation and exit from mitosis, yet its regulation is poorly understood. The conserved Cdc20 and Cdh1 proteins were identified as limiting, substrate-specific activators of APC-dependent proteolysis. CDC20 was required for the degradation of the APC substrate Pds1 but not for that of other APC substrates, such as Clb2 and Ase1. Conversely, cdh1 Delta mutants were impaired in the degradation of Ase1 and Clb2 but not in that of Pds1. Overexpression of either CDC20 or CDH1 was sufficient to induce APC-dependent proteolysis of the appropriate target in stages of the cell cycle in which substrates are normally stable.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute			Visintin, Rosella/J-9690-2012	Visintin, Rosella/0000-0001-6758-9946; Amon, Angelika/0000-0001-9837-0314				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SKOWYRA D, IN PRESS CELL; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; VISINTIN R, UNPUB; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	24	699	708	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					460	463		10.1126/science.278.5337.460	http://dx.doi.org/10.1126/science.278.5337.460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334304				2022-12-01	WOS:A1997YB35500044
J	Eng, CM; Schechter, C; Robinowitz, J; Fulop, G; Burgert, T; Levy, B; Zinberg, R; Desnick, RJ				Eng, CM; Schechter, C; Robinowitz, J; Fulop, G; Burgert, T; Levy, B; Zinberg, R; Desnick, RJ			Prenatal genetic carrier testing using triple disease screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TAY-SACHS-DISEASE; CYSTIC-FIBROSIS; GAUCHER DISEASE; ASHKENAZI JEWS; HUMAN GENOME; POPULATION; MUTATIONS; COMMON	Context.-Rapid progress in gene discovery has dramatically increased diagnostic capabilities for carrier screening and prenatal testing for genetic diseases. However, simultaneous prenatal carrier screening for prevalent genetic disease has not been evaluated, and patient acceptance and attitudes toward this testing strategy remain undefined. Objective.-To evaluate an educational, counseling, and carrier testing program for 3 genetic disorders: Tay-Sachs disease (TSD), type 1 Gaucher disease (GD), and cystic fibrosis (CF) that differ in detectability, severity, and availability of therapy. Design.-Potential participants received education and genetic counseling, gave informed consent, chose screening tests, and completed pre-education and posteducation questionnaires that assessed knowledge, attitudes toward genetic testing, and disease testing preferences. Setting.-Medical genetics referral center. Patients.-Volunteer sample of 2824 Ashkenazi Jewish individuals enrolled as couples who were referred for TSD testing. Intervention.-Genetic counseling, education, and ii chosen, genetic testing for any or all 3 disorders. Main Outcome Measure.-Acceptance of screening for each of the 3 disorders. Secondary outcomes include attitudes toward genetic testing and reproductive considerations. Results.-Of the 2824 individuals tested for TSD, 97% and 95% also chose testing for CF and GD, respectively. The frequency of detected carriers was 1.21 for TSD, 1:25 for CF, and 1:18 for GD. Twenty-one carrier couples were identified, counseled, and all postconception couples opted for prenatal diagnosis. Pre-education and posteducation questionnaires revealed that patients initially knew little about the diseases, but acquired disease information and increased knowledge of genetic concepts. Education and genetic counseling increased understanding and retention of genetic concepts and disease-related information, and minimized test-related anxiety. Although individuals sought screening for all 3 diseases, reproductive attitudes and decisions varied directly with disease severity and treatability. Conclusions.-These findings emphasize the importance of genetic counseling for prenatal carrier testing and may improve understanding, acceptance, and informed decision making for prenatal carrier screening for multiple genetic diseases.	CUNY MT SINAI SCH MED, DEPT PEDIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT COMMUNITY MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Eng, CM (corresponding author), CUNY MT SINAI SCH MED, DEPT HUMAN GENET, BOX 1497, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NCRR NIH HHS [2M01 RR00071] Funding Source: Medline; NHGRI NIH HHS [1R01 HG006440] Funding Source: Medline; NICHD NIH HHS [5P30 HD28822] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BEUTLER E, 1992, BLOOD, V79, P1662; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; Beutler E., 1995, METABOLIC MOL BASES, P2641; Brock DJH, 1996, LANCET, V347, P148, DOI 10.1016/S0140-6736(96)90340-2; CUTTING GR, 1992, AM J HUM GENET, V50, P1185; DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409; ENG CM, 1995, AM J HUM GENET, V57, P302; GRODY WW, IN PRESS AM J HUM GE; GUYER MS, 1995, P NATL ACAD SCI USA, V92, P10841, DOI 10.1073/pnas.92.24.10841; HIETALA M, 1995, AM J HUM GENET, V56, P1493; KABACK M, 1993, JAMA-J AM MED ASSOC, V270, P2307, DOI 10.1001/jama.270.19.2307; Lindeman R., 1980, INTRO BIVARIATE MULT; MASSARIK F, 1981, GENETIC DIS CONTROL, P102; McCabe ERB, 1996, JAMA-J AM MED ASSOC, V275, P548, DOI 10.1001/jama.1996.03530310054033; Morris J K, 1995, J Med Screen, V2, P22; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; ROWLEY PT, 1984, AM J HUM GENET, V36, P677; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCRIVER CR, 1995, METABOLIC MOL BASES, P2839; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; TOUCHETTE N, 1995, NAT MED, V1, P501, DOI 10.1038/nm0695-501; TRIGGSRAINE BL, 1992, AM J HUM GENET, V51, P793; TRIGGSRAINE BL, 1990, NEW ENGL J MED, V323, P6, DOI 10.1056/NEJM199007053230102; VOGEL F, 1996, HUM GENET, P559; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; Wilkinson L., 1990, SYSTAT SYSTEM STAT; IN PRESS GENETIC TES	29	61	61	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1268	1272		10.1001/jama.278.15.1268	http://dx.doi.org/10.1001/jama.278.15.1268			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333269				2022-12-01	WOS:A1997XZ70900033
J	Kushida, CA; Efron, B; Guilleminault, C				Kushida, CA; Efron, B; Guilleminault, C			A predictive morphometric model for the obstructive sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; models, anatomic; mouth; neck; body mass index	CLINICAL-FEATURES; AIRWAY; ABNORMALITIES; MORPHOLOGY	Background: Mathematical formulas have been used to clinically predict whether patients will develop the obstructive steep apnea syndrome (OSAS). However, these models do not take into account the disproportionate craniofacial anatomy that accompanies OSAS independently of obesity. Objective: To determine the accuracy of a morphometric model, which combines measurements of the oral cavity with body mass index and neck circumference, in predicting whether a patient has OSAS. Design: 6-month prospective study. Setting: University-based tertiary referral sleep clinic and research center. Participants: 300 consecutive patients evaluated for sleep disorders for the first time. Measurements: Body mass index, neck circumference, and oral cavity measurements were obtained, and a model value was calculated for each patient. Polysomnography was used to determine the number of abnormal respiratory events that occurred during sleep. Sleep apnea was defined as more than five episodes of apnea or hypopnea per hour of sleep. Results: The morphometric model had a sensitivity of 97.6% (95% Cl, 95% to 98.9%), a specificity of 100% (Cl, 92% to 100%), a positive predictive Value of 100% (Cl, 98.5% to 100%), and a negative predictive value of 88.5% (Cl, 77% to 96%). No significant discrepancies were revealed in tests of intermeasurer and test-retest reliability. Conclusions: The morphometric model provides a rapid, accurate, and reproducible method for predicting whether patients in an ambulatory setting have OSAS. The model may be clinically useful as a screening toot for OSAS rather than as a replacement for polysomnography.			Kushida, CA (corresponding author), STANFORD UNIV, SLEEP DISORDERS CLIN & RES CTR, 401 QUARRY RD, SUITE 3301-A, STANFORD, CA 94305 USA.				NIA NIH HHS [AG00164-07, AG07772] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007772] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Sleep Disorders Association, 1997, INT CLASS SLEEP DIS; Clemente C., 1981, ANATOMY REGIONAL ATL, V2nd ed.; CRONBACH LJ, 1972, DEPENDABILITY BEHAV, P78; CRONBACH LJ, 1990, ESSENTIALS PSYCHOL T, P195; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; DENNISON WM, 1965, PEDIATRICS, V36, P336; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; FERGUSON KA, 1995, CHEST, V108, P375, DOI 10.1378/chest.108.2.375; Goodman R, 1970, FACE GENETIC DISORDE; HAYDEN GD, 1977, DISORDERS RESP TRACT; HOFFSTEIN V, 1992, EUR RESPIR J, V5, P377; HOFFSTEIN V, 1993, SLEEP, V16, P118; JAMIESON A, 1986, SLEEP, V9, P469, DOI 10.1093/sleep/9.4.469; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KATZ I, 1990, AM REV RESPIR DIS, V141, P1228, DOI 10.1164/ajrccm/141.5_Pt_1.1228; KEENAN SP, 1993, SLEEP, V16, pS133, DOI 10.1093/sleep/16.suppl_8.S133; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; LANIADO N, 1987, SLEEP RES, V16, P378; LOWE AA, 1986, AM J ORTHOD DENTOFAC, V90, P484, DOI 10.1016/0889-5406(86)90108-3; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MATTSON DE, 1986, STATISTICS; PARTINEN M, 1988, CHEST, V93, P1199, DOI 10.1378/chest.93.6.1199; RAUSCHER H, 1993, THORAX, V48, P275, DOI 10.1136/thx.48.3.275; RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355; ROJEWSKI TE, 1982, LARYNGOSCOPE, V92, P246; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; Swets J. A., 1982, EVALUATION DIAGNOSTI; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	31	180	197	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				581	+		10.7326/0003-4819-127-8_Part_1-199710150-00001	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341055				2022-12-01	WOS:A1997YB41900001
J	Lang, AE; Lozano, AM; Montgomery, E; Duff, J; Tasker, R; Hutchinson, W				Lang, AE; Lozano, AM; Montgomery, E; Duff, J; Tasker, R; Hutchinson, W			Posteroventral medial pallidotomy in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORE ASSESSMENT PROGRAM; VENTRAL PALLIDOTOMY; GPI PALLIDOTOMY; TRANSPLANTATION; SYMPTOMS	Background Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up. Methods Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (''off'' period) and while taking their optimal medical regimens (''on'' period). All patients were examined preoperatively, and 39 were examined at six months; 27 of the patients were also examined at one year, and 11 at two years. Results The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent). The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two yeats. The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months. Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery. The complications of surgery were generally well tolerated, and there were no significant changes in the use of medication. Conclusions In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability. Much of the benefit is sustained at two years, although some improvements, such as those on the ipsilateral side and in axial symptoms, wane within the first year. The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy. (C) 1997, Massachusetts Medical Society.	TORONTO HOSP,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA; UNIV ARIZONA,COLL MED,DEPT NEUROL,TUCSON,AZ	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Arizona	Lang, AE (corresponding author), TORONTO HOSP,MOVEMENT DISORDERS CTR,DIV NEUROL,399 BATHURST ST,MP 11-306,TORONTO,ON M5T 2S8,CANADA.		Lang, Anthony/ABF-8114-2021; Lozano, Andres M/A-5058-2012	Lozano, Andres M./0000-0001-8257-3694; Lang, Anthony/0000-0003-1229-3667				Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Davis KD, 1997, NAT MED, V3, P671, DOI 10.1038/nm0697-671; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Fazzini E, 1997, NEUROLOGY, V48, P1273, DOI 10.1212/WNL.48.5.1273; Galvez-Jimenez Nestor, 1996, Neurology, V46, pA402; GALVEZJIMENEZ N, 1996, MOVEMENT DISORD, V11, P242; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; IACONO RP, 1995, J CLIN NEUROSCI, V2, P140, DOI 10.1016/0967-5868(95)90007-1; IACONO RP, 1995, NEUROSURGERY, V36, P1118, DOI 10.1227/00006123-199506000-00008; Johansson F, 1997, J NEUROL NEUROSUR PS, V62, P125, DOI 10.1136/jnnp.62.2.125; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; LAITINEN LV, 1995, NEUROSURG CLIN N AM, V6, P105; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Lang A. E. T., 1989, QUANTIFICATION NEURO, P285; LANG AE, 1995, MOVEMENT DISORD, V10, P527, DOI 10.1002/mds.870100426; LANG AE, IN PRESS ADV UNDERST; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Lozano A, 1996, J NEUROSURG, V84, P194, DOI 10.3171/jns.1996.84.2.0194; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; SAINTCYR JA, 1996, MOV DISORD S1, V0011, P00161; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SUTTON JP, 1995, NEUROSURGERY, V36, P1112; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x	25	384	389	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1036	1042		10.1056/NEJM199710093371503	http://dx.doi.org/10.1056/NEJM199710093371503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321531				2022-12-01	WOS:A1997XZ84400003
J	Cowles, CR; Odorizzi, G; Payne, GS; Emr, SD				Cowles, CR; Odorizzi, G; Payne, GS; Emr, SD			The AP-3 adaptor complex is essential for cargo-selective transport to the yeast vacuole	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; GOLGI-COMPLEX; DIPEPTIDYL AMINOPEPTIDASE; PROTEIN COMPLEX; ALPHA-FACTOR; CLATHRIN; GENE; MEMBRANE; ENDOCYTOSIS; MUTANTS	Three distinct adaptor protein (AP) complexes involved in protein trafficking have been identified. AP-1 and AP-2 mediate protein sorting at the trans-Golgi network and plasma membrane, respectively, whereas the function of AP-3 has not been defined. A screen for factors specifically involved in transport of alkaline phosphatase (ALP) from the Golgi to the vacuole/lysosome has identified Apl6p and Apl5p of the yeast AP-3 complex. Deletion of each of the four AP-3 subunits results in selective mislocalization of ALP and the vacuolar t-SNARE, Vam3p (but not CPS and CPY), while deletion of AP-1 and AP-2 subunits has no effect on vacuolar protein delivery. This study, therefore, provides evidence that the AP-3 complex functions in cargo-selective protein transport from the Golgi to the vacuole/lysosome.	UNIV CALIF SAN DIEGO,SCH MED,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Odorizzi, Greg/0000-0002-1143-1098	NCI NIH HHS [CA58689, CA 58689] Funding Source: Medline; NIGMS NIH HHS [GM32703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; COWLES CR, 1994, J CELL SCI, V107, P3449; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Feng DF, 1996, METHOD ENZYMOL, V266, P368; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; RAD MR, 1995, J CELL SCI, V108, P1605; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROBINSON JS, 1991, MOL CELL BIOL, V12, P5813; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SHERMAN F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; SPRAGUE GF, 1981, J MOL BIOL, V153, P323, DOI 10.1016/0022-2836(81)90281-3; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEPP JD, 1995, MOL BIOL CELL, V6, P41, DOI 10.1091/mbc.6.1.41; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; Wada Y, 1997, J CELL SCI, V110, P1299; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	48	333	343	2	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					109	118		10.1016/S0092-8674(01)80013-1	http://dx.doi.org/10.1016/S0092-8674(01)80013-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335339	Bronze			2022-12-01	WOS:A1997XZ80900013
J	Guacci, V; Koshland, D; Strunnikov, A				Guacci, V; Koshland, D; Strunnikov, A			A direct link between sister chromatid cohesion and chromosome condensation revealed through the analysis of MCD1 in S-cerevisiae	CELL			English	Article							UBIQUITOUS PROTEIN FAMILY; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CELL-CYCLE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; GENE; DNA; MITOSIS; PROTEOLYSIS	The S. cerevisiae MCD1 (mitotic chromosome determinant) gene was identified in genetic screens for genes important for chromosome structure. MCD1 is essential for viability and homologs are found from yeast to humans. Analysis of the mcd1 mutant and cell cycle-dependent expression pattern of Mcd1p suggest that this protein functions in chromosome morphogenesis from S phase through mitosis. The mcd1 mutant is defective in sister chromatid cohesion and chromosome condensation. The physical association between Mcd1p and Smc1p, one of the SMC family of chromosomal proteins, further suggests that Mcd1p functions directly on chromosomes. These data implicate Mcd1p as a nexus between cohesion and condensation. We present a model for mitotic chromosome structure that incorporates this previously unsuspected link.	NICHHD,UNIT CHROMOSOME STRUCT & FUNCT,NIH,MOL EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Guacci, V (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES MED INST,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.			Strunnikov, Alexander/0000-0002-9058-2256	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999, Z01 HD001903-11] Funding Source: Medline; NIGMS NIH HHS [GM41718] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPH KW, 1977, CELL, V12, P805, DOI 10.1016/0092-8674(77)90279-3; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1993, COLD SPRING HARB SYM, V58, P677, DOI 10.1101/SQB.1993.058.01.075; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAWRENCE JB, 1988, CELL, V52, P51; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cb.01.110185.001445; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Rao P N, 1984, Symp Fundam Cancer Res, V37, P45; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; ROSE MD, 1990, METHODS YEAST GENETI; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; Wilson E. B., 1925, CELL DEV HEREDITY; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; YU S, 1995, CELL STRUCT FUNCT, V20, P263, DOI 10.1247/csf.20.263	53	674	683	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					47	57		10.1016/S0092-8674(01)80008-8	http://dx.doi.org/10.1016/S0092-8674(01)80008-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335334	Green Accepted, Bronze			2022-12-01	WOS:A1997XZ80900008
J	Glinka, A; Wu, W; Onichtchouk, D; Blumenstock, C; Niehrs, C				Glinka, A; Wu, W; Onichtchouk, D; Blumenstock, C; Niehrs, C			Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus	NATURE			English	Article							HOMEOBOX GENE; SPEMANNS ORGANIZER; SIGNALING PATHWAYS; EMBRYOS; MESODERM; EXPRESSION; HOMOLOG; XWNT-8	The Spemann organizer of the amphibian embryo can be subdivided into two discrete activities, namely trunk organizer and head organizer(1). Several factors secreted from the organizer that are involved in trunk organization are thought to act by repressing Bmp signalling(2-4). With the exception of the secreted factor cerberus(5), little is known about head-organizer inducers, Here we show that co-expression of a dominant-negative Bmp receptor with inhibitors of the Wnt-signalling pathway in Xenopus leads to the induction of complete secondary axes, including a head, This induction does not require expression of the siamois marker of Nieuwkoop centre signalling, suggesting that cells are directly shifting to head-organizer fate, Furthermore, we fmd that cerberus is a potent inhibitor of Wnt signalling, Our results indicate that head-organizer activity results from the simultaneous repression of Bmp and Wnt signalling and they suggest a mechanism for region-specific induction by the organizer.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV MOL EMBRYOL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Onichtchouk, Daria/E-1741-2012	Onichtchouk, Daria/0000-0001-6497-1445				BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Gammill LS, 1997, DEVELOPMENT, V124, P471; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GERHART J, 1991, BOD MAR LAB, P57; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Itoh K, 1995, DEVELOPMENT, V121, P3979; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; PANNESE M, 1995, DEVELOPMENT, V121, P707; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4	30	300	307	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					517	519		10.1038/39092	http://dx.doi.org/10.1038/39092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333244				2022-12-01	WOS:A1997XY90900062
J	Schuchat, A; Robinson, K; Wenger, JD; Harrison, LH; Farley, M; Reingold, AL; Lefkowitz, L; Perkins, BA				Schuchat, A; Robinson, K; Wenger, JD; Harrison, LH; Farley, M; Reingold, AL; Lefkowitz, L; Perkins, BA			Bacterial meningitis in the United States in 1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLUENZAE TYPE-B; HAEMOPHILUS-INFLUENZAE; CONJUGATE VACCINE; HEMOPHILUS-INFLUENZAE; ANTIMICROBIAL RESISTANCE; MENINGOCOCCAL-DISEASE; RISK-FACTORS; CHILDREN; POLYSACCHARIDE; EMERGENCE	Background Before the introduction of the conjugate vaccines, Haemophilus influenzae type b was the major cause of bacterial meningitis in the United States, and meningitis was primarily a disease of infants and young children. We describe the epidemiologic features of bacterial meningitis five years after the H. influenzae type b conjugate vaccines were licensed for routine immunization of infants. Methods Data were collected from active, population-based surveillance for culture-confirmed meningitis and other invasive bacterial disease during 1995 in laboratories serving all the acute care hospitals in 22 counties of four states (total population, more than 10 million). The rates were compared with those for 1986 obtained by similar surveillance. Results On the basis of 248 cases of bacterial meningitis in the surveillance areas, the rates of meningitis (per 100,000) for the major pathogens in 1995 were Streptococcus pneumoniae, 1.1; Neisseria meningitidis, 0.6; group B streptococcus, 0.3; Listeria monocytogenes, 0.2; and H. influenzae, 0.2. Group B streptococcus was the predominant pathogen among newborns, N. meningitidis among children 2 to 18 years old, and S. pneumoniae among adults. Pneumococcal meningitis had the highest case fatality rate (21 percent) and in 36 percent of cases was caused by organisms that were not susceptible to penicillin. From these data, we estimate that 5755 cases of bacterial meningitis were caused by these five pathogens in the United States in 1995, as compared with 12,920 cases in 1986, a reduction of 55 percent. The median age of persons with bacterial meningitis increased greatly, from 15 months in 1986 to 25 years in 1995, largely as a result of a 94 percent reduction in the number of cases of ii. influenzae meningitis. Conclusions Because of the vaccine-related decline in meningitis due to H. influenzae type b, bacterial meningitis in the United Slates is now a disease predominantly of adults rather than of infants and young children. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA; JOHNS HOPKINS SCH HYG & PUBL HLTH, BALTIMORE, MD USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA; EMORY UNIV, SCH MED, ATLANTA, GA USA; CALIF EMERGING INFECT PROGRAM, BERKELEY, CA USA; VANDERBILT UNIV, MED CTR, NASHVILLE, TN USA	Centers for Disease Control & Prevention - USA; Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University; California Emerging Infections Program; Vanderbilt University	Schuchat, A (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, RESP DIS BRANCH, ATLANTA, GA 30333 USA.							ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; Blumberg HM, 1996, J INFECT DIS, V173, P365, DOI 10.1093/infdis/173.2.365; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; *COMM OBST PRACT, 1996, 173 ACOG COMM OBST P; DEMORAES C, 1992, LANCET, V340, P1554; DEMORAES JC, 1992, LANCET, V340, P1074; DOERN GV, 1986, DIAGN MICR INFEC DIS, V4, P95, DOI 10.1016/0732-8893(86)90143-4; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; FRASER DW, 1975, AM J EPIDEMIOL, V102, P394, DOI 10.1093/oxfordjournals.aje.a112178; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JONSDOTTIR KE, 1992, LANCET, V340, P252, DOI 10.1016/0140-6736(92)90529-C; JORGENSEN JH, 1990, ANTIMICROB AGENTS CH, V34, P2075, DOI 10.1128/AAC.34.11.2075; Kaspar DL, 1996, J CLIN INVEST, V98, P2308, DOI 10.1172/JCI119042; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MOHLEBOETANI JC, 1993, PEDIATR INFECT DIS J, V12, P589, DOI 10.1097/00006454-199307000-00009; MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2; NCCLS, 1997, METH DIL ANT SUSC TE; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; RODRIGUES LP, 1971, J IMMUNOL, V107, P1071; Scheifele DW, 1996, CAN MED ASSOC J, V154, P1041; Scheifele DW, 1996, CAN MED ASSOC J, V154, P1319; SCHOENDORF KC, 1994, PEDIATRICS, V93, P663; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; TAKALA AK, 1994, LARYNGOSCOPE, V104, P731; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; WARD J, 1994, VACCINES, P337; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; 1996, MMWR-MORBID MORTAL W, V45, P853; 1996, MMWR-MORBID MORTAL W, V45, P1010	41	837	891	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					970	976		10.1056/NEJM199710023371404	http://dx.doi.org/10.1056/NEJM199710023371404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9395430	Bronze			2022-12-01	WOS:A1997XY42300004
J	Hilden, J				Hilden, J			Discrepant analysis - or behaviour?	LANCET			English	Editorial Material							SENSITIVITY; SPECIFICITY; BIAS				Hilden, J (corresponding author), UNIV COPENHAGEN,DEPT BIOSTAT,BLEGDAMSVEJ 3,DK-2200 COPENHAGEN N,DENMARK.							DIAMOND GA, 1986, J CHRON DIS, V39, P343, DOI 10.1016/0021-9681(86)90119-0; DIETZ K, 1985, J MATH BIOL, V22, P117; Hadgu A, 1997, STAT MED, V16, P1391, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1391::AID-SIM636>3.0.CO;2-1; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HILDEN J, 1986, J CHRON DIS, V39, P853, DOI 10.1016/0021-9681(86)90087-1; KEIDING N, 1991, J R STAT SOC A STAT, V154, P371, DOI 10.2307/2983150; McGee DL, 1996, LANCET, V348, P1307, DOI 10.1016/S0140-6736(05)65781-9	7	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					902	902		10.1016/S0140-6736(05)63264-3	http://dx.doi.org/10.1016/S0140-6736(05)63264-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314866				2022-12-01	WOS:A1997XY67200006
J	Butland, BK; Strachan, DP; Lewis, S; Bynner, J; Butler, N; Britton, J				Butland, BK; Strachan, DP; Lewis, S; Bynner, J; Butler, N; Britton, J			Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ECZEMA; ATOPY; PREVALENCE; ASTHMA; CHILDREN; ALLERGY; DISEASE; SMOKING	Objective: To investigate whether changes in certain perinatal and social factors explain the increased prevalence of hay fever and eczema among British adolescents between 1974 and 1986. Design: Two prospective birth cohort studies. Setting: England, Wales, and Scotland. Subjects: 11 195 children born 3-9 March 1958 and 9387 born 5-11 April 1970. Main outcome measures: Parental reports of eczematous rashes and of hay fever or allergic rhinitis in the previous 12 months at age 16. Results: The prevalence of the conditions over the 12 month period increased between 1974 and 1986 from 3.1% to 6.4% (prevalence ratio 2.04 (95% confidence interval 1.79 to 2.32)) for eczema and from 12.0% to 23.3% (prevalence ratio 1.93 (1.82 to 2.06)) for hay fever. Both conditions were more commonly reported among children of higher birth order and those who were breast fed for longer than 1 month. Eczema was more commonly reported among girls and hay fever among boys. The prevalence of hay fever decreased sharply between social classes I and V, increased with maternal age up to the early 30s, and was lower in children whose mothers smoked during pregnancy. Neither condition varied significantly with birth weight When adjusted for these factors, the relative odds of hay fever (1986 v 1974) increased from 2.23 (2.05 to 2.43) to 2.40 (2.19 to 2.63). Similarly, the relative odds of eczema rose from 2.02 (1.73 to 2.36) to 2.14 (1.81 to 2.52). Conclusions: Taken together, changes between cohorts in sex, birth weight, birth order, maternal age, breast feeding, maternal smoking during pregnancy, and father's social dass at birth did not seem to explain any of the observed rise in the prevalence of hay fever and eczema. However, correlates of these factors which have changed over time may still underlie recent increases' in allergic disease.	UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,INT CTR CHILD STUDIES,LONDON EC1V 0HB,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; City University London; University of London; University College London	Butland, BK (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Britton, John R/G-9705-2011	Butland, Barbara/0000-0001-9952-3108				ASTARITA C, 1988, CLIN ALLERGY, V18, P341, DOI 10.1111/j.1365-2222.1988.tb02881.x; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; Butler NR, 1986, BIRTH 5 STUDY HLTH B; DAVIE R, 1972, BIRTH 7 FULL STAT AP; FINN R, 1992, LANCET, V340, P1453; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; Golding J, 1986, BIRTH 5 STUDY HLTH B; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; *LUNG ASTHM INF AG, 1993, 935 ST GEORG HOSP ME; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; *REG GEN ENGL WAL, 1951, CLASS OCC; *REG GEN ENGL WAL, 1966, CLASS OCC; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496, DOI 10.1136/adc.67.4.496; SAARINEN UM, 1979, LANCET, V2, P163; *SAS I, 1989, SAS STAT US GUID VER; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132	25	178	182	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					717	721		10.1136/bmj.315.7110.717	http://dx.doi.org/10.1136/bmj.315.7110.717			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314757	Green Published			2022-12-01	WOS:A1997XX67400023
J	Toczyski, DP; Galgoczy, DJ; Hartwell, LH				Toczyski, DP; Galgoczy, DJ; Hartwell, LH			CDC5 and CKII control adaptation to the yeast DNA damage checkpoint	CELL			English	Article							CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; BUDDING YEAST; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; RAD9 CHECKPOINT; BINDING PROTEIN	A single double-stranded DNA (dsDNA) break will cause yeast cells to arrest in G2/M at the DNA damage checkpoint. If the dsDNA break cannot be repaired, cells will eventually override (that is, adapt to) this checkpoint, even though the damage that elicited the arrest is still present. Here, we report the identification of two adaptation-defective mutants that remain permanently arrested as large-budded cells when faced with an irreparable dsDNA break in a nonessential chromosome. This adaptation-defective phenotype was entirely relieved by deletion of RAD9, a gene required for the G2/M DNA damage checkpoint arrest. We show that one mutation resides in CDC5, which encodes a polo-like kinase, whereas a second, less penetrant, adaptation-defective mutant is affected at the CKB2 locus, which encodes a nonessential specificity subunit of casein kinase II.			Toczyski, DP (corresponding author), FRED HUTCHINSON CANC RES CTR, 1100 FAIRVIEW AVE N, C3-167, SEATTLE, WA 98109 USA.				NCI NIH HHS [CAO9437] Funding Source: Medline; NIGMS NIH HHS [GM-17709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017709, R01GM017709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HARTWELL LH, 1973, GENETICS, V74, P267; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; REED JC, 1994, J BIOL CHEM, V269, P18192; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	41	357	359	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1097	1106		10.1016/S0092-8674(00)80375-X	http://dx.doi.org/10.1016/S0092-8674(00)80375-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323137	Bronze			2022-12-01	WOS:A1997XX76800015
J	Nightingale, SL				Nightingale, SL			Interim recommendations issued for patients exposed to fenfluramine and dexfenfluramine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-01	WOS:A1997YH98700007
J	Kamijo, T; Zindy, F; Roussel, MF; Quelle, DE; Downing, JR; Ashmun, RA; Grosveld, G; Sherr, CJ				Kamijo, T; Zindy, F; Roussel, MF; Quelle, DE; Downing, JR; Ashmun, RA; Grosveld, G; Sherr, CJ			Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF)	CELL			English	Article							AUSTRALIAN MELANOMA KINDREDS; CELL-CYCLE INHIBITION; FAMILIAL MELANOMA; HUMAN CANCERS; SPONTANEOUS IMMORTALIZATION; RETINOBLASTOMA-PROTEIN; P16(INK4) EXPRESSION; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; CDK INHIBITORS	The INK4a tumor suppressor locus encodes p16(INK4a), an inhibitor of cyclin D-dependent kinases, and p19(ARF), an alternative reading frame protein that also blocks cell proliferation. Surprisingly, mice lacking p19(ARF) but expressing functional p16(INK4a) develop tumors early in life. Their embryo fibroblasts (MEFs) do not senesce and are transformed by oncogenic Ha-ras alone. Conversion of ARF(+/+) or ARF(+/-) MEF strains to continuously proliferating cell lines involves loss of either p19(ARF) or p53. p53-mediated checkpoint control is unperturbed in ARF-null fibroblast strains, whereas p53-negative cell lines are resistant to p19(ARF)-induced growth arrest. Therefore, INK4a encodes growth inhibitory proteins that act upstream of the retinoblastoma protein and p53. Mutations and deletions targeting this locus in cancer cells are unlikely to be functionally equivalent.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Downing, James R./N-8102-2018; Roussel, Martine F/F-1469-2016; Sherr, Charles J/N-8074-2018	Roussel, Martine F/0000-0002-1740-8139; Sherr, Charles J/0000-0002-5516-6206; Quelle, Dawn/0000-0001-8776-0122	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA71907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FUKUSAWA K, 1996, SCIENCE, V271, P1744; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; Herzog CR, 1996, ONCOGENE, V13, P1885; HIRAMA T, 1995, BLOOD, V86, P841; Holland EA, 1995, ONCOGENE, V11, P2289; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kubo Y, 1997, BIOCHEM BIOPH RES CO, V232, P38, DOI 10.1006/bbrc.1997.6217; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAITO M, 1989, CARCINOGENESIS, V3, P187; Noble JR, 1996, ONCOGENE, V13, P1259; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Parry D, 1996, MOL CELL BIOL, V16, P3844; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; REYMOND A, 1995, ONCOGENE, V11, P1173; Reznikoff CA, 1996, CANCER RES, V56, P2886; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Tanaka H, 1997, INT J CANCER, V70, P437, DOI 10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.3.CO;2-I; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WICK ST, 1995, ONCOGENE, V11, P2013; YANG R, 1995, CANCER RES, V55, P2503; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	65	1325	1373	0	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 28	1997	91	5					649	659		10.1016/S0092-8674(00)80452-3	http://dx.doi.org/10.1016/S0092-8674(00)80452-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393858	Bronze			2022-12-01	WOS:A1997YH96000012
J	Kumar, A; Commane, M; Flickinger, TW; Horvath, CM; Stark, GR				Kumar, A; Commane, M; Flickinger, TW; Horvath, CM; Stark, GR			Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; INTERFERON-ALPHA; ACTIVATION; TRANSCRIPTION; INHIBITION; PATHWAY; GAMMA; GENE; PROTEINS	Signal transducers and activators of transcription (STATs) enhance transcription of specific genes in response to cytokines and growth factors. STAT1 is also required for efficient constitutive expression of the caspases Ice, Cpp32, and Ich-l in human fibroblasts. As a consequence, STAT1-null cells are resistant to apoptosis by tumor necrosis factor alpha (TNF-alpha). Reintroduction of STAT1 alpha restored both TNF-alpha-induced apoptosis and the expression of Ice, Cpp32, and Ich-1. Variant STAT1 proteins carrying point mutations that inactivate domains required for STAT dimer formation nevertheless restored protease expression and sensitivity to apoptosis, indicating that the functions of STAT1 required for these activities are different from those that mediate induced gene expression.	CLEVELAND CLIN FDN,LERNER RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; ROCKEFELLER UNIV,MOL CELL BIOL LAB,NEW YORK,NY 10021	Cleveland Clinic Foundation; Rockefeller University				Horvath, Curt/0000-0003-2449-225X	NCI NIH HHS [P01 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHATTERJEEKISHO.M, UNPUB; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FRAER A, 1996, CELL, V85, P781; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HOVANESIAN AG, 1993, SEMIN VIROL, V4, P23; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEUNG SY, UNPUB; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUBEN BY, 1988, CANCER RES, V48, P6006; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wilson Z. E., UNPUB	27	430	438	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1630	1632		10.1126/science.278.5343.1630	http://dx.doi.org/10.1126/science.278.5343.1630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374464				2022-12-01	WOS:A1997YJ87400043
J	Sijbesma, RP; Beijer, FH; Brunsveld, L; Folmer, BJB; Hirschberg, JHKK; Lange, RFM; Lowe, JKL; Meijer, EW				Sijbesma, RP; Beijer, FH; Brunsveld, L; Folmer, BJB; Hirschberg, JHKK; Lange, RFM; Lowe, JKL; Meijer, EW			Reversible polymers formed from self-complementary monomers using quadruple hydrogen bonding	SCIENCE			English	Article							ASSOCIATION CHAIN POLYMERS; COPOLYMERS	Units of 2-ureido-4-pyrimidone that dimerize strongly in a self-complementary array of four cooperative hydrogen bonds were used as the associating end group in reversible self-assembling polymer systems. The unidirectional design of the binding sites prevents uncontrolled multidirectional association or gelation. Linear polymers and reversible networks were formed from monomers with two and three binding sites, respectively. The thermal and environmental control over lifetime and bond strength makes many properties, such as viscosity, chain length, and composition, tunable in a way not accessible to traditional polymers. Hence, polymer networks with thermodynamically controlled architectures can be formed, for use in, for example, coatings and hot melts, where a reversible, strongly temperature-dependent rheology is highly advantageous.	EINDHOVEN UNIV TECHNOL,ORGAN CHEM LAB,NL-5600 MB EINDHOVEN,NETHERLANDS; DSM RES BV,NL-6160 MD GELEEN,NETHERLANDS	Eindhoven University of Technology; DSM NV			Lewis, Christopher L/I-8254-2015; Sijbesma, Rintje Pieter P/D-3551-2012; Meijer, E.W./K-7632-2013	Sijbesma, Rintje Pieter P/0000-0002-8975-636X; Meijer, E.W./0000-0003-4126-7492; Brunsveld, Luc/0000-0001-5675-511X				Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; ALEXANDER C, 1994, MACROMOL SYMP, V77, P283, DOI 10.1002/masy.19940770130; BEIJER FH, UNPUB; BLADON P, 1993, MACROMOLECULES, V26, P6604, DOI 10.1021/ma00076a045; CATES ME, 1987, MACROMOLECULES, V20, P2289, DOI 10.1021/ma00175a038; DUCHARME Y, 1988, J ORG CHEM, V53, P5787, DOI 10.1021/jo00259a037; EISENBACH CD, 1995, MACROMOL CHEM PHYSIC, V196, P1077, DOI 10.1002/macp.1995.021960410; Flory PJ., 1953, PRINCIPLES POLYM CHE; Fouquey C., 1990, ADV MATER, V2, P254; HILGER C, 1992, MACROMOLECULES, V25, P2498, DOI 10.1021/ma00035a031; KOTERA M, 1994, J CHEM SOC CHEM COMM, P197, DOI 10.1039/c39940000197; LEE CM, 1994, POLYMER, V35, P4550, DOI 10.1016/0032-3861(94)90801-X; LEHN JM, 1993, MAKROMOL CHEM-M SYMP, V69, P1, DOI 10.1002/masy.19930690103; LILLYA CP, 1992, MACROMOLECULES, V25, P2076, DOI 10.1021/ma00034a003; MOLLER M, 1987, ACS S SER, V350, pCH7; MURRAY TJ, 1992, J AM CHEM SOC, V114, P4010, DOI 10.1021/ja00036a079; STPOURCAIN CB, 1995, MACROMOLECULES, V28, P4116, DOI 10.1021/ma00116a010	17	1849	1920	29	833	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1601	1604		10.1126/science.278.5343.1601	http://dx.doi.org/10.1126/science.278.5343.1601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374454				2022-12-01	WOS:A1997YJ87400033
J	Rosen, ED; Chan, JCY; Idusogie, E; Clotman, F; Vlasuk, G; Luther, T; Jalbert, LR; Albrecht, S; Zhong, L; Lissens, A; Schoonjans, L; Moons, L; Collen, D; Castellino, FJ; Carmeliet, P				Rosen, ED; Chan, JCY; Idusogie, E; Clotman, F; Vlasuk, G; Luther, T; Jalbert, LR; Albrecht, S; Zhong, L; Lissens, A; Schoonjans, L; Moons, L; Collen, D; Castellino, FJ; Carmeliet, P			Mice lacking factor VII develop normally but suffer fatal perinatal bleeding	NATURE			English	Article							VISCERAL YOLK-SAC; TISSUE FACTOR; BLOOD-COAGULATION; EXPRESSION; INITIATOR; DEFICIENT; BIOLOGY; PROTEIN; EMBRYOS; CELLS	Blood coagulation in vivo is initiated by factor VII (FVII) binding to its cellular receptor tissue factor (TF)(1-4). FVII is the only known ligand for TF, so it was expected that FVII-deficient embryos would have a similar phenotype to TF-deficient embryos, which have defective vitello-embryonic circulation and die around 9.5 days of gestation(5-8), Surprisingly, we find that FVII-deficient (FVII-/-) embryos developed normally, FVII-/- mice succumbed perinatally because of fatal haemorrhaging from normal blood vessels. At embryonic day 9.5, maternal-fetal transfer of FVII was undetectable and survival of embryos did not depend on TF-FVII-initiated fibrin formation. Thus, the TF-/- embryonic lethal and the FVII-/- survival-phenotypes suggest a role for TF during embryogenesis beyond fibrin formation.	FLANDERS INTERUNIV, INST BIOTECHNOL, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM; UNIV NOTRE DAME, CTR TRANSGENE RES, NOTRE DAME, IN 46556 USA; UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA; UNIV LOUVAIN, LAB DEV GENET, B-1348 LOUVAIN, BELGIUM; CORVAS INT INC, SAN DIEGO, CA 92121 USA; TECH UNIV DRESDEN, INST PATHOL, D-01307 DRESDEN, GERMANY	University of Notre Dame; University of Notre Dame; Technische Universitat Dresden			Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Moons, Lieve (Godelieve)/0000-0003-0186-1411				Albrecht S, 1996, THROMB HAEMOSTASIS, V75, P772; Auerbach R, 1996, STEM CELLS, V14, P269, DOI 10.1002/stem.140269; BEEBY TL, 1993, THROMB HAEMOSTASIS, V70, P465; BOURGET P, 1995, CLIN PHARMACOKINET, V28, P161, DOI 10.2165/00003088-199528020-00006; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Carmeliet P, 1997, AM J PATHOL, V150, P761; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FREEMAN SJ, 1981, J EMBRYOL EXP MORPH, V66, P223; FREEMAN SJ, 1983, J EMBRYOL EXP MORPH, V73, P307; Idusogie E, 1996, THROMB HAEMOSTASIS, V75, P481; ISHII S, 1995, ARZNEIMITTEL-FORSCH, V45-1, P644; KUMADA T, 1988, BLOOD, V71, P728; LANDOR M, 1995, ANN ALLERG ASTHMA IM, V74, P279; Luther T, 1996, AM J PATHOL, V149, P101; MORRISSEY JH, 1993, BLOOD, V81, P734; NEMERSON Y, 1995, THROMB HAEMOSTASIS, V74, P180; PETERSEN LC, 1995, THROMB RES, V79, P1, DOI 10.1016/0049-3848(95)00069-4; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922; Toomey JR, 1996, BLOOD, V88, P1583; VANMAELEFABRY G, 1995, TOXICOL IN VITRO, V9, P671, DOI 10.1016/0887-2333(95)00064-F	29	181	185	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					290	294		10.1038/36862	http://dx.doi.org/10.1038/36862			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384381				2022-12-01	WOS:A1997YG66700064
J	Edelmann, W; Yang, K; Umar, A; Heyer, J; Lau, K; Fan, KH; Liedtke, W; Cohen, PE; Kane, MF; Lipford, JR; Yu, NJ; Crouse, GF; Pollard, JW; Kunkel, T; Lipkin, M; Kolodner, R; Kucherlapati, R				Edelmann, W; Yang, K; Umar, A; Heyer, J; Lau, K; Fan, KH; Liedtke, W; Cohen, PE; Kane, MF; Lipford, JR; Yu, NJ; Crouse, GF; Pollard, JW; Kunkel, T; Lipkin, M; Kolodner, R; Kucherlapati, R			Mutation in the mismatch repair gene Msh6 causes cancer susceptibility	CELL			English	Article							NONPOLYPOSIS COLON-CANCER; COLORECTAL TUMORIGENESIS; HETERODUPLEX REPAIR; TUMOR-CELLS; DNA; MICE; HETERODIMER; HOMOLOG; MOUSE; DEFICIENCY	Mice carrying a null mutation in the mismatch repair gene Msh6 were generated by gene targeting. Cells that were homozygous for the mutation did not produce any detectable MSH6 protein, and extracts prepared from these cells were defective for repair of single nucleotide mismatches. Repair of 1, 2, and 4 nucleotide insertion/deletion mismatches was unaffected. Mice that were homozygous for the mutation had a reduced life span. The mice developed a spectrum of tumors, the most predominant of which were gastrointestinal tumors and B-as well as T-cell lymphomas. The tumors did not show any microsatellite instability. We conclude that MSH6 mutations, like those in some other members bf the family of mismatch repair genes, lead to cancer susceptibility, and germline mutations in this gene may be associated with a cancer predisposition syndrome that does not show microsatellite instability.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL GENET,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,STRANG CANC RES LAB,BRONX,NY 10461; NIEHS,NIH,RES TRIANGLE PK,NC 27709; DANA FARBER CANC INST,BOSTON,MA 02115; LUDWIG INST CANC RES,LA JOLLA,CA 92093; EMORY UNIV,ATLANTA,GA 30322	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Dana-Farber Cancer Institute; Ludwig Institute for Cancer Research; Emory University	Edelmann, W (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Kucherlapati, Raju/ABC-8807-2021; Liedtke, Wolfgang/GNH-1878-2022; Liedtke, Wolfgang B/G-4633-2011		NCI NIH HHS [CA 67944, CA 44704, CA 54050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067944, R01CA054050, P01CA044704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6062; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Corradi A, 1996, GENOMICS, V36, P288, DOI 10.1006/geno.1996.0464; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KOLODNER RD, 1995, CANCER RES, V55, P242; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PETTOMAKI P, 1997, IN PRESS GASTROENTER; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; THOMAS DC, 1995, METHODS COMPANION ME, P187; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	51	303	312	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					467	477		10.1016/S0092-8674(00)80433-X	http://dx.doi.org/10.1016/S0092-8674(00)80433-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390556	Bronze			2022-12-01	WOS:A1997YG49200008
J	Kenny, B; DeVinney, R; Stein, M; Reinscheid, DJ; Frey, EA; Finlay, BB				Kenny, B; DeVinney, R; Stein, M; Reinscheid, DJ; Frey, EA; Finlay, BB			Enteropathogenic E-coli (EPEC) transfers its receptor for intimate adherence into mammalian cells	CELL			English	Article							ESCHERICHIA-COLI; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; EFFACING LESIONS; GENETIC-LOCUS; PROTEIN; ACTIN; PHOSPHORYLATION; EXPRESSION; SECRETION	Enteropathogenic E. coli (EPEC) belongs to a group of bacterial pathogens that induce epithelial cell actin rearrangements resulting in pedestal formation beneath adherent bacteria. This requires the secretion of specific virulence proteins needed for signal transduction and intimate adherence. EPEC interaction induces tyrosine phosphorylation of a protein in the host membrane, Hp90, which is the receptor for the EPEC outer membrane protein, intimin. Hp90-intimin interaction is essential for intimate attachment and pedestal formation. Here, we demonstrate that Hp90 is actually a bacterial protein (Tir). Thus, this bacterial pathogen inserts its own receptor into mammalian cell surfaces, to which it then adheres to trigger additional host signaling events and actin nucleation. It is also tyrosine-phosphorylated upon transfer into the host cell.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, DEPT MICROBIOL & IMMUNOL, BIOTECHNOL LAB, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia				, Brendan/0000-0001-7455-360X				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; DONNENBERG MS, 1990, FEMS MICROBIOL LETT, V69, P83, DOI 10.1016/0378-1097(90)90417-O; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; FINLAY BB, 1992, INFECT IMMUN, V60, P2541, DOI 10.1128/IAI.60.6.2541-2543.1992; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; FOUBISTER V, 1994, J EXP MED, V179, P993, DOI 10.1084/jem.179.3.993; FOUBISTER V, 1994, INFECT IMMUN, V62, P3038, DOI 10.1128/IAI.62.7.3038-3040.1994; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; GOMEZDUARTE OG, 1995, INFECT IMMUN, V63, P1767; ISMAILI A, 1995, INFECT IMMUN, V63, P3316, DOI 10.1128/IAI.63.9.3316-3326.1995; JARVIS KG, 1995, P NATL ACAD SCI USA, V92, P7996, DOI 10.1073/pnas.92.17.7996; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kenny B, 1997, INFECT IMMUN, V65, P2528, DOI 10.1128/IAI.65.7.2528-2536.1997; KENNY B, 1995, P NATL ACAD SCI USA, V92, P7991, DOI 10.1073/pnas.92.17.7991; Kenny B, 1997, INFECT IMMUN, V65, P2606, DOI 10.1128/IAI.65.7.2606-2612.1997; Kenny B, 1996, MOL MICROBIOL, V20, P313, DOI 10.1111/j.1365-2958.1996.tb02619.x; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; MANJARREZHERNANDEZ HA, 1992, LANCET, V339, P521, DOI 10.1016/0140-6736(92)90340-9; McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; Rosenshine I, 1996, INFECT IMMUN, V64, P966, DOI 10.1128/IAI.64.3.966-973.1996; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Stein M, 1996, J BACTERIOL, V178, P6546, DOI 10.1128/jb.178.22.6546-6554.1996; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x	31	958	988	0	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	1997	91	4					511	520		10.1016/S0092-8674(00)80437-7	http://dx.doi.org/10.1016/S0092-8674(00)80437-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390560	Bronze			2022-12-01	WOS:A1997YG49200012
J	Heyning, JE; Mead, JG				Heyning, JE; Mead, JG			Thermoregulation in the mouths of feeding gray whales	SCIENCE			English	Article							RETE	Vascular structures for heat conservation in the tongue of the gray whale (Eschrichtius robustus) are reported here. Numerous individual countercurrent heat exchangers are found throughout the massive tongue, These converge at the base of the tongue to form a bilateral pair of retia. Temperature measurements from the oral cavity of a live gray whale indicate that more heat may be lost through the blubber layer over the body than through the tongue, despite the fact that the tongue is far more vascularized and has much less insulation, These heal exchangers substantially reduce heat loss when these whales feed in cold waters.	NATL MUSEUM NAT HIST,DIV MAMMALS,WASHINGTON,DC 20560	Smithsonian Institution; Smithsonian National Museum of Natural History	Heyning, JE (corresponding author), NAT HIST MUSEUM LOS ANGELES,SECT VERTEBRATES,900 EXPOSIT BLVD,LOS ANGELES,CA 90007, USA.							BRODIE P, 1985, CAN J ZOOL, V63, P2267, DOI 10.1139/z85-336; CARTE A, 1869, PHILOS T R SOC LONDO, V158, P201; Elsner R., 1974, FUNCTIONAL ANATOMY M, P143; FORD TJ, 1992, NATURE, V359, P680, DOI 10.1038/359680a0; HEYNING JE, 1993, NATURE, V361, P24, DOI 10.1038/361024b0; HOKKANEN JEI, 1990, J THEOR BIOL, V145, P465, DOI 10.1016/S0022-5193(05)80482-5; IRVING L, 1955, J APPL PHYSIOL, V7, P355, DOI 10.1152/jappl.1955.7.4.355; PFEIFFER CJ, 1990, ACTA ANAT, V139, P141; ROMMEL SA, 1992, ANAT RECORD, V232, P150, DOI 10.1002/ar.1092320117; ROMMEL SA, 1993, ANAT REC, V237, P537; RYG M, 1993, J ZOOL, V230, P193, DOI 10.1111/j.1469-7998.1993.tb02682.x; Schmidt-Nielsen K., 1997, ANIMAL PHYSL ADAPTAT; SCHOLANDER P. F., 1958, HVALRADETS SKRIFTER SCI RESULTS MARINE BIOL RES, V44, P1; SCHOLANDER PF, 1955, J APPL PHYSIOL, V8, P279, DOI 10.1152/jappl.1955.8.3.279; SLIJPER EJ, 1936, CAPITA ZOOLOGICA, V617, P1; van Utrecht WL, 1958, ZOOL ANZ, V161, P77	16	21	21	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1138	1139		10.1126/science.278.5340.1138	http://dx.doi.org/10.1126/science.278.5340.1138			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353198				2022-12-01	WOS:A1997YE65200057
J	Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ				Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ			Pain and treatment of pain in minority patients with cancer - The Eastern Cooperative Oncology Group minority outpatient pain study	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT; SEVERITY	Background: Clinics that primarily see members of ethnic minority groups have been found to provide inadequate treatment of cancer-related pain. The extent of undertreatment of pain in these patients and the factors that contribute to undertreatment are not known. Objectives: To evaluate the severity of cancer-related pain and the adequacy of prescribed analgesics in minority outpatients with cancer. Design: Prospective clinical study. Setting: Eastern Cooperative Oncology Group. Patients: 281 minority outpatients with recurrent or metastatic cancer. Measurements: Patients and physicians independently rated severity of pain, pain-related functional impairment, and pain relief obtained by taking analgesic drugs. Analgesic adequacy was determined on the basis of accepted guidelines. Results: 77% of patients reported disease-related pain or took analgesics; 41% of patients reporting pain had severe pain. Sixty-five percent of minority patients did not receive guideline-recommended analgesic prescriptions compared with 50% of nonminority patients (P < 0.001). Hispanic patients in particular reported less pain relief and had less adequate analgesia. Conclusions: The awareness that minority patients do not receive adequate pain control and that better assessment of pain is needed may improve control of cancer-related pain in this patient population.	WESTAT CORP, ROCKVILLE, MD 20850 USA; SAN JUAN COMMUNITY CLIN ONCOL PROGRAM, SAN JUAN, PR 00936 USA; INDIANA UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; ST MARYS HOSP, DEPT MED, HEMATOL ONCOL UNIT, ROCHESTER, NY 14611 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	Westat; Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [U10CA049883, U10CA023318, U10CA021076] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49883, CA 23318, CA 21076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; Cleeland C.S., 1999, EFFECT CANC QUALITY, P293; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; FORD ES, 1995, HEALTH SERV RES, V30, P237; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Raczynski James M., 1993, Ethnicity and Disease, V3, P290; SATARIANO ER, 1992, AM J PUBLIC HEALTH, V82, P195, DOI 10.2105/AJPH.82.2.195; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; TODD KH, 1994, JAMA-J AM MED ASSOC, V271, P925, DOI 10.1001/jama.271.12.925; *US DEP HHS PHS, 1994, AHCPR PUBL; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; World Health Organization, 1986, CANC PAIN REL	17	380	385	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					813	816		10.7326/0003-4819-127-9-199711010-00006	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD898	9382402				2022-12-01	WOS:A1997YD89800005
J	Nyangulu, DS; Harries, AD; Kangombe, C; Yadidi, AE; Chokani, K; Cullinan, T; Maher, D; Nunn, P; Salaniponi, FM				Nyangulu, DS; Harries, AD; Kangombe, C; Yadidi, AE; Chokani, K; Cullinan, T; Maher, D; Nunn, P; Salaniponi, FM			Tuberculosis in a prison population in Malawi	LANCET			English	Article							NEW-YORK-CITY; ASSOCIATION; INFECTION; SYSTEM	Background Much concern has been expressed about the high prevalence of tuberculosis in prisons in industrialised countries, Since there is almost no information from developing countries, we investigated the rate of pulmonary tuberculosis in a large prison in Malawi. Methods Between May and July, 1996, we carried out an active case-finding survey in Zomba Central Prison, Malawi, through the National Tuberculosis Control Programme. We interviewed prisoners, and those with a cough of at least 1 week's duration were screened by sputum-smear microscopy. If microscopy was negative, prisoners underwent chest radiography. We offered HIV testing, with voluntary consent and counselling before and after tests, to all prisoners, whether positive or negative for pulmonary tuberculosis. Findings 914 (70%) of 1315 prisoners were screened (905 men, nine women; mean age 30 years [SD 11]), 47 (5%) screened prisoners (all men) had pulmonary tuberculosis: 14 were taking antituberculosis treatment and 33 were undiagnosed at the start of the study; 18 were sputum-smear positive and 15 were sputum-smear negative. 16 (73%) of 22 prisoners with previously undiagnosed pulmonary tuberculosis and 30 (75%) of 40 prisoners with cough but no evidence of pulmonary tuberculosis were HIV seropositive, In all prisoners, except one, symptoms of pulmonary tuberculosis had developed after they had entered prison. Interpretation We found a high rate of pulmonary tuberculosis in Zomba Central Prison, which suggests active transmission of tuberculosis. As a result of this study, the National Tuberculosis Control Programme has implemented interventions in eight prisons in Malawi to improve tuberculosis control, including collection of health data, education of prisoners and clinical staff about tuberculosis, active screening of prisoners for pulmonary tuberculosis by sputum-smear microscopy, and active case-finding in the prisons.	MINIST HLTH,NATL TB CONTROL PROGRAMME,LILONGWE,MALAWI; UNIV MALAWI,COLL MED,LILONGWE,MALAWI; ZOMBA CENT PRISON,ZOMBA,MALAWI; WHO,GLOBAL TB PROGRAMME,CH-1211 GENEVA,SWITZERLAND	University of Malawi; World Health Organization				Maher, Dermot/0000-0003-0466-1976				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; *CDCP, 1989, MMWR-MORBID MORTAL W, V38, P313; CHAVES F, 1993, MED CLIN-BARCELONA, V101, P525; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; Harries A. D., 1994, P241; Harries AD, 1997, T ROY SOC TROP MED H, V91, P416, DOI 10.1016/S0035-9203(97)90262-5; MARTIN V, 1994, TUBERCLE LUNG DIS, V74, P49; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151	11	68	72	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1284	1287		10.1016/S0140-6736(97)05023-X	http://dx.doi.org/10.1016/S0140-6736(97)05023-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357408				2022-12-01	WOS:A1997YD68900010
J	Gordon, M				Gordon, M			Is the best yet to be?	LANCET			English	Article							LIMITS; CARE				Gordon, M (corresponding author), BAYCREST CTR GERIATR CARE,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.							CALLAHAN D, 1994, GERONTOLOGIST, V34, P393, DOI 10.1093/geront/34.3.393; CAMPION EW, 1994, NEW ENGL J MED, V330, P1819, DOI 10.1056/NEJM199406233302509; CASSEL CK, 1992, HEALTH AFFAIR, V11, P87, DOI 10.1377/hlthaff.11.2.87; COHEN GD, 1997, 7 DEADLY MYTHS UNCOV; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; GORDON M, 1993, CAN MED ASSOC J, V148, P393; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; ROOS NP, 1991, AM J PUBLIC HEALTH, V81, P63, DOI 10.2105/AJPH.81.1.63; ROSENTHAL J, 1997, NY TIMES        0309, P39; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; Scharf S, 1996, DRUG AGING, V9, P399, DOI 10.2165/00002512-199609060-00002; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2354; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; WEINBERGER M, 1993, AM J PUBLIC HEALTH, V83, P338, DOI 10.2105/AJPH.83.3.338; Williams TF, 1997, J AM GERIATR SOC, V45, P244, DOI 10.1111/j.1532-5415.1997.tb04516.x; 1997, NY TIMES        0309	16	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1166	1167		10.1016/S0140-6736(97)05069-1	http://dx.doi.org/10.1016/S0140-6736(97)05069-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB199	9343520				2022-12-01	WOS:A1997YB19900048
J	Webb, AK; Hanley, SP				Webb, AK; Hanley, SP			Personal paper: The conflict in transferring a cystic fibrosis specialist service between two hospitals in Manchester	BRITISH MEDICAL JOURNAL			English	Article									N MANCHESTER HLTH AUTHOR,MANCHESTER M8 5RB,LANCS,ENGLAND		Webb, AK (corresponding author), WYTHENSHAWE HOSP,NW LUNG CTR,BRADBURY CYST FIBROSIS UNIT,MANCHESTER M23 9LT,LANCS,ENGLAND.							FORSYTHE M, 1994, BRIT MED J, V308, P151, DOI 10.1136/bmj.308.6922.151; Hughes D, 1995, Health Serv J, V105, P18; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; SMITH R, 1992, BRIT MED J, V305, P1308, DOI 10.1136/bmj.305.6865.1308; SMITH R, 1994, BRIT MED J, V309, P1644, DOI 10.1136/bmj.309.6969.1644; WEBB AK, 1994, THORAX, V49, P291, DOI 10.1136/thx.49.4.291	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1009	1011		10.1136/bmj.315.7114.1009	http://dx.doi.org/10.1136/bmj.315.7114.1009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365304	Green Published			2022-12-01	WOS:A1997YC30700031
J	Datta, SR; Dudek, H; Tao, X; Masters, S; Fu, HA; Gotoh, Y; Greenberg, ME				Datta, SR; Dudek, H; Tao, X; Masters, S; Fu, HA; Gotoh, Y; Greenberg, ME			Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery	CELL			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; GROWTH-FACTOR; APOPTOSIS; TRANSDUCTION; INHIBITION; ACTIVATION; MECHANISMS	Growth factors can promote cell survival by activating the phosphatidylinositide-3'-OH kinase and its downstream target, the serine-threonine kinase Akt. However, the mechanism by which Akt functions to promote survival is not understood. We show that growth factor activation of the PI3'K/Akt signaling pathway culminates in the phosphorylation of the BCL-2 family member BAD, thereby suppressing apoptosis and promoting cell survival. Akt phosphorylates BAD in vitro and in vivo, and blocks the BAD-induced death of primary neurons in a site-specific manner. These findings define a mechanism by which growth factors directly inactivate a critical component of the cell-intrinsic death machinery.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,GRAD PROGRAM MOL THERAPEUT & TOXICOL,ATLANTA,GA 30322	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Emory University; Emory University			Roszak, Joanna/F-4003-2010	Datta, Sandeep/0000-0002-8068-3862	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NIGMS NIH HHS [GM53165] Funding Source: Medline; NINDS NIH HHS [NS28829] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; BARRES BA, 1993, DEVELOPMENT, V118, P283; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COFFER PJ, 1992, EUR J BIOCHEM, V205, P1217; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GALLI C, 1995, J NEUROSCI, V15, P1172; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miller TM, 1996, J NEUROSCI, V16, P7487; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Vemuri GS, 1996, DEVELOPMENT, V122, P2529; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	4771	4950	1	188	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					231	241		10.1016/S0092-8674(00)80405-5	http://dx.doi.org/10.1016/S0092-8674(00)80405-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346240	Bronze			2022-12-01	WOS:A1997YC35000010
J	Wutz, A; Smrzka, OW; Schweifer, N; Schellander, K; Wagner, EF; Barlow, DP				Wutz, A; Smrzka, OW; Schweifer, N; Schellander, K; Wagner, EF; Barlow, DP			Imprinted expression of the Igf2r gene depends on an intronic CpG island	NATURE			English	Article							H19 GENE; METHYLATION; MOUSE; CHROMOSOME; REPLICATION; CREATION; PATTERNS; REGIONS; MICE; DNA	Gametic imprinting is a developmental process that induces parental-specific expression or repression of autosomal and X-chromosome-linked genes(1,2). The mouse Igf2r gene (encoding the receptor for insulin-like growth factor type-2) is imprinted and is expressed from the maternal allele after embryonic implantation(3). We previously proposed that methylation of region 2, a region rich in cytosine-guanine doublets (a 'CpG island') in the second intron of Igf2r, is the imprinting signal that maintains expression of the maternal allele(4). Here we use mouse transgenes to test the role of region 2 and the influence of chromosome location on Igf2r imprinting, Yeast artificial chromosome transgenes successfully reproduced the imprinted methylation and expression pattern of the endogenous Igf2r gene; deletion of region 2 from these transgenes caused a loss of imprinting and restored biallelic Igf2r expression, These results define a primary role for region 2 and a negligible role for chromosomal location in Igf2r imprinting; they also show that methylation imprints can maintain allelic expression, Short transgenes containing only region 2 and yeast artificial chromosome transgenes with an inactive Igf2r promoter do not attract parental-specific methylation. All transgenes showing paternal-specific repression of Igf2r produced an antisense RNA whose transcription was dependent on region 2, The production of an antisense RNA by the repressed parental allele is reminiscent of the imprinting of the Igf2/H19 gene pair(5) and may indicate that expression competition could play a general role in imprinting.	NETHERLANDS CANC INST,NL-1066 CX AMSTERDAM,NETHERLANDS; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; BOEHRINGER INGELHEIM R&D,A-1121 VIENNA,AUSTRIA; UNIV BONN,D-53115 BONN,GERMANY	Netherlands Cancer Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim; University of Bonn				Wagner, Erwin F/0000-0001-7872-0196				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BICKMORE WA, 1995, J CELL SCI, V108, P2801; BIRD AP, 1993, CURR BIOL, V3, P275, DOI 10.1016/0960-9822(93)90177-P; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; Hogan B., 2014, MANIPULATING MOUSE E; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; Leighton PA, 1996, BIOL REPROD, V54, P273, DOI 10.1095/biolreprod54.2.273; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LERCHNER WL, 1996, MECH DEVELOP, V61, P1; LEWIS BC, 1992, GENET ANAL-BIOMOL E, V9, P86, DOI 10.1016/1050-3862(92)90003-N; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; PALDI A, 1995, CURR BIOL, V5, P1030, DOI 10.1016/S0960-9822(95)00207-7; Pfeifer K, 1996, P NATL ACAD SCI USA, V93, P13876, DOI 10.1073/pnas.93.24.13876; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; Sambrook J., 1989, MOL CLONING LABORATO, P743; Schweifer N, 1997, GENOMICS, V43, P285, DOI 10.1006/geno.1997.4816; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373	27	476	492	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					745	749		10.1038/39631	http://dx.doi.org/10.1038/39631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338788				2022-12-01	WOS:A1997YA95900059
J	Annas, GJ				Annas, GJ			The bell tolls for a constitutional right to physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; *NY STAT TASK FORC, 1997, DEATH IS SOUGHT ASS; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785	4	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1098	1103		10.1056/NEJM199710093371523	http://dx.doi.org/10.1056/NEJM199710093371523			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321541	Green Published			2022-12-01	WOS:A1997XZ84400032
J	deMuizon, C; Cifelli, RL; Paz, RC				deMuizon, C; Cifelli, RL; Paz, RC			The origin of the dog-like borhyaenoid marsupials of South America	NATURE			English	Article							MAMMALS	Dog-like marsupials (superfamily Borhyaenoidea) were the largest predacious mammals during the Tertiary period in South America(1). They are critical to our understanding of marsupial origin, phylogeny and palaeobiogeography because they have been related to various marsupial lineages of several continents: didelphoids(2) (mainly New World, but also Europe, Asia and Africa), pediomyrid(3), stagodontids(4) (North America), dasyuroids(5) (Australia) and deltatheroidans(6) (predominantly Asian). These relationships, based mainly on dental morphology, have been discussed and rejected several times(2,3,7,8). Here we report the discovery of exceptionally well preserved skulls and skeletons, referrable to the didelphoid Andinodelphys, which shed new light on the phylogenetic and palaeobiogeographic origin of dog-like marsupials. The skulls of Mayulestes (boryhyaenoid)(9), Andinodelphys and Pucadelphys (didelphoids)(10,11) from the early Palaeocene epoch of Bolivia are the oldest known for American marsupials. Comparison of their basicranial anatomy suggests that dog-like marsupials are closely related to an early didelphimorphian radiation in South America, rather than to Asiatic (deltatheroidan), North American (stagodontid), or Australian(dasyuroid) lineages.	UNIV OKLAHOMA,OKLAHOMA MUSEUM NAT HIST,NORMAN,OK 73019; UNIV MAYOR SAN SIMON,MUSEO ARQUEOL,COCHABAMBA,BOLIVIA	University of Oklahoma System; University of Oklahoma - Norman	deMuizon, C (corresponding author), MUSEUM NATL HIST NAT,CNRS,URA 12,PALEONTOL LAB,8 RUE BUFFON,F-75005 PARIS,FRANCE.		De Muizon, Christian/Q-7986-2019; De Muizon, Christian/P-4335-2017	De Muizon, Christian/0000-0002-1247-8867; De Muizon, Christian/0000-0002-1247-8867				Aplin K.P., 1987, pxv; Archer M., 1982, P397; Archer M., 1976, Australian J Zool, VNo. 39, P1; BONAPARTE JF, 1990, NATL GEOGR RES, V6, P63; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P295; CIFELLI RL, 1993, P NATL ACAD SCI USA, V90, P9413, DOI 10.1073/pnas.90.20.9413; CIFELLI RL, 1993, MAMMAL PHYLOGENY, P205; CIFELLI RL, IN PRESS J PALEONTOL; CIFELLI RL, IN PRESS J MAMM EVOL; Clemens W.A., 1986, CONTRIBUTIONS GEOLOG, V3, P55, DOI DOI 10.2113/GSR0CKY.24.SPECIAL_; Clemens W. A., 1966, U CALIFORNIA PUBLICA, V62, P1; De Muizon Christian, 1993, Annales de Paleontologie, V79, P233; DEMUIZON C, 1994, NATURE, V370, P208, DOI 10.1038/370208a0; DEMUIZON C, IN PRESS GEODIVERSIT; DEMUIZON C, 1992, REV TECN YAC PETROL, V12, P393; Fox R.C., 1987, P161; FOX RC, 1979, J PALEONTOL, V53, P733; Fox Richard C., 1995, P247; HOFFSTETTER R, 1972, CR ACAD SCI D NAT, V274, P2635; MARSHALL L G, 1978, University of California Publications in Geological Sciences, V117, P1; Marshall L.G., 1980, P345; Marshall Larry G., 1995, Memoires du Museum National d'Histoire Naturelle, V165, P21; MARSHALL LG, 1992, LETHAIA, V25, P361, DOI 10.1111/j.1502-3931.1992.tb01639.x; MARSHALL LG, 1988, NATL GEOGR RES, V4, P23; MARSHALL LG, 1977, SYST ZOOL, V26, P410, DOI 10.2307/2412796; MARSHALL LG, 1990, CURRENT MAMMALOGY, P343; MATTHEW WD, 1916, B AM MUS NAT HIST, V35, P447; Simpson G. G., 1980, CURIOUS HIST S AM MA; Szalay FS, 1996, J VERTEBR PALEONTOL, V16, P474, DOI 10.1080/02724634.1996.10011335; SZALAY FS, 1994, EVOLUTIONARY HIST PR	30	53	55	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					486	489		10.1038/39029	http://dx.doi.org/10.1038/39029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333235				2022-12-01	WOS:A1997XY90900053
J	Agerton, T; Valway, S; Gore, B; Pozsik, C; Plikaytis, B; Woodley, C; Onorato, I				Agerton, T; Valway, S; Gore, B; Pozsik, C; Plikaytis, B; Woodley, C; Onorato, I			Transmission of a highly drug-resistant strain (strain W1) of Mycobacterium tuberculosis - Community outbreak and nosocomial transmission via a contaminated bronchoscope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION	Context.-Nosocomial transmission of multidrug-resistant tuberculosis (MDR TB) has been reported primarily in New York State and has generally been presumed to occur via respiratory aerosols. Objective.-To assess nosocomial transmission of MDR TB. In 1995, 8 patients with MDR TB were identified in South Carolina; all were resistant to 7 drugs and had matching DNA fingerprints (strain W1). Community links were identified for 5 patients (Patients 1-5). However, no links were identified for the other 3 patients (Patients 6-8) except being hospitalized at the same hospital as 1 community patient. Design.-Outbreak investigation. Setting.-Community and hospital. Patients.-Eight patients whose MDR TB isolates had DNA fingerprint patterns matching strain W1. Main Outcome Measures.-Clinical characteristics of patients with strain W1 Mycobacterium tuberculosis isolates. Results.-Patient 5 (community patient) and Patient 8, diagnosed April 1995 and November 1995, respectively, had clinical courses consistent with MDR TB, with smear-positive and culture-positive specimens and cavitary lesions on chest radiograph; both died of MDR TB less than 1 month after diagnosis. Patients 6 and 7 (diagnosed May 1995) each had 1 positive culture for MDR TB; specimens were collected during bronchoscopy. Patient 6 had a skin test conversion after bronchoscopy. Neither Patient 6 nor Patient 7 had a clinical course consistent with MDR TB, neither was treated for MDR TB, and both are alive and well. No evidence of laboratory contamination of specimens, transmission on inpatient wards, or contact among patients was found. All 4 received bronchoscopies in May 1995; Patients 6, 7, and 8 had bronchoscopies 1, 12, and 17 days, respectively, after Patient 5. Observations revealed that bronchoscope cleaning was inadequate, and the bronchoscope was never immersed in disinfectant. Conclusions.-Inadequate cleaning and disinfection of the bronchoscope after the procedure performed on Patient 5 led to subsequent false-positive cultures in Patients 6 and 7 and transmission of infection to Patient 6 and active MDR TB to Patient 8.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV PROGRAM,EPIDEM PROGRAM OFF,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV HIV STD TB LAB RES,NATL CTR INFECT DIS,ATLANTA,GA 30333; S CAROLINA DEPT HLTH & ENVIRONM CONTROL,COLUMBIA,SC 29201	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Agerton, T (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-10,ATLANTA,GA 30333, USA.							*AM THOR SOC, 1994, AM J RESP CRIT CARE, V149, P1359; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BENNETT SN, 1994, AM J RESP CRIT CARE, V150, P245, DOI 10.1164/ajrccm.150.1.8025757; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P675; *CDCP, 1994, COR CURR TUB WHAT CL; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; FITCH LE, 1991, J HOSP INFECT, V17, P322, DOI 10.1016/0195-6701(91)90287-I; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GUBLER JGH, 1992, CHEST, V101, P1245, DOI 10.1378/chest.101.5.1245; HUSEN L, 1971, CHEST, V60, P540, DOI 10.1378/chest.60.6.540; IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152; JEREB JA, 1995, ARCH INTERN MED, V155, P854, DOI 10.1001/archinte.155.8.854; KENT DC, 1967, ARCH ENVIRON HEALTH, V14, P580, DOI 10.1080/00039896.1967.10664795; MARTIN MA, 1994, AM J INFECT CONTROL, V22, P19, DOI 10.1016/0196-6553(94)90087-6; NELSON KE, 1983, AM REV RESPIR DIS, V127, P97, DOI 10.1164/arrd.1983.127.1.97; NICHOLSON G, 1995, J HOSP INFECT, V29, P257, DOI 10.1016/0195-6701(95)90272-4; PRIGOGINE T, 1988, J HOSP INFECT, V11, P93, DOI 10.1016/0195-6701(88)90047-3; SCHMIDEK HH, 1967, CAN MED ASSOC J, V97, P178; TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767, DOI 10.1128/JCM.31.4.767-770.1993; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WHEELER PW, 1989, J INFECT DIS, V159, P954, DOI 10.1093/infdis/159.5.954; World Health Organization, 1977, INT CLASS DIS	25	126	131	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1073	1077		10.1001/jama.278.13.1073	http://dx.doi.org/10.1001/jama.278.13.1073			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315765				2022-12-01	WOS:A1997XX30300030
J	Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF				Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF			Validation of preferences for life-sustaining treatment: Implications for advance care planning	ANNALS OF INTERNAL MEDICINE			English	Article						advance directives; life support care; health status; treatment outcomes	STATES WORSE; DIRECTIVES; ATTITUDES; STABILITY; CHOICES; QUALITY; VALUES; DEATH	Background: Treatment preferences established before life-threatening illness occurs may differ from actual decisions because of changes in preferences or poor understanding of the link between prospective preferences and outcomes. Objective: To evaluate the validity of prospective treatment preferences by examining their concordance with ratings of health states. Design: Survey of seven cohorts of persons with diverse health status. Home-and hospital-based interviews were conducted at baseline and at 6, 18, and 30 months. Setting: The greater Seattle area. Participants: Younger and older well adults; persons with chronic conditions, terminal cancer, or AIDS; stroke survivors; and nursing home residents. Measurements: Concordance between six treatment preferences and five health state ratings (on a seven-point scale) was assessed by using logistic regression to measure the increase in odds of treatment refusal for each one-point change in health state ratings. Preferences were considered concordant if treatments were refused in health states rated as worse than death and were accepted in health states rated as better than death. Reasons for discordance were elicited at the final interview. Results: The probability of refusal of prospective treatment was strongly related to health state ratings. Odds ratios ranged from 1.7 to 1.9 (P < 0.001) for every treatment. When patients were shown their discordant preferences, they had a coherent explanation or changed their health state rating or treatment preference to make the two concordant. Conclusions: Prospective life-sustaining treatment preferences show high convergent validity. For most persons, treatment preferences are grounded in a consistent belief system. Concordance and discordance between treatment preferences and health state ratings offer clinicians the opportunity to explore patients' Values and reasoning.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Patrick, DL (corresponding author), UNIV WASHINGTON, DEPT HLTH SERV, BOX 357660, SEATTLE, WA 98195 USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	AHRQ HHS [HS06343] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DOUKAS DJ, 1993, J CLIN ETHIC, V4, P41; EMANUEL LL, 1994, ARCH INTERN MED, V154, P209, DOI 10.1001/archinte.1994.00420020131014; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; Patrick D, 1993, HLTH STATUS HLTH POL; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; Pearlman R. A., 1994, Journal of General Internal Medicine, V9, P97; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; PEARLMAN RA, 1995, PUBLICATION NAT TECH; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; Schonwetter RS, 1996, J AM GERIATR SOC, V44, P954, DOI 10.1111/j.1532-5415.1996.tb01867.x; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; *STAT CORP, 1993, STAT REF MAN; Sutherland H J, 1982, Med Decis Making, V2, P299, DOI 10.1177/0272989X8200200306; Tonelli MR, 1996, CHEST, V110, P816, DOI 10.1378/chest.110.3.816; TORRANCE GW, 1982, VALUES LONG TERM CAR; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	25	88	91	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					509	+		10.7326/0003-4819-127-7-199710010-00002	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY733	9313018				2022-12-01	WOS:A1997XY73300002
J	Coste, J; Letrait, M; Carel, JC; Tresca, JP; Chatelain, P; Rochiccioli, P; Louis, J; Chaussain, JL; Job, JC				Coste, J; Letrait, M; Carel, JC; Tresca, JP; Chatelain, P; Rochiccioli, P; Louis, J; Chaussain, JL; Job, JC			Long term results of growth hormone treatment in France in children of short stature: population, register based study	BRITISH MEDICAL JOURNAL			English	Article							FINAL HEIGHT; PUBERTAL DEVELOPMENT; GH DEFICIENCY; THERAPY	Objectives: To describe the growth of children treated with growth hormone and to evaluate the prognostic factors for height at the end of treatment Design: Register based cohort study. Setting: French national register of all children treated with growth hormone. Subjects: 3233 short stature children (3165 of whom were deficient in growth hormone) who were treated with growth hormone (excluding children with Turner's syndrome) and whose treatment started between 1973 and 1989, last data being recorded in December 1993. Main outcome measures: Annual changes in height, and height at the end of treatment. Results: Mean height SD score at the end of treatment, after a mean of 4.3 years, was -2, corresponding to gain in mean height SD score of 1 and to a height SD score of 1.1 below tar-get height Ln all, 923 children prematurely stopped taking growth hormone treatment, mainly because of insufficient response (insufficient growth) or tiredness. Variables that predicted height at the end of treatment were age, target height, aetiology of short stature, use of puberty inhibitors, and type of growth hormone. Conclusions: The outcome of children of short stature with growth hormone deficiency who were treated with growth hormone has been less favourable than initially assumed. Growth hormone treatment has not restored normal growth to these children, The highly demanding nature and high costs of this treatment require an optimised prescription, and this remains to be determined.	HOP COCHIN,INST RECH THERAPEUT,F-75674 PARIS,FRANCE; ASSOC FRANCE HYPOPHYSE,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Coste, J (corresponding author), UNIV PARIS 05,HOP COCHIN,FAC COCHIN,DEPT BIOSTAT & INFORMAT MED,ACHARD 7,F-75674 PARIS 14,FRANCE.		Carel, Jean-Claude/AAZ-7691-2020	Carel, Jean-Claude/0000-0002-0424-6767				ALLEN DB, 1990, J PEDIATR-US, V117, P16, DOI 10.1016/S0022-3476(05)82438-2; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; BERGMAN U, 1992, J CLIN EPIDEMIOL, V45, P313, DOI 10.1016/0895-4356(92)90092-2; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BLETHEN SL, 1993, J CLIN ENDOCR METAB, V76, P574, DOI 10.1210/jc.76.3.574; BRAMSWIG J, 1995, HORM RES, V43, P126, DOI 10.1159/000184256; BURNS EC, 1981, CLIN ENDOCRINOL, V14, P587, DOI 10.1111/j.1365-2265.1981.tb02969.x; BURNS EC, 1981, EUR J PEDIATR, V137, P155; CACCIARI E, 1994, J CLIN ENDOCR METAB, V79, P1663, DOI 10.1210/jc.79.6.1663; Carel JC, 1996, J CLIN ENDOCR METAB, V81, P3318, DOI 10.1210/jc.81.9.3318; CHIPMAN JJ, 1995, HORM RES, V43, P129, DOI 10.1159/000184257; COLE T, 1993, KIGS REPORT, V10, P37; FRISCH H, 1995, HORM RES, V43, P132, DOI 10.1159/000184258; GRECO L, 1995, BRIT MED J, V310, P696, DOI 10.1136/bmj.310.6981.696; Greulich WW, 1970, RADIOGRAPHIC ATLAS S; HIBI I, 1989, J CLIN ENDOCR METAB, V69, P221, DOI 10.1210/jcem-69-2-221; HIBI I, 1989, ACTA ENDOCRINOL-COP, V120, P409, DOI 10.1530/acta.0.1200409; Hindmarsh PC, 1996, LANCET, V348, P13, DOI 10.1016/S0140-6736(96)01038-0; JOB JC, 1988, ARCH FR PEDIATR, V45, P169; MAES M, 1994, KABI INT GROWTH STUD, V11, P15; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; PRICE DA, 1994, PROGR GROWTH HORMONE; Ranke MB, 1996, HORM RES, V45, P64, DOI 10.1159/000184851; Ranke MB, 1994, PROGR GROWTH HORMONE; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; *SAS I, 1990, SAS US GUID; Sempe M., 1979, AUXOLOGIE METHODES S; Sempe P., 1971, CROISSANCE MATURATIO; SEVERI F, 1995, HORM RES, V43, P138, DOI 10.1159/000184260; VANDENBROECK J, 1995, J PEDIATR-US, V127, P729, DOI 10.1016/S0022-3476(95)70161-3; VANDENBROECK J, 1988, EUR J PEDIATR, V147, P245, DOI 10.1007/BF00442688	32	68	68	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					708	713		10.1136/bmj.315.7110.708	http://dx.doi.org/10.1136/bmj.315.7110.708			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314755	Green Published			2022-12-01	WOS:A1997XX67400021
J	Siegel, D; Lopez, J				Siegel, D; Lopez, J			Trends in antihypertensive drug use in the United States - Do the JNC V recommendations affect prescribing?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; HYPERTENSION; THERAPY; TRIALS; MEN	Context.-The choice of pharmacological treatment for the approximately 50 million people in the United States with hypertension has important therapeutic and financial implications. Objectives.-To describe national antihypertensive medication prescribing patterns for 1992 and 1995; to explore the influence of the Fifth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V), published in 1993, which recommended diuretics and beta-blockers as first-line antihypertensive therapy unless contraindicated; and to estimate the impact of these prescribing patterns on the cost of antihypertensive treatment. Design.-All prescriptions for drugs approved for the treatment of hypertension dispensed by 35 000 retail pharmacies were tabulated for 1992 and 1995 (62% of all US retail pharmacies were surveyed). Main Outcome Measures.-Number of prescriptions for each dosage form of medication and national cost estimates based on wholesale costs of medications dispensed. Results.-In 1992, of the 10 most frequently prescribed antihypertensive drugs, 3 were calcium antagonists, 3 were angiotensin-converting enzyme (ACE) inhibitors, 3 were beta-blockers, and 1 was the combination of triamterene and hydrochlorothiazide. In 1995, 4 were calcium antagonists, 3 were ACE inhibitors, 1 was a beta-blocker, 1 was the combination of triamterene and hydrochlorothiazide, and 1 an alpha-blocker, In 1992, calcium antagonists accounted for 33% of antihypertensive prescriptions compared with 38% in 1995, ACE inhibitor use went from 25% to 33%, beta-blocker use from 18% to 11%, and diuretic use from 16% to 8%, The estimated wholesale costs for calcium antagonists in 1995 dollars increased from $2.67 billion in 1992 to $2.86 billion in 1995; ACE inhibitor costs increased from $1.37 billion to $1.67 billion; costs for diuretics declined from $353 million to $168 million; and costs for beta-blockers declined from $763 million to $433 million. Conclusions.-From 1992 to 1995 use of calcium antagonists and ACE inhibitors for treatment of hypertension increased and diuretics and beta-blockers declined, suggesting that the recommendations from JNC V had little effect on prescribing patterns, The cost implications of these practice patterns are enormous.	DEPT VET AFFAIRS, NO CALIF HLTH CARE SYST, SERV PHARM, MARTINEZ, CA 94553 USA; UNIV CALIF DAVIS, DEPT MED, DAVIS, CA USA	University of California System; University of California Davis	Siegel, D (corresponding author), DEPT VET AFFAIRS, NO CALIF HLTH CARE SYST, MED SERV 111, 150 MUIR RD, MARTINEZ, CA 94553 USA.							[Anonymous], 1988, ARCH INTERN MED, V148, P1023; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; COLLINS JG, 1993, VITAL HLTH STAT 10, V182, P1; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Conti C R, 1996, Am J Cardiol, V78, P13, DOI 10.1016/S0002-9149(96)00733-3; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; Lenfant C, 1996, JAMA-J AM MED ASSOC, V275, P1604, DOI 10.1001/jama.275.20.1604; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; RAMSPACHER S, 1996, HOSP HARM, V31, P624; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SIMONSEN LLP, 1993, PHARM TIMES, V59, P29; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Soumerai SB, 1988, AUST J HOSP PHARM S, V18, P9; *US DHHS, 1994, HEART FAIL MAN PAT L; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; 1996, PHARM TIMES, V62, P27; 1995, 1995 DRUG TOPICS RED; 1993, AM DRUG, V207, P49; 1996, AM DRUG, V212, P18	28	165	169	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1745	1748		10.1001/jama.278.21.1745	http://dx.doi.org/10.1001/jama.278.21.1745			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388150				2022-12-01	WOS:A1997YH98700028
J	Kondo, M; Weissman, IL; Akashi, K				Kondo, M; Weissman, IL; Akashi, K			Identification of clonogenic common lymphoid progenitors in mouse bone marrow	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; RECEPTOR-GAMMA-CHAIN; B-CELL; C-KIT; INTERLEUKIN-7 RECEPTOR; T-CELLS; TRANSCRIPTIONAL CONTROL; MURINE INTERLEUKIN-7; DENDRITIC CELLS; PRECURSOR CELLS	The existence of a common lymphoid progenitor that can only give rise to T cells, B cells, and natural killer (NK) cells remains controversial and constitutes an important gap in the hematopoietic lineage maps. Here, we report that the Lin(-)IL-7R(+)Thy-1(-)Sca-1(lo)c-Kit(lo) population from adult mouse bone marrow possessed a rapid lymphoid-restricted (T, B, and NK) reconstitution capacity in vivo but completely lacked myeloid differentiation potential either in vivo or in vitro. A single Lin(-)IL-7R(+)Thy-1(-)Sca-1(lo)c-Kit(lo) cell could generate at least both T and B cells. These data provide direct evidence for the existence of common lymphoid progenitors in sites of early hematopoiesis.	STANFORD UNIV,SCH MED,DEPT PATHOL,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [CA42551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1996, IMMUNITY, V5, P147, DOI 10.1016/S1074-7613(00)80491-4; AKASHI K, 1991, J CELL PHYSIOL, V148, P446, DOI 10.1002/jcp.1041480317; AKASHI K, 1993, LEUKEMIA RES, V17, P549, DOI 10.1016/0145-2126(93)90083-W; Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; ANTICA M, 1994, BLOOD, V84, P111; ANTIN JH, 1992, BLOOD, V80, P2964; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Carlyle JR, 1997, J EXP MED, V186, P173, DOI 10.1084/jem.186.2.173; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; FISCHER A, 1992, Immunodeficiency Reviews, V3, P83; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODFREY DI, 1992, J IMMUNOL, V149, P2281; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRISON DE, 1992, P NATL ACAD SCI USA, V89, P10134, DOI 10.1073/pnas.89.21.10134; HIRAYAMA F, 1995, BLOOD, V86, P4527, DOI 10.1182/blood.V86.12.4527.bloodjournal86124527; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; IKUTA K, 1991, INT J CELL CLONING, V9, P451; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Markert M L, 1994, Immunodeficiency, V5, P141; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; MIRRO J, 1986, BLOOD, V67, P689; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cellbio.11.1.35; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; MULDER AH, 1987, EXP HEMATOL, V15, P99; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; OKADA S, 1991, BLOOD, V78, P1706; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2728; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; SUDA J, 1984, BLOOD, V64, P393; SUDA T, 1989, BLOOD, V74, P1936; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; THOMAS ED, 1991, BLOOD CELLS, V17, P259; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; VISSER JWM, 1990, EXP HEMATOL, V18, P248; vonFreedenJeffry U, 1997, IMMUNITY, V7, P147, DOI 10.1016/S1074-7613(00)80517-8; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	70	1582	1618	3	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					661	672		10.1016/S0092-8674(00)80453-5	http://dx.doi.org/10.1016/S0092-8674(00)80453-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393859	Bronze			2022-12-01	WOS:A1997YH96000013
J	Linderoth, NA; Simon, MN; Russel, M				Linderoth, NA; Simon, MN; Russel, M			The filamentous phage pIV multimer visualized by scanning transmission electron microscopy	SCIENCE			English	Article							GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE PROTEIN; SECRETION; EXPORT; CHANNELS; PATHWAY; PORINS; FORMS	A family of homomultimeric outer-membrane proteins termed secretins mediates the secretion of large macromolecules such as enzymes and filamentous bacteriophages across bacterial outer membranes to the extracellular milieu. The secretin encoded by done filamentous phage fl was purified. Mass determination of individual molecules by scanning transmission electron microscopy revealed two forms, a unit multimer composed of about 14 subunits and a multimer dimer. The secretin is roughly cylindrical and has an internal diameter of about 80 angstroms, which is large enough to accommodate filamentous phage (diameter of 65 angstroms).	ROCKEFELLER UNIV,NEW YORK,NY 10021; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Rockefeller University; United States Department of Energy (DOE); Brookhaven National Laboratory					PHS HHS [P41-4401777] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chen LY, 1996, J BIOL CHEM, V271, P2703, DOI 10.1074/jbc.271.5.2703; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Daefler S, 1997, J MOL BIOL, V266, P978, DOI 10.1006/jmbi.1996.0866; Drake SL, 1995, MOL MICROBIOL, V18, P975, DOI 10.1111/j.1365-2958.1995.18050975.x; ENDEMANN H, 1995, J MOL BIOL, V250, P496, DOI 10.1006/jmbi.1995.0393; GENIN S, 1994, MOL GEN GENET, V243, P112, DOI 10.1007/BF00283883; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; KAZMIERCZAK BI, 1994, J MOL BIOL, V238, P187, DOI 10.1006/jmbi.1994.1280; LAVER WG, 1969, VIROLOGY, V38, P105, DOI 10.1016/0042-6822(69)90132-9; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; Lindeberg M, 1996, MOL MICROBIOL, V20, P175, DOI 10.1111/j.1365-2958.1996.tb02499.x; LINDEROTH N, UNPUB; Linderoth NA, 1996, J BACTERIOL, V178, P1962, DOI 10.1128/jb.178.7.1962-1970.1996; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; Model P., 1988, BACTERIOPHAGES, P375; NEWHALL WJ, 1980, INFECT IMMUN, V27, P475, DOI 10.1128/IAI.27.2.475-482.1980; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; RUSSEL M, 1995, TRENDS MICROBIOL, V3, P223, DOI 10.1016/S0966-842X(00)88929-5; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Wall J., 1979, INTRO ANAL ELECTRON, P333; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WALL JS, 1985, P 43 ANN M EL MICR S, P716	30	123	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1635	1638		10.1126/science.278.5343.1635	http://dx.doi.org/10.1126/science.278.5343.1635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374466				2022-12-01	WOS:A1997YJ87400045
J	Slusarski, DC; Corces, VG; Moon, RT				Slusarski, DC; Corces, VG; Moon, RT			Interaction of Wnt and a frizzled homologue triggers G-protein-linked phosphatidylinositol signalling	NATURE			English	Article							SIGNALING PATHWAY; RECEPTOR; PHOSPHOLIPASE-A2	In Drosophila, members of the frizzled family of tissue-polarity genes encode proteins that are likely to function as cell-surface receptors of the type known as Wnt receptors, and to initiate signal transduction across the cell membrane(1,2), although how they do this is unclear. We show here that the rat protein Frizzled-2 causes an increase in the release of intracellular calcium which is enhanced by Xwnt-5a, a member of the Wnt family. This release of intracellular calcium is suppressed by an inhibitor of the enzyme inositol monophosphatase and hence of the phosphatidylinositol signalling pathway; this suppression can be rescued by injection of the compound myo-inositol, which overcomes the decrease in this intermediate caused by the inhibitor. Agents that inhibit specific G-protein subunits, pertussis toxin, GDP-beta-S and alpha-transducin also inhibit the calcium release triggered by Xwnt-5a and rat Frizzled-2. Our results indicate that some Wnt proteins work through specific Frizzled homologues to stimulate the phosphatidylinositol signalling pathway via heterotrimeric G-protein subunits.	UNIV WASHINGTON, SCH MED, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Johns Hopkins University			Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Slusarski, Diane/0000-0003-3793-8636; Corces, Victor/0000-0001-5140-4337				ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; Ault KT, 1996, DEVELOPMENT, V122, P2033; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; REINHARD E, 1995, DEV BIOL, V170, P50, DOI 10.1006/dbio.1995.1194; SILK ST, 1989, J BIOL CHEM, V264, P21466; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Wang YS, 1996, J BIOL CHEM, V271, P4468; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	17	526	537	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					410	413		10.1038/37138	http://dx.doi.org/10.1038/37138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389482				2022-12-01	WOS:A1997YH54900066
J	Kaletta, T; Schnabel, H; Schnabel, R				Kaletta, T; Schnabel, H; Schnabel, R			Binary specification of the embryonic lineage in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; CELLULAR INTERACTIONS; POLARITY; PROTEIN; PATTERN; LOCUS; GLP-1; AXES	In Caenorhabditis elegans, the early embryo contains five somatic founder cells (known as AB, MS, E, C and D) which give rise to very different lineages, Two simply produce twenty intestinal (E) or muscle (D) cells each, whereas the remainder produce a total of 518 cells which collectively contribute in a complex pattern to a variety of tissues(1). A central problem in embryonic development is to understand how the developmental potential of blastomeres is restricted to permit the terminal expression of such complex differentiation patterns, Here we identify a gene, lit-1, that appears to play a central role in controlling the asymmetry of cell division during embryogenesis in C. elegans. Mutants in lit-1 suggest that its product controls up to six consecutive binary snitches which cause one of the two equivalent cells produced at each cleavage to assume a posterior fate. Most blastomere identities in C, elegans may therefore stem from a process of stepwise binary diversification.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Kaletta, Titus/F-5361-2012					Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; Hodgkin J, 1997, GENETICS, V146, P149; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; RIDDLE DL, 1997, MONOGRAPH COLD SPRIN, V33; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Schnabel R, 1997, DEV BIOL, V184, P234, DOI 10.1006/dbio.1997.8509; SCHNABEL R, 1990, DEVELOPMENT, V108, P107; Schnabel R, 1996, BIOESSAYS, V18, P591, DOI 10.1002/bies.950180711; STJOHNSTON D, 1992, CELL, V68, P201; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wood WB, 1988, NEMATODE CAENORHABDI	24	134	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					294	298		10.1038/36869	http://dx.doi.org/10.1038/36869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384382				2022-12-01	WOS:A1997YG66700065
J	Bouma, MJ; Kovats, RS; Goubet, SA; Cox, JSH; Haines, A				Bouma, MJ; Kovats, RS; Goubet, SA; Cox, JSH; Haines, A			Global assessment of El Nino's disaster burden	LANCET			English	Article							SOUTHERN-OSCILLATION; MALARIA; EVENTS; ENSO	Background Natural disasters have profound effects on health and require medical intervention as part of relief operations. The world's populations are becoming increasingly Vulnerable to extreme weather events, which are responsible for most natural disasters. The El Nino Southern Oscillation (ENSO) is the most prominent global climate system associated with year-to-year weather variability and extreme events. We have estimated the burden on human health of natural disasters associated with ENSO. Methods We used time-series regression analysis of the relation between El Nino years and the annual rates of persons affected by natural disasters per 1000 population during 1964-93, globally and also by region and disaster type. Correlations between sea-surface temperature (SST) anomalies (index of ENSO) and the rates of persons affected by natural disasters per 1000 population were determined globally, by region and by disaster type. Findings The rate of persons affected by natural disasters worldwide is strongly associated with ENSO; rates are greater during the first El Nino year (p=0.05) and the following year (p=0.01) than in the pre-Nino year. The correlation between rates of persons affected by natural disasters and SST anomalies in the Eastern Pacific (a key ENSO indicator) is highest in the last quarter of the previous year (r=0.53, p<0.01). These associations are strongest in South Asia, the region where more than 50% of all disaster Victims live. Worldwide, rates of persons affected by drought/famine (half of all disaster victims) and by Volcanic eruptions show significant associations with the ENSO cycle, being highest in the post-Nino year and El Nino year, respectively, and being significantly associated with SST anomalies. Interpretation The strong relation between ENSO and populations affected by natural disasters can be described as a ''natural disaster cycle''. Determining the phase in this cycle, using SST from the Eastern Equatorial Pacific, could benefit disaster preparedness on a global scale, for South Asia in particular, and for all populations affected by drought/famine and volcanic disasters.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT INFECT & TROP DIS, LONDON WC1E 7HT, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 7HT, ENGLAND; ROYAL FREE HOSP, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON, ENGLAND; UCL, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON W1N 8AA, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School				Kovats, Sari/0000-0002-4823-8099; Haines, Andy/0000-0002-8053-4605				Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; BUCHANONSMITH M, 1996, FAMINE EARLY WARNING; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHATFIELD C, 1992, ANAL TIME SERIES INT, P136; CHEN D, 1995, SCIENCE, V269, P1699, DOI 10.1126/science.269.5231.1699; DILLEY M, 1995, DISASTERS, V19, P181, DOI 10.1111/j.1467-7717.1995.tb00338.x; Glantz M. H., 1994, P WORKSH ENSO FEWS B; GLANTZ MH, 1982, OCEANUS, V27, P14; *INT FED RED CROSS, 1996, WORLD DIS REP 1996; International Decade for Natural Disaster Reduction, 1994, YOK STRAT PLAN ACT S; McCarthy M, 1997, LANCET, V350, P344; MICMICHAEL AJ, 1996, CLIMATE CHANGE HUMAN; NICHOLLS N, 1988, J CLIMATOL, V8, P91, DOI 10.1002/joc.3370080109; Noji E.K., 1997, PUBLIC HLTH CONSEQUE; PARKER DE, 1994, J GEOPHYS RES, V99, P373; Quinn W. H., 1987, J GEOPHYS RES, V92, P449; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; SAPIR DG, 1992, DISASTERS, V16, P74, DOI 10.1111/j.1467-7717.1992.tb00378.x; SPENNEMANN DHR, 1995, DISASTERS, V19, P194, DOI 10.1111/j.1467-7717.1995.tb00339.x; *UN, 1995, DEM YB 1993; *WORLD MET ORG, 1998, 819 WMO; WU GX, 1992, MON WEATHER REV, V120, P958, DOI 10.1175/1520-0493(1992)120<0958:AGSOTR>2.0.CO;2	23	61	64	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1435	1438		10.1016/S0140-6736(97)04509-1	http://dx.doi.org/10.1016/S0140-6736(97)04509-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371167				2022-12-01	WOS:A1997YF95300010
J	Moritz, S; Bates, T; Henderson, SM; Humphreys, S; Michell, MJ				Moritz, S; Bates, T; Henderson, SM; Humphreys, S; Michell, MJ			Variation in management of small invasive breast cancers detected on screening in the former South East Thames region: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; SURVIVAL; RADIOTHERAPY; IRRADIATION; LUMPECTOMY; SURGERY; WOMEN	Objective: To examine the variation in surgical and adjuvant treatment of breast cancer of known histology and detected on screening in a large cohort of patients treated by the surgeons of a health region, Design: Part prospective, part retrospective observational study; using the databases of a region's breast screening programme and of the cancer registry. Setting: The former South East Thames redon. Subjects: 600 women aged 49-79 who presented during 1991-2 with invasive breast cancer up to 20 mm in diameter that had been detected on screening. These patients were treated by 35 surgeons. Main outcome measures: Mastectomy rate by surgeon and the use of adjuvant treatment (radiotherapy, tamoxifen, and chemotherapy) were compared with risk factors, tumour grade, resection margins, and axillary node status. Results: The mastectomy rate varied between nil and 80%, although the numbers at these extremes were small (0/13 v 8/10). Surgeons operating on more than 20 such cases had a lower mastectomy rate (15%) than surgeons treating fewer cases (23%), but this difference was confounded by variation in casemix. There were also wide variations in mastectomy rates and in axillary sampling rates that were independent of casemix or caseload. There was broad agreement on the use of adjuvant tamoxifen (94%), but few patients received chemotherapy (2.5%). 78 patients (19%) did not receive radiotherapy, including 51 out of 317 patients with unfavourable tumours, and 26 patients did not receive tamoxifen. Whether the patient received adjuvant treatment was more dependent on referral by the surgeon than the risk factors for local recurrence and was independent of caseload. Conclusion: Mastectomy rates for similar rumours vary widely by surgeon independently of casemix or caseload, but surgeons with a higher caseload tend to have a lower mastectomy rate. Omission of postoperative radiotherapy or tamoxifen after conservative treatment is not related to risk factors for local recurrence or caseload, Confidential feedback of treatment profiles to individual surgeons has been used, but when benefit has been established treatment should be guided by evidence based protocol.	WILLIAM HARVEY HOSP, ASHFORD TN24 OLZ, KENT, ENGLAND; UNIV LONDON KINGS COLL HOSP, S THAMES E BREAST SCREENING QUAL ASSURANCE REFERE, LONDON SE5 9RS, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London			Bates, Tom/AAB-1893-2021	Bates, Tom/0000-0001-5554-1945				ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; [Anonymous], 1992, Lancet, V339, P1; ANSELL D, 1993, CANCER, V72, P2974, DOI 10.1002/1097-0142(19931115)72:10<2974::AID-CNCR2820721019>3.0.CO;2-M; Ayanian JZ, 1996, BREAST CANCER RES TR, V40, P65, DOI 10.1007/BF01806003; BAAK JPA, 1992, HUM PATHOL, V23, P989, DOI 10.1016/0046-8177(92)90259-6; BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; Baum M, 1996, BRIT MED J, V312, P1155; BELL J, 1994, BRIT MED J, V308, P1508, DOI 10.1136/bmj.308.6942.1508a; Berrino F, 1995, IARC SCI PUBLICATION, V132; BLAMEY RW, 1994, BRIT MED J, V309, P1076, DOI 10.1136/bmj.309.6961.1076; *BRIT ASS SURG ONC, 1992, BASO 2 TRIAL PROT RA; CAMPBELL I, 1993, ANN ROY COLL SURG, V75, P13; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; *DEP HLTH, 1995, POP HLTH OUTC IND 19; *DEP HLTH, 1994, POL FRAM WORK COMM C; Dixon JM, 1996, BRIT J SURG, V83, P997, DOI 10.1002/bjs.1800830737; DIXON JM, 1995, BRIT MED J, V311, P1515, DOI 10.1136/bmj.311.7019.1515; FENTIMAN IS, 1991, LANCET, V337, P221, DOI 10.1016/0140-6736(91)92172-X; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; GELBER RD, 1994, J NATL CANCER I, V86, P652, DOI 10.1093/jnci/86.9.652; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; Harries SA, 1997, BREAST, V6, P21, DOI 10.1016/S0960-9776(97)90538-5; ISCOE NA, 1994, CAN MED ASSOC J, V150, P345; LILJEGREN G, 1994, JNCI-J NATL CANCER I, V86, P717, DOI 10.1093/jnci/86.9.717; MCCARTHY M, 1991, EUR J CANCER, V27, P579, DOI 10.1016/0277-5379(91)90222-Y; MORRIS J, 1992, BRIT J SURG, V79, P1312, DOI 10.1002/bjs.1800791223; Moss S M, 1994, J Med Screen, V1, P193; *NAT COORD GROUP S, 1996, NHS BSP PUBL, V20; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; Richards MA, 1996, BRIT J CANCER, V73, P751, DOI 10.1038/bjc.1996.131; SACKS NPM, 1992, BREAST, V1, P41; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Schnitt SJ, 1996, CANCER, V77, P1094, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1094::AID-CNCR14>3.3.CO;2-J; VANDONGEN JA, 1992, EUR J CANCER, V28A, P801, DOI 10.1016/0959-8049(92)90118-L; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8; YARNOLD JR, 1994, BRIT MED J, V308, P714, DOI 10.1136/bmj.308.6930.714a	38	24	24	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	1997	315	7118					1266	1272		10.1136/bmj.315.7118.1266	http://dx.doi.org/10.1136/bmj.315.7118.1266			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390053	Green Published			2022-12-01	WOS:A1997YG64500019
J	Furukawa, T; Morrow, EM; Cepko, CL				Furukawa, T; Morrow, EM; Cepko, CL			Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation	CELL			English	Article							RAT OPSIN GENE; TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR GENE; NUCLEAR-PROTEIN BINDING; CIS-ACTING ELEMENT; MOLECULAR-GENETICS; NERVOUS-SYSTEM; CELL-DEVELOPMENT; UPSTREAM REGION; RHODOPSIN GENE	We have isolated a novel otx-like homeobox gene, Crx, from the mouse retina. Crx expression is restricted to developing and mature photoreceptor cells. CRX bound and transactivated the sequence TAATCC/A, which is found upstream of several photoreceptor-specific genes, including the opsin genes from many species. Overexpression of Crx using a retroviral vector increased the frequency of clones containing exclusively rod photoreceptors and reduced the frequency of clones containing amacrine interneurons and Muller glial cells. In addition, presumptive photoreceptor cells expressing a dominant-negative form of CRX failed to form proper photoreceptor outer segments and terminals. Crx is a novel photoreceptor-specific transcription factor and plays a crucial role in the differentiation of photoreceptor cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute			Morrow, Eric/J-2767-2013	Morrow, Eric/0000-0003-3430-3520	NEI NIH HHS [R01 EY0 8064] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008064] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BALLYCUIF L, 1995, MECH DEVELOP, V49, P49, DOI 10.1016/0925-4773(94)00301-3; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CEPKO CL, 1997, CURRENT PROTOCOLS MO; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; CHIU MI, 1994, J NEUROSCI, V14, P3426; Chou WH, 1996, NEURON, V17, P1101, DOI 10.1016/S0896-6273(00)80243-3; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Dowling J.E., 1987, RETINA APPROACHABLE; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HICKS D, 1987, J HISTOCHEM CYTOCHEM, V35, P1317, DOI 10.1177/35.11.3655327; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JIN YS, 1994, NATURE, V372, P780, DOI 10.1038/372780a0; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LAVAIL MM, 1987, INVEST OPHTH VIS SCI, V28, P1043; LI YB, 1994, MECH DEVELOP, V48, P229, DOI 10.1016/0925-4773(94)90062-0; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; Liu Q, 1996, ONCOGENE, V12, P207; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; MORI H, 1994, MOL BRAIN RES, V27, P221, DOI 10.1016/0169-328X(94)90004-3; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NI M, 1992, CURR EYE RES, V11, P219, DOI 10.3109/02713689209001773; NIR I, 1984, J CELL BIOL, V98, P1788, DOI 10.1083/jcb.98.5.1788; PANNESE M, 1995, DEVELOPMENT, V121, P707; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Saha MS, 1992, CURR OPIN GENET DEV, V2, P582, DOI 10.1016/S0959-437X(05)80176-5; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STEPANIK PL, 1993, EXP EYE RES, V57, P189, DOI 10.1006/exer.1993.1114; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; TREISMAN J, 1989, CELL, V59, P553; TUMER DL, 1987, NATURE, V328, P131; Vandendries ER, 1996, DEV BIOL, V173, P243, DOI 10.1006/dbio.1996.0020; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; YANG XJ, 1993, J NEUROSCI, V13, P3006; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YU X, 1994, J MOL NEUROSCI, V5, P259, DOI 10.1007/BF02736726; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	60	692	709	5	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					531	541		10.1016/S0092-8674(00)80439-0	http://dx.doi.org/10.1016/S0092-8674(00)80439-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390562	Bronze			2022-12-01	WOS:A1997YG49200014
J	Hueber, AO; Zornig, M; Lyon, D; Suda, T; Nagata, S; Evan, GI				Hueber, AO; Zornig, M; Lyon, D; Suda, T; Nagata, S; Evan, GI			Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis	SCIENCE			English	Article							T-CELL HYBRIDOMAS; FAS-LIGAND; IMMUNE EVASION; TUMOR-CELLS; DEATH; BCL-2; FAS/APO-1; PROTEIN; MICE; FIBROBLASTS	Induction of apoptosis by oncogenes like c-myc may be important in restraining the emergence of neoplasia, However, the mechanism by which c-myc induces apoptosis is unknown. CD95 (also termed Fas or APO-I) is a cell surface transmembrane receptor of the tumor necrosis factor receptor family that activates an intrinsic apoptotic suicide program in cells upon binding either its ligand CD95L or antibody, c-myc-induced apoptosis was shown to require interaction on the cell surface between CD95 and its ligand. c-Myc acts downstream of the CD95 receptor by sensitizing cells to the CD95 death signal. Moreover, IGF-I signaling and Bcl-2 suppress c-myc-induced apoptosis by also acting downstream of CD95, These findings link two apoptotic pathways previously thought to be independent and establish the dependency of Myc on CD95 signaling for its killing activity.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; OSAKA UNIV, SCH MED, DEPT GENET, SUITA, OSAKA 565, JAPAN	Cancer Research UK; Osaka University			Anne-Odile, Hueber/G-4352-2013; Anne-Odile, Hueber/P-9860-2019; Nagata, Shigekazu/AAG-3203-2019	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446; Nagata, Shigekazu/0000-0001-9758-8426				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HUEBER AO, UNPUB; ITOH N, 1993, J IMMUNOL, V151, P621; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, UNPUB; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; ZORNIG M, 1995, ONCOGENE, V10, P2397	35	318	324	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1305	1309		10.1126/science.278.5341.1305	http://dx.doi.org/10.1126/science.278.5341.1305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360929				2022-12-01	WOS:A1997YG04300048
J	Ivics, Z; Hackett, PB; Plasterk, RH; Izsvak, Z				Ivics, Z; Hackett, PB; Plasterk, RH; Izsvak, Z			Molecular reconstruction of Sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells	CELL			English	Article							P-ELEMENT; CAENORHABDITIS-ELEGANS; GENE-TRANSFER; MUTAGENESIS; DROSOPHILA; ZEBRAFISH; SUPERFAMILY; SEQUENCES; GENOME; TC3	Members of the Tc1/mariner superfamily of transposons isolated from fish appear to be transpositionally inactive due to the accumulation of mutations. Molecular phylogenetic data were used to construct a synthetic transposon, Sleeping Beauty, which could be identical or equivalent to an ancient element that dispersed in fish genomes in part by horizontal transmission between species. A consensus sequence of a transposase gene of the salmonid subfamily of elements was engineered by eliminating the inactivating mutations. Sleeping Beauty transposase binds to the inverted repeats of salmonid transposons in a substrate-specific manner, and it mediates precise cut-and-paste transposition in fish as well as in mouse and human cells. Sleeping Beauty is an active DNA-transposon system from vertebrates for genetic transformation and insertional mutagenesis.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST HUMAN GENET,ST PAUL,MN 55108; NETHERLANDS CANC INST,DIV MOL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS; HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOCHEM,H-6701 SZEGED,HUNGARY	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Netherlands Cancer Institute; Hungarian Academy of Sciences; Hungarian Biological Research Center			Wilson, Matthew H/K-3193-2013		NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006625] Funding Source: NIH RePORTER; NCRR NIH HHS [R01-RR06625] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; Beall EL, 1997, GENE DEV, V11, P2137, DOI 10.1101/gad.11.16.2137; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; COLLOMS SD, 1994, NUCLEIC ACIDS RES, V22, P5548, DOI 10.1093/nar/22.25.5548; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; DEVON RS, 1995, NUCLEIC ACIDS RES, V23, P1644, DOI 10.1093/nar/23.9.1644; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; Gibbs P. D. L., 1994, Molecular Marine Biology and Biotechnology, V3, P317; GIERL A, 1988, EMBO J, V7, P4045, DOI 10.1002/j.1460-2075.1988.tb03298.x; Gonzales AE, 1996, VET MICROBIOL, V48, P283, DOI 10.1016/0378-1135(95)00143-3; GOODIER JL, 1994, J MOL BIOL, V241, P26, DOI 10.1006/jmbi.1994.1470; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; HANDLER AM, 1993, ARCH INSECT BIOCHEM, V22, P373, DOI 10.1002/arch.940220306; Hartl DL, 1997, TRENDS GENET, V13, P197, DOI 10.1016/S0168-9525(97)01087-1; Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008; IZSVAK Z, 1995, MOL GEN GENET, V247, P312, DOI 10.1007/BF00293199; IZSVAK Z, 1997, IN PRESS J BIOCH CEL; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; Kidwell MG, 1992, CURR OPIN GENET DEV, V2, P868, DOI 10.1016/S0959-437X(05)80109-1; Koga A, 1996, NATURE, V383, P30, DOI 10.1038/383030a0; Lam WL, 1996, J MOL BIOL, V257, P359, DOI 10.1006/jmbi.1996.0168; Lam WL, 1996, P NATL ACAD SCI USA, V93, P10870, DOI 10.1073/pnas.93.20.10870; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lee MD, 1996, VET MICROBIOL, V50, P143, DOI 10.1016/0378-1135(96)00007-7; Lohe AR, 1997, P NATL ACAD SCI USA, V94, P1293, DOI 10.1073/pnas.94.4.1293; LOHE AR, 1995, MOL BIOL EVOL, V12, P62, DOI 10.1093/oxfordjournals.molbev.a040191; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; OOSUMI T, 1995, NATURE, V378, P873; OSBORNE BI, 1995, CURR OPIN CELL BIOL, V7, P406, DOI 10.1016/0955-0674(95)80097-2; PLASTERK RH, 1995, METHOD CELL BIOL, P59; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; RADICE AD, 1994, MOL GEN GENET, V244, P606, DOI 10.1007/BF00282750; RIO DC, 1988, J MOL BIOL, V200, P411, DOI 10.1016/0022-2836(88)90250-1; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	41	1006	1124	5	87	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					501	510		10.1016/S0092-8674(00)80436-5	http://dx.doi.org/10.1016/S0092-8674(00)80436-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390559	Bronze			2022-12-01	WOS:A1997YG49200011
J	Hu, YM; Wang, YQ; Luo, ZX; Li, CK				Hu, YM; Wang, YQ; Luo, ZX; Li, CK			A new symmetrodont mammal from China and its implications for mammalian evolution	NATURE			English	Article							FUNCTIONAL-ANATOMY; SHOULDER GIRDLE; EAR	A new symmetrodont mammal has been discovered in the Mesozoic era (Late Jurassic or Early Cretaceous period) of Liaoning Province, China, Archaic therian mammals, including symmetrodonts, are extinct relatives of the living marsupial and placental therians. However, these archaic therians have been mostly documented by fragmentary fossils. This new fossil taxon, represented by a nearly complete postcranial skeleton and a partial skull with dentition, is the best-preserved symmetrodont mammal yet discovered. It provides a new insight into the relationships of the major lineages of mammals and the evolution of the mammalian skeleton. Our analysis suggests that this new taxon represents a part of the early therian radiation before the divergence of living marsupials and placentals; that therians and multituberculates are more closely related to each other than either group is to other mammalian lineages; that archaic therians lacked the more parasagittal posture of the forelimb of most living therian mammals; and that archaic therians, such as symmetrodonts, retained the primitive feature of a finger-like promontorium (possibly with a straight cochlea) of the non-therian mammals. The fully coiled cochlea evolved later in more derived therian mammals, and is therefore convergent to the partially coiled cochlea of monotremes.	CARNEGIE MUSEUM NAT HIST, SECT VERTEBRATE PALEONTOL, PITTSBURGH, PA 15213 USA; CHINESE ACAD SCI, INST VERTEBRATE PALEONTOL & PALEOANTHROPOL, BEIJING 100044, PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS			Luo, Zhe-XI/AAU-2263-2021					Cassiliano M.L., 1979, P150; Chen P., 1980, B NANJING I GEOL PAL, V1, P22; CHEN PJ, 1994, CRETACEOUS RES, V15, P245, DOI 10.1006/cres.1994.1015; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P332; Clemens W. A., 1963, Palaeontology, V6, P373; Crompton A., 1971, EARLY MAMMALS, P65; Crompton A.W., 1979, P59; CROMPTON AW, 1993, MAMMAL PHYLOGENY, P30; FOX RC, 1985, J PALEONTOL, V59, P21; Gambaryan PP, 1997, ACTA PALAEONTOL POL, V42, P13; GRAYBEAL A, 1989, ZOOL J LINN SOC-LOND, V96, P107, DOI 10.1111/j.1096-3642.1989.tb01823.x; HOPSON JA, 1994, MAJOR FEATURES VERTE, P190; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; HOU LH, 1995, NATURE, V377, P616, DOI 10.1038/377616a0; JENKINS FA, 1973, AM J ANAT, V137, P281, DOI 10.1002/aja.1001370304; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; JENKINS FA, 1974, J MORPHOL, V144, P71, DOI 10.1002/jmor.1051440105; JENKINS FA, 1979, J ZOOL, V188, P379; JENKINS FA, 1988, J VERTEBR PALEONTOL, V6, P1; Ji Q., 1996, CHINESE GEOL, V233, P30; Ji Q., 1997, CHINESE GEOL, V238, P38; Jin F, 1996, VERTEBRATA PALASIATI, V34, P102; KEMP TS, 1983, ZOOL J LINN SOC-LOND, V77, P353, DOI 10.1111/j.1096-3642.1983.tb00859.x; KERMACK KA, 1981, ZOOL J LINN SOC-LOND, V71, P1, DOI 10.1111/j.1096-3642.1981.tb01127.x; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSKA Z, 1987, NATURE, V326, P871, DOI 10.1038/326871a0; KIELANJAWOROWSKA Z, 1986, PHILOS T R SOC B, V313, P525, DOI 10.1098/rstb.1986.0055; KLIMA M, 1987, ADV ANAT EMBRYOL CEL, V109, P1; Klima M., 1973, Advances Anat Embryol Cell Biol, V47, P1; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; Lillegraven J.A., 1991, Contributions to Geology University of Wyoming, V28, P39; Luo Z., 1991, Journal of Vertebrate Paleontology, V11, P220; LUO ZX, 1994, J VERTEBR PALEONTOL, V14, P341, DOI 10.1080/02724634.1994.10011564; LUO ZX, 1995, J VERTEBR PALEONTOL, V15, P113, DOI 10.1080/02724634.1995.10011211; Marshall Larry G., 1995, Memoires du Museum National d'Histoire Naturelle, V165, P21; MENG J, 1995, NATURE, V377, P141, DOI 10.1038/377141a0; MENG J, 1995, J VERTEBR PALEONTOL, V15, P122, DOI 10.1080/02724634.1995.10011212; Rougier G.W., 1992, Journal of Vertebrate Paleontology, V12, P188; Rougier G.W., 1993, THESIS U NACL BUENOS; Rougier Guillermo W., 1996, American Museum Novitates, V3183, P1; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; SERENO PC, 1995, NATURE, V377, P144, DOI 10.1038/377144a0; SMIPSON GG, 1928, CATALOGUE MESOZOIC M; SMITH PE, 1995, CAN J EARTH SCI, V32, P1426, DOI 10.1139/e95-115; Wang Yuanqing, 1995, P221; Wible J.R., 1991, Journal of Vertebrate Paleontology, V11, P1; WIBLE JR, 1993, MAMMAL PHYLOGENY, V1, P45; Zeller U., 1989, ABHANDLUNGEN SENCKEN, V545, P1; [No title captured]	50	180	212	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					137	142		10.1038/36505	http://dx.doi.org/10.1038/36505			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367151				2022-12-01	WOS:A1997YF49400043
J	Smith, GD; Hart, C; Ferrell, C; Upton, M; Hole, D; Hawthorne, V; Watt, G				Smith, GD; Hart, C; Ferrell, C; Upton, M; Hole, D; Hawthorne, V; Watt, G			Birth weight of offspring and mortality in the Renfrew and Paisley study: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; BODY-FAT DISTRIBUTION; RISK-FACTORS; URBAN SCOTLAND; HIP RATIO; WOMEN; MEN; DETERMINANTS	Objective: To investigate the association between birth weight of offspring and mortality among fathers and mothers in the west of Scotland. Design: Prospective observational study. Participants: 794 married couples in Renfrew district of the west of Scotland. Main outcome measures: Mortality from all causes and from cardiovascular disease over 15 year follow up. Results: Women who had heavier babies were taller, had higher body mass index and better lung function, and were less likely to be smokers than mothers of lighter babies. Fathers of heavier babies were taller and less likely to be smokers than fathers of lighter babies. Mortality was inversely related to offspring's birth weight for both mothers (relative rate for a 1 kg lower birth weight 1.82 (95% confidence interval 1.23 to 2.70)) and fathers (relative rate 1.35 (1.03 to 1.79)). For mortality from cardiovascular disease, inverse associations were seen for mothers (2.00 (1.18 to 3.33)) and fathers (1.52 (1.03 to 2.17)). Adjustment for blood pressure, plasma cholesterol, body mass index, height, social class, area based deprivation category, smoking, lung function, angina, bronchitis, and electrocardiographic evidence of ischaemia had little effect on these risk estimates, although levels of statistical significance were reduced. Conclusions: Birth weight of offspring was related inversely to mortality, from all causes and cardiovascular disease, in this cohort. The strength of this association was greater than would have been expected by the degree of concordance of birth weights across generations, but an extensive range of potential confounding factors could not account for the association. Mortality is therefore influenced by a factor related to birth weight that is transmissible across generations.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,LANARK,SCOTLAND; UNIV GLASGOW,WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW G20 7LR,LANARK,SCOTLAND; RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Glasgow; University of Glasgow; University of Glasgow; University of Michigan System; University of Michigan	Smith, GD (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,CANYNGE HALL,BRISTOL BS8 2PR,AVON,ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Upton, Mark/0000-0003-0839-1141				Alberman E, 1992, Paediatr Perinat Epidemiol, V6, P134, DOI 10.1111/j.1365-3016.1992.tb00755.x; BARKER DJP, 1995, NUTR CHILD HLTH; Brown JE, 1996, EPIDEMIOLOGY, V7, P62, DOI 10.1097/00001648-199601000-00011; EMANUEL I, 1993, ISSUES REV TERATOL, V6, P47; Emery E M, 1993, Am J Health Promot, V7, P342; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; *GEN REG OFF, 1966, GEN REG OFF CLASS OC; Godfrey KM, 1997, BRIT J OBSTET GYNAEC, V104, P663, DOI 10.1111/j.1471-0528.1997.tb11975.x; HART N, 1993, POPULATION STUDIES, V47, P24; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; *IND SCI COMM SMOK, 1988, 4 REP IND SCI COMM S; KLEBANOFF MA, 1989, PEDIATRICS, V84, P343; KOUPILOVA I, IN PRESS J EPIDEMIOL; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LANGHOFFROOS J, 1987, CLIN GENET, V32, P240; LARSSON B, 1992, AM J EPIDEMIOL, V135, P266, DOI 10.1093/oxfordjournals.aje.a116280; Little R E, 1987, Paediatr Perinat Epidemiol, V1, P19, DOI 10.1111/j.1365-3016.1987.tb00084.x; MAGNUS P, 1984, CLIN GENET, V26, P397; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; Pembrey M., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P111; PETERS TJ, 1983, BRIT J OBSTET GYNAEC, V90, P1040, DOI 10.1111/j.1471-0528.1983.tb06442.x; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; POWER C, 1994, BRIT MED J, V308, P1270, DOI 10.1136/bmj.308.6939.1270; RICHEDWARDS J, 1995, AM J EPIDEMIOL, V141, pS78; SANDERSON M, 1995, PAEDIATR PERINAT EP, V9, P391, DOI 10.1111/j.1365-3016.1995.tb00162.x; *SAS I, 1991, SAS LANG PROC US 2 V; SCHMIDT MI, 1992, DIABETES CARE, V15, P912, DOI 10.2337/diacare.15.7.912; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SUTTON GC, 1980, ANN HUM BIOL, V7, P449, DOI 10.1080/03014468000004561; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WATT GCM, 1995, SCOT MED J, V40, P108, DOI 10.1177/003693309504000403; WILD RA, 1990, FERTIL STERIL, V54, P255; World Health Organization, 1977, INT CLASS DIS	34	106	106	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1189	1193		10.1136/bmj.315.7117.1189	http://dx.doi.org/10.1136/bmj.315.7117.1189			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393220	Green Published			2022-12-01	WOS:A1997YF25200017
J	Tinetti, ME; Williams, CS				Tinetti, ME; Williams, CS			Falls, injuries due to falls, and the risk of admission to a nursing home	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; ELDERLY PEOPLE; OLDER PERSONS; FUNCTIONAL STATUS; COMMUNITY; POPULATION; ADULTS; EFFICACY; CARE; FEAR	Background Falls warrant investigation as a risk factor for nursing home admission because falls are common and are associated with functional disability and because they may be preventable. Methods We conducted a prospective study of a probability sample of 1103 people over 71 years of age who were living in the community. Data on demographic and medical characteristics, use of health care, and cognitive, functional, psychological, and social functioning were obtained at base line and one year later during assessments in the participants' homes. The primary outcome studied was the number of days from the initial assessment to a first longterm admission to a skilled-nursing facility during three years of follow-up, Patients were assigned to four categories during follow-up: those who had no falls, those who had one fall without serious injury, those who had two or more falls without serious injury, and those who had at least one fall causing serious injury. Results A total of 133 participants (12.1 percent) had long-term admissions to nursing homes. In an unadjusted model, the risk of admission increased progressively, as compared with that for the patients with no falls, for those with a single noninjurious fall (relative risk, 4.9; 95 percent confidence interval, 3.2 to 7.5), those with multiple noninjurious falls (relative risk, 8.5; 95 percent confidence interval, 3.4 to 21.2), and those with at least one fall causing serious injury (relative risk, 19.9; 95 percent confidence interval, 12.2 to 32.6). Adjustment for other risk factors lowered these ratios to 3.1 (95 percent confidence interval, 1.9 to 4.9) for one noninjurious fall, 5.5 (95 percent confidence interval, 2.1 to 14.2) for two or more noninjurious falls, and 10.2 (95 percent confidence interval, 5.8 to 17.9) for at least one fall causing serious injury, but the association between falls and admission to a nursing home remained strong and significant. The population attributable risk of long-term admission to a nursing home for these three groups (the proportion of admissions directly attributable to the three categories of falls) was 13 percent, 3 percent, and 10 percent, respectively. Conclusions Among older people living in the community falls are a strong predictor of placement in a skilled-nursing facility; interventions that prevent falls and their sequelae may therefore delay or reduce the frequency of nursing home admissions. (C) 1997, Massachusetts Medical Society.			Tinetti, ME (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.				NIA NIH HHS [R01 AG07447, P60AG10487] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Dunn J E, 1993, J Aging Health, V5, P194, DOI 10.1177/089826439300500203; Foley D J, 1992, J Aging Health, V4, P155, DOI 10.1177/089826439200400201; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GREENE VL, 1990, J GERONTOL, V45, pS250, DOI 10.1093/geronj/45.6.S250; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; JETTE AM, 1992, GERONTOLOGIST, V32, P634, DOI 10.1093/geront/32.5.634; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KIEL DP, 1991, MED CARE, V29, P221; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LIU K, 1991, MED CARE, V29, P125, DOI 10.1097/00005650-199102000-00005; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; MURTAUGH CM, 1990, MED CARE, V28, P952, DOI 10.1097/00005650-199010000-00009; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.1995.03520410035023; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Seeman T. E., 1993, J AGING HEALTH, V5, P455, DOI DOI 10.1177/089826439300500403; Spielberger CD, 1970, STAI MANUAL; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; WOLINSKY FD, 1993, J GERONTOL, V48, pS93; WOLINSKY FD, 1992, MED CARE, V30, P587, DOI 10.1097/00005650-199207000-00002	37	917	939	2	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1279	1284		10.1056/NEJM199710303371806	http://dx.doi.org/10.1056/NEJM199710303371806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC920	9345078				2022-12-01	WOS:A1997YC92000006
J	Han, SH; Dillon, SR; Zheng, B; Shimoda, M; Schlissel, MS; Kelsoe, G				Han, SH; Dillon, SR; Zheng, B; Shimoda, M; Schlissel, MS; Kelsoe, G			V(D)J recombinase activity in a subset of germinal center B lymphocytes	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; LIGHT-CHAIN; IN-SITU; RECIPROCAL PARTNERS; GENE REARRANGEMENT; CELLS; MATURATION; SELECTION; MECHANISM; ANTIGEN	Reexpression of the V(D)J recombinase-activating genes RAG1 and RAG2 in germinal center B cells creates the potential for immunoglobulin gene rearrangement and the generation of new antigen receptor specificities. intermediate products of V(D)J recombination are abundant in a subset of germinal center B cells, demonstrating that the kappa immunoglobulin light-chain locus becomes a substrate for renewed V(D)J recombinase activity. This recombinationally active cell compartment contains many heavy-chain VDJ rearrangements that encode low-affinity or nonfunctional antibody. In germinal centers, secondary V(D)J recombination may be induced by diminished binding to antigen ligands, thereby limiting abrupt changes in receptor specificity to B cells that are usually eliminated from the germinal center reaction, This restriction preserves efficient antigen-driven selection in germinal centers while allowing for saltations in the somatic evolution of B cells.	UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOL & CELL BIOL,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024335, R01AI040227, R37AI040227] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48722] Funding Source: Medline; NIAID NIH HHS [AI40227, AI24335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLMAN DM, 1993, J IMMUNOL, V151, P4431; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; CERASOLI D, UNPUB; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; COICO RF, 1983, J IMMUNOL, V131, P2254; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; Cornall RJ, 1995, CURR OPIN IMMUNOL, V7, P804, DOI 10.1016/0952-7915(95)80052-2; COTTER F, 1990, BLOOD, V76, P131; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Han S.-G., UNPUB; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; HAN SH, 1995, J IMMUNOL, V155, P556; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kimoto H, 1997, EUR J IMMUNOL, V27, P268, DOI 10.1002/eji.1830270140; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MILLER C, 1995, J IMMUNOL, V155, P3377; Miller Carla, 1994, Aging Immunology and Infectious Disease, V5, P249; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347	38	252	254	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					301	305		10.1126/science.278.5336.301	http://dx.doi.org/10.1126/science.278.5336.301			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323211				2022-12-01	WOS:A1997YA56400048
J	Shinde, UP; Liu, JJ; Inouye, M				Shinde, UP; Liu, JJ; Inouye, M			Protein memory through altered folding mediated by intramolecular chaperones	NATURE			English	Article							SUBTILISIN BPN'; PRO-SEQUENCE; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; KINETIC-ANALYSIS; PROPEPTIDE; CATALYSIS; PATHWAY; INHIBITION; MECHANISM	The 77-residue propeptide of subtilisin acts as an intramolecular chaperone that organizes the correct folding of its own protease domain, Similar folding mechanisms are used by several prokaryotic and eukaryotic proteins, including prohormone-convertases. Here we show that the intramolecular chaperone of subtilisin facilitates folding by acting as a template for its protease domain, although it does not form part of that domain. Subtilisin E folded by an intramolecular chaperone with an Ile(-48)-to-Val mutation acquires an 'altered' enzymatically active conformation that differs from wild-type subtilisin E. Although both the altered and wild-type subtilisins have identical amino-acid sequences, as determined by amino-terminal sequencing and mass spectrometry, they bind their cognate intramolecular chaperones with 4.5-fold greater affinity than non-cognate intramolecular chaperones, when added in trans. The two subtilisins also have different secondary structures, thermostability and substrate specificities. Our results indicate that an identical polypeptide can fold into an altered conformation through a mutated intramolecular chaperone and maintains memory of the folding process. Such a phenomenon, which we term 'protein memory', map be important in investigations of protein folding.			Shinde, UP (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.							ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BRYAN PN, 1995, INTRAMOLECULAR CHAPE, P85; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KLIBANOV AM, 1995, NATURE, V374, P596, DOI 10.1038/374596a0; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LEE YC, 1992, FEMS MICROBIOL LETT, V92, P73, DOI 10.1016/0378-1097(92)90544-X; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MATHEWS BW, 1995, ADV PROTEIN CHEM, V462, P240; RICHO GR, 1994, J BIOL CHEM, V269, P14806; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; RUSSELL AJ, 1988, J BIOL CHEM, V263, P11624; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SILEN JL, 1989, NATURE, V341, P362; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WINTHER JR, 1994, J BIOL CHEM, V269, P7006; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	30	131	136	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					520	522		10.1038/39097	http://dx.doi.org/10.1038/39097			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333245				2022-12-01	WOS:A1997XY90900063
J	Tei, H; Okamura, H; Shigeyoshi, Y; Fukuhara, C; Ozawa, R; Hirose, M; Sakaki, Y				Tei, H; Okamura, H; Shigeyoshi, Y; Fukuhara, C; Ozawa, R; Hirose, M; Sakaki, Y			Circadian oscillation of a mammalian homologue of the Drosophila period gene	NATURE			English	Article							SUPRACHIASMATIC NUCLEUS; CLOCK GENE; MELANOGASTER; BEHAVIOR; PROTEIN; PRODUCT; LESIONS; SYSTEM	Many biochemical, physiological and behavioural processes in organisms ranging from microorganisms to vertebrates exhibit circadian rhythms(1). In Drosophila, the gene period (per) is required for the circadian rhythms of locomotor activity and eclosion behaviour(2). Oscillation in the levels of per mRNA and Period (dPer) protein in the fly brain is thought to be responsible for the rhythmicity(3,4). However, no per homologues in animals other than insects have been identified. Here we identify the human and mouse genes (hPER and mPer, respectively) encoding PAS-domain (PAS, a dimerization domain present in Per, Amt and Sim)-containing polypeptides that aro highly homologous to dPer. Besides this structural resemblance, mPer shows autonomous circadian oscillation in its expression in the suprachiasmatic nucleus, which is the primary circadian pacemaker in the mammalian brain(5,6). Clock, a mammalian clock gene encoding a PAS-containing polypeptide(7,8), has now been cloned: it is likely that the Per homologues dimerize with other molecule(s) such as Clock through PAS-PAS interaction in the circadian clock system.	KOBE UNIV, SCH MED, DEPT ANAT & BRAIN SCI, CHUO KU, KOBE, HYOGO 650, JAPAN; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Kobe University; Scripps Research Institute	Tei, H (corresponding author), UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Okamura, Hitoshi/0000-0002-3013-4881				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Ban Y, 1997, J NEUROSCI, V17, P3920; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; EDMUNDS LN, 1988, CELLULAR MOL BASIS B; GILLETTE MU, 1987, BRAIN RES BULL, V19, P135, DOI 10.1016/0361-9230(87)90176-6; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; ITO T, 1993, ELECTROPHORESIS, V14, P278, DOI 10.1002/elps.1150140149; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sambrook J., 1989, MOL CLONING; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131; ZERR DM, 1990, J NEUROSCI, V10, P2749	27	640	669	2	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					512	516		10.1038/39086	http://dx.doi.org/10.1038/39086			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333243				2022-12-01	WOS:A1997XY90900061
J	Nakajima, T; Uchida, C; Anderson, SF; Lee, CG; Hurwitz, J; Parvin, JD; Montminy, M				Nakajima, T; Uchida, C; Anderson, SF; Lee, CG; Hurwitz, J; Parvin, JD; Montminy, M			RNA helicase a mediates association of CBP with RNA polymerase II	CELL			English	Article							TRANSCRIPTION FACTOR CREB; GENE-TRANSCRIPTION; DOSAGE COMPENSATION; DEPENDENT ACTIVATOR; MOLECULAR-CLONING; MALELESS PROTEIN; COACTIVATOR CBP; BINDING PROTEIN; X-CHROMOSOME; COMPLEX	The coactivator CBP has been proposed to stimulate the expression of certain signal-dependent genes via its association with RNA polymerase II complexes. Here we show that complex formation between CBP and RNA polymerase II requires RNA helicase A (RHA), a nuclear DNA/RNA helicase that is related to the Drosophila male dosage compensation factor mle, In transient transfection assays, RHA was found to cooperate with CBP in mediating target gene activation via the CAMP responsive factor CREB. As a mutation in RHA that compromised its helicase activity correspondingly reduced CREB-dependent transcription, we propose that RHA may induce local changes in chromatin structure that promote engagement of the transcriptional apparatus on signal responsive promoters.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV MOL ONCOL,BOSTON,MA 02115; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Memorial Sloan Kettering Cancer Center			Parvin, Jeffrey D/C-8955-2009	jhangiry, parvin/0000-0003-1415-7212	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037828, R01GM053504, R01GM037828] Funding Source: NIH RePORTER; NCI NIH HHS [CA54418] Funding Source: Medline; NIGMS NIH HHS [GM53504, GM37828] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BHATTACHARYA S, 1996, NATURE, V383, P343; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CG, 1993, J BIOL CHEM, V268, P16822; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parker D, 1996, MOL CELL BIOL, V16, P694; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422	27	455	474	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1107	1112		10.1016/S0092-8674(00)80376-1	http://dx.doi.org/10.1016/S0092-8674(00)80376-1			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323138	Bronze			2022-12-01	WOS:A1997XX76800016
J	Sidrauski, C; Walter, P				Sidrauski, C; Walter, P			The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response	CELL			English	Article							TRANSFER-RNA LIGASE; KAR2 BIP GENE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; 2-5A-DEPENDENT RNASE; YEAST; PATHWAY; OLIGOMERIZATION; PHOSPHORYLATION; INTERFERON	The endoplasmic reticulum (ER) communicates with the nucleus through the unfolded protein response (UPR), which senses accumulation of unfolded proteins in the ER lumen and leads to increased transcription of genes encoding ER-resident chaperones. As a key regulatory step in this signaling pathway, the mRNA encoding the UPR-specific transcription factor Hac1p becomes spliced by a unique mechanism that requires tRNA ligase but not the spliceosome. Splicing is initiated upon activation of Ire1p, a transmembrane kinase that lies in the ER and/or inner nuclear membrane. We show that Ire1p is a bifunctional enzyme: in addition to being a kinase, it is a site-specific endoribonuclease that cleaves HAC1 mRNA specifically at both splice junctions. The addition of purified tRNA ligase completes splicing; we therefore have reconstituted HAC1 mRNA splicing in vitro from purified components.			Sidrauski, C (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; GREER CL, 1986, MOL CELL BIOL, V6, P635, DOI 10.1128/MCB.6.2.635; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; Moore M., 1993, RNA WORLD, P303; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; STERN S, 1988, METHOD ENZYMOL, V164, P481; SWEET DJ, 1993, CURR BIOL, V3, P622, DOI 10.1016/0960-9822(93)90014-F; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	33	626	657	0	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1031	1039		10.1016/S0092-8674(00)80369-4	http://dx.doi.org/10.1016/S0092-8674(00)80369-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323131	Bronze			2022-12-01	WOS:A1997XX76800009
J	Nightingale, SL				Nightingale, SL			Final standards for mammography facilities issued	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-01	WOS:A1997YH98700009
J	Cui, JQ; Shin, T; Kawano, T; Sato, H; Kondo, E; Toura, I; Kaneko, Y; Koseki, H; Kanno, M; Taniguchi, M				Cui, JQ; Shin, T; Kawano, T; Sato, H; Kondo, E; Toura, I; Kaneko, Y; Koseki, H; Kanno, M; Taniguchi, M			Requirement for V(alpha)14 NKT cells in IL-12-mediated rejection of tumors	SCIENCE			English	Article							RECEPTOR-ALPHA-CHAIN; LYMPHOCYTE MATURATION FACTOR; ANTI-MELANOMA ANTIBODY; IFN-GAMMA PRODUCTION; CLASS-I MOLECULES; BETA T-CELLS; HETERODIMERIC CYTOKINE; STIMULATORY FACTOR; LIVER METASTASIS; THYMOCYTES	A lymphocyte subpopulation, the V(alpha)14 natural killer T (NKT) cells, expresses both NK1.1 and a single invariant T cell receptor encoded by the V(alpha)14 and J(alpha)281 gene segments, Mice with a deletion of the J(alpha)281 gene segment were found to exclusively lack this subpopulation. The V(alpha)14 NKT cell-deficient mice could no longer mediate the interleukin-12 (IL-12)-induced rejection of tumors. Although the antitumor effect of IL-12 Was thought to be mediated through natural killer cells and T cells, V(alpha)14 NKT cells were found to be an essential target of IL-12, and they mediated their cytotoxicity by an NK-like effector mechanism after activation with IL-12.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL IMMUNOL,CHUO KU,CHIBA 260,JAPAN; JAPAN SCI & TECHNOL CORP,CORE RES EVOL SCI & TECHNOL,TOKYO,JAPAN	Chiba University; Japan Science & Technology Agency (JST)			Taniguchi, Masaru/N-7932-2015; Koseki, Haruhiko/I-3825-2014	Taniguchi, Masaru/0000-0001-7821-7179; Koseki, Haruhiko/0000-0001-8424-5854; Kanno, masamoto/0000-0001-9169-3444				Akasaka T, 1996, DEVELOPMENT, V122, P1513; Ando K, 1997, J IMMUNOL, V158, P5283; BALLAS ZK, 1990, J IMMUNOL, V145, P1039; BARBERAGUILLEM E, 1989, CANCER RES, V49, P4003; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; BRUNDA MJ, 1984, INT J CANCER, V34, P421, DOI 10.1002/ijc.2910340321; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; GATELY MK, 1991, J IMMUNOL, V147, P874; GUNJI Y, 1986, JPN J CANCER RES, V77, P595; HASHIMOTO W, 1995, J IMMUNOL, V154, P4333; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KOPPER L, 1982, J CANCER RES CLIN, V103, P31, DOI 10.1007/BF00410303; KOSEKI H, 1990, P NATL ACAD SCI USA, V87, P5248, DOI 10.1073/pnas.87.14.5248; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MAKINO Y, 1993, J EXP MED, V177, P1399, DOI 10.1084/jem.177.5.1399; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; Makino Y, 1996, P NATL ACAD SCI USA, V93, P6516, DOI 10.1073/pnas.93.13.6516; MARASKOVSKY E, 1989, J IMMUNOL, V143, P1210; Masuda K, 1997, J IMMUNOL, V158, P2076; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NASTALA CL, 1994, J IMMUNOL, V153, P1697; NORES GA, 1987, J IMMUNOL, V139, P3171; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; Takahashi M, 1996, J IMMUNOL, V156, P2436; Taniguchi M, 1996, P NATL ACAD SCI USA, V93, P11025, DOI 10.1073/pnas.93.20.11025; Tardif M, 1996, INT J CANCER, V68, P97, DOI 10.1002/(SICI)1097-0215(19960927)68:1<97::AID-IJC17>3.0.CO;2-3; Teicher BA, 1996, INT J CANCER, V65, P80, DOI 10.1002/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M; WAKABAYASHI S, 1981, NATURE, V294, P748, DOI 10.1038/294748a0; WAKABAYASHI S, 1984, JPN J CANCER RES, V75, P427; WEIGENT DA, 1983, BIOCHEM BIOPH RES CO, V111, P525, DOI 10.1016/0006-291X(83)90338-8; WOLF SF, 1991, J IMMUNOL, V146, P3074; ZOU JP, 1995, INT IMMUNOL, V7, P1135, DOI 10.1093/intimm/7.7.1135	45	1091	1128	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1623	1626		10.1126/science.278.5343.1623	http://dx.doi.org/10.1126/science.278.5343.1623			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374462				2022-12-01	WOS:A1997YJ87400041
J	Grassme, H; Gulbins, E; Brenner, B; Ferlinz, K; Sandhoff, K; Harzer, K; Lang, F; Meyer, TF				Grassme, H; Gulbins, E; Brenner, B; Ferlinz, K; Sandhoff, K; Harzer, K; Lang, F; Meyer, TF			Acidic sphingomyelinase mediates entry of N-gonorrhoeae into nonphagocytic cells	CELL			English	Article							HUMAN EPITHELIAL-CELLS; CULTURED-MAMMALIAN-CELLS; NEISSERIA-GONORRHOEAE; SIGNALING PATHWAY; HEPARAN-SULFATE; INDUCED APOPTOSIS; BACTERIAL ENTRY; TYROSINE PHOSPHORYLATION; SALMONELLA-TYPHIMURIUM; SHIGELLA-FLEXNERI	Invasion of human mucosal cells by N. gonorrhoeae via the binding to heparansulfate proteoglycan receptors is considered a crucial event of the infection. Using different human epithelial cells and primary fibroblasts, we show here an activation of the phosphatidylcholine-specific phospholipase C (PC-PLC) and acidic sphingomyelinase (ASM) by N. gonorrhoeae, resulting in the release of diacylglycerol and ceramide. Genetic and/or pharmacological blockade of ASM and PC-PLC cause inhibition of cellular invasion by N. gonorrhoeae. Complementation of ASM-deficient fibroblasts from Niemann-Pick disease patients restored N. gonorrhoeae-induced signaling and entry processes. The activation of PC-PLC and ASM, therefore, is an essential requirement for the entry of N. gonorrhoeae into distinct nonphagocytic human cell types including several epithelial cells and primary fibroblasts.	MAX PLANCK INST BIOL,INFEKT BIOL ABT,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST INFEKT BIOL,MOL BIOL ABT,D-10117 BERLIN,GERMANY; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY; UNIV TUBINGEN,INST HIRNFORSCH,D-72070 TUBINGEN,GERMANY; UNIV BONN,D-53121 BONN,GERMANY	Max Planck Society; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Bonn			Meyer, Thomas F. F/J-2485-2013; Gulbins, Erich/L-6989-2014	Meyer, Thomas F. F/0000-0002-6120-8679; Gulbins, Erich/0000-0002-3117-1342				Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; Apicella MA, 1996, J INFECT DIS, V173, P636, DOI 10.1093/infdis/173.3.636; BESSEN D, 1986, INFECT IMMUN, V54, P154, DOI 10.1128/IAI.54.1.154-160.1986; BHAT KS, 1991, MOL MICROBIOL, V6, P1073; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; Bos MP, 1997, INFECT IMMUN, V65, P2353, DOI 10.1128/IAI.65.6.2353-2361.1997; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; Chen T, 1996, P NATL ACAD SCI USA, V93, P14851, DOI 10.1073/pnas.93.25.14851; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Duensing TD, 1997, INFECT IMMUN, V65, P964, DOI 10.1128/IAI.65.3.964-970.1997; Fussenegger M, 1996, MOL MICROBIOL, V19, P1357, DOI 10.1111/j.1365-2958.1996.tb02479.x; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GomezDuarte OG, 1997, INFECT IMMUN, V65, P3857; GOTSCHLICH EC, 1987, P NATL ACAD SCI USA, V84, P8135, DOI 10.1073/pnas.84.22.8135; Grassme HUC, 1996, INFECT IMMUN, V64, P1621; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; Higuchi M, 1996, J IMMUNOL, V157, P297; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISSACS RD, 1994, J CLIN INVEST, V93, P809; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; LAMBDEN PR, 1979, J GEN MICROBIOL, V114, P305, DOI 10.1099/00221287-114-2-305; LIANG OD, 1992, INFECT IMMUN, V60, P899, DOI 10.1128/IAI.60.3.899-906.1992; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCGEE ZA, 1983, REV INFECT DIS, V5, P708; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PARUCHURI DK, 1990, P NATL ACAD SCI USA, V87, P333, DOI 10.1073/pnas.87.1.333; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; SAUER G, 1984, P NATL ACAD SCI-BIOL, V81, P3263, DOI 10.1073/pnas.81.11.3263; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; SWANSON J, 1988, J EXP MED, V168, P2121, DOI 10.1084/jem.168.6.2121; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; VANPUTTEN JPM, 1990, J MED MICROBIOL, V33, P35, DOI 10.1099/00222615-33-1-35; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; VIRJI M, 1984, J GEN MICROBIOL, V130, P1089; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; WEEL JFL, 1991, J EXP MED, V174, P705, DOI 10.1084/jem.174.3.705; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; ZHANG JP, 1992, CELL, V69, P861, DOI 10.1016/0092-8674(92)90296-O	64	245	254	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					605	615		10.1016/S0092-8674(00)80448-1	http://dx.doi.org/10.1016/S0092-8674(00)80448-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393854	Green Published, Bronze			2022-12-01	WOS:A1997YH96000008
J	Plautz, JD; Kaneko, M; Hall, JC; Kay, SA				Plautz, JD; Kaneko, M; Hall, JC; Kay, SA			Independent photoreceptive circadian clocks throughout Drosophila	SCIENCE			English	Article							PERIOD GENE; BEHAVIORAL RHYTHMS; MELANOGASTER; EXPRESSION; SYSTEM; MUTANTS; CELLS; LIGHT; HEAD; TIME	Transgenic Drosophila that expressed either luciferase or green fluorescent protein driven From the promoter of the clock gene period were used lo monitor the circadian clock in explanted head, thorax, and abdominal tissues. The tissues (including sensory bristles in the leg and wing) showed rhythmic bioluminescence, and the rhythms could be reset by light, The photoreceptive properties of the explanted tissues indicate that unidentified photoreceptors are likely to contribute to photic signal transduction to the clock. These results show that autonomous circadian oscillators are present throughout the body, and they suggest that individual cells in Drosophila are capable of supporting their own independent clocks.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, NATL SCI FDN, CTR BIOL TIMING, LA JOLLA, CA 92037 USA; BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA; BRANDEIS UNIV, NATL SCI FDN, CTR BIOL TIMING, WALTHAM, MA 02254 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Brandeis University; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing			Kay, Steve A/F-6025-2011; Weydahl, Andi/C-6391-2008	Kay, Steve A/0000-0002-0402-2878; Kaneko, Maki/0000-0002-2489-6185	NIMH NIH HHS [MH-51573] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARGAMASO SM, 1995, BIOPHYS CHEM, V56, P3, DOI 10.1016/0301-4622(95)00009-M; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; EWER J, 1992, J NEUROSCI, V12, P3321; GIEBULTOWICZ JM, 1989, SCIENCE, V245, P1098, DOI 10.1126/science.245.4922.1098; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HANDLER AM, 1979, NATURE, V279, P236, DOI 10.1038/279236a0; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; Hege DM, 1997, J BIOL RHYTHM, V12, P300, DOI 10.1177/074873049701200402; Ito K, 1997, CELL TISSUE RES, V290, P1, DOI 10.1007/s004410050901; JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARTINEZGOMEZ M, 1994, PHYSIOL BEHAV, V55, P651, DOI 10.1016/0031-9384(94)90040-X; MCMILLAN JP, 1975, J COMP PHYSIOL, V102, P251, DOI 10.1007/BF01464359; MENAKER M, 1996, CIRCADIAN ORG OSCILL, P39; OKEEFE LP, 1987, PHYSIOL BEHAV, V41, P193, DOI 10.1016/0031-9384(87)90353-2; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; POWER J, 1995, J NEUROGENET, V9, P227, DOI 10.3109/01677069509084159; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Sehgal A, 1996, MOL CELL NEUROSCI, V7, P165, DOI 10.1006/mcne.1996.0013; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1982, J COMP PHYSIOL, V146, P245, DOI 10.1007/BF00610244; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TRUMAN JW, 1974, J COMP PHYSIOL, V95, P281, DOI 10.1007/BF00609702; TRUMAN JW, 1972, J COMP PHYSIOL, V81, P99, DOI 10.1007/BF00693553; VanGelder RN, 1995, CURR BIOL, V5, P1424, DOI 10.1016/S0960-9822(95)00280-6; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106	39	504	513	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1632	1635		10.1126/science.278.5343.1632	http://dx.doi.org/10.1126/science.278.5343.1632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374465				2022-12-01	WOS:A1997YJ87400044
J	Rivers, JK; Roof, MI				Rivers, JK; Roof, MI			Sentinel lymph-node biopsy in melanoma: is less surgery better?	LANCET			English	Editorial Material									BRITISH COLUMBIA CANC AGCY,VANCOUVER,BC V5Z 4E8,CANADA; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030	British Columbia Cancer Agency; University of Texas System; UTMD Anderson Cancer Center	Rivers, JK (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DIV DERMATOL,VANCOUVER,BC V5Z 4E8,CANADA.		Rivers, Jason/K-1031-2019	Rivers, Jason/0000-0002-0131-1607				Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; Brady MS, 1997, ARCH DERMATOL, V133, P1014, DOI 10.1001/archderm.133.8.1014; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Piepkorn M, 1997, ARCH DERMATOL, V133, P995, DOI 10.1001/archderm.133.8.995; Ross MI, 1996, SEMIN SURG ONCOL, V12, P394, DOI 10.1002/(SICI)1098-2388(199611/12)12:6<394::AID-SSU4>3.0.CO;2-5; WANG XN, 1994, ANN SURG, V220, P768, DOI 10.1097/00000658-199412000-00010	7	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1336	1337		10.1016/S0140-6736(97)22045-3	http://dx.doi.org/10.1016/S0140-6736(97)22045-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365442				2022-12-01	WOS:A1997YE87200002
J	Hoffenberg, R; Lock, M; Tilney, N; Casabona, C; Daar, AS; Guttmann, RD; Kennedy, I; Nundy, S; RadcliffeRichards, J; Sells, RA				Hoffenberg, R; Lock, M; Tilney, N; Casabona, C; Daar, AS; Guttmann, RD; Kennedy, I; Nundy, S; RadcliffeRichards, J; Sells, RA			Should organs from patients in permanent vegetative state be used for transplantation?	LANCET			English	Article									ROYAL LIVERPOOL HOSP, RENAL TRANSPLANT UNIT, INT FORUM TRANSPLANT ETH, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND; DEPT SOCIAL STUDIES MED, MONTREAL, PQ, CANADA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV DEUSTO, CATEDRA DERECHRO & GENOMA HUMANO, BILBAO, SPAIN; SULTAN QABOOS UNIV, COLL MED, DEPT SURG, AL KHOUD, OMAN; ROYAL VICTORIA HOSP, MONTREAL, PQ H3A 1A1, CANADA; ALL INDIA INST MED SCI, DEPT GASTROINTESTINAL SURG, NEW DELHI, INDIA	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Harvard University; Brigham & Women's Hospital; University of Deusto; Sultan Qaboos University; McGill University; Royal Victoria Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi				Nundy, Samiran/0000-0002-1757-3919				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; *BRIT MED ASS ETH, 1992, DISC PAP TREATM PAT; CELESIA, 1993, ANN NEUROL, V33, P386; CRAWFORD R, 1996, BRIT MED J, V313, P5; Dyer C, 1997, BRIT MED J, V314, P996; *HL, 1994, REP SEL COMM MED ETH	8	21	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1320	1321		10.1016/S0140-6736(97)02306-4	http://dx.doi.org/10.1016/S0140-6736(97)02306-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357422				2022-12-01	WOS:A1997YD68900045
J	Farmer, PB				Farmer, PB			Diesel fuel and exhaust emissions: Is there a human carcinogenic risk?	LANCET			English	Editorial Material							CARBON-BLACK; EXPOSURE; ADDUCTS; RATS; DNA				Farmer, PB (corresponding author), UNIV LEICESTER,MRC,TOXICOL UNIT,LEICESTER LE1 9HN,LEICS,ENGLAND.							HEINRICH U, 1995, INHAL TOXICOL, V7, P533, DOI 10.3109/08958379509015211; *INT AG RES CANC, 1989, IARC MON, V46, P41; IPCS (International Programme on Chemical Safety), 1996, ENV HLTH CRIT, V171; LEVY LS, 1995, INDOOR ENVIRON, V4, P254; Nielsen PS, 1996, TOXICOL LETT, V86, P27, DOI 10.1016/0378-4274(96)83963-4; Nielsen PS, 1996, CARCINOGENESIS, V17, P1021, DOI 10.1093/carcin/17.5.1021; NIKULA KJ, 1995, FUND APPL TOXICOL, V25, P80, DOI 10.1006/faat.1995.1042	7	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1118	1118		10.1016/S0140-6736(05)63786-5	http://dx.doi.org/10.1016/S0140-6736(05)63786-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343497				2022-12-01	WOS:A1997YB19900006
J	Lahita, RG				Lahita, RG			Influence of age on Henoch Schonlein purpura	LANCET			English	Editorial Material											Lahita, RG (corresponding author), COLUMBIA UNIV,ST LUKES ROOSEVELT MED CTR,DEPT RHEUMATOL,NEW YORK,NY 10019, USA.							BERTHOUX FC, 1978, NEW ENGL J MED, V298, P1034; Blanco R, 1997, ARTHRITIS RHEUM, V40, P859, DOI 10.1002/art.1780400513; Escudero A, 1996, Allergol Immunopathol (Madr), V24, P22; MERRILL J, 1994, BRIT J RHEUMATOL, V33, P586; MICHEL BA, 1992, J RHEUMATOL, V19, P721; MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114; TancredeBohin E, 1997, ARCH DERMATOL, V133, P438, DOI 10.1001/archderm.133.4.438	7	23	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1116	1117		10.1016/S0140-6736(05)63784-1	http://dx.doi.org/10.1016/S0140-6736(05)63784-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343495	hybrid			2022-12-01	WOS:A1997YB19900004
J	Elliot, JL; Stansberry, JA; Olkin, CB; Agner, MA; Davies, ME				Elliot, JL; Stansberry, JA; Olkin, CB; Agner, MA; Davies, ME			Triton's distorted atmosphere	SCIENCE			English	Article							STELLAR OCCULTATION; MODEL; VOYAGER-2; DYNAMICS; NEPTUNE; 28-SGR; CYCLE	A stellar-occultation light curve for Triton shows asymmetry that can be understood if Triton's middle atmosphere is distorted from spherical symmetry. Although a globally oblate model can explain the data, the inferred atmospheric flattening is so large that it could be caused only by an unrealistic internal mass distribution or highly supersonic zonal winds, Cyclostrophic winds confined to a jet near Triton's northern or southern limbs (or both) could also be responsible for the details of the light curve, but such winds are required to be slightly supersonic. Hazes and clouds in the atmosphere are unlikely to have caused the asymmetry in the fight curve.	MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA; LOWELL OBSERV, FLAGSTAFF, AZ 86001 USA; RAND CORP, SANTA MONICA, CA 90407 USA	Massachusetts Institute of Technology (MIT); RAND Corporation	Elliot, JL (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, BLDG 54-422, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.		Olkin, Catherine/AAF-5160-2019	Olkin, Catherine/0000-0002-5846-716X; Stansberry, John/0000-0003-2434-5225				Bevington P. R., 1969, DATA REDUCTION ERROR; BROADFOOT AL, 1989, SCIENCE, V246, P1459, DOI 10.1126/science.246.4936.1459; DAVIES ME, 1991, J GEOPHYS RES, V96, P15; ELLIOT JL, 1977, ASTROPHYS J, V217, P661, DOI 10.1086/155612; ELLIOT JL, 1992, ASTRON J, V103, P991, DOI 10.1086/116121; ELLIOT JL, 1976, SKY TELESCOPE, V52, P23; HANSEN CJ, 1992, ICARUS, V99, P273, DOI 10.1016/0019-1035(92)90146-X; HILLIER J, 1994, ICARUS, V109, P284, DOI 10.1006/icar.1994.1094; Holton J.R., 2013, INTRO DYNAMIC METEOR; HUBBARD WB, 1988, ASTROPHYS J, V325, P490, DOI 10.1086/166019; HUBBARD WB, 1993, ASTRON ASTROPHYS, V269, P541; INGERSOLL AP, 1990, NATURE, V344, P315, DOI 10.1038/344315a0; IWMSA, COMMUNICATION; KRASNOPOLSKY VA, 1993, J GEOPHYS RES-PLANET, V98, P3065, DOI 10.1029/92JE02680; LELLOUCH E, 1986, NATURE, V324, P227, DOI 10.1038/324227a0; NICHOLSON PD, 1995, ICARUS, V113, P57, DOI 10.1006/icar.1995.1005; OLKIN CB, IN PRESS ICARUS; POLLACK JB, 1990, SCIENCE, V250, P440, DOI 10.1126/science.250.4979.440; SICARDY B, 1990, NATURE, V343, P350, DOI 10.1038/343350a0; SMITH BA, 1989, SCIENCE, V246, P1422, DOI 10.1126/science.246.4936.1422; SODERBLOM LA, 1990, SCIENCE, V250, P410, DOI 10.1126/science.250.4979.410; SPENCER JR, 1992, ICARUS, V99, P261, DOI 10.1016/0019-1035(92)90145-W; STONE EC, 1989, SCIENCE, V246, P1417, DOI 10.1126/science.246.4936.1417; Strobel DF, 1996, ICARUS, V120, P266, DOI 10.1006/icar.1996.0050; Strobel DF, 1995, SPACE SCI S, P1107; YELLE RV, 1991, ICARUS, V89, P347, DOI 10.1016/0019-1035(91)90182-S; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	27	13	13	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					436	439		10.1126/science.278.5337.436	http://dx.doi.org/10.1126/science.278.5337.436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334297				2022-12-01	WOS:A1997YB35500037
J	Murphy, GG; Glanzman, DL				Murphy, GG; Glanzman, DL			Mediation of classical conditioning in Aplysia californica by long-term potentiation of sensorimotor synapses	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; ASPARTATE RECEPTOR ANTAGONIST; SENSORY NEURONS; PRESYNAPTIC FACILITATION; CELLULAR MECHANISM; SYNAPTIC TRANSMISSION; SENSITIZATION; INTERNEURONS; HIPPOCAMPUS; TRANSMITTER	Long-term potentiation (LTP) is considered an important neuronal mechanism of learning and memory. Currently, however, there is no direct experimental link between LTP of an identified synapse and learning. A cellular analog of classical conditioning in Aplysia was used to determine whether this form of invertebrate learning involves N-methyl-D-aspartate (NMDA)-type LTP. The NMDA receptor-antagonist DL-2-amino-5-phosphonovalerate significantly disrupted synaptic enhancement after associative training but did not disrupt synaptic enhancement after nonassociative training. Thus, classical conditioning in Aplysia appears to be mediated, in part, by LTP due to activation of NMDA-related receptors.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INTERDEPT GRAD PROGRAM NEUROSCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029563, R37NS029563] Funding Source: NIH RePORTER; NIMH NIH HHS [F31-MH11136] Funding Source: Medline; NINDS NIH HHS [NS29563] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; BYRNE J, 1974, J NEUROPHYSIOL, V37, P1041, DOI 10.1152/jn.1974.37.5.1041; CAREW TJ, 1984, J NEUROSCI, V4, P1217; CAREW TJ, 1981, J NEUROSCI, V1, P1426; CAREW TJ, 1983, SCIENCE, V219, P397, DOI 10.1126/science.6681571; CASTELLUCCI VF, 1974, P NATL ACAD SCI USA, V71, P5004, DOI 10.1073/pnas.71.12.5004; CLARK GA, 1994, LEARN MEMORY, V1, P243; CLEARY LJ, 1995, LEARN MEMORY, V2, P133, DOI 10.1101/lm.2.3-4.133; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DAVIS S, 1992, J NEUROSCI, V12, P21; ELIOT LS, 1994, J NEUROSCI, V14, P368; FROST WN, 1988, J NEUROBIOL, V19, P297, DOI 10.1002/neu.480190402; FROST WN, 1995, J NEUROPHYSIOL, V73, P2413, DOI 10.1152/jn.1995.73.6.2413; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1995, TRENDS NEUROSCI, V18, P30, DOI 10.1016/0166-2236(95)93947-V; GLANZMAN DL, 1994, J NEUROBIOL, V25, P666, DOI 10.1002/neu.480250608; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HAWKINS RD, 1989, J NEUROSCI, V9, P4236; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P304, DOI 10.1152/jn.1981.45.2.304; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P315, DOI 10.1152/jn.1981.45.2.315; HEBB DO, 1949, ORG BEHAVIOR; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P113, DOI 10.1098/rspb.1994.0016; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P215, DOI 10.1098/rspb.1994.0031; Lin XY, 1997, J NEUROPHYSIOL, V77, P667, DOI 10.1152/jn.1997.77.2.667; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACKEY SL, 1989, J NEUROSCI, V9, P4227; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Murphy G.P., UNPUB; Murphy GG, 1996, P NATL ACAD SCI USA, V93, P9931, DOI 10.1073/pnas.93.18.9931; OCORR KA, 1985, P NATL ACAD SCI USA, V82, P2548, DOI 10.1073/pnas.82.8.2548; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; TRUDEAU LE, 1993, J NEUROPHYSIOL, V70, P1221, DOI 10.1152/jn.1993.70.3.1221; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WALTERS ET, 1983, BRAIN RES, V280, P165, DOI 10.1016/0006-8993(83)91186-1; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	49	109	113	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					467	471		10.1126/science.278.5337.467	http://dx.doi.org/10.1126/science.278.5337.467			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334306				2022-12-01	WOS:A1997YB35500046
J	Fleming, DT; McQuillan, GM; Johnson, RE; Nahmias, AJ; Aral, SO; Lee, FK; StLouis, ME				Fleming, DT; McQuillan, GM; Johnson, RE; Nahmias, AJ; Aral, SO; Lee, FK; StLouis, ME			Herpes simplex virus type 2 in the United States, 1976 TO 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUALLY-TRANSMITTED DISEASES; GENITAL HERPES; RISK-FACTORS; INFECTION; TRANSMISSION; WOMEN; SEROCONVERSION; ANTIBODIES; REACTIVATION; PREVALENCE	Background Herpes simplex virus type 2 (HSV-2) infection is usually transmitted sexually and can cause recurrent, painful genital ulcers. In neonates the infection is potentially lethal. We investigated the seroprevalence and correlates of HSV-2 infection in the United States and identified changes in HSV-2 seroprevalence since the late 1970s. Methods Serum samples and questionnaire data were collected during the National Health and Nutrition Examination Surveys (NHANES) II (1976 to 1980) and III (1988 to 1994). HSV-2 antibody was assessed with an immunodot assay specific for glycoprotein gG-2 of HSV-2. Results From 1988 to 1994, the seroprevalence of HSV-2 in persons 12 years of age or older in the United States was 21.9 percent (95 percent confidence interval, 20.2 to 23.6 percent), corresponding to 45 million infected people in the noninstitutionalized civilian population. The seroprevalence was higher among women (25.6 percent) than men (17.8 percent) and higher among blacks (45.9 percent) than whites (17.6 percent). Less than 10 percent of all those who were seropositive reported a history of genital herpes infection. In a multivariate model, the independent predictors of HSV-2 seropositivity were female sex, black race or Mexican-American ethnic background, older age, less education, poverty, cocaine use, and a greater lifetime number of sexual partners. As compared with the period from 1976 to 1980, the age-adjusted seroprevalence of HSV-2 rose 30 percent (95 percent confidence interval, 15.8 to 45.8 percent). The seroprevalence quintupled among white teenagers and doubled among whites in their twenties. Among blacks and older whites, the increases were smaller. Conclusions Since the late 1970s, the prevalence of HSV-2 infection has increased by 30 percent, and HSV-2 is now detectable in roughly one of five persons 12 years of age or older nationwide. Improvements in the prevention of HSV-2 infection are needed, particularly since genital ulcers may facilitate the transmission of the human immunodeficiency virus. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,NATL CTR HIV STD & TB PREVENT,DIV STD PREVENT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; EMORY UNIV,SCH MED,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Emory University								ANDERSON JE, 1992, SEX TRANSM DIS, V19, P320, DOI 10.1097/00007435-199211000-00004; ARAL SO, 1991, JAMA-J AM MED ASSOC, V266, P2570, DOI 10.1001/jama.266.18.2570; ARAL SO, 1994, CHLAMYDIAL INFECT, P17; Becker TM, 1996, SEX TRANSM DIS, V23, P138, DOI 10.1097/00007435-199603000-00009; Bourne N, 1996, J INFECT DIS, V173, P800, DOI 10.1093/infdis/173.4.800; *BUR CENS, 1991, CURR POP REP SER P, V60; CAMERON DW, 1989, LANCET, V2, P403; Carmack MA, 1996, J INFECT DIS, V174, P899, DOI 10.1093/infdis/174.5.899; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; *CDCP DIV STD PREV, 1996, SEX TRANSM DIS SURV, P30; COLEMAN RM, 1983, J CLIN MICROBIOL, V18, P287, DOI 10.1128/JCM.18.2.287-291.1983; COREY L, 1994, SEX TRANSM DIS, V21, pS38; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; ELANDTJOHNSON RC, 1980, SURVIVAL MODELS DATA, P69; ENG TR, 1997, HIDDEN EPIDEMIC CONF, P1; EZZATI T, 1993, 1992 P SURV RES METH, P339; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; *I MED, 1985, DIS IMP US, V1, P280; *INT WORK GROUP VA, 1996, AIDS, V10; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P87; KASSLER WJ, 1994, AIDS, V8, P351, DOI 10.1097/00002030-199403000-00009; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; KOST K, 1992, FAM PLANN PERSPECT, V24, P244, DOI 10.2307/2135853; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LAUMANN EO, 1994, SOCIAL ORG SEXUALITY, P172; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; MCDOWELL A, 1981, DHHS PUBLICATION; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MOHADJER L, 1996, NATL HLTH NUTR EXAMI, V3; MORAN JS, 1989, PUBLIC HEALTH REP, V104, P560; MOSHER WD, 1990, FAM PLANN PERSPECT, V22, P198, DOI 10.2307/2135493; MOSHER WD, 1991, FAM PLANN PERSPECT, V23, P107; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P667, DOI 10.1056/NEJM197309272891305; NAHMIAS AJ, 1996, GENITAL NEONATAL HER, P93; *NAT CTR HLTH STAT, 1994, DHHS PUBL; OBERLE MW, 1989, AM J TROP MED HYG, V41, P224, DOI 10.4269/ajtmh.1989.41.224; OLEARY A, 1995, WOMEN RISK ISSUES PR, P13; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; PROBER CG, 1992, CLIN INFECT DIS, V15, P1031, DOI 10.1093/clind/15.6.1031; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SEIDMAN SN, 1992, AM J PUBLIC HEALTH, V82, P1297, DOI 10.2105/AJPH.82.9.1297; Shah BV, 1996, SUDAAN USERS MANUAL; SONENSTEIN FL, 1989, FAM PLANN PERSPECT, V21, P152, DOI 10.2307/2135805; Stanberry L. R., 1996, GENITAL NEONATAL HER, P109; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; STRAUS SE, 1996, 36 INT C ANT AG CHEM, P178; TELZAK EE, 1993, ANN INTERN MED, V119, P1181, DOI 10.7326/0003-4819-119-12-199312150-00005; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; WALD A, 1996, 36 INT C ANT AG CHEM; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1993, MMWR-MORBID MORTAL W, V42, P589; 1991, MMWR-MORBID MORTAL W, V39, P929	58	868	907	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1105	1111		10.1056/NEJM199710163371601	http://dx.doi.org/10.1056/NEJM199710163371601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329932				2022-12-01	WOS:A1997YA91200001
J	Yan, SD; Fu, J; Soto, C; Chen, X; Zhu, HJ; AlMohanna, F; Collison, K; Zhu, AP; Stern, E; Saido, T; Tohyama, M; Ogawa, S; Roher, A; Stern, D				Yan, SD; Fu, J; Soto, C; Chen, X; Zhu, HJ; AlMohanna, F; Collison, K; Zhu, AP; Stern, E; Saido, T; Tohyama, M; Ogawa, S; Roher, A; Stern, D			An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease	NATURE			English	Article							PRECURSOR PROTEIN; IN-VITRO; PRESENILIN-1; ACCUMULATION; APOPTOSIS; SECRETION; NEURONS; CELLS; GENERATION; EXPRESSION	Amyloid-beta is a neurotoxic peptide which Is implicated In the pathogenesis of Alzheimer's disease. It binds an intracellular polypeptide known as ERAB, thought to be a hydroxysteroid dehydrogenase enzyme, which Is expressed in normal tissues, but is overexpressed In neurons affected In Alzheimer's disease, ERAB immunoprecipitates with amyloid-beta, and when cell cultures are exposed to amyloid-beta, ERAB inside the cell is rapidly redistributed to the plasma membrane, The toxic effect of amyloid-beta on these cells is prevented by blocking ERAB and is enhanced by overexpression of ERAB. By Interacting with intracellular amyloid-beta, ERAB may therefore contribute to the neuronal dysfunction associated with Alzheimer's disease.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG & PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT CELLULAR BIOPHYS,NEW YORK,NY 10032; NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; KING FAISAL SPECIALIST HOSP & RES CTR,RIYADH 11211,SAUDI ARABIA; OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,SUITA,OSAKA 565,JAPAN; SUN HLTH RES INST,HALDEMAN LAB ALZHEIMERS DIS RES,SUN CITY,AZ 85372	Columbia University; Columbia University; New York University; King Faisal Specialist Hospital & Research Center; Osaka University; Banner Research; Banner Health; Banner Sun Health Research Institute	Yan, SD (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Fu, Jin/A-3510-2012; Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ELKHOURY J, 1996, NATURE, V382, P685; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRACKOWIAK J, 1995, BRAIN RES, V676, P225, DOI 10.1016/0006-8993(94)01465-T; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Roses AD, 1996, NAT MED, V2, P267, DOI 10.1038/nm0396-267; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/S0304-3940(96)12970-0; SCHEMBRI MA, 1995, J BACTERIOL, V177, P4501, DOI 10.1128/jb.177.15.4501-4507.1995; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TIERNARI P, 1997, P NATL ACAD SCI USA, V94, P4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Urmoneit B, 1997, LAB INVEST, V77, P157; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7784; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	48	319	354	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					689	695						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338779				2022-12-01	WOS:A1997YA95900043
J	ShattuckEidens, D; Oliphant, A; McClure, M; McBride, C; Gupte, J; Rubano, T; Pruss, D; Tavtigian, SV; Teng, DHF; Adey, N; Staebell, M; Gumpper, K; Lundstrom, R; Hulick, M; Kelly, M; Holmen, J; Lingenfelter, B; Manley, S; Fujimura, F; Luce, M; Ward, B; CannonAlbright, L; Steele, L; Offit, K; Gilewski, T; Norton, L; Brown, K; Schulz, C; Hampel, H; Schluger, A; Giulotto, E; Zoli, W; Ravaioli, A; Nevanlinna, H; Pyrhonen, S; Rowley, P; Loader, S; Osborne, MP; Daly, M; Tepler, I; Weinstein, PL; Scalia, JL; Michaelson, R; Scott, RJ; Radice, P; Pierotti, MA; Garber, JE; Isaacs, C; Peshkin, B; Lippman, ME; Dosik, MH; Caligo, MA; Greenstein, RM; Pilarski, R; Weber, B; Burgemeister, R; Frank, TS; Skolnick, MH; Thomas, A				ShattuckEidens, D; Oliphant, A; McClure, M; McBride, C; Gupte, J; Rubano, T; Pruss, D; Tavtigian, SV; Teng, DHF; Adey, N; Staebell, M; Gumpper, K; Lundstrom, R; Hulick, M; Kelly, M; Holmen, J; Lingenfelter, B; Manley, S; Fujimura, F; Luce, M; Ward, B; CannonAlbright, L; Steele, L; Offit, K; Gilewski, T; Norton, L; Brown, K; Schulz, C; Hampel, H; Schluger, A; Giulotto, E; Zoli, W; Ravaioli, A; Nevanlinna, H; Pyrhonen, S; Rowley, P; Loader, S; Osborne, MP; Daly, M; Tepler, I; Weinstein, PL; Scalia, JL; Michaelson, R; Scott, RJ; Radice, P; Pierotti, MA; Garber, JE; Isaacs, C; Peshkin, B; Lippman, ME; Dosik, MH; Caligo, MA; Greenstein, RM; Pilarski, R; Weber, B; Burgemeister, R; Frank, TS; Skolnick, MH; Thomas, A			BRCA 1 sequence analysis in women at high risk for susceptibility mutations - Risk factor analysis and implications for genetic testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER FAMILIES; PROTEIN TRUNCATION TEST; OVARIAN-CANCER; STRONG CANDIDATE; POLYMORPHISMS; FREQUENCY	Context.-A mutation in the BRCA1 gene may confer substantial risk for breast and/or ovarian cancer, However, knowledge regarding all possible mutations and the relationship between risk factors and mutations is incomplete. Objectives.-To identify BRCA1 mutations and to determine factors that best predict presence of a deleterious BRCA1 mutation in patients with breast and/or ovarian cancer. Design.-A complete sequence analysis of the BRCA1 coding sequence and flanking intronic regions was performed in 798 women in a collaborative effort involving institutions from the United States, Italy, Germany, Finland, and Switzerland. Participants.-Institutions selected 798 persons representing families (1 person for each family) thought to be at elevated a priori risk of BRCA1 mutation due to potential risk factors, such as multiple cases of breast cancer, early age of breast cancer diagnosis, and cases of ovarian cancer, No participant was from a family in which genetic markers showed linkage to the BRCA1 locus. Major Outcome Measures.-Sequence variants detected in this sample are presented along with analyses designed to determine predictive characteristics of those testing positive for BRCA1 mutations. Results.-In 102 women (12.8%), clearly deleterious mutations were detected. Fifty new genetic alterations were found including 24 deleterious mutations, 24 variants of unknown significance, and 2 rare polymorphisms. In a subset of 71 Ashkenazi Jewish women, only 2 distinct deleterious mutations were found: 185delAG in 17 cases and 5382insC in 7 cases. A bias in prior reports for mutations in exon 11 was revealed, Characteristics of a patient's specific diagnosis (unilateral or bilateral breast cancer, with or without ovarian cancer), early age at diagnosis, Ashkenazi Jewish ethnicity, and family history of cancer were positively associated with the probability of her carrying a deleterious BRCA1 mutation. Conclusions.-Using logistic regression analysis, we provide a method for evaluating the probability of a woman's carrying a deleterious BRCA1 mutation for a wide range of cases, which can be an important tool for clinicians as they incorporate genetic susceptibility testing into their medical practice.	MYRIAD GENET INC, SALT LAKE CITY, UT 84108 USA; MYRIAD GENET LABS INC, SALT LAKE CITY, UT USA; UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY USA; UNIV PAVIA, DEPT GENET & MICROBIOL, I-27100 PAVIA, ITALY; OSPED GB MORGAGNI L PIERANTONE, DEPT MED ONCOL, FORLI, ITALY; IST ONCOL ROMAGNOLO, FORLI, ITALY; OSPED INFERMI RIMINI, DEPT ONCOL, RIMINI, ITALY; UNIV HELSINKI, CENT HOSP, DEPT OBSTET & GYNECOL, FIN-00290 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT ONCOL, HELSINKI, FINLAND; UNIV ROCHESTER, ROCHESTER, NY USA; STRANG CANC PREVENT CTR, NEW YORK, NY USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; BENNETT CANC CTR, STAMFORD, CT USA; CANC CTR ST BARNABAS, LIVINGSTON, NJ USA; KANTONSSPITAL, DEPT FORSCH, CH-4031 BASEL, SWITZERLAND; IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY; DANA FARBER CANC INST, BOSTON, MA 02115 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; N SHORE HEMATOL ONCOL ASSOCIATES PC, SETAUKET, NY USA; IST ANAT PATOL, PISA, ITALY; UNIV CONNECTICUT, HLTH SCI CTR, DIV HUMAN GENET, FARMINGTON, CT USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA	Myriad Genetics, Inc; Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Memorial Sloan Kettering Cancer Center; University of Pavia; Hospital of Rimini; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Rochester; Fox Chase Cancer Center; Kantonsspital Aarau AG (KSA); University of Basel; Fondazione IRCCS Istituto Nazionale Tumori Milan; Harvard University; Dana-Farber Cancer Institute; Georgetown University; University of Connecticut; University of Pennsylvania			Caligo, Adelaide Maria/K-4289-2018; Scott, Rodney J/B-2827-2013; Pilarski, Robert/X-3256-2019; Pilarski, Robert/E-3871-2011; Hampel, Heather/AAV-4041-2020; Radice, Paolo/O-3119-2013	Caligo, Adelaide Maria/0000-0003-0589-1829; Scott, Rodney J/0000-0001-7724-3404; Hampel, Heather/0000-0001-7558-9794; Radice, Paolo/0000-0001-6298-4111; Pierotti, Marco Alessandro/0000-0002-7431-8332; GIULOTTO, ELENA/0000-0002-4705-2049; Thomas, Alun/0000-0001-5650-7044; albright, lisa/0000-0003-2602-3668	NATIONAL CANCER INSTITUTE [R01CA055914] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 1997, CANC FACTS FIG 1997; Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Barker DF, 1996, GENET EPIDEMIOL, V13, P595; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Berman DB, 1996, AM J HUM GENET, V58, P1166; Brown MA, 1996, ONCOGENE, V12, P2507; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; Puget N, 1997, CANCER RES, V57, P828; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Serova O, 1996, AM J HUM GENET, V58, P42; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TAVTIGIAN SV, 1997, GEN MOTORS CANC RES; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	29	312	318	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1242	1250		10.1001/jama.278.15.1242	http://dx.doi.org/10.1001/jama.278.15.1242			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333265				2022-12-01	WOS:A1997XZ70900029
J	Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI				Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI			Preserved acute pain and reduced neuropathic pain in mice lacking PKC gamma	SCIENCE			English	Article							PROTEIN-KINASE-C; RAT SPINAL-CORD; SENSORY NEURONS; DORSAL HORN; MUTANT MICE; NERVE INJURY; SUBSTANTIA GELATINOSA; JOINT INFLAMMATION; PERSISTENT PAIN; INCREASES	In normal animals, peripheral nerve injury produces a persistent, neuropathic pain state in which pain is exaggerated and can be produced by nonpainful stimuli. Here, mice that lack protein kinase C gamma (PKC gamma) displayed normal responses to acute pain stimuli, but they almost completely failed to develop a neuropathic pain syndrome after partial sciatic nerve section, and the neurochemical changes that occurred in the spinal cord after nerve injury were blunted. Also, PKC gamma was shown to be restricted to a small subset of dorsal horn neurons, thus identifying a potential biochemical target for the prevention and therapy of persistent pain.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 92143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 92143 USA; MIT, CTR CANC RES, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Malmberg, AB (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 92143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS021445, P50NS021445, R01NS014627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008377] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08377] Funding Source: Medline; NINDS NIH HHS [NS 14627, NS 21445] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BENNETT GJ, 1980, J COMP NEUROL, V194, P809, DOI 10.1002/cne.901940407; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CODERRE TJ, 1992, NEUROSCI LETT, V140, P181, DOI 10.1016/0304-3940(92)90097-Q; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CODERRE TJ, 1989, J NEUROPHYSIOL, V62, P48, DOI 10.1152/jn.1989.62.1.48; Dubner R, 1994, TXB PAIN, P225; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNT SP, 1992, SENSORY NEURONS DIVE, P60; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; KNYIHARCSILLIK E, 1981, PROG HISTOCHEM CYTOC, V14, P1; LANGFORD LA, 1979, J COMP NEUROL, V184, P193, DOI 10.1002/cne.901840111; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; Lin Q, 1996, J NEUROSCI, V16, P3026; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; Malmberg AB, 1997, J NEUROSCI, V17, P7462; MAO J, 1993, J NEUROPHYSIOL, V70, P470, DOI 10.1152/jn.1993.70.2.470; MAO JR, 1995, NEUROSCI LETT, V198, P75, DOI 10.1016/0304-3940(95)11975-3; MAO JR, 1992, BRAIN RES, V588, P144, DOI 10.1016/0006-8993(92)91354-H; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; NAHIN RL, 1994, PAIN, V58, P95, DOI 10.1016/0304-3959(94)90189-9; PALECEK J, 1994, J NEUROPHYSIOL, V71, P529, DOI 10.1152/jn.1994.71.2.529; REES H, 1995, J PHYSIOL-LONDON, V484, P437, DOI 10.1113/jphysiol.1995.sp020676; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; SLUKA KA, 1993, NEUROREPORT, V5, P109, DOI 10.1097/00001756-199311180-00003; SLUKA KA, 1993, PAIN, V55, P217, DOI 10.1016/0304-3959(93)90150-N; WAKISAKA S, 1991, NEUROSCI LETT, V124, P200, DOI 10.1016/0304-3940(91)90093-9; WOOLF CJ, 1983, J COMP NEUROL, V221, P313, DOI 10.1002/cne.902210307	39	529	564	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					279	283		10.1126/science.278.5336.279	http://dx.doi.org/10.1126/science.278.5336.279			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323205				2022-12-01	WOS:A1997YA56400042
J	Imamura, T; Takase, M; Nishihara, A; Oeda, E; Hanai, J; Kawabata, M; Miyazono, K				Imamura, T; Takase, M; Nishihara, A; Oeda, E; Hanai, J; Kawabata, M; Miyazono, K			Smad6 inhibits signalling by the TGF-beta superfamily	NATURE			English	Article							MAD-RELATED PROTEIN; SIGNALING PATHWAYS; RECEPTORS	SMBD proteins(1) have been identified as signalling mediators of the TGF-beta superfamily, which is involved in a range of biological activities including cell growth, morphogenesis, development and immune responses(2,3). Smad1, Smad2, Smad3 and Smad5 are ligand-specific Smad1 and Smad5 transduce signals from bone morphogenetic proteins(4-7), and Smad2 and Smad3 mediate signalling by TGF-beta and activin(8,9), whereas Smad4 acts as a common signalling component(10). For example, Smad2 is phosphorylated by the TGF-beta type I receptor upon ligand binding, forms a heteromer with Smad4 and then translocates into the nucleus where it activates transcription(10,11). Here we report the isolation of Smad6 in the mouse. Smad6 is quite different in structure from the other SMAD proteins, and forms stable associations with type I receptors. Smad6 interferes with the phosphorylation of Smad2 and the subsequent heteromerization with Smad4, but does not inhibit the activity of Smad3, Smad6 also inhibits the phosphorylation of Smad1 that is induced by the bone morphogenetic protein type IB receptor. These data indicate that signals of the TGF-beta superfamily are regulated both positively and negatively by members of the SMAD family.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; JAPAN SOC PROMOT SCI,RES FUTURE PROGRAM,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science								Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NAKAO A, IN PRESS EMBO J; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	16	839	884	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					622	626		10.1038/39355	http://dx.doi.org/10.1038/39355			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335505				2022-12-01	WOS:A1997YA00800065
J	Monaghan, AP; Bock, D; Gass, P; Schwager, A; Wolfer, DP; Lipp, HP; Schutz, G				Monaghan, AP; Bock, D; Gass, P; Schwager, A; Wolfer, DP; Lipp, HP; Schutz, G			Defective limbic system in mice lacking the tailless gene	NATURE			English	Article							RECEPTOR SUPERFAMILY; DROSOPHILA; MOUSE; HIPPOCAMPUS; RAT	The gene tailless is a member of the superfamily of genes that encode transcription factors of the ligand-activated nuclear receptor type, and is expressed in the invertebrate and vertebrate brain(1-4). In mice, its transcripts are restricted to the periventricular zone of the forebrain(4), the site of origin of neurons and glia. Here we use homologous recombination to generate mice that lack a functional tailless protein. Homozygous mutant mice are viable at birth, indicating that tailless is not required for prenatal survival; however, adult mutant mice show a reduction in the size of rhinencephalic and limbic structures, including the olfactory, infrarhinal and entorhinal cortex, amygdala and dentate gyrus. Both male and female mice are more aggressive than usual and females lack normal maternal instincts. These animals therefore enable a molecular approach to be taken towards understanding the genetic architecture and morphogenesis of the forebrain.	GERMAN CANC RES CTR,DIV MOL BIOL CELL 1,D-69120 HEIDELBERG,GERMANY; UNIV ZURICH IRCHEL,INST ANAT,CH-8057 ZURICH,SWITZERLAND	Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich			Wolfer, David P/B-3293-2016	Wolfer, David P/0000-0002-5957-1401				ALBERT DJ, 1984, NEUROSCI BIOBEHAV R, V8, P5, DOI 10.1016/0149-7634(84)90017-4; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; EDWARDS DA, 1993, PHYSIOL BEHAV, V53, P611, DOI 10.1016/0031-9384(93)90162-9; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GILAD GM, 1979, BRAIN RES, V160, P17, DOI 10.1016/0006-8993(79)90597-3; GOODLETT CR, 1982, PHYSIOL BEHAV, V28, P1077, DOI 10.1016/0031-9384(82)90178-0; Gray J., 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Kandel E. R., 1995, ESSENTIALS NEURAL SC; Keefe J. O., 1978, HIPPOCAMPUS COGNITIV; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; YU RT, 1994, NATURE, V370, P375, DOI 10.1038/370375a0	20	150	157	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					515	517		10.1038/37364	http://dx.doi.org/10.1038/37364			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394001				2022-12-01	WOS:A1997YJ86500053
J	vandenBerg, C; Willemsen, V; Hendriks, G; Weisbeek, P; Scheres, B				vandenBerg, C; Willemsen, V; Hendriks, G; Weisbeek, P; Scheres, B			Short-range control of cell differentiation in the Arabidopsis root meristem	NATURE			English	Article							SHOOT; REGULATOR; CLAVATA1; GENES; FATE	Meristems are distinctive regions of plants that have capacity for continuous growth. Their developmental activity generates the majority of plant organs(1). It is currently unknown how cell division and cell differentiation are orchestrated in meristems, although genetic studies have demonstrated the relevance of a proper balance between the two processes(2-6), Root meristems contain a distinct central region of mitotically inactive cells, the quiescent centre(7), the function of which has remained elusive until now. Here we present laser ablation and genetic data that show that in Arabidopsis thalinna the quiescent centre inhibits differentiation of surrounding cells. Differentiation regulation occurs within the range of a single cell, in a manner strikingly similar to examples in animal development, such as during delamination of Drosophila neuroblasts(8). Our data indicate that pattern formation in the root meristem is controlled by a balance between short-range signals inhibiting differentiation and signals that reinforce cell fate decisions(9).	UNIV UTRECHT,DEPT MOL CELL BIOL,NL-3584 CH UTRECHT,NETHERLANDS	Utrecht University			Hendriks, Giel/A-9731-2010	Scheres, Ben/0000-0001-5400-9578				BARLOW P, 1974, NEW PHYTOL, V73, P937, DOI 10.1111/j.1469-8137.1974.tb01323.x; CHENG JC, 1995, PLANT PHYSIOL, V107, P365, DOI 10.1104/pp.107.2.365; CLARK SE, 1993, DEVELOPMENT, V119, P397; Clark SE, 1996, DEVELOPMENT, V122, P1567; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; CLOWES F. A. L., 1956, NEW PHYTOL, V55, P29, DOI 10.1111/j.1469-8137.1956.tb05264.x; Endrizzi K, 1996, PLANT J, V10, P967, DOI 10.1046/j.1365-313X.1996.10060967.x; FELDMAN LJ, 1975, CAN J BOT, V53, P2796, DOI 10.1139/b75-307; HEJNOWICZ Z, 1991, PLANTA, V184, P1, DOI 10.1007/BF00208228; JACKSON D, 1994, DEVELOPMENT, V120, P405; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Scheres B, 1996, PLANT SOIL, V187, P97, DOI 10.1007/BF00011661; SCHERES B, 1994, DEVELOPMENT, V120, P2475; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0	18	497	515	4	80	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					287	289		10.1038/36856	http://dx.doi.org/10.1038/36856			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384380	Green Submitted			2022-12-01	WOS:A1997YG66700063
J	Izurieta, HS; Strebel, PM; Blake, PA				Izurieta, HS; Strebel, PM; Blake, PA			Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTHY-CHILDREN; FOLLOW-UP; CHICKENPOX; CORTICOSTEROIDS; INFECTIONS; EFFICACY; TRIALS	Context.-Because lyophilized varicella vaccine must be stored frozen at -15 degrees C or less (less than or equal to 5 degrees F) and administered within 30 minutes after reconstitution, the potential exists for decreased vaccine effectiveness when the vaccine is used under field conditions. Objectives.-To describe an outbreak of varicella in a child care center and to determine postlicensure effectiveness of varicella vaccine. Design.-Retrospective cohort study. Setting.-A child care center in DeKalb County, Georgia, in 1996. Participants.-Of the 184 children registered in the child care center, 148 were eligible for the study based on absence of history of varicella before January 1, 1996. Main Outcome Measures.-Data on disease status, severity and impact of disease, and risk factors for varicella and for vaccine failure were obtained from parents and their children's pediatricians, Varicella vaccine effectiveness was calculated among children aged 12 months or older (eligible for vaccination) using the cohort method. Results.-The outbreak started on January 17, 1996, and lasted 15 weeks. Of the 148 eligible children, 81 (55%) developed varicella, Cases among children younger than 12 months (n=7) were more severe than cases among older children, Varicella occurred in 9 (14%) of 66 vaccinated children and 72 (88%) of 82 unvaccinated children. Varicella was less severe and resulted in fewer days of absence from the child care center among vaccinated compared with unvaccinated cases. Varicella vaccine effectiveness against all forms of disease was 86% (95% confidence interval [CI], 73%-92%), and against moderate-to-severe varicella disease it was 100% (95% CI, 96%-100%). Vaccinated children with asthma or other reactive airway diseases were 7.1 times more likely to have varicella than were vaccinated children without reactive airway diseases (95% CI, 2.4-21.3). Conclusions.-Varicella vaccine administered under routine conditions in physicians' offices was highly effective in preventing varicella in an outbreak characterized by intense exposure. The role of asthma and other reactive airway diseases as risk factors for varicella disease and vaccine failure deserves to be investigated further.	GEORGIA DEPT HUMAN RESOURCES,DIV PUBL HLTH,ATLANTA,GA									[Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], 1994, WORD PROCESSING DATA; ARBETER AM, 1984, AM J DIS CHILD, V138, P434, DOI 10.1001/archpedi.1984.02140430012004; ASANO Y, 1994, PEDIATRICS, V94, P524; ASANO Y, 1982, BIKEN J, V25, P43; AZBUG MJ, 1993, J PEDIATR, V123, P577; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P912, DOI 10.1111/j.1365-2222.1995.tb00391.x; BRUNELL PA, 1988, PEDIATRICS, V81, P779; CHOONG K, 1995, PEDIATR INFECT DIS J, V14, P809; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; DELCLAUX B, 1992, PRESSE MED, V21, P1432; FINGER R, 1994, PUBLIC HEALTH REP, V109, P750; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; GERSHON A, 1991, REV INFECT DIS S11, V13, P5957; IPSEN J, 1984, SCAND J SOC MED, V12, P121, DOI 10.1177/140349488401200305; JONES SEE, 1995, PEDIATR INFECT DIS J, V14, P404; JUST M, 1985, POSTGRAD MED J, V61, P129; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; KUTTER B, 1991, VACCINE, V9, P643; Lee E.T., 1992, STATISTICAL METHODS; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; PREBLUD SR, 1981, PEDIATRICS, V68, P14; REMINGTON RD, 1985, STATISTICS APPLICATI, P187; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; TINKELMAN DG, 1992, PEDIATRICS, V90, P479; WELCH MJ, 1994, J ASTHMA, V31, P43, DOI 10.3109/02770909409056768; Wharton M, 1996, INFECT DIS CLIN N AM, V10, P571, DOI 10.1016/S0891-5520(05)70313-5; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; WHITE CJ, 1991, PEDIATRICS, V87, P604	31	117	122	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1495	1499						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363968				2022-12-01	WOS:A1997YE44500032
J	Wald, NJ; Law, MR; Morris, JK; Bagnall, AM				Wald, NJ; Law, MR; Morris, JK; Bagnall, AM			Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; MYOCARDIAL-INFARCTION; SEROPOSITIVITY; ASSOCIATION; CANCER	Objective-To determine whether there is an independent association between Hel Design-Prospective study with measurement of IgG antibody titres specific to H pylori on stored serum samples from 648 men who died from ischaemic heart disease and 1296 age matched controls who did not (nested case-control design). Subjects-21 520 professional men aged 35-64 who attended the British United Provident Association (BUPA) medical centre in London between 1975 and 1982 for routine medical examination. Main outcome measure-Death from ischaemic heart disease. Results-The odds of death from ischaemic heart disease in men with H pylori infection relative to that in men without infection was 1.06 (95% confidence interval 0.86 to 1.31), In a separate group of 206 people attending the centre, plasma fibrinogen was virtually the same in those who were positive for H pylori (2.62 g/l) and those who were negative (2.64 g/l). Conclusions-A study that by its size and design minimised both random error and socioeconomic bias found no relation between H pylori infection and ischaemic heart disease. The validity of the study was shown by its confirmation of the recognised association between H pylori infection and stomach cancer (odds ratio 4.0 (1.9 to 8.2); P < 0.001). Eradication of H pylori infection may greatly reduce the incidence of stomach cancer, one of the most common causes of death from cancer worldwide, but it cannot be expected to have any effect in preventing ischaemic heart disease.	ROYAL LONDON SCH MED & DENT, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London	Wald, NJ (corresponding author), ST BARTHOLOMEWS, BUPA EPIDEMIOL RES GRP, DEPT ENVIRONM & PREVENT MED, WOLFSON INST PREVENT MED, LONDON, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				Aceti A, 1996, BRIT MED J, V313, P428; AROMAA A, 1996, GUT S2, V3, pA91; Balaban DH, 1996, GASTROENTEROLOGY, V110, pA55; Caselli M., 1996, Gut, V39, pA91; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; Gerning N. Ossei, 1996, Gut, V39, pA91; Lip GYH, 1996, BRIT MED J, V312, P250; MALNICK SDH, 1996, GUT, V39, pA63; MARTINDEARGILA C, 1995, LANCET, V346, P310, DOI 10.1016/S0140-6736(95)92195-8; MCDONAGH TA, 1996, GUT               S1, V38, pA1; MENDALL MA, 1994, BRIT HEART J, V71, P437; MORGANDO A, 1995, LANCET, V345, P1380; MURRAY LJ, 1995, BRIT HEART J, V74, P497; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; Parente F, 1997, BRIT MED J, V314, P1318, DOI 10.1136/bmj.314.7090.1318; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Ponzetto A, 1996, BRIT MED J, V312, P251; Rathbone B, 1996, HEART, V76, P308, DOI 10.1136/hrt.76.4.308; Strandberg T. E., 1996, Gut, V39, pA92; Strandberg TE, 1997, BRIT MED J, V314, P1317, DOI 10.1136/bmj.314.7090.1317; Vakil N., 1996, Gut, V39, pA91; WALD N, 1980, LANCET, V2, P813; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	27	127	134	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	1997	315	7117					1199	1201		10.1136/bmj.315.7117.1199	http://dx.doi.org/10.1136/bmj.315.7117.1199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393222	Green Published			2022-12-01	WOS:A1997YF25200019
J	Nguyen, MT; Camenisch, T; Snouwaert, JN; Hicks, E; Coffman, TM; Anderson, PAW; Malouf, MN; Koller, BH				Nguyen, MT; Camenisch, T; Snouwaert, JN; Hicks, E; Coffman, TM; Anderson, PAW; Malouf, MN; Koller, BH			The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth	NATURE			English	Article							PATENT DUCTUS-ARTERIOSUS; PROSTANOID RECEPTORS; CLOSURE; INDOMETHACIN; CLONING; SUBTYPE; RATS	Survival of newborn placental mammals depends on closure of the ductus arteriosus (DA), an arterial connection in the fetus which directs blood away from the pulmonary circulation and towards the placenta where oxygenation occurs(1). Here we show that morphological changes resulting in closure of the DA in mice are virtually identical to those observed in larger mammals, including humans(2), and that maintenance of the DA in the open, or patent, stare in fetal mice is dependent on prostaglandin synthesis, This requirement is absent in mice lacking the prostaglandin E-2 EP4 receptor (EP4(-/-) mice). In EP4(-/-) mice of the 129 strain, remodelling of the DA fails to occur after birth, resulting in a left-to-right shunt of blood and subseqently in death. This suggests that the neonatal drop in prostaglandin E-2 (refs 3-7) that triggers ductal closure is sensed through the EP4 receptor, In contrast, 5% of EP4(-/-) mice of mixed genetic background survive, and selective breeding of these mice leads to a 21% survival rate, suggesting that alleles at other loci can provide an alternative mechanism for ductal closure.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; DUKE UNIV,DEPT MED,DURHAM,NC 27710; DURHAM VET AFFAIRS MED CTR,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV PEDIAT CARDIOL,DURHAM,NC 27710; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; University of North Carolina; University of North Carolina Chapel Hill				Camenisch, Todd/0000-0002-7797-9822				CHALLIS JRG, 1976, PROSTAGLANDINS, V11, P1041, DOI 10.1016/0090-6980(76)90011-3; CHRISTIANSEN NC, 1975, LANCET, V2, P24; CLYMAN RI, 1987, SEMIN PERINATOL, V11, P64; CLYMAN RI, 1980, J PEDIATR-US, V97, P455, DOI 10.1016/S0022-3476(80)80205-8; CLYMAN RI, 1980, PROSTAGLANDINS, V15, P325; COCEANI F, 1980, SEMIN PERINATOL, V4, P109; COCEANI F, 1994, BIOCHEM PHARMACOL, V48, P1315, DOI 10.1016/0006-2952(94)90552-5; COCEANI F, 1973, CAN J PHYSIOL PHARM, V51, P220, DOI 10.1139/y73-031; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; ELLIOTT RB, 1975, LANCET, V1, P140; ENGELHARDT JF, 1992, J CLIN INVEST, V90, P2598, DOI 10.1172/JCI116155; FRIEDMAN WF, 1976, NEW ENGL J MED, V295, P526, DOI 10.1056/NEJM197609022951003; GERSONY WM, 1986, PEDIATR CLIN N AM, V33, P545; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; HEYMANN MA, 1976, NEW ENGL J MED, V295, P530, DOI 10.1056/NEJM197609022951004; HEYMANN MA, 1975, PHYSIOL REV, V55, P62, DOI 10.1152/physrev.1975.55.1.62; HONDA A, 1993, J BIOL CHEM, V268, P7759; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Jager BV, 1942, AM J PATHOL, V18, P595; JARKOVSKA D, 1992, PHYSIOL RES, V41, P323; MITCHELL MD, 1980, J REPROD FERTIL, V58, P283, DOI 10.1530/jrf.0.0580283; MOHN A, 1995, DNA CLONING, V4, P143; MOISE KJ, 1988, NEW ENGL J MED, V319, P327, DOI 10.1056/NEJM198808113190602; MOMMA K, 1987, PEDIATR RES, V22, P567, DOI 10.1203/00006450-198711000-00018; OLLEY PM, 1976, CIRCULATION, V53, P728, DOI 10.1161/01.CIR.53.4.728; PATTERSON DF, 1979, PEDIATR CARDIOL, V2, P45; PIPER PJ, 1970, NATURE, V225, P600, DOI 10.1038/225600a0; REGAN JW, 1994, MOL PHARMACOL, V46, P213; SHARPE GL, 1975, PROSTAGLANDINS, V9, P585, DOI 10.1016/0090-6980(75)90064-7; SMITH GCS, 1994, J PHARMACOL EXP THER, V271, P390	30	272	279	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					78	81		10.1038/36342	http://dx.doi.org/10.1038/36342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363893				2022-12-01	WOS:A1997YE47700055
J	Huang, ZP; Hankinson, SE; Colditz, GA; Stampfer, MJ; Hunter, DJ; Manson, JE; Hennekens, CH; Rosner, B; Speizer, FE; Willett, WC				Huang, ZP; Hankinson, SE; Colditz, GA; Stampfer, MJ; Hunter, DJ; Manson, JE; Hennekens, CH; Rosner, B; Speizer, FE; Willett, WC			Dual effects of weight and weight gain on breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; POSTMENOPAUSAL WOMEN; RELATIVE WEIGHT; HORMONE LEVELS; HEIGHT; SIZE; ASSOCIATION; ESTROGENS; SURVIVAL; LIFE	Context.-Breast cancer is a major cause of mortality among women. It is important to identify modifiable risk factors for this disease. Objective.-To examine body mass index (BMI) at the age of 18 years and at midlife and adult weight change in relation to breast cancer incidence and mortality. Design.-Cohort study. Setting.-A cohort of 95 256 US female nurses aged 30 to 55 years who were followed up for 16 years. Main Outcome Measure.-Incident and fatal breast cancer. Results.-During 1 203 498 person-years, 2517 incident breast cancers (60% postmenopausal) were documented. Higher current BMI was associated with lower breast cancer incidence before menopause and was minimally associated with incidence after menopause. However, a stronger positive relationship was seen among postmenopausal women who never used hormone replacement (relative risk=1.59 for BMI >31 kg/m(2) vs less than or equal to 20 kg/m(2); 95% confidence interval, 1.09-2.32; P for trend <.001). Higher BMI at the age of 18 years was associated with lower breast cancer incidence both before and after menopause. Weight gain after the age of 18 years was unrelated to breast cancer incidence before menopause, but was positively associated with incidence after menopause. This increased risk with weight gain was limited to women who never used postmenopausal hormones; among these women, the relative risk was 1.99 (95% confidence interval, 1.43-2.76) for weight gain of more than 20 kg vs unchanged weight (P for trend <.001). Current BMI and weight gain were even more strongly associated with fatal postmenopausal breast cancer. In this population, the percentage of postmenopausal breast cancer accounted for by weight gain alone was approximately 16% and by hormone replacement therapy alone was 5%, but when the interaction between these variables was considered, together they accounted for about one third of postmenopausal breast cancers. Conclusions.-Avoiding adult weight gain may contribute importantly to the prevention of breast cancer after menopause, particularly among women who do not use postmenopausal hormones.	HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, CAMBRIDGE, MA 02138 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [5-R25-CA57711-04, CA40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA057711, R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARDBARBASH R, 1990, CANCER RES, V50, P2152; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BARNESJOSIAH D, 1995, CANCER CAUSE CONTROL, V6, P112, DOI 10.1007/BF00052771; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; DANIELL HW, 1993, BREAST CANCER RES TR, V25, P193, DOI 10.1007/BF00689833; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KUMAR NB, 1995, CANCER-AM CANCER SOC, V76, P243, DOI 10.1002/1097-0142(19950715)76:2<243::AID-CNCR2820760214>3.0.CO;2-R; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; Lipworth L, 1996, EPIDEMIOLOGY, V7, P96, DOI 10.1097/00001648-199601000-00017; LONDON SJ, 1989, JAMA-J AM MED ASSOC, V262, P2853; NEGRI E, 1988, AM J EPIDEMIOL, V128, P1207, DOI 10.1093/oxfordjournals.aje.a115075; NEWCOMB PA, 1995, EPIDEMIOLOGY, V6, P318, DOI 10.1097/00001648-199505000-00022; PATHAK DR, 1992, AM J EPIDEMIOL, V135, P153, DOI 10.1093/oxfordjournals.aje.a116268; Potischman N, 1996, JNCI-J NATL CANCER I, V88, P756, DOI 10.1093/jnci/88.11.756; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SENIE RT, 1992, ANN INTERN MED, V116, P26, DOI 10.7326/0003-4819-116-1-26; TORNBERG SA, 1994, BRIT J CANCER, V69, P358, DOI 10.1038/bjc.1994.65; TRETLI S, 1990, BRIT J CANCER, V62, P299, DOI 10.1038/bjc.1990.282; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; URSIN G, 1995, EPIDEMIOLOGY, V6, P137, DOI 10.1097/00001648-199503000-00009; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P731, DOI 10.1093/oxfordjournals.aje.a114156; Ziegler RG, 1996, J NATL CANCER I, V88, P650, DOI 10.1093/jnci/88.10.650	27	592	598	1	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1407	1411		10.1001/jama.278.17.1407	http://dx.doi.org/10.1001/jama.278.17.1407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355998				2022-12-01	WOS:A1997YC91700026
J	Horton, R				Horton, R			The omnipresent still syndrome	LANCET			English	Article																		GALBRAITH JK, 1994, NEW ENGL J MED, V331, P484; Glasgow-McDowell M A, 1996, N C Med J, V57, P401; SINGER PN, 1997, SELECTED WORKS, P235; Walker A., 1997, AGEING EUROPE; WILLIAMS A, 1997, BMJ-BRIT MED J, V314, P8	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1156	1156		10.1016/S0140-6736(05)63816-0	http://dx.doi.org/10.1016/S0140-6736(05)63816-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343514				2022-12-01	WOS:A1997YB19900042
J	Lye, M				Lye, M			Access to advances in cardiology	LANCET			English	Article							MYOCARDIAL-INFARCTION; DRUG-THERAPY				Lye, M (corresponding author), UNIV LIVERPOOL,UNIV CLIN DEPT,DUNCAN BLDG,LIVERPOOL L69 3GA,MERSEYSIDE,ENGLAND.							Abrahamsson P, 1996, CARDIOL ELDER, V4, P89; ADAMS JN, 1995, BRIT HEART J, V73, P87; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P525; *EUR SEC PREV STUD, 1996, LANCET, V347, P1203; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; Fishkind D, 1997, J AM GERIATR SOC, V45, P809, DOI 10.1111/j.1532-5415.1997.tb01506.x; Gottlieb S, 1997, CIRCULATION, V95, P342; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Krumholz HM, 1997, AM J CARDIOL, V79, P581, DOI 10.1016/S0002-9149(96)00819-3; LYE M, IN PRESS TXB GERIATR; Newman J, 1997, ARCH INTERN MED, V157, P1103; *NHS EX, 1997, EL9741 DEP HLTH NHS; OKEEFFE ST, 1996, HEART FAILURE CLIN P, P47; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Playford DA, 1997, DRUG AGING, V10, P444, DOI 10.2165/00002512-199710060-00005; Ramanathan K, 1996, DRUG AGING, V8, P237, DOI 10.2165/00002512-199608040-00002; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; *TASK FORC WORK GR, 1997, EUR HEART J, V18, P736	20	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1162	1163		10.1016/S0140-6736(97)08414-6	http://dx.doi.org/10.1016/S0140-6736(97)08414-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343518				2022-12-01	WOS:A1997YB19900046
J	Crane, BR; Arvai, AS; Gachhui, R; Wu, CQ; Ghosh, DK; Getzoff, ED; Stuehr, DJ; Tainer, JA				Crane, BR; Arvai, AS; Gachhui, R; Wu, CQ; Ghosh, DK; Getzoff, ED; Stuehr, DJ; Tainer, JA			The structure of nitric oxide synthase oxygenase domain and inhibitor complexes	SCIENCE			English	Article							CYTOCHROME-C PEROXIDASE; L-ARGININE; NO SYNTHASE; PROTEIN; SITE; COORDINATION; REPLACEMENT; REFINEMENT; CATALYSIS; ERRORS	The nitric oxide synthase oxygenase domain (NOSox) oxidizes arginine to synthesize the cellular signal and defensive cytotoxin nitric oxide (NO). Crystal structures determined for cytokine-inducible NOSox reveal an unusual fold and heme environment for stabilization of activated oxygen intermediates key for catalysis. A winged beta sheet engenders a curved alpha-beta domain resembling a baseball catcher's mitt with heme clasped in the palm. The location of exposed hydrophobic residues and the results of mutational analysis place the dimer interface adjacent to the heme-binding pocket. Juxtaposed hydrophobic O-2- and polar L-arginine-binding sites occupied by imidazole and aminoguanidine, respectively, provide a template for designing dual-function inhibitors and imply substrate-assisted catalysis.	CLEVELAND CLIN, DEPT IMMUNOL, CLEVELAND, OH 44106 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute; Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL58883] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRITTAIN T, 1992, EUR J BIOCHEM, V209, P793, DOI 10.1111/j.1432-1033.1992.tb17350.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CRANE BR, UNPUB; FUREY W, 1990, AM CRYST ASS M AB PA, V33, P18; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; GHOSH D, UNPUB; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIBBS MR, 1990, J MOL BIOL, V213, P167; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mansuy Daniel, 1995, P537; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Mueller Ernest J., 1995, P83; MURSHUDOV G, 1994, ACTA CRYSTALLOGR D, V50, P760; MURSHUDOV G, 1996, P DAR STUD WEEK, P157; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poulos Thomas L., 1995, P125; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; STUEHR D, 1997, ANN REV PHARM TOXICO, V18, P707; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	52	318	326	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					425	431		10.1126/science.278.5337.425	http://dx.doi.org/10.1126/science.278.5337.425			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334294				2022-12-01	WOS:A1997YB35500034
J	Mizutani, Y; Kitagawa, T				Mizutani, Y; Kitagawa, T			Direct observation of cooling of heme upon photodissociation of carbonmonoxy myoglobin	SCIENCE			English	Article							RESOLVED RESONANCE-RAMAN; SPERM WHALE MYOGLOBIN; RELAXATION; DYNAMICS; SPECTROSCOPY; STILBENE; ENERGY; LASER; HEMOGLOBIN; PROTEINS	The formation of vibrationally excited heme upon photodissociation of carbonmonoxy myoglobin and its subsequent vibrational energy relaxation was monitored by picosecond anti-Stokes resonance Raman spectroscopy. The anti-Stokes intensity of the nu(4) band showed immediate generation of vibrationally excited hemes and biphasic decay of the excited populations. The best fit to double exponentials gave time constants of 1.9 +/- 0.6 and 16 +/- 9 picoseconds for vibrational population decay and 3.0 +/- 1.0 and 25 +/- 14 picoseconds for temperature relaxation of the photolyzed heme when a Boltzmann distribution was assumed. The decay of the nu(4) anti-Stokes intensity was accompanied by narrowing and frequency upshift of the Stokes counterpart. This direct monitoring of the cooling dynamics of the heme cofactor within the globin matrix allows the characterization of the vibrational energy flow through the protein moiety and to the water bath.	OKAZAKI NATL RES INST,INST MOL SCI,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB)			Mizutani, Yasuhisa/B-3809-2009					ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BAKKER HJ, 1990, NATURE, V347, P745, DOI 10.1038/347745a0; ELSAESSER T, 1991, ANNU REV PHYS CHEM, V42, P83; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GREENE BI, 1978, P NATL ACAD SCI USA, V75, P5255, DOI 10.1073/pnas.75.11.5255; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; KEYES MH, 1971, J AM CHEM SOC, V93, P2035; Kruglik SG, 1997, CHEM PHYS LETT, V266, P283, DOI 10.1016/S0009-2614(97)00008-0; LI M, 1993, J CHEM PHYS, V98, P5499, DOI 10.1063/1.464899; LI P, 1994, BIOPHYS J, V66, P430, DOI 10.1016/S0006-3495(94)80793-3; LIAN TQ, 1994, J PHYS CHEM-US, V98, P11648, DOI 10.1021/j100096a005; Lim MH, 1996, J PHYS CHEM-US, V100, P12043, DOI 10.1021/jp9536458; LINGLE R, 1991, J PHYS CHEM-US, V95, P9320, DOI 10.1021/j100176a053; MARTIN JL, 1983, P NATL ACAD SCI-BIOL, V80, P173, DOI 10.1073/pnas.80.1.173; MATOUSEK P, 1995, CHEM PHYS LETT, V237, P373, DOI 10.1016/0009-2614(95)00324-W; Nakabayashi T, 1997, J PHYS CHEM A, V101, P3494, DOI 10.1021/jp963303h; PETRICH JW, 1987, BIOCHEMISTRY-US, V26, P7914, DOI 10.1021/bi00398a056; PHILLIPS DL, 1993, CHEM PHYS, V175, P1, DOI 10.1016/0301-0104(93)80224-W; RAFTERY D, 1994, J CHEM PHYS, V101, P8572, DOI 10.1063/1.468052; SATO S, 1994, APPL PHYS B-LASERS O, V59, P415, DOI 10.1007/BF01081064; SCHOMACKER KT, 1984, J CHEM PHYS, V80, P4701, DOI 10.1063/1.446535; Schultz SL, 1997, J PHYS CHEM A, V101, P1000, DOI 10.1021/jp962454h; SENSION RJ, 1993, J CHEM PHYS, V98, P6291, DOI 10.1063/1.464824; Simpson MC, 1997, J AM CHEM SOC, V119, P5110, DOI 10.1021/ja961198j	26	226	228	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					443	446		10.1126/science.278.5337.443	http://dx.doi.org/10.1126/science.278.5337.443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334299				2022-12-01	WOS:A1997YB35500039
J	Lowe, CJ; Wray, GA				Lowe, CJ; Wray, GA			Radical alterations in the roles of homeobox genes during echinoderm evolution	NATURE			English	Article							MORPHOLOGY; EXPRESSION; PHYLOGENY; MOLECULES; HOMOLOGY	Echinoderms possess one of the most highly derived body architectures of all metazoan phyla, with radial symmetry, a calcitic endoskeleton, and a water vascular system(1,2). How these dramatic morphological changes evolved has been the subject of extensive speculation and debate(3-5), but remains unresolved. Because echinoderms are closely related to chordates and postdate the protostome/deuterostome divergence(2,3,6,7), they must have evolved from bilaterally symmetrical ancestors(1-6). Here we report the expression domains in echinoderms of three important developmental regulatory genes (distal-less, engrailed and orthodenticle), all of which encode transcription factors that contain a homeodomain(8). Our findings show that the reorganization of body architecture involved extensive changes in the deployment and roles of homeobox genes. These changes include modifications in the symmetry of expression domains and the evolution of several new developmental roles, as well as the loss of roles conserved between arthropods and chordates. Some of these modifications seem to have evolved very early in the history of echinoderms, whereas others probably evolved during the subsequent diversification of adult and larval morphology, These results demonstrate the evolutionary lability of regulatory genes that are widely viewed as conservative.	SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook				Lowe, Christopher/0000-0002-7789-8643				Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Bolker JA, 1996, BIOESSAYS, V18, P489, DOI 10.1002/bies.950180611; Brusca R.C., 1990, INVERTEBRATES; Dan, 1968, INVERTEBRATE EMBRYOL; DAVID B, IN PRESS P 9 INT ECH; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DICKINSON WJ, 1995, TRENDS GENET, V11, P119, DOI 10.1016/S0168-9525(00)89015-0; DOLECKI GJ, 1988, GENE, V64, P21, DOI 10.1016/0378-1119(88)90477-5; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; GAN L, 1995, DEV BIOL, V167, P517, DOI 10.1006/dbio.1995.1046; HOLLAND ND, 1988, ECHINODERM PHYLOGENY, P13; Holland P.W.H., 1990, Seminars in Developmental Biology, V1, P135; Hyman L.H., 1955, INVERTEBRATES, V4; Jefferies RPS, 1996, ACTA ZOOL-STOCKHOLM, V77, P101, DOI 10.1111/j.1463-6395.1996.tb01256.x; Lacalli TC, 1996, PHILOS T R SOC B, V351, P1737, DOI 10.1098/rstb.1996.0155; MALINDA KM, 1994, DEV BIOL, V164, P562, DOI 10.1006/dbio.1994.1224; NIELSEN C, 1995, ANIMAL EVOLUTIION IN; PANGANIBAN G, 1997, P NATL ACAD SCI USA, V94, P2162; PATEL NH, 1994, SCIENCE, V266, P581, DOI 10.1126/science.7939712; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATEL NH, METHOD CELL BIOL, V44, P446; Raff R. A., 1996, SHAPE LIFE; Sharman AC, 1996, NETH J ZOOL, V46, P47, DOI 10.1163/156854295X00050; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Smith A. B., 1988, ECHINODERM PHYLOGENY, P85; STRATHMANN MF, 1987, REPROD DEV MARINE IN; TURBEVILLE JM, 1994, MOL BIOL EVOL, V11, P648; WEDEEN CJ, 1991, DEVELOPMENT, V113, P805	29	219	225	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					718	721		10.1038/39580	http://dx.doi.org/10.1038/39580			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338781				2022-12-01	WOS:A1997YA95900052
J	Dahiyat, BI; Mayo, SL				Dahiyat, BI; Mayo, SL			De novo protein design: Fully automated sequence selection	SCIENCE			English	Article							AMINO-ACIDS; MACROMOLECULAR STRUCTURES; DISTANCE GEOMETRY; NMR-SPECTROSCOPY; COILED COILS; PROPENSITIES; PEPTIDE; PACKING; POLYPEPTIDE; TRANSITION	The first fully automated design and experimental validation of a novel sequence for an entire protein is described. A computational design algorithm based on physical chemical potential functions and stereochemical constraints was used to screen a combinatorial library of 1.9 x 10(27) possible amino acid sequences for compatibility with the design target, a beta beta alpha protein motif based on the polypeptide backbone structure of a zinc finger domain. A BLAST search shows that the designed sequence, full sequence design 1 (FSD-1), has very low identity to any known protein sequence. The solution structure of FSD-1 was solved by nuclear magnetic resonance spectroscopy and indicates that FSD-1 forms a compact well-ordered structure, which is in excellent agreement with the design target structure, This result demonstrates that computational methods can perform the immense combinatorial search required for protein design, and it suggests that an unbiased and quantitative algorithm can be used in various structural contexts.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125; CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; California Institute of Technology					NIGMS NIH HHS [GM08346] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Betz SF, 1996, BIOCHEMISTRY-US, V35, P6955, DOI 10.1021/bi960095a; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; COHEN FE, 1982, J MOL BIOL, V156, P821, DOI 10.1016/0022-2836(82)90144-9; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Dahiyat BI, 1996, PROTEIN SCI, V5, P895, DOI 10.1002/pro.5560050511; Dahiyat BI, 1997, P NATL ACAD SCI USA, V94, P10172, DOI 10.1073/pnas.94.19.10172; Dahiyat BI, 1997, PROTEIN SCI, V6, P1333, DOI 10.1002/pro.5560060622; DAHIYAT BI, UNPUB; DeMaeyer M, 1997, FOLD DES, V2, P53; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; GOLDSTEIN RF, 1994, BIOPHYS J, V66, P1335, DOI 10.1016/S0006-3495(94)80923-3; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HELLINGA HW, 1991, J MOL BIOL, V222, P787, DOI 10.1016/0022-2836(91)90511-4; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JACKSON DY, 1994, SCIENCE, V266, P243, DOI 10.1126/science.7939659; JANIN J, 1980, J MOL BIOL, V143, P95, DOI 10.1016/0022-2836(80)90126-6; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KLEMBA M, 1995, NAT STRUCT BIOL, V2, P368, DOI 10.1038/nsb0595-368; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; Marvin JS, 1997, P NATL ACAD SCI USA, V94, P4366, DOI 10.1073/pnas.94.9.4366; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, COMPUTATIONAL ASPECT; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Struthers MD, 1996, J AM CHEM SOC, V118, P3073, DOI 10.1021/ja954014u; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; Su A, 1997, PROTEIN SCI, V6, P1701, DOI 10.1002/pro.5560060810; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008; Wuthrich K., 1986, NMR PROTEINS NUCL AC	51	887	981	0	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					82	87		10.1126/science.278.5335.82	http://dx.doi.org/10.1126/science.278.5335.82			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311930				2022-12-01	WOS:A1997XZ12400041
J	Rubinstein, M; Phillips, TJ; Bunzow, JR; Falzone, TL; Dziewczapolski, G; Zhang, G; Fang, Y; Larson, JL; McDougall, JA; Chester, JA; Saez, C; Pugsley, TA; Gershanik, O; Low, MJ; Grandy, DK				Rubinstein, M; Phillips, TJ; Bunzow, JR; Falzone, TL; Dziewczapolski, G; Zhang, G; Fang, Y; Larson, JL; McDougall, JA; Chester, JA; Saez, C; Pugsley, TA; Gershanik, O; Low, MJ; Grandy, DK			Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine	CELL			English	Article							METHYL-D-ASPARTATE; EXTRACELLULAR DOPAMINE; TYROSINE-HYDROXYLASE; NUCLEUS-ACCUMBENS; FUNCTIONAL-CHARACTERIZATION; GLUTAMATE-RECEPTOR; SUBSTANTIA-NIGRA; NOVELTY SEEKING; PRIMATE BRAIN; BASAL GANGLIA	The human dopamine D4 receptor (D4R) has received considerable attention because of its high affinity for the atypical antipsychotic clozapine and the unusually polymorphic nature of its gene. To clarify the in vivo role of the D4R, we produced and analyzed mutant mice (D4R(-/-)) lacking this protein. Although less active in open field tests, D4R(-/-) mice outperformed wildtype mice on the rotarod and displayed locomotor supersensitivity to ethanol, cocaine, and methamphetamine. Biochemical analyses revealed that dopamine synthesis and its conversion to DOPAC were elevated in the dorsal striatum from D4R(-/-) mice. Based on these findings, we propose that the D4R modulates normal, coordinated and drug-stimulated motor behaviors as well as the activity of nigrostriatal dopamine neurons.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BEHAV NEUROSCI,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; UNIV BUENOS AIRES,INST INVEST FARMACOL,RA-1053 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,INST INVEST INGN GENET & BIOL MOL,CONICET,RA-1053 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,DEPT QUIM BIOL,FCEYN,RA-1053 BUENOS AIRES,DF,ARGENTINA; DEPT VET AFFAIRS MED CTR,RES SERV,PORTLAND,OR 97201; HOSP UNIV VIRGEN DEL ROCIO,SEVILLE 41013,SPAIN; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,ANN ARBOR,MI 48105	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Virgen del Rocio University Hospital; Pfizer			Falzone, Tomás/W-2528-2019; Sáez, Carmen/B-9468-2015; IBIS, TUMORIGENESIS/P-3506-2015	Sáez, Carmen/0000-0002-8600-0508; Falzone, Tomas/0000-0002-7984-1149; Low, Malcolm/0000-0002-9900-3708; Dziewczapolski, Gustavo/0000-0003-1393-485X	NIAAA NIH HHS [P60 AA010760] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; Ariano MA, 1997, BRAIN RES, V752, P26, DOI 10.1016/S0006-8993(96)01422-9; ARNT J, 1995, EUR J PHARMACOL, V283, P55, DOI 10.1016/0014-2999(95)00292-S; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; Bergson C, 1995, J NEUROSCI, V15, P7821; BOUVIER C, 1995, EUR J PHARM-MOLEC PH, V290, P11, DOI 10.1016/0922-4106(95)90011-X; CAMP DM, 1994, BRAIN RES, V668, P180, DOI 10.1016/0006-8993(94)90523-1; CARLSSON A, 1975, J NEURAL TRANSM, V40, P99; CARTER CJ, 1982, NEUROPHARMACOLOGY, V21, P379, DOI 10.1016/0028-3908(82)90019-3; CHRISTOFFERSEN CL, 1995, NEUROSCIENCE, V67, P373, DOI 10.1016/0306-4522(95)00047-M; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DAR MS, 1984, J NEURAL TRANSM, V60, P283, DOI 10.1007/BF01249100; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; FADDA F, 1991, ALCOHOL ALCOHOLISM S, V1, P439; FISHBURN CS, 1995, FEBS LETT, V361, P215, DOI 10.1016/0014-5793(95)00168-9; FREED CR, 1985, SCIENCE, V229, P62, DOI 10.1126/science.4012312; Geijer T, 1997, ALCOHOL CLIN EXP RES, V21, P35; GEORGE SR, 1993, BIOCHEM BIOPH RES CO, V196, P107, DOI 10.1006/bbrc.1993.2222; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; IMPERATO A, 1986, J PHARMACOL EXP THER, V239, P219; ISHII A, 1991, BIOCHEM BIOPH RES CO, V176, P1051, DOI 10.1016/0006-291X(91)90389-O; Kotler M, 1997, MOL PSYCHIATR, V2, P251, DOI 10.1038/sj.mp.4000248; KRISCH I, 1994, J PHARMACOL EXP THER, V271, P343; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; MAISONNEUVE IM, 1990, BRAIN RES, V535, P221, DOI 10.1016/0006-8993(90)91604-F; MEADORWOODRUFF JH, 1994, NEUROPSYCHOPHARMACOL, V10, P239, DOI 10.1038/npp.1994.27; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; Muramatsu T, 1996, J MED GENET, V33, P113, DOI 10.1136/jmg.33.2.113; OVERTON P, 1992, J NEURAL TRANSM-PARK, V4, P1, DOI 10.1007/BF02257617; Phillips TJ, 1996, INT REV NEUROBIOL, V39, P243, DOI 10.1016/S0074-7742(08)60669-8; PHILLIPS TJ, 1991, PSYCHOPHARMACOLOGY, V103, P557, DOI 10.1007/BF02244259; PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x; PHILLIPS TJ, 1995, ALCOHOL CLIN EXP RES, V19, P269, DOI 10.1111/j.1530-0277.1995.tb01502.x; Pugsley TA, 1995, J PHARMACOL EXP THER, V275, P1355; RASSNICK S, 1992, PSYCHOPHARMACOLOGY, V109, P92, DOI 10.1007/BF02245485; REYNOLDS GP, 1994, J NEUROCHEM, V63, P1576; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; VANTOL HHM, 1992, NATURE, V358, P149; WADDINGTON JL, 1993, REGULATION UNCONDITI, P51; WEISS F, 1992, J NEUROSCI, V12, P4372; Werner P, 1996, MOL PHARMACOL, V49, P656; WESTERINK BHC, 1992, N-S ARCH PHARMACOL, V345, P523, DOI 10.1007/BF00168943; White FJ, 1996, ANNU REV NEUROSCI, V19, P405, DOI 10.1146/annurev.ne.19.030196.002201; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215; ZORN SH, 1994, EUR J PHARM-MOLEC PH, V269, pR1, DOI 10.1016/0922-4106(94)90047-7	59	391	401	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					991	1001		10.1016/S0092-8674(00)80365-7	http://dx.doi.org/10.1016/S0092-8674(00)80365-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323127	Bronze			2022-12-01	WOS:A1997XX76800005
J	Century, KS; Shapiro, AD; Repetti, PP; Dahlbeck, D; Holub, E; Staskawicz, BJ				Century, KS; Shapiro, AD; Repetti, PP; Dahlbeck, D; Holub, E; Staskawicz, BJ			NDR1, a pathogen-induced component required for Arabidopsis disease resistance	SCIENCE			English	Article							LEUCINE-RICH REPEAT; ARTIFICIAL CHROMOSOME LIBRARY; PERONOSPORA-PARASITICA; YAC LIBRARY; THALIANA; GENE; IDENTIFICATION; TOMATO; LOCUS; CONSTRUCTION	Plant disease resistance (R) genes confer an ability to resist infection by pathogens expressing specific corresponding avirulence genes. In Arabidopsis thaliana, resistance to both bacterial and fungal pathogens, mediated by several R gene products, requires the NDR1 gene. Positional cloning was used to isolate NDR1, which encodes a 660-base pair open reading frame. The predicted 219-amino acid sequence suggests that NDR1 may be associated with a membrane. NDR1 expression is induced in response to pathogen challenge and may function to integrate various pathogen recognition signals.	UNIV CALIF BERKELEY, DEPT PLANT & MICROBIAL BIOL, BERKELEY, CA 94720 USA; HORT RES INT, DEPT PLANT PATHOL & WEED SCI, WELLESBOURNE CV35 9EF, WARWICK, ENGLAND	University of California System; University of California Berkeley; University of Warwick								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; Gopalan S, 1996, PLANT J, V10, P591, DOI 10.1046/j.1365-313X.1996.10040591.x; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HOLUB EB, 1994, MOL PLANT MICROBE IN, V7, P223, DOI 10.1094/MPMI-7-0223; JORGENSEN RA, 1987, PLANT MOL BIOL, V8, P3, DOI 10.1007/BF00016429; KARRER EE, IN PRESS PLANT MOL B; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUNKEL BN, 1993, PLANT CELL, V5, P865, DOI 10.1105/tpc.5.8.865; Parker JE, 1996, PLANT CELL, V8, P2033, DOI 10.1105/tpc.8.11.2033; PONGOR S, 1994, NUCLEIC ACIDS RES, V22, P3610; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49	29	280	306	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	1997	278	5345					1963	1965		10.1126/science.278.5345.1963	http://dx.doi.org/10.1126/science.278.5345.1963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395402				2022-12-01	WOS:A1997YL00200040
J	Wiesmann, C; Fuh, G; Christinger, HW; Eigenbrot, C; Wells, JA; deVos, AM				Wiesmann, C; Fuh, G; Christinger, HW; Eigenbrot, C; Wells, JA; deVos, AM			Crystal structure at 1.7 angstrom resolution of VEGF in complex with domain 2 of the Flt-1 receptor	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL-TRANSDUCTION; TYROSINE KINASE; LIGAND-BINDING; ANGIOGENESIS; IDENTIFICATION; VASCULOGENESIS; EXPRESSION; LETHALITY	Vascular endothelial growth factor (VEGF) is a homodimeric hormone that induces proliferation of endothelial cells through binding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracellular portions of which consist of seven immunoglobulin domains. We show that the second and third domains of Flt-1 are necessary and sufficient for binding VEGF with near-native affinity, and that domain 2 alone binds only 60-fold less tightly than wild-type. The crystal structure of the complex between VEGF and the second domain of Flt-1 shows domain 2 in a predominantly hydrophobic interaction with the ''poles'' of the VEGF dimer. Based on this structure and on mutational data, we present a model of VEGF bound to the first four domains of Flt-1.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Wells, Jim A/O-9854-2016	Wiesmann, Christian/0000-0002-4092-9880				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barleon B, 1997, J BIOL CHEM, V272, P10382; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MERRIT EA, 1994, ACTA CRYSTALLOGR D, V53, P240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; [No title captured]	41	409	473	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					695	704		10.1016/S0092-8674(00)80456-0	http://dx.doi.org/10.1016/S0092-8674(00)80456-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393862	Bronze			2022-12-01	WOS:A1997YH96000016
J	Fichera, ME; Roos, DS				Fichera, ME; Roos, DS			A plastid organelle as a drug target in apicomplexan parasites	NATURE			English	Article							TOXOPLASMA-GONDII; MACROLIDE ANTIBIOTICS; CLINDAMYCIN; ENCEPHALITIS; AZITHROMYCIN; INHIBITION; QUINOLONES; SPIRAMYCIN; RESISTANT; MUTANTS	Parasites of the phylum Apicomplexa include many important human and veterinary pathogens such as Plasmodium (malaria), Toxoplasma (a leading opportunistic infection associated with AIDS and congenital neurological birth defects), and Eimeria (an economically significant disease of poultry and cattle)(1-4). Recent studies have identified an unusual organelle in these parasites(5-7): a plastid that appears to have been acquired by secondary endosymbiosis of a green alga(7). Here ive show that replication of the apicomplexan plastid (apicoplast) genome in Toxoplasma gondii tachyzoites can be specifically inhibited using ciprofloxacin, and that this inhibition blocks parasite replication. Moreover, parasite death occurs with peculiar kinetics that are identical to those observed after exposure to clindamycin and macrolide antibiotics(8,9), which have been proposed to target protein synthesis in the apicoplast(9,10). Conversely, clindamycin (and functionally related compounds) immediately inhibits plastid replication upon drug application-the earliest effect so far described for these antibiotics. Our results directly link apicoplast function with parasite survival, validating this intriguing organelle as an effective target for parasiticidal drug design.	UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania				Roos, David Siker/0000-0001-6725-4089				ARAUJO FG, 1991, EUR J CLIN MICROBIOL, V10, P519, DOI 10.1007/BF01963942; BECKERS CJM, 1995, J CLIN INVEST, V95, P367, DOI 10.1172/JCI117665; *CDC, HLTH INF; CUNDLIFFE E, 1990, RIBOSOME, P479; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; FURET YX, 1991, EUR J CLIN MICROBIOL, V10, P249, DOI 10.1007/BF01966997; Haberkorn A, 1996, PARASITOL RES, V82, P193, DOI 10.1007/s004360050094; Khan AA, 1996, ANTIMICROB AGENTS CH, V40, P1855, DOI 10.1128/AAC.40.8.1855; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KRAJCOVIC J, 1989, ANTIMICROB AGENTS CH, V33, P1883, DOI 10.1128/AAC.33.11.1883; LANE HC, 1994, ANN INTERN MED, V120, P945, DOI 10.7326/0003-4819-120-11-199406010-00007; Le Bras Jacques, 1996, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V190, P471; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MCCABE RE, 1989, DRUGS, V38, P973, DOI 10.2165/00003495-198938060-00008; McConkey GA, 1997, J BIOL CHEM, V272, P2046, DOI 10.1074/jbc.272.4.2046; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; PFEFFERKORN ER, 1992, ANTIMICROB AGENTS CH, V36, P1091, DOI 10.1128/AAC.36.5.1091; PFEFFERKORN ER, 1994, ANTIMICROB AGENTS CH, V38, P31, DOI 10.1128/AAC.38.1.31; PFEFFERKORN ER, 1993, J PARASITOL, V79, P559, DOI 10.2307/3283383; ROGERS MJ, 1997, RNA, V3, P1; ROIZEN N, 1995, PEDIATRICS, V95, P11; ROOS DS, 1994, METHOD CELL BIOL, V45, P28; Srivastava IK, 1997, J BIOL CHEM, V272, P3961, DOI 10.1074/jbc.272.7.3961; Vogel G, 1997, SCIENCE, V275, P1422, DOI 10.1126/science.275.5305.1422; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; YOON CK, 1997, NY TIMES        0311, pC3	30	454	472	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					407	409		10.1038/37132	http://dx.doi.org/10.1038/37132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389481				2022-12-01	WOS:A1997YH54900065
J	Bennett, P; Edwards, D				Bennett, P; Edwards, D			Use of magnesium sulphate in obstetrics	LANCET			English	Editorial Material							CEREBRAL-PALSY; PRETERM LABOR; SULFATE; RISK				Bennett, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DIV PAEDIAT OBSTET & GYNAECOL, LONDON W12 0HS, ENGLAND.			Bennett, Phillip/0000-0002-6253-4919				ATKINSON MW, 1995, AM J OBSTET GYNECOL, V173, P1219, DOI 10.1016/0002-9378(95)91357-2; COTTON DB, 1984, J REPROD MED, V29, P92; deHaan HH, 1997, AM J OBSTET GYNECOL, V176, P18, DOI 10.1016/S0002-9378(97)80005-1; DULEY L, 1995, LANCET, V345, P1455; HIGBY K, 1993, AM J OBSTET GYNECOL, V168, P1247, DOI 10.1016/0002-9378(93)90376-T; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; NELSON KB, 1995, PEDIATRICS, V95, P263; PANETH N, 1997, PEDIATRICS, V99, pE11; PENRICE J, 1997, PEDIATR RES, V41, P1; Schendel DE, 1996, JAMA-J AM MED ASSOC, V276, P1805, DOI 10.1001/jama.276.22.1805; Witlin AG, 1997, AM J OBSTET GYNECOL, V176, P623, DOI 10.1016/S0002-9378(97)70558-1	11	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1491	1491		10.1016/S0140-6736(05)63935-9	http://dx.doi.org/10.1016/S0140-6736(05)63935-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388392				2022-12-01	WOS:A1997YH11500003
J	Babior, BM; Matzner, Y				Babior, BM; Matzner, Y			The familial Mediterranean fever gene - Cloned at last	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FLUIDS		HADASSAH UNIV HOSP, IL-91240 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	Babior, BM (corresponding author), SCRIPPS RES INST, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI-24227] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024227, R01AI024227] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; GOLDFINGER SE, 1972, NEW ENGL J MED, V287, P1302; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MATZNER Y, 1995, CRIT REV ONCOL HEMAT, V18, P197, DOI 10.1016/1040-8428(94)00130-L	6	53	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1548	1549		10.1056/NEJM199711203372112	http://dx.doi.org/10.1056/NEJM199711203372112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366590				2022-12-01	WOS:A1997YG24900012
J	Lynch, ED; Lee, MK; Morrow, JE; Welcsh, PL; Leon, PE; King, MC				Lynch, ED; Lee, MK; Morrow, JE; Welcsh, PL; Leon, PE; King, MC			Nonsyndromic deafness DFNA1 associated with mutation of a human homolog of the Drosophila gene diaphanous	SCIENCE			English	Article							LIMB DEFORMITY LOCUS; ACTIN-FILAMENTS; FORMINS; TRANSCRIPTS	The gene responsible for autosomal dominant, fully penetrant, nonsyndromic sensorineural progressive hearing loss in a large Costa Rican kindred was previously localized to chromosome 5q31 and named DFNA1. Deafness in the family is associated with a protein-truncating mutation in a human homolog of the Drosophila gene diaphanous. The truncation is caused by a single nucleotide substitution in a splice donor, leading to a four-base pair insertion in messenger RNA and a frameshift, The diaphanous protein is a profilin ligand and target of Rho that regulates polymerization of actin, the major component of the cytoskeleton of hair cells of the inner ear.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV COSTA RICA, SCH MED, SAN JOSE, COSTA RICA; UNIV COSTA RICA, CTR RES CELLULAR & MOL BIOL, SAN JOSE, COSTA RICA	University of Washington; University of Washington Seattle; Universidad Costa Rica; Universidad Costa Rica	Lynch, ED (corresponding author), UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA.			King, Mary-Claire/0000-0001-9426-1743	NIDCD NIH HHS [R01-DC01076] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001076] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banfi S, 1997, HUM MOL GENET, V6, P1745, DOI 10.1093/hmg/6.10.1745; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FLOCK A, 1977, J CELL BIOL, V75, P339, DOI 10.1083/jcb.75.2.339; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; GORLIN RJ, 1995, OXFORD MONOGRAPHS ME, V28, P1; ITOH M, 1982, HEARING RES, V6, P277, DOI 10.1016/0378-5955(82)90060-0; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Lee M., UNPUB; LEON PE, 1981, AM J HUM GENET, V33, P209; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; LIU XZ, IN PRESS NATURE GENE; LYNCH ED, UNPUB; MAAS RL, 1991, AM J HUM GENET, V48, P687; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; Sambrook J, 1989, MOL CLONING; Steel KP, 1996, CURR OPIN NEUROBIOL, V6, P520, DOI 10.1016/S0959-4388(96)80059-6; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; TILNEY LG, 1982, HEARING RES, V7, P181, DOI 10.1016/0378-5955(82)90013-2; Tyson J, 1996, HUM MOL GENET, V5, P2055, DOI 10.1093/hmg/5.12.2055; VOGT TF, 1993, P NATL ACAD SCI USA, V90, P5554, DOI 10.1073/pnas.90.12.5554; Wang CC, 1997, GENOMICS, V39, P303, DOI 10.1006/geno.1996.4519; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; WynshawBoris A, 1997, MOL MED, V3, P372, DOI 10.1007/BF03401684; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	39	306	332	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1315	1318		10.1126/science.278.5341.1315	http://dx.doi.org/10.1126/science.278.5341.1315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360932				2022-12-01	WOS:A1997YG04300051
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			BLAST off!	SCIENCE			English	Editorial Material																		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2	2	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					501	502						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381147				2022-12-01	WOS:A1997YB35500056
J	Clarke, VRJ; Ballyk, BA; Hoo, KH; Mandelzys, A; Pellizzari, A; Bath, CP; Thomas, J; Sharpe, EF; Davies, CH; Ornstein, PL; Schoepp, DD; Kamboj, RK; Collingridge, GL; Lodge, D; Bleakman, D				Clarke, VRJ; Ballyk, BA; Hoo, KH; Mandelzys, A; Pellizzari, A; Bath, CP; Thomas, J; Sharpe, EF; Davies, CH; Ornstein, PL; Schoepp, DD; Kamboj, RK; Collingridge, GL; Lodge, D; Bleakman, D			A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission	NATURE			English	Article							INDUCED EPILEPTIFORM ACTIVITY; AMINO-ACID RECEPTORS; KAINIC ACID; GLUTAMATE RECEPTORS; RAT HIPPOCAMPUS; NERVOUS-SYSTEM; AMPA RECEPTORS; NEURONS; DESENSITIZATION; PHARMACOLOGY	The principal excitatory neurotransmitter in the vertebrate central nervous system, L-glutamate, acts on three classes of ionotripic glutamate receptors, named after the agonists AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxalole-4-propionic acid),NMDA (N-methyl-D-aspartate) and kainate(1). The development of selective pharmacological agents has led to a detailed understanding of the physiological and pathological roles of AMPA and NMDA receptors(2-8). in contrast, the lack of selective kainate receptor ligands has greatly hindered progress in understanding the roles of kainate receptors(9,10). Here we describe the effects of a potent and selective agonist, ATPA ((RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid) and a selective antagonist, LY294486 ((3SR, 4aRS, 6SR, 8aRS)-6-((((1H-tetrazol-5-yl) methyl)oxy)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid), of the GluR5 subtype of kainate receptor(11). We have used these agents to show that kainate receptors, comprised of or containing GluR5 subunits, regulate synaptic inhibition in the hippocampus, an action that could contribute to the epileptogenic effects of kainate(12-17).	ELI LILLY & CO, LILLY RES CTR LTD, WINDLESHAM GU20 6PH, SURREY, ENGLAND; UNIV BRISTOL, DEPT ANAT, BRISTOL BS8 1TD, AVON, ENGLAND; ALLELIX BIOPHARMACEUT, MISSISSAUGA, ON L4V 1V7, CANADA; UNIV EDINBURGH, DEPT PHARMACOL, EDINBURGH EH8 9JZ, MIDLOTHIAN, SCOTLAND; ELI LILLY & CO, LILLY CORP CTR, INDIANAPOLIS, IN 46285 USA	Eli Lilly; University of Bristol; University of Edinburgh; Eli Lilly			collingridge, graham/AAI-8362-2020; Ornstein, Paul/E-4212-2016; Collingridge, Graham L/C-4605-2015	Ornstein, Paul/0000-0002-4335-1877; Collingridge, Graham L/0000-0002-9572-5359; Clarke, Vernon/0000-0002-6154-6555	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Bleakman D, 1996, MOL PHARMACOL, V49, P581; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAVIES CH, 1993, NEUROPHARMACOLOGY, V32, P1071, DOI 10.1016/0028-3908(93)90073-C; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; FELDMEYER D, 1994, CURR BIOL, V4, P82, DOI 10.1016/S0960-9822(00)00021-X; FISHER RS, 1984, J NEUROSCI, V4, P1312; Fletcher EJ, 1996, PHARMACOL THERAPEUT, V70, P65, DOI 10.1016/0163-7258(96)00014-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; KEHL SJ, 1984, NEUROSCIENCE, V11, P111, DOI 10.1016/0306-4522(84)90217-3; KORCZAK B, 1995, RECEPTOR CHANNEL, V3, P41; KROGSGAARDLARSE.P, 1994, EXCITATORY AMINO ACI, P34; LAURIDSEN J, 1985, J MED CHEM, V28, P668, DOI 10.1021/jm50001a022; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Partin KM, 1996, MOL PHARMACOL, V49, P142; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SLOVITER RS, 1981, NEUROPHARMACOLOGY, V20, P1003, DOI 10.1016/0028-3908(81)90088-5; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; WILDING TJ, 1995, MOL PHARMACOL, V47, P582	30	362	372	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					599	603		10.1038/39315	http://dx.doi.org/10.1038/39315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335499				2022-12-01	WOS:A1997YA00800059
J	Sheardown, SA; Duthie, SM; Johnston, CM; Newall, AET; Formstone, EJ; Arkell, RM; Nesterova, TB; Alghisi, GC; Rastan, S; Brockdorff, N				Sheardown, SA; Duthie, SM; Johnston, CM; Newall, AET; Formstone, EJ; Arkell, RM; Nesterova, TB; Alghisi, GC; Rastan, S; Brockdorff, N			Stabilization of Xist RNA mediates initiation of X chromosome inactivation	CELL			English	Article							MOUSE EMBRYOS; CONTROLLING ELEMENTS; LINKED GENES; FEMALE MOUSE; EXPRESSION; STABILITY; CELLS; DIFFERENTIATION; METHYLATION; EUKARYOTES	The onset of X inactivation is preceded by a marked increase in the level of Xist RNA. Here we demonstrate that increased stability of Xist RNA is the primary determinant of developmental up-regulation. Unstable transcript is produced by both alleles in XX ES cells and in XX embryos prior to the onset of random X inactivation. Following differentiation, transcription of unstable RNA from the active X chromosome allele continues for a period following stabilization and accumulation of transcript on the inactive X allele. We discuss the implications of these findings in terms of models for the initiation of random and imprinted X inactivation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CTR CLIN SCI,X INACTIVAT GRP,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CTR CLIN SCI,EMBRYOL GRP,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London			Arkell, Ruth/AAR-8471-2021; arkell, ruth m/D-1525-2009	Arkell, Ruth/0000-0002-6213-7323; arkell, ruth m/0000-0002-6213-7323; Nesterova, Tatyana/0000-0001-7740-4386; Brockdorff, Neil/0000-0003-4838-2653				BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BEDDINGTON R, 1987, P43; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1969, GENET RES, V14, P223, DOI 10.1017/S0016672300002068; CHEW LJ, 1994, MOL ENDOCRINOL, V8, P603, DOI 10.1210/me.8.5.603; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; DREWS U, 1974, CELL, V1, P3, DOI 10.1016/0092-8674(74)90148-2; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; Hendrich BD, 1997, NUCLEIC ACIDS RES, V25, P2661, DOI 10.1093/nar/25.13.2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hogan B., 2014, MANIPULATING MOUSE E; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MARTIN GR, 1978, NATURE, V271, P329, DOI 10.1038/271329a0; MCBURNEY MW, 1980, CELL, V21, P357, DOI 10.1016/0092-8674(80)90472-9; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RACK KA, 1994, HUM MOL GENET, V3, P1053, DOI 10.1093/hmg/3.7.1053; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1982, J EMBRYOL EXP MORPH, V71, P11; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; RUSSELL LB, 1965, GENETICS, V52, P470; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHEARDOWN SA, 1997, IN PRESS GENE; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; Simmler MC, 1996, HUM MOL GENET, V5, P1713, DOI 10.1093/hmg/5.11.1713; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; TAKAGI N, 1982, CHROMOSOMA, V85, P275, DOI 10.1007/BF00294971; WEBB S, 1992, GENET RES, V59, P205, DOI 10.1017/S0016672300030494; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	52	217	223	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					99	107		10.1016/S0092-8674(01)80012-X	http://dx.doi.org/10.1016/S0092-8674(01)80012-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335338	Bronze			2022-12-01	WOS:A1997XZ80900012
J	vonBulow, GU; Bram, RJ				vonBulow, GU; Bram, RJ			NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily	SCIENCE			English	Article							DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; KAPPA-B; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; APOPTOSIS; BINDING; LIGAND; FAMILY; GENE	Activation of the nuclear factor of activated T cells transcription factor (NF-AT) is a key event underlying lymphocyte action. The CAML (calcium-modulator and cyclophilin ligand) protein is a coinducer of NF-AT activation when overexpressed in Jurkat T cells. A member of the tumor necrosis factor receptor superfamily was isolated by Virtue of its affinity for CAML. Cross-linking of this lymphocyte-specific protein, designated TACl (transmembrane activator and CAML-interactor), on the surface of transfected Jurkat cells with TACl-specific antibodies led to activation of the transcription factors NF-AT, AP-1, acid NF kappa B. TACl-induced activation of NF-AT was specifically blocked by a dominant-negative CAML mutant, thus implicating CAML as a signaling intermediate.	ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; HOLLOWAY MP, UNPUB; JAIN J, 1993, NATURE, V35, P352; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; VONBULOW GU, UNPUB; WILSONRAWLS J, 1994, VIROLOGY, V201, P66, DOI 10.1006/viro.1994.1266	32	296	341	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					138	141		10.1126/science.278.5335.138	http://dx.doi.org/10.1126/science.278.5335.138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311921				2022-12-01	WOS:A1997XZ12400057
J	Bloland, PB; Kazembe, PN; Watkins, WM; Doumbo, OK; Nwanyanwu, OC; Ruebush, TK				Bloland, PB; Kazembe, PN; Watkins, WM; Doumbo, OK; Nwanyanwu, OC; Ruebush, TK			Malarone-donation programme in Africa	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA; EFFICACY; CHLOROQUINE; RESISTANCE		LILONGWE CENT HOSP,LILONGWE,MALAWI; WELLCOME TRUST RES LABS,NAIROBI,KENYA; UNIV MALI,FAC MED & PHARM,DEPT EPIDEMIOL & PARASIT DIS,BAMAKO,MALI; US AGCY INT DEV,LILONGWE,MALAWI	University of Bamako; United States Agency for International Development (USAID)	Bloland, PB (corresponding author), CTR DIS CONTROL & PREVENT,MALARIA EPIDEMIOL SECT,DIV PARASIT DIS F22,NATL CTR INFECT DIS,ATLANTA,GA 30341, USA.							BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Bruce-Chwatt L.J., 1986, CHEMOTHERAPY MALARIA, Vsecond; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; Nwanyanwu OC, 1996, TROP MED INT HEALTH, V1, P231; Plowe CV, 1996, AM J TROP MED HYG, V55, P467, DOI 10.4269/ajtmh.1996.55.467; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Radloff PD, 1996, T ROY SOC TROP MED H, V90, P682, DOI 10.1016/S0035-9203(96)90435-6; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Trigg JK, 1997, ACTA TROP, V63, P185, DOI 10.1016/S0001-706X(96)00617-1; WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P63, DOI 10.1016/0035-9203(94)90479-0; WHO, 1994, WHOMAL941067	11	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1624	1625		10.1016/S0140-6736(97)06082-0	http://dx.doi.org/10.1016/S0140-6736(97)06082-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393355				2022-12-01	WOS:A1997YH98600046
J	Solovey, A; Lin, Y; Browne, P; Choong, S; Wayner, E; Hebbel, RP				Solovey, A; Lin, Y; Browne, P; Choong, S; Wayner, E; Hebbel, RP			Circulating activated endothelial cells in sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDITERRANEAN SPOTTED-FEVER; VASCULAR ENDOTHELIUM; MONOCLONAL-ANTIBODY; RICKETTSIA-CONORII; STEADY-STATE; WHOLE-BLOOD; EXPRESSION; INFARCTION; DISEASE; INJURY	Background The vascular wall participates in the pathogenesis of sickle cell disease. To determine whether the endothelium is activated in this disease, we studied the number, origin, and surface phenotype of circulating endothelial cells in patients with sickle cell anemia. Methods We used immunohistochemical examination of buffy-coat smears to enumerate circulating endothelial cells, and we evaluated the surface phenotype by applying immunofluorescence microscopy to preparations of circulating endothelial cells. A panel of antibodies was used, including a specific anti-endothelial-cell antibody, P1H12. Results Mean (+/-SD) numbers of circulating endothelial cells in normal blood donors, patients with sickle cell trait, and patients with hemolytic anemias not due to hemoglobin S were 2.6+/-1.6, 3.0+/-2.6, and 2.0+/-0.8 per milliliter of whole blood, respectively. Patients with sickle cell anemia who presented with acute painful episodes had 22.8+/-18.2 circulating endothelial cells per milliliter of blood (P<0.001 for the comparison with normal donors), and patients with no such events within one month before or after blood sampling had 13.2+/-11.8 circulating endothelial cells per milliliter of blood (P=0.002 for the comparison with normal donors and P=0.019 for the comparison with patients with acute events). Serial observations of three patients showed a tendency toward higher levels of circulating endothelial cells at the onset of acute painful crises. The average viability of circulating endothelial cells was 66+/-30 percent. In patients with sickle cell anemia, regardless of clinical status, the circulating endothelial cells were predominantly microvascular in origin (CD36-positive), and most of the cells expressed four markers of endothelial-cell activation: intercellular adhesion molecule 1, vascular-cell adhesion molecule 1, E-selectin, and P-selectin. Conclusions Our studies suggest that the vascular endothelium is activated in patients with sickle cell anemia, regardless of the patients' clinical status. Adhesion proteins on activated endothelial cells may have a role in the vascular pathology of sickle cell disease. (C) 1997, Massachusetts Medical Society.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	Solovey, A (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455, USA.		Lin, Yi/K-1510-2013	Browne, Paul/0000-0001-5310-1487; Lin, Yi/0000-0002-1556-6416	NHLBI NIH HHS [HL 55174, P01 HL055552] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055552, R01HL055174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKINOLA NO, 1992, J CLIN PATHOL, V45, P902, DOI 10.1136/jcp.45.10.902; BLEI F, 1994, BLOOD, V84, pA409; Bouvier C., 1970, THROMB DIATH HAEMO, V40, P163; BRENNER BM, 1989, J CLIN INVEST, V84, P1373, DOI 10.1172/JCI114309; DRANCOURT M, 1992, J INFECT DIS, V166, P660, DOI 10.1093/infdis/166.3.660; Embury Stephen H., 1994, P311; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FAVALORO EJ, 1993, IMMUNOL CELL BIOL, V71, P571, DOI 10.1038/icb.1993.63; GEORGE F, 1991, J IMMUNOL METHODS, V139, P65, DOI 10.1016/0022-1759(91)90352-G; GEORGE F, 1993, BLOOD, V82, P2109; GEORGE F, 1992, BLOOD S, V80, pA12; GERRITY RG, 1976, EXP MOL PATHOL, V24, P59, DOI 10.1016/0014-4800(76)90057-5; GREFTE A, 1993, J INFECT DIS, V167, P270, DOI 10.1093/infdis/167.2.270; Gupta K, 1997, EXP CELL RES, V230, P244, DOI 10.1006/excr.1996.3421; Hebbel RP, 1997, J LAB CLIN MED, V129, P288, DOI 10.1016/S0022-2143(97)90176-1; HLADOVEC J, 1978, KLIN WOCHENSCHR, V56, P1033, DOI 10.1007/BF01476669; KLUG PP, 1982, BLOOD CELLS, V8, P175; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; PERCIVALLE E, 1993, J CLIN INVEST, V92, P663, DOI 10.1172/JCI116635; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; RODGERS GM, 1988, FASEB J, V2, P116, DOI 10.1096/fasebj.2.2.3277885; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SBARBATI R, 1991, BLOOD, V77, P764; SINGHAL A, 1993, LANCET, V341, P651, DOI 10.1016/0140-6736(93)90418-G; Solovey A., 1996, Blood, V88, p648A; SOWEMIMOCOKER SO, 1989, AM J HEMATOL, V31, P263, DOI 10.1002/ajh.2830310409; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; SUGIHARA K, 1992, BLOOD, V80, P2634; SWERLICK RA, 1992, J IMMUNOL, V148, P78	32	497	535	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1584	1590		10.1056/NEJM199711273372203	http://dx.doi.org/10.1056/NEJM199711273372203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371854				2022-12-01	WOS:A1997YH52100003
J	Joutel, A; Vahedi, K; Corpechot, C; Troesch, A; Chabriat, H; Vayssiere, C; Cruaud, C; Maciazek, J; Weissenbach, J; Bousser, MG; Bach, JF; TournierLasserve, E				Joutel, A; Vahedi, K; Corpechot, C; Troesch, A; Chabriat, H; Vayssiere, C; Cruaud, C; Maciazek, J; Weissenbach, J; Bousser, MG; Bach, JF; TournierLasserve, E			Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR; AUTOSOMAL-DOMINANT ARTERIOPATHY; MULTI-INFARCT DEMENTIA; SUBCORTICAL INFARCTS; LEUKOENCEPHALOPATHY; DROSOPHILA; RECEPTOR; GENE; ACTIVATION; SERRATE	Background CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy) is commonly overlooked or misdiagnosed owing to its recent identification and its variable mode of presentation. The defective gene in CADASIL is Notch3, which encodes a large transmembrane receptor. To set up a diagnostic test and to delineate the Notch3 domains involved in CADASIL, we undertook mutations analysis in this gene in a group of CADASIL patients. Methods 50 unrelated patients with CADASIL and 100 healthy controls were screened for mutations along the entire Notch3 sequence, by means of single-strand conformation polymorphism, heteroduplex, and sequence analysis. Findings Strongly stereotyped mis-sense mutations, located within the epidermal-growth-factor-like (EGF-like) repeats, in the extracellular domain of Notch3, were detected in 45 patients, Clustering of mutations within the two exons encoding the first five EGF-like repeats was observed (32 patients). All these mutations lead to toss or gain of a cysteine residue and therefore to an unpaired number of cysteine residues within a given EGF domain. None of these mutations was found in the 100 controls. Interpretation Because of the strong clustering and highly stereotyped nature of the pathogenetic mutations detected in CADASIL patients, an easy and reliable diagnostic test for CADASIL is feasible, The findings suggest that aberrant dimerisation of Notch3, due to abnormal disulphide bridging with another Notch3 molecule or with another protein, may be involved in the pathogenesis of this disorder.	UNIV PARIS 05, INSERM, U25, F-75730 PARIS, FRANCE; HOP LARIBOISIERE, F-75475 PARIS, FRANCE; BIOMERIEUX, LYON, FRANCE; GENETHON, EVRY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; bioMerieux			Joutel, Anne/K-5601-2017; Tournier-Lasserve, Elisabeth/N-7134-2017; Chabriat, Hugues/G-5699-2010	Joutel, Anne/0000-0003-3963-3860; Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Chabriat, Hugues/0000-0001-8436-6074; Cruaud, Corinne/0000-0002-4752-7278				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; DAVOUS P, 1991, REV NEUROL-FRANCE, V147, P376; DECELIS JF, 1991, P NATL ACAD SCI USA, V88, P632, DOI 10.1073/pnas.88.2.632; Ducros A, 1996, AM J HUM GENET, V58, P171; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RUCHOUX MM, 1995, ACTA NEUROPATHOL, V89, P500; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONNINEN V, 1987, EUR NEUROL, V27, P209, DOI 10.1159/000116158; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SOURANDER P, 1977, ACTA NEUROPATHOL, V39, P247, DOI 10.1007/BF00691704; STEVENS DL, 1977, LANCET, V1, P1364; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256	24	505	529	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1511	1515		10.1016/S0140-6736(97)08083-5	http://dx.doi.org/10.1016/S0140-6736(97)08083-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388399				2022-12-01	WOS:A1997YH11500010
J	Misiani, R; Mantero, G; Bellavita, P; Mori, L; Vicari, O; Marchesi, D; Primi, D				Misiani, R; Mantero, G; Bellavita, P; Mori, L; Vicari, O; Marchesi, D; Primi, D			GB virus C infection in patients with type II mixed cryoglobulinemia	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-G VIRUS; UNKNOWN ETIOLOGY; LONG-TERM; ASSOCIATION; THERAPY	Background: Hepatitis C virus (HCV) infection is present in most but not all patients with type II mixed cryoglobulinemia. Objective: To investigate the role of GB virus C (GBV-C) in type II mixed cryoglobulinemia. Design: Retrospective study of serum and cryoprecipitate samples. Setting: Tertiary care hospital in Bergamo, Italy. Patients: 58 cryoglobulinemic patients, 35 of whom were treated with interferon-alpha. Measurements: GB virus C RNA was determined by a reverse-transcription polymerase chain reaction assay done by using primers derived from the conserved GBV-C helicase region. Results: GB virus C RNA was detected in serum specimens from 23 of 58 cryoglobulinemic patients (40% [95% CI, 27% to 53%]) and 1 of 145 healthy blood donors (0.7%) (P < 0.001). Twenty of the 23 patients with GBV-C RNA were simultaneously infected with HCV. Unlike antibodies to HCV and HCV RNA, GBV-C RNA did not concentrate in cryoprecipitate in patients co-infected with GBV-C and HCV. Furthermore, the therapeutic effectiveness of interferon-alpha in patients with coinfection was related to the disappearance of HCV RNA but not GBV-C RNA from serum. None of 3 patients with GBV-C infection alone had detectable GBV-C RNA in cryoprecipitate. Conclusions: Infection with GBV-C, usually associated with HCV, is common in patients with type II mixed cryoglobulinemia but is unlikely to have a primary role in this disease.	OSPED RIUNITI BERGAMO, SERV IMMUNOEMATOL, I-24128 BERGAMO, ITALY; OSPED RIUNITI BERGAMO, DIV NEFROL & DIALISI, I-24128 BERGAMO, ITALY; SPEDALI CIVILI BRESCIA, CONSORZIO BIOTECHNOL, I-25123 BRESCIA, ITALY; OSPED RIUNITI BERGAMO, CTR TRASFUS, I-24128 BERGAMO, ITALY	Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Hospital Spedali Civili Brescia; Ospedali Riuniti di Bergamo								AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; Byrnes JJ, 1996, LANCET, V348, P472, DOI 10.1016/S0140-6736(05)64562-X; CACOUB P, 1994, AM J MED, V96, P124, DOI 10.1016/0002-9343(94)90132-5; DAMMACCO F, 1994, BLOOD, V84, P3336, DOI 10.1182/blood.V84.10.3336.bloodjournal84103336; DiBisceglie AM, 1996, ANN INTERN MED, V125, P772, DOI 10.7326/0003-4819-125-9-199611010-00013; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LEVEY JM, 1994, MEDICINE, V73, P53, DOI 10.1097/00005792-199401000-00005; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MANTERO G, 1991, CLIN CHEM, V37, P422; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MISIANI R, 1994, NEW ENGL J MED, V330, P751, DOI 10.1056/NEJM199403173301104; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; WEINER SM, 1996, 9 TRIENN INT S VIR H, P167; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	20	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					891	894		10.7326/0003-4819-127-10-199711150-00005	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382367				2022-12-01	WOS:A1997YF54500005
J	Freund, CL; GregoryEvans, CY; Furukawa, T; Papaioannou, M; Looser, J; Ploder, L; Bellingham, J; Ng, D; Herbrick, JAS; Duncan, A; Scherer, SW; Tsui, LC; LoutradisAnagnostou, A; Jacobson, SG; Cepko, CL; Bhattacharya, SS; McInnes, RR				Freund, CL; GregoryEvans, CY; Furukawa, T; Papaioannou, M; Looser, J; Ploder, L; Bellingham, J; Ng, D; Herbrick, JAS; Duncan, A; Scherer, SW; Tsui, LC; LoutradisAnagnostou, A; Jacobson, SG; Cepko, CL; Bhattacharya, SS; McInnes, RR			Cone-rod dystrophy due to mutations in a novel photoreceptor-specific homeobox gene (CRX) essential for maintenance of the photoreceptor	CELL			English	Article							RETINITIS-PIGMENTOSA; RETINAL DYSTROPHY; CHROMOSOME 19Q; HUMAN GENOME; CONGENITAL AMAUROSIS; CRYSTAL-STRUCTURE; LINKAGE ANALYSIS; DNA; DIFFERENTIATION; HOMEODOMAIN	Genes associated with inherited retinal degeneration have been found to encode proteins required for phototransduction, metabolism, or structural support of photoreceptors. Here we show that mutations in a novel photoreceptor-specific homeodomain transcription factor gene (CRX) cause an autosomal dominant form of cone-rod dystrophy (adCRD) at the CORD2 locus on chromosome 19q13. In affected members of a CORD2-linked family, the highly conserved glutamic acid at the first position of the recognition helix is replaced by alanine (E80A). In another CRD family, a 1 bp deletion (E168 [Delta bp]) within a novel sequence, the WSP motif, predicts truncation of the C-terminal 132 residues of CRX. Mutations in the CRX gene cause adCRD either by haploinsufficiency or by a dominant negative effect and demonstrate that CRX is essential for the maintenance of mammalian photoreceptors.	HOSP SICK CHILDREN, RES INST, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT PEDIAT, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1A8, CANADA; UCL, INST OPHTHALMOL, DEPT MOL GENET, LONDON EC1V 9EL, ENGLAND; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CTR THALASSEMIA, UNIT PRENATAL DIAG, GR-11526 ATHENS, GREECE; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; UNIV PENN, SCHEIE EYE INST, PHILADELPHIA, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of London; University College London; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Queens University - Canada; University of Pennsylvania; Pennsylvania Medicine			Bhattacharya, Shom/N-2926-2016; Scherer, Stephen/B-3785-2013; Bellingham, James/GVS-8955-2022; Gregory-Evans, Cheryl Y/G-9550-2011; Tsui, Lap-chee/A-1081-2010	Bhattacharya, Shom/0000-0002-1601-6344; Scherer, Stephen/0000-0002-8326-1999; Bellingham, James/0000-0003-3368-5221; Jacobson, Samuel/0000-0003-2122-169X	NATIONAL EYE INSTITUTE [R01EY005627, R01EY008064] Funding Source: NIH RePORTER; NEI NIH HHS [EY05627, R01 EY0 8064] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALLIKMETS R, 1997, IN PRESS SCIENCE; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BALCIUNIENE J, 1995, GENOMICS, V30, P281, DOI 10.1006/geno.1995.9876; BASCOM RA, 1995, HUM MOL GENET, V4, P1895, DOI 10.1093/hmg/4.10.1895; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Cau E, 1997, DEVELOPMENT, V124, P1611; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHUMAKOV IM, 1995, NATURE, V377, P175; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; DUNCAN AMV, 1994, GENOMICS, V19, P400, DOI 10.1006/geno.1994.1084; EVANS K, 1994, NAT GENET, V6, P210, DOI 10.1038/ng0294-210; EVANS K, 1995, ARCH OPHTHALMOL-CHIC, V113, P195, DOI 10.1001/archopht.1995.01100020079033; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fulton AB, 1996, ARCH OPHTHALMOL-CHIC, V114, P698, DOI 10.1001/archopht.1996.01100130690009; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gal A, 1997, PROG RETIN EYE RES, V16, P51, DOI 10.1016/S1350-9462(96)00021-3; GREGORY CY, 1994, AM J HUM GENET, V55, P1061; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kelsell RE, 1997, HUM MOL GENET, V6, P597, DOI 10.1093/hmg/6.4.597; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLYSTRA JA, 1993, CAN J OPHTHALMOL, V28, P79; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNZLER P, 1995, BIOL CHEM H-S, V376, P201; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LIN CC, 1985, CYTOGENET CELL GENET, V39, P269, DOI 10.1159/000132156; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; PAPAIOANNOU M, 1997, IN PRESS J MED GENET; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SCHERER S, 1991, P33; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SZYLYK JP, 1993, ARCH OPHTHALMOL-CHIC, V111, P781; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WARBURG M, 1991, AM J MED GENET, V39, P288, DOI 10.1002/ajmg.1320390309; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WU PX, 1997, DEVELOPMENT, V124, P219; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; YAGASAKI K, 1989, ARCH OPHTHALMOL-CHIC, V107, P701, DOI 10.1001/archopht.1989.01070010719034; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	66	429	445	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 14	1997	91	4					543	553		10.1016/S0092-8674(00)80440-7	http://dx.doi.org/10.1016/S0092-8674(00)80440-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390563	Green Published, hybrid			2022-12-01	WOS:A1997YG49200015
J	Joseph, S; Weiser, B; Noller, HF				Joseph, S; Weiser, B; Noller, HF			Mapping the inside of the ribosome with an RNA helical ruler	SCIENCE			English	Article							PEPTIDYL TRANSFERASE CENTER; ESCHERICHIA-COLI RIBOSOME; SEQUENCE-SPECIFIC CLEAVAGE; ANTICODON INTERACTION SITE; P-SITE; PROTEIN-SYNTHESIS; CROSS-LINKING; 70S RIBOSOMES; 16-S RNA; 16S RNA	The structure of ribosomal RNA (rRNA) in the ribosome was probed with hydroxyl radicals generated locally from iron(II) tethered to the 5' ends of anticodon stem-loop analogs (ASLs) of transfer RNA. The ASLs, ranging in length from 4 to 33 base pairs, bound to the ribosome in a messenger RNA-dependent manner and directed cleavage to specific regions of the 16S, 23S, and 5S rRNA chains. The positions and intensities of cleavage depended on whether the ASLs were bound to the ribosomal A or P site, and on the lengths of their stems, These data predict the three-dimensional locations of the rRNA targets relative to the positions of A- and P-site transfer RNAs inside the ribosome.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, RNA, CTR MOL BIOL, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRIMACOMBE R, 1988, JMB, V199, P155; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHAPMAN NM, 1977, J MOL BIOL, V109, P131, DOI 10.1016/S0022-2836(77)80049-1; DERIEMER LH, 1981, J LABELLED COMPD RAD, V18, P1517, DOI 10.1002/jlcr.2580181017; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; Fink DL, 1996, RNA, V2, P851; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GORNICKI P, 1984, J BIOL CHEM, V259, P493; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAN HY, 1994, P NATL ACAD SCI USA, V91, P4955, DOI 10.1073/pnas.91.11.4955; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; JOSEPH S, UNPUB; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LEVIEV I, 1995, NUCLEIC ACIDS RES, V23, P1512; MERRYMAN C, UNPUB; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OSSWALD M, 1995, NUCLEIC ACIDS RES, V23, P4635, DOI 10.1093/nar/23.22.4635; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P12565, DOI 10.1021/bi00165a004; POGOZELSKI WK, 1995, J AM CHEM SOC, V117, P6428, DOI 10.1021/ja00129a002; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; RINKE AJ, 1995, RNA, V1, P1018; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SANTER M, 1990, P NATL ACAD SCI USA, V87, P3700, DOI 10.1073/pnas.87.10.3700; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; SUNDARALINGAM M, 1975, P101; TAPPRICH WE, 1989, P NATL ACAD SCI USA, V86, P4927, DOI 10.1073/pnas.86.13.4927; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; TULLIUS TD, 1991, FREE RADICAL RES COM, V12-3, P521; TUSCHL T, 1994, SCIENCE, V266, P785, DOI 10.1126/science.7973630; VASSILENKO SK, 1981, J MOL BIOL, V152, P699, DOI 10.1016/0022-2836(81)90123-6; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; YUSUPOV MM, 1986, FEBS LETT, V197, P229, DOI 10.1016/0014-5793(86)80332-5	61	76	76	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1093	1098		10.1126/science.278.5340.1093	http://dx.doi.org/10.1126/science.278.5340.1093			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353184				2022-12-01	WOS:A1997YE65200043
J	Dixon, AK; Coulden, RA				Dixon, AK; Coulden, RA			Coronary artery calcification on computed tomography	LANCET			English	Editorial Material							CT SCANS; QUANTIFICATION				Dixon, AK (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND.							AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; BREEN JF, 1992, RADIOLOGY, V185, P435, DOI 10.1148/radiology.185.2.1410350; Callaway MP, 1997, BRIT J RADIOL, V70, P572, DOI 10.1259/bjr.70.834.9227248; DIXON AK, 1984, CLIN RADIOL, V35, P33, DOI 10.1016/S0009-9260(84)80228-7; ELKELES A, 1957, LANCET, V2, P714; KAUFMANN RB, 1994, RADIOLOGY, V190, P347, DOI 10.1148/radiology.190.2.8284380; MCCARTHY JH, 1974, BRIT HEART J, V36, P499; MOORE EH, 1989, RADIOLOGY, V172, P711, DOI 10.1148/radiology.172.3.2772178; Reinmuller R, 1987, DYNAMIC CARDIOVASCUL, V1, P139; Shemesh J, 1996, RADIOLOGY, V199, P665, DOI 10.1148/radiology.199.3.8637984; SHEMESH J, 1995, RADIOLOGY, V197, P779, DOI 10.1148/radiology.197.3.7480756; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	12	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1265	1265		10.1016/S0140-6736(05)62470-1	http://dx.doi.org/10.1016/S0140-6736(05)62470-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357403				2022-12-01	WOS:A1997YD68900005
J	Sorensen, HT; Sabroe, S; Rothman, KJ; Gillman, M; Fischer, P; Sorensen, TIA				Sorensen, HT; Sabroe, S; Rothman, KJ; Gillman, M; Fischer, P; Sorensen, TIA			Relation between weight and length at birth and body mass index in young adulthood: cohort study	BRITISH MEDICAL JOURNAL			English	Article							OBESITY; GROWTH		AARHUS UNIV,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS,DENMARK; BOSTON UNIV,SCH MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02215; HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215; 5TH CONSCRIPT DIST,DK-9000 AALBORG,DENMARK; UNIV COPENHAGEN HOSP,DANISH EPIDEMIOL SCI CTR,INST PREVENT MED,DK-1399 COPENHAGEN K,DENMARK	Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Aarhus University; University of Copenhagen	Sorensen, HT (corresponding author), AARHUS UNIV HOSP,DEPT INTERNAL MED 5,DK-8000 AARHUS,DENMARK.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Rothman, Kenneth/0000-0003-2398-1705				BINKIN NJ, 1988, PEDIATRICS, V82, P828; CHARNEY E, 1976, NEW ENGL J MED, V295, P6, DOI 10.1056/NEJM197607012950102; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; PECKHAM CS, 1983, BMJ-BRIT MED J, V286, P1237, DOI 10.1136/bmj.286.6373.1237; SEIDMAN DS, 1991, AM J DIS CHILD, V145, P782	5	174	179	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1137	1137						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374888	Green Published			2022-12-01	WOS:A1997YE61500027
J	Hudson, C; Clements, D; Friday, RV; Stott, D; Woodland, HR				Hudson, C; Clements, D; Friday, RV; Stott, D; Woodland, HR			Xsox17 alpha and -beta mediate endoderm formation in Xenopus	CELL			English	Article							IN-SITU HYBRIDIZATION; MESODERM INDUCTION; TRANSCRIPTIONAL REPRESSION; TRUNCATED ACTIVIN; GROWTH-FACTORS; EXPRESSION; LAEVIS; EMBRYOS; GENES; PROTEIN	We have isolated two Xenopus relatives of murine Sox17 expressed in gastrula presumptive endoderm. Xsox17 alpha and -beta expression can be induced in animal caps by activin, but not by FGF. Ectopic expression of these genes in animal caps induces the expression of endoderm markers; this induction is blocked by overexpression of a fusion of the Xsox17 beta HMG domain to the Drosophila Engrailed repressor domain, as is induction of endoderm markers by activin and the expression of endodermal markers in whole embryos and isolated vegetal poles. These experiments, as well as the effects of the mRNAs on embryo phenotypes, suggest that the Xsox17 genes mediate an activin-induced endoderm differentiation pathway in animal caps and are involved in normal endoderm differentiation in embryos.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick			Hudson, Clare/X-7618-2019	Hudson, Clare/0000-0003-1585-8328	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; Conlon FL, 1996, DEVELOPMENT, V122, P2427; COOK JP, 1993, BIOCONJUGATE CHEM, V4, P440, DOI 10.1021/bc00024a005; DEMARTIS A, 1994, MECH DEVELOP, V47, P19, DOI 10.1016/0925-4773(94)90092-2; Fan MJ, 1997, DEVELOPMENT, V124, P2581; GAMER LW, 1995, DEV BIOL, V171, P240, DOI 10.1006/dbio.1995.1275; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Henry GL, 1996, DEVELOPMENT, V122, P1007; Horb ME, 1997, DEVELOPMENT, V124, P1689; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Islam N, 1996, TRENDS GENET, V12, P459, DOI 10.1016/0168-9525(96)99990-4; JOHN A, 1995, DEVELOPMENT, V121, P1801; JONES EA, 1993, ROUX ARCH DEV BIOL, V202, P233, DOI 10.1007/BF02427884; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KNOCHEL W, 1986, J MOL EVOL, V23, P211, DOI 10.1007/BF02115578; Lemaire P, 1996, BIOESSAYS, V18, P701, DOI 10.1002/bies.950180904; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; LUKYANOV SA, 1994, BIOORG KHIM+, V20, P701; Nieuwkoop P.D., 1994, SYSTEMATICAL CHRONOL, DOI 10.1201/9781003064565-29; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; RICHARDSON JC, 1995, MECH DEVELOP, V52, P165, DOI 10.1016/0925-4773(95)00388-H; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Smith ST, 1996, DEVELOPMENT, V122, P3141; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; Weber H, 1996, DEVELOPMENT, V122, P1975; WILSON C, 1986, CELL, V47, P589, DOI 10.1016/0092-8674(86)90623-9; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; WYLIE CC, 1987, DEV BIOL, V119, P496, DOI 10.1016/0012-1606(87)90052-2	44	303	322	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					397	405		10.1016/S0092-8674(00)80423-7	http://dx.doi.org/10.1016/S0092-8674(00)80423-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363948	Bronze			2022-12-01	WOS:A1997YD94100013
J	Lin, VSY; Motesharei, K; Dancil, KPS; Sailor, MJ; Ghadiri, MR				Lin, VSY; Motesharei, K; Dancil, KPS; Sailor, MJ; Ghadiri, MR			A porous silicon-based optical interferometric biosensor	SCIENCE			English	Article							GENE-EXPRESSION; ARRAYS; MICROARRAY; POLYMER; SURFACE	A biosensor has been developed based on induced wavelength shifts in the Fabry-Perot fringes in the visible-light reflection spectrum of appropriately derivatized thin films of porous silicon semiconductors. Binding of molecules induced changes in the refractive index of the porous silicon. The validity and sensitivity of the system are demonstrated for small organic molecules (biotin and digoxigenin), 16-nucleotide DNA oligomers, and proteins (streptavidin and antibodies) at pico- and femtomolar analyte concentrations. The sensor is also highly effective for detecting single and multilayered molecular assemblies.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Sailor, Michael J/H-9044-2017	Sailor, Michael J/0000-0002-4809-9826	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM047165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18309, 2SO6 GM47165-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bard A. J., 1980, ELECTROCHEMICAL METH, DOI 10.1021/ed060pa25; BARNARD SM, 1991, SCIENCE, V251, P927, DOI 10.1126/science.2000492; BRECHT A, 1995, BIOSENS BIOELECTRON, V10, P923, DOI 10.1016/0956-5663(95)99230-I; BRECHT A, 1997, FRONTIERS BIOSENSORI, V2, P1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DOAN VV, 1992, SCIENCE, V256, P1791, DOI 10.1126/science.256.5065.1791; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; GOPEL W, 1989, SENSORS UPDATE, V1; HEMENWAY BR, 1989, APPL PHYS LETT, V55, P349, DOI 10.1063/1.101905; HICKMAN JJ, 1991, SCIENCE, V252, P688, DOI 10.1126/science.252.5006.688; Kittel C., 1986, INTRO SOLID STATE PH, V6th; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; Motohashi A, 1996, JPN J APPL PHYS 1, V35, P4253, DOI 10.1143/JJAP.35.4253; NEU DR, 1993, J PHYS CHEM-US, V97, P5713, DOI 10.1021/j100123a041; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; RIKLIN A, 1995, NATURE, V376, P672, DOI 10.1038/376672a0; Rossi B. B., 1957, OPTICS; ROWELL FJ, 1991, BIOCHEM SOC T, V19, P32, DOI 10.1042/bst0190032; SCHECHTER I, 1995, ANAL CHEM, V67, P3727, DOI 10.1021/ac00116a018; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHINOHARA Y, 1995, J BIOCHEM-TOKYO, V117, P1076; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; STIEVENARD D, 1995, APPL PHYS LETT, V67, P1570, DOI 10.1063/1.114942; Watanabe K, 1996, SENSOR ACTUAT B-CHEM, V33, P194, DOI 10.1016/0925-4005(96)80097-9	25	1135	1315	8	381	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					840	843		10.1126/science.278.5339.840	http://dx.doi.org/10.1126/science.278.5339.840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346478				2022-12-01	WOS:A1997YD47900040
J	Skinner, PJ; Koshy, BT; Cummings, CJ; Klement, IA; Helin, K; Servadio, A; Zoghbi, HY; Orr, HT				Skinner, PJ; Koshy, BT; Cummings, CJ; Klement, IA; Helin, K; Servadio, A; Zoghbi, HY; Orr, HT			Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures	NATURE			English	Article							SPINOCEREBELLAR ATAXIA; COILED BODY; TYPE-1; LOCALIZATION; ONCOPROTEIN; EXPRESSION; REPEAT; CELLS; GENE	Spinocerebellar ataxia type 1 (SCA1) is one of several neurodegenerative disorders caused by an expansion of a polyglutamine tract(1,2). It is characterized by ataxia, progressive motor deterioration, and loss of cerebellar Purkinje cells(1). To understand the pathogenesis of SCA1, we examined the subcellular localization of wild-type human ataxin-1 (the protein encoded by the SCA1 gene) and mutant ataxin-1 in the Purkinje cells of transgenic mice(3). We found that ataxin-1 localizes to the nuclei of cerebellar Purkinje cells, Normal ataxin-1 localizes to several nuclear structures similar to 0.5 mu m across, whereas the expanded ataxin-1 localizes to a single similar to 2-mu m structure, before the onset of ataxia. Mutant ataxin-1 localizes to a single nuclear structure in affected neurons of SCA1 patients. Similarly, COS-1 cells transfected with wild-type or mutant ataxin-1 show a similar pattern of nuclear localization; with expanded ataxin-1 occurring in larger structures that are fewer in number than those of normal ataxin-1. Colocalization studies show that mutant ataxin-1 causes a specific redistribution of the nuclear matrix-associated domain containing promyelocytic leukaemia protein(4-7). Nuclear matrix preparations demonstrate that ataxin-1 associates with the nuclear matrix in Purkinje and COS cells. We therefore propose that a critical aspect of SCA1 pathogenesis involves the disruption of a nuclear matrix-associated domain.	UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CELL & MOL BIOL PROGRAM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Zoghbi, Huda/0000-0002-0700-3349; Helin, Kristian/0000-0003-1975-6097; Skinner, Pamela/0000-0003-3388-1687; Orr, Harry/0000-0001-6118-741X	Telethon [38/B, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; [Anonymous], ADV NEUROL; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BISOTTO S, 1995, J CELL SCI, V108, P1873; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; CHAN EKL, 1994, NUCLEIC ACIDS RES, V22, P4462, DOI 10.1093/nar/22.21.4462; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dhordain P, 1995, ONCOGENE, V11, P2689; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MATILLA A, UNPUB P NATL ACAD SC; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; ROBITAILLE Y, 1995, ACTA NEUROPATHOL, V90, P572; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; STUURMAN N, 1992, J CELL SCI, V101, P773; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TELLEZNAGEL I, 1974, J NEUROPATH EXP NEUR, V33, P308, DOI 10.1097/00005072-197404000-00008; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8	29	469	478	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					971	974		10.1038/40153	http://dx.doi.org/10.1038/40153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353120				2022-12-01	WOS:A1997YD29900056
J	Nee, S; May, RM				Nee, S; May, RM			Extinction and the loss of evolutionary history	SCIENCE			English	Article							GENETIC DIVERSITY; CONSERVATION; BIODIVERSITY; POPULATIONS; TAXONOMY	Extinction episodes, such as the anthropogenic one currently under way, result in a pruned tree of life. But what fraction of the underlying evolutionary history survives when k of n species in a taxon are lost? This is relevant both to how species loss has translated into a loss of evolutionary history and to assigning conservation priorities. Here it is shown that approximately 80 percent of the underlying tree of life can survive even when approximately 95 percent of species are lost, and that algorithms that maximize the amount of evolutionary history preserved are not much better than choosing the survivors at random. Given the political, economic, and social realities constraining conservation biology, these findings may be helpful.			Nee, S (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.							BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Courtillot V, 1996, NATURE, V381, P146, DOI 10.1038/381146a0; DONOGHUE MJ, 1985, BRYOLOGIST, V88, P172, DOI 10.2307/3243026; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; ERWIN TL, 1991, SCIENCE, V253, P750, DOI 10.1126/science.253.5021.750; FAITH DP, 1994, BIOL CONSERV, V68, P69, DOI 10.1016/0006-3207(94)90548-7; GUYER C, 1993, EVOLUTION, V47, P253, DOI [10.2307/2410133, 10.1111/j.1558-5646.1993.tb01214.x]; HESSE H, 1987, GLASS BEARD GAME; HEY J, 1992, EVOLUTION, V46, P627, DOI [10.1111/j.1558-5646.1992.tb02071.x, 10.2307/2409633]; Hibbett DS, 1996, CONSERV BIOL, V10, P1321, DOI 10.1046/j.1523-1739.1996.10051321.x; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; KRAJEWSKI C, 1991, SCIENCE, V254, P918, DOI 10.1126/science.254.5034.918-a; Lawton JH, 1995, EXTINCTION RATES; LAWTON JH, 1994, OIKOS, V71, P1; Lovelock J, 1997, PHILOS T ROY SOC B, V352, P143, DOI 10.1098/rstb.1997.0009; Martin G, 1996, NATURE, V380, P666, DOI 10.1038/380666a0; MAY RM, 1990, NATURE, V347, P129, DOI 10.1038/347129a0; Mooers AO, 1997, Q REV BIOL, V72, P31, DOI 10.1086/419657; MORITZ C, 1994, TRENDS ECOL EVOL, V9, P373, DOI 10.1016/0169-5347(94)90057-4; NEE S, 1995, PHILOS T ROY SOC B, V349, P25, DOI 10.1098/rstb.1995.0087; NEI M, 1975, EVOLUTION, V29, P1, DOI [10.1111/j.1558-5646.1975.tb00807.x, 10.2307/2407137]; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Pimm SL, 1997, NATURE, V387, P231, DOI 10.1038/387231a0; PURVIS A, 1995, P ROY SOC B-BIOL SCI, V260, P329, DOI 10.1098/rspb.1995.0100; RAUP DM, 1993, EXTINCTION; SLATKIN M, 1991, GENETICS, V129, P555; STANLEY SM, 1994, SCIENCE, V266, P1340, DOI 10.1126/science.266.5189.1340; STANLEY SM, 1987, EVOLUTION, V41, P1177; TAVARE S, 1984, THEOR POPUL BIOL, V26, P119, DOI 10.1016/0040-5809(84)90027-3; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; [No title captured]	32	214	221	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					692	694		10.1126/science.278.5338.692	http://dx.doi.org/10.1126/science.278.5338.692			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381180				2022-12-01	WOS:A1997YC32300056
J	Holtz, JH; Asher, SA				Holtz, JH; Asher, SA			Polymerized colloidal crystal hydrogel films as intelligent chemical sensing materials	NATURE			English	Article							N-ISOPROPYLACRYLAMIDE; RESPONSIVE POLYMERS; PHASE-TRANSITIONS; GELS; POLY(N-ISOPROPYLACRYLAMIDE); DIFFRACTION; KINETICS; WATER; TEMPERATURE; SEPARATION	Chemical sensors' respond to the presence of a specific analyte in a variety of ways, One of the most convenient is a change in optical properties, and in particular a visually perceptible colour change. Here we report the preparation of a material that changes colour in response to a chemical signal by means of a change in diffraction (rather than absorption) properties. Our material is a crystalline colloidal array(2-12) of polymer spheres (roughly 100 nm diameter) polymerized within a hydrogel(13,14) that swells and shrinks reversibly in the presence of certain analytes (here metal ions and glucose). The crystalline colloidal array diffracts light at (visible) wavelengths determined by the lattice spacing(2-12), which gives rise to an intense colour. The hydrogel contains either a molecular-recognition group that binds the analyte selectively (crown ethers for metal ions), or a molecular-recognition agent that reacts with the analyte selectively. These recognition events cause the gel to swell owing to an increased osmotic pressure, which increases the mean separation between the colloidal spheres and so shifts the Bragg peak of the diffracted light to longer wavelengths. We anticipate that this strategy can be used to prepare 'intelligent' materials responsive to a wide range of analytes, including viruses.	UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								AASTUEN DJW, 1986, PHYS REV LETT, V57, P1733, DOI 10.1103/PhysRevLett.57.1733; ACKERSON BJ, 1981, PHYS REV LETT, V46, P123, DOI 10.1103/PhysRevLett.46.123; Asher S.A., 1986, Patent No. [US4632517A, 4632517]; Asher S.A., 1986, SPECTROSCOPY, V1, P26; ASHER SA, 1994, J AM CHEM SOC, V116, P4997, DOI 10.1021/ja00090a059; ASHER SA, 1986, Patent No. 4627689; CARLSON RJ, 1984, APPL SPECTROSC, V38, P297, DOI 10.1366/0003702844555548; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; DUBEY RK, 1995, TALANTA, V42, P65, DOI 10.1016/0039-9140(94)00217-G; DUSEK K, 1993, ADV POLYM SCI, V109; DUSEK K, 1993, ADV POLYM SCI, V110; FILLMORE DJ, 1979, J CHEM PHYS, V70, P1214; FLORY J, 1953, PRINCIPLES POLYM SCI; FUJISHIGE S, 1989, J PHYS CHEM-US, V93, P3311, DOI 10.1021/j100345a085; GEHRKE SH, 1986, CHEM ENG SCI, V41, P2153, DOI 10.1016/0009-2509(86)87131-7; GEHRKE SH, 1993, ADV POLYM SCI, V110, P81; GRIMSHAW PE, 1989, CHEM ENG SCI, V44, P827, DOI 10.1016/0009-2509(89)85256-X; HAKIKI A, 1994, J CHEM PHYS, V101, P9054, DOI 10.1063/1.468034; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI [DOI 10.1080/10601326808051910, 10.1080/10601326808051910]; HILTNER PA, 1969, J PHYS CHEM-US, V73, P2386, DOI 10.1021/j100727a049; HILTNER PA, 1971, J PHYS CHEM-US, V75, P1881, DOI 10.1021/j100681a020; HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; HURD AJ, 1982, PHYS REV A, V26, P2869, DOI 10.1103/PhysRevA.26.2869; IRIE M, 1993, ADV POLYM SCI, V110, P49; IRIE M, 1993, POLYMER, V34, P4531, DOI 10.1016/0032-3861(93)90160-C; IZATT RM, 1976, J AM CHEM SOC, V98, P7626, DOI 10.1021/ja00440a029; JANATA J, 1989, PRINCIPLES CHEM SENS; KATAOKA K, 1994, MACROMOLECULES, V27, P1061, DOI 10.1021/ma00082a028; KATAOKA K, 1995, MACROMOLECULES, V28, P3336, DOI 10.1021/ma00113a038; Khokhlov AR, 1996, MACROMOLECULES, V29, P681, DOI 10.1021/ma946426d; KOPOLOW S, 1973, MACROMOLECULES, V6, P133; KRIEGER IM, 1968, J AM CHEM SOC, V90, P3114, DOI 10.1021/ja01014a025; KUBOTA K, 1990, J PHYS CHEM-US, V94, P5154, DOI 10.1021/j100375a070; LI Y, 1990, J CHEM PHYS, V92, P1365, DOI 10.1063/1.458148; MCCURLEY MF, 1994, BIOSENS BIOELECTRON, V9, P527, DOI 10.1016/0956-5663(94)90015-9; OKANO T, 1993, ADV POLYM SCI, V110, P179; OSADA Y, 1993, PROG POLYM SCI, V18, P187, DOI 10.1016/0079-6700(93)90025-8; PETERS A, 1986, MACROMOLECULES, V19, P1952, DOI 10.1021/ma00161a029; Popov A.I., 1979, COORDINATION CHEM MA; RABA J, 1995, CRIT REV ANAL CHEM, V25, P1, DOI 10.1080/10408349508050556; RUNDQUIST PA, 1989, J CHEM PHYS, V91, P4932, DOI 10.1063/1.456734; Savage M.D., 1992, AVIDIN BIOTIN CHEM H; SCHALKHAMMER T, 1995, SENSOR ACTUAT B-CHEM, V24, P166, DOI 10.1016/0925-4005(95)85036-8; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; SHEPPARD NF, 1995, SENSOR ACTUAT B-CHEM, V28, P95, DOI 10.1016/0925-4005(94)01542-P; TANAKA T, 1978, PHYS REV LETT, V40, P820, DOI 10.1103/PhysRevLett.40.820; WANG KL, 1993, ADV POLYM SCI, V110, P67; Weissman JM, 1996, SCIENCE, V274, P959, DOI 10.1126/science.274.5289.959; YOKOI K, 1995, ANAL CHIM ACTA, V316, P363, DOI 10.1016/0003-2670(95)00375-A; ZEN JM, 1994, ANAL CHIM ACTA, V296, P77, DOI 10.1016/0003-2670(94)85152-2	50	1711	1787	52	1377	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					829	832		10.1038/39834	http://dx.doi.org/10.1038/39834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349814				2022-12-01	WOS:A1997YC14800051
J	Jones, AH				Jones, AH			Literature and medicine: Garcia Marquez' Love in the Time of Cholera	LANCET			English	Editorial Material											Jones, AH (corresponding author), UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,ASHBEL SMITH BLDG SUITE 2-210,301 UNIV BLVD,GALVESTON,TX 77555, USA.							BELLVILLADA GH, 1990, G MARQUEZ MAN HIS WO, P192; BOOKER MK, 1993, LOVE TIME CHOLERA ST, V17, P181; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; COLUMBUS CK, 1992, TWENTIETH CENT LIT, V38, P89; CONTI MS, 1996, WORLD PRESS REV  OCT, P60; DICKEY J, 1969, EYE BEATERS BLOOD VI, P31; DOWNIE RS, 1991, J MED ETHICS, V17, P93, DOI 10.1136/jme.17.2.93; DOWNIE RS, 1991, J MED ETHICS, V17, P98; FIDDIAN R, 1987, GG MARQUEZ NEW READI, P192; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; Marquez G. G, 1988, LOVE TIME CHOLERA; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; Moore AR, 1978, MISSING MED TEXT HUM; RABUZZI KA, 1982, LIT MED, V1, P1; Tennyson Alfred, 1971, TENNYSONS POETRY, P54; Trautmann J., 1978, ROLE HUMANITIES MED, P32	16	3	6	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1169	1172		10.1016/S0140-6736(97)09249-0	http://dx.doi.org/10.1016/S0140-6736(97)09249-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	YB199	9379818				2022-12-01	WOS:A1997YB19900050
J	WeverlingRijnsburger, AWE; Blauw, GJ; Lagaay, AM; Knook, DL; Meinders, AE; Westendorp, RGJ				WeverlingRijnsburger, AWE; Blauw, GJ; Lagaay, AM; Knook, DL; Meinders, AE; Westendorp, RGJ			Total cholesterol and risk of mortality in the oldest old	LANCET			English	Article							POPULATION-BASED SURVEY; SERUM-CHOLESTEROL; MYOCARDIAL-INFARCTION; FOLLOW-UP; AGED 85; PRAVASTATIN; CANCER; TRANSPLANTATION; ASSOCIATION; MORBIDITY	Background The impact of total serum cholesterol as a risk factor for cardiovascular disease decreases with age, which casts doubt on the necessity for cholesterol-lowering therapy in the elderly. We assessed the influence of total cholesterol concentrations on specific and all-cause mortality in people aged 85 years and over. Methods In 724 participants (median age 89 years), total cholesterol concentrations were measured and mortality risks calculated over 10 years of follow-up. Three categories of total cholesterol concentrations were defined <5.0 mmol/L, 5.0-6.4 mmol/L, and greater than or equal to 6.5 mmol/L. In a subgroup of 137 participants, total cholesterol was measured again after 5 years of follow-up. Mortality risks for the three categories of total cholesterol concentrations were estimated with a Cox proportional-hazards model, adjusted for age, sex, and cardiovascular risk factors. The primary causes of death were coded according to the International Classification of Diseases (ICD-9). Findings During 10 years of follow-up from Dec 1, 1986, to Oct 1, 1996, a total of 642 participants died. Each 1 mmol/L increase in total cholesterol corresponded to a 15% decrease in mortality (risk ratio 0.85 [95% CI 0.79-0.91]). This risk estimate was similar in the subgroup of participants who had stable cholesterol concentrations over a 5-year period. The main cause of death was cardiovascular disease with a similar mortality risk in the three total cholesterol categories. Mortality from cancer and infection was significantly lower among the participants in the highest total cholesterol category than in the other categories, which largely explained the lower all-cause mortality in this category. Interpretation in people older than 85 years, high total cholesterol concentrations are associated with longevity owing to lower mortality from cancer and infection. The effects of cholesterol-lowering therapy have yet to be assessed.	LEIDEN UNIV,MED CTR,DEPT CLIN EPIDEMIOL,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	WeverlingRijnsburger, AWE (corresponding author), LEIDEN UNIV,MED CTR,DEPT GEN INTERNAL MED,SECT GERONTOL & GERIATR,POB 9600,C1-R45,NL-2300 RC LEIDEN,NETHERLANDS.		Blauw, Gerard/GWD-1079-2022; Blauw, Gerard/AAW-7904-2021					*AM ASS CLIN CHEM, 1994, GER CLIN CHEM REF VA, P312; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946; Corti MC, 1997, ANN INTERN MED, V126, P753, DOI 10.7326/0003-4819-126-10-199705150-00001; Crouse JR, 1997, ARCH INTERN MED, V157, P1305, DOI 10.1001/archinte.157.12.1305; DelgadoRodriguez M, 1997, INFECT CONT HOSP EP, V18, P9; DEVRIES CL, 1993, CARDIOLOGY, V82, P89, DOI 10.1159/000175861; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Katznelson S, 1996, TRANSPLANTATION, V61, P1469, DOI 10.1097/00007890-199605270-00010; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; KROMHOUT D, 1988, ARCH INTERN MED, V148, P1051, DOI 10.1001/archinte.148.5.1051; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LAGAAY AM, 1992, ARCH GERONTOL GERIAT, V15, P115, DOI 10.1016/0167-4943(92)90012-S; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Netea MG, 1996, J CLIN INVEST, V97, P1366, DOI 10.1172/JCI118556; OLDHAM PD, 1962, J CHRON DIS, V15, P969, DOI 10.1016/0021-9681(62)90116-9; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; Sharp SJ, 1997, EPIDEMIOLOGY, V8, P132, DOI 10.1097/00001648-199703000-00002; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; World Health Organization, 1977, INT CLASS DIS; Zureik M, 1997, EPIDEMIOLOGY, V8, P137, DOI 10.1097/00001648-199703000-00003; 1995, LANCET, V333, P1301	27	362	377	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1119	1123		10.1016/S0140-6736(97)04430-9	http://dx.doi.org/10.1016/S0140-6736(97)04430-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343498				2022-12-01	WOS:A1997YB19900008
J	Klumpp, M; Baumeister, W; Essen, LO				Klumpp, M; Baumeister, W; Essen, LO			Structure of the substrate binding domain of the thermosome, an archaeal group II chaperonin	CELL			English	Article							T-COMPLEX POLYPEPTIDE-1; CYTOSOLIC CHAPERONIN; MOLECULAR CHAPERONE; THERMOPHILIC ARCHAEBACTERIUM; CYTOPLASMIC CHAPERONIN; EUKARYOTIC CYTOSOL; CRYSTAL-STRUCTURE; BETA-ACTIN; HEAT-SHOCK; PROTEIN	The crystal structure of the substrate binding domain of the thermosome, the archaeal group II chaperonin, has been determined at 2.3 Angstrom resolution. The core resembles the apical domain of GroEL but lacks the hydrophobic residues implied in binding of substrates to group I chaperonins. Rather, a large hydrophobic surface patch is found in a novel helix-turn-helix motif, which is characteristic of all group II chaperonins including the eukaryotic TRiC/CCT complex. Models of the holochaperonin, which are consistent with cryo electron microscopy data, suggest a dual role of this helical protrusion in substrate binding and controlling access to the central cavity independent of a GroES-like cochaperonin.	MAX PLANCK INST BIOCHEM,DEPT MOL STRUCT BIOL,D-82152 PLANEGG,GERMANY; MAX PLANCK INST BIOCHEM,DEPT MEMBRANE BIOCHEM,D-82152 PLANEGG,GERMANY	Max Planck Society; Max Planck Society			Essen, Lars-Oliver/L-3862-2016	Essen, Lars-Oliver/0000-0003-4272-4026; Klumpp, Martin/0000-0003-3373-9605				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Andra S, 1996, FEBS LETT, V379, P127, DOI 10.1016/0014-5793(95)01493-4; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BRUNGER AT, 1992, XPLOR VERSION 3 1; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; ELLIS J, 1992, NATURE, V358, P191, DOI 10.1038/358191a0; ELLIS RJ, 1996, ACTA CRYSTALLOGR A, V47, P392; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nitsch M, 1997, J MOL BIOL, V267, P142, DOI 10.1006/jmbi.1996.0849; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WALDMANN T, 1995, BIOL CHEM H-S, V376, P119, DOI 10.1515/bchm3.1995.376.2.119; WALDMANN T, 1995, FEBS LETT, V376, P67, DOI 10.1016/0014-5793(95)01248-8; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	44	137	140	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					263	270		10.1016/S0092-8674(00)80408-0	http://dx.doi.org/10.1016/S0092-8674(00)80408-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346243	Bronze			2022-12-01	WOS:A1997YC35000013
J	Groux, H; OGarra, A; Bigler, M; Rouleau, M; Antonenko, S; deVries, JE; Roncarolo, MG				Groux, H; OGarra, A; Bigler, M; Rouleau, M; Antonenko, S; deVries, JE; Roncarolo, MG			A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis	NATURE			English	Article							T-HELPER-2 POPULATIONS; INTERLEUKIN-10 IL-10; MICE; PROLIFERATION; STIMULATION; EXPRESSION; CLONES; ANERGY	Induction and maintenance of peripheral tolerance are important mechanisms to maintain the balance of the immune system. In addition to the deletion of T cells and their failure to respond in certain circumstances, active suppression mediated by T cells or T-cell factors has been proposed as a mechanism for maintaining peripheral tolerance(1). However, the inability to isolate and clone regulatory T cells involved in antigen-specific inhibition of immune responses has made it difficult to understand the mechanisms underlying such active suppression. Here we show that chronic activation of both human and murine CD4(+) T cells in the presence of interleukin (IL)-10 gives rise to CD4(+) T-cell clones with low proliferative capacity, producing high levels of IL-10, low levels of IL-2 and no IL-4. These antigen-specific T-cell clones suppress the proliferation of CD4(+) T cells in response to antigen, and prevent colitis induced in SCID mice by pathogenic CD4(+)CD45RB(high) splenic T cells. Thus IL-10 drives the generation of a CD4(+) T-cell subset, designated T regulatory cells 1 (Tr1), which suppresses antigen-specific immune responses and actively downregulates a pathological immune response in vivo.	DNAX RES INST MOL & CELLULAR BIOL INC, DEPT HUMAN IMMUNOL, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Rouleau, Matthieu/D-5774-2016	Rouleau, Matthieu/0000-0002-0075-9880; O'Garra, Anne/0000-0001-9845-6134; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ABRAMOWICZ D, 1993, TRANSPLANT P, V25, P312; ALLEN RD, 1993, EUR J IMMUNOL, V23, P333, DOI 10.1002/eji.1830230205; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BECKER JC, 1994, INT IMMUNOL, V6, P1605, DOI 10.1093/intimm/6.10.1605; BLAZAR BR, 1995, BLOOD, V85, P842, DOI 10.1182/blood.V85.3.842.bloodjournal853842; Cannella B, 1996, J NEUROSCI RES, V45, P735, DOI 10.1002/(SICI)1097-4547(19960915)45:6<735::AID-JNR10>3.0.CO;2-V; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; GERMAIN RN, 1981, SCAND J IMMUNOL, V13, P1, DOI 10.1111/j.1365-3083.1981.tb00104.x; GORCZYNSKI RM, 1994, J IMMUNOL, V152, P2011; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; HAU HS, 1996, J AUTOIMMUN, V9, P331; JENKINS MK, 1990, J IMMUNOL, V144, P16; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEE MS, 1994, J CLIN INVEST, V93, P1332, DOI 10.1172/JCI117092; MALEFYT RD, 1991, J EXP MED, V174, P915; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NISITANI S, 1995, EUR J IMMUNOL, V25, P3047, DOI 10.1002/eji.1830251110; Nossal G J, 1987, Int Rev Immunol, V2, P321, DOI 10.3109/08830188709044760; OGarra A, 1996, CHEM IMMUNOL, V63, P1; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; RENNICK D, 1995, INTERLEUKIN 10, P141; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUZUKI T, 1995, J EXP MED, V182, P477, DOI 10.1084/jem.182.2.477; Weiner HL, 1996, FASEB J, V10, pA1444; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	30	2964	3123	2	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					737	742		10.1038/39614	http://dx.doi.org/10.1038/39614			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338786				2022-12-01	WOS:A1997YA95900057
J	Kothakota, S; Azuma, T; Reinhard, C; Klippel, A; Tang, J; Chu, KT; McGarry, TJ; Kirschner, MW; Koths, K; Kwiatkowski, DJ; Williams, LT				Kothakota, S; Azuma, T; Reinhard, C; Klippel, A; Tang, J; Chu, KT; McGarry, TJ; Kirschner, MW; Koths, K; Kwiatkowski, DJ; Williams, LT			Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; ICE/CED-3 PROTEASE; ACTIN; CELLS; INHIBITION; SUBSTRATE; IDENTIFICATION; PLASMA; CED-3; MICE	The caspase-3 (CPP32, apopain, YAMA) family of cysteinyl proteases has been implicated as key mediators of apoptosis in mammalian cells, Gelsolin was identified as a substrate for caspase-3 by screening the translation products of small complementary DNA pools for sensitivity to cleavage by caspase-3. Gelsolin was cleaved in vivo in a caspase-dependent manner in cells stimulated by Fas. Caspase-cleaved gelsolin severed actin filaments in vitro in a Ca2+-independent manner, Expression of the gelsolin cleavage product in multiple cell types caused the cells to round up, detach from the plate, and undergo nuclear fragmentation. Neutrophils isolated from mice lacking gelsolin had delayed onset of both blebbing and DNA fragmentation, following apoptosis induction, compared with wild-type neutrophils. Thus, cleaved gelsolin may be one physiological effector of morphologic change during apoptosis.	CHIRON CORP,EMERYVILLE,CA 94608; BRIGHAM & WOMENS HOSP,DIV EXPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Novartis; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054188, P01HL048743] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48743, R01 HL54188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Asch HL, 1996, CANCER RES, V56, P4841; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; King RW, 1997, SCIENCE, V277, P973, DOI 10.1126/science.277.5328.973; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; KWIATKOWSKI DJ, UNPUB; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cb.11.110195.002433; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; TANAKA M, 1995, CANCER RES, V55, P3228; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WEEDS AG, 1991, BIOCHEM SOC T, V19, P1016, DOI 10.1042/bst0191016; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	37	978	1013	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					294	298		10.1126/science.278.5336.294	http://dx.doi.org/10.1126/science.278.5336.294			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323209				2022-12-01	WOS:A1997YA56400046
J	Tsuneizumi, K; Nakayama, T; Kamoshida, Y; Kornberg, TB; Christian, JL; Tabata, T				Tsuneizumi, K; Nakayama, T; Kamoshida, Y; Kornberg, TB; Christian, JL; Tabata, T			Daughters against dpp modulates dpp organizing activity in Drosophila wing development	NATURE			English	Article							PATTERN; PROTEIN; MORPHOGEN; HEDGEHOG; XENOPUS; EXPRESSION; MESODERM; MOTHERS; FAMILY; GENES	The family of TGF-beta signalling molecules play inductive roles in various developmental contexts(1). One member of this family, Drosophila Decapentaplegic (Dpp)(2) serves as a morphogen that patterns both the embryo(3,1) and adult(4,5). We have now isolated a gene, Daughters against dpp (Dad), whose transcription is induced by Dpp, Dad shares weak homology with Drosophila Mad (Mothers against dpp)(6), a protein required for transduction of Dpp signals. In contrast to Mad or the activated Dpp receptor, whose overexpression hyperactivates the Dpp signalling pathway, overexpression of Dad blocks Dpp activity, Expression of Dad together with either Mad or the activated receptor rescues phenotypic defects induced by each protein alone. Dad can also antagonize the activity of a vertebrate homologue of Dpp, bone morphogenetic protein (BMP-4; ref. 7), as evidenced by induction of dorsal or neural fate following overexpression in Xenopus embryos. We conclude that the pattern-organizing mechanism governed by Dpp involves a negative-feedback circuit in which Dpp induces expression of its own antagonist, Dad, This feedback loop appears to be conserved in vertebrate development.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,TOKYO 113,JAPAN; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of Tokyo; Oregon Health & Science University; University of California System; University of California San Francisco			Nakayama, Takuya/J-5812-2015	Nakayama, Takuya/0000-0002-5531-6710				BLITZ IL, 1995, DEVELOPMENT, V121, P993; BRAND AH, 1993, DEVELOPMENT, V118, P401; Burke R, 1996, DEVELOPMENT, V122, P2261; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ito K, 1997, DEVELOPMENT, V124, P761; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAI CJ, 1995, DEVELOPMENT, V121, P2349; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MACIASSILVA M, 1997, CELL, V87, P1215; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MOON RT, 1989, TECHNIQUE, V1, P76; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; ZECCA M, 1995, DEVELOPMENT, V121, P2265	32	346	352	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					627	631		10.1038/39362	http://dx.doi.org/10.1038/39362			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335506				2022-12-01	WOS:A1997YA00800066
J	Garbe, E; LeLorier, J; Boivin, JF; Suissa, S				Garbe, E; LeLorier, J; Boivin, JF; Suissa, S			Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids	LANCET			English	Article							INTRAOCULAR-PRESSURE	Background Ocular hypertension and open-angle glaucoma are well-known side-effects of treatment with topical ophthalmic glucocorticoids. There is uncertainty about the risk of these disorders with oral glucocorticoid therapy. Methods Data from the Quebec universal health insurance programme for the elderly were used to identify 9793 patients with a new diagnosis of ocular hypertension or open-angle glaucoma, or on newly prescribed treatment for these disorders (cases). 38 325 controls were randomly selected from ophthalmology patients seen in the same month and year as the case (index date). Current use of oral glucocorticoids was defined as that within 14 days of the index date. All glucocorticoid doses were converted to the equivalent amount of hydrocortisone. The case-control analysis was done by conditional logistic regression and adjusted for age, sex, systemic hypertension, diabetes mellitus, ophthalmic glucocorticoids, glucocorticoid injections, and variables related to general health. Findings The mean ages of cases and controls were similar (74.9 [SD 6.3] vs 74.7 [6.4]). The adjusted odds ratio of ocular hypertension or open-angle glaucoma for current users of oral glucocorticoids compared with non-users was 1.41 (95% CI 1.22-1.63). There was a dose-related increase in the adjusted odds ratios for current users: 1.26 (1.01-1.56) for less than 40 mg per day of hydrocortisone, 1.37 (1.06-1.76) for patients on 40-79 mg per day, and 1.88 (1.40-2.53) for patients on 80 mg or more per day. The odds ratios also increased with the duration of treatment over the first 11 months of exposure. Interpretation The use of oral glucocorticoids increases the risk of ocular hypertension or open-angle glaucoma in elderly patients. In patients in this age-group who need long-term treatment with high doses of oral glucocorticoids, monitoring of intraocular pressure may be justified.	ROYAL VICTORIA HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ H3A 2T5,CANADA; UNIV MONTREAL,HOTEL DIEU,CTR RECH,MONTREAL,PQ H3C 3J7,CANADA; POTSDAM INST PHARMACOEPIDEMIOL & TECHNOL ASSESSME,POTSDAM,GERMANY	McGill University; Royal Victoria Hospital; McGill University; Laval University; Universite de Montreal								ABEL R, 1987, AVERYS DRUG TREATMEN, P387; ADHIKARY HP, 1982, BRIT J OPHTHALMOL, V66, P290, DOI 10.1136/bjo.66.5.290; ALFANO JE, 1963, AM J OPHTHALMOL, V56, P245, DOI 10.1016/0002-9394(63)91858-0; [Anonymous], 1982, EPIDEMIOLOGIC RES; ARMALY MF, 1986, GLAUCOMA, P697; BECKER B, 1963, ARCH OPHTHALMOL-CHIC, V70, P500; BERNSTEIN HN, 1962, ARCH OPHTHALMOL-CHIC, V68, P742; CLARK WG, 1992, GOTHS MED PHARM, P773; DAVID DS, 1969, LANCET, V2, P149; DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GODEL V, 1972, ACTA OPHTHALMOL, V50, P655; HAYNES R C JR, 1990, P1431; Hodapp EA, 1982, SECONDARY GLAUCOMAS, P258; KITAZAWA Y, 1976, AM J OPHTHALMOL, V82, P492, DOI 10.1016/0002-9394(76)90500-6; LEE PF, 1958, AM J OPHTHALMOL, V46, P328, DOI 10.1016/0002-9394(58)90256-3; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; LONG WF, 1977, AM J OPTOM PHYS OPT, V54, P248; QUIGLEY HA, 1993, NEW ENGL J MED, V328, P1097, DOI 10.1056/NEJM199304153281507; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; Skuta GL, 1996, GLAUCOMAS, P1177; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; STERN JJ, 1953, AM J OPHTHALMOL, V36, P389, DOI 10.1016/0002-9394(53)91389-0; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; WEINREB RN, 1981, INVEST OPHTH VIS SCI, V21, P403; *WHO, 1977, 9 REV C 1975; WILLIAMSON J, 1969, BRIT J OPHTHALMOL, V53, P361, DOI 10.1136/bjo.53.6.361	27	111	113	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					979	982		10.1016/S0140-6736(97)03392-8	http://dx.doi.org/10.1016/S0140-6736(97)03392-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329512				2022-12-01	WOS:A1997XZ71000008
J	Liem, KF; Tremml, G; Jessell, TM				Liem, KF; Tremml, G; Jessell, TM			A role for the roof plate and its resident TGF beta-related proteins in neuronal patterning in the dorsal spinal cord	CELL			English	Article							NEURAL CREST CELLS; BONE MORPHOGENETIC PROTEIN-4; FLOOR PLATE; SONIC HEDGEHOG; VERTEBRATE DEVELOPMENT; NERVOUS-SYSTEM; MOTOR-NEURONS; EXPRESSION; ACTIVIN; DIFFERENTIATION	Distinct neuronal cell types are generated at characteristic times and positions in the dorsal horn of the spinal cord. We provide evidence that the identity and pattern of generation of dorsal neurons depend initially on BMP-mediated signals that derive from the epidermal ectoderm and induce dorsal midline cells of the roof plate. Roof plate cells provide a secondary source of TGF beta-related signals that are required for the generation of distinct classes of dorsal interneurons. These inductive interactions involve both qualitative and quantitative differences in signaling by TGF beta-related factors and temporal changes in the response of neural progenitor cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10021	Columbia University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN J, 1984, DEV RAT SPINAL CORD; Arkell R, 1997, DEVELOPMENT, V124, P1; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; Brown AG, 1981, ORG SPINAL CORD; CARPENTER EM, 1992, DEV BIOL, V150, P144, DOI 10.1016/0012-1606(92)90014-8; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Dudley AT, 1997, DEV DYNAM, V208, P349; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; Eichmann A, 1997, MECH DEVELOP, V65, P111, DOI 10.1016/S0925-4773(97)00063-4; EIDE AL, 1997, ANAT EMBRYOL, V197, P195; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gale NW, 1996, ONCOGENE, V13, P1343; GURDON JB, 1994, NATURE, V225, P40; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; LEBER SM, 1995, J NEUROSCI, V15, P1236; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; MUHR J, 1997, IN PRESS NEURON; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NEWGREEN DF, 1986, INT REV CYTOL, V103, P89, DOI 10.1016/S0074-7696(08)60834-7; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; OPPENHEIM RW, 1988, J COMP NEUROL, V275, P159, DOI 10.1002/cne.902750202; PITUELLO F, 1995, P NATL ACAD SCI USA, V92, P6952, DOI 10.1073/pnas.92.15.6952; PUOPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	62	457	465	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					127	138		10.1016/S0092-8674(01)80015-5	http://dx.doi.org/10.1016/S0092-8674(01)80015-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335341	Bronze			2022-12-01	WOS:A1997XZ80900015
J	Nunn, AJ; Mulder, DW; Kamali, A; Ruberantwari, A; KengeyaKayondo, JF; Whitworth, J				Nunn, AJ; Mulder, DW; Kamali, A; Ruberantwari, A; KengeyaKayondo, JF; Whitworth, J			Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE PROGRESSION; HOMOSEXUAL MEN; AFRICAN CITY; AIDS; IMMUNODEFICIENCY; SURVIVAL; SEX; AGE; SEROCONVERSION; HEMOPHILIACS	Objective: To assess the impact of HIV-1 infection on mortality over five years in a rural Ugandan population. Design: Longitudinal cohort study followed up annually by a house to house census and medical survey. Setting: Rural population in south west Uganda. Subjects: About 10 000 people from 15 villages who were enrolled in 1989-90 or later. Main outcome measures: Number of deaths from all causes, death rates, mortality fraction attributable to HIV-1 infection. Results: Of 9777 people resident in the study area in 1989-90, 8833 (90%) had an unambiguous result on testing for HIV-1 antibody; throughout the period of follow up adult seroprevalence was about 8%. During 35 083 person years of follow up, 459 deaths occurred, 273 in seronegative subjects and 186 in seropositive subjects, corresponding to standardised death rates of 8.1 and 129.3 per 1000 person years. Standardised death rates for adults were 10.4 (95% confidence interval 9.0 to 11.8) and 114.0 (93.2 to 134.8) per 1000 person years respectively, The mortality fraction attributable to HIV-1 infection was 41% for adults and was in excess of 70% for men aged 25-44 and women aged 20-44 years. Median survival from time of enrolment was less than three years in subjects aged 55 years or more who were infected with HIV-1. Life expectancy from birth in the total population resident at any time was estimated to be 42.5 years (41.4 years in men; 43.5 years in women), which compares with 58.3 years (56.5 years in men; 60.5 years in women) in people known to be seronegative. Conclusions: These data confirm that in a rural African population HIV-1 infection is associated with high death rates and a substantial reduction in life expectancy.	UGANDA VIRUS RES INST, MED RES PROGRAMME AIDS, ENTEBBE, UGANDA; UNIV AMSTERDAM, ACAD MED CTR, INST SOCIAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS; MRC, AIDS PROGRAMME, ENTEBBE, UGANDA	Uganda Virus Research Institute; University of Amsterdam; Academic Medical Center Amsterdam	Nunn, AJ (corresponding author), UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND.			Nunn, Andrew/0000-0002-9158-4595				ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BLATT SP, 1995, J INFECT DIS, V171, P837, DOI 10.1093/infdis/171.4.837; BORGDORFF MW, 1995, GENITOURIN MED, V71, P212; BULTERYS M, 1993, AIDS, V7, P1269, DOI 10.1097/00002030-199309000-00019; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DONDERO TJ, 1994, LANCET, V343, P989, DOI 10.1016/S0140-6736(94)90120-1; Duesberg P, 1996, BRIT MED J, V312, P210; DUESBERG PH, 1995, LANCET, V346, P1371, DOI 10.1016/S0140-6736(95)92389-6; DUESBERG PH, 1995, GENETICA, V95, P51, DOI 10.1007/BF01435001; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; Low N, 1996, GENITOURIN MED, V72, P12; MANN JM, 1986, JAMA-J AM MED ASSOC, V255, P3255, DOI 10.1001/jama.255.23.3255; MARTIN JN, 1995, AM J EPIDEMIOL, V142, P1221, DOI 10.1093/oxfordjournals.aje.a117581; MELNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915, DOI 10.1001/jama.272.24.1915; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; NUNN AJ, 1994, METHOD INFORM MED, V33, P170; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; PHILLIPS AN, 1994, AIDS, V8, P831, DOI 10.1097/00002030-199406000-00017; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; Sabin CA, 1996, BMJ-BRIT MED J, V312, P207, DOI 10.1136/bmj.312.7025.207; SCHECHTER MT, 1995, J ACQ IMMUN DEF SYND, V8, P474, DOI 10.1097/00042560-199504120-00007; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014	33	99	99	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					767	771						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345167	Green Published, Green Submitted			2022-12-01	WOS:A1997XY91100016
J	Chung, CD; Liao, JY; Liu, B; Rao, XP; Jay, P; Berta, P; Shuai, K				Chung, CD; Liao, JY; Liu, B; Rao, XP; Jay, P; Berta, P; Shuai, K			Specific inhibition of Stat3 signal transduction by PIAS3	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; ACTIVATION; GENE; TRANSCRIPTION; PROTEINS; CLONING; PATHWAY; GAMMA; DNA	The signal transducer and activator of transcription-3 (Stat3) protein is activated by the interleukin 6 (IL-6) family of cytokines, epidermal growth factor, and leptin. A protein named PIAS3 (protein inhibitor of activated STAT) that binds to Stat3 was isolated and characterized. The association of PIAS3 with Stat3 in vivo was only observed in cells stimulated with ligands that cause the activation of Stat3. PIAS3 blocked the DNA-binding activity of Stat3 and inhibited Stat3-mediated gene activation. Although Stat1 is also phosphorylated in response to IL-6, PIAS3 did not interact with Stat1 or affect its DNA-binding or transcriptional activity. The results indicate that PIAS3 is a specific inhibitor of Stat3.	UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; CTR RECH BIOCHIM MACROMOL,F-34000 MONTPELLIER,FRANCE; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; Universite de Montpellier; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Jay, Philippe/ABD-9223-2020	Jay, Philippe/0000-0003-0156-5700	NCI NIH HHS [T32CA09056] Funding Source: Medline; NIAID NIH HHS [AI39612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039612] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chung C.-A., UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Leveillard Thierry, 1993, Gene Expression, V3, P135; LIAO J, UNPUB, P63509; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	21	777	833	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1803	1805		10.1126/science.278.5344.1803	http://dx.doi.org/10.1126/science.278.5344.1803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388184				2022-12-01	WOS:A1997YJ90100050
J	Deming, TJ				Deming, TJ			Facile synthesis of block copolypeptides of defined architecture	NATURE			English	Article							ANHYDRIDES; ACID	Many natural polymeric materials (particularly structural proteins) display a hierarchy of structure over several length scales. Block copolymers are able to self-assemble into ordered nanostructures(1,2), but the random-coiled nature of their polymer chains usually suppresses any further levels of organization. The use of components with regular structures, such as rigid-rod polymers, can increase the extent of spatial organization in self-assembling materials(3). But the synthesis of such polymeric components typically involves complicated reaction steps that are not suitable for large-scale production. Proteins form hierarchically organized structures in which the fundamental motifs are generally alpha-helical coils and beta-sheets(4). Attempts to synthesize polypeptides with well-defined amino-acid sequences, which might adopt similar organized structures, have been plagued by unwanted side reactions(5) that give rise to products with a wide range of molecular weights(6-10), hampering the formation of well-defined peptide block copolymers(11-17). Here I describe a polymerization strategy that overcomes these difficulties by using organonickel initiators which suppress chain-transfer and termination side reactions. This approach allows the facile synthesis of block copolypeptides with well-defined sequences, which might provide new peptide-based biomaterials with potential applications in tissue engineering, drug delivery and biomimetic composite formation.	UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara	Deming, TJ (corresponding author), UNIV CALIF SANTA BARBARA,DEPT MAT,SANTA BARBARA,CA 93106, USA.		Deming, Timothy/I-5411-2013	Deming, Timothy/0000-0002-0594-5025				Bamford C.H.E.A., 1956, SYNTHETIC POLYPEPTID; BLOCK H, 1983, POLY GAMMA BENZYL LA; CARDINAUX F, 1977, BIOPOLYMERS, V16, P2005, DOI 10.1002/bip.1977.360160914; CASTANO AM, 1994, ORGANOMETALLICS, V13, P2262, DOI 10.1021/om00018a020; COLLMAN JP, 1987, PRINCIPLES APPLICATI; Deming TJ, 1997, J AM CHEM SOC, V119, P2759, DOI 10.1021/ja962625w; Deming TJ, 1997, ADV MATER, V9, P299, DOI 10.1002/adma.19970090404; Fetters L., 1987, ENCY POLYM SCI ENG, V10, P19; GRATZER WB, 1963, J AM CHEM SOC, V85, P1193, DOI 10.1021/ja00891a035; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; HOWARD JC, 1977, BIOPOLYMERS, V16, P2029, DOI 10.1002/bip.1977.360160915; IDELSON M, 1957, J AM CHEM SOC, V79, P3948, DOI 10.1021/ja01572a002; IDELSON M, 1958, J AM CHEM SOC, V80, P2387, DOI 10.1021/ja01543a012; INOUE K, 1994, J AM CHEM SOC, V116, P10783, DOI 10.1021/ja00102a053; Kricheldorf H. R., 1987, ALPHA AMINOACID N CA; Kricheldorf H. R., 1990, MODELS BIOPOLYMERS R; KUBOTA S, 1975, BIOPOLYMERS, V14, P305; LUNDBERG RD, 1957, J AM CHEM SOC, V79, P3961, DOI 10.1021/ja01572a004; Matsen MW, 1996, MACROMOLECULES, V29, P7641, DOI 10.1021/ma960744q; NOSHAY A, 1977, BLOCK COPOLYMERS; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SANO K, 1984, B CHEM SOC JPN, V57, P2741, DOI 10.1246/bcsj.57.2741; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; UHLIG E, 1980, Z ANORG ALLG CHEM, V465, P141, DOI 10.1002/zaac.19804650115; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887	25	521	607	8	247	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					386	389		10.1038/37084	http://dx.doi.org/10.1038/37084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389476				2022-12-01	WOS:A1997YH54900058
J	Hayward, RA; Manning, WG; Kaplan, SH; Wagner, EH; Greenfield, S				Hayward, RA; Manning, WG; Kaplan, SH; Wagner, EH; Greenfield, S			Starting insulin therapy in patients with type 2 diabetes - Effectiveness, complications, and resource utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION; MELLITUS; GLUCOSE; DISEASE; CARE; OUTCOMES; ILLNESS; IMPACT; TRIAL; BLOOD	Context.-Although experimental studies show that insulin therapy can be safe and efficacious in improving glycemic control in type 2 diabetes under optimal conditions (ie, using patient volunteers with close monitoring under strict study protocols), little is known about its effectiveness, complication rates, and associated resource utilization in actual clinical practice. Design.-Cohort study. Setting.-Large staff-model health maintenance organization. Participants.-A total of 8668 patients with type 2 diabetes cared for by generalist physicians from 1990 through 1993. Outcome Measures.-Resource use (hospitalizations, outpatient visits, laboratory testing, and home glucose monitoring) and glycemic control were evaluated using combined clinical, survey, and administrative information systems data. Detailed clinical case-mix data, including a newly validated case-mix method, the Total Illness Burden Index, were collected on a subsample of 1738 patients. Results.-Among patients starting insulin therapy, hemoglobin A(1c) (HbA(1c)) decreased by 0.9 percentage point (95% confidence interval, 0.7-1.0) at 1 year compared with those receiving stable medication regimens; however, 2 years after starting insulin therapy, 60% still had HbA(1c) levels of 8% or greater. There was no evidence that some primary care physicians achieved better results than other primary care physicians when starting insulin therapy in their patients. Patients with the poorest baseline glycemic control achieved substantially greater HbA(1c), reductions; those with a baseline HbA(1c) level of 13% had a 3-fold greater decline in HbA(1c) than those whose baseline HbA(1c) level was 9%, For a subset of all patients for whom detailed clinical case-mix data were obtained, those taking insulin had higher resource use than those taking sulfonylureas, independent of illness severity. After adjusting for age, sex, race, socioeconomic status, disease duration, and severity of diabetes and comorbidities, insulin: users had slightly more laboratory tests performed, 2.4 more outpatient visits per year, and almost 300 more fingersticks for home glucose testing per year compared with sulfonylurea users (all P<.01). Although 15% of patients receiving insulin therapy reported weekly symptoms of hypoglycemia, insulin therapy was not associated with an increase in emergency department visits (after case-mix adjustment) and resulted in only 0.5 hypoglycemia-related hospitalizations per 100 patient-years. Conclusions.-For patients with type 2 diabetes who were cared for by generalist physicians, starting insulin therapy was generally safe and effective in achieving moderate glycemic control in patients who initially had poor glycemic control. However, insulin therapy was associated with increases in resource use and was rarely effective in achieving tight glycemic control, even for those with moderate control.	ANN ARBOR VET AFFAIRS MED CTR, VET AFFAIRS CTR PRACTICE MANAGEMENT & OUTCOMES RE, ANN ARBOR, MI USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV HLTH SERV RES & POLICY, MINNEAPOLIS, MN 55455 USA; TUFTS UNIV NEW ENGLAND MED CTR, PRIMARY CARE OUTCOMES RES INST, BOSTON, MA 02111 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; Tufts Medical Center; Group Health Cooperative				Greenfield, Sheldon/0000-0003-4628-1998; Kaplan, Sherrie/0000-0002-8644-5849	AHRQ HHS [HSO 666501] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; ALLEN BT, 1990, DIABETES CARE, V13, P1044, DOI 10.2337/diacare.13.10.1044; ANDERSON RM, 1988, DIABETES CARE, V11, P519, DOI 10.2337/diacare.11.7.519; [Anonymous], 1996, DIABETES CARE, V19, pS8; CAVE D, 1995, BENEFITS Q, V2, P6; Colwell JA, 1996, ANN INTERN MED, V124, P178, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00020; Colwell JA, 1996, DIABETES CARE, V19, P896, DOI 10.2337/diacare.19.8.896; Duan N., 1983, J EC BUSINESS STATIS, V1, P115, DOI [DOI 10.2307/1391852, 10.2307/1391852]; GLAUBER HS, 1992, DIABETES CARE, V15, P870, DOI 10.2337/diacare.15.7.870; GREENFIELD S, 1994, DIABETES CARE, V17, P32; Greenfield S., 1995, JGIM, V10, P67; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; GREENFIELD S, 1995, MED CARE, V33, pAS47; GREENFIELD S, 1994, AM J KIDNEY DIS, V24, P298, DOI 10.1016/S0272-6386(12)80195-8; KLEIN CE, 1993, J GEN INTERN MED, V8, P597, DOI 10.1007/BF02599711; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1987, AM J EPIDEMIOL, V126, P415, DOI 10.1093/oxfordjournals.aje.a114673; KrouselWood MA, 1996, J GEN INTERN MED, V11, P32, DOI 10.1007/BF02603483; LITTLE RR, 1991, CLIN CHEM, V37, P1725; Manning W. G., 1981, HLTH EC HLTH EC; MANNING WG, 1987, J ECONOMETRICS, V35, P59, DOI 10.1016/0304-4076(87)90081-9; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; MCMAHON LF, 1989, ANN INTERN MED, V111, P318, DOI 10.7326/0003-4819-111-4-318; *MED EC CO INC, 1996, 1996 RED BOOK; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peters B.G., 1994, J EUROPEAN PUBLIC PO, V1, P9, DOI [10.1080/13501769408406945, DOI 10.1080/13501769408406945]; PREGIBON D, 1980, APPL STAT, V29, P115; RAMSEY JB, 1969, J ROY STAT SOC B, V31, P350; Rettig B A, 1985, Nebr Med J, V70, P370; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TUKEY JW, 1949, BIOMETRICS, V5, P232, DOI 10.2307/3001938; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361	37	195	197	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1663	1669		10.1001/jama.278.20.1663	http://dx.doi.org/10.1001/jama.278.20.1663			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388085				2022-12-01	WOS:A1997YG85900027
J	Fukuda, M; Asano, S; Nakamura, T; Adachi, M; Yoshida, M; Yanagida, M; Nishida, E				Fukuda, M; Asano, S; Nakamura, T; Adachi, M; Yoshida, M; Yanagida, M; Nishida, E			CRM1 is responsible for intracellular transport mediated by the nuclear export signal	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ORDER CHROMOSOME STRUCTURE; CELL-CYCLE; PROTEIN; LOCALIZATION; REV; IDENTIFICATION; SEQUENCE; TRANSCRIPTION; NUCLEOPORIN	The discovery of nuclear export signals (NESs) in a number of proteins revealed the occurrence of signal-dependent transport of proteins from the nucleus to the cytoplasm(1-14). Although the consensus motif of the NESs has been shown to be a leucine-rich, short amino-acid sequence(2,6,7), its receptor has not been identified. A cytotoxin leptomycin B (LMB) has recently been suggested to inhibit the NES-mediated transport of Rev protein(15). Here we show that LMB is a potent and specific inhibitor of the NES-dependent nuclear export of proteins. Moreover, we have found a protein of relative molecular mass 110K (p110) in Xenopus oocyte extracts that binds to the intact NES but not to the mutated, non-functional NES. The binding of p110 to NES is inhibited by LMB. We show that p110 is CRM1, which is an evolutionarily conserved protein(16-18) originally found as an essential nuclear protein in fission yeas(16) and known as a likely target of LMB19. We also show that nuclear export of a fission yeast protein, Dsk1, which has a leucine-rich NES, is disrupted in wildtype yeast treated with LMB or in the crm1 mutant. These results indicate that CRM1 is an essential mediator of the NES-dependent nuclear export of proteins in eukaryotic cells.	KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014; Yoshida, Minoru/C-8049-2014; Fukuda, Makoto/S-9748-2019	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Yoshida, Minoru/0000-0002-4376-5674; Fukuda, Makoto/0000-0003-0112-9925				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORMEROD M, 1997, EMBO J, V16, P807; Fornerod M, 1996, ONCOGENE, V13, P1801; FORNEROD M, 1997, CELL, V98, P1051; Fridell RA, 1996, EMBO J, V15, P5408, DOI 10.1002/j.1460-2075.1996.tb00924.x; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STUZT F, 1995, CELL, V82, P495; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	29	1013	1027	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					308	311		10.1038/36894	http://dx.doi.org/10.1038/36894			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384386				2022-12-01	WOS:A1997YG66700069
J	Ash, EL; Sudmeier, JL; DeFabo, EC; Bachovchin, WW				Ash, EL; Sudmeier, JL; DeFabo, EC; Bachovchin, WW			A low-barrier hydrogen bond in the catalytic triad of serine proteases? Theory versus experiment	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; ALPHA-LYTIC PROTEASE; N-15 NMR-SPECTROSCOPY; ACTIVE-SITE; HISTIDINE; MECHANISM; ACID; CONSTANTS; COMPLEXES; TRYPSIN	Cleland and Kreevoy recently advanced the idea that a special type of hydrogen bond (H-bond), termed a low-barrier hydrogen bond (LBHB), may account for the ''missing'' transition state stabilization underlying the catalytic power of many enzymes, and Frey ef al. have proposed that the H-bond between aspartic acid 102 and histidine 57 in the catalytic triad of serine proteases is an example of a catalytically important LBHB. Experimental facts are here considered regarding the aspartic acid-histidine and cis-urocanic H-bonds that are inconsistent with fundamental tenets of the LBHB hypothesis. The inconsistencies between theory and experiment in these paradigm systems cast doubt on the existence of LBHBs, as currently defined, within enzyme active sites.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; GEORGE WASHINGTON UNIV,SCH MED,DEPT DERMATOL,WASHINGTON,DC 20037	Tufts University; George Washington University			Ash, Elissa L./AAA-5982-2021; william.bachovchin@tufts.edu/AAA-3538-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027927] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27927] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASH EL, UNPUB; BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BACHOVCHIN WW, 1994, STABLE ISOTOPE APPL, P41; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DAY RM, 1995, THEIS TUFTS U BOSTON; FARRJONES S, 1993, J AM CHEM SOC, V115, P6813, DOI 10.1021/ja00068a044; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; FUJIWARA FY, 1974, J AM CHEM SOC, V96, P7625, DOI 10.1021/ja00832a005; FUJIWARA FY, 1974, J AM CHEM SOC, V96, P7632; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GOLUBEV NS, 1994, BIOCHEMISTRY-MOSCOW+, V59, P447; GUTHRIE JP, 1996, CHEM BIOL, V4, P259; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; Hibbert Frank., 1990, ADV PHYS ORG CHEM, V26, P255; HORSLEY WJ, 1968, J AM CHEM SOC, V90, P3738, DOI 10.1021/ja01016a025; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P338; KETTNER CA, 1988, BIOCHEMISTRY-US, V27, P7682, DOI 10.1021/bi00420a017; LEGON AC, 1980, P ROY SOC LOND A MAT, V370, P213, DOI 10.1098/rspa.1980.0030; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; MARKLEY JL, 1996, BIOCHEMISTRY-US, V35, P1102; MARKLEY JL, 1979, BIOL APPL MAGNETIC R; MILLEN DJ, 1979, J CHEM SOC F2, V75, P592; ROBERTS JD, 1982, J AM CHEM SOC, V104, P3945, DOI 10.1021/ja00378a027; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; SAKIYAMA F, 1983, J BIOCHEM-TOKYO, V94, P1661; SANTUCCI I, 1995, THESIS FLINDERS U S; Schowen R., 1988, MECHANISTIC PRINCIPL, P119; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; Smirnov SN, 1996, J AM CHEM SOC, V118, P4094, DOI 10.1021/ja953445+; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220	37	172	173	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1128	1132		10.1126/science.278.5340.1128	http://dx.doi.org/10.1126/science.278.5340.1128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353195				2022-12-01	WOS:A1997YE65200054
J	Marrazzo, JM; White, CL; Krekeler, B; Celum, CL; Lafferty, WE; Stamm, WE; Handsfield, HH				Marrazzo, JM; White, CL; Krekeler, B; Celum, CL; Lafferty, WE; Stamm, WE; Handsfield, HH			Community-based urine screening for Chlamydia trachomatis with a ligase chain reaction assay	ANNALS OF INTERNAL MEDICINE			English	Article						Chlamydia trachomatis; urine; adolescence; polymerase chain reaction; ligase chain reaction	LEUKOCYTE ESTERASE TEST; SEXUALLY-TRANSMITTED DISEASE; PELVIC INFLAMMATORY DISEASE; FAMILY-PLANNING CLINICS; ADOLESCENT GIRLS; INFECTION; WOMEN; PREVALENCE; DIAGNOSIS; SPECIMENS	Background: Urine tests for Chlamydia trachomatis permit expansion of screening beyond traditional clinic environments. Prevention of infection in teenagers is a high priority. Objective: To define the prevalence of C. trachomatis among teenagers by using the ligase chain reaction assay on urine specimens and to evaluate leukocyte esterase testing of urine specimens as an indicator of infection. Design: Cross-sectional study. Setting: An adolescent clinic, a juvenile detention facility, seven school-based clinics, and three community-based youth organizations in Seattle, Washington. Participants: 10 118 sexually active teenagers and young adults. Measurements: Chlamydia trachomatis infection detected in urine specimens by ligase chain reaction assay and leukocyturia detected by leukocyte esterase testing. Results: The prevalence of chlamydial infection among female participants was 8.6% and declined with increasing age; among male participants, it was 5.4% and increased with increasing age. In female participants, independent predictors of infection were being 17 years of age or younger (odds ratio [OR], 1.49), having had two or more sex partners in the previous 2 months (OR, 1.61), and having genitourinary symptoms (OR, 1.46). In male participants, independent predictors were being of nonwhite race or ethnicity (OR, 2.00 to 3.08), having had two or more sex partners in the previous 2 months (OR, 1.57), and having used a condom during the most recent sexual encounter (OR, 0.67). For identifying infection in male participants, the sensitivity of leukocyte esterase testing was 58.9%, the specificity was 94.9%, the positive predictive value was 38.4%, and the negative predictive value was 97.7%. Conclusions: Chlamydial infection is common in teenagers and young adults in community settings. The urine ligase chain reaction assay will permit widespread screening for C. trachomatis, but leukocyte esterase testing had low sensitivity for selecting persons for screening with this assay. Indicators of chlamydial infection differed substantially in male and female participants.	UNIV WASHINGTON, HARBORVIEW MED CTR, SEXUALLY TRANSMITTED DIS CLIN, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DIV INFECT DIS, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; SEATTLE KING CTY DEPT PUBL HLTH, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Marrazzo, Jeanne/0000-0002-9277-7364	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007140, U19AI031448] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI-07140, U19 AI/MH-31448] Funding Source: Medline; PHS HHS [R30/CCR011496] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADDISS DG, 1990, SEX TRANSM DIS, V17, P138, DOI 10.1097/00007435-199007000-00006; ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; ANESTAD G, 1995, J CLIN MICROBIOL, V33, P2483, DOI 10.1128/JCM.33.9.2483-2484.1995; BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; BIRO FM, 1994, PEDIATRICS, V93, P476; BRITTON TF, 1992, AM J GYNECOL HLTH, V6, P24; CARPENTER WR, 1993, CLIN CHEM, V39, P1934; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P375; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P193; DILLE BJ, 1993, J CLIN MICROBIOL, V31, P729, DOI 10.1128/JCM.31.3.729-731.1993; *DIV STD PREV, 1996, SEX TRANSM DIS SURV; GAYDOS CA, 1996, 1996 NAT STD PREV C; GENC M, 1993, JAMA-J AM MED ASSOC, V270, P2057, DOI 10.1001/jama.270.17.2057; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; HUMPHREYS JT, 1992, SEX TRANSM DIS, V19, P47, DOI 10.1097/00007435-199201000-00010; Katz BP, 1996, SEX TRANSM DIS, V23, P226, DOI 10.1097/00007435-199605000-00011; KLAUSNER JD, 1996, 1996 NAT STD PREV C; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; MCNAGNY SE, 1992, J INFECT DIS, V165, P573, DOI 10.1093/infdis/165.3.573; MORRIS RE, 1993, SEX TRANSM DIS, V20, P198, DOI 10.1097/00007435-199307000-00004; Mosure DJ, 1997, J ADOLESCENT HEALTH, V20, P6, DOI 10.1016/S1054-139X(96)00157-7; PATRICK DM, 1994, GENITOURIN MED, V70, P187; Ridgway GL, 1996, J CLIN PATHOL, V49, P116, DOI 10.1136/jcp.49.2.116; Rietmeijer CA, 1997, SEX TRANSM DIS, V24, P429, DOI 10.1097/00007435-199708000-00008; SADOF MD, 1987, JAMA-J AM MED ASSOC, V258, P1932, DOI 10.1001/jama.258.14.1932; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; Schachter J, 1996, LANCET, V348, P1308, DOI 10.1016/S0140-6736(05)65783-2; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SHAFER MA, 1993, JAMA-J AM MED ASSOC, V270, P2065, DOI 10.1001/jama.270.17.2065; Stamm WE, 1990, SEXUALLY TRANSMITTED, P181; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WEINSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41, DOI 10.1093/oxfordjournals.aje.a116200; WERNER MJ, 1991, J ADOLESCENT HEALTH, V12, P326, DOI 10.1016/0197-0070(91)90008-A; WINTER L, 1990, SEX TRANSM DIS, V17, P30, DOI 10.1097/00007435-199017010-00007; WOOD DL, 1990, PEDIATRICS, V86, P666; 1996, MMWR-MORBID MORTAL W, V45, P883; 1994, MMWR-MORBID MORTAL W, V43, P366	44	107	108	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					796	+		10.7326/0003-4819-127-9-199711010-00004	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382400				2022-12-01	WOS:A1997YD89800003
J	Fischer, TM; Blazis, DEJ; Priver, NA; Carew, TJ				Fischer, TM; Blazis, DEJ; Priver, NA; Carew, TJ			Metaplasticity at identified inhibitory synapses in Aplysia	NATURE			English	Article							SIPHON WITHDRAWAL REFLEX; TERM SYNAPTIC PLASTICITY; GILL-WITHDRAWAL; GAIN-CONTROL; TAIL SHOCK; SEROTONIN; SENSITIZATION; FACILITATION; DISHABITUATION; DISSOCIATION	Synaptic plasticity is an important feature of neural networks involved in the encoding of information. In the analysis of longterm potentiation and long-term depression, several examples have emerged in which this plasticity is itself modulated(1-3). This higher-order form of plasticity has been referred to as 'metaplasticity'(4), a modification of synapses reflected as a change in the ability to induce or maintain plasticity. These observations raise the question of the possible advantage of regulating the intrinsic plastic properties of a synapse. The neural circuit mediating the siphon withdrawal reflex in Aplysia provides a useful network in which to examine this question directly. Inhibitory synapses in this circuit (from L30 neurons) exhibit a variety of forms of activity-dependent short-term synaptic enhancement which contribute to dynamic gain control in the siphon withdrawal reflex(5-9). Here we report that tail shock, an extrinsic modulatory input of known behavioural relevance, induces differential metaplasticity at this synapse, attenuating its ability to exhibit short-term synaptic enhancement after presynaptic activation (augmentation and post-tetanic potentiation), while leaving intact its capacity for enhancement during activation. This attenuation of inhibition at the synaptic level seems to mediate comparable attenuation of inhibitory modulation at both network and behavioural levels.	YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520	Yale University								Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ABRAMS TW, 1984, P NATL ACAD SCI-BIOL, V81, P7956, DOI 10.1073/pnas.81.24.7956; BLAZIS DEJ, 1993, NEURAL COMPUT, V5, P213, DOI 10.1162/neco.1993.5.2.213; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CAREW TJ, 1983, SCIENCE, V219, P397, DOI 10.1126/science.6681571; DELANEY KR, 1994, J NEUROSCI, V14, P5885; FISCHER TM, 1995, J NEUROSCI, V15, P762; FISCHER TM, 1993, J NEUROSCI, V13, P1302; FISCHER TM, IN PRESS J NEUROPHYS; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; FITZGERALD K, 1991, J NEUROSCI, V11, P2510; FROST WN, 1988, J NEUROBIOL, V19, P297, DOI 10.1002/neu.480190402; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; HAWKINS RD, 1989, J NEUROSCI, V9, P4236; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P304, DOI 10.1152/jn.1981.45.2.304; HICKIE C, 1995, J NEUROPHYSIOL, V74, P307, DOI 10.1152/jn.1995.74.1.307; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; KANEKO S, BEHAV BRAIN RES, V45, P97; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Lieb JR, 1997, J NEUROPHYSIOL, V77, P1249, DOI 10.1152/jn.1997.77.3.1249; LIFE SCI, 1996, KANE, V60, P245; MARCUS EA, 1988, SCIENCE, V241, P210, DOI 10.1126/science.3388032; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; WALTERS ET, 1991, BIOL BULL, V180, P241, DOI 10.2307/1542394; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	27	65	65	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					860	865		10.1038/39892	http://dx.doi.org/10.1038/39892			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349819				2022-12-01	WOS:A1997YC14800060
J	Cao, A; Saba, L; Galanello, R; Rosatelli, C				Cao, A; Saba, L; Galanello, R; Rosatelli, C			Molecular diagnosis and carrier screening for beta thalassemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRADIENT GEL-ELECTROPHORESIS; LOCUS-CONTROL REGION; PRENATAL-DIAGNOSIS; ALPHA-THALASSEMIA; FETAL HEMOGLOBIN; GLOBIN GENE; DNA; MUTATIONS; TRANSCRIPTION; HETEROGENEITY	Thalassemias are common autosomal recessive disorders especially in populations of Mediterranean, Middle Eastern, and Far Eastern descent. Relatively high incidence is also observed in people of Asian Indian origin but the incidence is more limited in those of African descent. beta Thalassemias are heterogeneous at the molecular level, with more than 150 different molecular defects identified to date. Despite this heterogeneity, each at-risk population has its own spectrum of common mutations, usually from 5 to 10, a finding that simplifies mutation analysis. Homozygosity for beta thalassemias usually results in transfusion-dependent thalassemia major and, rarely, in mild non-transfusion-dependent conditions. Molecular diagnosis may be used to define genotypes associated with mild forms. Advances in carrier diagnosis using hematologic analysis followed by mutation analysis have made possible the population screening of women al childbearing age and prenatal diagnosis. This approach in combination with nondirective genetic counseling has resulted in a consistent decline of the birth of affected homozygotes in several Mediterranean at-risk populations, as well as knowledge of the risks of being a carrier. Molecular diagnosis of homozygotes and identification of carriers of beta thalassemia may lead to improved clinical management of patients with the disorder and prevention of the birth of affected homozygotes.			Cao, A (corresponding author), UNIV CAGLIARI, IST CLIN & BIOL ETA EVOLUT, VIA JENNER S-N, I-09121 CAGLIARI, ITALY.			ROSATELLI, MARIA CRISTINA/0000-0001-6821-3190; SABA, Luisella/0000-0002-3470-3279				ANGASTINIOTIS M, 1988, CYPRUS THALASSEMIA C, V23, P417; [Anonymous], 1983, Bull World Health Organ, V61, P63; BAYSAL E, 1995, HEMOGLOBIN, V19, P213, DOI 10.3109/03630269509036943; BENNANI C, 1993, BRIT J HAEMATOL, V84, P335, DOI 10.1111/j.1365-2141.1993.tb03075.x; BOLLEKENS JA, 1991, HEMATOL ONCOL CLIN N, V5, P399, DOI 10.1016/S0889-8588(18)30422-2; CAI SP, 1990, J CLIN INVEST, V85, P550, DOI 10.1172/JCI114471; CAO A, 1993, BAILLIERE CLIN HAEM, V6, P263, DOI 10.1016/S0950-3536(05)80072-1; CAO A, 1987, Blood Reviews, V1, P169, DOI 10.1016/0268-960X(87)90032-4; CAO A, 1985, ANN NY ACAD SCI, V445, P380, DOI 10.1111/j.1749-6632.1985.tb17208.x; CAO A, 1997, CIBA F S, V197, P137; Cao A, 1990, EUR J INTERN MED, V1, P227; CHEHAB FF, 1987, BLOOD, V69, P1141; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; GALANELLO R, 1984, HEMOGLOBIN, V8, P25; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GONZALEZREDONDO JM, 1988, BLOOD, V72, P1007; GONZALEZREDONDO JM, 1989, BLOOD, V73, P1705; GRANT A, 1991, LANCET, V337, P1491; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; KANAVAKIS E, 1982, BRIT J HAEMATOL, V52, P465, DOI 10.1111/j.1365-2141.1982.tb03916.x; KATTAMIS C, 1990, BRIT J HAEMATOL, V74, P342, DOI 10.1111/j.1365-2141.1990.tb02593.x; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KULOZIK AE, 1991, J CLIN INVEST, V87, P2142, DOI 10.1172/JCI115246; LIEINJO LE, 1989, AM J HUM GENET, V45, P971; LIU JZ, 1989, HEMOGLOBIN, V13, P585, DOI 10.3109/03630268908993109; LOUDIANOS G, 1990, BLOOD, V75, P526; Loukopoulos D, 1996, SEMIN HEMATOL, V33, P76; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MELIS MA, 1983, BLOOD, V62, P226; MILLER BA, 1987, NEW ENGL J MED, V316, P244, DOI 10.1056/NEJM198701293160504; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; ONER R, 1990, HEMOGLOBIN, V14, P1, DOI 10.3109/03630269009002250; ORKIN SH, 1992, BLOOD, V80, P575; Poncz M, 1988, Oxf Surv Eukaryot Genes, V5, P163; PORTER JB, 1990, SEMIN HEMATOL, V27, P95; ROSATELLI C, 1984, HEMOGLOBIN, V8, P25, DOI 10.3109/03630268408996958; ROSATELLI C, 1994, HEMATOL PATHOL, V8, P25; ROSATELLI MC, 1992, AM J HUM GENET, V50, P422; ROSATELLI MC, 1992, HUM GENET, V89, P585; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; THEIN SL, 1990, AM J HUM GENET, V47, P369; THEIN SL, 1988, BRIT J HAEMATOL, V70, P225, DOI 10.1111/j.1365-2141.1988.tb02468.x; THEIN SL, 1992, BRIT J HAEMATOL, V80, P273, DOI 10.1111/j.1365-2141.1992.tb08132.x; THEIN SL, 1993, BAILLIERE CLIN HAEM, V6, P151, DOI 10.1016/S0950-3536(05)80069-1; WEATHERALL DJ, 1991, NATURE, V349, P275, DOI 10.1038/349275a0; Weatherall DJ., 1981, THALASSEMIA SYNDROME; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WOOD WG, 1993, BAILLIERE CLIN HAEM, V6, P177, DOI 10.1016/S0950-3536(05)80070-8	52	55	59	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1273	1277		10.1001/jama.278.15.1273	http://dx.doi.org/10.1001/jama.278.15.1273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333270				2022-12-01	WOS:A1997XZ70900034
J	Falvo, MR; Clary, GJ; Taylor, RM; Chi, V; Brooks, FP; Washburn, S; Superfine, R				Falvo, MR; Clary, GJ; Taylor, RM; Chi, V; Brooks, FP; Washburn, S; Superfine, R			Bending and buckling of carbon nanotubes under large strain	NATURE			English	Article							INSTABILITIES; FLEXIBILITY; ENERGETICS	The curling of a graphitic sheet to form carbon nanotubes(1) produces a class of materials that seem to have extraordinary electrical and mechanical properties(2). In particular, the high elastic modulus of the graphite sheets means that the nanotubes might be stiffer and stronger than and other known material(3-5), with beneficial consequences for their application in composite bulk materials and as individual elements of nanometre-scale devices and sensors(6). The mechanical properties are predicted to be sensitive to details of their structure and to the presence of defects(7), which means that measurements on individual nanotubes are essential to establish these properties. Here we show that multiwalled carbon nanotubes can be bent repeatedly through large angles using the tip of an atomic force microscope, without undergoing catastrophic failure. We observe a range of responses to this high-strain deformation, which together suggest that nanotubes are remarkably flexible and resilient.	UNIV N CAROLINA,DEPT PHYS & ASTRON,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT COMP SCI,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Superfine, Richard/A-1968-2012	Superfine, Richard/0000-0002-2569-071X				AXELRAD EL, 1985, INT J NONLINEAR MECH, V20, P249, DOI 10.1016/0020-7462(85)90033-2; CHOPRA NG, 1995, NATURE, V377, P135, DOI 10.1038/377135a0; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; DESPRES JF, 1995, CARBON, V33, P87, DOI 10.1016/0008-6223(95)91118-Q; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; EBBESEN TW, 1997, CARBON NANOTUBES PRE, P225; FINCH M, 1995, SURFACE MODIFICATION, P13; FRITSCH DS, 1994, INFORMATION PROCESSI, P365; Iijima S, 1996, J CHEM PHYS, V104, P2089, DOI 10.1063/1.470966; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; JU GT, 1992, INT J SOLIDS STRUCT, V29, P1143, DOI 10.1016/0020-7683(92)90140-O; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; LIEBER C, 1997, B AM PHYS SOC, V42, P591; Lu JP, 1997, PHYS REV LETT, V79, P1297, DOI 10.1103/PhysRevLett.79.1297; PIZER SM, IN PRESS COMPUT VISI; ROBERTSON DH, 1992, PHYS REV B, V45, P12592, DOI 10.1103/PhysRevB.45.12592; RUOFF RS, 1995, CARBON, V33, P925, DOI 10.1016/0008-6223(95)00021-5; RUOFF RS, 1995, RECENT ADV CHEM PHYS, V2; SAWADA S, 1992, SOLID STATE COMMUN, V83, P917, DOI 10.1016/0038-1098(92)90911-R; TAYLOR RM, 1993, NANOMANIPULATOR VIRT, P127; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Yakobson BI, 1996, PHYS REV LETT, V76, P2511, DOI 10.1103/PhysRevLett.76.2511; Yakobson BI, 1997, COMP MATER SCI, V8, P341, DOI 10.1016/S0927-0256(97)00047-5; ZHOU O, 1994, SCIENCE, V263, P1744, DOI 10.1126/science.263.5154.1744	25	1324	1402	8	398	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					582	584		10.1038/39282	http://dx.doi.org/10.1038/39282			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335495				2022-12-01	WOS:A1997YA00800053
J	Kauhanen, J; Kaplan, GA; Goldberg, DE; Salonen, JT				Kauhanen, J; Kaplan, GA; Goldberg, DE; Salonen, JT			Beer binging and mortality: results from the Kuopio ischaemic heart disease risk factor study, a prospective population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EASTERN FINNISH MEN; ACUTE MYOCARDIAL-INFARCTION; ALCOHOL-CONSUMPTION; PHYSICAL-ACTIVITY; CORONARY; WINE; DRINKERS	Objective: To examine the association between beer binging (regular sessions of heavy beer drinking) and mortality. Design: Prospective population based study with the baseline assessment of level of alcohol intake (dose), by type of drink and drinking pattern, previous and existing diseases, socioeconomic background, occupational status, involvement in organisations during leisure time, physical activity in leisure time, body mass index, blood pressure, serum lipids and plasma fibrinogen concentration, during an average of 7.7 years' follow up of mortality. Setting: Finland. Subjects: A population sample of 1641 men who consumed beer who were aged 42, 48, 54, or 60 years at baseline. Main outcome measures: All cause mortality, cardiovascular mortality, death due to external causes, fatal myocardial infarctions. Results: The risk of death was substantially increased in men whose usual dose of beer was 6 or more bottles per session compared with men who usually consumed less than 3 bottles, after adjustment forage and total alcohol consumption (relative risk 3.01 (95% confidence interval 1.54 to 5.90) for all deaths; 7.10 (2.01 to 25.12) for external deaths; and 6.50 (2.05 to 20.61) for fatal myocardial infarction). The association changed only slightly when smoking, occupational status, previous diseases, systolic blood pressure, low density lipoprotein and high density lipoprotein cholesterol concentration, plasma fibrinogen concentration, body mass index, marital status, leisure time physical activity, and involvement in organisations were controlled for. Conclusion: The pattern of beer binging is associated with increased risk of death, independently of the total average consumption of alcoholic drinks. The relation is not explained by known behavioural, psychosocial, or biological risk factors. Death due to injuries and other external causes is overrepresented.	UNIV KUOPIO, PUBL HLTH RES INST, FIN-70211 KUOPIO, FINLAND; UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA; HUMAN POPULAT LAB, BERKELEY, CA 94704 USA	University of Eastern Finland; University of Michigan System; University of Michigan	Kauhanen, J (corresponding author), UNIV KUOPIO, DEPT PUBL HLTH & GEN PRACTICE, BOX 1627, FIN-70211 KUOPIO, FINLAND.		Kauhanen, Jussi/ABC-4064-2021; Kaplan, George/AAJ-2398-2020		NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beaglehole R, 1992, Drug Alcohol Rev, V11, P275, DOI 10.1080/09595239200185811; Cox DR., 1984, ANAL SURVIVAL DATA; Dahlstrom, 1975, MMPI HDB RES APPL, V2; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; GAZIANO JM, 1995, BRIT MED J, V311, P3, DOI 10.1136/bmj.311.6996.3a; GREENFIELD TK, 1986, INT J ADDICT, V21, P1059, DOI 10.3109/10826088609077255; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Irgens-Jensen O, 1981, SIFA STENSILSERIE, V44; ISTVAN J, 1995, INT J EPIDEMIOL, V24, P543, DOI 10.1093/ije/24.3.543; JACKSON R, 1995, LANCET, V346, P716, DOI 10.1016/S0140-6736(95)91496-X; KAPLAN GA, 1994, EPIDEMIOLOGY, V5, P495; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; *OY ALKO AB, 1995, ALC STAT YB 1994; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Simpura J, 1987, FINNISH DRINKING HAB, V35; *WHO, 1989, INT J EPIDEMIOL S1, V18, pS38; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676	28	197	201	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	1997	315	7112					846	851		10.1136/bmj.315.7112.846	http://dx.doi.org/10.1136/bmj.315.7112.846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353504	Green Submitted, Green Published			2022-12-01	WOS:A1997YA00700022
J	Sun, ZS; Albrecht, U; Zhuchenko, O; Bailey, J; Eichele, G; Lee, CC				Sun, ZS; Albrecht, U; Zhuchenko, O; Bailey, J; Eichele, G; Lee, CC			RIGUI, a putative mammalian ortholog of the Drosophila period gene	CELL			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; SUPRACHIASMATIC NUCLEUS; PARS TUBERALIS; MELATONIN RECEPTORS; MESSENGER-RNA; CLOCK; PROTEIN; LIGHT; RAT; ZEITGEBERS	The molecular components of mammalian circadian clocks are elusive. We have isolated a human gene termed RIGUI that encodes a bHLH/PAS protein 44% homologous to Drosophila period. The highly conserved mouse homolog (m-rigui) is expressed in a circadian pattern in the suprachiasmatic nucleus (SCN), the master regulator of circadian clocks in mammals. Circadian expression in the SCN continues in constant darkness, and a shift in the light/dark cycle evokes a proportional shift of m-rigui expression in the SCN. m-rigui transcripts also appear in a periodic pattern in Purkinje neurons, pars tuberalis, and retina, but with a timing of oscillation different from that seen in the SCN. Sequence homology and circadian patterns of expression suggest that RIGUI is a mammalian ortholog of the Drosophila period gene, raising the possibility that a regulator of circadian clocks is conserved.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; MAX PLANCK INST EXPT ENDOCRINOL,D-30625 HANNOVER,GERMANY	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society			Albrecht, Urs/A-9831-2011; Jansen, Heiko T./A-5770-2008; Sun, Zhongsheng/AAS-4883-2020	Albrecht, Urs/0000-0002-0663-8676; Jansen, Heiko T./0000-0003-0178-396X; Sun, Zhongsheng/0000-0002-7640-5026				Albrecht U, 1997, MOL CELLULAR METHODS, P23; ARENDT J, 1987, CHRONOBIOL INT, V4, P273, DOI 10.3109/07420528709078534; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ASCHOFF J, 1969, AEROSPACE MED, V40, P844; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DEREVIERS MM, 1989, NEUROSCI LETT, V100, P89, DOI 10.1016/0304-3940(89)90665-4; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Fraschini F, 1993, LIGHT BIOL RHYTHMS M, P121; GOTO M, 1989, J PINEAL RES, V7, P195, DOI 10.1111/j.1600-079X.1989.tb00667.x; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; IJDO JW, 1992, GENOMICS, V14, P1019, DOI 10.1016/S0888-7543(05)80125-9; KALLIONIEMI OP, 1994, GENOMICS, V20, P125, DOI 10.1006/geno.1994.1138; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KRAFT M, 1995, DIS MON, V41, P501; LEE CC, 1995, HUM MOL GENET, V4, P1373, DOI 10.1093/hmg/4.8.1373; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; NAKAZAWA K, 1991, P NATL ACAD SCI USA, V88, P7576, DOI 10.1073/pnas.88.17.7576; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SIWICKI KK, 1992, J NEUROGENET, V8, P33, DOI 10.3109/01677069209167270; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; STANKOV B, 1991, NEUROENDOCRINOLOGY, V53, P214, DOI 10.1159/000125721; Sun Z. S., 1996, American Journal of Human Genetics, V59, pA160; SWAAB DF, 1996, HYPOTHALAMIC INTEGRA, P349; TAKAHASHI JS, 1987, BRAIN RES, V405, P199, DOI 10.1016/0006-8993(87)91010-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Teicher MH, 1997, ARCH GEN PSYCHIAT, V54, P124; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Vignau J, 1993, LIGHT BIOL RHYTHMS M, P261; WEAVER DR, 1990, ENDOCRINOLOGY, V127, P2607, DOI 10.1210/endo-127-5-2607; WEHR TA, 1996, HYPOTHALAMIC INTEGRA, P321; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	47	558	581	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1003	1011		10.1016/S0092-8674(00)80366-9	http://dx.doi.org/10.1016/S0092-8674(00)80366-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323128	Bronze			2022-12-01	WOS:A1997XX76800006
J	Wawryk, A; Mavromatis, C; Gold, M				Wawryk, A; Mavromatis, C; Gold, M			Electronic monitoring of vaccine cold chain in a metropolitan area	BRITISH MEDICAL JOURNAL			English	Article							STORAGE	Successful immunisation strategies depend on the provision of immunogenic vaccines and the correct manufacture and storage of those vaccines, Studies in developed and developing countries have shown that vaccines are stored inadequately and that the vaccine cold chain can be disrupted.(1 2) We measured the temperature of vaccines stored long term in a metropolitan area of a developed country using electronic data loggers to determine how long vaccines had been exposed to temperatures < 0 degrees C.	WOMENS & CHILDRENS HOSP,DEPT PAEDIAT,ADELAIDE,SA,AUSTRALIA; CHILD & YOUTH HLTH,ADELAIDE,SA 5000,AUSTRALIA	Womens & Childrens Hospital Australia								LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MCLEAN AA, 1982, ANN INTERN MED, V97, P451, DOI 10.7326/0003-4819-97-3-451_1; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756; *WHO, 1980, EPIDEMIOL REC, V50, P385	4	16	18	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					518	518		10.1136/bmj.315.7107.518	http://dx.doi.org/10.1136/bmj.315.7107.518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329306	Green Published			2022-12-01	WOS:A1997XU50600018
J	Hess, RA; Bunick, D; Lee, KH; Bahr, J; Taylor, JA; Korach, KS; Lubahn, DB				Hess, RA; Bunick, D; Lee, KH; Bahr, J; Taylor, JA; Korach, KS; Lubahn, DB			A role for oestrogens in the male reproductive system	NATURE			English	Article							ESTROGEN-RECEPTOR GENE; DUCTULI-EFFERENTES; SPERM COUNTS; EPIDIDYMIS; TESTIS; MOUSE; RAT; DISRUPTION; SECRETION; ESTRADIOL	Oestrogen is considered to be the 'female' hormone, whereas testosterone is considered the 'male' hormone. However,both hormones are present in both sexes. Thus sexual distinctions are not qualitative differences, but rather result from quantitative divergence in hormone concentrations and differential expressions of steroid hormone receptors. In males, oestrogen is present in low concentrations in blood, but can be extraordinarily high in semen, and as high as 250 pg ml(-1) in rete testis fluids(1,2), which is higher than serum oestradiol in the female(3). It is well known that male reproductive tissues express oestrogen receptors(4-7), but the role of oestrogen in male reproduction has remained unclear. Here we provide evidence of a physiological role for oestrogen in male reproductive organs. We show that oestrogen regulates the reabsorption of luminal fluid in the head of the epididymis. Disruption of this essential function causes sperm to enter the epididymis diluted, rather than concentrated, resulting in infertility. This finding raises further concern over the potential direct effects of environmental oestrogens on male reproduction and reported declines in human sperm counts(8,9).	UNIV ILLINOIS,DEPT ANIM SCI,URBANA,IL 61801; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65211; NIEHS,RES TRIANGLE PK,NC 27709	University of Illinois System; University of Illinois Urbana-Champaign; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hess, RA (corresponding author), UNIV ILLINOIS,DEPT VET BIOSCI,2001 S LINCOLN AVE,URBANA,IL 61802, USA.			Korach, Kenneth/0000-0002-7765-418X; Hess, Rex/0000-0003-2649-3563	FOGARTY INTERNATIONAL CENTER [F06TW002317] Funding Source: NIH RePORTER; FIC NIH HHS [F06 TW002317] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; CHAN HC, 1995, J CELL PHYSIOL, V164, P271, DOI 10.1002/jcp.1041640207; CLULOW J, 1994, EXP PHYSIOL, V79, P915, DOI 10.1113/expphysiol.1994.sp003817; COOKE PS, 1991, ENDOCRINOLOGY, V128, P2874, DOI 10.1210/endo-128-6-2874; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Fisher JS, 1997, J ENDOCRINOL, V153, P485, DOI 10.1677/joe.0.1530485; FREE MJ, 1979, BIOL REPROD, V20, P269, DOI 10.1095/biolreprod20.2.269; GANJAM VK, 1976, ENDOCRINOLOGY, V99, P1618, DOI 10.1210/endo-99-6-1618; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; Hess R.A., 1993, METHODS REPROD TOXIC, P52; HESS RA, 1991, FUND APPL TOXICOL, V17, P733, DOI 10.1016/0272-0590(91)90181-3; Hess RA, 1997, J ANDROL, V18, P602; ILIO KY, 1994, MICROSC RES TECHNIQ, V29, P432, DOI 10.1002/jemt.1070290604; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KRAUSE W, 1992, INT J ANDROL, V15, P14, DOI 10.1111/j.1365-2605.1992.tb01110.x; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Robaire B., 1988, P999; SCHLEICHER G, 1984, HISTOCHEMISTRY, V81, P139, DOI 10.1007/BF00490107; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SMITH EP, 1995, NEW ENGL J MED, V332, P131; SMITH GILLIAN, 1962, JOUR ENDOCRINOL, V23, P385, DOI 10.1677/joe.0.0230385; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; WAKELING AE, 1991, CANCER RES, V51, P3867; WEST NB, 1990, BIOL REPROD, V42, P533, DOI 10.1095/biolreprod42.3.533; YEUNG CH, 1991, AM J ANAT, V191, P261, DOI 10.1002/aja.1001910306	31	711	740	2	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					509	512		10.1038/37352	http://dx.doi.org/10.1038/37352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9393999	Green Accepted			2022-12-01	WOS:A1997YJ86500051
J	Spanswick, D; Smith, MA; Groppi, VE; Logan, SD; Ashford, MLJ				Spanswick, D; Smith, MA; Groppi, VE; Logan, SD; Ashford, MLJ			Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels	NATURE			English	Article							K+ CHANNELS; OBESE GENE; RAT FATTY; OB-R; RECEPTOR; IDENTIFICATION; EXPRESSION; CLONING; BRAIN; MICE	Leptin, the protein encoded by the obese (ob) gene, is secreted from adipose tissue and is thought to act in the central nervous system to regulate food intake and body weight(1,2). It has been proposed that leptin acts in the hypothalamus(3-5), the main control centre for satiety and energy expenditure(6). Mutations in leptin or the receptor isoform (Ob-R-L) present in hypothalamic neurons result in profound obesity and symptoms of non-insulin-dependent diabetes(7-10). Here we show that leptin hyperpolarizes glucose-receptive hypothalamic neurons of lean Sprague-Dawley and Zucker rats, but is ineffective on neurons of obese Zucker (fa/fa) rats. This hyperpolarization is due to the activation of a potassium current, and is not easily recovered on removal of leptin, but is reversed by applying the sulphonylurea, tolbutamide. Single-channel recordings demonstrate that leptin activates an ATP-sensitive potassium (K-ATP) channel. Our data indicate that the K-ATP channel may function as the molecular end-point of the pathway following leptin activation of the Ob-R-L receptor in hypothalamic neurons.	UNIV ABERDEEN,INST MED SCI,DEPT BIOMED SCI,ABERDEEN AB25 2ZD,SCOTLAND; PHARMACIA & UPJOHN INC,KALAMAZOO,MI 49001	University of Aberdeen; Pfizer			Smith, Mark/K-5792-2017	Smith, Mark/0000-0003-1474-5225; Ashford, Michael/0000-0002-0861-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHFORD MLJ, 1990, PFLUG ARCH EUR J PHY, V415, P479, DOI 10.1007/BF00373626; ASHFORD MLJ, 1990, BRIT J PHARMACOL, V101, P531, DOI 10.1111/j.1476-5381.1990.tb14116.x; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Glaum SR, 1996, MOL PHARMACOL, V50, P230; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; KEIFFER TJ, 1997, DIABETES, V26, P1087; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; LEVIN BE, 1996, AM J PHYSIOL-REG I, V40, pR491; Matson C.A., 1996, DIABETES REV, V4, P488; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; OOMURA Y, 1969, NATURE, V222, P282, DOI 10.1038/222282a0; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rock FL, 1996, HORM METAB RES, V28, P748, DOI 10.1055/s-2007-979892; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Satoh N, 1997, NEUROSCI LETT, V224, P149, DOI 10.1016/S0304-3940(97)00163-8; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STREAMSON C, 1996, DIABETES, V45, P1141; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TREHERNE JM, 1991, J NEUROENDOCRINOL, V3, P323, DOI 10.1111/j.1365-2826.1991.tb00282.x; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Yamashita T, 1997, DIABETES, V46, P1077, DOI 10.2337/diabetes.46.6.1077; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	521	553	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					521	525		10.1038/37379	http://dx.doi.org/10.1038/37379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394003				2022-12-01	WOS:A1997YJ86500055
J	Raskin, DM; deBoer, PAJ				Raskin, DM; deBoer, PAJ			The MinE ring: An FtsZ-independent cell structure required for selection of the correct division site in E-coli	CELL			English	Article							TOPOLOGICAL SPECIFICITY FACTOR; GREEN FLUORESCENT PROTEIN; ESCHERICHIA-COLI; SEPTUM PLACEMENT; BINDING-PROTEIN; MUTANTS; ENCODES; LOCUS; INHIBITORS; HOMOLOGS	E. coli cell division is mediated by the FtsZ ring and associated factors. Selection of the correct division site requires the combined action of an inhibitor of FtsZ ring formation (MinCD) and of a topological specificity factor that somehow prevents MinCD action at the middle of the cell (MinE). Here we show that a biologically active MinE-Gfp fusion accumulates in an annular structure near the middle of young cells. Formation of the MinE ring required MinD but was independent of MinC and continued in nondividing cells in which FtsZ function was inhibited. The results indicate that the MinE ring represents a novel cell structure, which allows FtsZ ring formation at midcell by suppressing MinCD activity at this site.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Raskin, David/AAZ-5973-2021	Raskin, David/0000-0001-7421-7809; de Boer, Piet/0000-0002-5375-6317	NIGMS NIH HHS [T32GM08056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addinall SG, 1996, J BACTERIOL, V178, P7167, DOI 10.1128/jb.178.24.7167-7172.1996; Addinall SG, 1996, J BACTERIOL, V178, P3877, DOI 10.1128/jb.178.13.3877-3884.1996; ADLER HI, 1967, P NATL ACAD SCI USA, V57, P321, DOI 10.1073/pnas.57.2.321; Baumann P, 1996, P NATL ACAD SCI USA, V93, P6726, DOI 10.1073/pnas.93.13.6726; BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; BI E, 1990, J BACTERIOL, V172, P5610, DOI 10.1128/jb.172.10.5610-5616.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Cha JH, 1997, J BACTERIOL, V179, P1671, DOI 10.1128/jb.179.5.1671-1683.1997; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; DEBOER PAJ, 1988, J BACTERIOL, V170, P2106, DOI 10.1128/jb.170.5.2106-2112.1988; Donachie WD, 1996, J BACTERIOL, V178, P5971, DOI 10.1128/jb.178.20.5971-5976.1996; Edwards DH, 1997, MOL MICROBIOL, V24, P905, DOI 10.1046/j.1365-2958.1997.3811764.x; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; HIGASHITANI A, 1995, BIOCHEM BIOPH RES CO, V209, P198, DOI 10.1006/bbrc.1995.1489; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; Huang J, 1996, J BACTERIOL, V178, P5080, DOI 10.1128/jb.178.17.5080-5085.1996; LEE SY, 1993, MOL MICROBIOL, V7, P601, DOI 10.1111/j.1365-2958.1993.tb01151.x; LEVIN PA, 1992, J BACTERIOL, V174, P6717, DOI 10.1128/JB.174.21.6717-6728.1992; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; LUTKENHAUS J, 1996, ESCHERICHIA COLI SAL, P1615; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; PICHOFF S, 1995, MOL MICROBIOL, V18, P321, DOI 10.1111/j.1365-2958.1995.mmi_18020321.x; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Rothfield LI, 1996, CELL, V84, P183, DOI 10.1016/S0092-8674(00)80971-X; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; TEATHER RM, 1974, J BACTERIOL, V118, P407, DOI 10.1128/JB.118.2.407-413.1974; VARLEY AW, 1992, J BACTERIOL, V174, P6729, DOI 10.1128/JB.174.21.6729-6742.1992; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; ZHAO CR, 1995, P NATL ACAD SCI USA, V92, P4314	39	196	200	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					685	694		10.1016/S0092-8674(00)80455-9	http://dx.doi.org/10.1016/S0092-8674(00)80455-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393861	Bronze			2022-12-01	WOS:A1997YH96000015
J	Lin, K; Dorman, JB; Rodan, A; Kenyon, C				Lin, K; Dorman, JB; Rodan, A; Kenyon, C			daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans	SCIENCE			English	Article							C-ELEGANS; INTERACTING GENES; DAUER FORMATION; LONGEVITY; SEQUENCE; AGE-1; PATHWAY; HEAD	The wild-type Caenorhabditis elegans nematode ages rapidly, undergoing development, senescence, and death in less than 3 weeks. In contrast, mutants with reduced activity of the gene daf-2 a homolog of the insulin and insulin-like growth factor receptors, age more slowly than normal and live more than twice as long, These mutants are active and fully fertile and have normal metabolic rates. The life-span extension caused by daf-2 mutations requires the activity of the gene daf-16. daf-16 appears to play a unique role in life-span regulation and encodes a member of the hepatocyte nuclear factor 3 (HNF-3)/forkhead family of transcriptional regulators, In humans, insulin down-regulates the expression of certain genes by antagonizing the activity of HNF-3, raising the possibility that aspects of this regulatory system have been conserved.			Lin, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Rodan, Aylin/0000-0001-9202-2378	NIA NIH HHS [AG11816] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011816, R01AG011816] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APFELD J, UNPUB; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DORMAN JB, 1995, GENETICS, V141, P1399; Finch CE., 1990, LONGEVITY SENESCENCE; Flakoll Paul, 1996, P121; FRIEDMAN DB, 1988, GENETICS, V118, P75; FROHMAN MA, 1993, METHOD ENZYMOL, V28, P341; GOTTLIEB S, 1994, GENETICS, V137, P107; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; KENYON C, 1997, C ELEGANS, V2, P791; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LARSEN PL, 1995, GENETICS, V139, P1567; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 1996, GENETICS, V143, P1207; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1996, DIABETES MELLITUS, P234; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Plasterk Ronald H.A., 1997, Cold Spring Harbor Monograph Series, V33, P97; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL, 1997, C ELEGANS, P739; Smeal T, 1997, CURR OPIN GENET DEV, V7, P281, DOI 10.1016/S0959-437X(97)80139-6; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Vanfleteren JR, 1996, J EXP ZOOL, V274, P93, DOI 10.1002/(SICI)1097-010X(19960201)274:2&lt;93::AID-JEZ2&gt;3.0.CO;2-8; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VOWELS JJ, 1992, GENETICS, V130, P105; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381	33	1186	1215	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1319	1322		10.1126/science.278.5341.1319	http://dx.doi.org/10.1126/science.278.5341.1319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360933				2022-12-01	WOS:A1997YG04300052
J	Wang, JM; Hartling, JA; Flanagan, JM				Wang, JM; Hartling, JA; Flanagan, JM			The structure of ClpP at 2.3 angstrom resolution suggests a model for ATP-dependent proteolysis	CELL			English	Article							BACTERIAL CHAPERONIN GROEL; ESCHERICHIA-COLI CLPP; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONES; SERINE PROTEASES; SUBSTRATE-SPECIFICITY; PROTEIN; DEGRADATION; COMPONENT; 2-COMPONENT	We have determined the crystal structure of the proteolytic component of the caseinolytic Clp protease (ClpP) from E. coli at 2.3 Angstrom resolution using an ab initio phasing procedure that exploits the internal 14-fold symmetry of the oligomer. The structure of a ClpP monomer has a distinct fold that defines a fifth structural family of serine proteases but a conserved catalytic apparatus. The active protease resembles a hollow, solid-walled cylinder composed of two 7-fold symmetric rings stacked back-to-back. Its 14 proteolytic active sites are located within a central, roughly spherical chamber similar to 51 Angstrom in diameter. Access to the proteolytic chamber is controlled by two axial pores, each having a minimum diameter of similar to 10 Angstrom. From the structural features of ClpP, we suggest a model for its action in degrading proteins.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	United States Department of Energy (DOE); Brookhaven National Laboratory; Yale University					NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; BLOW DM, 1970, ANN REV BIOCH, V39, P60; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER AT, 1992, X PLCR VERSION 3 1 S; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Chen P, 1996, CELL, V86, P835, DOI 10.1016/S0092-8674(00)80157-9; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Drenth J, 1994, PRINCIPLES PROTEIN X; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; Goldberg A L, 1990, Semin Cell Biol, V1, P423; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORWICH AL, 1995, CURR BIOL, V5, P455, DOI 10.1016/S0960-9822(95)00089-3; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KATAYAMA Y, 1988, J BIOL CHEM, V263, P15226; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KLUG A, 1972, QUANT BIOL, V36, P483; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSTER AJ, 1995, MOL BIOL REP, V21, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1997, IN PRESS TRENDS BIOC; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P315; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Shin DH, 1996, J MOL BIOL, V262, P71, DOI 10.1006/jmbi.1996.0499; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOJTKOWIAK D, 1993, J BIOL CHEM, V268, P22609; WOO KM, 1989, J BIOL CHEM, V264, P2088	62	480	489	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					447	456		10.1016/S0092-8674(00)80431-6	http://dx.doi.org/10.1016/S0092-8674(00)80431-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390554	hybrid			2022-12-01	WOS:A1997YG49200006
J	Anderson, DM; Schneewind, O				Anderson, DM; Schneewind, O			A mRNA signal for the type III secretion of Yop proteins by Yersinia enterocolitica	SCIENCE			English	Article							TARGET-CELL CONTACT; GENETIC-ANALYSIS; TRANSPOSON TN5; EXPORT; TRANSLOCATION; MACROPHAGES; EXPRESSION; BACTERIAL; CYTOSOL; DOMAINS	Pathogenic Yersinia species have a specialized secretion system (type III) to target cytotoxic Yap proteins during infection. The signals of YopE and YopN sufficient for the secretion of translational reporter fusions were mapped to the first 15 codons, No common amino acid or peptide sequence could be identified among the secretion signals. Systematic mutagenesis of the secretion signal yielded mutants defective in Yop translation; however, no point mutants could be identified that specifically abolished secretion. Frameshift mutations that completely altered the peptide sequences of these signals also failed to prevent secretion. Thus, the signal that leads to the type III secretion of Yop proteins appears to be encoded in their messenger RNA rather than the peptide sequence.	UNIV CALIF LOS ANGELES,INST MOL BIOL,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles					NIAID NIH HHS [AI 07323] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REISS B, 1984, EMBO J, V3, P3317, DOI 10.1002/j.1460-2075.1984.tb02297.x; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Schesser K, 1996, J BACTERIOL, V178, P7227, DOI 10.1128/jb.178.24.7227-7233.1996; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	23	257	265	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1140	1143		10.1126/science.278.5340.1140	http://dx.doi.org/10.1126/science.278.5340.1140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353199				2022-12-01	WOS:A1997YE65200058
J	Daaka, Y; Luttrell, LM; Lefkowitz, RJ				Daaka, Y; Luttrell, LM; Lefkowitz, RJ			Switching of the coupling of the beta(2)-adrenergic receptor to different G proteins by protein kinase A	NATURE			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-ADRENERGIC-RECEPTOR; MAP KINASE; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT ACTIVATION; SIGNALING PATHWAYS; PERTUSSIS-TOXIN; TYROSINE-KINASE; GAMMA-SUBUNITS; FIBROBLASTS	Many of the G-grotein-coupled receptors for hormones that bind to the cell surface can signal to the interior of the cell through several different classes of G protein(1-4). Far example, although most of the actions of the prototype beta(2)-adrenergic receptor are mediated through G(s) proteins and thr cyclic-AMP-dependent protein kinase (PKA) system(5,6), beta-adrenergis receptors can also couple to G(i) proteins(1,2). Here we investigate the mechanism that controls the specificity of this coupling. We show that in HEK293 cells, stimulation of mitogen-activated protein (MAP) kinase by the beta(2)-adrenergic receptor is mediated by the beta gamma subunits of pertussis-toxin-sensitive G proteins through a pathway involving the non-receptor tyrosine kinase c-Src and the G protein Ras, Activation of this pathway by the beta(2)-adrenergic receptor requires that the receptor be phosphorylated by PKA because it is blocked by H-89, an inhibitor of PKA. Additionally, a mutant of the receptor, which lacks the sites normally phosphorylated by PKA, can activate adenylyl cyclase(5), the enzyme that generates cAMP, but not MAP kinase. Our results demonstrate that a mechanism previously shown to mediate uncoupling of the beta(2)-adrenergic receptor from G(s) and thus heterologous desensitization(7) (PKA-mediated receptor phosphorylation), also serves to 'switch' coupling of this receptor from G(s) to G(i) and initiate a new set of signalling events.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949				ABRAMSON SN, 1988, BIOCHEM PHARMACOL, V37, P4289, DOI 10.1016/0006-2952(88)90609-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; FAURE M, 1994, J BIOL CHEM, V269, P7851; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; HARWOOD SJ, 1996, BIOCHEM BIOPH RES CO, V224, P734; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; STRULOVICI B, 1984, SCIENCE, V225, P837, DOI 10.1126/science.6089331; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; XIAO RP, 1995, MOL PHARMACOL, V47, P322	28	1026	1044	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					88	91		10.1038/36362	http://dx.doi.org/10.1038/36362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363896				2022-12-01	WOS:A1997YE47700058
J	Fenczik, CA; Sethi, T; Ramos, JW; Hughes, PE; Ginsberg, MH				Fenczik, CA; Sethi, T; Ramos, JW; Hughes, PE; Ginsberg, MH			Complementation of dominant suppression implicates CD98 in integrin activation	NATURE			English	Article							OUT SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; MOLECULAR-CLONING; CELL-ADHESION; RECEPTOR; PROTEINS; BINDING; EXPRESSION; MONOCYTES; SURFACE	The integrin family of adhesion receptors are involved in cell growth, migration and tumour metastasis(1). Integrins are heterodimeric proteins composed of an alpha and a beta subunit, each with a large extracellular, a single transmembrane, and a short cytoplasmic domain. The dynamic regulation of integrin affinity for ligands in response to cellular signals is central to integrin function(2). This process is energy dependent and is mediated through integrin cytoplasmic domains(3). However, the cellular machinery regulating integrin affinity remains poorly understood. Here we describe a genetic strategy to disentangle integrin signalling pathways. Dominant suppression occurs when overexpression of isolated integrin beta(1) cytoplasmic domains blocks integrin activation. Proteins involved in integrin signalling were identified by their capacity to complement dominant suppression in an expression cloning scheme. CD98, an early T-cell activation antigen that associates with functional integrins(4), was found to regulate integrin activation. Furthermore, antibody-mediated crosslinking of CD98 stimulated beta(1) integrin-dependent cell adhesion. These data indicate that CD98 is involved in regulating integrin affinity, and validate an unbiased genetic approach to analysing integrin signalling pathways.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV EDINBURGH, SCH MED, DEPT RESP MED, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Scripps Research Institute; University of Edinburgh			Ramos, Joe/G-4074-2010	Ramos, Joe/0000-0002-9708-2115	NCI NIH HHS [F32 CA074529-01, F32 CA074529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA074529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHEN YP, 1994, J BIOL CHEM, V269, P18307; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HIRASAWA M, 1994, BRIT J CANCER, V70, P466, DOI 10.1038/bjc.1994.329; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INDIG FE, IN PRESS BIOCH J, V326; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MANNION BA, UNPUB FUNCTIONALLY A; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; [No title captured]	25	242	244	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					81	85		10.1038/36349	http://dx.doi.org/10.1038/36349			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363894				2022-12-01	WOS:A1997YE47700056
J	McNamara, RL; Lima, JAC; Whelton, PK; Powe, NR				McNamara, RL; Lima, JAC; Whelton, PK; Powe, NR			Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						cerebrovascular disorders; echocardiography, transesophageal; cost-benefit analysis; embolism and thrombosis; thrombolytic therapy	NONVALVULAR ATRIAL-FIBRILLATION; TRANSIENT ISCHEMIC ATTACKS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CEREBRAL-ISCHEMIA; DECISION-ANALYSIS; CARDIAC SOURCE; TRANSTHORACIC ECHOCARDIOGRAPHY; NATIONAL PERSPECTIVE; ARTERY DISEASE; BREAST-CANCER	Background: No consensus exists about the use of imaging strategies to identify potential cardiovascular sources of emboli in patients who have had strokes. Objective: To;determine the cost-effectiveness of various cardiac imaging strategies after stroke. Design: A Markov model decision analysis was used to evaluate the benefits and costs of nine diagnostic strategies, including transthoracic echocardiography, transesophageal echocardiography, sequential approaches, selective imaging, and no imaging. Setting: Simulated clinical practice in the United States. Patients: Hypothetical patients with a first stroke who were in normal sinus rhythm. Measurements: Echocardiographic detection rates of potential sources of emboli were ascertained by doing a systematic review of the literature. Values for event rates, anticoagulation effects, utilities, and costs were obtained from the literature and Medicare data. Results: When visualized left atrial thrombus was used as the only indication for anticoagulation, transesophageal echocardiography performed only in patients with a history of cardiac problems cost $9000 per quality-adjusted life-year; transesophageal echocardiography in all patients cost $13 000 per quality-adjusted life-year. Cost savings and decreased morbidity and mortality rates associated with reduction in preventable recurrent strokes substantially offset examination costs and risks of anticoagulation. These results were moderately sensitive to efficacy of anticoagulation and incidence of intracranial bleeding during anticoagulation and were mildly sensitive to prevalence of left atrial thrombus, rate of recurrent stroke in patients with thrombus, quality of life after stroke, cost of transesophageal echocardiography, and specificity of transesophageal echocardiography. Transthoracic echocardiography, alone or in sequence with transesophageal echocardiography, was not cost-effective compared with transesophageal echocardiography. Conclusion: Physicians should consider doing transesophageal echocardiography in all patients with new; onset stroke.	JOHNS HOPKINS MED INST, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, BALTIMORE, MD 21250 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; TULANE UNIV, MED CTR, SCH PUBL HLTH & TROP MED, NEW ORLEANS, LA 70112 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Tulane University					NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NHLBI NIH HHS [T32 HL07024-21] Funding Source: Medline; NIA NIH HHS [KO1 AG00561] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG000561] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amarenco P, 1996, NEW ENGL J MED, V334, P1216; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; [Anonymous], 1989, Arch Neurol, V46, P727; Ashraf T, 1996, AM J CARDIOL, V78, P409, DOI 10.1016/S0002-9149(96)00328-1; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BOWEN J, 1994, NEUROLOGY, V44, P1961, DOI 10.1212/WNL.44.10.1961; COMESS KA, 1994, J AM COLL CARDIOL, V23, P1598, DOI 10.1016/0735-1097(94)90662-9; CUJEC B, 1991, STROKE, V22, P727, DOI 10.1161/01.STR.22.6.727; DAHL T, 1995, J INTERN MED, V237, P323, DOI 10.1111/j.1365-2796.1995.tb01182.x; DEBELDER MA, 1992, BRIT HEART J, V67, P297; DEROOK FA, 1992, ANN INTERN MED, V117, P922, DOI 10.7326/0003-4819-117-11-922; DESBIENS NA, 1992, J GEN INTERN MED, V7, P131, DOI 10.1007/BF02598001; DIENER HC, 1991, STROKE, V22, P1229; DOBKIN B, 1995, NEUROLOGY, V45, pS6; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Fatkin D, 1996, AM J CARDIOL, V77, P321, DOI 10.1016/S0002-9149(97)89406-4; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GARDE A, 1983, STROKE, V14, P677, DOI 10.1161/01.STR.14.5.677; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; Gold MR., 1996, COST EFFECTIVENESS H; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HOFMANN T, 1990, LANCET, V336, P1421; JONES EF, 1993, AUST NZ J MED, V23, P477, DOI 10.1111/j.1445-5994.1993.tb01833.x; KESTLE J, 1989, CLIN RES, V37, pA316; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KUPERSMITH J, 1995, PROG CARDIOVASC DIS, V37, P307, DOI 10.1016/S0033-0620(05)80017-9; KUPERSMITH J, 1995, PROG CARDIOVASC DIS, V37, P243, DOI 10.1016/S0033-0620(05)80009-X; LABOVITZ AJ, 1993, AM J CARDIOL, V72, P1448, DOI 10.1016/0002-9149(93)90195-I; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; Lee AJ, 1996, MED CARE, V34, P811, DOI 10.1097/00005650-199608000-00008; LEUNG DY, 1995, STROKE, V26, P1820, DOI 10.1161/01.STR.26.10.1820; MAGAR DS, 1995, CANADIAN J CLIN PHAR, V2, P109; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MATCHAR DB, 1987, JAMA-J AM MED ASSOC, V258, P793, DOI 10.1001/jama.258.6.793; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MILLS E, 1978, NEW ENGL J MED, V299, P415, DOI 10.1056/NEJM197808242990810; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; Persson U, 1990, Int J Technol Assess Health Care, V6, P125; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACCO RL, 1989, STROKE, V20, P983, DOI 10.1161/01.STR.20.8.983; SANSOY V, 1995, AM J CARDIOL, V75, P166, DOI 10.1016/S0002-9149(00)80068-5; Seto TB, 1997, J AM COLL CARDIOL, V29, P122, DOI 10.1016/S0735-1097(96)00448-2; SHYU KG, 1994, CARDIOLOGY, V85, P53, DOI 10.1159/000176646; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TERENT A, 1994, STROKE, V25, P2363, DOI 10.1161/01.STR.25.12.2363; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; *US AG HLTH CAR PO, 1995, AHCPR PUBL; Whisnant JP, 1971, STROKE, V2, P11, DOI 10.1161/01.STR.2.1.11	57	74	77	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					775	+		10.7326/0003-4819-127-9-199711010-00001	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382398				2022-12-01	WOS:A1997YD89800001
J	Dogterom, M; Yurke, B				Dogterom, M; Yurke, B			Measurement of the force-velocity relation for growing microtubules	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; THERMAL FLUCTUATIONS; DYNAMIC INSTABILITY; FLEXURAL RIGIDITY; VARIABLE RATES; CELL MOTILITY; MOLECULE; DEPOLYMERIZATION; DRIVEN; MOTOR	Forces generated by protein polymerization are important for various forms of cellular motility. Assembling microtubules, for instance, are believed to exert pushing forces on chromosomes during mitosis. The force that a single microtubule can generate was measured by attaching microtubules to a substrate at one end and causing them lo push against a microfabricated rigid barrier at the other end. The subsequent buckling of the microtubules was analyzed to determine both the force on each microtubule end and the growth velocity. The growth velocity decreased from 1.2 micrometers per minute at zero force to 0.2 micrometer per minute at forces of 3 to 4 piconewtons. The force-velocity relation fits well to a decaying exponential, in agreement with theoretical models, but the rate of decay is faster than predicted.	AT&T BELL LABS, LUCENT TECHNOL, MURRAY HILL, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs								[Anonymous], 1987, LINEAR AGGREGATION T; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; DOGTEROM M, UNPUB; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Elbaum M, 1996, PHYS REV LETT, V76, P4078, DOI 10.1103/PhysRevLett.76.4078; Felgner H, 1996, J CELL SCI, V109, P509; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fygenson DK, 1997, PHYS REV E, V55, P850, DOI 10.1103/PhysRevE.55.850; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; Gittes F, 1996, BIOPHYS J, V70, P418, DOI 10.1016/S0006-3495(96)79585-1; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Hotani H, 1990, Adv Biophys, V26, P135, DOI 10.1016/0065-227X(90)90010-Q; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; INOUE S, 1967, J GEN PHYSIOL, V50, P529; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; KURZ JC, 1995, BIOCHEMISTRY-US, V34, P13374, DOI 10.1021/bi00041a014; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; SVOBODA K, 1994, CELL, V77, P733; VENLER P, 1994, J BIOL CHEM, V169, P13353; VENLER P, 1995, J BIOL CHEM, V270, P17056; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161	35	395	401	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					856	860		10.1126/science.278.5339.856	http://dx.doi.org/10.1126/science.278.5339.856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346483				2022-12-01	WOS:A1997YD47900045
J	Webb, BL; Cox, MM; Inman, RB				Webb, BL; Cox, MM; Inman, RB			Recombinational DNA repair: The RecF and RecR proteins limit the extension of RecA filaments beyond single-strand DNA gaps	CELL			English	Article							ESCHERICHIA-COLI RECF; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; BINDING-PROTEIN; NUCLEOSIDE TRIPHOSPHATE; DUPLEX DNA; EXCHANGE; PURIFICATION; COMPLEXES; PATHWAY	In the presence of both the RecF and RecR proteins, RecA filament extension from a single strand gap into adjoining duplex DNA is attenuated. RecR protein alone has no effect, and RecF protein alone has a reduced activity. The RecFR complexes bind randomly, primarily to the duplex regions of the DNA, and the extension of the RecA filament is halted at the first complex encountered. A very slow lengthening of RecA filaments observed in the presence of RecFR is virtually eliminated when RecF is replaced with an RecF mutant protein that does not hydrolyze ATP. These observations are incorporated into an expanded model for the functions of RecF, RecO, and RecR proteins in the early stages of postreplication DNA repair.			Webb, BL (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725, R01GM014711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07215, GM14711, GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO JC, 1993, J BIOL CHEM, V268, P1424; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; Hegde SP, 1996, J BACTERIOL, V178, P184, DOI 10.1128/jb.178.1.184-190.1996; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; JAIN SK, 1994, J BIOL CHEM, V269, P20653; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kogoma T, 1997, P NATL ACAD SCI USA, V94, P3483, DOI 10.1073/pnas.94.8.3483; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.bi.63.070194.005015; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kubista M, 1996, BIOLOGICAL STRUCTURE AND DYNAMICS, VOL 1, P49; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MADIRAJU MVVS, 1992, J BACTERIOL, V174, P7705, DOI 10.1128/JB.174.23.7705-7710.1992; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MAHDI AA, 1989, MOL GEN GENET, V216, P503, DOI 10.1007/BF00334397; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sandler SJ, 1996, MOL MICROBIOL, V19, P871, DOI 10.1046/j.1365-2958.1996.429959.x; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; SAWITZKE JA, 1994, J BACTERIOL, V176, P6730, DOI 10.1128/JB.176.21.6730-6737.1994; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1989, GENOME, V31, P520, DOI 10.1139/g89-100; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; TSENG YC, 1994, MUTAT RES, V315, P1; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0	57	155	169	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					347	356		10.1016/S0092-8674(00)80418-3	http://dx.doi.org/10.1016/S0092-8674(00)80418-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363943	Bronze			2022-12-01	WOS:A1997YD94100008
J	Supp, DM; Witte, DP; Potter, SS; Brueckner, M				Supp, DM; Witte, DP; Potter, SS; Brueckner, M			Mutation of an axonemal dynein affects left right asymmetry in inversus viscerum mice	NATURE			English	Article							SITUS-INVERSUS; INSERTIONAL MUTATION; MOUSE; EXPRESSION; GENE; RAT; IDENTIFICATION; MICROTUBULES; SEQUENCES; LEGLESS	The development of characteristic visceral asymmetries along the left-right (LR) axis in an initially bilaterally symmetrical embryo is an essential feature of vertebrate patterning. The allelic mouse mutations inversus viscerum (iv)(1,2) and legless (lgl)(3,4) produce LR inversion, or situs inversus, in half of live-born homozygotes, This suggests that the iv gene product drives correct LR determination, and in its absence this process is randomized(2), These mutations provide tools for studying the development of LR-handed asymmetry and provide mouse models of human lateralization defects. At the molecular level, the normally LR asymmetric expression patterns of nodal(5) and lefty(6) are randomized in iv/iv embryos, suggesting that iv functions early in the genetic hierarchy of LR specification, Here we report the positional cloning of an axonemal dynein heavy-chain gene, left/right-dynein (lrd), that is mutated in both lgl and iv, lrd is expressed in the node of the embryo at embryonic day 7.5, consistent with its having a role in LR development(7). Our findings indicate that dynein, a microtubule-based motor, is involved in the determination of LR-handed asymmetry and provide insight into the early molecular mechanisms of this process.	YALE UNIV, SCH MED, DEPT PEDIAT CARDIOL, NEW HAVEN, CT 06520 USA; CHILDRENS HOSP RES FDN, DIV DEV BIOL, CINCINNATI, OH 45229 USA; CHILDRENS HOSP RES FDN, DIV PATHOL, CINCINNATI, OH 45229 USA	Yale University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation			Supp, Dorothy/ABQ-7999-2022	Supp, Dorothy/0000-0002-2429-6630	NICHD NIH HHS [R01 HD024517] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024517] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AFZELIUS B A, 1976, Science (Washington D C), V193, P317; Afzelius BA, 1995, INT J DEV BIOL, V39, P839; Andrews KL, 1996, MOL BIOL CELL, V7, P71, DOI 10.1091/mbc.7.1.71; ASAI DJ, 1995, CELL MOTIL CYTOSKEL, V32, P129, DOI 10.1002/cm.970320212; ASAI DJ, 1994, J CELL SCI, V107, P839; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BROWN NA, 1991, CIBA F SYMP, V162, P182; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; DANOS MC, 1995, DEVELOPMENT, V121, P1467; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Jesuthasan S, 1997, CURR BIOL, V7, P31, DOI 10.1016/S0960-9822(06)00025-X; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MCGRATH J, 1992, GENOMICS, V14, P643, DOI 10.1016/S0888-7543(05)80163-6; MCNEISH JD, 1990, J EXP ZOOL, V253, P151, DOI 10.1002/jez.1402530205; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SINGH G, 1991, GENE DEV, V5, P2245, DOI 10.1101/gad.5.12a.2245; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; TANAKA Y, 1995, J CELL SCI, V108, P1883; THEURKAUF WE, 1994, DEV BIOL, V165, P352, DOI 10.1006/dbio.1994.1258; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Vaughan KT, 1996, GENOMICS, V36, P29, DOI 10.1006/geno.1996.0422	28	422	427	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					963	966		10.1038/40140	http://dx.doi.org/10.1038/40140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353118	Green Accepted			2022-12-01	WOS:A1997YD29900054
J	Mulley, GP				Mulley, GP			Myths of ageing	LANCET			English	Article							OLDER-PEOPLE				Mulley, GP (corresponding author), ST JAMES UNIV HOSP, ELDERLY SERV DIRECTORATE, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.							Agate J., 1970, PRACTICE GERIATRICS; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Ebrahim S, 1996, BRIT MED J, V313, P610; Forbes A, 1996, BRIT MED J, V313, P352, DOI 10.1136/bmj.313.7053.352; MANN E, 1996, PSYCHIAT ELDERLY, P89; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MANTON KG, 1995, J GERONTOL, V50, P5104; Markowe H, 1994, Health Trends, V26, P98; *MRC, 1994, HLTH UK ELD PEOPL MR; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Starr JM, 1997, AGE AGEING, V26, P295, DOI 10.1093/ageing/26.4.295; Travers AF, 1996, BRIT MED J, V313, P482; VERHAEGHEN P, 1993, J GERONTOL, V48, pP157, DOI 10.1093/geronj/48.4.P157; WYSOCKI CJ, 1989, ANN NY ACAD SCI, V561, P12, DOI 10.1111/j.1749-6632.1989.tb20966.x; Young J, 1996, BRIT MED J, V313, P677	15	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	1997	350	9085					1160	1161		10.1016/S0140-6736(97)08296-2	http://dx.doi.org/10.1016/S0140-6736(97)08296-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343517				2022-12-01	WOS:A1997YB19900045
J	Anderson, SA; Eisenstat, DD; Shi, L; Rubenstein, JLR				Anderson, SA; Eisenstat, DD; Shi, L; Rubenstein, JLR			Interneuron migration from basal forebrain to neocortex: Dependence on Dlx genes	SCIENCE			English	Article							LATERAL GANGLIONIC EMINENCE; NEURONS; CELLS; MOUSE; IMMUNOREACTIVITY; DISPERSION; EXPRESSION; CORTEX; BRAIN; ZONE	Although previous analyses indicate that neocortical neurons originate from the cortical proliferative zone, evidence suggests that a subpopulation of neocortical interneurons originates within the subcortical telencephalon. For example, gamma-aminobutyric acid (GABA)-expressing cells migrate in vitro from the subcortical telencephalon into the neocortex. The number of GABA-expressing cells in neocortical slices is reduced by separating the neocortex from the subcortical telencephalon. Finally, mice lacking the homeodomain proteins DLX-1 and DLX-2 show no detectable cell migration from the subcortical telencephalon to the neocortex and also have few GABA-expressing cells in the neocortex.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,CTR NEUROBIOL & PSYCHIAT,NINA IRELAND LAB DEV NEUROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Eisenstat, David/AAA-4653-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051561, K02MH001046] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH51561, K02 MH01046] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANDERSON S, UNPUB; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bhide PG, 1996, J COMP NEUROL, V374, P506; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; BUIFONE A, 1993, J NEUROSCI, V13, P3155; DEACON TW, 1994, BRAIN RES, V668, P211, DOI 10.1016/0006-8993(94)90526-6; DeCarlos JA, 1996, J NEUROSCI, V16, P6146; DEDIEGO I, 1994, EUR J NEUROSCI, V6, P983, DOI 10.1111/j.1460-9568.1994.tb00593.x; DEFELIPE J, 1993, CEREB CORTEX, V3, P273, DOI 10.1093/cercor/3.4.273; DELRIO JA, 1995, CEREB CORTEX, V5, P13, DOI 10.1093/cercor/5.1.13; DELRIO JA, 1992, J COMP NEUROL, V326, P501, DOI 10.1002/cne.903260403; Fishell G, 1997, CURR OPIN NEUROBIOL, V7, P62, DOI 10.1016/S0959-4388(97)80121-3; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; FISHELL G, 1995, DEVELOPMENT, V121, P803; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; LIU FC, 1992, J COMP NEUROL, V320, P304, DOI 10.1002/cne.903200304; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Metin C, 1996, J NEUROSCI, V16, P3219; Mione MC, 1997, J NEUROSCI, V17, P2018; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; PORTEUS MH, 1994, J NEUROSCI, V14, P6370; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; TAMAMAKI N, 1996, IN PRESS J NEUROSCI, V16; VANEDEN CG, 1989, J COMP NEUROL, V289, P213, DOI 10.1002/cne.902890204; WALSH C, 1993, NATURE, V362, P632, DOI 10.1038/362632a0	27	1145	1160	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					474	476		10.1126/science.278.5337.474	http://dx.doi.org/10.1126/science.278.5337.474			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334308				2022-12-01	WOS:A1997YB35500048
J	Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA				Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA			Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor	SCIENCE			English	Article							SPINOTHALAMIC TRACT NEURONS; EXCITATORY AMINO-ACIDS; GENE-RELATED PEPTIDE; DORSAL HORN NEURONS; MEDIATED INTERNALIZATION; NEUROKININ-1 RECEPTORS; TRIGEMINAL NUCLEUS; AXONAL-TRANSPORT; SENSORY NEURONS; DOWN-REGULATION	Substance P is released in the spinal cord in response to painful stimuli, but its role in nociceptive signaling remains unclear, When a conjugate of substance P and the ribosome-inactivating protein saporin was infused into the spinal cord, it was internalized and cytotoxic to lamina I spinal cord neurons that express the substance P receptor. This treatment left responses to mild noxious stimuli unchanged, but markedly attenuated responses to highly noxious stimuli and mechanical and thermal hyperalgesia. Thus, lamina I spinal cord neurons that express the substance P receptor play a pivotal role in the transmission of highly noxious stimuli and the maintenance of hyperalgesia.	UNIV MINNESOTA, SCH DENT, DEPT PREVENT SCI, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; ADV TARGETING SYST, CARLSBAD, CA 92008 USA; VET ADM MED CTR, NEUROL SERV 147, NASHVILLE, TN 37212 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mantyh, PW (corresponding author), VET ADM MED CTR, MOL NEUROBIOL LAB 151, MINNEAPOLIS, MN 55417 USA.			Lappi, Douglas/0000-0003-4239-7387	NIMH NIH HHS [MH56368] Funding Source: Medline; NINDS NIH HHS [NS31223, NS23970] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R44MH056368, R43MH056368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023970, R37NS023970, R29NS031223] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; BENYA RV, 1994, J BIOL CHEM, V269, P11721; BOEHMER CG, 1989, PEPTIDES, V10, P1179, DOI 10.1016/0196-9781(89)90011-9; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BRIMIJOIN S, 1980, BRAIN RES, V191, P443, DOI 10.1016/0006-8993(80)91293-7; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; COX BM, 1993, HDB EXPT PHARM OPIOI, V1, P145; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DELFIACCO M, 1994, NEUROREPORT, V5, P2349, DOI 10.1097/00001756-199411000-00035; DICKENSON AH, 1995, BRIT J ANAESTH, V75, P193, DOI 10.1093/bja/75.2.193; DING YQ, 1995, BRAIN RES, V674, P336, DOI 10.1016/0006-8993(95)00022-I; DOUGHERTY PM, 1995, PAIN, V61, P411, DOI 10.1016/0304-3959(94)00222-Z; DOUGHERTY PM, 1993, BRAIN RES REV, V18, P227, DOI 10.1016/0165-0173(93)90003-I; DOUGHERTY PM, 1994, J NEUROPHYSIOL, V72, P1464, DOI 10.1152/jn.1994.72.4.1464; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; DUGGAN AW, 1991, NEUROSCI LETT, V122, P191, DOI 10.1016/0304-3940(91)90855-N; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; Iversen LL, 1996, NATURE, V383, P759, DOI 10.1038/383759a0; IWASHITA T, 1992, BRAIN RES, V581, P59, DOI 10.1016/0006-8993(92)90344-9; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; KAR S, 1994, EUR J NEUROSCI, V6, P345, DOI 10.1111/j.1460-9568.1994.tb00277.x; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; LITTLEWOOD NK, 1995, NEUROSCIENCE, V66, P597, DOI 10.1016/0306-4522(95)00039-L; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Marshall GE, 1996, NEUROSCIENCE, V72, P255, DOI 10.1016/0306-4522(95)00558-7; MUNGLANI R, 1995, BRIT J ANAESTH, V75, P186, DOI 10.1093/bja/75.2.186; MUNRO FE, 1993, NEUROPEPTIDES, V25, P299, DOI 10.1016/0143-4179(93)90047-E; NAGY I, 1994, NEUROREPORT, V5, P2105, DOI 10.1097/00001756-199410270-00029; NAGY I, 1993, NEUROSCIENCE, V52, P1029, DOI 10.1016/0306-4522(93)90549-U; NICOL GD, 1992, J NEUROSCI, V12, P1917; QUARTU M, 1992, J CHEM NEUROANAT, V5, P143, DOI 10.1016/0891-0618(92)90040-W; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SALTER MW, 1991, NEUROSCIENCE, V43, P601, DOI 10.1016/0306-4522(91)90319-J; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; Simone D A, 1992, Curr Opin Neurobiol, V2, P479, DOI 10.1016/0959-4388(92)90183-L; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; Traub RJ, 1996, PAIN, V67, P151, DOI 10.1016/0304-3959(96)03076-X; URBAN L, 1994, TRENDS NEUROSCI, V17, P432, DOI 10.1016/0166-2236(94)90018-3; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WUWONG JR, 1995, J PHARMACOL EXP THER, V274, P499; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x; YAMAMOTO T, 1993, ANESTHESIOLOGY, V79, P1042, DOI 10.1097/00000542-199311000-00023	52	498	512	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					275	279		10.1126/science.278.5336.275	http://dx.doi.org/10.1126/science.278.5336.275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323204				2022-12-01	WOS:A1997YA56400041
J	Ingram, D; Sanders, K; Kolybaba, M; Lopez, D				Ingram, D; Sanders, K; Kolybaba, M; Lopez, D			Case-control study of phyto-oestrogens and breast cancer	LANCET			English	Article							NUTRITION EXAMINATION SURVEY; ISOFLAVONOID PHYTOESTROGENS; ALCOHOL-CONSUMPTION; NATIONAL-HEALTH; POSSIBLE ROLES; DIETARY-FAT; LIGNANS; WOMEN; EXCRETION; RISK	Background Phyto-oestrogens are a group of naturally occurring chemicals derived from plants; they have a structure similar to oestrogen, and form part of our diet. They also have potentially anticarcinogenic biological activity. We did a case-control study to assess the association between phyto-oestrogen intake (as measured by urinary excretion) and the risk of breast cancer. Methods Women with newly diagnosed early breast cancer were interviewed by means of questionnaires, and a 72 h urine collection and blood sample were taken before any treatment started. Controls were randomly selected from the electoral roll after matching for age and area of residence. 144 pairs were included for analysis. The urine samples were assayed for the isoflavonic phyto-oestrogens daidzein, genistein, and equol, and the lignans enterodiol, enterolactone, and matairesinol. Findings After adjustment for age at menarche, parity, alcohol intake, and total fat intake, high excretion of both equol and enterolactone was associated with a substantial reduction in breast-cancer risk, with significant trends through the quartiles: equol odds ratios were 1.00, 0.45 (95% CI 0.20, 1.02), 0.52 (0.23, 1.17), and 0.27 (0.10, 0.69)-trend p=0.009-and enterolactone odds ratios were 1.00, 0.91 (0.41, 1.98), 0.65 (0.29, 1.44), 0.36 (0.15, 0.86)-trend p=0.013 For most other phytoestrogens there was a reduction in risk, but it did nat reach significance. Difficulties with the genistein assay precluded analysis of that substance. Interpretation There is a substantial reduction in breast-cancer risk among women with a high intake (as measured by excretion) of phyto-oestrogens-particularly the isoflavonic phyto-oestrogen equol and the lignan enterolactone. These findings could be important in the prevention of breast cancer.	QUEEN ELIZABETH II MED CTR,UNIV DEPT SURG,PERTH,WA,AUSTRALIA	University of Western Australia			Lopez, Derrick/AAH-5046-2021	Lopez, Derrick/0000-0003-0677-0420				Adlercreutz H., 1991, Nutrition, toxicity, and cancer., P137; ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1986, J STEROID BIOCHEM, V25, P791, DOI 10.1016/0022-4731(86)90310-9; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; ADLERCREUTZ H, 1982, LANCET, V2, P1295; ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; ADLERCREUTZ H, 1993, SCAND J CLIN LAB INV, V53, P5, DOI 10.3109/00365519309090693; ADLERCREUTZ H, 1991, CLIN CHIM ACTA, V199, P263, DOI 10.1016/0009-8981(91)90120-2; ADLERCREUTZ H, 1986, ADV MASS SPECTROM, V85, P1293; ADLERERCUTZ CHT, 1995, J NUTR, V125, pS575; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AXELSON M, 1984, J ENDOCRINOL, V102, P49, DOI 10.1677/joe.0.1020049; AXELSON M, 1982, NATURE, V298, P659, DOI 10.1038/298659a0; BURGE JC, 1992, JPEN, V17, P529; DWYER JT, 1994, J AM DIET ASSOC, V94, P739, DOI 10.1016/0002-8223(94)91939-9; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; HUSE DM, 1974, AM J CLIN NUTR, V27, P771, DOI 10.1093/ajcn/27.8.771; HUTCHINS AM, 1995, J AM DIET ASSOC, V95, P545, DOI 10.1016/S0002-8223(95)00149-2; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KELLY GE, 1995, P SOC EXP BIOL MED, V208, P40, DOI 10.3181/00379727-208-43829; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; LAMPE JW, 1994, AM J CLIN NUTR, V60, P122, DOI 10.1093/ajcn/60.1.122; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SETCHELL KDR, 1984, AM J CLIN NUTR, V40, P569, DOI 10.1093/ajcn/40.3.569; SETCHELL KDR, 1981, LANCET, V2, P4; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; THOMPSON LU, 1991, NUTR CANCER, V16, P43, DOI 10.1080/01635589109514139; VANTVEER P, 1991, INT J CANCER, V47, P649, DOI 10.1002/ijc.2910470503; VANVEER P, 1989, CANCER RES, V49, P4020; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263	34	579	608	0	53	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					990	994		10.1016/S0140-6736(97)01339-1	http://dx.doi.org/10.1016/S0140-6736(97)01339-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329514				2022-12-01	WOS:A1997XZ71000010
J	Verrees, M				Verrees, M			Secondary survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1047	1047						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315747				2022-12-01	WOS:A1997XX30300002
J	Fischer, U; Liu, Q; Dreyfuss, G				Fischer, U; Liu, Q; Dreyfuss, G			The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; L929 MOUSE FIBROBLASTS; SMALL NUCLEAR-RNA; NUCLEOCYTOPLASMIC TRANSPORT; CAP TRIMETHYLATION; PROTEIN-BINDING; GENE FREQUENCY; M3G CAP; PATHWAY; DOMAIN	Spinal muscular atrophy (SMA) is an often fatal neuromuscular disease that has been directly linked to the protein product of the Survival of Motor Neurons (SMN) gene. The SMN protein is tightly associated with a novel protein, SIP1, and together they form a complex with several spliceosomal snRNP proteins. Here we show that the SMN-SIP1 complex is associated with spliceosomal snRNAs U1 and U5 in the cytoplasm of Xenopus oocytes. Antibodies directed against the SMN-SIP1 complex strongly interfere with the cytoplasmic assembly of the common (Sm) snRNP proteins with spliceosomal snRNAs and with the import of the snRNP complex into the nucleus. Thus, the SMN-SIP1 complex is directly involved in the biogenesis of spliceosomal snRNPs. Defects in spliceosomal snRNP biogenesis may, therefore, be the cause of SMA.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020; Dreyfuss, Gideon/D-1218-2013	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591; Dreyfuss, Gideon/0000-0001-8129-8774				BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Liu Q, 1996, COLD SPRING HARB SYM, V61, P689; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; Moore M., 1993, RNA WORLD, P303; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Reddy R, 1988, STRUCTURE FUNCTION M, P1, DOI [10.1007/978-3-642-73020-7_1, 10.1007/978-3-642-73020-7_1.]; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; SAUTERER RA, 1990, J BIOL CHEM, V265, P1048; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2	39	535	549	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1023	1029		10.1016/S0092-8674(00)80368-2	http://dx.doi.org/10.1016/S0092-8674(00)80368-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323130	hybrid			2022-12-01	WOS:A1997XX76800008
J	Horiuchi, H; Lippe, R; McBride, HM; Rubino, M; Woodman, P; Stenmark, H; Rybin, V; Wilm, M; Ashman, K; Mann, M; Zerial, M				Horiuchi, H; Lippe, R; McBride, HM; Rubino, M; Woodman, P; Stenmark, H; Rybin, V; Wilm, M; Ashman, K; Mann, M; Zerial, M			A novel Rab5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function	CELL			English	Article							GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; ENDOCYTIC MEMBRANE-FUSION; VACUOLAR PROTEINS; BOVINE BRAIN; YEAST; VESICLES; PATHWAY; DOCKING; CELLS	The small GTPase Rab5 plays an essential role in endocytic traffic. Rab GDP dissociation inhibitor delivers Rab5 to the membrane, where a nucleotide exchange activity allows recruitment of an effector protein, Rabaptin-5. Here we uncovered a novel 60 kDa Rab5-binding protein, Rabex-5. Rabex-5 forms a tight physical complex with Rabaptin-5, and this complex is essential for endocytic membrane fusion. Sequencing of mammalian Rabex-5 by nanoelectrospray mass spectrometry and cloning revealed striking homology to Vps9p, a yeast protein implicated in endocytic traffic. Rabex-5 displays GDP/GTP exchange activity on Rab5 upon delivery of the GTPase to the membrane. This demonstrates that a soluble exchange factor coupled to a Rab effector translocates from cytosol to the membrane, where the complex stabilizes the GTPase in the active state.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MANCHESTER,SCH BIOL SCI,DIV BIOCHEM,MANCHESTER M13 9PT,LANCS,ENGLAND; NORWEGIAN RADIUM HOSP,DEPT BIOCHEM,N-0310 OSLO,NORWAY	European Molecular Biology Laboratory (EMBL); University of Manchester; University of Oslo			McBride, Heidi M/C-1162-2008; Ashman, Keith/G-2328-2011; Mann, Matthias/A-3454-2013; Stenmark, Harald/B-8868-2008; McBride, Heidi M./ABD-5774-2021	McBride, Heidi M/0000-0003-4666-2280; Mann, Matthias/0000-0003-1292-4799; McBride, Heidi M./0000-0003-4666-2280; Lippe, Roger/0000-0001-5066-3070; Wilm, Matthias/0000-0002-5461-6834				Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1996, MOL CELL BIOL, V16, P2369; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; LI GP, 1994, J BIOL CHEM, V269, P14631; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; SHEVCHENKO A, 1996, ANAL CHEM, V68, P820; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1995, METHOD ENZYMOL, V257, P243; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	48	460	479	2	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1149	1159		10.1016/S0092-8674(00)80380-3	http://dx.doi.org/10.1016/S0092-8674(00)80380-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323142	Bronze			2022-12-01	WOS:A1997XX76800020
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Just one word: Plastics	SCIENCE			English	Article																		DORDICK JS, COMMUNICATION; Wang P, 1997, NAT BIOTECHNOL, V15, P789, DOI 10.1038/nbt0897-789; YANG Z, 1995, J AM CHEM SOC, V117, P4843, DOI 10.1021/ja00122a014	3	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1849	1849						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324772				2022-12-01	WOS:A1997XX29800054
J	Saitoh, O; Kubo, Y; Miyatani, Y; Asano, T; Nakata, H				Saitoh, O; Kubo, Y; Miyatani, Y; Asano, T; Nakata, H			RGS8 accelerates G-protein-mediated modulation of K+ currents	NATURE			English	Article							MUSCARINIC POTASSIUM CHANNEL; GTPASE-ACTIVATING PROTEINS; BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; XENOPUS OOCYTES; ALPHA-SUBUNITS; FAMILY; CELLS; DESENSITIZATION; INHIBITION	Transmembrane signal transduction via heterotrimeric G proteins is reported to be inhibited by RGS (regulators of G-protein signalling) proteins(1-4). These RGS proteins work by increasing the GTPase activity of G protein alpha-subunits (G alpha), thereby driving G proteins into their inactive GDP-bound form(5-7). However, it is not known how RGS proteins regulate the kinetics of physiological responses that depend on G proteins. Here we report the isolation of a full-length complementary DNA encoding a neural-tissue-specific RGS protein, RGS8, and the determination of its function. We show that RGS8 binds preferentially to the alpha-subunits G alpha o and G alpha i3 and that it functions as a GTPase-activating protein (GAP). When co-expressed in Xenopus oocytes with a G-protein-coupled receptor and a G-protein-coupled inwardly rectifying K+ channel (GIRK1/2), RGS8 accelerated not only the turning off but also the turning on of the GIRK1/2 current upon receptor stimulation, without affecting the dose-response relationship. We conclude that RGS8 accelerates the modulation of G-protein-coupled channels and is not just a simple negative regulator. This property of RGS8 may be crucial for the rapid regulation of neuronal excitability upon stimulation of G-protein-coupled receptors.	TOKYO METROPOLITAN INST NEUROSCI,DEPT NEUROPHYSIOL,FUCHU,TOKYO 183,JAPAN; INST DEV RES,AICHI HUMAN SERV CTR,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Saitoh, O (corresponding author), TOKYO METROPOLITAN INST NEUROSCI,DEPT MOL & CELLULAR NEUROBIOL,2-6 MUSASHIDAI,FUCHU,TOKYO 183,JAPAN.			Kubo, Yoshihiro/0000-0001-6707-0837				Abe M, 1996, EXP CELL RES, V229, P48, DOI 10.1006/excr.1996.0342; ASANO T, 1988, J BIOCHEM-TOKYO, V103, P950, DOI 10.1093/oxfordjournals.jbchem.a122392; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Saugstad JA, 1996, J NEUROSCI, V16, P5979; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Werner P, 1996, MOL PHARMACOL, V49, P656; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865	24	183	189	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					525	529		10.1038/37385	http://dx.doi.org/10.1038/37385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394004				2022-12-01	WOS:A1997YJ86500056
J	Alexander, FE				Alexander, FE			Blood transfusion and risk of non-Hodgkin lymphoma	LANCET			English	Editorial Material							TIME TRENDS				Alexander, FE (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							Adami J, 1997, ANN INTERN MED, V127, P365, DOI 10.7326/0003-4819-127-5-199709010-00004; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; Brandt L, 1996, BRIT J CANCER, V73, P1148, DOI 10.1038/bjc.1996.220; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; Cerhan JR, 1997, J NATL CANCER I, V89, P314, DOI 10.1093/jnci/89.4.314; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; DEVESA SS, 1992, CANCER RES, V52, pS5432; GELB AB, 1994, HUM PATHOL, V25, P953, DOI 10.1016/0046-8177(94)90018-3; HARTGE P, 1992, CANCER RES, V52, pS5566; MANN R, 1994, J TRAUMA, V37, P220, DOI 10.1097/00005373-199408000-00012; Mckinney P A, 1990, Leuk Lymphoma, V2, P67, DOI 10.3109/10428199009042516; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; RollandPortal I, 1997, INT J EPIDEMIOL, V26, P945, DOI 10.1093/ije/26.5.945; Schreiber GB, 1997, J ACQ IMMUN DEF SYND, V14, P263, DOI 10.1097/00042560-199703010-00011	15	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1414	1415		10.1016/S0140-6736(05)64203-1	http://dx.doi.org/10.1016/S0140-6736(05)64203-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371161				2022-12-01	WOS:A1997YF95300004
J	Collins, MM; Ransohoff, DF; Barry, MJ				Collins, MM; Ransohoff, DF; Barry, MJ			Early detection of prostate cancer - Serendipity strikes again	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med			DIGITAL RECTAL EXAMINATION; FECAL OCCULT BLOOD; COLORECTAL-CANCER; ANTIGEN; ADENOCARCINOMA; DIAGNOSIS; STAGE-T1C; BIOPSIES; VOLUME; TRIAL	An underappreciated characteristic of prostate cancer screening is that it may detect some prostate cancers solely by serendipity or chance, Serendipity, previously described in the detection of colonic neoplasms, could affect prostate cancer detection when a screening test result is abnormal for reasons other than the presence of prostate cancer, but prostate cancer is coincidentally detected during the subsequent evaluation of the abnormal screening result. We reviewed published articles about prostate cancer screening, searching for evidence of serendipity. We defined serendipity in digital rectal examination (DRE) screening as the discovery of a prostate cancer by the random biopsy of an area of the prostate gland other than the palpable suspicious area that prompted the biopsy. We defined serendipity in prostate-specific antigen (PSA) screening as the discovery of a prostate cancer by the random biopsy of a nonpalpable (stage T1c) prostate cancer less than 1.0 cm(3) in volume, since tumors less than 1.0 cm(3) are generally too small to cause elevated PSA levels. We found that serendipity may be responsible for the detection of more than one quarter of apparently DRE-detected prostate cancers and up to one quarter of apparently PSA-detected cancers. Additionally, serendipity played a larger role in the detection of smaller tumors that are common but of uncertain clinical significance. We conclude that serendipity-detected prostate cancers contribute to an overestimation of the true information value of DRE and PSA screening. Whether serendipity is advantageous in prostate cancer screening depends on the as yet uncertain outcomes for men with smaller prostate cancers. However, given our estimates of the potential magnitude of the impact of serendipity, the currently popular DRE- and PSA-based screening strategy may not be optimal. If smaller prostate cancers are important, then we are not finding enough; if they are unimportant, then we are finding too many that we may feel compelled to treat aggressively.	MASSACHUSETTS GEN HOSP, MED SERV, DIV GEN MED, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC USA; UNIV N CAROLINA, DEPT EPIDEMIOL, CHAPEL HILL, NC USA	Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					AHRQ HHS [HS 08397] Funding Source: Medline; BHP HRSA HHS [5T32PE11001-08] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		BARRY MJ, 1995, UROLOGY, V46, P2, DOI 10.1016/S0090-4295(99)80151-4; BARRY MJ, 1995, ACP J CLUB, V123, P19; BILLEBAUD T, 1992, EUR UROL, V21, P6; BRAWN PN, 1991, CANCER, V68, P1592, DOI 10.1002/1097-0142(19911001)68:7<1592::AID-CNCR2820680721>3.0.CO;2-M; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; COLEY CM, 1995, UROLOGY, V46, P125, DOI 10.1016/S0090-4295(99)80181-2; Dugan JA, 1996, JAMA-J AM MED ASSOC, V275, P288, DOI 10.1001/jama.275.4.288; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; Eskew LA, 1997, J UROLOGY, V157, P199, DOI 10.1016/S0022-5347(01)65322-9; FLANIGAN RC, 1994, J UROLOGY, V152, P1506, DOI 10.1016/S0022-5347(17)32457-6; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Geary ES, 1996, J UROLOGY, V156, P1056, DOI 10.1016/S0022-5347(01)65701-X; GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6; Harmon Taz, 1997, Journal of Urology, V157, P365; Humphrey PA, 1996, J UROLOGY, V155, P816, DOI 10.1016/S0022-5347(01)66316-X; Karakiewicz PI, 1996, UROLOGY, V48, P747, DOI 10.1016/S0090-4295(96)00230-0; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; Levine Michael A., 1997, Journal of Urology, V157, P64; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1993, UROL CLIN N AM, V20, P687; OHORI M, 1994, CANCER-AM CANCER SOC, V74, P104, DOI 10.1002/1097-0142(19940701)74:1<104::AID-CNCR2820740119>3.0.CO;2-5; PROROK P, 1994, CAN J ONCOL S, V4, P102; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; SCALETSCKY R, 1994, J UROLOGY, V152, P129, DOI 10.1016/S0022-5347(17)32834-3; SCARDINO PT, 1992, HUM PATHOL, V23, P211, DOI 10.1016/0046-8177(92)90102-9; Schroder F H, 1994, Can J Oncol, V4 Suppl 1, P102; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; Vashi Apoorva E., 1997, Journal of Urology, V157, P365; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107	34	44	44	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1516	1519		10.1001/jama.1997.03550180066039	http://dx.doi.org/10.1001/jama.1997.03550180066039			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YE445	9363972				2022-12-01	WOS:A1997YE44500036
J	Bootman, MD; Berridge, MJ; Lipp, P				Bootman, MD; Berridge, MJ; Lipp, P			Cooking with calcium: The recipes for composing global signals from elementary events	CELL			English	Article							1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; HELA-CELLS; XENOPUS OOCYTES; GATED CHANNELS; CYTOSOLIC CA2+; MODULATION; RECEPTORS; PATTERNS	Recent studies have suggested that global intracellular Ca2+ signals arise from the summation and coordination of subcellular elementary release events (e.g., ''Ca2+ puffs''), although the modes of recruitment of such signals are unknown. In order to understand how cells utilize elementary Ca2+ release events, we imaged Ca2+ transients evoked through the phosphoinositide pathway in HeLa cells using confocal microscopy. During the pacemaker phase leading to the global Ca2+ signal, elementary Ca2+ release events were recruited in (1) frequency, (2) amplitude, and (3) spatial domains. Since each digital elementary event contributes to a small change of the analog cytosolic Ca2+ concentration, the net effect of the advancement in the three domains is to drive the ambient Ca2+ concentration toward a threshold where the signal becomes regenerative, resulting in a global Ca2+ wave.	BABRAHAM INST, MOL SIGNALLING LAB, CAMBRIDGE CB2 4AT, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge			Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Bootman MD, 1996, CELL CALCIUM, V20, P97, DOI 10.1016/S0143-4160(96)90099-8; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Lipp P, 1997, J PHYSIOL-LONDON, V502, P1, DOI 10.1111/j.1469-7793.1997.001bl.x; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Reber BFX, 1996, PFLUG ARCH EUR J PHY, V432, P893, DOI 10.1007/s004240050213; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; WOJCIKIEWICZ RJH, 1993, J EXP BIOL, V184, P145; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	28	315	319	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					367	373		10.1016/S0092-8674(00)80420-1	http://dx.doi.org/10.1016/S0092-8674(00)80420-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363945	Bronze			2022-12-01	WOS:A1997YD94100010
J	Hunter, DJ; Hankinson, SE; Laden, F; Colditz, GA; Manson, JE; Willett, WC; Speizer, FE; Wolff, MS				Hunter, DJ; Hankinson, SE; Laden, F; Colditz, GA; Manson, JE; Willett, WC; Speizer, FE; Wolff, MS			Plasma organochlorine levels and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DICHLORODIPHENYL DICHLOROETHENE DDE; POLYCHLORINATED-BIPHENYLS PCBS; BLOOD-LEVELS; HUMAN-MILK; SERUM; WOMEN; PESTICIDES; ESTROGENS; RESIDUES; LACTATION	Background Exposure to ''environmental estrogens'' such as organochlorines in pesticides and industrial chemicals has been proposed as a cause of increasing rates of breast cancer. Several studies have reported higher blood levels of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) and polychlorinated biphenyls (PCBs) in patients with breast cancer than in controls. Methods We measured plasma levels of DDE and PCBs prospectively among 240 women who gave a blood sample in 1989 or 1990 and who were subsequently given a diagnosis of breast cancer before June 1, 1992. We compared these levels with those measured in matched control women in whom breast cancer did not develop. Data on DDE were available for 236 pairs, and data on PCBs were available for 230 pairs. Results The median level of DDE was lower among case patients than among controls (4.71 vs, 5.35 parts per billion, P = 0.14), as was the median level of PCBs (4.49 vs. 4.68 parts per billion, P = 0.72), The multivariate relative risk of breast cancer for women in the highest quintile of exposure as compared with women in the lowest quintile was 0.72 for DDE (95 percent confidence interval, 0.37 to 1.40) and 0.66 for PCBs (95 percent confidence interval, 0.32 to 1.37). Exposure to high levels of both DDE and PCBs was associated with a nonsignificantly lower risk of breast cancer (relative risk for women in the highest quintiles of both DDE and PCBs as compared with women in the lowest, 0.43; 95 percent confidence interval, 0.13 to 1.44). Conclusions Our data do not support the hypothesis that exposure to 2,2-bis(p-chlorophenyl)-1,1,1-trichloroethane (DDT) and PCBs increases the risk of breast cancer. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, SCH MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD CTR CANC PREVENT, BOSTON, MA USA; MT SINAI HOSP, DIV ENVIRONM & OCCUPAT MED, NEW YORK, NY 10029 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Icahn School of Medicine at Mount Sinai	Hunter, DJ (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, U01CA049449, R01CA040356, U01CA062984, R01CA049449] Funding Source: NIH RePORTER; NCI NIH HHS [CA49449, CA40356, U01 CA/ES62984] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON LF, 1994, J NATL CANCER I, V86, P576, DOI 10.1093/jnci/86.8.576; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BERGERON JM, 1994, ENVIRON HEALTH PERSP, V102, P780, DOI 10.2307/3432139; BRESLOW NE, 1980, IARC SCI PUBL, V32, P249; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; DEWAILLY E, 1994, J NATL CANCER I, V86, P232, DOI 10.1093/jnci/86.3.232; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; Gammon MD, 1996, CANCER EPIDEM BIOMAR, V5, P467; Gammon MD, 1997, CANCER EPIDEM BIOMAR, V6, P327; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; KUTZ FW, 1991, REV ENVIRON CONTAM T, V120, P1; Laden F, 1997, CANCER EPIDEM BIOMAR, V6, P333; LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; ROBISON AK, 1985, TOXICOL LETT, V27, P109, DOI 10.1016/0378-4274(85)90127-4; ROGAN WJ, 1987, AM J PUBLIC HEALTH, V77, P1294, DOI 10.2105/AJPH.77.10.1294; ROGAN WJ, 1986, AM J PUBLIC HEALTH, V76, P172, DOI 10.2105/AJPH.76.2.172; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P551; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SAVAGE EP, 1981, AM J EPIDEMIOL, V113, P413, DOI 10.1093/oxfordjournals.aje.a113109; SCRIBNER JD, 1981, CARCINOGENESIS, V2, P1235, DOI 10.1093/carcin/2.12.1235; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; vantVeer P, 1997, BMJ-BRIT MED J, V315, P81, DOI 10.1136/bmj.315.7100.81; WASSERMANN M, 1976, B ENVIRON CONTAM TOX, V15, P478, DOI 10.1007/BF01685076; WIEMEYER SN, 1984, ARCH ENVIRON CON TOX, V13, P529, DOI 10.1007/BF01056332; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; WOLFF MS, 1995, ENVIRON HEALTH PERSP, V103, P141, DOI 10.2307/3432524; WOLFF MS, 1992, ENVIRON RES, V59, P202, DOI 10.1016/S0013-9351(05)80240-3; WOLFF MS, 1991, B ENVIRON CONTAM TOX, V47, P499, DOI 10.1007/BF01700936	33	278	284	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1253	1258		10.1056/NEJM199710303371801	http://dx.doi.org/10.1056/NEJM199710303371801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345073	Bronze			2022-12-01	WOS:A1997YC92000001
J	Condic, ML; Letourneau, PC				Condic, ML; Letourneau, PC			Ligand-induced changes in integrin expression regulate neuronal adhesion and neurite outgrowth	NATURE			English	Article							EXTRACELLULAR-MATRIX; LAMININ RECEPTORS; SENSORY NEURONS; GROWTH CONES; IN-VITRO; FIBRONECTIN; SUBUNIT; CHICK; LOCOMOTION; MIGRATION	Receptors of the integrin family are expressed by every cell type and are the primary means by which cells interact with the extracellular matrix. The control of integrin expression affects a wide range of developmental and cellular processes, including the regulation of gene expression, cell adhesion, cell morphogenesis and cell migration(1-3). Here we show that the concentration of substratum-bound ligand (laminin) post-translationally regulates the amount of receptor (alpha(6) beta(1) integrin) expressed on the surface of sensory neurons. When ligand availability is low, surface amounts of receptor increase, whereas integrin RNA and total integrin protein decrease. Ligand concentration determines surface levels of integrin by altering the rate at which receptor is removed from the cell surface. Furthermore, increased expression of integrin at the cell surface is associated with increased neuronal cell adhesion and neurite outgrowth, These results indicate that integrin regulation maintains neuronal growth-cone motility over a broad range of ligand concentrations, allowing axons to invade different tissues during development and regeneration.	UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Condic, ML (corresponding author), UNIV UTAH, SCH MED, DEPT ANAT & NEUROBIOL, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.		Letourneau, Paul C/A-6764-2009					ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BUETTNER HM, 1991, DEV BIOL, V145, P266, DOI 10.1016/0012-1606(91)90125-M; CAI J, 1995, CELL, V83, P693; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DUBAND JL, 1991, J CELL SCI, V98, P517; GAIETTA G, 1994, J CELL SCI, V107, P3339; GOMEZ TM, 1994, J NEUROSCI, V14, P5959; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; MCCARTHY JB, 1984, J CELL BIOL, V98, P1474, DOI 10.1083/jcb.98.4.1474; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; TOMASELLI KJ, 1993, J NEUROSCI, V13, P4880; VEKEMAN S, 1993, FEBS LETT, V327, P207, DOI 10.1016/0014-5793(93)80171-P; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; WEAVER CD, 1995, J NEUROSCI, V15, P5275	29	156	159	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					852	856		10.1038/39878	http://dx.doi.org/10.1038/39878			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349817				2022-12-01	WOS:A1997YC14800058
J	Butler, RN				Butler, RN			Living longer, contributing longer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MT SINAI MED CTR,INT LONGEV CTR US,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai								BASS SA, 1996, GENERATIONS      SPR, P29; FAIRLIE H, 1988, NEW REPUBLIC, V198, P19; HARTOOTYAN RA, 1996, ENCY GERONTOLOGY, V2, P613; *IND SECT, 1996, GIV VOL US; *LINK HOUS, 1997, AGING TODAY, V18, P11; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593	6	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1372	1373		10.1001/jama.278.16.1372	http://dx.doi.org/10.1001/jama.278.16.1372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343470				2022-12-01	WOS:A1997YA90500040
J	Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL				Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL			Effects of residence in Alzheimer disease special care units on functional outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM DATA SET; NURSING-HOME; DEMENTIA; IMPACT; PREDICTORS; STATE; MDS	Context.-Alzheimer disease special care units (SCUs) in nursing homes are increasingly prevalent, but little is known about their effects on residents' outcomes. Objective.-To analyze the effect of SCU residence on the rates at which residents decline in functional status. Design.-A cohort of nursing home residents assessed at multiple points during about 1 year. Facility staff completed all assessments using the Minimum Data Set for Nursing Home Resident Assessment and Care Screening (MDS). Setting.-Medicare-or Medicaid-certified nursing facilities. Patients or Other Participants.-All nursing home residents in 1993 and early 1994 in Kansas, Maine, Mississippi, and South Dakota. Serial MDS assessments of 77 337 residents in more than 800 facilities, including 1228 residents in 48 facilities with SCUs. Main Outcome Measures.-Decline in locomotion, transferring, toileting, eating, dressing, and a summary activities of daily living index; decline in urinary and bowel continence; and significant weight loss. Results.-No statistically significant difference was observed in the speed of decline for residents in SCUs and traditional units in any of the 9 outcomes. Residents were matched on a variety of characteristics, and subgroup analyses were performed. In none did we observe a pattern of better outcomes among SCU residents. Conclusions.-Although SCUs may have provided unmeasured benefits to families and residents, it does not appear that those benefits included any slowing in the rates of functional decline experienced by individuals with dementia.	UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC; RES TRIANGLE INST,DIV STAT RES,RES TRIANGLE PK,NC 27709; RES TRIANGLE INST,PROGRAM AGING & LONG TERM CARE,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; Research Triangle Institute	Phillips, CD (corresponding author), MENORAH PK CTR AGING,MYERS RES INST,BEACHWOOD,OH 44122, USA.				NIA NIH HHS [5-U01-AG10313-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG010313] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON WE, 1994, GERONTOLOGIST, V34, P775, DOI 10.1093/geront/34.6.775; *ADV PAN ALZH DIS, 1991, DHHS PUBL; Allison P.D., 1982, SOCIOL METHODOL, V13, P61, DOI [10.2307/270718, DOI 10.2307/270718]; *ALZH DIS REL DIS, 1992, GUID DIGN GOALS SPEC; BanaszakHoll J, 1996, HEALTH SERV RES, V31, P97; BENSON DM, 1987, J AM GERIATR SOC, V35, P319, DOI 10.1111/j.1532-5415.1987.tb04638.x; BOLING K, 1991, DEMENTIA UNITS LONG, P3; BRAUN BI, 1991, J AM GERIATR SOC, V39, P329, DOI 10.1111/j.1532-5415.1991.tb02896.x; CHAFETZ P K, 1991, Clinical Gerontologist, V11, P19, DOI 10.1300/J018v11n01_03; CLEARY TA, 1988, GERONTOLOGIST, V28, P511, DOI 10.1093/geront/28.4.511; GOLD DT, 1991, GERONTOLOGIST, V31, P467, DOI 10.1093/geront/31.4.467; GRANT LA, 1995, J AM GERIATR SOC, V43, P569, DOI 10.1111/j.1532-5415.1995.tb06108.x; GREEN CR, 1993, J AM GERIATR SOC, V41, P654, DOI 10.1111/j.1532-5415.1993.tb06740.x; Greene J A, 1985, J Tenn Med Assoc, V78, P559; HARDWICK S, 1994, STATES 1994 PROFILES; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; HAWES C, 1997, FAMILY MEMBERS VIEWS; HEINEMANN GD, 1985, RES AGING, V7, P363, DOI 10.1177/0164027585007003003; HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982; HOLMES D, 1990, GERONTOLOGIST, V30, P178, DOI 10.1093/geront/30.2.178; HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/nur.4770150506; *I MED COMM NURS H, 1986, IMPR QUAL NURS HOM; *JOINT COMM ACCR H, 1993, STAND SURV PROT DEM; MATHEW L, 1988, AM J ALZHEIMERS CARE, V3, P16; MEHR DR, 1995, GERONTOLOGIST, V35, P179, DOI 10.1093/geront/35.2.179; MOR V, 1996, GENERATIONS, V19, P24; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS JN, 1991, RESIDENT ASSESSMENT; NORRISBAKER C, IN PRESS MEASURING E; *OFF TECHN ASS, 1992, PUBL OFF TECHN ASS; *OFF TECHN ASS, 1987, OTABA323; OHTA RJ, 1988, GERONTOLOGIST, V28, P803, DOI 10.1093/geront/28.6.803; PHILLIPS CD, IN PRESS ALZHEIMERS; RITER RN, 1992, GERONTOLOGIST, V32, P184, DOI 10.1093/geront/32.2.184; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rovner BW, 1996, J AM GERIATR SOC, V44, P7, DOI 10.1111/j.1532-5415.1996.tb05631.x; Shah BV, 1996, SUDAAN USERS MANUAL; SLOANE PD, 1991, JAMA-J AM MED ASSOC, V265, P1278, DOI 10.1001/jama.265.10.1278; SLOANE PD, 1995, GERONTOLOGIST, V35, P103, DOI 10.1093/geront/35.1.103; STARK AJ, 1995, GERONTOLOGIST, V35, P648, DOI 10.1093/geront/35.5.648; SWANSON EA, 1993, ARCH PSYCHIATR NURS, V5, P292; WELLS Y, 1987, AUST NZ J PSYCHIAT, V21, P524, DOI 10.3109/00048678709158920; ZINN JS, 1994, GERONTOLOGIST, V34, P371, DOI 10.1093/geront/34.3.371	44	58	58	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1340	1344		10.1001/jama.278.16.1340	http://dx.doi.org/10.1001/jama.278.16.1340			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343465				2022-12-01	WOS:A1997YA90500035
J	Giwercman, A; Thomsen, JK; Hertz, J; Berthelsen, JG; Jensen, V; Meinecke, B; Thormann, L; Storm, HH; Skakkebaek, NE				Giwercman, A; Thomsen, JK; Hertz, J; Berthelsen, JG; Jensen, V; Meinecke, B; Thormann, L; Storm, HH; Skakkebaek, NE			Prevalence of carcinoma in situ of the testis in 207 oligozoospermic men from infertile couples: prospective study of testicular biopsies	BRITISH MEDICAL JOURNAL			English	Article							GERM-CELL TUMORS; INSITU; MANAGEMENT; NEOPLASIA	Objective: To investigate the prevalence of carcinoma in situ of the testis in a group of oligozoospermic men from infertile couples. Design: A consecutive group of oligozoospermic men from infertile couples were offered bilateral testicular biopsy. The observed prevalence of carcinoma in situ was compared with the expected prevalence of testicular cancer in a corresponding age matched population of Danish men, assuming all untreated cases of carcinoma in situ progress to tumour stage, This calculation was based on data from the Danish Cancer Registry. Subjects: 207 men aged 18-50 years who had sperm density below 10 million/ml in two samples within the previous 2 years or sperm density below 20 million/ml in two samples within the previous 2 years and a history of cryptorchidism or one or two atrophic testicles (orchidometer volume less than 15 cm(3)), or both. Interventions: Bilateral testicular biopsies. Main outcome measures: Carcinoma in situ in the biopsy specimen. Results: No case of carcinoma in situ was found among the 207 men, The expected number in a normal age matched population of corresponding size was 0.8. Conclusion: There is no increase in risk of carcinoma in situ of the testis in moderately oligozoospermic men of couples referred because of infertility.	UNIV COPENHAGEN,HERLEV HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; UNIV COPENHAGEN,GENTOFTE HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; CENT HOSP HILLEROD,DEPT OBSTET & GYNAECOL,DK-3400 HILLEROD,DENMARK; UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; DANISH CANC SOC,DIV CANC EPIDEMIOL,DANISH CANC REGISTRY,COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Danish Cancer Society	Giwercman, A (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT GROWTH & REPROD,SECT 5064,DK-2100 COPENHAGEN,DENMARK.			Storm, Hans/0000-0001-7223-8198				BERTHELSEN JG, 1982, BRIT MED J, V285, P1683, DOI 10.1136/bmj.285.6356.1683; BERTHELSEN JG, 1981, SCAND J UROL NEPHROL, V15, P165, DOI 10.3109/00365598109179596; BETTOCCHI C, 1994, J ANDROL, V15, pS14; BRUUN E, 1987, INT J ANDROL, V10, P199, DOI 10.1111/j.1365-2605.1987.tb00184.x; CHEMES HE, 1995, J ANDROL S, pP24; Dieckmann KP, 1996, J CLIN ONCOL, V14, P3126, DOI 10.1200/JCO.1996.14.12.3126; DIECKMANN KP, 1993, J CANC RES CLIN ONCO, V119, P1; GIWERCMAN A, 1987, INT J ANDROL, V10, P173, DOI 10.1111/j.1365-2605.1987.tb00180.x; GIWERCMAN A, 1993, EUR UROL, V23, P104; MULLER J, 1987, INT J ANDROL, V10, P147, DOI 10.1111/j.1365-2605.1987.tb00176.x; MUMPEROW E, 1992, UROL INT, V48, P162, DOI 10.1159/000282322; NUESCHBACHMANN IH, 1977, SCHWEIZ MED WSCHR, V107, P795; PRYOR JP, 1983, BRIT J UROL, V55, P780, DOI 10.1111/j.1464-410X.1983.tb03425.x; ROWLEY MJ, 1966, FERTIL STERIL, V17, P177; SCHUTTE B, 1988, C SCHIRREN S ADV AND, P188; SKAKKEBAEK NE, 1978, HISTOPATHOLOGY, V2, P157, DOI 10.1111/j.1365-2559.1978.tb01706.x; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; WEST AB, 1985, J UROLOGY, V133, P107, DOI 10.1016/S0022-5347(17)48810-0	19	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					989	991		10.1136/bmj.315.7114.989	http://dx.doi.org/10.1136/bmj.315.7114.989			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365296	Green Published			2022-12-01	WOS:A1997YC30700021
J	McKenna, G; Schousboe, M; Paltridge, G				McKenna, G; Schousboe, M; Paltridge, G			Lesson of the week - Subjective change in ejaculate as symptom of infection with Schistosoma haematobium in travellers	BRITISH MEDICAL JOURNAL			English	Article									CANTERBURY HLTH,SEX HLTH CTR,CHRISTCHURCH,NEW ZEALAND; CANTERBURY HLTH,CANTERBURY HLTH LABS,CHRISTCHURCH,NEW ZEALAND	Canterbury Health Laboratories								CORACHAN M, 1994, AM J TROP MED HYG, V50, P580, DOI 10.4269/ajtmh.1994.50.580; GELFAND M, 1970, AM J TROP MED HYG, V19, P779, DOI 10.4269/ajtmh.1970.19.779; McKenna G, 1996, AUST NZ J MED, V26, P226, DOI 10.1111/j.1445-5994.1996.tb00888.x; NAIDOO P, 1992, VENEREOLOGY, V5, P97; 1993, MMWR-MORBID MORTAL W, V42, P565	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1000	1001		10.1136/bmj.315.7114.1000	http://dx.doi.org/10.1136/bmj.315.7114.1000			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC307	9365301	Green Published			2022-12-01	WOS:A1997YC30700028
J	Verma, R; Annan, RS; Huddleston, MJ; Carr, SA; Reynard, G; Deshaies, RJ				Verma, R; Annan, RS; Huddleston, MJ; Carr, SA; Reynard, G; Deshaies, RJ			Phosphorylation of Sic1p by G(1) Cdk required for its degradation and entry into S phase	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SELECTIVE DETECTION; MASS-SPECTROMETRY; G1 CYCLINS; START; PHOSPHOPEPTIDES; TRANSITION; PATHWAY; FAMILY	G(1) cyclin-dependent kinase (Cdk)-triggered degradation of the S-phase Cdk inhibitor Sic1p has been implicated in the transition from G(1) to S phase in the cell cycle of budding yeast. A multidimensional electrospray mass spectrometry technique was used to map G(1) Cdk phosphorylation sites in Sic1p both in vitro and in vivo. A Sic1p mutant lacking three Cdk phosphorylation sites did not serve as a substrate for Cdc34p-dependent ubiquitination in vitro, was stable in vivo, and blocked DNA replication. Moreover, purified phosphoSic1p was ubiquitinated in cyclin-depleted G(1) extract, indicating that a primary function of G(1) cyclins is to tag Sic1p for destruction. These data suggest a molecular model of how phosphorylation and proteolysis cooperate to bring about the G(1)/S transition in budding yeast.	SMITHKLINE BEECHAM PHARMACEUT,MASS SPECTROMETRY RES LAB,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	Verma, R (corresponding author), CALTECH,DIV BIOL,BOX 156-29,PASADENA,CA 91125, USA.		Carr, Steven A./AAH-8366-2019; Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052466] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52466-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FELDMAN RMR, IN PRESS CELL; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; HENCHOZ S, IN PRESS GENES DEV; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Mathias N, 1996, MOL CELL BIOL, V16, P6634; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; REYNARD GJ, UNPUB; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SKOWYRA D, IN PRESS CELL; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, METHOD ENZYMOL, V283, P366; Verma R. P., UNPUB; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	28	389	398	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					455	460		10.1126/science.278.5337.455	http://dx.doi.org/10.1126/science.278.5337.455			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334303				2022-12-01	WOS:A1997YB35500043
J	McCord, TB; Carlson, RW; Smythe, WD; Hansen, GB; Clark, RN; Hibbitts, CA; Fanale, FP; Granahan, JC; Segura, M; Matson, DL; Johnson, TV; Martin, PD				McCord, TB; Carlson, RW; Smythe, WD; Hansen, GB; Clark, RN; Hibbitts, CA; Fanale, FP; Granahan, JC; Segura, M; Matson, DL; Johnson, TV; Martin, PD			Organics and other molecules in the surfaces of Callisto and Ganymede	SCIENCE			English	Article							GALILEAN SATELLITES; REFLECTANCE SPECTRUM; INTERNAL STRUCTURE; OPTICAL-CONSTANTS; CARBON-DIOXIDE; ICE ANALOGS; MU-M; FROST	Five absorption features are reported at wavelengths of 3.4, 3.88, 4.05, 4.25, and 4.57 micrometers in the surface materials of the Galilean satellites Callisto and Ganymede from analysis of reflectance spectra returned by the Galileo mission near-infrared mapping spectrometer. Candidate materials include CO2, organic materials (such as tholins containing C=N and C-H), SO2, and compounds containing an SH-functional group; CO2, SO2, and perhaps cyanogen [(CN)(2)] may be present within the surface material itself as collections of a few molecules each. The spectra indicate that the primary surface constituents are water ice and hydrated minerals.	CALTECH,JET PROP LAB,PASADENA,CA 91109; US GEOL SURVEY,DENVER,CO 80225; SCI & TECHNOL INT INC,HONOLULU,HI	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey	McCord, TB (corresponding author), UNIV HAWAII,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822, USA.		Hibbitts, Charles/B-7787-2016	Hibbitts, Charles/0000-0001-9089-4391				Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; Anderson JD, 1997, NATURE, V387, P264, DOI 10.1038/387264a0; ANDERSON JD, 1997, NATURE, V276, P1236; Bishop JL, 1997, METEORIT PLANET SCI, V32, pA14; BLAKE D, 1991, SCIENCE, V254, P548, DOI 10.1126/science.11538372; CALVIN WM, 1991, ICARUS, V89, P305, DOI 10.1016/0019-1035(91)90180-2; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; Clark R. N., 1986, SATELLITES, P437; CLARK RN, UNPUB USGS DIGITAL S; Colthup N., 1975, INTRO INFRARED RAMAN, V2nd; CRUIKSHANK DP, 1991, ICARUS, V94, P345, DOI 10.1016/0019-1035(91)90233-J; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; FALK M, 1987, J CHEM PHYS, V86, P560, DOI 10.1063/1.452307; FANALE FP, 1979, NATURE, V280, P761, DOI 10.1038/280761a0; Farmer V.C., 1974, INFRARED SPECTRA MIN; FARRELL EF, 1967, AM MINERAL, V52, P380; FINK U, 1973, ASTROPHYS J, V179, pL155, DOI 10.1086/181139; FINK UWE, 1975, ICARUS, V24, P411, DOI 10.1016/0019-1035(75)90058-5; Goody R.M., 1989, ATMOSPHERIC RAD, P67; HOBBS PV, 1974, ICE PHYSICS; IRVINE WM, 1968, ICARUS, V8, P324, DOI 10.1016/0019-1035(68)90083-3; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; MCCORD TB, 1997, T AM GEOPHYS UNION, V78, pS202; MCCORD TB, 1996, B AM ASTRON SOC, V28, P1138; MCCORD TB, 1996, T AM GEOPHYS UNION, V77, pF445; MCDONALD GD, 1991, ICARUS, V94, P354, DOI 10.1016/0019-1035(91)90234-K; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; Notesco G, 1997, ICARUS, V126, P336, DOI 10.1006/icar.1996.5654; OCKMAN N, 1958, ADV PHYS, V7, P199, DOI 10.1080/00018735800101227; PIERSON RH, 1956, ANAL CHEM, V28, P1218, DOI 10.1021/ac60116a002; PILCHER CB, 1972, SCIENCE, V178, P1087, DOI 10.1126/science.178.4065.1087; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; ROUSH TL, 1990, ICARUS, V86, P355, DOI 10.1016/0019-1035(90)90225-X; SALISBURY JW, 1991, INFRARED SPECTRA MIN; SANDFORD SA, 1988, ICARUS, V76, P201, DOI 10.1016/0019-1035(88)90069-3; SANDFORD SA, 1990, ASTROPHYS J, V355, P357, DOI 10.1086/168770; Sill G. T., 1982, SATELLITES JUPITER, P174; SMYTHE WD, 1979, NATURE, V280, P766, DOI 10.1038/280766a0; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; Swayze G., 1993, B AM ASTRON SOC, V25, P1033; WARREN SG, 1986, APPL OPTICS, V25, P2650, DOI 10.1364/AO.25.002650; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WATSON K, 1963, ICARUS, V1, P361; Whittet DCB, 1996, ASTRON ASTROPHYS, V315, pL357; Wilkening L. L, 1982, IAU C 61 COMET DISCO, P85; WOOD DL, 1967, J CHEM PHYS, V47, P2220, DOI 10.1063/1.1703295; [No title captured]; 1996, SCIENCE, V274, P377	54	138	140	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					271	275		10.1126/science.278.5336.271	http://dx.doi.org/10.1126/science.278.5336.271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323203				2022-12-01	WOS:A1997YA56400040
J	Kretzschmar, M; Doody, J; Massague, J				Kretzschmar, M; Doody, J; Massague, J			Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1	NATURE			English	Article							MAD-RELATED PROTEIN; GROWTH-FACTOR-BETA; SIGNALING PATHWAYS; TRANSDUCTION; SPECIFICITY; RECEPTORS; DPC4	The growth factor TGF-beta, bone morphogenetic proteins (BMPs) and related factors regulate cell proliferation, differentiation and apoptosis, controlling the development and maintenance of most tissues(1,2). Their signals are transmitted through the phosphorylation of the tumour-suppressor SMAD proteins by receptor protein serine/threonine kinases (RS/TKs)(3-10), leading to the nuclear accumulation(5,9,11,12) and transcriptional activity of SMAD proteins(6,12,13). Here we report that Smad1, which mediates BMP signals, is also a target of mitogenic growth-factor signalling through epidermal growth factor and hepatocyte growth factor receptor protein tyrosine kinases (RTKs). Phosphorylation occurs at specific serines within the region linking the inhibitory and effector domains of Smad1, and is catalysed by the Erk family of mitogen-activated protein kinases. In contrast to the BMP-stimulated phosphorylation of Smad1, which affects carboxy-terminal serines and induces nuclear accumulation of Smad1(6), Erk-mediated phosphorylation specifically inhibits the nuclear accumulation of Smad1. Thus, Smad1 receives opposing regulatory inputs through RTKs and RS/TKs, and it is this balance that determines the level of Smad1 activity in the nucleus, and so possibly the role of Smad1 in the control of cell fate.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BERNIER SM, 1992, J CELL PHYSIOL, V152, P317, DOI 10.1002/jcp.1041520213; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ganan Y, 1996, DEVELOPMENT, V122, P2349; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	34	747	774	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					618	622		10.1038/39348	http://dx.doi.org/10.1038/39348			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335504				2022-12-01	WOS:A1997YA00800064
J	Labarrere, CA; Nelson, DR; Faulk, WP				Labarrere, CA; Nelson, DR; Faulk, WP			Endothelial activation and development of coronary artery disease in transplanted human hearts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN CARDIAC ALLOGRAFTS; TISSUE-PLASMINOGEN-ACTIVATOR; ADHESION MOLECULE EXPRESSION; ANTIENDOTHELIAL ANTIBODIES; VASCULAR IMMUNOPATHOLOGY; PROCOAGULANT ACTIVITY; CHRONIC REJECTION; MOUSE HEARTS; RECIPIENTS; CELLS	Context.-The development of coronary artery disease in heart transplants is often associated with graft failure, Early detection of allografts prone to develop this disease is essential to institute new therapeutic approaches that could prolong allograft function. Objective.-To determine if early activation of arterial/arteriolar endothelium predicts the development of coronary artery disease, graft failure, or both in transplanted human hearts. Design.-Prospective cohort study. Setting.-Heart Transplant Center. Participants.-A total of 121 consecutive adult cardiac allograft recipients who received transplants between 1988 and 1995 and were followed up through 1996. Main Outcome Measures.-Development of coronary artery disease and graft failure, Methods.-Immunocytochemistry was performed on serial endomyocardial biopsy specimens to evaluate endothelial activation markers (intercellular adhesion molecule-1 and histocompatibility antigen HLA-DR) in arteries and arterioles. The presence and progression of coronary artery disease was evaluated by annual coronary angiograms with side-by-side comparisons, Results.-None of the 121 donor hearts showed arterial/arteriolar endothelial activation before transplantation. Arterial/arteriolar endothelial activation was present in 78 and absent in 43 of 121 allografts during the first 3 months after transplantation. The time of appearance and the proportion of biopsy specimens showing endothelial activation during these first 3 months were significantly associated with the risk of developing coronary artery disease, the progression of the disease, and the time required to develop the disease (P<.001). Significantly more patients with arterial/arteriolar endothelial activation died or received a second transplant (P<.001). Conclusions.-Activation of arterial/arteriolar endothelium in transplanted human hearts predicts development of coronary artery disease and increased risk of graft failure.	METHODIST RES INST, CLARIAN HLTH, CTR HLTH SERV RES, INDIANAPOLIS, IN 46202 USA; RILEY HOSP, INDIANAPOLIS, IN USA	Indiana University System; James Whitcomb Riley Hospital Children	Labarrere, CA (corresponding author), METHODIST RES INST, CLARIAN HLTH, CTR REPROD & TRANSPLANTAT IMMUNOL, 1701 N SENATE BLVD, INDIANAPOLIS, IN 46202 USA.			Nelson, David/0000-0002-3240-0725				ADAMS DH, 1993, IMMUNOL REV, V134, P5, DOI 10.1111/j.1600-065X.1993.tb00637.x; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Billingham M E, 1990, J Heart Transplant, V9, P587; BRISCOE DM, 1995, TRANSPLANTATION, V59, P204, DOI 10.1097/00007890-199501270-00009; CRISP SJ, 1994, J HEART LUNG TRANSPL, V13, P81; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; FAULK WP, 1989, SEMIN THROMB HEMOST, V15, P88, DOI 10.1055/s-2007-1002691; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; FAULK WP, 1995, TRANSPLANT P, V27, P1944; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, pS125; FAULK WP, 1994, SEMIN HEMATOL, V31, P26; FAULK WP, 1992, ARCH PATHOL LAB MED, V116, P1337; FAULK WP, 1994, MAJOR PROBL PATHOL, V30, P49; Gag SZ, 1996, J AM COLL CARDIOL, V28, P673, DOI 10.1016/0735-1097(96)00201-X; GAO SZ, 1994, J HEART LUNG TRANSPL, V13, P1119; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; KARNOVSKY MJ, 1994, CLIN TRANSPLANT, V8, P308; LABARRERE CA, 1993, TRANSPLANTATION, V55, P1056, DOI 10.1097/00007890-199305000-00021; LABARRERE CA, 1994, CIRCULATION, V89, P1599, DOI 10.1161/01.CIR.89.4.1599; LABARRERE CA, 1995, NEW ENGL J MED, V333, P1111, DOI 10.1056/NEJM199510263331704; LABARRERE CA, 1995, TRANSPLANT P, V27, P1941; LABARRERE CA, 1995, TRANSPLANT P, V27, P1939; LABARRERE CA, 1994, AM J OBSTET GYNECOL, V171, P165, DOI 10.1016/0002-9378(94)90464-2; MEHRA MR, 1995, J AM COLL CARDIOL, V26, P1537, DOI 10.1016/0735-1097(95)00357-6; MILLER LW, 1995, TRANSPLANT REV, V9, P77; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POSTON RN, 1992, AM J PATHOL, V140, P665; ROSE EA, 1992, J HEART LUNG TRANSPL, V11, pS120; RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391; RUSSELL PS, 1994, J IMMUNOL, V152, P5135; RUSSELL PS, 1994, AM J PATHOL, V144, P260; SALOMON RN, 1991, AM J PATHOL, V138, P791; SCHOEN JF, 1994, ROBBINS PATHOLOGIC B, P467; SCHROEDER JS, 1991, NEW ENGL J MED, V324, P1805, DOI 10.1056/NEJM199106203242509; STOVIN PGI, 1993, J HEART LUNG TRANSPL, V12, P110; TANIO JW, 1994, CIRCULATION, V89, P1760, DOI 10.1161/01.CIR.89.4.1760; TAYLOR PM, 1992, TRANSPLANTATION, V54, P451, DOI 10.1097/00007890-199209000-00013; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; VERSTRAETE M, 1992, THROMBOSIS CARDIOVAS, P175; WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469	45	90	93	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1169	1175		10.1001/jama.278.14.1169	http://dx.doi.org/10.1001/jama.278.14.1169			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326477				2022-12-01	WOS:A1997XY42200035
J	Poon, CS; Merrill, CK				Poon, CS; Merrill, CK			Decrease of cardiac chaos in congestive heart failure	NATURE			English	Article							LOW-DIMENSIONAL CHAOS; NONLINEAR DYNAMICS; RATE-VARIABILITY; TIME-SERIES; FIBRILLATION; TURBULENCE; CARDIOLOGY	The electrical properties of the mammalian heart undergo many complex transitions In normal and diseased states(1-7). It has been proposed that the normal heartbeat may display complex nonlinear dynamics, including deterministic chaos(8,9), and that such cardiac chaos may be a useful physiological marker for the diagnosis(10-12) and management(13,14) of certain heart trouble, However, it is not clear whether the heartbeat series of healthy and diseased hearts are chaotic or stochastic(15-17), or whether cardiac chaos represents normal or abnormal behaviour's. Here we have used a highly sensitive technique, which is robust to random noise, to detect chaos(19). We analysed the electrocardiograms from a group of healthy subjects and those with severe congestive heart failure (CHF), a clinical condition associated with a high risk of sudden death. The short-term variations of beat-to-beat interval exhibited strongly and consistently chaotic behaviour in all healthy subjects, but were frequently interrupted by periods of seemingly non-chaotic fluctuations in patients with CHE Chaotic dynamics in the CHF data, even when discernible, exhibited a high degree of random variability over time, suggesting a weaker form of chaos. These findings suggest that cardiac chaos is prevalent in healthy heart, and a decrease in such chaos may be indicative of CHF.			Poon, CS (corresponding author), MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA.							Barahona M, 1996, NATURE, V381, P215, DOI 10.1038/381215a0; CASOLO G, 1989, AM J CARDIOL, V64, P1162, DOI 10.1016/0002-9149(89)90871-0; CHIALVO DR, 1987, NATURE, V330, P749, DOI 10.1038/330749a0; CHIALVO DR, 1990, NATURE, V343, P653, DOI 10.1038/343653a0; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; DENTON TA, 1990, AM HEART J, V120, P1419, DOI 10.1016/0002-8703(90)90258-Y; GARFINKEL A, 1995, TRENDS CARDIOVAS MED, V5, P76, DOI 10.1016/1050-1738(94)00083-2; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; Glass L, 1996, PHYS TODAY, V49, P40, DOI 10.1063/1.881510; GLASS L, 1990, J CARDIOVASC ELECTR, V1, P481; Goldberger AL, 1996, LANCET, V347, P1312, DOI 10.1016/S0140-6736(96)90948-4; GOLDBERGER AL, 1988, EXPERIENTIA, V44, P983, DOI 10.1007/BF01939894; GOLDBERGER AL, 1991, NEWS PHYSIOL SCI, V6, P87, DOI 10.1152/physiologyonline.1991.6.2.87; GREBOGI C, 1984, PHYSICA D, V13, P261, DOI 10.1016/0167-2789(84)90282-3; Ivanov PC, 1996, NATURE, V383, P323, DOI 10.1038/383323a0; JALIFE J, 1990, ANN NY ACAD SCI, P591; KANTERS JK, 1994, J CARDIOVASC ELECTR, V5, P591, DOI 10.1111/j.1540-8167.1994.tb01300.x; KAPLAN DT, 1990, CIRC RES, V67, P886, DOI 10.1161/01.RES.67.4.886; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; POMEAU Y, 1980, COMMUN MATH PHYS, V74, P189, DOI 10.1007/BF01197757; SKINNER JE, 1990, BIO-TECHNOL, V8, P1018, DOI 10.1038/nbt1190-1018; SKINNER JE, 1993, AM HEART J, V125, P731, DOI 10.1016/0002-8703(93)90165-6; SMITH JM, 1984, P NATL ACAD SCI-BIOL, V81, P233, DOI 10.1073/pnas.81.1.233; Sugihara G, 1996, P NATL ACAD SCI USA, V93, P2608, DOI 10.1073/pnas.93.6.2608; Turcott RG, 1996, ANN BIOMED ENG, V24, P269, DOI 10.1007/BF02667355; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648	26	251	266	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					492	495		10.1038/39043	http://dx.doi.org/10.1038/39043			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333237				2022-12-01	WOS:A1997XY90900055
J	Suwa, G; Asfaw, B; Beyene, Y; White, TD; Katoh, S; Nagaoka, S; Nakaya, H; Uzawa, K; Renne, P; WoldeGabriel, G				Suwa, G; Asfaw, B; Beyene, Y; White, TD; Katoh, S; Nagaoka, S; Nakaya, H; Uzawa, K; Renne, P; WoldeGabriel, G			The first skull of Australopithecus boisei	NATURE			English	Article							LAKE TURKANA; EARLY HOMINID; KENYA; HOMO; EVOLUTION; ETHIOPIA; REGION; EAST; WEST	Australopithecus boisei was first described from a cranium recovered in 1959 from Olduvai Gorge, Tanzania(1,2). This and subsequent finds, mostly from Kenya's Turkana basin(3-5), resulted in its characterization as a specialized Australopithecus species with a hyper-robust masticatory apparatus(2,4,6). A distinct A. boisei facial morphology has been emphasized to differentiate robust Australopithecus lineages from East and South Africa(6). A preference for closed and/or wet habitats has been hypothesizes. Here we report some new A. boisei specimens, including the taxon's first cranium and associated mandible, from Konso, Ethiopia These fossils extend the known geographical range of A. boisei. They provide clear evidence for the coexistence of A. boisei and Homo erectus within a predominantly dry grassland environment. The A. boisei specimens from Konso demonstrate considerable morphological variation within the species. The unexpected combination of cranial and facial features of this skull cautions against the excessive taxonomic splitting of early hominids based on morphological detail documented in small and/or geographically restricted samples.	RIFT VALLEY RES SERV,ADDIS ABABA,ETHIOPIA; MINIST INFORMAT & CULTURE,DEPT ARCHAEOL & ANTHROPOL,CRCCH,ADDIS ABABA,ETHIOPIA; UNIV CALIF BERKELEY,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720; HYOGO MUSEUM HIMAN & NAT ACTIV,DIV EARTH SCI,SANDA,HYOGO 66913,JAPAN; NAGASAKI UNIV,DEPT GEOG,NAGASAKI 852,JAPAN; KAGAWA UNIV,DEPT EARTH SCI,TAKAMATSU,KAGAWA 852,JAPAN; BERKELEY GEOCHRONOL CTR,BERKELEY,CA 94709; LOS ALAMOS NATL LAB,EES1 D462,LOS ALAMOS,NM 87545	University of California System; University of California Berkeley; Nagasaki University; Kagawa University; Berkeley Geochronolgy Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Suwa, G (corresponding author), UNIV TOKYO,DEPT SCI BIOL,BUNKYO KU,TOKYO 113,JAPAN.			Renne, Paul/0000-0003-1769-5235				Albrecht Gene H., 1993, P123; [Anonymous], 1987, SCI GEOL B; ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; BROWN B, 1993, AM J PHYS ANTHROPOL, V91, P137, DOI 10.1002/ajpa.1330910202; Brunet M, 1996, CR ACAD SCI II A, V322, P907; CARNEY J, 1971, NATURE, V230, P509, DOI 10.1038/230509a0; DUBRUL EL, 1977, AM J PHYS ANTHROPOL, V47, P305, DOI 10.1002/ajpa.1330470211; GOWLETT JAJ, 1981, NATURE, V294, P125, DOI 10.1038/294125a0; HARRIS JM, 1983, KOOBI FORA RES PROJE, V2; HARRIS JM, 1991, KOOBI FORA RES PROJE, V3; Holloway R L, 1983, Hum Neurobiol, V2, P105; Kimbel W.H., 1988, P259; Kimbel WH, 1997, AM J PHYS ANTHROPOL, V103, P235, DOI 10.1002/(SICI)1096-8644(199706)103:2<235::AID-AJPA8>3.3.CO;2-V; LEAKEY LSB, 1959, NATURE, V184, P491, DOI 10.1038/184491a0; LEAKEY LSB, 1964, NATURE, V202, P5, DOI 10.1038/202005a0; LEAKEY MG, 1978, KOOBI FORA RES PROJE, V1; LEAKEY REF, 1988, AM J PHYS ANTHROPOL, V76, P1, DOI 10.1002/ajpa.1330760102; MCCOLLUM MA, 1993, J HUM EVOL, V24, P87, DOI 10.1006/jhev.1993.1009; Rak Y., 1983, AUSTRALOPITHECINE FA, DOI [10.1016/B978-0-12-576280-9.50006-7, DOI 10.1016/B978-0-12-576280-9.50006-7]; RIGHTMIRE GP, 1993, AM J PHYS ANTHROPOL, V90, P1, DOI 10.1002/ajpa.1330900102; SCHRENK F, 1993, NATURE, V365, P833, DOI 10.1038/365833a0; Shipman P., 1988, P343; Suwa G, 1996, AM J PHYS ANTHROPOL, V101, P247, DOI 10.1002/(SICI)1096-8644(199610)101:2<247::AID-AJPA9>3.0.CO;2-Z; Tobias P.V, 1967, OLDUVAI GORGE, V2; UCHIDA A, 1996, PEABODY MUSEUM B, V4; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOOD B, 1994, AM J PHYS ANTHROPOL, V95, P117, DOI 10.1002/ajpa.1330950202; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B. A., 1991, HOMINID CRANIAL REMA, V4	30	80	82	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					489	492		10.1038/39037	http://dx.doi.org/10.1038/39037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XY909	9333236				2022-12-01	WOS:A1997XY90900054
J	Nightingale, SL				Nightingale, SL			Implanted brain stimulator approved to control tremors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-01	WOS:A1997XX30300009
J	Mostad, SB; Overbaugh, J; DeVange, DM; Welch, MJ; Chohan, B; Mandaliya, K; Nyange, P; Martin, HL; NdinyaAchola, J; Bwayo, JJ; Kreiss, JK				Mostad, SB; Overbaugh, J; DeVange, DM; Welch, MJ; Chohan, B; Mandaliya, K; Nyange, P; Martin, HL; NdinyaAchola, J; Bwayo, JJ; Kreiss, JK			Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina	LANCET			English	Article							LONG TERMINAL REPEAT; IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUALLY-TRANSMITTED DISEASES; CERVICOVAGINAL SECRETIONS; BACTERIAL VAGINOSIS; WOMEN; TRANSMISSION; DNA; ASSOCIATION; LYMPHOCYTES	Background Factors that influence shedding of HIV-1 infected cells in cervical and vaginal secretions may be important determinants of sexual and vertical transmission of the virus. We investigated whether hormonal contraceptive use, vitamin A deficiency, and other variables were risk factors for cervical and vaginal shedding of HIV-infected cells. Methods Between December, 1994, and April, 1996, women who attended a municipal sexually transmitted diseases (STDs) clinic in Mombasa, Kenya, and had previously tested positive for HIV-1, were invited to take part in our cross-sectional study. Cervical and vaginal secretions from 318 women were evaluated for the presence of HIV-1 infected cells by PCR amplification of gag DNA sequences. Findings HIV-1 infected cells were detected in 51% of endocervical and 14% of vaginal-swab specimens. Both cervical and vaginal shedding of HIV-1 infected cells were highly associated with CD4 lymphocyte depletion (p=0.0000) and p=0.003, respectively). After adjustment for CD4 count, cervical proviral shedding was significantly associated with use of depot medroxyprogesterone acetate (odds ratio 2.9, 95% CI 1.5-5.7), and with use of low-dose and high-dose oral contraceptive pills (3.8, 1.4-9.9 and 12.3, 1.5-101, respectively), Vitamin A deficiency was highly predictive of vaginal HIV-1 DNA shedding. After adjustment for CD4 count, severe vitamin A deficiency, moderate deficiency, and low normal vitamin A status were associated with 12.9, 8.0, and 4.9-fold increased odds of vaginal shedding, respectively. Gonococcal cervicitis (3.1, 1.1-9.8) and vaginal candidiasis (2.6, 1.2-5.4) were also correlated with significant increases in HIV-1 DNA detection, but Chlamydia trachomatis and Trichomonas vaginalis were not. Interpretation Our study documents several novel correlates of HIV-1 shedding in cervical and vaginal secretions, most notably hormonal contraceptive use and vitamin A deficiency. These factors may be important determinants of sexual or vertical transmission of HIV-1 and are of public health importance because they are easily modified by simple interventions.	UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; COAST PROV GEN HOSP,MOMBASA,KENYA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Nairobi	Mostad, SB (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,IARTP,BOX 359909,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039996, R01AI038518, R37AI038518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38518, AI 39996] Funding Source: Medline; NIDDK NIH HHS [DK35816] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amatayakul Kosin, 1994, P363; [Anonymous], 1992, BMJ, V304, P809; BRENNER PF, 1977, AM J OBSTET GYNECOL, V129, P133, DOI 10.1016/0002-9378(77)90733-5; CAROL W, 1992, EXP CLIN ENDOCRINOL, V99, P12, DOI 10.1055/s-0029-1211124; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; CORMACK D, 1987, HAMS HISTOLOGY, P638; EFRON JJ, 1996, JAMA-J AM MED ASSOC, V275, P36; ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251, DOI 10.1128/JCM.27.2.251-256.1989; FURTH PA, 1990, AIDS RES HUM RETROV, V6, P553, DOI 10.1089/aid.1990.6.553; GHOSH D, 1992, J VIROL, V66, P586, DOI 10.1128/JVI.66.1.586-590.1992; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GROSSMAN CJ, 1984, ENDOCR REV, V5, P435, DOI 10.1210/edrv-5-3-435; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; John GC, 1997, J INFECT DIS, V175, P57, DOI 10.1093/infdis/175.1.57; KOLESNITCHENKO V, 1992, AIDS RES HUM RETROV, V8, P1977, DOI 10.1089/aid.1992.8.1977; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; LANDAY A, 1993, AIDS, V7, P1565, DOI 10.1097/00002030-199312000-00004; MISHELL DR, 1972, AM J OBSTET GYNECOL, V114, P923, DOI 10.1016/0002-9378(72)90098-1; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; ORTIZ A, 1977, J CLIN ENDOCR METAB, V44, P32, DOI 10.1210/jcem-44-1-32; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P200; Schuurs A. H. W. M., 1994, P379; SEMBA RD, 1994, CLIN INFECT DIS, V19, P489, DOI 10.1093/clinids/19.3.489; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; SOMMER A, 1996, VITAMIN A DEFICIENCY; Speroff L, 1996, CLIN GUIDE CONTRACEP, P25; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; VANDEPERRE P, 1988, GENITOURIN MED, V64, P30; WOFSY CB, 1986, LANCET, V1, P527; YAMAGUCHI K, 1994, AIDS, V8, P1675, DOI 10.1097/00002030-199412000-00006	36	249	254	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					922	927		10.1016/S0140-6736(97)04240-2	http://dx.doi.org/10.1016/S0140-6736(97)04240-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314871				2022-12-01	WOS:A1997XY67200011
J	Wylie, PAL; Stevens, D; Drake, W; Stuart, J; Cartwright, K				Wylie, PAL; Stevens, D; Drake, W; Stuart, J; Cartwright, K			Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS; OUTBREAK; MENINGITIS; PENICILLIN	Objective: To study changes in the epidemiology and management of meningococcal disease in one health district during a period of high local incidence of disease. Design: Prospective case ascertainment and data collection over 14 years, with retrospective analysis of cases. Setting: West Gloucestershire (population 320 000). Subjects: Residents developing meningococcal disease between 1 January 1982 and 31 December 1995. Results: 252 cases of invasive meningococcal disease were identified, of which 102 (40%) were officially notified and 191 (76%) were confirmed by culture from a deep site. The observed disease incidence of 5.6/100 000/year was about 2.7 times the national incidence (as measured by either statutory notifications or reference laboratory reports). The period 1983-90 was characterised by a prolonged localised outbreak due to serogroup B serotype 15 sulphonamide resistant (B15R) strains. General practitioners gave benzylpenicillin before hospital admission to 18% of patients who presented with meningococcal disease in the first half of the study period and to 40% who presented in the second half. The overall case fatality rate was 6.7% (17/252). Four deaths were directly or indirectly related to lumbar puncture. Of 120 patients whose lumbar puncture yielded meningococci, nine (8%) showed no abnormality on initial examination. Conclusions: Neither laboratory records nor formal notifications alone can give an accurate estimate of the incidence of meningococcal disease. Because of the dangers of lumbar puncture, the frequency of misleading negative initial findings, and the advent of new diagnostic techniques, the need for samples of cerebrospinal fluid should be critically questioned in each case of suspected meningococcal disease.	GLOUCESTERSHIRE ROYAL HOSP,DEPT PAEDIAT,GLOUCESTER GL1 3NN,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,PUBL HLTH LAB,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital; Gloucestershire Royal Hospital								*ADV LIF SUPP GROU, 1993, ADV PAED LIF SUPP PR; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT KAV, 1991, EPIDEMIOL INFECT, V106, P133, DOI 10.1017/S0950268800056491; CARTWRIGHT KAV, 1986, LANCET, V2, P558; CARTWRIGHT KAV, 1989, J CLIN PATHOL, V42, P634, DOI 10.1136/jcp.42.6.634; DAVIES LA, 1989, COMMUNITY MED, V11, P239; *DEP HLTH SOC SEC, 1988, PLCMO882 DHHS; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; Jones D M, 1995, Commun Dis Rep CDR Rev, V5, pR125; Jones D M, 1993, Commun Dis Rep CDR Rev, V3, pR129; JONES DM, 1993, J INFECTION, V27, P83, DOI 10.1016/0163-4453(93)93978-D; Laxton C E, 1994, Commun Dis Rep CDR Rev, V4, pR85; NADEL S, 1995, MENINGOCOCCAL DIS, P207; Newcombe J, 1996, J CLIN MICROBIOL, V34, P1637, DOI 10.1128/JCM.34.7.1637-1640.1996; NI HL, 1992, LANCET, V340, P1432, DOI 10.1016/0140-6736(92)92622-M; PELTOLA H, 1993, LANCET, V342, P509, DOI 10.1016/0140-6736(93)91642-Y; PELTOLA H, 1982, LANCET, V2, P595; POOLMAN JT, 1986, LANCET, V2, P555; *RES COMM BSSI, 1995, J INFECTION, V30, P89; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; SAMUELSSON S, 1992, EPIDEMIOL INFECT, V108, P19, DOI 10.1017/S0950268800049463; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; WEIHE P, 1988, SCAND J INFECT DIS, V20, P291, DOI 10.3109/00365548809032454; Woodward C M, 1995, Commun Dis Rep CDR Rev, V5, pR135	25	58	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					774	779						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345169	Green Published			2022-12-01	WOS:A1997XY91100019
J	Jarrett, RJ				Jarrett, RJ			Should we screen for gestational diabetes?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUCOSE-TOLERANCE; PREGNANCY; MELLITUS; NIDDM; WOMEN											ALES KL, 1989, LANCET, V1, P1187; *AM COLL OBST GYN, 1994, MAN DIAB MELL PREGN; Barker DJP, 1992, FETAL INFANT ORIGINS; Coustan DR, 1996, JAMA-J AM MED ASSOC, V275, P1199, DOI 10.1001/jama.275.15.1199; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; Gabbe SG, 1989, CARBOHYD METABOL, VIV, P309; Gavin JR, 1997, DIABETES CARE, V20, P1183; Goldenberg RL, 1996, JAMA-J AM MED ASSOC, V275, P1127, DOI 10.1001/jama.275.14.1127; HANSON U, 1990, DIABETOLOGIA, V33, P100, DOI 10.1007/BF00401047; JARRETT RJ, 1993, BMJ-BRIT MED J, V306, P37, DOI 10.1136/bmj.306.6869.37; MOLSTEDPEDERSEN L, 1989, CARBOHYD METABOL, V4, P277; NELSONPIERCY C, 1994, DIABETIC MED, V11, P493, DOI 10.1111/j.1464-5491.1994.tb00313.x; OSULLIVAN JB, 1964, DIABETES, V13, P278; ROBERTS RN, 1993, DIABETIC MED, V10, P438, DOI 10.1111/j.1464-5491.1993.tb00095.x; SAMANTA A, 1989, DIABETES RES CLIN PR, V7, P127, DOI 10.1016/0168-8227(89)90103-4; TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd	18	33	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	1997	315	7110					736	737		10.1136/bmj.315.7110.736	http://dx.doi.org/10.1136/bmj.315.7110.736			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314761	Green Published			2022-12-01	WOS:A1997XX67400027
J	Scales, SJ; Pepperkok, R; Kreis, TE				Scales, SJ; Pepperkok, R; Kreis, TE			Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPII and COPI	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; BETA-COP; INTERMEDIATE COMPARTMENT; COATED VESICLES; BREFELDIN-A; SECRETORY PATHWAY; MEMBRANE GLYCOPROTEIN; MONOCLONAL-ANTIBODY; VIRAL GLYCOPROTEIN	Exocytic transport from the endoplasmic reticulum (ER) to the Golgi complex has been visualized in living cells using a chimera of the temperature-sensitive glycoprotein of vesicular stomatitis virus and green fluorescent protein (ts-G-GFP(ct)). Upon shifting to permissive temperature, ts-G-GFP(ct) concentrates into COPII-positive structures close to the ER, which then build up to form an intermediate compartment or transport complex, containing ERGIC-53 and the KDEL receptor, where COPII is replaced by COPI. These structures appear heterogenous and move in a microtubule-dependent manner toward the Golgi complex. Our results suggest a sequential mode of COPII and COPI action and indicate that the transport complexes are ER-to-Golgi transport intermediates from which COPI may be involved in recycling material to the ER.	UNIV GENEVA,DEPT CELL BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283; Pepperkok, Rainer/0000-0002-9762-3583				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P553; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAWANO JI, 1994, J HISTOCHEM CYTOCHEM, V42, P363, DOI 10.1177/42.3.8308253; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cellbio.11.1.677; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1994, J CELL BIOL, V124, P55; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; WHITNEY JA, 1995, CELL, V83, P703	71	416	426	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1137	1148		10.1016/S0092-8674(00)80379-7	http://dx.doi.org/10.1016/S0092-8674(00)80379-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323141	Bronze			2022-12-01	WOS:A1997XX76800019
J	Schwacha, A; Kleckner, N				Schwacha, A; Kleckner, N			Interhomolog bias during meiotic recombination: Meiotic functions promote a highly differentiated interhomolog-only pathway	CELL			English	Article							DOUBLE-STRAND BREAK; SYNAPTONEMAL COMPLEX-FORMATION; SISTER-CHROMATID EXCHANGE; SACCHAROMYCES-CEREVISIAE; RAD51 PROTEIN; CHROMOSOME SYNAPSIS; RECA HOMOLOGS; YEAST MEIOSIS; HOT-SPOT; DNA	Meiotic recombination occurs preferentially between homologous nonsister chromatids rather than between sisters, opposite to the bias of mitotic recombinational repair. We have examined formation of joint molecule recombination intermediates (JMs) between homologs and between sisters in yeast strains lacking the meiotic chromosomal protein Red1, the meiotic recA homolog Dmc1, and/or mitotic recA homolog(s), Rad51, Rad55, and Rad57. Mutant phenotypes imply that most meiotic recombination occurs via an interhomolog-only pathway along which interhomolog bias is established early, prior to or during double strand break (DSB) formation, and then enforced, just at the time when DSBs initiate JM formation. A parallel, less differentiated pathway yields intersister and, probably, a few interhomolog events. Coordinate action of mitotic recA homologs as one functional unit, two functions of RED1, and an interhomolog interaction function of DMC1 are also revealed.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM44794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LK, 1997, P NATL ACAD SCI USA, V94, P6868, DOI 10.1073/pnas.94.13.6868; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1986, GENETICS, V113, P551; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; GAME JC, 1989, GENETICS, V123, P695; Gilbertson LA, 1996, GENETICS, V144, P27; HABER JE, 1984, GENETICS, V106, P185; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; HEYER WD, 1994, EXPERIENTIA, V50, P223, DOI 10.1007/BF01924005; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON JA, 1985, GENETICS, V109, P303; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; KADYK LC, 1992, GENETICS, V132, P387; KENNEY S, 1996, GENES CELLS, V1, P475; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MaoDraayer Y, 1996, GENETICS, V144, P71; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Petes TD, 1995, ADV GENET, V33, P41, DOI 10.1016/S0065-2660(08)60330-2; PORTER SE, 1993, GENETICS, V134, P5; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; ROCKMILL B, 1990, GENETICS, V126, P563; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SCHWACHA A, 1996, THESIS HARVARD U CAM; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SUN H, 1991, MOL CELL BIOL, V11, P6328, DOI 10.1128/MCB.11.12.6328; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; ZENVIRTH D, 1997, IN PRESS GENES CELLS	48	356	362	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1123	1135		10.1016/S0092-8674(00)80378-5	http://dx.doi.org/10.1016/S0092-8674(00)80378-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323140	Bronze			2022-12-01	WOS:A1997XX76800018
J	Bouma, MJ; Dye, C				Bouma, MJ; Dye, C			Cycles of malaria associated with El Nino in Venezuela	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOUTHERN OSCILLATION; EPIDEMICS; MAIZE	Context.-Malaria has been increasing globally, and epidemics tend to occur when weather conditions favor this vector-borne disease, Long-term meteorologic forecasting using El Nino Southern Oscillation (ENSO) may assist in anticipating epidemics and targeting scarce resources. Objective.-To determine whether malaria epidemics in Venezuela are related to ENSO and rainfall and to determine whether such a relationship could be used to predict outbreaks. Design.-Retrospective analysis of national malaria morbidity (1975-1995) and mortality (1910-1935) data in the coastal zone and interior of Venezuela in relation to El Nino events and rainfall. Main Outcome Measure.-Correlation between malaria mortality and morbidity and sea surface temperatures (SSTs) in the Eastern Tropical Pacific, a parameter of ENSO. Results.-Malaria mortality and morbidity have increased by an average of 36.5% (95% confidence interval, 3.7%-69.3%; P=.004) in years following recognized El Nino events, A moderate correlation was found between Pacific tropical SST during a Nino event and malaria 1 year later (r=0.50, P<.001). Malaria mortality is more strongly related to drought in the year preceding outbreaks than to rainfall during epidemic years. Conclusions.-Historic and recent data from Venezuela demonstrate that malaria increases by an average of about one third in the year following a Nino event; change in malaria risk can be predicted from Pacific SSTs in the previous year, Therefore, the occurrence of an EI Nino event may help predict malaria epidemics in this part of South America.			Bouma, MJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793				Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHRISTOPHERS R, 1911, SCI MEMOIRS OFFICERS; *DEP MET, 1978, B CLIM ANN; FONTAINE RE, 1961, AM J TROP MED HYG, V10, P795, DOI 10.4269/ajtmh.1961.10.795; GABALDON A., 1946, Tijeretazos sobre Malaria, V10, P191; GABALDON A, 1949, T ROY SOC TROP MED H, V43, P113, DOI 10.1016/0035-9203(49)90037-1; GABALDON A, 1949, MALARIOLOGY; GIGLIOLI G., 1939, Agric. J. Brit. Guiana, V10, P4; GONZALEZ PE, 1948, DATOS DETALLADOS CLI; Kiladis GN, 1989, J CLIMATE, V2, P1069, DOI 10.1175/1520-0442(1989)002<1069:GCAAWE>2.0.CO;2; MCDONALD G, 1953, TROP DIS B, V50, P871; MOLINEAUX L, 1988, MALARIA; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; Nisbet R. M, 1982, MODELLING FLUCTUATIN; PACKARD RM, 1984, J AFR HIST, V25, P189, DOI 10.1017/S0021853700022854; PARKER DE, 1994, J GEOPHYS RES, V99, P373; Ropelewski CF, 1989, J CLIMATE, V2, P268, DOI 10.1175/1520-0442(1989)002<0268:PPAWTH>2.0.CO;2; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; *SMITHS I, 1961, WORLD WEATH REC; *SMITHS I, 1971, WORLD WEATH REC; SWELLENGREBEL NH, 1940, COLONIAL I AMSTERDAM, V16; *WHO, 1977, WKLY EPIDEMIOL REC; WHO, 1979, WHO TECHN REP SER, V640; *WORLD MET ORG, 1992, CLIM SYST MON MON B; YACOB KBM, 1946, J MALAR I INDIA, V6, P273; Zurbrigg S., 1994, Parassitologia (Rome), V36, P121	28	130	143	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1772	1774		10.1001/jama.278.21.1772	http://dx.doi.org/10.1001/jama.278.21.1772			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388155				2022-12-01	WOS:A1997YH98700033
J	Kuroo, M; Matsumura, Y; Aizawa, H; Kawaguchi, H; Suga, T; Utsugi, T; Ohyama, Y; Kurabayashi, M; Kaname, T; Kume, E; Iwasaki, H; Iida, A; ShirakiIida, T; Nishikawa, S; Nagai, R; Nabeshima, Y				Kuroo, M; Matsumura, Y; Aizawa, H; Kawaguchi, H; Suga, T; Utsugi, T; Ohyama, Y; Kurabayashi, M; Kaname, T; Kume, E; Iwasaki, H; Iida, A; ShirakiIida, T; Nishikawa, S; Nagai, R; Nabeshima, Y			Mutation of the mouse klotho gene leads to a syndrome resembling ageing	NATURE			English	Article							LACTASE-PHLORIZIN HYDROLASE; ELONGATION FACTOR-1-ALPHA; SUPERFAMILY; PROMOTER; MICE	A new gene, termed klotho, has been identified that is involved in the suppression of several ageing phenotypes. A defect in klotho gene expression in the mouse results in a syndrome that resembles human ageing, Including a short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema. The gene encodes a membrane protein that shares sequence similarity with the B-glucosidase enzymes. The klotho gene product may function as part of a signalling pathway that regulates ageing in vivo and morbidity In age-related diseases.	GUNMA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,MAEBASHI,GUMMA 371,JAPAN; UNIV TOKYO,FAC MED,DEPT ORTHOPAED SURG,BUNKYO KU,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN; TANABE SEIYAKU CO LTD,LEAD OPTIMIZAT RES LAB,TODA,SAITAMA 335,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN; KYOWA HAKKO KOGYO CO LTD,PHARMACEUT RES LABS,NAGAIZUMI,SHIZUOKA 411,JAPAN; JRDC,CREST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Gunma University; University of Tokyo; Kumamoto University; Mitsubishi Tanabe Pharma Corporation; Kyowa Kirin Ltd; Kyowa Kirin Ltd; Japan Science & Technology Agency (JST); Osaka University	Kuroo, M (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV MOL GENET,4-1-1 OGAWAHIGASKI,KODAIRA,TOKYO 187,JAPAN.							Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; CHUTTANI A, 1995, HDB PHYSL, V11, P309; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HAUSMAN PB, 1985, HDB BIOL AGING, P414; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; KANAME T, 1993, CYTOGENET CELL GENET, V64, P195, DOI 10.1159/000133573; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KUROO M, 1995, CIRC RES, V76, P148, DOI 10.1161/01.RES.76.1.148; LANSING AI, 1959, ARTERIAL WALL, P136; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MASER EJ, 1995, HDB PHYSL, V11, P3; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P155; ROBBINS SL, 1981, BASIC PATHOLOGY, P3; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J., 1989, MOL CLONING; TAKEDA T, 1991, J AM GERIATR SOC, V39, P911, DOI 10.1111/j.1532-5415.1991.tb04460.x; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOLFSON L, 1992, PRINCIPLES GERIATRIC, P75; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	26	2541	2740	3	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					45	51		10.1038/36285	http://dx.doi.org/10.1038/36285			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363890				2022-12-01	WOS:A1997YE47700045
J	Turner, R; Stratton, I; Horton, V; Manley, S; Zimmet, P; Mackay, IR; Shattock, M; Bottazzo, GF; Holman, R				Turner, R; Stratton, I; Horton, V; Manley, S; Zimmet, P; Mackay, IR; Shattock, M; Bottazzo, GF; Holman, R			UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes	LANCET			English	Article							ANTIBODIES; MELLITUS; RELATIVES; IDDM; DIAGNOSIS; ADULTS; ONSET; DISEASE; MARKERS	Background Autoantibodies to islet-cell cytoplasm (ICA) and glutamic acid decarboxylase (GADA) can occur in apparently typical, non-insulin dependent diabetes mellitus (type 2). We investigated whether the presence of either or both antibodies characterises a subtype of diabetes and provides better prediction of requirement for insulin therapy by 6 years' follow-up than clinical variables. Methods We measured ICA and GADA at diagnosis of diabetes in a representative population of 3672 white patients with type 2 diabetes, aged between 25 and 65 years. The phenotype was assessed by age of onset, body-mass index, percentage haemoglobin A(1c) (HbA(1c)), and islet beta-cell function. We investigated the need for insulin therapy among 1538 patients not assigned insulin and followed up for 6 years from diagnosis. Findings The proportion of patients with ICA and GADA decreased with increasing age at diagnosis (from 33 [21%] of 157 patients aged 25-65 to 66 [4%] of 1769 aged 55-65 for ICA; from 53 [34%] to 122 [7%] for GADA). Among patients younger than 35 at diagnosis, those with ICA or GADA had lower body-mass index than those without (mean 24.9 [SD 6.0] vs 31.7 [7.3] kg/m(2); p<0.0001 and had higher percentage of HbA(1c) (9.7 vs 8.7%, p<0.05). 94% of patients with ICA and 84% of those with GADA required insulin therapy by 6 years, compared with 14% of those without the antibodies (p<0.0001). Among patients older than 55 at diagnosis, the difference between those with and without antibodies in body-mass index was smaller (27.2 [5.4] vs 28.6 [4.8] kg/m(2), p<0.001); 44% of those with ICA, 34% of those with GADA, and 5% with neither antibody required insulin therapy by 6 years (p<0.0001). Among patients older than 45 years, body-mass index and HbA(1c) provided little predictive information for insulin requirement, whereas the positive predictive values of GADA (greater than or equal to 60 U/L) alone, or both GADA (greater than or equal to 20 U/L) and ICA (>5 U/L), for insulin therapy were 52% and 68%. Interpretation Among young adults with type 2 diabetes, the phenotype of those with ICA or GADA antibodies was similar to that of classic juvenile-onset insulin-dependent diabetes, and either phenotype or antibodies predicted insulin requirement. In older adults, the phenotype was closer to that of patients without antibodies and only the presence of antibodies predicted an increased likelihood of insulin requirement.	INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MONASH UNIV,DEPT BIOCHEM & MOL BIOL,CLAYTON,VIC 3168,AUSTRALIA; ST BARTHOLOMEWS & ROYAL LONDON MED SCH & DENT,DEPT IMMUNOL,LONDON,ENGLAND	Monash University; University of London; Queen Mary University London	Turner, R (corresponding author), RADCLIFFE INFIRM,DIABET RES LABS,UK PROSPECT DIBAET STUDY GRP,WOODSTOCK RD,OXFORD OX2 6HE,ENGLAND.		stratton, irene/AAZ-3627-2020; Mackay, Ian R/A-7228-2010; Zimmet, Paul/O-8486-2019	stratton, irene/0000-0003-1172-7865; Zimmet, Paul/0000-0003-0627-0776; Manley, Susan/0000-0002-8298-4511				BAEKKESKOV V, 1990, NATURE, V347, P152; BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BONIFACIO E, 1995, DIABETOLOGIA, V38, P816, DOI 10.1007/s001250050358; BOTTAZZO GF, 1993, DIABETES, V42, P778; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; CHEN QY, 1993, PEDIATR RES, V34, P785, DOI 10.1203/00006450-199312000-00018; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; GLEICHMANN H, 1984, DIABETOLOGIA, V27, P90, DOI 10.1007/BF00275656; GOTTSATER A, 1995, DIABETES RES CLIN PR, V27, P133, DOI 10.1016/0168-8227(95)01026-A; GROOP L, 1988, DIABETES, V37, P99, DOI 10.2337/diabetes.37.1.99; GROOP LC, 1986, DIABETES, V35, P237, DOI 10.2337/diabetes.35.2.237; IRVINE WJ, 1977, LANCET, V1, P1025; KOBAYASHI T, 1993, DIABETES CARE, V16, P780, DOI 10.2337/diacare.16.5.780; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; NABARRO JDN, 1991, DIABETIC MED, V8, P59, DOI 10.1111/j.1464-5491.1991.tb01517.x; NISKANEN LK, 1995, DIABETES CARE, V18, P1557, DOI 10.2337/diacare.18.12.1557; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SANJEEVI CB, 1996, DIABETOLOGIA, V39, pS301; Seissler J, 1996, DIABETOLOGIA, V39, P1351, DOI 10.1007/s001250050582; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; *UKPDS GROUP, IN PRESS UK PROSP DI, V24; *UKPDS GROUP, 1991, DIABETOLOGIA, V34, P877; VERGE CF, 1994, DIABETOLOGIA, V37, P113; Willis JA, 1996, DIABETES RES CLIN PR, V33, P89, DOI 10.1016/0168-8227(96)01281-8; ZIMMET PZ, 1994, DIABETIC MED, V11, P299, DOI 10.1111/j.1464-5491.1994.tb00275.x; 1985, LANCET, V2, P809	30	562	610	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1288	1293		10.1016/S0140-6736(97)03062-6	http://dx.doi.org/10.1016/S0140-6736(97)03062-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357409				2022-12-01	WOS:A1997YD68900011
J	Pufahl, RA; Singer, CP; Peariso, KL; Lin, SJ; Schmidt, PJ; Fahrni, CJ; Culotta, VC; PennerHahn, JE; OHalloran, TV				Pufahl, RA; Singer, CP; Peariso, KL; Lin, SJ; Schmidt, PJ; Fahrni, CJ; Culotta, VC; PennerHahn, JE; OHalloran, TV			Metal ion chaperone function of the soluble Cu(I) receptor Atx1	SCIENCE			English	Article							WILSON-DISEASE GENE; COPPER-TRANSPORTING ATPASE; MENKES DISEASE; IRON UPTAKE; CHEMISTRY; COMPLEX; MECHANISM; PROTEINS; ENCODES; BINDING	Reactive and potentially toxic cofactors such as copper ions are imported into eukaryotic cells and incorporated into target proteins by unknown mechanisms. Atx1, a prototypical copper chaperone protein from yeast, has now been shown to act as a soluble cytoplasmic copper(l) receptor that can adopt either a two-or three-coordinate metal center in the active site. Atx1 also associated directly with the Atx1-like cytosolic domains of Ccc2, a vesicular protein defined in genetic studies as a member of the copper-trafficking pathway. The unusual structure and dynamics of Atx1 suggest a copper exchange function for this protein and related domains in the Menkes and Wilson disease proteins.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; UNIV MICHIGAN, DEPT CHEM, ANN ARBOR, MI 48109 USA; JOHNS HOPKINS UNIV, DEPT ENVIRONM HLTH SCI, BALTIMORE, MD 21205 USA	Northwestern University; Northwestern University; University of Michigan System; University of Michigan; Johns Hopkins University			O'Halloran, Thomas/ABE-6125-2021; Peariso, Katrina/AAQ-2090-2021; Penner-Hahn, James/GYD-3750-2022; Peariso, Katrina/Y-1516-2019	O'Halloran, Thomas/0000-0001-8732-5059; Penner-Hahn, James/0000-0003-0314-1274; Peariso, Katrina/0000-0003-1616-8329	NIGMS NIH HHS [GM-50016, GM-54111, GM-38047, R01 GM054111] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050016, R01GM038047, R29GM038047, R01GM054111, R37GM050016] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CHEESMAN BV, 1988, J AM CHEM SOC, V110, P6359, DOI 10.1021/ja00227a014; COUCOUVANIS D, 1980, INORG CHEM, V19, P2993, DOI 10.1021/ic50212a030; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DASILVA JRR, 1991, BIOL CHEM ELEMENTS, P396; Dieckmann GR, 1997, J AM CHEM SOC, V119, P6195, DOI 10.1021/ja964351i; ERIKSSON PO, 1993, J BIOMOL NMR, V3, P613; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GITSCHLER J, COMMUNICATION; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; Hausinger RP, 1996, MECH METALLOCENTER A; Hobman JL, 1997, MET IONS BIOL SYST, V34, P527; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KOCH SA, 1984, INORG CHEM, V23, P121, DOI 10.1021/ic00170a001; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIN SJ, 1997, J BIOL CHEM, V272, P9214; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; SOLOMON EI, 1996, CHEM REV, V96, P2653; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; THORP HH, 1992, INORG CHEM, V31, P1585, DOI 10.1021/ic00035a012; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; Utschig LM, 1997, INORG CHEM, V36, P2926, DOI 10.1021/ic960571l; VALENTINE JS, 1994, BIOINORG CHEM, V1, P253; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Winge DR, 1997, J BIOL INORG CHEM, V2, P2, DOI 10.1007/s007750050100; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	580	594	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					853	856		10.1126/science.278.5339.853	http://dx.doi.org/10.1126/science.278.5339.853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346482				2022-12-01	WOS:A1997YD47900044
J	Donaldson, GC; Keatinge, WR				Donaldson, GC; Keatinge, WR			Mortality related to cold weather in elderly people in southeast England, 1979-94	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT PHYSIOL,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London			Donaldson, Gavin/M-7992-2017	Donaldson, Gavin/0000-0002-5538-4190				DONALDSON GC, IN PRESS J EPIDEMIOL; KEATINGE WR, 1989, INT J BIOMETEOROL, V33, P71, DOI 10.1007/BF01686280; McDowall M, 1981, POPUL TRENDS, V26, P16	3	39	39	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1055	1056		10.1136/bmj.315.7115.1055	http://dx.doi.org/10.1136/bmj.315.7115.1055			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366732	Green Published			2022-12-01	WOS:A1997YD44500021
J	Hieter, P; Boguski, M				Hieter, P; Boguski, M			Functional genomics: It's all how you read it	SCIENCE			English	Editorial Material							GENE-EXPRESSION; STRATEGY		NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Hieter, P (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED GENET,CTR MOL MED & THERAPEUT,VANCOUVER,BC V6T 124,CANADA.							DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1997, NAT GENET, V5, P325; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goodfellow P, 1997, NAT GENET, V16, P209, DOI 10.1038/ng0797-209; *HARV I HUM GEN, 1997, S GEN GEN THER MEAN; MCKUSICK V, IN PRESS GENOMICS; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Oliver S, 1996, TRENDS GENET, V12, P241, DOI 10.1016/0168-9525(96)30053-X; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	18	228	267	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					601	602		10.1126/science.278.5338.601	http://dx.doi.org/10.1126/science.278.5338.601			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381168				2022-12-01	WOS:A1997YC32300036
J	Orentlicher, D				Orentlicher, D			The Supreme Court and physician-assisted suicide - Rejecting assisted suicide but embracing euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TERMINALLY ILL; CANCER		INDIANA UNIV,SCH LAW,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis								Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P206; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; Cherny N I, 1994, J Palliat Care, V10, P31; ENCK RE, 1994, MED CARE TERMINALLY, P166; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; Ramani S, 1996, SOUTH MED J, V89, P1101, DOI 10.1097/00007611-199611000-00017; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311	14	100	100	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1236	1239		10.1056/NEJM199710233371713	http://dx.doi.org/10.1056/NEJM199710233371713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9340517				2022-12-01	WOS:A1997YB71800013
J	Resnick, NM; Marcantonio, ER				Resnick, NM; Marcantonio, ER			How should clinical care of the aged differ?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; EFFICACY; THERAPY		HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA	Harvard University; Harvard Medical School	Resnick, NM (corresponding author), BRIGHAM & WOMENS HOSP,DIV GERONTOL,75 FRANCIS ST,BOSTON,MA 02115, USA.		Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812, P01AG004390] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04390, AG-08812] Funding Source: Medline; NIDDK NIH HHS [DK-49482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDUCCI L, 1991, J AM GERIATR SOC, V39, P1113, DOI 10.1111/j.1532-5415.1991.tb02879.x; Balducci L, 1992, Oncology (Williston Park), V6, P62; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CASSEL CK, 1997, GERIATRIC MED; Fries JF, 1981, VITALITY AGING; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; KAPOOR WN, 1997, GERIATRIC MED, P757; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LIPSITZ LA, 1983, ANN INTERN MED, V99, P92, DOI 10.7326/0003-4819-99-1-92; MOKSHAGUNDAM S, 1993, J AM GERIATR SOC, V41, P1361, DOI 10.1111/j.1532-5415.1993.tb06488.x; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; RESNICK NM, 1995, LANCET, V346, P94, DOI 10.1016/S0140-6736(95)92117-6; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SIVENIUS J, 1995, BMJ-BRIT MED J, V310, P25, DOI 10.1136/bmj.310.6971.25; Tinetti ME, 1997, GERIATRIC MED, P787	16	63	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1157	1158		10.1016/S0140-6736(05)63817-2	http://dx.doi.org/10.1016/S0140-6736(05)63817-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343515				2022-12-01	WOS:A1997YB19900043
J	KowenzLeutz, E; Herr, P; Niss, K; Leutz, A				KowenzLeutz, E; Herr, P; Niss, K; Leutz, A			The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation	CELL			English	Article							AVIAN LEUKEMIA VIRUSES; DNA-BINDING DOMAIN; HEMATOPOIETIC-CELLS; NF-M; MYELOID CELLS; C-MYB; TRANSCRIPTIONAL CONTROL; TRANSLOCATION PROTEIN; MOLECULAR-CLONING; PRE-B	The homeobox gene GBX2 was identified as a target gene of the v-Myb oncoprotein encoded by the avian myeloblastosis virus (AMV). GBX2 activation by c-Myb requires signal transduction emanating from the cell surface while the leukemogenic AMV v-Myb constitutively induces the GBX2 gene. Mutations in the DHA binding domain of AMV-Myb render it independent of signaling events and concomitantly abrogate the collaboration between Myb and CCAAT Enhancer Binding Proteins (C/EBP), which are involved in granulocyte differentiation. Ectopic expression of GBX2 in growth factor-dependent myeloblasts induces monocytic features and independence from exogenous cytokines, reflecting distinct features of AMV-transformed cells. Our results suggest that Myb or factors it interacts with contribute to hematopoietic lineage choice and differentiation in a signal transduction-dependent fashion.	MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BULFONE A, 1993, J NEUROSCI, V13, P3155; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; EWERT DL, 1984, J IMMUNOL, V132, P2524; FAINSOD A, 1989, FEBS LETT, V250, P381, DOI 10.1016/0014-5793(89)80760-4; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KAADEN OR, 1977, MED MICROBIOL IMMUN, V163, P157, DOI 10.1007/BF02126676; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEHRL JH, 1994, CRIT REV ONCOL HEMAT, V16, P145, DOI 10.1016/1040-8428(94)90046-9; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1996, ONCOGENE, V13, P223; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MOSCOVICI C, 1982, TRANSFORMATION HEMOP, V1; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	48	87	88	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	1997	91	2					185	195		10.1016/S0092-8674(00)80401-8	http://dx.doi.org/10.1016/S0092-8674(00)80401-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346236	Bronze			2022-12-01	WOS:A1997YC35000006
J	Schiodt, FV; Rochling, FA; Casey, DL; Lee, WM				Schiodt, FV; Rochling, FA; Casey, DL; Lee, WM			Acetaminophen toxicity in an urban county hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC MISADVENTURE; INDUCED HEPATOTOXICITY; MEDICAL PROGRESS; N-ACETYLCYSTEINE; LIVER; ALCOHOL; ETHANOL; FAILURE; ASSOCIATION	Background The prevalence and characteristics of acetaminophen associated liver injury in hospitalized patients are not well defined. Methods We identified patients hospitalized for excessive acetaminophen ingestion at an urban county hospital over a 40-month period (1992 to 1995) and reviewed their medical records to determine the incidence and clinical features of the ingestions and their outcomes. Results Of the 71 patients studied, 50 were classified as having taken acetaminophen during suicide attempts and 21 as having accidentally poisoned themselves while attempting to relieve pain, The suicidal patients had ingested almost twice as much acetaminophen as those in the accidental-overdose group (median, 20 vs. 12 g; P=0.009), Among the patients for whom data were available, 63 percent of those in the accidental-overdose group and 25 percent of those in the suicidal group were chronic alcohol abusers (P=0.009). The patients in the accidental-overdose group more often had severe liver necrosis (aminotransferase levels, >3500 IU per liter; 52 percent vs, 14 percent; P=0.002) and were more likely to have hepatic coma (33 percent vs. 6 percent, P=0.006). There were four deaths (19 percent) in the accidental-overdose group and one (2 percent) in the suicidal group (P=0.04). Five patients - three in the accidental-overdose group and two in the suicidal group - had ingested 4 g of acetaminophen or less. Acetaminophen ingestion accounted for 12 percent of all patients hospitalized with overdoses (71 of 589) and 40 percent of patients with acute liver failure (10 of 25) during the study period. Conclusions In an urban county hospital, patients hospitalized with acetaminophen toxicity related to accidental misuse had higher rates of morbidity and mortality than those who attempted suicide, even though the latter had taken more acetaminophen. A higher frequency of chronic alcohol abuse among the patients with accidental overdoses may be one explanation. (C) 1997, Massachusetts Medical Society.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,LIVER DIV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Altman DG, 1991, PRACTICAL STAT MED R; BLACK M, 1984, ANNU REV MED, V35, P577, DOI 10.1146/annurev.me.35.020184.003045; BLACK M, 1986, ANN INTERN MED, V104, P427, DOI 10.7326/0003-4819-104-3-427; BROTODIHARDJO AE, 1992, MED J AUSTRALIA, V157, P382, DOI 10.5694/j.1326-5377.1992.tb137246.x; FRENCH SW, 1993, EXP MOL PATHOL, V58, P61, DOI 10.1006/exmp.1993.1006; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HUGHES R D, 1991, Gut, pS86; Johnston SC, 1997, MEDICINE, V76, P185, DOI 10.1097/00005792-199705000-00004; KUMAR S, 1991, ARCH INTERN MED, V151, P1189, DOI 10.1001/archinte.151.6.1189; LEE WM, 1994, NEW ENGL J MED, V330, P584; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; LICHT H, 1980, ANN INTERN MED, V92, P511, DOI 10.7326/0003-4819-92-4-511_1; Litovitz TL, 1996, AM J EMERG MED, V14, P487, DOI 10.1016/S0735-6757(96)90160-6; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; MAKIN AJ, 1997, ACUTE LIVER FAILURE, P32; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MUTIMER DJ, 1994, GUT, V35, P809, DOI 10.1136/gut.35.6.809; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; VALE JA, 1995, LANCET, V346, P547, DOI 10.1016/S0140-6736(95)91385-8; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WOOTTON FT, 1990, SOUTHERN MED J, V83, P1047, DOI 10.1097/00007611-199009000-00017; Zimmerman HJ, 1995, HEPATOLOGY, V22, P1898; ZIMMERMAN HJ, 1995, HEPATOLOGY, V22, P767, DOI 10.1002/hep.1840220312	28	296	301	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1112	1117		10.1056/NEJM199710163371602	http://dx.doi.org/10.1056/NEJM199710163371602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329933				2022-12-01	WOS:A1997YA91200002
J	Schwartz, SM; Siscovick, DS; Longstreth, WT; Psaty, BM; Beverly, RK; Raghunathan, TE; Lin, DY; Koepsell, TD				Schwartz, SM; Siscovick, DS; Longstreth, WT; Psaty, BM; Beverly, RK; Raghunathan, TE; Lin, DY; Koepsell, TD			Use of low-dose oral contraceptives and stroke in young women	ANNALS OF INTERNAL MEDICINE			English	Article						contraceptives, oral; cerebrovascular disorders; norgestrel; cerebrovascular hemorrhage; cerebral infarction	CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; PROGESTOGENS; MENOPAUSE; ESTROGEN; RISK	Background: Low-dose oral contraceptives are widely used, but there are limited data on the cerebrovascular risks associated with these medications. Objective: To determine whether use of low-dose oral contraceptives influences the risk for stroke. Design: Population-based case-control study. Setting: Women 18 to 44 years of age who resided in western Washington State between 1991 and 1995. Participants: Patients with ischemic stroke (n = 60). hemorrhagic stroke (n = 102), and other types of stroke (n = 11) and controls identified through random-digit dialing (n = 485). Measurements: Details about oral contraceptive use and other risk factors for stroke were obtained through in-person interviews. Results: The estimated incidences of hemorrhagic stroke and ischemic stroke were 6.4 and 4.3 per 100,000 women-years, respectively. Compared with women who had never used oral contraceptives (after adjustment for risk factors for stroke), current users of low-dose oral contraceptives had estimated odds ratios of 0.93 (95% Cl, 0.37 to 2.31) for hemorrhagic stroke and 0.89 (Cl, 0.27 to 2.94) for ischemic stroke. Compared with past users of oral contraceptives, current users had odds ratios of 1.41 (Cl, 0.67 to 2.96) for hemorrhagic stroke and 1.37 (Cl, 0.49 to 3.81) for ischemic stroke. For past users compared with never users, the odds ratios were 0.59 (Cl, 0.30 to 1.18) for hemorrhagic stroke and 0.57 (Cl, 0.25 to 1.32) for ischemic stroke. The odds ratio for hemorrhagic stroke in current users of low-dose oral contraceptives containing norgestrel or levonorgestrel was elevated (3.23 [Cl, 1.24 to 8.41]). Among patients with hemorrhagic stroke, the odds ratio for aneurysmal bleeding associated with current use of low-dose oral contraceptives containing norgestrel or levonorgestrel was 4.46 (Cl, 1.58 to 12.53). Conclusions: The overall risk for stroke and type of stroke was not increased among current users of low-dose oral contraceptives in the study population. Larger studies are needed to clarify both the relation of risk for stroke to past use of oral contraceptives and the possible association between current use of norgestrel-containing oral contraceptives and hemorrhagic stroke.	UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NICHD NIH HHS [HD-1-31-7] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1973, Lancet, V1, P1399; BOLOGNIA JL, 1989, MATURITAS, V11, P295, DOI 10.1016/0378-5122(89)90026-1; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; GANGAR KF, 1991, LANCET, V338, P839; GODSLAND IF, 1995, CONTRACEPTION, V52, P143, DOI 10.1016/0010-7824(95)00153-2; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; MEADE TW, 1977, LANCET, V2, P948; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PHILLIPS A, 1987, CONTRACEPTION, V36, P181, DOI 10.1016/0010-7824(87)90013-8; Poulter NR, 1996, LANCET, V348, P505; Poulter NR, 1996, LANCET, V348, P498; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; *ROYAL COLL GEN PR, 1977, LANCET, V2, P727; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1993, METHOD INFORM MED, V32, P222	23	93	96	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				596	+		10.7326/0003-4819-127-8_Part_1-199710150-00003	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341057				2022-12-01	WOS:A1997YB41900003
J	SoderbergNaucler, C; Fish, KN; Nelson, JA				SoderbergNaucler, C; Fish, KN; Nelson, JA			Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors	CELL			English	Article							VERSUS-HOST DISEASE; GRANULOCYTE-MACROPHAGE PROGENITORS; MARROW TRANSPLANT RECIPIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; BONE-MARROW; MURINE CYTOMEGALOVIRUS; GENE-EXPRESSION; IN-VIVO; INFECTION; LYMPHOCYTES	Reactivation of human cytomegalovirus (HCMV) results in severe disease in AIDS patients and immunocompromised patients receiving blood transfusions or organ or bone marrow grafts. Although the site of HCMV latency is unknown, blood cells have been implicated as a viral reservoir. In this study, we demonstrate HCMV reactivation in vitro from seven consecutive healthy donors through allogeneic stimulation of peripheral blood mononuclear cells (PBMCs). HCMV replication was detected at 17 days poststimulation, and virus was recovered after long-term culture from a macrophage expressing dendritic cell markers. Thus, these observations demonstrate that PBMCs harbor latent HCMV, which reactivates in a myeloid lineage cell upon allogeneic stimulation.	OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL,PORTLAND,OR 97201	Oregon Health & Science University			Fish, Kenneth/AAX-3067-2020	Fish, Kenneth/0000-0003-1774-3815	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21640] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS DO, 1992, MACROPHAGE, P77; BOSTROM L, 1990, BONE MARROW TRANSPL, V5, P321; Britt W. J., 1996, FIELDS VIROLOGY, P2493; BRITT WJ, 1992, J VIROL, V66, P6747, DOI 10.1128/JVI.66.11.6747-6754.1992; BRUNING JH, 1986, TRANSPLANTATION, V41, P695, DOI 10.1097/00007890-198606000-00005; BRYTTING M, 1995, TRANSPLANTATION, V60, P961; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CHOU SW, 1986, NEW ENGL J MED, V314, P1418, DOI 10.1056/NEJM198605293142205; DOCKE WD, 1994, LANCET, V343, P238; Fish KN, 1996, J VIROL, V70, P1855, DOI 10.1128/JVI.70.3.1855-1862.1996; FISH KN, 1995, J VIROL, V69, P3737, DOI 10.1128/JVI.69.6.3737-3743.1995; FLECKENSTEIN B, 1982, GENE, V18, P39, DOI 10.1016/0378-1119(82)90054-3; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GNANN JW, 1988, AM J PATHOL, V132, P239; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAMILTON JD, 1995, TRANSPLANTATION, V39, P290; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JORDAN MC, 1982, J CLIN INVEST, V70, P762, DOI 10.1172/JCI110672; Kieff E., 1996, FIELDS VIROLOGY, P2343; KOFFRON AJ, 1995, SCAND J INF DIS S, V99, P612; Kondo K, 1996, P NATL ACAD SCI USA, V93, P11137, DOI 10.1073/pnas.93.20.11137; KONDO K, 1994, P NATL ACAD SCI USA, V91, P11879, DOI 10.1073/pnas.91.25.11879; LONNQVIST B, 1984, TRANSPLANTATION, V38, P465, DOI 10.1097/00007890-198411000-00004; MACIEJEWSKI JP, 1992, BLOOD, V80, P170; Mandanas RA, 1996, AM J HEMATOL, V51, P104; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; MELNICK JL, 1995, BIOESSAYS, V17, P899, DOI 10.1002/bies.950171012; Mendelson M, 1996, J GEN VIROL, V77, P3099, DOI 10.1099/0022-1317-77-12-3099; MERCER JA, 1988, J VIROL, V62, P987, DOI 10.1128/JVI.62.3.987-997.1988; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MINTON EJ, 1994, J VIROL, V68, P4017, DOI 10.1128/JVI.68.6.4017-4021.1994; MYERSON D, 1984, HUM PATHOL, V15, P430, DOI 10.1016/S0046-8177(84)80076-3; NOVASSAGH M, 1996, BLOOD, V88, P1277; OLDING LB, 1975, J EXP MED, V141, P561, DOI 10.1084/jem.141.3.561; Pollock JL, 1997, VIROLOGY, V227, P168, DOI 10.1006/viro.1996.8303; REDDEHASE MJ, 1994, J EXP MED, V179, P185, DOI 10.1084/jem.179.1.185; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; Roizman B, 1996, FIELDS VIROLOGY, P2231; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHMADER KE, 1992, J INFECT DIS, V166, P1403, DOI 10.1093/infdis/166.6.1403; SCHRIER RD, 1990, J VIROL, V64, P3280, DOI 10.1128/JVI.64.7.3280-3288.1990; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SIMMONS P, 1990, P NATL ACAD SCI USA, V87, P1386, DOI 10.1073/pnas.87.4.1386; Sinzger C, 1996, J INFECT DIS, V173, P240, DOI 10.1093/infdis/173.1.240; SINZGER C, 1993, J INFECT DIS, V167, P1427, DOI 10.1093/infdis/167.6.1427; SODERBERG C, 1993, J VIROL, V67, P3166; Soderberg C, 1996, TRANSPLANTATION, V61, P600; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; STODDART CA, 1994, J VIROL, V68, P6243, DOI 10.1128/JVI.68.10.6243-6253.1994; TAYLORWIEDEMAN J, 1994, J VIROL, V68, P1597, DOI 10.1128/JVI.68.3.1597-1604.1994; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; TEGTMEIER GE, 1989, ARCH PATHOL LAB MED, V113, P236; TOROKSTORB B, 1992, ANN HEMATOL SA, V64, P128; vandenBerg AP, 1996, CLIN TRANSPLANT, V10, P224; VONLAER D, 1995, BLOOD, V86, P4086, DOI 10.1182/blood.V86.11.4086.bloodjournal86114086; VONLAER D, 1995, J INFECT DIS, V172, P365, DOI 10.1093/infdis/172.2.365; YAGYU K, 1993, TRANSPLANT P, V25, P1152; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	59	529	545	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					119	126		10.1016/S0092-8674(01)80014-3	http://dx.doi.org/10.1016/S0092-8674(01)80014-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335340	Bronze			2022-12-01	WOS:A1997XZ80900014
J	Nightingale, SL				Nightingale, SL			New guidance for prescription drug TV and radio advertising proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-01	WOS:A1997XX30300006
J	Kutay, U; Bischoff, FR; Kostka, S; Kraft, R; Gorlich, D				Kutay, U; Bischoff, FR; Kostka, S; Kraft, R; Gorlich, D			Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; SEGREGATION GENE CSE1; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; CHROMOSOME SEGREGATION; HNRNP A1; RAN-GTP; RAN/TC4 HOMOLOG; YEAST; LOCALIZATION	NLS proteins are transported into the nucleus by the importin alpha/beta heterodimer. Importin alpha binds the NLS, while importin beta mediates translocation through the nuclear pore complex. After translocation, RanGTP, whose predicted concentration is high in the nucleus and low in the cytoplasm, binds importin beta and displaces importin alpha. Importin alpha must then be returned to the cytoplasm, leaving the NLS protein behind. Here, we report that the previously identified CAS protein mediates importin alpha re-export. CAS binds strongly to importin alpha only in the presence of RanGTP, forming an importin alpha/CAS/RanGTP complex. Importin alpha is released from this complex in the cytoplasm by the combined action of RanBP1 and RanGAP1. CAS binds preferentially to NLS-free importin alpha, explaining why import substrates stay in the nucleus.	UNIV HEIDELBERG, ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT MOL BIOL MITOSE, D-69120 HEIDELBERG, GERMANY; ZENTRUM MOL MED, D-13122 BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)			Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DEANE R, 1997, IN PRESS MOL CELL BI; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fridell RA, 1997, J CELL SCI, V110, P1325; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZAURRALDE E, 1997, IN PRESS EMBO J; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	72	516	526	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1061	1071		10.1016/S0092-8674(00)80372-4	http://dx.doi.org/10.1016/S0092-8674(00)80372-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323134	Bronze			2022-12-01	WOS:A1997XX76800012
J	Folkner, WM; Yoder, CF; Yuan, DN; Standish, EM; Preston, RA				Folkner, WM; Yoder, CF; Yuan, DN; Standish, EM; Preston, RA			Interior structure and seasonal mass redistribution of Mars from radio tracking of Mars Pathfinder	SCIENCE			English	Article							INERTIA; OBLIQUITY; MOMENT; CYCLE	Doppler and range measurements to the Mars Pathfinder lander made using its radio communications system have been combined with similar measurements from the Viking landers to estimate improved values of the precession of Mars' pole of rotation and the variation in Mars' rotation rate. The observed precession of -7576 +/- 35 milliarc seconds of angle per year implies a dense core and constrains possible models of interior composition. The estimated annual variation in rotation is in good agreement with a model of seasonal mass exchange of carbon dioxide between the atmosphere and ice caps.			Folkner, WM (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							BILLS BG, 1989, GEOPHYS RES LETT, V16, P385, DOI 10.1029/GL016i005p00385; CAZENAVE A, 1981, GEOPHYS RES LETT, V8, P245, DOI 10.1029/GL008i003p00245; CHAO BF, 1990, J GEOPHYS RES-SOLID, V95, P14755, DOI 10.1029/JB095iB09p14755; Davies M., 1996, CELESTIAL MECH, V63, P127, DOI DOI 10.1007/BF00693410; FOLKNER WM, 1994, ASTRON ASTROPHYS, V287, P279; Folkner WM, 1997, J GEOPHYS RES-PLANET, V102, P4057, DOI 10.1029/96JE02125; FRANCOIS LM, 1990, J GEOPHYS RES-SOLID, V95, P14761, DOI 10.1029/JB095iB09p14761; KAULA WM, 1979, GEOPHYS RES LETT, V6, P194, DOI 10.1029/GL006i003p00194; KONOPLIV AS, 1995, PUBLICATION JET PROP; LAUL JC, 1986, GEOCHIM COSMOCHIM AC, V50, P875, DOI 10.1016/0016-7037(86)90370-4; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; REASENBERG RD, 1977, J GEOPHYS RES, V82, P369, DOI 10.1029/JB082i002p00369; ROSEN RD, 1983, J GEOPHYS RES-OCEANS, V88, P5451, DOI 10.1029/JC088iC09p05451; Sears F.W., 1968, INTRO THEORY RELATIV; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; Yoder CF, 1997, J GEOPHYS RES-PLANET, V102, P4065, DOI 10.1029/96JE03642	20	232	242	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1749	1752		10.1126/science.278.5344.1749	http://dx.doi.org/10.1126/science.278.5344.1749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388168				2022-12-01	WOS:A1997YJ90100034
J	Sheng, HZ; Moriyama, K; Yamashita, T; Li, H; Potter, SS; Mahon, KA; Westphal, H				Sheng, HZ; Moriyama, K; Yamashita, T; Li, H; Potter, SS; Mahon, KA; Westphal, H			Multistep control of pituitary organogenesis	SCIENCE			English	Article							HOMEOBOX GENE LHX3; HOMEODOMAIN FACTOR; PIT-1; LIM; EXPRESSION	Lhx3 and Lhx4 (Gsh4), two closely related LIM homeobox genes, determine formation of the pituitary gland in mice. Rathke's pouch is formed in two steps-first as a rudiment and later as a definitive pouch. Lhx3 and Lhx4 have redundant control over formation of the definitive pouch. Lhx3 controls a subsequent step of pituitary fate commitment. Thereafter, Lhx3 and Lhx4 together regulate proliferation and differentiation of pituitary-specific cell lineages. Thus, Lhx3 and Lhx4 dictate pituitary organ identity by controlling developmental decisions at multiple stages of organogenesis.	NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN; ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Shimane University; Academia Sinica - Taiwan; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Baylor College of Medicine								BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DIAKOKU S, 1982, DEV BIOL, V90, P198; ETKIN W, 1967, NEUROENDOCRINOLOGY, P261; FERRAND R, 1972, Archives de Biologie, V83, P297; KAUFMAN MH, 1992, ATLAS MOUSE DEVELOPM; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; ROBINSON GW, 1991, NEW BIOL, V3, P1183; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Yamashita T, 1997, GENOMICS, V44, P144, DOI 10.1006/geno.1997.4852; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	18	295	295	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1809	1812		10.1126/science.278.5344.1809	http://dx.doi.org/10.1126/science.278.5344.1809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388186				2022-12-01	WOS:A1997YJ90100052
J	Bao, WH; Srinivasan, SR; Valdez, R; Greenlund, KJ; Wattigney, WA; Berenson, GS				Bao, WH; Srinivasan, SR; Valdez, R; Greenlund, KJ; Wattigney, WA; Berenson, GS			Longitudinal changes in cardiovascular risk from childhood to young adulthood in offspring of parents with coronary artery disease - The Bogalusa Heart Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; CHILDREN; OVERWEIGHT; OBESITY; CHOLESTEROL; HISTORY; ADOLESCENTS; TRENDS	Context.-Although the association between parental coronary artery disease (CAD) and its risk factors in the offspring is known, the timing and the course of development of risk factors from childhood to adulthood in the offspring is not known. Objective.-To examine the association between parental CAD and longitudinal changes in risk factor profile from childhood to young adulthood in offspring. Design.-Cohort study. Setting.-Bogalusa, La, a semirural, biracial community. Participants.-Individuals with clinically verified parental history of CAD (n = 271) vs those without such a history (n=1253) Mean age at first CAD event was 50 years for fathers and 52 years for mothers. Main Outcome Measures.-Body mass index, subscapular skinfolds, blood pressure, and triglyceride, cholesterol (total, very low-density lipoprotein [VLDL-C], low-density lipoprotein [LDL-C], and high-density lipoprotein [HDL-C] cholesterols), glucose, and insulin levels. Results.-The offspring of parents with CAD were consistently overweight beginning in childhood. Their levels of total serum cholesterol, LDL-C, plasma glucose, and insulin became significantly higher at older ages, because of a higher rate of increase in these risk factors over time. In adulthood, the offspring with a positive parental history had a higher prevalence of obesity (body mass index >85th percentile in the National Health and Nutrition Examination Survey I, 35% vs 26%, P=.01), elevated total cholesterol (>6.2 mmol/L [240 mg/dL], 8.4% vs 4.8%, P=.05) and LDL-C levels (>4.1 mmol/L [160 mg/dL], 12.4% vs 4.7%, P=.05), and hyperglycemia (glucose, >6.6 mmol/L, 2.7% vs 0.4%, P<.001), as well as a higher coexistence of these conditions (P=.01). Further, the prevalence of dyslipidemia, either involving only LDL-C or LDL-C in combination with HDL-C or triglycerides or both, was significantly higher in the adult offspring with parental CAD. Conclusions.-Offspring of parents with early CAD were overweight beginning in childhood and developed an adverse cardiovascular risk factor profile ai an increased rate. These observations have important implications for prevention and intervention.	TULANE UNIV,SCH PUBL HLTH & TROP MED,TULANE CTR CARDIOVASC HLTH,NEW ORLEANS,LA 70112	Tulane University				Valdez, Rodolfo/0000-0001-9979-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032194] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038844, U01HL038844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38844] Funding Source: Medline; NICHD NIH HHS [HD-32194] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BAO WH, 1995, CIRCULATION, V91, P365, DOI 10.1161/01.CIR.91.2.365; BAO WH, 1994, ARCH INTERN MED, V154, P1842; Bao WH, 1996, ARCH INTERN MED, V156, P1315, DOI 10.1001/archinte.156.12.1315; *BECKM INSTR INC, 1976, BECKM GLUC AN OP MAN; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; BLONDE CV, 1981, PREV MED, V10, P25, DOI 10.1016/0091-7435(81)90003-7; BUCOLO G, 1973, CLIN CHEM, V19, P476; BURKE GL, 1991, CIRCULATION, V84, P1176, DOI 10.1161/01.CIR.84.3.1176; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; *EXP PAN BLOOD CHO, 1992, PEDIATRICS S, V89, P529; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GIDDING SS, 1995, J PEDIATR-US, V127, P868, DOI 10.1016/S0022-3476(95)70020-X; Greenlund KJ, 1997, AM J MED SCI, V313, P220, DOI 10.1097/00000441-199704000-00005; HARLAN WR, 1993, ANN NY ACAD SCI, V699, P1, DOI 10.1111/j.1749-6632.1993.tb18831.x; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; KANNEL WB, 1974, MED CLIN N AM, V58, P363, DOI 10.1016/S0025-7125(16)32163-0; KARIM MR, 1988, GEE ASAS MACRO LONGI; KHAW K, 1982, CIRCULATION, V74, P239; KHOURY P, 1980, AM J EPIDEMIOL, V112, P524, DOI 10.1093/oxfordjournals.aje.a113022; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; Lipid Research Clinics Program, 1974, DHEW PUBL; MOSSBERG HO, 1989, LANCET, V2, P491; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839; *NAT CHOL ED PROGR, 1993, JAMA-J AM MED ASSOC, V269, P3015; POLONSKY SM, 1993, PEDIATRICS, V91, P92; RISSANEN AM, 1977, BRIT HEART J, V39, P875, DOI 10.1136/hrt.39.8.875; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; *SAS I INC, 1989, SAS STAT 7 US GUID V; SHEAR CL, 1985, AM J EPIDEMIOL, V122, P762, DOI 10.1093/oxfordjournals.aje.a114159; SMOAK CG, 1987, AM J EPIDEMIOL, V125, P364, DOI 10.1093/oxfordjournals.aje.a114543; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; Srinivasan SR., 1983, CRC HDB ELECTROPHORE, P185; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; WEBBER LS, 1979, PREV MED, V8, P407, DOI 10.1016/0091-7435(79)90018-5; [No title captured]; 1990, JAMA-J AM MED ASSOC, V264, P3018	40	125	130	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1749	1754		10.1001/jama.278.21.1749	http://dx.doi.org/10.1001/jama.278.21.1749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388151				2022-12-01	WOS:A1997YH98700029
J	Nightingale, SL				Nightingale, SL			New warning information for Rezulin labeling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-01	WOS:A1997YH98700008
J	Boston, BA; Blaydon, KM; Varnerin, J; Cone, RD				Boston, BA; Blaydon, KM; Varnerin, J; Cone, RD			Independent and additive effects of central POMC and leptin pathways on murine obesity	SCIENCE			English	Article							AGOUTI GENE; ECTOPIC EXPRESSION; MICE; RECEPTOR; CLONING; PROTEIN	The lethal yellow (A(Y)/a) mouse has a defect in proopiomelanocortin (POMC) signaling in the brain that leads to obesity, and is resistant to the anorexigenic effects of the hormone leptin. It has been proposed that the weight-reducing effects of leptin are thus transmitted primarily by way of POMC neurons. However, the central effects of defective POMC signaling, and the absence of leptin, on weight gain in double-mutant lethal yellow (A(Y)/a) leptin-deficient (lep(ob)/lep(ob)) mice were shown to be independent and additive, Furthermore, deletion of the leptin gene restored leptin sensitivity to A(Y)/a mice. This result implies that in the A(Y)/a mouse, obesity is independent of leptin action, and resistance to leptin results from desensitization of leptin signaling.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; MERCK RES LABS,DEPT GENET & MOL BIOL,RAHWAY,NJ 07065	Oregon Health & Science University; Oregon Health & Science University; Merck & Company					NICHD NIH HHS [HD33703] Funding Source: Medline; NIDDK NIH HHS [DK02404, DK/AR517330] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002404] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; DICKIE MM, 1962, J HERED, V53, P4; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Gura T, 1997, SCIENCE, V275, P751, DOI 10.1126/science.275.5301.751; HALAAS JL, 1997, P NATL ACAD SCI USA, V944, P8878; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; PLOCHER TA, 1976, METABOLISM, V25, P593, DOI 10.1016/0026-0495(76)90013-5; SEELY RJ, IN PRESS NATURE; SHIMIZU H, 1989, AM J PHYSIOL, V256, P494; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; WOLFF GL, 1963, GENETICS, V48, P1041; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	25	206	207	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1641	1644		10.1126/science.278.5343.1641	http://dx.doi.org/10.1126/science.278.5343.1641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374468				2022-12-01	WOS:A1997YJ87400047
J	Thomas, SA; Palmiter, RD				Thomas, SA; Palmiter, RD			Impaired maternal behavior in mice lacking norepinephrine and epinephrine	CELL			English	Article							OLFACTORY-BULB; TARGETED DISRUPTION; RECEPTOR SUBTYPE; POSTPARTUM RATS; SHEEP; RECOGNITION; EXPERIENCE; PARTURITION; GENE; CYCLOHEXIMIDE	The roles of norepinephrine (NE) and epinephrine in behavior were investigated by targeted disruption of the dopamine beta-hydroxylase (Dbh) gene, thereby eliminating these compounds in vivo. Most heterozygous pups born to Dbh(-/-) females died within several days of birth and were often found scattered within the bedding. Potential causes including deficits in olfaction and lactation were not apparent. A deficit in maternal behavior was confirmed by the lack of pup retrieval exhibited by Dbh(-/-) virgin females. Restoration of NE shortly before but not after birth induced females that previously abandoned their litters to act maternally. Our results suggest that NE is responsible for longlasting changes that promote maternal behavior during both development and parturition in mice.	UNIV WASHINGTON,DEPT BIOCHEM,HOWARD HUGHES MED INST,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle					NICHD NIH HHS [HD09172] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNES CD, 1991, PROGR BRAIN RES, V88; BLASS EM, 1980, SCIENCE, V210, P15, DOI 10.1126/science.6997992; BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; CALAMANDREI G, 1994, BEHAV NEUROSCI, V108, P113, DOI 10.1037/0735-7044.108.1.113; CALAMANDREI G, 1992, PHYSIOL BEHAV, V52, P901, DOI 10.1016/0031-9384(92)90369-D; DICKINSON C, 1988, PHYSIOL BEHAV, V43, P313, DOI 10.1016/0031-9384(88)90193-X; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P957, DOI 10.1037/h0036414; FLEMING AS, 1990, BEHAV NEURAL BIOL, V53, P64, DOI 10.1016/0163-1047(90)90814-M; GRANDELMAN R, 1970, SCIENCE, V171, P210; Holets V.R., 1990, PHARM NORADRENALINE, P1; KABA H, 1988, NEUROSCIENCE, V25, P1007, DOI 10.1016/0306-4522(88)90053-X; KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766; KENDRICK KM, 1988, BRAIN RES, V439, P1, DOI 10.1016/0006-8993(88)91455-2; KEVERNE EB, 1982, NATURE, V296, P148, DOI 10.1038/296148a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; KEVERNE EB, 1988, PSYCHONEUROENDOCRINO, V13, P127, DOI 10.1016/0306-4530(88)90010-8; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; LEVY F, 1993, BEHAV NEUROSCI, V107, P662, DOI 10.1037/0735-7044.107.4.662; LEVY F, 1990, BEHAV NEUROSCI, V104, P464, DOI 10.1037/0735-7044.104.3.464; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MALENFANT SA, 1991, PHYSIOL BEHAV, V49, P289, DOI 10.1016/0031-9384(91)90045-P; MOLTZ H, 1975, NEUROENDOCRINOLOGY, V19, P252, DOI 10.1159/000122445; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; NUMAN M, 1988, BEHAV NEUROSCI, V102, P381, DOI 10.1037/0735-7044.102.3.381; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PISSONNIER D, 1985, PHYSIOL BEHAV, V35, P361, DOI 10.1016/0031-9384(85)90309-9; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; ROSENBERG P, 1977, PHARMACOL BIOCHEM BE, V6, P21, DOI 10.1016/0091-3057(77)90155-1; ROSENBERG P, 1976, PHARMACOL BIOCHEM BE, V4, P647, DOI 10.1016/0091-3057(76)90215-X; ROSENBLATT JS, 1967, SCIENCE, V156, P1512, DOI 10.1126/science.156.3781.1512; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; SMOTHERMAN WP, 1974, BEHAV BIOL, V12, P55, DOI 10.1016/S0091-6773(74)91026-8; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Szabadi E, 1991, ADRENOCEPTORS STRUCT; Tafari AT, 1997, J NEUROSCI, V17, P4275; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Thomas SA, 1997, BEHAV NEUROSCI, V111, P579, DOI 10.1037/0735-7044.111.3.579; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0	41	133	133	2	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					583	592		10.1016/S0092-8674(00)80446-8	http://dx.doi.org/10.1016/S0092-8674(00)80446-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393852	Bronze			2022-12-01	WOS:A1997YH96000006
J	Iwahashi, H; Eguchi, Y; Yasuhara, N; Hanafusa, T; Matsuzawa, Y; Tsujimoto, Y				Iwahashi, H; Eguchi, Y; Yasuhara, N; Hanafusa, T; Matsuzawa, Y; Tsujimoto, Y			Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy	NATURE			English	Article							MOTOR-NEURON GENE; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; CELL-DEATH; SURVIVAL; PROTEIN; EXPRESSION; BCL-X(L); ADULT; BAD	Spinal muscular atrophy (SMA) is a motor neuron disease characterized by degeneration of the anterior horn cells of the spinal cord. It is a common fatal autosomal recessive disorder and linkage studies have identified two candidate genes, SMN (ref. 1) and NAIP (ref. 2), both on chromosome 5q13. Although NAIP protein is know to have an anti-apoptotic function(3), the function of SMN has been unclear and it shows no significant sequence similarity to any other protein. The SMN gene is deleted or interrupted on both chromosomes in nearly all SMA patients(1) Here we show that SMN interacts with Bcl-2, another anti-apoptotic that co-expression of SMN with Bcl-2 confers a synergistic preventive effect against Bar-induced or Fas-mediated apoptosis, although SMN itself has only a weak anti-apoptotic activity. SMNY272C, which carries a missense mutation and was found in an SMA patient who exceptionally retained SMN on one allele(1), exerts no synergism with Bcl-2. Furthermore, the product of a truncated transcript lacking exon 7, which was derived from an SMN gene carrying an intragenic mutation or from the SMN copy gene (C)BCD541 (ref. 1) retained in all SMA patients, had no synergistic activity but instead had a dominant-negative effect on full-length SMN. Our results indicate that an absent or decreased anti-apoptotic activity of SMN in concert with Bcl-2 underlies the pathogenesis of SMA.	OSAKA UNIV,SCH MED,DEPT MED GENET,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Iwahashi, Hitoshi/S-1360-2019					AKAO Y, 1994, CANCER RES, V54, P2468; Burlet P, 1996, J MED GENET, V33, P281, DOI 10.1136/jmg.33.4.281; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; MERRY DE, 1994, DEVELOPMENT, V120, P301; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	17	170	173	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					413	417		10.1038/37144	http://dx.doi.org/10.1038/37144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389483				2022-12-01	WOS:A1997YH54900067
J	Roubey, RAS; Hoffman, M				Roubey, RAS; Hoffman, M			From antiphospholipid syndrome to antibody-mediated thrombosis	LANCET			English	Editorial Material							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; PROCOAGULANT ACTIVITY; ANTICOAGULANT; BINDING; MEMBRANES; MONOCYTES; IGG		DUKE UNIV, DEPT PATHOL, DURHAM, NC 27706 USA	Duke University	Roubey, RAS (corresponding author), UNIV N CAROLINA, DIV RHEUMATOL & IMMUNOL, CHAPEL HILL, NC 27599 USA.		Hoffman, Maureane/D-1025-2009	Hoffman, Maureane/0000-0001-7123-0100				Cuadrado MJ, 1997, ARTHRITIS RHEUM-US, V40, P834, DOI 10.1002/art.1780400509; DELPAPA N, 1995, CLIN EXP RHEUMATOL, V13, P179; GINSBERG JS, 1993, BLOOD, V81, P2958; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; KITTNER SJ, 1992, STROKE, V23, pI19; KORNBERG A, 1994, J IMMUNOL, V153, P1328; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; Pradier O, 1996, BLOOD, V87, P3768, DOI 10.1182/blood.V87.9.3768.bloodjournal8793768; Rand JH, 1997, NEW ENGL J MED, V337, P154, DOI 10.1056/NEJM199707173370303; Rao LVM, 1996, BLOOD, V88, P4173; Roubey RAS, 1996, ARTHRITIS RHEUM-US, V39, P1444, DOI 10.1002/art.1780390903; SCHVED JF, 1992, AM J HEMATOL, V41, P92, DOI 10.1002/ajh.2830410205; SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276; Takeya H, 1997, J CLIN INVEST, V99, P2260, DOI 10.1172/JCI119401; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q	15	78	80	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1491	1493		10.1016/S0140-6736(05)63936-0	http://dx.doi.org/10.1016/S0140-6736(05)63936-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388393				2022-12-01	WOS:A1997YH11500004
J	Rosenberg, ES; Billingsley, JM; Caliendo, AM; Boswell, SL; Sax, PE; Kalams, SA; Walker, BD				Rosenberg, ES; Billingsley, JM; Caliendo, AM; Boswell, SL; Sax, PE; Kalams, SA; Walker, BD			Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; IN-VITRO; IMMUNE-RESPONSE; DEFICIENT MICE; LYMPHOCYTES; RECOGNITION; ANTIGEN; CYTOMEGALOVIRUS; IMMUNIZATION	Virus-specific CD4(+) T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4(+) T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines. In persons with chronic infection, HIV-1-specific proliferative responses to p24 were inversely related to viral load. Strong HIV-1-specific proliferative responses were also detected following treatment of acutely infected persons with potent antiviral therapy. The HIV-1-specific helper cells are likely to be important in immunotherapeutic interventions and vaccine development.	MASSACHUSETTS GEN HOSP, PARTNERS AIDS RES CTR, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; FENWAY COMMUNITY HLTH CTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital					NIAID NIH HHS [F32-AI09738, R01-AI28568] Funding Source: Medline; PHS HHS [R01-A136550] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009738, R01AI028568] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; DOLAN MJ, 1995, J INFECT DIS, V172, P79, DOI 10.1093/infdis/172.1.79; EPSTEIN JS, 1985, J INFECT DIS, V152, P727, DOI 10.1093/infdis/152.4.727; Harrer T, 1996, J IMMUNOL, V156, P2616; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; KALAMS S, UNPUB; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KROWKA JF, 1989, J CLIN INVEST, V83, P1198, DOI 10.1172/JCI114001; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENCE J, 1989, J CLIN INVEST, V83, P1843, DOI 10.1172/JCI114090; Lekutis C, 1997, J IMMUNOL, V158, P4471; Lekutis C, 1997, J IMMUNOL, V159, P2049; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; PANTALEO G, 1995, NEW ENGL J MED, V69, P5838; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; PONTESILLI O, 1994, AIDS RES HUM RETROV, V10, P113, DOI 10.1089/aid.1994.10.113; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; ROSENBERG E, UNPUB; Schnittman SM, 1997, AIDS RES HUM RETROV, V13, P815, DOI 10.1089/aid.1997.13.815; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SCHWARTZ D, 1994, AIDS RES HUM RETROV, V10, P1703, DOI 10.1089/aid.1994.10.1703; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; Thomsen AR, 1996, J IMMUNOL, V157, P3074; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; WAHREN B, 1987, J VIROL, V61, P2017, DOI 10.1128/JVI.61.6.2017-2023.1987; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Weissman D, 1996, J EXP MED, V183, P687, DOI 10.1084/jem.183.2.687	42	1571	1602	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1447	1450		10.1126/science.278.5342.1447	http://dx.doi.org/10.1126/science.278.5342.1447			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367954				2022-12-01	WOS:A1997YG85800040
J	Naren, AP; Nelson, DJ; Xie, WW; Jovov, B; Pevsner, J; Bennett, MK; Benos, DJ; Quick, MW; Kirk, KL				Naren, AP; Nelson, DJ; Xie, WW; Jovov, B; Pevsner, J; Bennett, MK; Benos, DJ; Quick, MW; Kirk, KL			Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; N-TYPE; CALCIUM CHANNELS; EPITHELIAL-CELLS; PROTEIN-KINASE; CL CHANNEL; COMPLEX; PHOSPHORYLATION; TRANSPORT	The cystic fibrosis gene encodes a cyclic AMP-gated chloride channel (CFTR) that mediates electrolyte transport across the luminal surfaces of a variety of epithelial cells(1-4). The molecular mechanisms that modulate CFTR activity in epithelial tissues are poorly understood, Here we show that CFTR is regulated by an epithelially expressed syntaxin (syntaxin 1A), a membrane protein that also modulates neurosecretion(5-7) and calcium-channel gatings(8-11) in brain, Syntaxin 1A physically interacts with CFTR chloride channels and regulates CFTR-mediated currents both in Xenopus oocytes and in epithelial cells that normally express these proteins. The physical and functional interactions between syntaxin 1A and CFTR are blocked by a syntaxin-binding protein of the Munc18 protein family (also called n-Sec1; refs 12-14). Our results indicate that CFTR function in epithelial cells is regulated by an interplay between syntaxin and Munc18 isoforms.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT NEUROBIOL,BIRMINGHAM,AL 35294; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60037; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60037; KENNEDY KRIEGER INST,DEPT NEUROSCI,BALTIMORE,MD 21250; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21250; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Chicago; University of Chicago; Kennedy Krieger Institute; Johns Hopkins University; University of California System; University of California Berkeley								ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEBER E, 1994, J CELL BIOL, V125, P538; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092	26	179	181	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					302	305		10.1038/36882	http://dx.doi.org/10.1038/36882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384384				2022-12-01	WOS:A1997YG66700067
J	Rodvold, KA; Danziger, LH; Quinn, JP				Rodvold, KA; Danziger, LH; Quinn, JP			Single daily doses of aminoglycosides - Commentary	LANCET			English	Editorial Material									UNIV ILLINOIS,COLL MED,DEPT MED,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rodvold, KA (corresponding author), UNIV ILLINOIS,COLL PHARM,DEPT PHARM PRACTICE,CHICAGO,IL 60612, USA.							Ali MZ, 1997, CLIN INFECT DIS, V24, P796, DOI 10.1093/clinids/24.5.796; Bailey TC, 1997, CLIN INFECT DIS, V24, P786, DOI 10.1093/clinids/24.5.786; Bertino JS, 1997, CLIN INFECT DIS, V24, P820, DOI 10.1093/clinids/24.5.820; Freeman CD, 1997, J ANTIMICROB CHEMOTH, V39, P677, DOI 10.1093/jac/39.6.677; GILBERT DN, 1997, CLIN INFECT DIS, V21, P816; Hatala R, 1997, CLIN INFECT DIS, V24, P810, DOI 10.1093/clinids/24.5.810; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Urban A W, 1997, Curr Clin Top Infect Dis, V17, P236	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1412	1412		10.1016/S0140-6736(97)22046-5	http://dx.doi.org/10.1016/S0140-6736(97)22046-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371159				2022-12-01	WOS:A1997YF95300002
J	Munoz, V; Thompson, PA; Hofrichter, J; Eaton, WA				Munoz, V; Thompson, PA; Hofrichter, J; Eaton, WA			Folding dynamics and mechanism of beta-hairpin formation	NATURE			English	Article							SHORT LINEAR PEPTIDE; AQUEOUS-SOLUTION; PROTEIN; STABILITY; DESIGN	Protein chains coil into alpha-helices and beta-sheet structures. Knowing the timescales and mechanism of formation of these basic structural elements is essential for understanding how proteins fold(1). For the past 40 years, alpha-helix formation has been extensively investigated in synthetic and natural peptides(2-5), including by nanosecond kinetic studies(6,7). In contrast, the mechanism of formation of beta structures has not been studied experimentally. The minimal beta-structure element is the beta-hairpin, which is also the basic component of antiparallel beta-sheets. Here we use a nanosecond laser temperature-jump apparatus to study the kinetics of folding a beta-hairpin consisting of 16 amino-acid residues. Folding of the hairpin occurs in 6 mu s at room temperature, which is about 30 times slower than the rate of alpha-helix formation(6,7). We have developed a simple statistical mechanical model that provides a structural explanation for this result, Our analysis also shows that folding of a beta-hairpin captures much of the basic physics of protein folding; including stabilization by hydrogen bonding and hydrophobic interactions, two-state behaviour, and a funnel-like, partially rugged energy landscape.			Munoz, V (corresponding author), NIDDK,PHYS CHEM LAB,NIH,BLDG 5,BETHESDA,MD 20892, USA.							BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BLANCO FJ, 1993, J AM CHEM SOC, V115, P5887, DOI 10.1021/ja00066a092; BLANCO FJ, 1994, NAT STRUCT BIOL, V1, P584, DOI 10.1038/nsb0994-584; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; deAlba E, 1996, FOLD DES, V1, P133, DOI 10.1016/S1359-0278(96)00022-3; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; GRUENEWALD B, 1979, BIOPHYS CHEM, V9, P137, DOI 10.1016/0301-4622(79)87008-8; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; Klimov DK, 1997, PHYS REV LETT, V79, P317, DOI 10.1103/PhysRevLett.79.317; KOBAYASHI N, 1993, PEPTIDE CHEMISTRY 1992, P278; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; MUNOZ V, 1995, CURR OPIN BIOTECH, V6, P382, DOI 10.1016/0958-1669(95)80066-2; PHILLIPS CM, 1995, P NATL ACAD SCI USA, V92, P7292, DOI 10.1073/pnas.92.16.7292; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; SEARLE MS, 1995, NAT STRUCT BIOL, V2, P999, DOI 10.1038/nsb1195-999; Sieber V, 1996, BIOCHEMISTRY-US, V35, P181, DOI 10.1021/bi950681o; Thompson PA, 1997, BIOCHEMISTRY-US, V36, P9200, DOI 10.1021/bi9704764; Thompson PA, 1997, TECH PROT CHEM, V8, P735, DOI 10.1016/S1080-8914(97)80072-5; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p; ZIMM BH, 1959, P NATL ACAD SCI USA, V45, P1601, DOI 10.1073/pnas.45.11.1601	24	858	865	4	122	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					196	199		10.1038/36626	http://dx.doi.org/10.1038/36626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367160				2022-12-01	WOS:A1997YF49400060
J	Atwell, S; Ultsch, M; DeVos, AM; Wells, JA				Atwell, S; Ultsch, M; DeVos, AM; Wells, JA			Structural plasticity in a remodeled protein-protein interface	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; MONOVALENT PHAGE DISPLAY; CRYSTAL-STRUCTURE; RECEPTOR; MUTAGENESIS; RESOLUTION; COMPLEX; EPITOPE; MUTANT	Remodeling of the interface between human growth hormone (hGH) and the extracellular domain of its receptor was studied by deleting a critical tryptophan residue (at position 104) in the receptor, creating a large cavity, and selecting a pentamutant of hGH by phage display that fills the cavity and largely restores binding affinity. A 2.1 Angstrom resolution x-ray structure of the mutant complex showed that the receptor cavity was filled by selected hydrophobic mutations of hGH. Large structural rearrangements occurred in the inter face at sites that were distant from the mutations. Such plasticity may be a means for protein-protein interfaces to adapt to mutations as they coevolve.	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; University of California System; University of California San Francisco			Wells, Jim A/O-9854-2016					ATWELL S, UNPUB; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLACKSON T, UNPUB; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; VEITER IR, 1996, PROTEIN SCI, V5, P2399; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141	25	158	174	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1125	1128		10.1126/science.278.5340.1125	http://dx.doi.org/10.1126/science.278.5340.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353194				2022-12-01	WOS:A1997YE65200053
J	Pegoraro, A; Singh, A; Bakir, AA; Arruda, JAL; Dunea, G				Pegoraro, A; Singh, A; Bakir, AA; Arruda, JAL; Dunea, G			Simplified screening for microalbuminuria	ANNALS OF INTERNAL MEDICINE			English	Article							URINARY ALBUMIN EXCRETION; DIABETIC-PATIENTS; PREDICTOR	Background: Screening for microalbuminuria is increasingly advocated as a way to diagnose early renal involvement in diabetes and other diseases. It usually entails the use of a radioimmunoassay that is expensive and not always readily available. Objective: To assess the efficacy of three simple and inexpensive tests for ruling out microalbuminuria. Design: Cross-sectional study. Setting: Outpatient clinics. Patients: 221 patients from primary care clinics and a diabetes clinic. Measurements: Random urine specimens were tested for albumin by using Micral-Test immunoassay strips (Boehringer Mannheim, Mannheim, Germany) and for protein by using sulfosalicylic acid testing and impregnated dipsticks (Chemstrips, Boehringer Mannheim). Radioimmunoassay for albumin was used for all specimens as standard for comparison. Results: When less than 20 mg/L was considered the upper limit of normal for albumin concentration, Micral-Test, sulfosalicylic acid testing, and Chemstrips had negative predictive values of 99%, 95%, and 96%, respectively. Seventy-four specimens tested negative on both sulfosalicylic acid and Chemstrips; the negative predictive value of these two tests combined was 99%. Conclusions: The combination of sulfosalicylic acid testing and Chemstrips was as good as and less expensive than Micral-Test in ruling out microalbuminuria.	UNIV ILLINOIS, NEPHROL SECT, CHICAGO, IL 60612 USA; W SIDE VET ADM MED CTR, CHICAGO, IL USA; HEKTOEN INST MED RES, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pegoraro, A (corresponding author), COOK CTY HOSP, NEPHROL SECT, 637 S WOOD ST, CHICAGO, IL 60612 USA.							BASHYAM MM, 1993, DIABETES CARE, V16, P634, DOI 10.2337/diacare.16.4.634; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; COWELL CT, 1986, DIABETOLOGIA, V29, P97, DOI 10.1007/BF00456117; DEGRAUW WJC, 1995, DIABETIC MED, V12, P657; ESHOJ O, 1987, DIABETIC MED, V4, P531, DOI 10.1111/j.1464-5491.1987.tb00924.x; GYURE WL, 1977, CLIN CHEM, V23, P876; HASSLACHER C, 1993, CLIN BIOCHEM, V26, P283, DOI 10.1016/0009-9120(93)90126-Q; HUTCHISON AS, 1988, CLIN CHEM, V34, P2019; JOHNSTON J, 1993, BRIT MED J, V306, P493, DOI 10.1136/bmj.306.6876.493-a; KUTTER D, 1995, EUR J CLIN CHEM CLIN, V33, P243; LEFLOCH JP, 1994, DIABETIC MED, V11, P349; MARSHALL SM, 1992, CLIN CHEM, V38, P588; MEYER NL, 1994, AM J OBSTET GYNECOL, V170, P137; MOGENSEN CE, 1987, KIDNEY INT, V31, P673, DOI 10.1038/ki.1987.50; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; SILVER A, 1986, CLIN CHEM, V32, P1303; TAI J, 1990, DIABETES RES CLIN PR, V9, P137, DOI 10.1016/0168-8227(90)90105-3; TIU SC, 1993, DIABETES CARE, V16, P616, DOI 10.2337/diacare.16.4.616; WINOCOUR PH, 1992, BRIT MED J, V304, P1196, DOI 10.1136/bmj.304.6836.1196	19	20	20	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					817	819		10.7326/0003-4819-127-9-199711010-00007	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382403				2022-12-01	WOS:A1997YD89800006
J	Mercurio, F; Zhu, HY; Murray, BW; Shevchenko, A; Bennett, BL; Li, JW; Young, DB; Barbosa, M; Mann, M				Mercurio, F; Zhu, HY; Murray, BW; Shevchenko, A; Bennett, BL; Li, JW; Young, DB; Barbosa, M; Mann, M			IKK-1 and IKK-2: Cytokine-activated I kappa B kinases essential for NF-kappa B activation	SCIENCE			English	Article							TRANSCRIPTION FACTORS; ALPHA PROTEOLYSIS; MASS-SPECTROMETRY; PHOSPHORYLATION; PROTEINS; UBIQUITINATION; DEGRADATION; SIGNAL; FAMILY; IDENTIFICATION	Activation of the transcription factor nuclear factor kappa B (NF-kappa B) is controlled by sequential phosphorylation, ubiquitination, and degradation of its inhibitory subunit I kappa B. A large multiprotein complex, the I kappa B kinase (IKK) signalsome, was purified from Hela cells and found to contain a cytokine-inducible I kappa B kinase activity that phosphorylates I kappa B-alpha and I kappa B-beta. Two components of the IKK signalsome, IKK-1 and IKK-2, were identified as closely related protein serine kinases containing leucine zipper and helix-loop-helix protein interaction motifs. Mutant versions of IKK-2 had pronounced effects on RelA nuclear translocation and NF-kappa B-dependent reporter activity, consistent with a critical role for the IKK kinases in the NF-kappa B signaling pathway.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	European Molecular Biology Laboratory (EMBL); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Mercurio, F (corresponding author), SIGNAL PHARMACEUT INC,5555 OBERLIN AVE,SAN DIEGO,CA 92121, USA.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; murray, brion/0000-0003-1591-2566				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, EMBO J, V13, P1842; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MAININ NL, 1997, NATURE, V385, P540; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mann M, 1996, TRENDS BIOCHEM SCI, V21, P494, DOI 10.1016/S0968-0004(96)30042-X; Manning AM, 1996, DRUG DISCOV TODAY, V1, P151, DOI 10.1016/1359-6446(96)10015-5; MERCURIO F, UNPUB; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	1800	1876	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					860	866		10.1126/science.278.5339.860	http://dx.doi.org/10.1126/science.278.5339.860			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346484				2022-12-01	WOS:A1997YD47900046
J	Schott, GD				Schott, GD			Bisphosphonates for pain relief in reflex sympathetic dystrophy?	LANCET			English	Editorial Material											Schott, GD (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							Adami S, 1997, ANN RHEUM DIS, V56, P201, DOI 10.1136/ard.56.3.201; Cortet B, 1997, CLIN RHEUMATOL, V16, P51, DOI 10.1007/BF02238763; DEVOGELAER JP, 1988, J BONE MINER RES  S1, V3, pSI22; Dray A, 1996, PROG BRAIN RES, V110, P85; KOZIN F, 1992, CLIN EXP RHEUMATOL, V10, P401; MAILLEFERT JF, 1995, ANN RHEUM DIS, V54, P687, DOI 10.1136/ard.54.8.687-a; OYEN WJG, 1993, PAIN, V55, P151, DOI 10.1016/0304-3959(93)90144-E; REHMAN MTA, 1992, BONE, V13, P116; SCHOTT GD, 1995, LANCET, V345, P634, DOI 10.1016/S0140-6736(95)90528-6; SELBY PL, 1994, DIABETIC MED, V11, P28, DOI 10.1111/j.1464-5491.1994.tb00225.x; Strang P, 1996, ACTA ONCOL, V35, P50, DOI 10.3109/02841869609083968; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147	12	16	76	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1117	1117		10.1016/S0140-6736(05)63785-3	http://dx.doi.org/10.1016/S0140-6736(05)63785-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343496				2022-12-01	WOS:A1997YB19900005
J	PericakVance, MA; Bass, MP; Yamaoka, LH; Gaskell, PC; Scott, WK; Terwedow, HA; Menold, MM; Conneally, PM; Small, GW; Vance, JM; Saunders, AM; Roses, AD; Haines, JL				PericakVance, MA; Bass, MP; Yamaoka, LH; Gaskell, PC; Scott, WK; Terwedow, HA; Menold, MM; Conneally, PM; Small, GW; Vance, JM; Saunders, AM; Roses, AD; Haines, JL			Complete genomic screen in late-onset familial Alzheimer disease - Evidence for a new locus on chromosome 12	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFFECTED RELATIVE PAIRS; LINKAGE STRATEGIES; ALLELE; GENE; TRAITS; POLYMORPHISM; ASSOCIATION; DIAGNOSIS	Context.-Four genetic loci have been identified as contributing to Alzheimer disease (AD), including the amyloid precursor protein gene, the presenilin 1 gene, the presenilin 2 gene, and the apolipoprotein E gene, but do not account for all the genetic risk for AD. Objective.-To identify additional genetic risk factors for late-onset AD. Design.-A complete genomic screen was performed (N=280 markers). Critical values for chromosomal regional follow-up were a P value of .05 or less for affected relative pair analysis or sibpair analysis, a parametric lod score of 1.0 or greater, or both. Regional follow-up included analysis of additional markers and a second data set. Setting.-Clinic populations in the continental United States. Patients.-From a series of multiplex families affected with late-onset (greater than or equal to 60 years) AD ascertained during the last 14 years (National Insititute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders Association diagnostic criteria) and for which DNA has been obtained, a subset of 16 families (135 total family members, 52 of whom were patients with AD) was used for the genomic screen. A second subset of 38 families (216 total family members, 89 of whom were patients with AD) was used for the follow-up analysis. Main Outcome Measures.-Linkage analysis results generated using both genetic model-dependent (led score) and model-independent methods. Results.-Fifteen chromosomal regions warranted initial follow-up. Follow-up analyses revealed 4 regions of continued interest on chromosomes 4, 6, 12, and 20, with the strongest results observed for chromosome 12. Peak 2-point affecteds-only rod scores (n=54) were 1.3, 1.6, 2.7, and 2.2 and affected relative pairs P values (n=54) were .04, .03, .14, and .04 for D125373, D12S1057, D1251042, and D12S390, respectively. Sibpair analysis (n=54) resulted in maximum lod scores (MLSs) of 1.5, 2.6, 3.2, and 2.3 for these markers, with a peak multipoint MLS of 3.5. A priori stratification by APOEgenotype identified 27 families that had at least 1 member with AD whose genotype did not contain an APOE*4 allele. Analysis of these 27 families resulted in MLSs of 1.0, 2.4, 3.7, and 3.3 and a peak multipoint MLS of 3.9. Conclusions.-A complete genomic screen in families affected with late-onset AD identified 4 regions of interest after follow-up. Chromosome 12 gave the strongest and most consistent results with a peak multipoint MLS of 3.5, suggesting that this region contains a new susceptibility gene for AD. Additional analyses are necessary to identify the chromosome 12 susceptibility gene for AD and to follow up the regions of interest on chromosomes 4, 6, and 20.	MASSACHUSETTS GEN HOSP,MOL NEUROGENET UNIT,CHARLESTOWN,MA; INDIANA UNIV,MED CTR,DEPT MED & MOL GENET,INDIANAPOLIS,IN; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT,LOS ANGELES,CA	Harvard University; Massachusetts General Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Los Angeles	PericakVance, MA (corresponding author), DUKE UNIV,MED CTR,MED GENET SECT,DEPT MED,BOX 3445,DURHAM,NC 27710, USA.		Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009	Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404; Vance, Jeffery/0000-0003-3815-8199	NATIONAL INSTITUTE ON AGING [U24AG021886] Funding Source: NIH RePORTER; NIA NIH HHS [U24 AG021886] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; *CAS W RES U, 1994, SAGE STAT AN GEN EP; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAUSSET J, 1986, PRESSE MED, V15, P1801; Davis S, 1996, AM J HUM GENET, V58, P867; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HERRINGTON R, 1995, NATURE, V375, P754; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOCKE PA, 1995, GENET EPIDEMIOL, V12, P83, DOI 10.1002/gepi.1370120108; MAX W, 1993, NEUROLOGY, V43, pS6; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1994, CURRENT PROTOCOLS HU; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1990, AM J HUM GENET, V46, P222; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roses A. D., 1995, American Journal of Human Genetics, V57, pA202; ROSES AD, 1997, EMERY RIMOINS PRINCI, P1807; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCOTT WK, IN PRESS NEUROGENETI; Smalley SL, 1996, AM J HUM GENET, V58, P844; STRITTMATTER WJ, 1990, P NATL ACAD SCI USA, V90, P1971; Vance JM, 1996, AM J HUM GENET, V58, P757; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	31	302	308	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1237	1241		10.1001/jama.278.15.1237	http://dx.doi.org/10.1001/jama.278.15.1237			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333264				2022-12-01	WOS:A1997XZ70900028
J	Karason, K; Wallentin, L; Larsson, B; Sjostrom, L				Karason, K; Wallentin, L; Larsson, B; Sjostrom, L			Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSIVE PATIENTS; BLOOD-PRESSURE; ARTERIAL-HYPERTENSION; INSULIN-RESISTANCE; HEART; GEOMETRY; HYPERTROPHY; REDUCTION; YOUNG	Objectives: To investigate the consequences of longstanding obesity on left ventricular mass and structure and to examine the effects of weight loss on these variables, Design: Cross sectional survey and controlled intervention study. Setting: City of Gothenburg and surrounding areas, Sweden. Subjects: 41 obese patients treated with weight reducing gastric surgery, 31 obese patients treated conventionally, and 43 non-obese subjects. Main outcome measures: Changes in left ventricular mass and relative wall thickness. Results: Obese patients had higher blood pressure, greater left ventricular mass, and increased relative wall thickness than did matched non-obese control subjects. Obese subjects treated with gastric surgery had a substantial weight loss and a significant reduction in all variables when compared with conventionally treated obese subjects. Univariate and multivariate analysis of pooled data from the two groups of obese subjects showed that changes in relative wall thickness and left ventricular mass were more closely related to the change in weight than to the concomitant change in blood pressure. Conclusions: Structural heart abnormalities occurring in conjunction with obesity diminish after weight loss, The regression in these structural aberrations is better predicted by the weight loss than by the accompanying reduction in blood pressure. To prevent or improve abnormalities of heart structure in obese people, weight control should be the primary goal; it should be regarded as at least as important as regulating blood pressure.	SAHLGRENS UNIV HOSP,DEPT CLIN PHYSIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT MED,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital	Karason, K (corresponding author), SAHLGRENS UNIV HOSP,DEPT CARDIOL,S-41345 GOTHENBURG,SWEDEN.			Karason, Kristjan/0000-0002-2802-1191				AGABITIROSEI E, 1989, AM J HYPERTENS, V2, P70; ALEXANDE.JK, 1972, CIRCULATION, V45, P310, DOI 10.1161/01.CIR.45.2.310; ALEXANDER JK, 1962, CARDIOVASCULAR RES C, V63, P39; ALPERT MA, 1994, AM J CARDIOL, V73, P918, DOI 10.1016/0002-9149(94)90829-X; ALPERT MA, 1985, AM J CARDIOL, V55, P783, DOI 10.1016/0002-9149(85)90156-0; BYRD BF, 1989, AM HEART J, V118, P133, DOI 10.1016/0002-8703(89)90083-5; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DEVEREUX RB, 1995, J AM COLL CARDIOL, V25, P885, DOI 10.1016/0735-1097(94)00547-4; FAGARD R, 1992, EUR HEART J, V13, P1373, DOI 10.1093/oxfordjournals.eurheartj.a060069; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HSUEH WA, 1994, ENDOCRIN METAB CLIN, V23, P405, DOI 10.1016/S0889-8529(18)30105-1; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; LAUER MS, 1992, J AM COLL CARDIOL, V19, P130, DOI 10.1016/0735-1097(92)90063-S; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LICATA G, 1994, AM J HYPERTENS, V7, P314, DOI 10.1093/ajh/7.4.314; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1982, LANCET, V1, P1165; MESSERLI FH, 1983, AM J MED, V74, P808, DOI 10.1016/0002-9343(83)91071-9; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; SASSON Z, 1993, CIRCULATION, V88, P1431, DOI 10.1161/01.CIR.88.4.1431; SJOSTROM L, 1992, INT J OBESITY, V16, P465; VERDECCHIA P, 1995, J AM COLL CARDIOL, V25, P871, DOI 10.1016/0735-1097(94)00424-O; WILLIAMS GH, 1997, HEART DIS TXB CARDIO, P1887	28	120	121	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					912	916						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361540	Green Published			2022-12-01	WOS:A1997YB07300023
J	Uysal, KT; Wiesbrock, SM; Marino, MW; Hotamisligil, GS				Uysal, KT; Wiesbrock, SM; Marino, MW; Hotamisligil, GS			Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; TYROSINE KINASE-ACTIVITY; ADIPOSE-TISSUE; EXPRESSION; RECEPTOR; PHOSPHORYLATION	Obesity is highly associated with insulin resistance and is the biggest risk factor for non-insulin-dependent diabetes mellitus(1-3). The molecular basis of this common syndrome, however, is poorly understood. It has been suggested that tumour necrosis factor (TNF)-alpha is a candidate mediator of insulin resistance in obesity as it is overexpressed in the adipose tissues of rodents and humans(4-10) and it blocks the action of insulin in cultured cells and whole animals(10-14). To investigate the role of TNF-alpha in obesity and insulin resistance, we have generated obese mice with a targeted null mutation in the gene encoding TNF-alpha and those encoding the two receptors for TNF-alpha. The absence of TNF-alpha resulted in significantly improved insulin sensitivity in both diet-induced obesity and that resulting for the ob/ob model of obesity. The TNF alpha-deficient obese mice had lower levels of circulating free fatty acids, and were protected from the obesity-related reduction in the insulin receptor signalling in muscle and fat tissues, These results indicate that TNF-alpha is an important mediator of insulin resistance in obesity through its effects on several important sites of insulin action.	HARVARD UNIV,SCH PUBL HLTH,DIV BIOL SCI,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; MEM SLOAN KETTERING CANC CTR,LUDWIG INST CANC RES,NEW YORK,NY 10021	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center			Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793				BODEN G, 1997, DIABETES, V45, P3; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; COLEMAN DL, 1982, MOUSE BIOMEDICAL RES, P125; CORNELIUS P, 1989, BIOCHEM BIOPH RES CO, V165, P429, DOI 10.1016/0006-291X(89)91088-7; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Fiedorek Fred T. Jr., 1996, P604; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; OLFESKY JM, 1990, DIABETES MELLITUS, P121; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; WHITE MF, 1994, J BIOL CHEM, V269, P1	26	1742	1824	1	106	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					610	614		10.1038/39335	http://dx.doi.org/10.1038/39335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335502				2022-12-01	WOS:A1997YA00800062
J	Wang, YZ; Small, DL; Stanimirovic, DB; Morley, P; Durkin, JP				Wang, YZ; Small, DL; Stanimirovic, DB; Morley, P; Durkin, JP			AMPA receptor-mediated regulation of a G(i)-protein in cortical neurons	NATURE			English	Article							NUCLEOTIDE-BINDING-PROTEINS; METABOTROPIC GLUTAMATE-RECEPTOR; BETA-GAMMA-SUBUNITS; PERTUSSIS TOXIN; ACID; LOCALIZATION; MECHANISMS; AGONIST; KINASES	Excitatory synaptic transmission in the central nervous system is mediated primarily by the release of glutamate from presynaptic terminals onto postsynaptic channels gated by N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors(1,2). The myriad intracellular responses arising from the activation of the NMDA and AMPA receptors have previously been attributed to the flow of Ca2+ and/or Na+ through these ion channels(1-6). Here we report that the binding of the agonist AMPA. to its receptor can generate intracellular signals that are independent of Ca2+ and Na+ in rat cortical neurons, In the absence of intracellular Ca2+ and Na+, AMPA, but not NMDA, brought about changes in a guanine-nucleotide-binding protein (G alpha(il)) that inhibited pertussis toxin-mediated ADP-ribosylation of the protein in an in vitro assay, This effect was observed in intact neurons treated with AMPA as well as in isolated membranes exposed to AMPA, and was also found in MIN6 cells, which express functional AMPA receptors but have no metabotropic glutamate receptors, AMPA also inhibited forskolin-stimulated activity of adenylate cyclase in neurons, demonstrating that G(i) proteins were activated. Moreover, both G beta gamma blockage and co-precipitation experiments demonstrated that the modulation of the G(i) protein arose from the association of G alpha(il) with the glutamate receptor-1 (GluR1) subunit, These results suggest that, as well as acting as an ion channel, the APA receptor can exhibit metabotropic activity.			Wang, YZ (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,CELLULAR NEUROBIOL GRP,100 SUSSEX DR,OTTAWA,ON K1A 0R6,CANADA.							Brauner-Osborne H, 1996, J MED CHEM, V39, P3188, DOI 10.1021/jm9602569; CARNEY DH, 1992, THROMBIN STRUCTURE F, P351; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Durkin JP, 1996, J NEUROCHEM, V66, P951; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GHOSH A, 1995, SCIENCE, V268, P238; GIOVANELLI A, 1991, P NATL ACAD SCI USA, V88, P10069, DOI 10.1073/pnas.88.22.10069; GONOI T, 1994, J BIOL CHEM, V269, P16989; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KASAHARA J, 1994, FEBS LETT, V355, P41, DOI 10.1016/0014-5793(94)01170-2; KATADA T, 1986, J BIOL CHEM, V261, P8182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLIGAN G, 1988, BIOCHEM J, V255, P1; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; Sorenson EM, 1996, J PHARMACOL EXP THER, V277, P1733; Wang YZ, 1996, EXP CELL RES, V225, P382, DOI 10.1006/excr.1996.0189; WANG YZ, 1995, J BIOL CHEM, V270, P22783, DOI 10.1074/jbc.270.39.22783; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977	23	122	125	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					502	504		10.1038/39062	http://dx.doi.org/10.1038/39062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333240				2022-12-01	WOS:A1997XY90900058
J	Cummings, P; Grossman, DC; Rivara, FP; Koepsell, TD				Cummings, P; Grossman, DC; Rivara, FP; Koepsell, TD			State gun safe storage laws and child mortality due to firearms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Since 1989, several states have passed laws that make gun owners criminally liable if someone is injured because a child gains unsupervised access to a gun. These laws are controversial, and their effect on firearm-related injuries is unknown. Objective.-To determine if state laws that require safe storage of firearms are associated with a reduction in child mortality due to firearms. Design.-An ecological study of firearm mortality from 1979 through 1994. Setting.-All 50 states and the District of Columbia. Participants.-All children younger than 15 years. Main Outcome Measures.-Unintentional deaths, suicides, and homicides due to firearms. Results.-Laws that make gun owners responsible for storing firearms in a manner that makes them inaccessible to children were in effect for at least 1 year in 12 states from 1990 through 1994. Among children younger than 15 years, unintentional shooting deaths were reduced by 23% (95% confidence interval, 6%-37%) during the years covered by these laws. This estimate was based on within-state comparisons adjusted for national trends in unintentional firearm-related mortality. Gun-related homicide and suicide showed modest declines, but these were not statistically significant. Conclusions.-State safe storage laws intended to make firearms less accessible to children appear to prevent unintentional shooting deaths among children younger than 15 years.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98104; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cummings, P (corresponding author), UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,BOX 359960,325 9TH AVE,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P207; Day NE., 1987, STATISTICAL METHODS, VII, P131; FISHER LD, 1993, BIOSTATISTICS METHOD, P389; FURJUOH SN, 1996, INJ PREV, V2, P278; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; GAYNOR PE, 1994, INTRO TIME SERIES MO, P410; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; KLECK G, 1991, POINT BLANK GUNS VIO, P51; MAGUIRE K, 1994, SOURCEBOOK CRIMINAL, P203; MAUTE ML, 1995, RUTGERS LJ, V26, P431; MCCULLAGH P, 1989, GEN LINEAR MODELS, P39; MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425; SINGH GK, 1996, MONTHLY VITAL STAT R, P55; WHITE AM, 1993, HOUS L REV, V30, P1389; World Health Organization, 1977, INT CLASS DIS	16	123	124	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1084	1086		10.1001/jama.278.13.1084	http://dx.doi.org/10.1001/jama.278.13.1084			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315767				2022-12-01	WOS:A1997XX30300032
J	Rieder, R; Economou, T; Wanke, H; Turkevich, A; Crisp, J; Bruckner, J; Dreibus, G; McSween, HY				Rieder, R; Economou, T; Wanke, H; Turkevich, A; Crisp, J; Bruckner, J; Dreibus, G; McSween, HY			The chemical composition of Martian soil and rocks returned by the mobile alpha proton x-ray spectrometer: Preliminary results from the x-ray mode	SCIENCE			English	Article								The alpha proton x-ray spectrometer (APXS) on board the rover of the Mars Pathfinder mission measured the chemical composition of six soils and five rocks at the Ares Vallis landing site, The soil analyses show similarity to those determined by the Viking missions. The analyzed rocks were partially covered by dust but otherwise compositionally similar to each other. They are unexpectedly high in silica and potassium, but low in magnesium compared to martian soils and martian meteorites, The analyzed rocks are similar in composition to terrestrial andesites and close to the mean composition of Earth's crust. Addition of a mafic component and reaction products of volcanic gases to the local rock material is necessary to explain the soil composition.	MAX PLANCK INST CHEM,D-55020 MAINZ,GERMANY; UNIV CHICAGO,ENRICO FERMI INST,CHICAGO,IL 60637; CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV TENNESSEE,DEPT GEOL SCI,KNOXVILLE,TN 37996	Max Planck Society; University of Chicago; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Tennessee System; University of Tennessee Knoxville			Crisp, Joy/H-8287-2016	Crisp, Joy/0000-0002-3202-4416				BAIRD AK, 1976, SCIENCE, V194, P1288, DOI 10.1126/science.194.4271.1288; Banin A., 1992, MARS, P594; CLARK BC, 1993, GEOCHIM COSMOCHIM AC, V57, P4575, DOI 10.1016/0016-7037(93)90183-W; CLARK BC, 1979, GEOPHYS RES LETT, V6, P811, DOI 10.1029/GL006i010p00811; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; ECONOMOU TE, 1976, NUCL INSTRUM METHODS, V134, P391, DOI 10.1016/0029-554X(76)90298-6; ECONOMOU TE, 1970, J GEOPHYS RES, V75, P6514, DOI 10.1029/JB075i032p06514; Eugster O, 1997, GEOCHIM COSMOCHIM AC, V61, P2749, DOI 10.1016/S0016-7037(97)00115-4; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; LEBAS MJ, 1986, J PETROL, V27, P745, DOI 10.1093/petrology/27.3.745; LONGHI J, 1992, MARS, P184; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; Rieder R, 1997, J GEOPHYS RES-PLANET, V102, P4027, DOI 10.1029/96JE03918; WANKE H, 1988, PHILOS T R SOC A, V325, P545, DOI 10.1098/rsta.1988.0067	14	369	376	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1771	1774		10.1126/science.278.5344.1771	http://dx.doi.org/10.1126/science.278.5344.1771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388173				2022-12-01	WOS:A1997YJ90100039
J	Zhang, BL; Gallegos, M; Puoti, A; Durkin, E; Fields, S; Kimble, J; Wickens, MP				Zhang, BL; Gallegos, M; Puoti, A; Durkin, E; Fields, S; Kimble, J; Wickens, MP			A conserved RNA-binding protein that regulates sexual fates in the C-elegans hermaphrodite germ line	NATURE			English	Article							3' UNTRANSLATED REGION; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; TRANSLATIONAL REGULATION; DROSOPHILA EMBRYO; SPLICING FACTORS; GENE; NANOS; PATTERN; PUMILIO	The nematode Caenorhabditis elegans has two sexes, males and hermaphrodites. Hermaphrodites initially produce sperm but switch to producing oocytes. This switch appears to be controlled by the 3' untranslated region of fem-3 messenger RNA. We have now identified a binding factor (FBF) which is a cytoplasmic protein that binds specifically to the regulatory region of fem-3 3'UTR and mediates the sperm/oocyte switch. The RNA-binding domain of FBF consists of a stretch of eight tandem repeats and two short flanking regions. This structural element is conserved in several proteins Including Drosophila Pumilio, a regulatory protein that controls pattern formation in the fly by binding to a 3'UTR. We propose that FBF and Pumilio are members of a widespread family of sequence-specific RNA-binding proteins.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SEATTLE,WA 98195; UNIV WISCONSIN,HOWARD HUGHES MED INST,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,LAB CELL & MOL BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Puoti, Alessandro/E-5700-2012; Puoti, Alessandro/ABE-9963-2021	Puoti, Alessandro/0000-0002-1396-7662				AHRINGER J, 1992, EMBO J, V11, P2303, DOI 10.1002/j.1460-2075.1992.tb05289.x; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AHRINGER J, 1991, THESIS U WISCONSIN M; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BARTON MK, 1987, GENETICS, V115, P107; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; COGLIEVINA M, 1995, YEAST, V11, P767, DOI 10.1002/yea.320110808; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; Curtis D, 1997, EMBO J, V16, P834, DOI 10.1093/emboj/16.4.834; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FITCH DHA, 1997, C ELEGANS, V0002, P00815; FU XD, 1995, RNA, V1, P663; GEBAUER R, 1997, BIOESSAYS, V19, P23; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GRAHAM PL, 1993, DEV GENET, V14, P471, DOI 10.1002/dvg.1020140608; GRAHAM PL, 1993, GENETICS, V133, P919; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1986, GENETICS, V114, P15; Hodgkin J, 1997, C ELEGANS, P881; LEHMANN R, 1991, DEVELOPMENT, V112, P679; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MEYER BJ, 1997, C ELEGANS, V2, P209; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; SCHEDL T, 1989, GENETICS, V123, P755; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHEDL T, 1988, GENETICS, V119, P43; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/S0968-0004(96)10039-6; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WARD S, 1986, J CELL BIOL, V102, P1778, DOI 10.1083/jcb.102.5.1778; Waterston Robert H., 1997, Cold Spring Harbor Monograph Series, V33, P23; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHARTON RP, 1992, SEMINARS DEV BIOL, V3, P391; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Wickens M., 1996, TRANSLATIONAL CONTRO, P411; ZAMORE P, IN PRESS RNA; [No title captured]	46	416	431	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					477	484		10.1038/37297	http://dx.doi.org/10.1038/37297			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9393998				2022-12-01	WOS:A1997YJ86500041
J	Husman, AMD; Koot, M; Cornelissen, M; Keet, IPM; Brouwer, M; Broersen, SM; Bakker, M; Roos, MTL; Prins, M; deWolf, F; Coutinho, RA; Miedema, F; Goudsmit, J; Schuitemaker, H				Husman, AMD; Koot, M; Cornelissen, M; Keet, IPM; Brouwer, M; Broersen, SM; Bakker, M; Roos, MTL; Prins, M; deWolf, F; Coutinho, RA; Miedema, F; Goudsmit, J; Schuitemaker, H			Association between CCR5 genotype and the clinical course of HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; CCR5 genotype; biological markers; viral load; CD4 lymphocyte count	HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; TYPE-1 INFECTION; HOMOSEXUAL-MEN; BIOLOGICAL PHENOTYPE; PROGRESSION; AIDS; INDIVIDUALS; RECEPTOR; PATHOGENESIS	Background: Heterozygosity for a 32-nucleotide deletion in the C-C chemokine receptor 5 gene (CCR5 Delta 32) is associated with delayed disease progression in persons infected with HIV-1. Objective: To compare the predictive value of CCR5 genotype with that of established markers in the clinical course of HIV-1 infection. Design: Retrospective longitudinal study and nested case-control study. The latter included only long-term survivors, who were individually matched with progressors. Setting: Amsterdam, the Netherlands. Participants: 364 homosexual men with HIV-1 infection. Measurements: Polymerase chain reaction was used for CCR5 genotyping. Univariate and multivariate Cox proportional hazard analyses were done for disease progression with CCR5 genotype, CD4(+) T-lymphocyte counts, T-lymphocyte function, HIV-1 biological phenotype (syncytium-inducing or non-syncytium-inducing HIV-1), and viral RNA load in serum as covariates. Results: In the case-control study, 48% of long-term survivors were heterozygous for CCR5 Delta 32 compared with 9% of progressors (odds ratio, 6.9 [95% CI, 1.9 to 24.8]). in the total study sample, CCR5 Delta 32 heterozygotes had significantly delayed disease progression (P < 0.001; relative hazard, 0.4 [CI, 0.3 to 0.6]), a 1.5-fold slower decrease in CD4(+) T-lymphocyte count (P = 0.01), and a 2.6-fold lower viral RNA load (P = 0.01) at approximately 2.3 years after seroconversion compared with CCR5 wild-type homozygotes. At the end of the study, both groups showed the same prevalence of syncytium-inducing HIV-1, but CCR5 Delta 32 heterozygotes had a delayed conversion rate. The protective effect of CCR5 Delta 32 heterozygosity was stronger in the presence of only non-syncytium-inducing HIV-1. The CCR5 genotype predicted disease progression independent of viral RNA load, CD4(+) T-lymphocyte counts, T-lymphocyte function, and HIV-1 biological phenotype. Conclusions: The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT CLIN VIROIMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; DEPT CLIN VIROIMMUNOL, LAB EXPT & CLIN IMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS									Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEGRUTTOLA V, 1994, BIOMETRICS, V50, P1003, DOI 10.2307/2533439; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; DEWOLF F, IN PRESS AIDS; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Faucett CL, 1996, STAT MED, V15, P1663, DOI 10.1002/(SICI)1097-0258(19960815)15:15<1663::AID-SIM294>3.0.CO;2-1; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; Fouchier RAM, 1995, AIDS RES HUM RETROV, V11, P1473, DOI 10.1089/aid.1995.11.1473; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; Koot M, 1996, J INFECT DIS, V173, P349, DOI 10.1093/infdis/173.2.349; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; PHILLIPS AN, 1992, AIDS, V6, P1391, DOI 10.1097/00002030-199211000-00025; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665; 1987, MMWR-MORBID MORTAL W, V36, P15	41	228	231	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					882	+		10.7326/0003-4819-127-10-199711150-00004	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382366				2022-12-01	WOS:A1997YF54500004
J	Jones, CM; OBrien, K; Blinkhorn, AS; Rood, JP				Jones, CM; OBrien, K; Blinkhorn, AS; Rood, JP			Dentists' agreement on treatment of asymptomatic impacted third molar teeth: interview study	BRITISH MEDICAL JOURNAL			English	Article							3RD MOLARS; REMOVAL		UNIV MANCHESTER,DEPT DENT MED & SURG,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester				O'Brien, Kevin/0000-0001-5747-247X				[Anonymous], 1980, J Oral Surg, V38, P235; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; LOPES V, 1995, BRIT J ORAL MAX SURG, V33, P33, DOI 10.1016/0266-4356(95)90083-7; MERCIER P, 1992, INT J ORAL MAX SURG, V21, P17, DOI 10.1016/S0901-5027(05)80447-3; SHEPHERD JP, 1994, BRIT MED J, V309, P620, DOI 10.1136/bmj.309.6955.620	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1204	1204		10.1136/bmj.315.7117.1204	http://dx.doi.org/10.1136/bmj.315.7117.1204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393225	Green Published			2022-12-01	WOS:A1997YF25200022
J	Tu, YP; Wang, J; Ross, EM				Tu, YP; Wang, J; Ross, EM			Inhibition of brain G(z) GAP and other RGS proteins by palmitoylation of G protein alpha subunits	SCIENCE			English	Article							BINDING REGULATORY PROTEIN; GTPASE-ACTIVATING PROTEINS; LIPID MODIFICATIONS; MEMBRANE ATTACHMENT; PERTUSSIS TOXIN; AMINO-TERMINUS; BETA-GAMMA; MYRISTOYLATION; RECEPTOR; G(S-ALPHA)	Palmitoylation of the alpha subunit of the guanine nucleotide-binding protein G(z) inhibited by more than 90 percent its response to the guanosine triphosphatase (GTPase)-accelerating activity of G(z) GAP, a G(z)-selective member of the regulators of G-protein signaling (RGS) protein family of GTPase-activating proteins (GAPs). Palmitoylation both decreased the affinity of G(z) GAP for the GTP-bound form of G alpha(z) by at least 90 percent and decreased the maximum rate of GTP hydrolysis. Inhibition was reversed by removal of the palmitoyl group by dithiothreitol. Palmitoylation of G alpha(z) also inhibited its response to the GAP activity of G alpha-interacting protein (GAIP), another RGS protein, and palmitoylation of G alpha(l1) inhibited ils response to RGS4. The extent of inhibition of G(z) GAP, GAIP, RGS4, and RGS10 correlated roughly with their intrinsic GAP activities for the G alpha target used in the assay. Reversible palmitoylation is thus a major determinant of G(z) deactivation after its stimulation by receptors, and may be a general mechanism for prolonging or potentiating G-protein signaling.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FERGUSON KM, 1991, METHOD ENZYMOL, V195, P188; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Hepler J.R., 1997, P NATL ACAD SCI USA, V94, p428; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MILLIGAN G, 1995, BIOCHEM SOC T, V23, P583, DOI 10.1042/bst0230583; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TU Y, UNPUB; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	39	119	123	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1132	1135		10.1126/science.278.5340.1132	http://dx.doi.org/10.1126/science.278.5340.1132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353196				2022-12-01	WOS:A1997YE65200055
J	Vijan, S; Hofer, TP; Hayward, RA				Vijan, S; Hofer, TP; Hayward, RA			Estimated benefits of glycemic control in microvascular complications in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, non-insulin-dependent; blood glucose; diabetic angiopathies; kidney failure, chronic; diabetic retinopathy	INTENSIVE INSULIN THERAPY; METABOLIC CONTROL; VASCULAR-DISEASE; RISK-FACTORS; GLYCOSYLATED HEMOGLOBIN; CLINICAL PROTEINURIA; GLYCATED HEMOGLOBIN; PLASMA-GLUCOSE; RENAL-FAILURE; LONDON COHORT	Background: The benefits of intensive glycemic control in patients with type 2 diabetes are not well quantified. It is therefore not clear which patients will benefit most from aggressive glycemic control. Objective: To evaluate the efficacy of glycemic control in type 2 diabetes. Design: Markov decision model. Patients: Diabetic patients at a health maintenance organization. Main Outcome Measures: Risks for developing blindness and end-stage renal disease; number of patients and patient-years needed to treat to prevent complications. Results: For a patient in whom diabetes developed before 50 years of age, reducing hemoglobin A(1c) levels from 9% to 7% results in an estimated 2.3-percentage point decrease (from 2.6% to 0.3%) in lifetime risk for blindness due to retinopathy. The same change in a patient with diabetes onset at 65 years of age would be expected to decrease the risk for blindness by 0.5 percentage points (from 0.5% to < 0.1%). However, the Markov model predicts substantially greater benefit when moving from poor to moderate glycemic control than when moving from moderate to almost-normal glycemic control. Targeting less than 20% of the patients at one health maintenance organization for intensified therapy may prevent more than 80% of the preventable patient-time spent blind. The risks for end-stage renal disease and the risk reduction provided by improved glycemic control are lower than those for blindness. Conclusions: This probability model, based on extrapolation from the experience with type 1 diabetes, suggests that patients with early onset of type 2 diabetes will accrue substantial benefit from almost-normal glycemic control. In patients with later onset, moderate glycemic control prevents most end-stage complications caused by microvascular disease. These results have important implications for informing patients and allocating health care resources.	VET AFFAIRS CTR PRACTICE MANAGEMENT & OUTCOMES RE, ANN ARBOR, MI USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI USA	University of Michigan System; University of Michigan			Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; AHRQ HHS [HSO 6665-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; [Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1995, DIABETES, V44, P968; [Anonymous], 1994, DIABETES CARE, V17, P616; [Anonymous], 1991, Ophthalmology, V98, P786; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; BABA T, 1992, DIABETES RES CLIN PR, V16, P157, DOI 10.1016/0168-8227(92)90088-9; Clark CM, 1996, ANN INTERN MED, V124, P184, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00022; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; Colwell JA, 1996, ANN INTERN MED, V124, P178, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00020; Colwell JA, 1996, DIABETES CARE, V19, P896, DOI 10.2337/diacare.19.8.896; COOPER ME, 1988, DIABETIC MED, V5, P361, DOI 10.1111/j.1464-5491.1988.tb01006.x; DECKERT T, 1991, DIABETIC MED, V8, P533; DWYER MS, 1985, DIABETES CARE, V8, P316, DOI 10.2337/diacare.8.4.316; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; GALL MA, 1993, DIABETOLOGIA, V36, P1071, DOI 10.1007/BF02374501; Harris MI, 1996, ANN INTERN MED, V124, P117, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00007; HAYWARD RA, 1997, IN PRESS JAMA; Henry RR, 1996, ANN INTERN MED, V124, P175, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00019; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; Jarrett R J, 1984, Diabet Med, V1, P17; JOHN L, 1994, DIABETES CARE, V17, P888, DOI 10.2337/diacare.17.8.888; Klein R, 1996, ANN INTERN MED, V124, P90, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00003; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KLEIN R, 1993, DIABETES CARE, V16, P1325, DOI 10.2337/diacare.16.10.1325; KLEIN R, 1985, DIABETES AM, P1; KROLEWSKI AS, 1977, DIABETOLOGIA, V13, P345, DOI 10.1007/BF01223277; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LIU QZ, 1993, DIABETOLOGIA, V36, P428, DOI 10.1007/BF00402279; MATLOCK MB, 1988, DIABETLOGIA, V31, P82; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; Medhi, 1994, STOCHASTIC PROCESSES; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MORISAKI N, 1994, J AM GERIATR SOC, V42, P142, DOI 10.1111/j.1532-5415.1994.tb04941.x; MORRISH NJ, 1990, DIABETOLOGIA, V33, P542, DOI 10.1007/BF00404142; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MOSS SE, 1988, OPHTHALMOLOGY, V95, P1340; MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; *NAT CTR HLTH STAT, 1995, VIT STAT US B, V2; Nathan DM, 1996, ANN INTERN MED, V124, P86, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00002; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PANZRAM G, 1981, DIABETOLOGIA, V20, P587; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; Peters B.G., 1994, J EUROPEAN PUBLIC PO, V1, P9, DOI [10.1080/13501769408406945, DOI 10.1080/13501769408406945]; PIART J, 1978, DIABETES CARE, V1, P252; PIART J, 1978, DIABETES CARE, V1, P168; POWRIE JK, 1994, BRIT MED J, V309, P1608, DOI 10.1136/bmj.309.6969.1608; RUDBERG S, 1993, DIABETOLOGIA, V36, P1309, DOI 10.1007/BF00400811; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHENFIELD GM, 1979, DIABETES METAB, V5, P149; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STEPHENSON JM, 1995, DIABETIC MED, V12, P149, DOI 10.1111/j.1464-5491.1995.tb00446.x; TEUSCHER A, 1994, LANCET, V343, P1097, DOI 10.1016/S0140-6736(94)90206-2; TURNER RC, 1991, DIABETOLOGIA, V34, P877; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; VANDERZWAAG R, 1983, DIABETES CARE, V6, P341, DOI 10.2337/diacare.6.4.341; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1983, BRIT MED J, V286, P598, DOI 10.1136/bmj.286.6365.598; WELBORN TA, 1984, DIABETOLOGIA, V27, P568, DOI 10.1007/BF00276969; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; YIP J, 1993, BRIT MED J, V306, P1235; 1989, MMWR-MORBID MORTAL W, V38, P546	69	165	166	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					788	+		10.7326/0003-4819-127-9-199711010-00003	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382399				2022-12-01	WOS:A1997YD89800002
J	Guenther, B; Onrust, R; Sali, A; ODonnell, M; Kuriyan, J				Guenther, B; Onrust, R; Sali, A; ODonnell, M; Kuriyan, J			Crystal structure of the delta' subunit of the cramp-loader complex of E-coli DNA polymerase III	CELL			English	Article							ESCHERICHIA-COLI; ADENYLATE KINASE; PROTEIN COMPLEX; GAMMA-SUBUNIT; ATP SYNTHASE; REPLICATION; HOLOENZYME; RESOLUTION; MECHANISM; TRIPHOSPHATE	The crystal structure of the delta' subunit of the clamp-loader complex of E. coli DNA polymerase III has been determined. Three consecutive domains in the structure are arranged in a C-shaped architecture. The N-terminal domain contains a nonfunctional nucleotide binding site. The catalytic component of the clamp-loader complex is the gamma subunit, which is homologous to delta'. A sequence-structure alignment suggests that nucleotides bind to gamma at an interdomain interface within the inner surface of the ''C.'' Th, alignment is extended to other clamp-loader complexes and to the RuvB family of DNA helicases, and suggests that each of these is assembled from C-shaped components that can open and close the jaws of the ''C'' in response to ATP binding and hydrolysis.	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University				O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM 45547, GM54762, GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839, R29GM054762, R01GM054762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CRONET P, 1995, J MOL BIOL, V249, P654, DOI 10.1006/jmbi.1995.0326; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUENTHER BD, 1996, THESIS ROCKEFELLER U; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOONIN EV, 1991, P NATL ACAD SCI USA, V88, P10647, DOI 10.1073/pnas.88.23.10647; Kornberg A., 1991, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1991, J BIOL CHEM, V266, P594; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOSSAL NG, 1984, BACTERIOPHAGE T, V4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; SANCHEZ R, 1997, IN PRESS PROT STRUCT; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YIN KC, 1986, NUCLEIC ACIDS RES, V14, P6541, DOI 10.1093/nar/14.16.6541; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	54	213	217	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					335	345		10.1016/S0092-8674(00)80417-1	http://dx.doi.org/10.1016/S0092-8674(00)80417-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363942	hybrid			2022-12-01	WOS:A1997YD94100007
J	Weissman, D; Rabin, RL; Arthos, J; Rubbert, A; Dybul, M; Swofford, R; Venkatesan, S; Farber, JM; Fauci, AS				Weissman, D; Rabin, RL; Arthos, J; Rubbert, A; Dybul, M; Swofford, R; Venkatesan, S; Farber, JM; Fauci, AS			Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor	NATURE			English	Article							INFECTION; DISEASE; VACCINE; ENTRY	Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) enter target cells by forming a complex between the viral envelope protein and two cell-surface membrane receptors: CD4 and a 7-span transmembrane chemokine receptor (reviewed in refs 1-3). Isolates of HIV that differ in cellular tropism use different subsets of chemokine receptors as entry cofactors: macrophage-tropic HIVs primarily use CCR5, whereas T-cell-tropic and dual-tropic isolates use CXCR4 (refs 1-3) receptors. HIV-mediated signal transduction through CCR5 is not required for efficient fusion and entry of HIV in vitro(4,5). Here we show that recombinant envelope proteins from macrophage-tropic HIV and SIV induce a signal through CCR5 on CD4(+) T cells and that envelope-mediated signal transduction through CCR5 induces chemotaxis of T cells. This chemotactic response may contribute to the pathogenesis of HIV in vivo by chemo-attracting activated CD4(+) cells to sites of viral replication(1,2). HIV-mediated signalling through CCR5 may also enhance viral replication in vivo by increasing the activation state of target cells. Alternatively, envelope-mediated CCR5 signal transduction may influence viral-associated cytopathicity or apoptosis.	NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,FLO CYTOMETRY UNIT,NIH,BETHESDA,MD 20892; NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Rabin, Ronald/0000-0003-3496-0504				Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Kozak SL, 1997, J VIROL, V71, P873, DOI 10.1128/JVI.71.2.873-882.1997; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; McElrath MJ, 1996, P NATL ACAD SCI USA, V93, P3972, DOI 10.1073/pnas.93.9.3972; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; Mossman SP, 1996, J VIROL, V70, P1953, DOI 10.1128/JVI.70.3.1953-1960.1996; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251; Oravecz T, 1996, J IMMUNOL, V157, P1329; Taub DD, 1996, J IMMUNOL, V156, P2095; TRIKOLA A, 1996, NATURE, V384, P184; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	18	298	304	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					981	985		10.1038/40173	http://dx.doi.org/10.1038/40173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353123				2022-12-01	WOS:A1997YD29900059
J	Banks, DA; Fossel, M				Banks, DA; Fossel, M			Telomeres, cancer, and aging - Altering the human life span	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL-CYCLE CONTROL; HUMAN-FIBROBLASTS; CAENORHABDITIS-ELEGANS; REPLICATIVE SENESCENCE; HEALTH-CARE; IN-VIVO; LONGEVITY; GENES; POLICY; IMPACT	Population projections of the aging global society and its fiscal and social impact have depended on assumptions regarding the human life span. Until now, the assumption that the maximum human life span is fixed has been justified. Recent advances in cell biology, genetics, and our understanding of the cellular processes that underlie aging, however, have shown that this assumption is invalid in a number of animal models and suggest that this assumption may become invalid for humans as well. In vitro alteration of telomeres affects cellular senescence, and in vivo manipulation of genes and diet can increase maximum life span in animal models if these discoveries are extended to humans. We may soon be able to extend the maximum human life span and postpone or prevent the onset of diseases associated with aging. Such a possibility requires that we recognize a growing uncertainty in any attempt to project international health care costs into the next few decades. The costs may be significantly lower than projections, if life span increases and age-related disabilities are postponed or less severe, or perhaps higher, if life span increases without altering the onset and severity of disability. An appropriate uncertainty regarding the human life span undermines any attempt to accurately predict health costs in the next century.	UNIV CALIF BERKELEY,RICHARD & RHODA GOLDMAN SCH PUBL POLICY,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CTR ECON & DEMOG AGING,BERKELEY,CA 94720; MICHIGAN STATE UNIV,COLL HUMAN MED,E LANSING,MI 48824	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Michigan State University; Michigan State University College of Human Medicine					NATIONAL INSTITUTE ON AGING [P20AG012839] Funding Source: NIH RePORTER; NIA NIH HHS [P20-AG-12839] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ALL AG RES, 1997, 7 DEADL MYTHS UNC FA; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Finch CE., 1990, LONGEVITY SENESCENCE; Fossel M, 1996, REVERSING HUMAN AGIN; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1980, P NATL ACAD SCI-BIOL, V77, P1885, DOI 10.1073/pnas.77.4.1885; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYFLICK L, 1994, WHY WE AGE, P313; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JAZWINSKI SM, 1997, NAT MAN HLTH CAR C B; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lane MA, 1997, AGE, V20, P45, DOI 10.1007/s11357-997-0004-2; LARSEN PL, 1995, GENETICS, V139, P1567; LE R, 1997, DEMOGRAPHY, V34, P67; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; Lundblad V, 1996, CELL, V87, P369, DOI 10.1016/S0092-8674(00)81358-6; MANTON KG, 1993, J GERONTOL, V48, P11, DOI 10.1093/geronj/48.Special_Issue.11; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Marcand S, 1996, CURR BIOL, V6, P1222, DOI 10.1016/S0960-9822(96)00701-4; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P1319, DOI 10.1001/jama.273.17.1319; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; *NIH, 1997, SEARCH SECR AG; OKAMOTO Y, 1992, BRIT MED J, V305, P403, DOI 10.1136/bmj.305.6850.403; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Oshima J, 1996, LANCET, V348, P1106, DOI 10.1016/S0140-6736(05)64456-X; Rao R. Nagaraja, 1996, Current Opinion in Oncology, V8, P516; Sallar AM, 1996, NEW ENGL J MED, V334, P537; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DWE, 1993, HUMAN LONGEVITY AGIN; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stewart C, 1997, NATURE, V385, P769, DOI 10.1038/385769a0; SULLIVAN DF, 1971, HSMHA HEALTH REP, V86, P347, DOI 10.2307/4594169; U. S. Bureau of the Census, 1996, STAT ABSTR US; US Bureau of the Census, 1995, STAT ABSTR US; VANDEWALLE E, 1990, MILBANK Q, V68, P10, DOI 10.2307/3350174; WEINDRUCH R, 1988, RETARDATION AGING DI; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Winker MA, 1996, JAMA-J AM MED ASSOC, V276, P1758, DOI 10.1001/jama.1996.03540210066037; Wise DA, 1997, DEMOGRAPHY, V34, P83, DOI 10.2307/2061661; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; 1997, BALTIMORE SUN   0805, pB5; 1996, SCIENCE, V274, P1989	59	29	30	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1345	1348		10.1001/jama.278.16.1345	http://dx.doi.org/10.1001/jama.278.16.1345			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343466				2022-12-01	WOS:A1997YA90500036
J	Sonke, GS; Stewart, AW; Beaglehole, R; Jackson, R; White, HD				Sonke, GS; Stewart, AW; Beaglehole, R; Jackson, R; White, HD			Comparison of case fatality in smokers and non-smokers after acute cardiac event	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION		UNIV AUCKLAND,FAC MED & HLTH SCI,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND; GREEN LANE HOSP,DEPT CARDIOL,AUCKLAND 3,NEW ZEALAND	University of Auckland				Sonke, Gabe/0000-0001-8088-9628; Jackson, Rod/0000-0001-5914-6934				BARBASH GI, 1995, J AM COLL CARDIOL, V26, P1222, DOI 10.1016/0735-1097(95)00299-5; Sonke GS, 1996, BRIT MED J, V313, P853; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WHITE HD, 1995, AM J CARDIOL, V75, P278, DOI 10.1016/0002-9149(95)80036-R	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					992	993		10.1136/bmj.315.7114.992	http://dx.doi.org/10.1136/bmj.315.7114.992			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365298	Green Published			2022-12-01	WOS:A1997YC30700023
J	Lewis, CE				Lewis, CE			Management of patients with HIV/AIDS - Who should care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY; PHYSICIANS		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								*CDCP, 1997, HIV AIDS SURV REP, V8, P7; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P826; DiMatteo M R, 1994, JAMA, V271, P83, DOI 10.1001/jama.271.1.79; DiMatteo MR, 1994, JAMA-J AM MED ASSOC, V271, P83; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; HUMMELL HJ, 1970, SOC SCI MED, V3, P597, DOI 10.1016/0037-7856(70)90028-4; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Kraft SK, 1997, ARCH FAM MED, V6, P29, DOI 10.1001/archfami.6.1.29; Lewis CE, 1996, WESTERN J MED, V164, P415; *US DEP HHS, 1997, FED REG         0619, V62, P33417	11	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1133	1134		10.1001/jama.278.14.1133	http://dx.doi.org/10.1001/jama.278.14.1133			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326458				2022-12-01	WOS:A1997XY42200003
J	Nightingale, SL				Nightingale, SL			Request for public comment on informed consent waiver rule in combat situations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-01	WOS:A1997XX30300007
J	Freitas, AA; Rocha, B				Freitas, AA; Rocha, B			Lymphocyte survival: A Red Queen hypothesis	SCIENCE			English	Editorial Material							CELLULAR COMPETITION; T-CELLS; SELECTION; MICE		INST NECKER,INSERM,U345,F-75015 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Freitas, AA (corresponding author), INST PASTEUR,LAB DYNAM LYPHOCYTAIRES,CNRS,URA 1961,F-75015 PARIS,FRANCE.		freitas, antonio/A-2482-2013	freitas, antonio/0000-0001-6392-7178				Agenes F, 1997, EUR J IMMUNOL, V27, P1801, DOI 10.1002/eji.1830270731; Carroll L., 1872, LOOKING GLASS; Freitas AA, 1996, EUR J IMMUNOL, V26, P2640, DOI 10.1002/eji.1830261115; FREITAS AA, 1995, EUR J IMMUNOL, V25, P1729, DOI 10.1002/eji.1830250636; JERNE NK, 1967, COLD SPRING HARB SYM, V32, P591; KIRBERG J, 1997, IN PRESS J EXP MED; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; McLean AR, 1997, P NATL ACAD SCI USA, V94, P5792, DOI 10.1073/pnas.94.11.5792; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TANCHOT C, 1997, IN PRESS J EXP MED; Van Valen L., 1973, EVOL THEORY, V1, P1, DOI DOI 10.1038/344864A0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M	16	25	25	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1950	1950		10.1126/science.277.5334.1950	http://dx.doi.org/10.1126/science.277.5334.1950			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9333949				2022-12-01	WOS:A1997XX84900029
